<SEC-DOCUMENT>0001601830-24-000052.txt : 20240509
<SEC-HEADER>0001601830-24-000052.hdr.sgml : 20240509
<ACCEPTANCE-DATETIME>20240509161155
ACCESSION NUMBER:		0001601830-24-000052
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		77
CONFORMED PERIOD OF REPORT:	20240331
FILED AS OF DATE:		20240509
DATE AS OF CHANGE:		20240509

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			RECURSION PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001601830
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				464099738
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40323
		FILM NUMBER:		24930724

	BUSINESS ADDRESS:	
		STREET 1:		41S RIO GRANDE STREET
		CITY:			SALT LAKE CITY
		STATE:			UT
		ZIP:			84101
		BUSINESS PHONE:		(385) 269-0203

	MAIL ADDRESS:	
		STREET 1:		41S RIO GRANDE STREET
		CITY:			SALT LAKE CITY
		STATE:			UT
		ZIP:			84101

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Recursion Pharmaceuticals, LLC
		DATE OF NAME CHANGE:	20140305
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>rxrx-20240331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:3e558803-1e4e-49a0-9bef-dda845cc7d19,g:dd7baf31-0188-4ca9-9996-087ebdfea724,d:575b7c0e32c142cfa1b028ec4e7e1359-->
<html xmlns:srt="http://fasb.org/srt/2023" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:rxrx="http://www.recursion.com/20240331" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>rxrx-20240331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-26">0001601830</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-27">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-28">2024</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-29">Q1</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="f-30">12/31</ix:nonNumeric><ix:nonNumeric contextRef="c-37" name="rxrx:LicenseAgreementTradingPeriodUsedForEquityValueDetermination" id="f-250">P7D</ix:nonNumeric><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:ImpairmentOfLeasehold" scale="0" id="f-301">0</ix:nonFraction><ix:nonNumeric contextRef="c-145" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-604">455</ix:nonNumeric><ix:nonNumeric contextRef="c-147" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-605">483</ix:nonNumeric><ix:nonNumeric contextRef="c-149" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-606">466</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="rxrx-20240331.xsd"/></ix:references><ix:resources><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="claim"><xbrli:measure>rxrx:claim</xbrli:measure></xbrli:unit><xbrli:unit id="vote"><xbrli:measure>rxrx:vote</xbrli:measure></xbrli:unit><xbrli:unit id="class"><xbrli:measure>rxrx:class</xbrli:measure></xbrli:unit><xbrli:unit id="phenomap"><xbrli:measure>rxrx:phenomap</xbrli:measure></xbrli:unit><xbrli:unit id="program"><xbrli:measure>rxrx:program</xbrli:measure></xbrli:unit><xbrli:unit id="performance_obligation"><xbrli:measure>rxrx:performance_obligation</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rxrx:ExchangeableStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rxrx:ExchangeableStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rxrx:TempusLabsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2023-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rxrx:TempusLabsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rxrx:TempusLabsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">rxrx:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">rxrx:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AssetUnderConstructionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AssetUnderConstructionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">rxrx:BioHiveSupercomputerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rxrx:Station41LeaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rxrx:Station41LeaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rxrx:Station41LeaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rxrx:ValenceDiscoveryIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-16</xbrli:startDate><xbrli:endDate>2023-05-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rxrx:ValenceDiscoveryIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rxrx:ExchangeableStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-16</xbrli:startDate><xbrli:endDate>2023-05-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rxrx:ValenceDiscoveryIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-16</xbrli:startDate><xbrli:endDate>2023-05-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rxrx:ValenceDiscoveryIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-16</xbrli:startDate><xbrli:endDate>2023-05-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rxrx:ValenceDiscoveryIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-16</xbrli:startDate><xbrli:endDate>2023-05-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rxrx:ValenceDiscoveryIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rxrx:ValenceDiscoveryIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rxrx:ValenceDiscoveryIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rxrx:CyclicaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-25</xbrli:startDate><xbrli:endDate>2023-05-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rxrx:CyclicaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-25</xbrli:startDate><xbrli:endDate>2023-05-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rxrx:CyclicaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-31</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rxrx:CyclicaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-25</xbrli:startDate><xbrli:endDate>2023-05-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rxrx:CyclicaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-25</xbrli:startDate><xbrli:endDate>2023-05-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rxrx:CyclicaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rxrx:CyclicaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rxrx:CyclicaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rxrx:RecursionValenceAndCyclicaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="rxrx:LeaseDescriptionAxis">rxrx:LondonLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="rxrx:LeaseDescriptionAxis">rxrx:LondonLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="rxrx:LeaseDescriptionAxis">rxrx:DataCenterLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-01</xbrli:startDate><xbrli:endDate>2024-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="rxrx:LeaseDescriptionAxis">rxrx:DataCenterLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-10-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rxrx:AtTheMarketOfferingProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-01</xbrli:startDate><xbrli:endDate>2023-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rxrx:AtTheMarketOfferingProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rxrx:AtTheMarketOfferingProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rxrx:NVDIAPrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rxrx:ExchangeableStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rxrx:NVDIAPrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rxrx:NVDIAPrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rxrx:NVDIAPrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rxrx:ValenceDiscoveryIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">rxrx:ChristopherGibsonAndAffiliatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rxrx:RocheAndGenentechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rxrx:RocheAndGenentechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="rxrx:RevenueRemainingPerformanceObligationAxis">rxrx:PhenomapsCreationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rxrx:RocheAndGenentechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="rxrx:RevenueRemainingPerformanceObligationAxis">rxrx:PhenomapsRawImagesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rxrx:RocheAndGenentechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="rxrx:RevenueRemainingPerformanceObligationAxis">rxrx:DevelopedAndCommercializedProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rxrx:RocheAndGenentechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rxrx:RocheAndGenentechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="rxrx:RevenueRemainingPerformanceObligationAxis">rxrx:GastrointestinalCancerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rxrx:RocheAndGenentechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="rxrx:RevenueRemainingPerformanceObligationAxis">rxrx:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rxrx:A2021EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">rxrx:TempusAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">rxrx:TempusAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">rxrx:TerryAnnBurrellMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">rxrx:TerryAnnBurrellMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">rxrx:TinaMarriottMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">rxrx:TinaMarriottMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">rxrx:MichaelSecoraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">rxrx:MichaelSecoraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i575b7c0e32c142cfa1b028ec4e7e1359_1"></div><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"/><td style="width:511.00pt"/><td style="width:1.0pt"/></tr><tr style="height:314pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;text-align:center"><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES </span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION </span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-Q</ix:nonNumeric></span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Mark One)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="f-2">&#9746;</ix:nonNumeric></span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">  </span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></div><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3">March&#160;31, 2024</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">or</span></div><div style="text-align:center"><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-4">&#9744;</ix:nonNumeric></span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the transition period from  </span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">            </span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to </span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">            </span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">        </span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="text-align:center"><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-40323</ix:nonNumeric></span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-6">RECURSION PHARMACEUTICALS, INC.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-7">Delaware</ix:nonNumeric>                                                                                             </span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-8">46-4099738</ix:nonNumeric></span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">                </span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(State or other jurisdiction of incorporation or organization)                                 (I.R.S. Employer Identification No.)</span></div><div style="padding-left:18pt;padding-right:18pt;text-align:center;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-9">41 S Rio Grande Street</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-10">Salt Lake City,</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-11">UT</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-12">84101</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Address of principal executive offices) (Zip code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-13">385</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-14">269 - 0203</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Registrant&#8217;s telephone number, including area code)</span></div></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"/><td style="width:201.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:97.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:208.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities registered pursuant to Section 12(b) of the Act:</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Trading symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-15">Class A Common Stock, par value $0.00001</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-16">RXRX</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-17">Nasdaq Global Select Market</ix:nonNumeric> </span></div></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"/><td style="width:511.00pt"/><td style="width:1.0pt"/></tr><tr style="height:126pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;         <ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-18">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">x</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">    No &#9744;</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). </span></div><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;          <ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-19">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">x</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">   No &#9744;</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and "emerging growth company" in Rule 12b-2 of the Exchange Act.</span></div></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"/><td style="width:103.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:22.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:223.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:132.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:22.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-20">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">x</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="f-21">&#9744;</ix:nonNumeric></span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-22">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"/><td style="width:511.00pt"/><td style="width:1.0pt"/></tr><tr style="height:92pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.       </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).   Yes </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-23">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">   No </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">As of April&#160;30, 2024, there were <ix:nonFraction unitRef="shares" contextRef="c-2" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-24">230,273,797</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-25">7,389,871</ix:nonFraction> of the registrant&#8217;s Class A and B common stock outstanding, respectively.</span></div></td></tr></table></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div></div></div><div id="i575b7c0e32c142cfa1b028ec4e7e1359_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i575b7c0e32c142cfa1b028ec4e7e1359_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:79.309%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.772%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ee;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ee;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i575b7c0e32c142cfa1b028ec4e7e1359_13">Part I </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i575b7c0e32c142cfa1b028ec4e7e1359_13">Financial Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ee;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ee;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i575b7c0e32c142cfa1b028ec4e7e1359_13">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1. </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i575b7c0e32c142cfa1b028ec4e7e1359_16">Financial Statements (unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ee;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ee;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i575b7c0e32c142cfa1b028ec4e7e1359_16">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2. </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i575b7c0e32c142cfa1b028ec4e7e1359_79">Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ee;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ee;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i575b7c0e32c142cfa1b028ec4e7e1359_79">21</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3. </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ee;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i575b7c0e32c142cfa1b028ec4e7e1359_112">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ee;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ee;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i575b7c0e32c142cfa1b028ec4e7e1359_112">29</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ee;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i575b7c0e32c142cfa1b028ec4e7e1359_115">Controls and Procedures </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ee;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ee;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i575b7c0e32c142cfa1b028ec4e7e1359_115">29</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ee;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ee;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i575b7c0e32c142cfa1b028ec4e7e1359_118">Part II </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i575b7c0e32c142cfa1b028ec4e7e1359_118">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ee;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ee;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i575b7c0e32c142cfa1b028ec4e7e1359_118">31</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i575b7c0e32c142cfa1b028ec4e7e1359_121">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ee;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ee;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i575b7c0e32c142cfa1b028ec4e7e1359_121">31</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A. </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i575b7c0e32c142cfa1b028ec4e7e1359_124">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ee;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ee;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i575b7c0e32c142cfa1b028ec4e7e1359_124">31</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i575b7c0e32c142cfa1b028ec4e7e1359_127">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ee;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ee;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i575b7c0e32c142cfa1b028ec4e7e1359_127">32</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i575b7c0e32c142cfa1b028ec4e7e1359_130">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ee;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ee;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i575b7c0e32c142cfa1b028ec4e7e1359_130">32</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 6. </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i575b7c0e32c142cfa1b028ec4e7e1359_136">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ee;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ee;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i575b7c0e32c142cfa1b028ec4e7e1359_136">33</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ee;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i575b7c0e32c142cfa1b028ec4e7e1359_139">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ee;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ee;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i575b7c0e32c142cfa1b028ec4e7e1359_139">34</a></span></div></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i575b7c0e32c142cfa1b028ec4e7e1359_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div id="i575b7c0e32c142cfa1b028ec4e7e1359_10"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cautionary Note Regarding Forward-Looking Statements</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q contains &#8220;forward-looking statements&#8221; about us and our industry within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;would,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;could,&#8221; &#8220;intend,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;contemplate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; or &#8220;continue&#8221; or the negative of these terms or other similar expressions. Forward-looking statements contained in this report may include without limitation those regarding: </span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our research and development programs;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the initiation, timing, progress, results, and cost of our current and future preclinical and clinical studies, including statements regarding the design of, and the timing of initiation and completion of, studies and related preparatory work, as well as the period during which the results of the studies will become available; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability of our clinical trials to demonstrate the safety and efficacy of our drug candidates, and other positive results; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability and willingness of our collaborators to continue research and development activities relating to our development candidates and investigational medicines; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">future agreements with third parties in connection with the commercialization of our investigational medicines and any other approved product;  </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing, scope, or likelihood of regulatory filings and approvals, including the timing of Investigational New Drug applications and final approval by the U.S. Food and Drug Administration, or FDA, of our current drug candidates and any other future drug candidates, as well as our ability to maintain any such approvals;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.2pt">the timing, scope, or likelihood of foreign regulatory filings and approvals, including our ability to maintain any such approvals; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the size of the potential market opportunity for our drug candidates, including our estimates of the number of patients who suffer from the diseases we are targeting and potential annual sales; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to identify viable new drug candidates for clinical development and the rate at which we expect to identify such candidates, whether through an inferential approach or otherwise; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectation that the assets that will drive the most value for us are those that we will identify in the future using our datasets and tools; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to develop and advance our current drug candidates and programs into, and successfully complete, clinical studies; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to reduce the time or cost or increase the likelihood of success of our research and development relative to the traditional drug discovery paradigm; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to improve, and the rate of improvement in, our infrastructure, datasets, biology, technology tools and drug discovery platform, and our ability to realize benefits from such improvements; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our expectations related to the performance and benefits of our BioHive supercomputer, including our planned expansion of the BioHive supercomputer capabilities; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to realize a return on our investment of resources and cash in our drug discovery collaborations; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to integrate acquired businesses with our existing programs and platform and realize a return on acquired assets;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our ability to leverage datasets acquired through licenses with third parties, including with Tempus, into increased machine learning capabilities, novel genetic associations and mechanisms, innovative therapeutics, or other beneficial outcomes;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our ability to derive value from our Recursion OS by licensing subsets of data and key tools;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the ability to construct and apply more and increasingly sophisticated foundation models and large language models across biology, chemistry and translation and to use these models to drive new, better programs into clinical development both in our own pipeline and with our current and future partners at scale;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.2pt">our ability to scale like a technology company, including scaling our Recursion OS, and to add more programs to our pipeline each year; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to successfully compete in a highly competitive market; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our manufacturing, commercialization and marketing capabilities and strategies; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans relating to commercializing our drug candidates, if approved, including the geographic areas of focus and sales strategy; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding the approval and use of our drug candidates in combination with other drugs; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the rate and degree of market acceptance and clinical utility of our current drug candidates, if approved, and other drug candidates we may develop; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our competitive position and the success of competing approaches that are or may become available; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i575b7c0e32c142cfa1b028ec4e7e1359_7">Table of Contents</a></span></div></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our estimates of the number of patients that we will enroll in our clinical trials and the timing of their enrollment; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the beneficial characteristics, safety, efficacy and therapeutic effects of our drug candidates; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans for further development of our drug candidates, including additional indications we may pursue; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to adequately protect and enforce our intellectual property and proprietary technology, including the scope of protection we are able to establish and maintain for intellectual property rights covering our current drug candidates and other drug candidates we may develop, receipt of patent protection, the extensions of existing patent terms where available, the validity of intellectual property rights held by third parties, the protection of our trade secrets, and our ability not to infringe, misappropriate or otherwise violate any third-party intellectual property rights; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of any intellectual property disputes and our ability to defend against claims of infringement, misappropriation, or other violations of intellectual property rights; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to keep pace with new technological developments; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to utilize third-party open source software and cloud-based infrastructure, on which we are dependent; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the adequacy of our insurance policies and the scope of their coverage; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential impact of a pandemic, epidemic, or outbreak of an infectious disease, such as COVID-19, or natural disaster, global political instability or warfare, and the effect of such outbreak or natural disaster, global political instability or warfare on our business and financial results;  </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to maintain our technical operations infrastructure to avoid errors, delays, or cybersecurity breaches;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our continued reliance on third parties to conduct additional clinical trials of our drug candidates, and for the manufacture of our drug candidates for preclinical studies and clinical trials; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain and negotiate favorable terms of, any collaboration, licensing, or other arrangements that may be necessary or desirable to research, develop, manufacture, or commercialize our platform and drug candidates;  </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the pricing and reimbursement of our current drug candidates and other drug candidates we may develop, if approved; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our estimates regarding expenses, future revenue, capital requirements and need for additional financing;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our financial performance; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the period over which we estimate our existing cash and cash equivalents will be sufficient to fund our future operating expenses and capital expenditure requirements; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to raise substantial additional funding; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of current and future laws and regulations, and our ability to comply with all regulations that we are, or may become, subject to; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the need to hire additional personnel and our ability to attract and retain such personnel; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of any current or future litigation, which may arise during the ordinary course of business and be costly to defend;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the need to raise additional capital may cause dilution to our stockholders, restrict our operations, require us to relinquish rights to our technologies or drug candidates, and divert management&#8217;s attention from our core business; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our anticipated use of our existing resources and the net proceeds from our initial public offering; and </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other risks and uncertainties, including those listed in the section titled &#8220;Risk Factors.&#8221; </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have based these forward-looking statements largely on our current expectations and projections about our business, the industry in which we operate, and financial trends that we believe may affect our business, financial condition, results of operations and prospects. These forward-looking statements are not guarantees of future performance or development. These statements speak only as of the date of this report and are subject to a number of risks, uncertainties and assumptions described in the section titled &#8220;Risk Factors&#8221; and elsewhere in this report. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, we undertake no obligation to update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, or otherwise. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this report. While we believe such information forms a reasonable basis for such statements, the information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i575b7c0e32c142cfa1b028ec4e7e1359_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">potentially available relevant information. These statements are inherently uncertain and you are cautioned not to unduly rely upon them.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iv</span></div></div></div><div id="i575b7c0e32c142cfa1b028ec4e7e1359_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i575b7c0e32c142cfa1b028ec4e7e1359_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I - FINANCIAL INFORMATION</span></div><div><span><br/></span></div><div id="i575b7c0e32c142cfa1b028ec4e7e1359_16"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Financial Statements.</span></div><div><span><br/></span></div><div id="i575b7c0e32c142cfa1b028ec4e7e1359_19"></div><div style="text-align:center"><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recursion Pharmaceuticals, Inc. </span></div><div style="text-align:center"><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets (unaudited)</span></div><div style="text-align:center"><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(in thousands, except share and per share amounts)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.508%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.597%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current assets</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-31">296,326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-32">391,565</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:RestrictedCashCurrent" format="ixt:num-dot-decimal" scale="3" id="f-33">3,195</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:RestrictedCashCurrent" format="ixt:num-dot-decimal" scale="3" id="f-34">3,231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-35">2,599</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-36">3,094</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-37">41,495</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-38">40,247</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-39">343,615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-40">438,137</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-41">6,629</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-42">6,629</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-43">86,716</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-44">86,510</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-45">35,501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-46">33,663</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-47">33,076</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-48">36,443</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-49">52,056</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-50">52,056</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets, non-current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="f-51">254</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="f-52">261</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-53">557,847</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-54">653,699</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-55">5,115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-56">3,953</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-57">26,070</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-58">46,635</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unearned revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-59">36,618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-60">36,426</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:NotesPayableCurrent" scale="3" id="f-61">55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:NotesPayableCurrent" scale="3" id="f-62">41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-63">6,062</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-64">6,116</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-65">73,920</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-66">93,171</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unearned revenue, non-current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-67">37,391</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-68">51,238</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes payable, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LongTermNotesPayable" format="ixt:num-dot-decimal" scale="3" id="f-69">1,071</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LongTermNotesPayable" format="ixt:num-dot-decimal" scale="3" id="f-70">1,101</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, non-current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-71">43,786</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-72">43,414</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="f-73">528</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="f-74">1,339</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-75">156,696</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-76">190,263</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note&#160;7)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-4" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-77"/></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-5" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-78"/></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-79"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-80">0.00001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-81"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-82">2,000,000,000</ix:nonFraction></ix:nonFraction> shares (Class A <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-83"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-84">1,989,032,117</ix:nonFraction></ix:nonFraction> and Class B <ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-85"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-86">10,967,883</ix:nonFraction></ix:nonFraction>) authorized as of March&#160;31, 2024 and December&#160;31, 2023; <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-87"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-88">237,508,682</ix:nonFraction></ix:nonFraction> shares (Class A <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-89"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-90">230,043,061</ix:nonFraction></ix:nonFraction>, Class B <ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-91"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-92">7,464,871</ix:nonFraction></ix:nonFraction> and Exchangeable <ix:nonFraction unitRef="shares" contextRef="c-10" decimals="INF" name="us-gaap:CommonStockSharesIssued" scale="0" id="f-93"><ix:nonFraction unitRef="shares" contextRef="c-10" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="f-94">750</ix:nonFraction></ix:nonFraction>) and <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-95"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-96">234,270,384</ix:nonFraction></ix:nonFraction> shares (Class A <ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-97"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-98">226,264,764</ix:nonFraction></ix:nonFraction>, Class B <ix:nonFraction unitRef="shares" contextRef="c-9" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-99"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-100">7,544,871</ix:nonFraction></ix:nonFraction> and Exchangeable <ix:nonFraction unitRef="shares" contextRef="c-11" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-101"><ix:nonFraction unitRef="shares" contextRef="c-11" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-102">460,749</ix:nonFraction></ix:nonFraction>) issued and outstanding as of March&#160;31, 2024 and December&#160;31, 2023, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-103">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-104">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-105">1,460,144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-106">1,431,056</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-107">1,058,995</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-108">967,622</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-109">401,151</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-110">463,436</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-111">557,847</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-112">653,699</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:130%">See the accompanying notes to these c</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:130%">ondensed </span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:130%">consolidated financial statements. </span></div><div style="text-align:center"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i575b7c0e32c142cfa1b028ec4e7e1359_22"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i575b7c0e32c142cfa1b028ec4e7e1359_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recursion Pharmaceuticals, Inc. </span></div><div style="text-align:center"><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)</span></div><div style="text-align:center"><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(in thousands, except share and per share amounts)</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.952%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.375%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three months ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-113">13,491</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-114">12,134</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="f-115">303</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-116">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-117">13,794</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-118">12,134</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating costs and expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-119">11,166</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-120">12,448</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-121">67,560</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-122">46,677</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-123">31,408</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-124">22,874</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total operating costs and expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-125">110,134</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-126">81,999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-127">96,340</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-128">69,865</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-129">4,188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-130">4,538</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss before income tax benefit</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-131">92,152</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-132">65,327</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-133">779</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-134">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss and comprehensive loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-135"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-136">91,373</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-137"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-138">65,327</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Per share data</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss per share of Class A, B and Exchangeable common stock, basic and diluted</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-139"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-140">0.39</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-16" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-141"><ix:nonFraction unitRef="usdPerShare" contextRef="c-16" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-142">0.34</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-average shares (Class A, B and Exchangeable) outstanding, basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-143"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-144">236,019,349</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-16" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-145"><ix:nonFraction unitRef="shares" contextRef="c-16" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-146">191,618,238</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See the accompanying notes to these c</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ondensed</span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> consolidated financial statements. </span></div><div style="text-align:center"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i575b7c0e32c142cfa1b028ec4e7e1359_28"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i575b7c0e32c142cfa1b028ec4e7e1359_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recursion Pharmaceuticals, Inc. </span></div><div style="text-align:center"><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Stockholders&#8217; Equity (unaudited)</span></div><div style="text-align:center"><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(in thousands, except share amounts)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.027%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.367%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.469%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Common Stock </span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional Paid-in-Capital</span></div></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Deficit</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Stockholders&#8217;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Equity</span></div></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Class A, B and Exchangeable)</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares </span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount </span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance as of December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-17" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-147">234,270,384</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-148">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-149">1,431,056</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-150">967,622</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-151">463,436</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-152">91,373</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-153">91,373</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock option exercises and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-21" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-154">2,317,083</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-155">2,088</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-156">2,088</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-157">16,127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-158">16,127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock sales issuances, net of issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-21" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-159">921,215</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-160">10,873</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-161">10,873</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance as of March 31, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-23" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-162">237,508,682</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-163">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-164">1,460,144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-165">1,058,995</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-166">401,151</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.027%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.367%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.469%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Common Stock</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional Paid-in-Capital</span></div></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Deficit</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Stockholders&#8217;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Equity</span></div></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Class A, B and Exchangeable)</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares </span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount </span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-26" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-167">191,022,864</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-168">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-169">1,125,360</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-170">639,556</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-171">485,806</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-172">65,327</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-173">65,327</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock option exercises and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-31" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-174">1,207,990</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-175">882</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-176">882</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-177">8,814</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-178">8,814</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance as of March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-33" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-179">192,230,854</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-180">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-181">1,135,056</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-182">704,883</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-183">430,175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See the accompanying notes to these condensed consolidated financial statements.</span></div><div style="text-align:center"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i575b7c0e32c142cfa1b028ec4e7e1359_31"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i575b7c0e32c142cfa1b028ec4e7e1359_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recursion Pharmaceuticals, Inc. </span></div><div style="text-align:center"><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows (unaudited)</span></div><div style="text-align:center"><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(in thousands) </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.274%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.275%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three months ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from operating activities</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-184">91,373</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-185">65,327</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-186">7,377</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-187">3,728</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-188">16,127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-189">8,814</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset impairment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:TangibleAssetImpairmentCharges" scale="3" id="f-190">108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:TangibleAssetImpairmentCharges" format="ixt:num-dot-decimal" scale="3" id="f-191">1,169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="3" id="f-192">2,472</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="3" id="f-193">1,988</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="f-194">560</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="f-195">716</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other receivables and assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="3" id="f-196">1,040</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="f-197">317</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unearned revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-198">13,655</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-199">12,134</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-200">1,168</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="f-201">339</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued development expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="rxrx:IncreaseDecreaseInAccruedDevelopmentExpense" scale="3" id="f-202">273</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="rxrx:IncreaseDecreaseInAccruedDevelopmentExpense" scale="3" id="f-203">676</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-204">18,857</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-205">9,846</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-206">3,794</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-207">2,444</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-208">102,300</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-209">73,316</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-210">6,653</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-211">5,175</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase of an intangible asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireIntangibleAssets" format="ixt:fixed-zero" scale="3" id="f-212">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="3" id="f-213">165</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-214">6,653</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-215">5,340</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from issuance of common shares, net of issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-216">10,873</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="f-217">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from equity incentive plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" format="ixt:num-dot-decimal" scale="3" id="f-218">3,050</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" format="ixt:num-dot-decimal" scale="3" id="f-219">1,946</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repayment of long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" scale="3" id="f-220">26</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" scale="3" id="f-221">24</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-222">13,897</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-223">1,922</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-12pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Effect of exchange rate changes on cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="f-224">219</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="f-225">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net change in cash, cash equivalents and restricted cash</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-226">95,275</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-227">76,734</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash, beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-228">401,425</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-229">559,112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash, cash equivalents and restricted cash, end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-230">306,150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-231">482,378</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental schedule of non-cash investing and financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued property and equipment</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="f-232">80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="f-233">244</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use asset additions and modifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-234">3,266</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-235">3,520</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financed equipment purchase</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="rxrx:FinancedEquipmentPurchase" format="ixt:fixed-zero" scale="3" id="f-236">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="rxrx:FinancedEquipmentPurchase" format="ixt:num-dot-decimal" scale="3" id="f-237">1,214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental schedule of cash flow information</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for operating leases</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeasePaymentsUse" format="ixt:num-dot-decimal" scale="3" id="f-238">3,955</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:OperatingLeasePaymentsUse" format="ixt:num-dot-decimal" scale="3" id="f-239">2,444</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See the accompanying notes to these condensed consolidated financial statements.</span></div><div style="text-align:center"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i575b7c0e32c142cfa1b028ec4e7e1359_34"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i575b7c0e32c142cfa1b028ec4e7e1359_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recursion Pharmaceuticals, Inc.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements (unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div id="i575b7c0e32c142cfa1b028ec4e7e1359_37"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 1.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:NatureOfOperations" id="f-240" continuedAt="f-240-1" escape="true">Description of the Business </ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="f-240-1"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recursion Pharmaceuticals, Inc. (Recursion, the Company, we or our) was originally formed as a limited liability</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">company on November 4, 2013 under the name Recursion Pharmaceuticals, LLC. In September 2016, the Company converted to a Delaware corporation and changed its name to Recursion Pharmaceuticals, Inc.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recursion is a clinical stage TechBio company decoding biology to industrialize drug discovery. The Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe, one of the world&#8217;s largest proprietary biological and chemical datasets. The Company integrates physical and digital components as iterative loops of atoms and bits scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in silico </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hypotheses into validated insights and novel chemistry.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2024, the Company had an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-8" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="9" id="f-241">1.1</ix:nonFraction> billion. The Company expects to incur substantial operating losses in future periods and will require additional capital to advance its drug candidates. The Company does not expect to generate significant revenue until the Company successfully completes significant drug development milestones with its subsidiaries or in collaboration&#160;with third parties, which the Company expects will take a number of years. In order to commercialize its drug candidates, the Company or its partners need to complete clinical development and comply with comprehensive regulatory requirements. The Company is subject to a number of risks and uncertainties similar to those of other companies of the same size within the biotechnology industry, such as the uncertainty of clinical trial outcomes, uncertainty of additional funding and a history of operating losses. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has funded its operations to date primarily through the issuance of convertible preferred stock and the issuance of Class A common stock (see Note 8, &#8220;Common Stock&#8221; for additional details). Additionally, the Company has received payments from its strategic partnerships (see Note 9, &#8220;Collaborative Development Contracts&#8221; for additional details). Recursion will likely be required to raise additional capital. As of March&#160;31, 2024, the Company did not have any unconditional outstanding commitments for additional funding. If the Company is unable to access additional funds when needed, it may not be able to continue the development of its products or the Company could be required to delay, scale back or abandon some or all of its development programs and other operations. The Company&#8217;s ability to access capital when needed is not assured and, if not achieved on a timely basis, could materially harm its business, financial condition and results of operations. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recursion believes that the Company&#8217;s existing cash and cash equivalents will be sufficient to fund the Company&#8217;s operating expenses and capital expenditures for at least the next 12 months.</span></div></ix:continuation><div><span><br/></span></div><div id="i575b7c0e32c142cfa1b028ec4e7e1359_40"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 2. <ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="f-242" continuedAt="f-242-1" escape="true">Basis of Presentation</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="f-242-1" continuedAt="f-242-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-243" escape="true"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited interim condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (SEC). Accordingly, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) have been condensed or omitted. These unaudited interim condensed consolidated financial statements should be read in conjunction with the Company&#8217;s audited consolidated financial statements and notes for the year ended December&#160;31, 2023. </span></div><div><span><br/></span></div><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is management&#8217;s opinion that these condensed consolidated financial statements include all normal and recurring adjustments necessary for a fair presentation of the Company&#8217;s financial statements. Revenue and net loss for any interim period are not necessarily indicative of future or annual results.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-244" continuedAt="f-244-1" escape="true"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2024, the SEC issued rule 33-11275, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Enhancement and Standardization of Climate-Related Disclosures for Investors</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The new rule requires Recursion to provide certain disclosures in the footnotes to the </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i575b7c0e32c142cfa1b028ec4e7e1359_7">Table of Contents</a></span></div></div><ix:continuation id="f-244-1"><ix:continuation id="f-242-2"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">financial statements of climate-related information. These disclosures include the impact of severe weather and other natural conditions on the Company&#8217;s consolidated balance sheet and statement of operations, to the extent they are material. Recursion will also need to disclose a rollforward of the beginning and ending balances of its carbon offsets and renewable energy credits or certificates (RECs), if they are a material component of meeting the Company&#8217;s climate-related targets and goals. Additionally, the Company will need to disclose whether and, if so, how severe weather events and other natural conditions and disclosed climate-related targets or transition plans materially affected estimates and assumptions in the financial statements. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The standard&#8217;s effective dates, if adopted, will be phased in depending on the disclosure requirement starting the annual period ending December&#160;31, 2025. In April 2024, the SEC voluntarily stayed implementation of the new climate-related disclosure requirements pending judicial review. The Company is currently evaluating the impact this rule will have on its consolidated financial statements and related disclosures.   </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2023-9, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The new standard updates disclosure requirements for Accounting Standards Codification (ASC) 740 primarily by requiring additional information in the income tax rate reconciliation and additional disclosures about income taxes paid. This standard will be effective for Recursion starting the annual period ending December 31, 2025. Early adoption is permitted for annual financial statements that have not yet been issued. The amendments can be applied on a prospective or retrospective basis. The adoption of this standard will not impact Recursion&#8217;s consolidated balance sheet and statement of operations.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU No. 2023-7, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The standard requires new disclosures related to ASC 280 including: disclosing significant segment expenses by category; requiring all the ASC 280 disclosures for Companies with a single reportable segment and; requiring an increased frequency of the ASC 280 disclosures. Recursion must apply the amendments retrospectively to each prior reporting period presented. This standard will be effective for Recursion starting the annual period ending December 31, 2024. Early adoption is permitted. The adoption of this standard will not impact Recursion&#8217;s consolidated balance sheet and statement of operations.</span></div></ix:continuation></ix:continuation><div><span><br/></span></div><div id="i575b7c0e32c142cfa1b028ec4e7e1359_43"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 3.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="rxrx:SupplementalBalanceSheetAndIncomeStatementInformationTextBlock" id="f-245" continuedAt="f-245-1" escape="true">Supplemental Financial Information </ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="f-245-1" continuedAt="f-245-2"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Tempus agreement</span></div><div><span><br/></span></div><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">November 2023</span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Recursion entered into a </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-37" name="rxrx:LicenseAgreementTerm" format="ixt-sec:durwordsen" id="f-246" continuedAt="f-246-1">five</ix:nonNumeric></span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-246-1">-year</ix:continuation> agreement with Tempus Labs, Inc. (Tempus) to purchase access to their records of patient-centric multimodal oncology data and use rights for therapeutic development purposes. This data will be used to improve the training of Recursion&#8217;s artificial intelligence and machine learning models and is expected to accelerate Recursion&#8217;s drug discovery process. Recursion is making annual payments, ranging between </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-5" name="rxrx:LicenseAgreementAnnualPayments" format="ixt:num-dot-decimal" scale="6" id="f-247">22.0</ix:nonFraction>&#160;million</span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-5" name="rxrx:LicenseAgreementAnnualPayments" format="ixt:num-dot-decimal" scale="6" id="f-248">42.0</ix:nonFraction>&#160;million</span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, up to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-5" name="rxrx:LicenseAgreementAggregatePayments" format="ixt:num-dot-decimal" scale="6" id="f-249">160.0</ix:nonFraction>&#160;million</span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in aggregate, to Tempus in cash or equity at the Company&#8217;s option. The equity value is determined by using the <span style="-sec-ix-hidden:f-250">seven</span>-trading day period dollar volume-weighted average price (VWAP) for Recursion Class A common stock ending on the day immediately preceding the date that is five business days prior to the payment date. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recursion is expensing the record purchases as &#8220;Research and Development&#8221; expenses in the Condensed Consolidated Statements of Operations as the records are purchased. To the extent that the Recursion payments to Tempus are greater than or less than the records purchased amount, Recursion records the applicable amount to &#8220;Other Current Assets&#8221; or &#8220;Accrued Expenses and Other Liabilities&#8221; on the Condensed Consolidated Balance Sheet, respectively. As of March&#160;31, 2024, Recursion had recorded $<ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-5" name="rxrx:LicenseAgreementPrepaidExpenses" format="ixt:num-dot-decimal" scale="6" id="f-251">16.0</ix:nonFraction>&#160;million within &#8220;Other Current Assets&#8221; on the Consolidated Balance Sheet related to the Tempus agreement.     </span></div></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i575b7c0e32c142cfa1b028ec4e7e1359_7">Table of Contents</a></span></div></div><ix:continuation id="f-245-2" continuedAt="f-245-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="f-252" escape="true"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.521%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-253">61,247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-254">60,096</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-255">46,289</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-256">45,929</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-257">22,356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-258">22,126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-259">5,677</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-260">3,231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-261">135,569</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-262">131,382</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-263">48,853</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-264">44,872</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-265">86,716</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-266">86,510</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense on property and equipment was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="f-267">4.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="f-268">3.6</ix:nonFraction>&#160;million during the three months ended March 31, 2024 and 2023, respectively</span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company recorded an insignificant impairment and an impairment of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:ImpairmentOfLeasehold" format="ixt:num-dot-decimal" scale="6" id="f-269">1.2</ix:nonFraction>&#160;million </span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">during the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended March 31, 2024 and 2023, respectively,</span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> related to construction projects for leasehold improvements as the Company no longer intended to use them. The impairment was recorded in &#8220;General and Administrative&#8221; in the Condensed Consolidated Statements of Operations.   </span></div><div><span><br/></span></div><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended March 31, 2023, the </span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company initiated and completed a project to upgrade the BioHive supercomputer for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-270">1.7</ix:nonFraction>&#160;million</span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The supercomputer was classified as office equipment in the above table.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="f-271" escape="true"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses and Other Liabilities</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.521%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-272">10,055</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-273">22,888</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="rxrx:AccruedDevelopmentCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-274">5,804</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="rxrx:AccruedDevelopmentCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-275">6,077</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued early discovery expenses</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="rxrx:AccruedEarlyDiscoveryExpensesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-276">2,610</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="rxrx:AccruedEarlyDiscoveryExpensesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-277">2,570</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued construction</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ConstructionPayableCurrent" format="ixt:fixed-zero" scale="3" id="f-278">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ConstructionPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-279">2,439</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Materials received not invoiced</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="rxrx:MaterialsReceivedNotInvoiced" format="ixt:num-dot-decimal" scale="3" id="f-280">1,184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="rxrx:MaterialsReceivedNotInvoiced" format="ixt:num-dot-decimal" scale="3" id="f-281">2,432</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued other expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-282">6,417</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-283">10,229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expense and other liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-284">26,070</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-285">46,635</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Notes Payable</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, the Company entered into a financing agreement for borrowing $<ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-286">1.9</ix:nonFraction> million as part of the supercomputer upgrade project. The debt will be repaid over a <ix:nonNumeric contextRef="c-50" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="f-287">three-year</ix:nonNumeric> period at a <ix:nonFraction unitRef="number" contextRef="c-51" decimals="2" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-288">7</ix:nonFraction>% interest rate. As of March&#160;31, 2024, the outstanding balance was $<ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="3" id="f-289">616</ix:nonFraction> thousand. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, the Company borrowed $<ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-290">992</ix:nonFraction> thousand, which was available as part of a lease agreement for use on tenant improvements. The note will be repaid over a <ix:nonNumeric contextRef="c-53" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:duryear" id="f-291">10</ix:nonNumeric>-year period at an <ix:nonFraction unitRef="number" contextRef="c-54" decimals="2" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-292">8</ix:nonFraction>% interest rate. As of March&#160;31, 2024, the outstanding balance was $<ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="3" id="f-293">510</ix:nonFraction> thousand.</span></div></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i575b7c0e32c142cfa1b028ec4e7e1359_7">Table of Contents</a></span></div></div><ix:continuation id="f-245-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock" id="f-294" escape="true"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Income, net</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InvestmentIncomeNonoperating" format="ixt:num-dot-decimal" scale="3" id="f-295">4,048</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:InvestmentIncomeNonoperating" format="ixt:num-dot-decimal" scale="3" id="f-296">4,660</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="f-297">20</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="f-298">19</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestRevenueExpenseNet" format="ixt:num-dot-decimal" scale="3" id="f-299">4,028</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:InterestRevenueExpenseNet" format="ixt:num-dot-decimal" scale="3" id="f-300">4,641</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2024 and 2023, interest income primarily related to earnings on cash and cash equivalents in money market funds. Interest income was included in &#8220;Other income, net&#8221; on the Condensed Consolidated Statements of Operations.</span></div></ix:continuation><div><span><br/></span></div><div id="i575b7c0e32c142cfa1b028ec4e7e1359_46"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 4. <ix:nonNumeric contextRef="c-1" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="f-302" continuedAt="f-302-1" escape="true">Acquisitions</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="f-302-1" continuedAt="f-302-2"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Valence Discovery Inc.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;16, 2023, Recursion acquired all of the outstanding equity interests in Valence Discovery Inc. (Valence), a privately-held machine learning (ML) / artificial intelligence (AI) digital chemistry company. The integration of Valence&#8217;s AI-based chemistry engine into Recursion&#8217;s operating system will allow Recursion to expand its technology-enabled drug discovery process. This will accelerate Recursion&#8217;s digital chemistry capabilities and its drug discovery process.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition of Valence was accounted for as a business combination using the acquisition method of accounting. The aggregate upfront consideration for the acquisition of Valence consisted of <ix:nonFraction unitRef="shares" contextRef="c-56" decimals="-5" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" format="ixt:num-dot-decimal" scale="6" id="f-303">2.2</ix:nonFraction> million shares of Recursion Class A common stock, <ix:nonFraction unitRef="shares" contextRef="c-57" decimals="-5" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" format="ixt:num-dot-decimal" scale="6" id="f-304">4.4</ix:nonFraction> million shares of a subsidiary of Recursion, exchangeable for shares of Recursion&#8217;s Class A common stock, <ix:nonFraction unitRef="shares" contextRef="c-58" decimals="-3" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" format="ixt:num-dot-decimal" scale="3" id="f-305">792</ix:nonFraction> thousand shares issuable upon exercise of stock options held by Valence equity award holders and deferred liabilities for additional consideration. An insignificant number of the aforementioned shares of consideration had not yet been issued as of March&#160;31, 2024.The final number of shares to be issued has not yet been finalized and so are subject to change. </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" id="f-306" continuedAt="f-306-1" escape="true"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes total consideration:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"><tr><td style="width:1.0%"/><td style="width:78.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.229%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of Recursion Class A common stock </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="rxrx:BusinessCombinationConsiderationTransferredEquityInterestsIssuable" format="ixt:num-dot-decimal" scale="3" id="f-307">11,096</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of Exchangeable stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" name="rxrx:BusinessCombinationConsiderationTransferredEquityInterestsIssuable" format="ixt:num-dot-decimal" scale="3" id="f-308">22,473</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of equity awards issued to Valance equity award holders</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="rxrx:BusinessCombinationConsiderationTransferredEquityInterestsIssuable" format="ixt:num-dot-decimal" scale="3" id="f-309">1,933</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred liabilities for additional consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" scale="3" id="f-310">396</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total consideration</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="3" id="f-311">35,898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="f-312" continuedAt="f-312-1" escape="true"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value of assets acquired and liabilities assumed as of the acquisition date:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"><tr><td style="width:1.0%"/><td style="width:78.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.229%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-313">4,235</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" name="rxrx:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherReceivables" scale="3" id="f-314">536</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible asset - technology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="3" id="f-315">15,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" scale="3" id="f-316">872</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-317">3,265</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="3" id="f-318">15,634</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-319">20,264</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired and liabilities assumed</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="3" id="f-320">35,898</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i575b7c0e32c142cfa1b028ec4e7e1359_7">Table of Contents</a></span></div></div><div><span><br/></span></div><ix:continuation id="f-302-2" continuedAt="f-302-3"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intangible asset related to Valence&#8217;s ML and AI digital chemistry platform. The estimated fair value of the intangible asset was determined using a cost approach. This valuation technique provides the fair value of an asset based on estimates of the total costs to develop the technology. Significant inputs used to determine the total cost includes the length of time required and service hours performed by Company employees. The technology intangible asset is being amortized on a straight-line basis over its <ix:nonNumeric contextRef="c-62" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:durwordsen" id="f-321">four-year</ix:nonNumeric> useful life.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill was calculated as the excess of the consideration transferred over the net assets recognized. The goodwill recognized represents the assembled workforce and expected synergies, including the ability to: (i) leverage Valence&#8217;s digital chemistry platform across Recursion&#8217;s business; (ii) leverage Valence&#8217;s ML and AI capabilities; (iii) integrate Recursion&#8217;s data and operating system into Valence&#8217;s platform; and (iv) accelerate Recursion&#8217;s pipeline. Goodwill was also impacted by the establishment of a deferred tax liability for the acquired identifiable intangible assets which have no tax basis. The goodwill is not deductible for tax purposes.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recursion&#8217;s condensed consolidated statement of operations during the three months ended March 31, 2024 included <ix:nonFraction unitRef="usd" contextRef="c-63" decimals="INF" name="us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" format="ixt:fixed-zero" scale="0" id="f-322">no</ix:nonFraction> net revenue and a $<ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-5" sign="-" name="us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" format="ixt:num-dot-decimal" scale="6" id="f-323">2.9</ix:nonFraction>&#160;million operating loss associated with Valence&#8217;s operations. As the acquisition occurred in May 2023, the Company is still finalizing the allocation of the purchase price to the individual assets acquired and liabilities assumed. The allocation of the purchase price included in the current period balance sheet is based on the best estimate of management and is preliminary and subject to change. The primary area subject to change relates to the valuation of other receivables. To assist management in the allocation, the Company engaged external specialists. The Company will finalize the amounts recognized as the information necessary to complete the analysis is obtained. The Company expects to finalize these amounts as soon as possible but no later than one year from the acquisition date.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cyclica Inc</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;25, 2023, Recursion acquired all of the outstanding equity interests in Cyclica Inc. (Cyclica), a privately-held Company that has built a digital chemistry software suite which enables mechanism of action deconvolution and generative chemistry suggestions based on desired targets. Cyclica&#8217;s platform is expected to enhance the optimization of Recursion&#8217;s compounds for efficacy while minimizing liabilities through generative machine learning approaches. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition of Cyclica was accounted for as a business combination using the acquisition method of accounting. The aggregate upfront consideration for the acquisition of Cyclica consisted of <ix:nonFraction unitRef="shares" contextRef="c-64" decimals="-5" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" format="ixt:num-dot-decimal" scale="6" id="f-324">5.8</ix:nonFraction> million shares of Recursion Class A common stock, cash payments, <ix:nonFraction unitRef="shares" contextRef="c-65" decimals="-5" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" format="ixt:num-dot-decimal" scale="6" id="f-325">1.0</ix:nonFraction> million shares issuable upon exercise of stock options held by Cyclica equity award holders and deferred liabilities for additional consideration. Approximately <ix:nonFraction unitRef="shares" contextRef="c-66" decimals="-3" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" format="ixt:num-dot-decimal" scale="3" id="f-326">182</ix:nonFraction> thousand of the aforementioned shares of Class A common stock consideration had not yet been issued as of March&#160;31, 2024. </span></div><div><span><br/></span></div><ix:continuation id="f-306-1"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes total consideration:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"><tr><td style="width:1.0%"/><td style="width:78.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.229%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of Recursion Class A common stock </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" name="rxrx:BusinessCombinationConsiderationTransferredEquityInterestsIssuable" format="ixt:num-dot-decimal" scale="3" id="f-327">49,915</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="3" id="f-328">6,505</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of equity awards issued to Cyclica equity award holders</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" name="rxrx:BusinessCombinationConsiderationTransferredEquityInterestsIssuable" format="ixt:num-dot-decimal" scale="3" id="f-329">3,852</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred liabilities for additional consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" scale="3" id="f-330">344</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total consideration</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="3" id="f-331">60,617</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i575b7c0e32c142cfa1b028ec4e7e1359_7">Table of Contents</a></span></div></div><ix:continuation id="f-302-3" continuedAt="f-302-4"><ix:continuation id="f-312-1"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value of assets acquired and liabilities assumed as of the acquisition date:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"><tr><td style="width:1.0%"/><td style="width:78.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.229%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-332">2,429</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="rxrx:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" format="ixt:num-dot-decimal" scale="3" id="f-333">1,685</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="rxrx:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherReceivables" scale="3" id="f-334">741</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="rxrx:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInvestments" format="ixt:num-dot-decimal" scale="3" id="f-335">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" scale="3" id="f-336">385</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets - technology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="3" id="f-337">28,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" scale="3" id="f-338">579</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unearned revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" format="ixt:num-dot-decimal" scale="3" id="f-339">1,754</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-340">2,075</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities, current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="rxrx:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilitiesCurrent" scale="3" id="f-341">66</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" scale="3" id="f-342">139</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="3" id="f-343">29,627</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-344">30,990</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired and liabilities assumed</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="3" id="f-345">60,617</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intangible assets are related to Cyclica&#8217;s digital chemistry platforms. The estimated fair value of the intangible assets were determined using a cost approach. This valuation technique provides the fair value of an asset based on estimates of the total costs to develop the technology. Significant inputs used to determine the total cost includes the length of time required and service hours performed by Company employees. The technology intangible assets are being amortized on a straight-line basis over their <ix:nonNumeric contextRef="c-70" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:durwordsen" id="f-346">three-year</ix:nonNumeric> useful lives.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill was calculated as the excess of the consideration transferred over the net assets recognized. The goodwill recognized represents the assembled workforce and expected synergies, including the ability to: (i) leverage Cyclica&#8217;s digital chemistry platform across Recursion&#8217;s business; (ii) leverage Cyclica&#8217;s ML and AI capabilities; (iii) integrate Recursion&#8217;s data and operating system into Cyclica&#8217;s platform; and (iv) accelerate Recursion&#8217;s pipeline. Goodwill was also impacted by the establishment of a deferred tax liability for the acquired identifiable intangible assets. The goodwill is not deductible for tax purposes.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recursion&#8217;s condensed consolidated statement of operations during the three months ended March 31, 2024 included immaterial net revenue and a $<ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-5" sign="-" name="us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" format="ixt:num-dot-decimal" scale="6" id="f-347">3.8</ix:nonFraction> million operating loss associated with Cyclica&#8217;s operations. As the acquisition occurred in May 2023, the Company is still finalizing the allocation of the purchase price to the individual assets acquired and liabilities assumed. The allocation of the purchase price included in the current period balance sheet is based on the best estimate of management and is preliminary and subject to change. The primary area subject to change relates to the valuation of the other receivables. To assist management in the allocation, the Company engaged external specialists. The Company will finalize the amounts recognized as the information necessary to complete the analysis is obtained. The Company expects to finalize these amounts as soon as possible but no later than one year from the acquisition date.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pro forma financial information  </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:BusinessAcquisitionProFormaInformationTextBlock" id="f-348" escape="true"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the unaudited pro forma combined results of operations of Recursion, Valence and Cyclica as if the acquisitions had occurred on January&#160;1, 2022:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.123%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended March 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenue</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-3" name="us-gaap:BusinessAcquisitionsProFormaRevenue" format="ixt:num-dot-decimal" scale="3" id="f-349">12,155</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-3" sign="-" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-350">73,514</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i575b7c0e32c142cfa1b028ec4e7e1359_7">Table of Contents</a></span></div></div><ix:continuation id="f-302-4"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited pro forma financial information was prepared using the acquisition method of accounting and was based on the historical financial information of Recursion, Valence and Cyclica. In order to reflect the occurrence of the acquisitions on January&#160;1, 2022 as required, the unaudited pro forma financial information includes adjustments to reflect the incremental amortization expense to be incurred based on the fair values of the identifiable intangible assets acquired and the additional stock compensation expense associated with the issuance of equity compensation related to the acquisitions. The unaudited pro forma financial information is not necessarily indicative of what the consolidated results of operations would have been had the acquisitions been completed on January&#160;1, 2022. In addition, the unaudited pro forma financial information is not a projection of the future results of operations of the combined company nor does it reflect the expected realization of any cost savings or synergies associated with the acquisitions.</span></div></ix:continuation><div><span><br/></span></div><div id="i575b7c0e32c142cfa1b028ec4e7e1359_49"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 5.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeasesTextBlock" id="f-351" continuedAt="f-351-1" escape="true">Leases </ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="f-351-1" continuedAt="f-351-2"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into various long-term real estate leases primarily related to office, research and development and operating activities. The Company&#8217;s leases have remaining terms from under <ix:nonNumeric contextRef="c-73" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:duryear" id="f-352">1</ix:nonNumeric> to <ix:nonNumeric contextRef="c-74" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:duryear" id="f-353">9</ix:nonNumeric> years and some of those leases include options that provide Recursion with the ability to extend the lease term for <ix:nonNumeric contextRef="c-4" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="f-354">five years</ix:nonNumeric>. The options are included in the lease term when it is reasonably certain that the option will be exercised. </span></div><div><span><br/></span></div><div style="margin-bottom:3pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:130%">For the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:130%">three months ended March 31, 2024 and 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:130%">, Recursion entered into lease modifications resulting in a decrease to the right-of-use asset and lease liability of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="rxrx:LesseeOperatingLeaseIncreaseDecreaseInOperatingLeaseLiabilityDueToLeaseModifications" format="ixt:num-dot-decimal" scale="6" id="f-355"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="rxrx:IncreaseDecreaseInOperatingLeaseRightOfUseAssets" format="ixt:num-dot-decimal" scale="6" id="f-356">3.1</ix:nonFraction></ix:nonFraction> million and an increase to the right-of-use asset and lease liability $<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="rxrx:IncreaseDecreaseInOperatingLeaseRightOfUseAssets" format="ixt:num-dot-decimal" scale="6" id="f-357"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="rxrx:LesseeOperatingLeaseIncreaseDecreaseInOperatingLeaseLiabilityDueToLeaseModifications" format="ixt:num-dot-decimal" scale="6" id="f-358">3.5</ix:nonFraction></ix:nonFraction> million</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:130%">, respectively</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:130%">. The modifications had no impact to the Condensed Consolidated Statements of Operations. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In </span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">January 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company entered into a lease agreement for office space in London, England with approximately </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="sqft" contextRef="c-75" decimals="0" name="rxrx:LesseeOperatingLeaseSquareFootageOfLeasedSpace" format="ixt:num-dot-decimal" scale="0" id="f-359">6,792</ix:nonFraction> </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">square feet (the &#8220;London Lease&#8221;). The right of use began </span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">January 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> when the control of the asset was obtained. The London Lease term is </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-76" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="f-360">5</ix:nonNumeric> years</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with a <ix:nonNumeric contextRef="c-76" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="f-361">five-year</ix:nonNumeric> renewal option. The London Lease includes provisions for escalating rent payments. Total fixed payments are expected to be approximately $<ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="6" id="f-362">7.9</ix:nonFraction> million, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">additionally there will be variable expenses including building service charges related to the lease.</span></div><div><span><br/></span></div><div style="margin-bottom:3pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:130%">In </span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:130%">February 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:130%">, the Company entered into a lease agreement for the supercomputer for the exclusive use of physical space in a data center of approximately </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="sqft" contextRef="c-77" decimals="0" name="rxrx:LesseeOperatingLeaseSquareFootageOfLeasedSpace" format="ixt:num-dot-decimal" scale="0" id="f-363">1,851</ix:nonFraction> square feet (</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:130%">the &#8220;Data Center Lease&#8221;). The right of use is expected to begin in the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:130%">second quarter of 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:130%"> and the Data Center Lease term is </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonNumeric contextRef="c-78" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="f-364">5</ix:nonNumeric> years</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:130%"> with a <ix:nonNumeric contextRef="c-78" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="f-365">five-year</ix:nonNumeric> renewal option. The lease includes provisions for escalating rent payments. Total fixed lease payments are expected to be approximately $<ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="6" id="f-366">13.0</ix:nonFraction> million with additional variable expenses, including utilities and tax expenses. The Company did not control the space or any of the assets being constructed as of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:130%">March&#160;31, 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:130%"> and therefore no right of use asset or lease liability was recorded on the Condensed Consolidated Balance Sheet as of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:130%">March&#160;31, 2024.</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:130%"> </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LeaseCostTableTextBlock" id="f-367" escape="true"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the lease cost were:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.613%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.544%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-368">2,472</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-369">1,998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="f-370">538</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="f-371">657</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease cost</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShortTermLeaseCost" scale="3" id="f-372">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:ShortTermLeaseCost" format="ixt:fixed-zero" scale="3" id="f-373">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease cost</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-374">3,050</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-375">2,655</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The remaining lease term and discount rate were:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.222%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-4" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-376">6.4</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-4" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-377">7.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i575b7c0e32c142cfa1b028ec4e7e1359_7">Table of Contents</a></span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="f-378" escape="true"><ix:continuation id="f-351-2"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of operating lease liabilities as of March&#160;31, 2024 were:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.392%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating leases</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="f-379">7,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-380">10,748</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-381">10,882</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="f-382">11,281</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="f-383">8,850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="rxrx:LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour" format="ixt:num-dot-decimal" scale="3" id="f-384">16,948</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="f-385">66,009</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="f-386">16,161</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-387">49,848</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div><span><br/></span></div><div id="i575b7c0e32c142cfa1b028ec4e7e1359_52"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 6.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="f-388" continuedAt="f-388-1" escape="true">Goodwill and Intangible Assets </ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="f-388-1" continuedAt="f-388-2"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="INF" name="us-gaap:GoodwillPeriodIncreaseDecrease" format="ixt:fixed-zero" scale="0" id="f-389"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:GoodwillPeriodIncreaseDecrease" format="ixt:fixed-zero" scale="0" id="f-390">no</ix:nonFraction></ix:nonFraction> changes to the carrying amount of goodwill during the three months ended March 31, 2024 and 2023. <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="f-391"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="f-392">No</ix:nonFraction></ix:nonFraction> goodwill impairment was recorded during the three months ended March 31, 2024 and 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets, Net</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="f-394" escape="true"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" id="f-393" escape="true"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes intangible assets:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.268%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.888%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross carrying amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net carrying amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross carrying amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net carrying amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Definite-lived intangible assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-395">44,426</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-396">12,336</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-397">32,090</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-398">44,426</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-399">8,969</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-400">35,457</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite-lived intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="3" id="f-401">986</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="3" id="f-402">986</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="3" id="f-403">986</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="3" id="f-404">986</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-405">45,412</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-406">12,336</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-407">33,076</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-408">45,412</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-409">8,969</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-410">36,443</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-388-2">Amortization expense was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-411">3.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-412">152</ix:nonFraction> thousand during the three months ended March 31, 2024 and 2023, respectively. The increase in amortization expense was due to the intangible assets purchased in the acquisitions, (see Note 4, &#8220;Acquisitions&#8221; for additional details). Amortization expense was included in Research and Development in the Condensed Consolidated Statements of Operations. <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="INF" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:fixed-zero" scale="0" id="f-413"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:fixed-zero" scale="0" id="f-414">No</ix:nonFraction></ix:nonFraction> indefinite-lived intangible asset impairment charges were recorded during the three months ended March 31, 2024 and 2023.</ix:continuation>  </span></div><div><span><br/></span></div><div id="i575b7c0e32c142cfa1b028ec4e7e1359_55"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 7. <ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-415" continuedAt="f-415-1" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="f-415-1" continuedAt="f-415-2"><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contract Obligations</span></div><div><span><br/></span></div><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company enters into contracts with clinical research organizations, drug manufacturers and other vendors&#160;for preclinical and clinical research studies, research and development supplies and other services and products for operating purposes. These contracts generally provide for termination on notice and are cancellable contracts.</span></div><div><span><br/></span></div><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnification </span></div><div><span><br/></span></div><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has agreed to indemnify its officers and directors for certain events or occurrences, while the officer or director is or was serving at the Company&#8217;s request in such capacity. The Company purchases directors and officers liability insurance coverage that provides for reimbursement to the Company for covered obligations and this is intended to limit the Company&#8217;s exposure and enable it to recover a portion of any amounts it pays under its </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i575b7c0e32c142cfa1b028ec4e7e1359_7">Table of Contents</a></span></div></div><ix:continuation id="f-415-2"><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">indemnification obligations. The Company had <ix:nonFraction unitRef="usd" contextRef="c-4" decimals="INF" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:fixed-zero" scale="0" id="f-416"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="INF" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:fixed-zero" scale="0" id="f-417">no</ix:nonFraction></ix:nonFraction> liabilities recorded for these agreements as of March&#160;31, 2024 and December&#160;31, 2023, as no amounts were probable. </span></div><div><span><br/></span></div><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Agreements </span></div><div><span><br/></span></div><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has signed employment agreements with certain key employees pursuant to which, if their employment is terminated following a change of control of the Company, the employees are entitled to receive certain benefits, including accelerated vesting of equity incentives. </span></div><div><span><br/></span></div><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Matters </span></div><div><span><br/></span></div><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may, from time to time, be involved in various legal proceedings arising in the normal course of business. An unfavorable resolution of any such matter could materially affect the Company&#8217;s future financial position, results of operations or cash flows. </span></div><div><span><br/></span></div><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, the Company entered into a lease agreement for laboratory and office space (the Industry Lease) with Industry Office SLC, LLC (the landlord). In March 2023, the Company sent a letter to the landlord detailing numerous construction delays and irregularities, deficiencies and deviations from applicable structural drawings and/or non-conforming conditions with applicable building codes. On June&#160;23, 2023, the landlord filed a lawsuit against the Company (</span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Industry Office SLC, LLC v. Recursion Pharmaceuticals, Inc.</span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 230904627) in the Third District Court for Salt Lake County, State of Utah (the Court), alleging anticipatory repudiation and breach of contract. The Plaintiff seeks monetary damages and attorney&#8217;s fees. In July 2023, the Company filed a motion to dismiss. In September 2023, Recursion was granted its motion to dismiss, and the Court provided the landlord until October&#160;23, 2023, to amend and re-file the dismissed complaint. On October&#160;23, 2023, the landlord filed an amended complaint again alleging anticipatory repudiation, breach of contract and breach of the implied covenant of good faith and fair dealing (the Amended Complaint) and seeks monetary damages and attorney&#8217;s fees. In November 2023, the Company filed a motion to dismiss the Amended Complaint. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Court set a hearing on the Company&#8217;s motion to dismiss in </span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">May 2024. As of</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2024, the Company had <ix:nonFraction unitRef="usd" contextRef="c-4" decimals="INF" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:fixed-zero" scale="0" id="f-418">no</ix:nonFraction> liability recorded for these events as an unfavorable outcome was not probable.</span></div><div><span><br/></span></div><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Industry Lease, in September 2023, the Company filed claims in the Court against the landlord alleging, among other things, breach of contract and fraudulent misrepresentation (the Counterclaims). In October 2023, the landlord filed an answer and denied the Company&#8217;s allegations asserted in the Counterclaims. The Company and the landlord are currently engaged in discovery. On October&#160;27, 2023, the Company filed a motion for partial judgment on the pleadings, seeking judgment on one of its <ix:nonFraction unitRef="claim" contextRef="c-79" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt-sec:numwordsen" scale="0" id="f-419">four</ix:nonFraction> counterclaims. The Court set a hearing on the Company&#8217;s motion for partial judgment on the pleadings in May 2024. The Company is unable to estimate the possible amount or range of amounts associated with the Counterclaims.</span></div></ix:continuation><div><span><br/></span></div><div id="i575b7c0e32c142cfa1b028ec4e7e1359_58"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 8. <ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-420" continuedAt="f-420-1" escape="true">Common Stock </ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="f-420-1" continuedAt="f-420-2"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each share of Class A common stock entitles the holder to <ix:nonFraction unitRef="vote" contextRef="c-6" decimals="INF" name="rxrx:CommonStockVotePerShare" format="ixt-sec:numwordsen" scale="0" id="f-421">one</ix:nonFraction> vote per share and each share of Class B common stock entitles the holder to <ix:nonFraction unitRef="vote" contextRef="c-8" decimals="INF" name="rxrx:CommonStockVotePerShare" scale="0" id="f-422">10</ix:nonFraction> votes per share on all matters submitted to a vote of the Company&#8217;s stockholders. Common stockholders are entitled to receive dividends, as may be declared by the Company&#8217;s Board of Directors. As of March&#160;31, 2024 and December&#160;31, 2023, <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:DividendsStock" format="ixt:fixed-zero" scale="0" id="f-423"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="INF" name="us-gaap:DividendsStock" format="ixt:fixed-zero" scale="0" id="f-424">no</ix:nonFraction></ix:nonFraction> dividends had been declared. </span></div><div><span><br/></span></div><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">At-The-Market Offering</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In </span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">August 2023</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company entered into an Open Market Sales Agreement (the &#8220;Sales Agreement&#8221;) with Jefferies LLC (the &#8220;Sales Agent&#8221;), to provide for the offering, issuance and sale of up to an aggregate amount of </span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-5" name="rxrx:SaleOfStockValueAuthorized" format="ixt:num-dot-decimal" scale="6" id="f-425">300.0</ix:nonFraction> million</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of its Class A common stock from time to time in &#8220;at-the-market&#8221; (ATM) offerings. As of&#160;March&#160;31, 2024, an amount of </span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-5" name="rxrx:SaleOfStockValueRemainingAuthorized" format="ixt:num-dot-decimal" scale="6" id="f-426">208.2</ix:nonFraction> million</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> remained available for future sales under the Sales Agreement. For the three months ended March 31, 2024, the Company has sold </span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-83" decimals="-3" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="3" id="f-427">921</ix:nonFraction>&#160;thousand</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shares and received net proceeds of </span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-428">10.9</ix:nonFraction> million</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> under the agreement. Recursion is not required to sell additional shares under the Sales Agreement. The Company will pay the Sales Agent a commission of up to <ix:nonFraction unitRef="number" contextRef="c-83" decimals="2" name="rxrx:SaleOfStockPercentageOfCommission" scale="-2" id="f-429">3</ix:nonFraction>% of the aggregate gross proceeds received from all sales of Class A common stock. The Sales Agreement continues until the earlier of selling all shares available under the Sales Agreement or terminated by written notice from either of the parties. The ATM Offering is being made under a prospectus supplement dated August&#160;8, 2023, and related prospectus filed with the Securities and Exchange </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i575b7c0e32c142cfa1b028ec4e7e1359_7">Table of Contents</a></span></div></div><ix:continuation id="f-420-2" continuedAt="f-420-3"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commission pursuant to our automatically effective shelf registration statement on Form S-3ASR (Registration No. 333-264845). </span></div><div><span><br/></span></div><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NVIDIA Private Placement</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In </span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">July 2023</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Recursion entered into a Stock Purchase Agreement for a private placement with NVIDIA Corporation (2023 Private Placement), pursuant to which the Company sold an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-84" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="6" id="f-430">7.7</ix:nonFraction> million shares of the Company&#8217;s Class A common stock at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-85" decimals="2" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="f-431">6.49</ix:nonFraction> per share for net proceeds of approximately </span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" format="ixt:num-dot-decimal" scale="6" id="f-432">49.9</ix:nonFraction> million. </span></div><div><span><br/></span></div><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Valence Acquisition Exchangeable Shares</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In </span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">May 2023</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in connection with the acquisition of Valence, the Company entered into an agreement to issue up to <ix:nonFraction unitRef="shares" contextRef="c-57" decimals="-5" name="rxrx:BusinessAcquisitionContingentConsiderationEquityInterestsIssuableNumberOfShares" format="ixt:num-dot-decimal" scale="6" id="f-433">5.9</ix:nonFraction> million shares of Class A common stock (the &#8220;Exchange Shares&#8221;), that may be issued upon exchange, retraction or redemption of exchangeable shares of a subsidiary of Recursion. Each exchangeable share of the subsidiary of Recursion entitles the holder to exchange those shares on a <ix:nonFraction unitRef="number" contextRef="c-87" decimals="INF" name="rxrx:CommonStockConversionRatio" format="ixt-sec:numwordsen" scale="0" id="f-434">one</ix:nonFraction>-for-one basis for Recursion&#8217;s Class A common stock. The shares are entitled to receive dividends economically equivalent to dividends declared by Recursion, are non-voting and are subject to customary adjustments for stock splits or other reorganizations. In addition, the Company may require all outstanding exchangeable shares to be exchanged into an equal number of Class A common stock upon the occurrence of certain events and at any time following the seventh anniversary of the closing of the Valence acquisition. The exchangeable shares are substantially the economic equivalent of the Class A shares and classified as common stock within the Company&#8217;s stockholders&#8217; equity. The Company&#8217;s calculation of weighted-average shares outstanding includes the exchangeable shares. As of March&#160;31, 2024, <ix:nonFraction unitRef="shares" contextRef="c-88" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="6" id="f-435">4.2</ix:nonFraction>&#160;million Exchangeable shares have been redeemed for Class A shares.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Registration Rights Agreements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Tempus agreement</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In </span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">November 2023</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in connection with the Tempus Agreement, the Company agreed to prepare and file a registration statement (or a prospectus supplement to an effective registration statement on Form S-3ASR that will become automatically effective upon filing with the SEC pursuant to Rule 462(e)) with the SEC, for resale of the shares of Class A common stock issued or issuable under the Tempus Agreement. A prospectus supplement to a registration statement (File No. 333-264845) was subsequently filed in </span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 2023</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to register shares issued to Tempus for the initial license fee under the Tempus Agreement for resale. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">After registration of any shares issued to Tempus under the Tempus Agreement, the Company has agreed to use commercially reasonable efforts to keep such registration statement effective until such date that all shares issued to Tempus covered by such registration statement have been sold or are able to be publicly sold by relying on Rule 144 of the Securities Act without registration.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">NVIDIA Private Placement</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In </span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">July 2023</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in connection with the 2023 Private Placement with NVIDIA, the Company entered into a Registration Rights Agreement providing for the registration for resale of the shares of Class A common stock issued in such transaction. A prospectus supplement to a registration statement (File No. 333-264845) was subsequently filed in </span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">August 2023</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to register the resale of the shares of Class A common stock issued to NVIDIA. The Company has agreed to use commercially reasonable efforts to keep the registration statement continuously effective until such date that all registrable securities under the agreement have been sold. In the event the holders cannot sell their shares due to certain circumstances causing the registration statement to be ineffective, the Company must pay each holder of shares outstanding on the date and each month thereafter <ix:nonFraction unitRef="number" contextRef="c-89" decimals="2" name="rxrx:PercentOfAggregatePurchasePricePaidByTheHolderDueIfAgreementIsBroken" scale="-2" id="f-436">1</ix:nonFraction>% of the aggregate purchase price with the maximum payable amount of <ix:nonFraction unitRef="number" contextRef="c-90" decimals="2" name="rxrx:PercentOfAggregatePurchasePricePaidByTheHolderDueIfAgreementIsBroken" scale="-2" id="f-437">5</ix:nonFraction>% of the aggregate purchase price. As of March&#160;31, 2024, there was <ix:nonFraction unitRef="usd" contextRef="c-91" decimals="INF" name="rxrx:RegistrationRightsAgreementAccruedLiability" format="ixt:fixed-zero" scale="3" id="f-438">no</ix:nonFraction> accrued liability related to this agreement, as it was not probable that a payment would be required.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Acquisitions</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In </span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">May 2023</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in connection with the acquisition of Valence, the Company entered into a Registration Agreement providing for the registration for resale of the shares of Class A common stock and Exchange Shares issued or issuable in such transaction. A registration statement on Form S-3ASR (File No. 333-272281) was filed to register </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i575b7c0e32c142cfa1b028ec4e7e1359_7">Table of Contents</a></span></div></div><ix:continuation id="f-420-3"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the shares for resale by the holders. The registration statement must remain effective for a period of not less than <ix:nonNumeric contextRef="c-92" name="rxrx:RegistrationRightsAgreementTerm" format="ixt-sec:durwordsen" id="f-439">three years</ix:nonNumeric>. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In </span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">May 2023</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in connection with the acquisition of Cyclica, the Company entered into a Registration Agreement providing for the registration for resale of the shares of Class A common stock issued in such transaction. A prospectus supplement to a registration statement (File No. 333-264845) was subsequently filed in </span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 2023</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to register the shares for resale by the holders. The registration statement must be continuously effective until the earlier of the date that all shares have been sold thereunder or are able to be publicly sold by relying on Rule 144 of the Securities Act without registration. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">2022 Private Placement</span></div><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, i</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n connection with the 2022 Private Placement, the Company entered into a Registration Rights Agreement providing for the registration for resale of the shares of Class A common stock issued in such transaction. A prospectus supplement to a registration statement (File No. 333-264845) was subsequently filed in </span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">October 2022</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to register the resale of the shares of Class A common stock by the Purchasers. The agreement must remain effective until registrable securities covered by the agreement have been publicly sold by the holders or all shares cease to be registrable securities. In the event the holders cannot sell their shares due to certain circumstances causing the agreement to be ineffective, the Company must pay each holder of shares outstanding on the date and each month thereafter <ix:nonFraction unitRef="number" contextRef="c-93" decimals="2" name="rxrx:PercentOfAggregatePurchasePricePaidByTheHolderDueIfAgreementIsBroken" scale="-2" id="f-440">1</ix:nonFraction>% of the aggregate purchase price paid by the holder without limit until the agreement is cured. As of March&#160;31, 2024, there was <ix:nonFraction unitRef="usd" contextRef="c-4" decimals="INF" name="rxrx:RegistrationRightsAgreementAccruedLiability" format="ixt:fixed-zero" scale="3" id="f-441">no</ix:nonFraction> accrued liability related to this agreement, as it was not probable that a payment would be required.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Class A and B Common Shares Authorization</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In </span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">April 2021</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company&#8217;s Board of Directors authorized <ix:nonFraction unitRef="class" contextRef="c-94" decimals="INF" name="rxrx:NumberOfClassesOfCommonStockAuthorized" format="ixt-sec:numwordsen" scale="0" id="f-442">two</ix:nonFraction> classes of common stock, Class A and Class B. The rights of the holders of Class A and B common stock are identical, except with respect to voting and conversion. Each share of Class A common stock is entitled to <ix:nonFraction unitRef="vote" contextRef="c-6" decimals="INF" name="rxrx:CommonStockVotePerShare" format="ixt-sec:numwordsen" scale="0" id="f-443">one</ix:nonFraction> vote per share. Each share of Class B common stock is entitled to <ix:nonFraction unitRef="vote" contextRef="c-8" decimals="INF" name="rxrx:CommonStockVotePerShare" scale="0" id="f-444">10</ix:nonFraction> votes per share and is convertible at any time into <ix:nonFraction unitRef="number" contextRef="c-6" decimals="INF" name="rxrx:CommonStockConversionRatio" format="ixt-sec:numwordsen" scale="0" id="f-445">one</ix:nonFraction> share of Class A common stock.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All Class B common stock is held by Christopher Gibson, Ph.D., the Company&#8217;s Chief Executive Officer (CEO), or his affiliates. As of March&#160;31, 2024, Dr. Gibson and his affiliates held outstanding shares of Class B common stock representing approximately <ix:nonFraction unitRef="number" contextRef="c-95" decimals="2" name="rxrx:AffiliatedHoldersOwnershipPercentage" scale="-2" id="f-446">25</ix:nonFraction>% of the voting power of the Company&#8217;s outstanding shares. This voting power may increase over time as Dr. Gibson vests in and exercises equity awards outstanding. If all the exchangeable equity awards held by Dr. Gibson had been fully vested, exercised and exchanged for shares of Class B common stock as of March&#160;31, 2024, Dr. Gibson and his affiliates would hold approximately <ix:nonFraction unitRef="number" contextRef="c-95" decimals="2" name="rxrx:AffiliatedHoldersPotentialOwnershipPercentageWhenOutstandingEquityAwardsVest" scale="-2" id="f-447">26</ix:nonFraction>% of the voting power of the Company&#8217;s outstanding shares. As a result, Dr. Gibson will be able to significantly influence any action requiring the approval of Recursion stockholders, including the election of the Board of Directors; the adoption of amendments to the Company&#8217;s certificate of incorporation and bylaws; and the approval of any merger, consolidation, sale of all or substantially all of the Company&#8217;s assets, or other major corporate transaction.</span></div></ix:continuation><div><span><br/></span></div><div id="i575b7c0e32c142cfa1b028ec4e7e1359_61"></div><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;9. <ix:nonNumeric contextRef="c-1" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="f-448" continuedAt="f-448-1" escape="true">Collaborative Development Contracts </ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="f-448-1" continuedAt="f-448-2"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Roche and Genentech</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Description</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, Recursion entered into a collaboration and license agreement with Roche and Genentech (collectively referred to as Roche). Recursion is constructing, using the Company&#8217;s imaging technology and proprietary machine-learning algorithms, unique maps of the inferred relationships amongst perturbation phenotypes in a given cellular context with the goal to discover and develop therapeutic small molecule programs in a gastrointestinal cancer indication and in key areas of neuroscience. Roche and Recursion will collaborate to select certain novel inferences with respect to small molecules or targets generated from the Phenomaps for further validation and optimization as collaboration programs. Roche and Recursion may also combine sequencing datasets from Roche with Recursion&#8217;s Phenomaps and collaborate to generate new algorithms to produce multi-modal maps from which additional collaboration programs may be initiated. For every collaboration program that successfully identifies potential therapeutic small molecules or validates a target, Roche will have an option to obtain an exclusive license to develop and commercialize such potential therapeutic small molecules or to exploit such target in the applicable exclusive field.</span></div></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i575b7c0e32c142cfa1b028ec4e7e1359_7">Table of Contents</a></span></div></div><ix:continuation id="f-448-2" continuedAt="f-448-3"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Pricing</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, Recursion received a $<ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="f-449">150.0</ix:nonFraction> million non-refundable upfront payment from the Company&#8217;s collaboration with Roche. Recursion is eligible for additional milestone payments based on performance progress of the collaboration. Each of the Phenomaps requested by Roche and created by Recursion may be subject to either an initiation fee, acceptance fee or both. Such fees could exceed $<ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-5" name="rxrx:RevenueRemainingPerformanceObligationVariableConsiderationAmount" format="ixt:num-dot-decimal" scale="6" id="f-450">250.0</ix:nonFraction> million for <ix:nonFraction unitRef="phenomap" contextRef="c-97" decimals="INF" name="rxrx:ContractWithCustomerMaximumAcceptedProduct" scale="0" id="f-451">16</ix:nonFraction> accepted Phenomaps. In addition, for a period of time after Roche&#8217;s acceptance of certain Phenomaps, Roche will have the option to obtain, subject to payment of an exercise fee, rights to use outside the collaboration the raw images generated in the course of creating those Phenomaps. If Roche exercises its external use option for all <ix:nonFraction unitRef="phenomap" contextRef="c-98" decimals="INF" name="rxrx:ContractWithCustomerMaximumAcceptedProduct" scale="0" id="f-452">12</ix:nonFraction> eligible Phenomaps, Roche&#8217;s associated exercise fee payments to Recursion could exceed $<ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-5" name="rxrx:RevenueRemainingPerformanceObligationVariableConsiderationAmount" format="ixt:num-dot-decimal" scale="6" id="f-453">250.0</ix:nonFraction> million. Under the collaboration, Roche may initiate up to <ix:nonFraction unitRef="program" contextRef="c-99" decimals="INF" name="rxrx:RevenueRemainingPerformanceObligationNumberOfProjectsThatMayBeInitiated" scale="0" id="f-454">40</ix:nonFraction> programs, each of which, if successfully developed and commercialized, could yield more than $<ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-5" name="rxrx:RevenueRemainingPerformanceObligationVariableConsiderationAmount" format="ixt:num-dot-decimal" scale="6" id="f-455">300.0</ix:nonFraction>&#160;million in development, commercialization and net revenue milestones for Recursion, as well as tiered royalties on net revenue.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Accounting</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This agreement represents a transaction with a customer and therefore is accounted for in accordance with ASC 606. Recursion has determined that it has <ix:nonFraction unitRef="performance_obligation" contextRef="c-100" decimals="INF" name="rxrx:RevenuePerformanceObligationNumberOfObligations" format="ixt-sec:numwordsen" scale="0" id="f-456">three</ix:nonFraction> performance obligations, <ix:nonFraction unitRef="performance_obligation" contextRef="c-101" decimals="INF" name="rxrx:RevenuePerformanceObligationNumberOfObligations" format="ixt-sec:numwordsen" scale="0" id="f-457">one</ix:nonFraction> related to gastrointestinal cancer and <ix:nonFraction unitRef="performance_obligation" contextRef="c-102" decimals="INF" name="rxrx:RevenuePerformanceObligationNumberOfObligations" format="ixt-sec:numwordsen" scale="0" id="f-458">two</ix:nonFraction> in neuroscience. These performance obligations are for performing research and development services for Roche to identify targets and medicines. The performance obligations also include potential licenses related to the intellectual property. The Company concluded that licenses within the contract are not distinct from the research and development services as they are interrelated due to the fact that the research and development services significantly impact the potential licenses. Any additional services are considered customer options and will be considered as separate contracts for accounting purposes.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has determined the transaction price to be $<ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="f-459">150.0</ix:nonFraction> million, comprised of the upfront payment. Recursion will fully constrain the amounts of variable consideration to be received from potential milestones considering the stage of development and the risks associated with the remaining development required to achieve each milestone. Recursion will re-evaluate the transaction price each reporting period. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction price was allocated to the performance obligations based on the estimated relative stand-alone selling price of each performance obligation as determined using an expected cost plus margin approach. The Company recognizes revenue over time based on costs incurred relative to total expected costs to perform the research and development services. Recursion determined that this method provides a faithful depiction of the transfer of control to the customer. This method of recognizing revenue requires the Company to make estimates of total costs to provide the services required under the performance obligations. Significant inputs used to determine the total costs included the length of time required, service hours performed by Company employees and materials costs. A significant change in these estimates could have a material effect on the timing and amount of revenue recognized in future periods. Recursion has estimated the completion of the performance obligations by 2026.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Additional Revenue Disclosures</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of the revenue recognized during the three months ended March 31, 2024 and 2023, primarily all of it was included in the unearned revenue balance as of December&#160;31, 2023 and 2022, respectively. Revenue recognized was from upfront payments received at the inception of the related contracts, which decreased the initial unearned revenue recognized. As of March&#160;31, 2024, the Company had $<ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="f-460">6.5</ix:nonFraction> million of costs incurred to fulfill a contract on its Condensed Consolidated Balance Sheet within &#8220;Other Current Assets.&#8221;</span></div></ix:continuation><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-448-3">Unearned revenue was classified as short-term and long-term on the Condensed Consolidated Balance Sheets based on the Company&#8217;s estimate of revenue that will be recognized during the next twelve months.</ix:continuation> </span></div><div><span><br/></span></div><div id="i575b7c0e32c142cfa1b028ec4e7e1359_64"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 10. <ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-461" continuedAt="f-461-1" escape="true">Stock-Based Compensation </ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="f-461-1" continuedAt="f-461-2"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, the Board of Directors and the stockholders of the Company adopted the 2021 Equity Incentive Plan (the 2021 Plan). The Company may grant stock options, restricted stock units (RSUs), stock appreciation rights, restricted stock awards and other forms of stock-based compensation. As of March&#160;31, 2024, <ix:nonFraction unitRef="shares" contextRef="c-104" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="6" id="f-462">18.9</ix:nonFraction> million shares of Class A common stock were available for grant.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i575b7c0e32c142cfa1b028ec4e7e1359_7">Table of Contents</a></span></div></div><div><span><br/></span></div><ix:continuation id="f-461-2" continuedAt="f-461-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="f-463" escape="true"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the classification of stock-based compensation expense for employees and non-employees within the Condensed Consolidated Statements of Operations: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.490%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.106%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-464">766</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-465">1,011</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-466">7,666</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-467">2,683</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-468">7,077</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-469">4,578</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-470">15,509</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-471">8,272</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options are primarily granted to executive leaders at the Company, generally vest over <ix:nonNumeric contextRef="c-111" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-472">four years</ix:nonNumeric> and expire no later than <ix:nonNumeric contextRef="c-111" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear" id="f-473">10</ix:nonNumeric> years from the date of grant. </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-474" escape="true"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity during the three months ended March 31, 2024 was as follows: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.467%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;(in thousands except share and per share amounts)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Exercise</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Price </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining&#160;Contractual Life (in years) </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value </span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-475">14,957,617</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-476">6.13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-80" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-477">7.0</ix:nonNumeric></span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-478">72,416</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-479">2,558,102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-480">10.09</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-481">178,609</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="f-482">12.70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-483">1,303,878</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-484">2.80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-485">11,575</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of March 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-486">16,033,232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-487">6.99</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-488">7.3</ix:nonNumeric></span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-489">64,131</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of March 31, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-490">8,909,647</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-491">5.49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-492">6.2</ix:nonNumeric></span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="3" id="f-493">51,959</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of options granted to employees is calculated on the grant date using the Black-Scholes option valuation model. The weighted-average grant-date fair values of stock options granted during the three months ended March 31, 2024 and 2023 were $<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-494">6.41</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-16" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-495">5.32</ix:nonFraction>, respectively. </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="f-496" escape="true"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following weighted-average assumptions were used to calculate the grant-date fair value of stock options: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.052%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;text-indent:62.99pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-111" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-497">6.3</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;text-indent:62.99pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-112" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-498">6.3</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:67.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-111" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-499">65</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:67.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-112" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-500">64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-111" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-501">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-112" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-502">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-111" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-503">4.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-112" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-504">3.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2024, $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="f-505">43.9</ix:nonFraction> million of unrecognized compensation cost related to stock options is expected to be recognized as expense over approximately the next <ix:nonNumeric contextRef="c-1" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:durwordsen" id="f-506">three years</ix:nonNumeric>. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">RSUs</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity awards granted to employees primarily consist of RSUs and generally vest over <ix:nonNumeric contextRef="c-113" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-507">four years</ix:nonNumeric>. The weighted-average grant-date fair value of RSUs generally is determined based on the number of units granted and the quoted price of Recursion&#8217;s common stock on the date of grant.  </span></div></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i575b7c0e32c142cfa1b028ec4e7e1359_7">Table of Contents</a></span></div></div><ix:continuation id="f-461-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock" id="f-508" escape="true"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes Recursion&#8217;s RSU activity during the three months ended March 31, 2024: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.133%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.784%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock units</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-average grant date fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-114" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-509">15,223,764</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-114" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-510">8.39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-115" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-511">1,840,877</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-115" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-512">10.46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-115" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-513">1,023,464</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-115" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-514">8.60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-115" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-515">409,634</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-115" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-516">7.99</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of March 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-116" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-517">15,631,543</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-116" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-518">8.63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair market value of RSUs vested was $<ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="f-519">13.0</ix:nonFraction> million during the three months ended March 31, 2024. As of March&#160;31, 2024, $<ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="6" id="f-520">124.8</ix:nonFraction> million of unrecognized compensation cost related to RSUs is expected to be recognized as expense over approximately the next <ix:nonNumeric contextRef="c-115" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:durwordsen" id="f-521">three years</ix:nonNumeric>.</span></div></ix:continuation><div><span><br/></span></div><div id="i575b7c0e32c142cfa1b028ec4e7e1359_67"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 11. <ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-522" continuedAt="f-522-1" escape="true">Income Taxes </ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="f-522-1" continuedAt="f-522-2"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations" format="ixt:fixed-zero" scale="0" id="f-523"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="INF" name="us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations" format="ixt:fixed-zero" scale="0" id="f-524">not</ix:nonFraction></ix:nonFraction> record any U.S. income tax expense during the three months ended March 31, 2024 and 2023. The Company has historically incurred operating losses and maintains a full valuation allowance against its U.S. net deferred tax assets. Foreign taxes were insignificant during the three months ended March 31, 2024 and 2023. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net operating losses (NOLs) and tax credit carry-forwards are subject to review and possible adjustment by the Internal Revenue Service (&#8220;IRS&#8221;) and may become subject to annual limitation due to ownership changes that occur under Section 382 of the Internal Revenue Code, as amended and similar state provisions. These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income. In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain shareholders or public groups in the stock of a corporation by more than 50% over a three-year period. As of March&#160;31, 2024, the Company was not limited on its NOLs and tax credit carry-forwards. The Company will continue to monitor future ownership changes for potential Section 382 limitations.  </span></div></ix:continuation><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-522-2">The Company files income tax returns in the United States, Canada, United Kingdom, Utah, California and Massachusetts. The Company is not currently under examination in any of these jurisdictions. The Company is subject to income tax examinations on all federal returns since the 2017 tax return.</ix:continuation> </span></div><div><span><br/></span></div><div id="i575b7c0e32c142cfa1b028ec4e7e1359_70"></div><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 12. <ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerShareTextBlock" id="f-525" continuedAt="f-525-1" escape="true">Net Loss Per Share </ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="f-525-1" continuedAt="f-525-2"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2024 and 2023, Recursion calculated net loss per share of Class A, Class B and Exchangeable common stock using the two-class method. Basic net loss per share is computed using the weighted-average number of shares outstanding during the period. Diluted net loss per share is computed using the weighted-average number of shares and the effect of potentially dilutive securities outstanding during the period. Potentially dilutive securities consist of stock options and other contingently issuable shares. For periods presented in which the Company reports a net loss, all potentially dilutive shares are anti-dilutive and as such are excluded from the calculation. </span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended March 31, 2024 and 2023</span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company reported a net loss and therefore basic and diluted loss per share were the same.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rights, including the liquidation and dividend rights, of the holders of the Company&#8217;s Class A, Class B and the Exchangeable common stock are identical, except with respect to voting. As a result, the undistributed earnings for each period are allocated based on the contractual participation rights of the Class A, Class B and the Exchangeable common stock as if the earnings for the period had been distributed. As the liquidation and dividend rights are identical, the undistributed earnings are allocated on a proportionate basis and the resulting amount per share for Class A, Class B and the Exchangeable common stock was the same during the three months ended March 31, 2024 and 2023.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i575b7c0e32c142cfa1b028ec4e7e1359_7">Table of Contents</a></span></div></div><div><span><br/></span></div><ix:continuation id="f-525-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="f-526" escape="true"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth the computation of basic and diluted net loss per share of Class A, Class B and Exchangeable common stock:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:68.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.126%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.128%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-527">91,373</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-528">65,327</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-529"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-530">236,019,349</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-16" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-531"><ix:nonFraction unitRef="shares" contextRef="c-16" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-532">191,618,238</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-533"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-534">0.39</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-16" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-535"><ix:nonFraction unitRef="usdPerShare" contextRef="c-16" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-536">0.34</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="f-537" escape="true"><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company excluded the following potential common shares from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.783%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.959%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Stock based compensation</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-117" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-538">11,159,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-118" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-539">8,534,876</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Tempus agreement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-119" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-540">5,143,690</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-120" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="f-541">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-542">16,302,940</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-16" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-543">8,534,876</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i575b7c0e32c142cfa1b028ec4e7e1359_73"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Note 13. <ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueDisclosuresTextBlock" id="f-544" continuedAt="f-544-1" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="f-544-1" continuedAt="f-544-2"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value hierarchy consists of the following three levels:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 &#8212; Valuations based on unadjusted quoted prices in active markets for identical assets that the company has the ability to access;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 &#8212; Valuations based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuations in which all significant inputs are observable in the market; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 &#8212; Valuations using significant inputs that are unobservable in the market and include the use of judgment by the company's management about the assumptions market participants would use in pricing the asset or liability.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to maintain a cash balance in a collateralized account to secure the Company&#8217;s credit cards. Additionally, the Company holds restricted cash related to an outstanding letter of credit issued by J.P. Morgan, which was obtained to secure certain Company obligations relating to tenant improvements. Recursion also holds restricted cash related to a Bill and Melinda Gates Foundation grant. </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="f-545" continuedAt="f-545-1" escape="true"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.098%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.297%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.452%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Basis of fair value measurement</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-546">276,697</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-547">276,697</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-548">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-549">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-3" name="rxrx:RestrictedCashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-550">9,824</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" name="rxrx:RestrictedCashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-551">9,824</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-3" name="rxrx:RestrictedCashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-552">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-3" name="rxrx:RestrictedCashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-553">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-554">286,521</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-555">286,521</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-556">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-557">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i575b7c0e32c142cfa1b028ec4e7e1359_7">Table of Contents</a></span></div></div><ix:continuation id="f-544-2"><ix:continuation id="f-545-1"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.098%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.297%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.452%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Basis of fair value measurement</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-558">322,653</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-559">322,653</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-560">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-561">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-3" name="rxrx:RestrictedCashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-562">9,860</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-3" name="rxrx:RestrictedCashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-563">9,860</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-3" name="rxrx:RestrictedCashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-564">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-3" name="rxrx:RestrictedCashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-565">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-566">332,513</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-567">332,513</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-568">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-569">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the financial instruments that are recognized at fair value on the Condensed Consolidated Balance Sheet, the Company has certain financial instruments that are recognized at amortized cost or some basis other than fair value. The carrying amount of these instruments are considered to be representative of their approximate fair values. </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock" id="f-570" escape="true"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the Company&#8217;s financial instruments that are not measured at fair value: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.531%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.992%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.448%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Book values</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair values</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of notes payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-3" name="us-gaap:LongTermDebtCurrent" scale="3" id="f-571">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-3" name="us-gaap:LongTermDebtCurrent" scale="3" id="f-572">41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-3" name="us-gaap:LongTermDebtCurrent" scale="3" id="f-573">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-3" name="us-gaap:LongTermDebtCurrent" scale="3" id="f-574">41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes payable, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-575">1,071</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-576">1,101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-577">1,071</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-578">1,101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-3" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-579">1,126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-3" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-580">1,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-3" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-581">1,126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-3" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-582">1,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><div id="i575b7c0e32c142cfa1b028ec4e7e1359_79"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i575b7c0e32c142cfa1b028ec4e7e1359_7">Table of Contents</a></span></div></div><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div><span><br/></span></div><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following is a discussion and analysis of the financial condition of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recursion Pharmaceuticals, Inc. (Recursion, the Company, we, us or our)</span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> and the results of operations. This commentary should be read in conjunction with the unaudited Condensed Consolidated Financial Statements and accompanying notes appearing in Item 1, &#8220;Financial Statements&#8221; and the Company&#8217;s audited consolidated financial statements and accompanying notes and "Management's Discussion and Analysis of Financial Condition and Results of Operations" included in the Annual Report on Form 10-K for the year ended December 31, 2023. This discussion, particularly information with respect to our future results of operations or financial condition, business strategy and plans and objectives of management for future operations, includes forward-looking statements that involve risks and uncertainties as described under the heading "Note About Forward-Looking Statements" in this Quarterly Report on Form 10-Q. You should review the disclosure under the heading "Risk Factors" in the Annual Report on Form 10-K for a discussion of important factors that could cause our actual results to differ materially from those anticipated in these forward-looking statements. We assume no obligation to revise or publicly release any revision to any forward-looking statements contained in this Quarterly Report on Form 10-Q, unless required by law.</span></div><div><span><br/></span></div><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investors and others should note that we announce material financial and other information to our investors using our investor relations website (https://ir.recursion.com/), SEC filings, press releases, public conference calls and webcasts. We use these channels as well as social media and blogs to communicate with our stakeholders and the public about our company, our services and other issues. It is possible that the information we post on social media and blogs could be deemed to be material information. Therefore, we encourage investors, the media and others interested in our company to review the information we post on the social media channels and blogs listed on our investor relations website. Information contained in, or that can be accessed through, our website is not a part of, and is not incorporated into, this report.</span></div><div><span><br/></span></div><div id="i575b7c0e32c142cfa1b028ec4e7e1359_82"></div><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Recursion is a leading clinical stage TechBio company decoding biology to industrialize drug discovery. Central to our mission is the Recursion Operating System (OS), a platform built across diverse technologies that enables us to map and navigate trillions of biological, chemical and patient-centric relationships across over 50 petabytes of proprietary data. We frame this integration of the physical and digital components as iterative loops, where scaled &#8216;wet-lab&#8217; biology, chemistry and patient-centric experimental data are organized by &#8216;dry-lab&#8217; computational tools in order to identify, validate and translate therapeutic insights. We believe Recursion&#8217;s unbiased, data-driven approach to understanding biology will bring more, new and better medicines at higher scale and lower cost to patients. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are three key value-drivers at Recursion: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">An expansive </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">pipeline </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of internally developed clinical and preclinical programs focused on precision oncology and genetically driven rare diseases with significant unmet need and market opportunities that could potentially exceed $1 billion in annual sales in some cases</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Transformational </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">partnerships </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with leading biopharma and technology companies to map and navigate intractable areas of biology, identify novel targets and develop potential new medicines by using advanced computational and data resources</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">An industry-leading </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">dataset </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">intentionally designed to capitalize on computational tools and accelerate value created through our pipeline, partnerships and technology products</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i575b7c0e32c142cfa1b028ec4e7e1359_7">Table of Contents</a></span></div></div><div style="text-align:center"><img src="rxrx-20240331_g1.jpg" alt="Recursion OS.jpg" style="height:314px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We drive value by scaling and leveraging the Recursion OS to generate, aggregate and integrate over 50 petabytes of data spanning large language model derived disease relevance and target-compound relationships, predicted protein-ligand binding interactions for ~36 billion compounds, over 250 million total staining and multi-timepoint live-cell (brightfield) phenomics experiments, over 1 million whole transcriptomics experiments, tens of thousands of ADME experiments using our automated DMPK module, InVivomics and multimodal precision oncology patient data. This dataset has been curated using over 50 human cell types, our cell manufacturing facility which has produced over 1 trillion hiPSC-derived neuronal cells since 2022, our in-house chemical library of over 1.7 million compounds, an </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in silico</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> library of over 1 trillion small molecules and other capabilities. We have built proprietary software applications and AI/ML models within the Recursion OS which predict and navigate over 6 trillion biological and chemical relationships. With our approach and our team of over 500 Recursionauts that is balanced between life scientists and computational and technical experts, we endeavor to turn drug discovery into a search problem, where we map and navigate biology in an unbiased manner in order to translate insights into more, new and better medicines at higher scale and lower cost to patients.</span></div><div><span><br/></span></div><div style="text-align:center"><img src="rxrx-20240331_g2.jpg" alt="PR Pipeline Q1 2024.jpg" style="height:354px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><div id="i575b7c0e32c142cfa1b028ec4e7e1359_85"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i575b7c0e32c142cfa1b028ec4e7e1359_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Business Highlights</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pipeline</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.15pt">Cerebral Cavernous Malformation (CCM) (REC-994):</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our Phase 2 SYCAMORE clinical trial is a randomized, double-blind, placebo-controlled study of two doses of REC-994 in participants with CCM. The primary endpoint of the study is safety and tolerability. Secondary and exploratory endpoints, including clinician measured outcomes, imaging of CCM lesions, patient reported outcomes and selected biomarkers, will be evaluated. This trial was fully enrolled in June 2023 with 62 participants, where the vast majority of participants who completed 12 months of treatment have entered the long-term extension study. We expect to share Phase 2 data in Q3 2024.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Neurofibromatosis Type 2 (NF2) (REC-2282): </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our adaptive Phase 2/3 POPLAR clinical trial is a randomized, two part study of REC-2282 in participants with progressive NF2-mutated meningiomas. Part 1 of the study is ongoing and is exploring two doses of REC-2282 in approximately 23 adults and 9 adolescents, with enrollment in adults expected to complete in Q2 2024. We expect to share Phase 2 safety and preliminary efficacy data in Q4 2024.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Familial Adenomatous Polyposis (FAP) (REC-4881):</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Phase 1b/2 TUPELO clinical trial is an open label, multicenter, two part study of REC-4881 in participants with FAP. Part 1 is complete and enrollment in Part 2 has commenced. We expect to share Phase 2 safety and preliminary efficacy data in H1 2025.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">AXIN1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">or APC</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Mutant Cancers (REC-4881): </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Phase 2 LILAC clinical trial is an open label, multicenter study of REC-4881 in participants with unresectable, locally advanced or metastatic cancer with </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AXIN1 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">APC </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mutations. This study was initiated at the end of 2023 with the first participant dosed in Q1 2024. Since that time, multiple participants are now enrolled. We expect to share Phase 2 safety and preliminary efficacy data in H1 2025.   </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Clostridioides difficile</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Infection (REC-3964):</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> REC-3964 is a first-in-class </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C. difficile </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">toxin inhibitor and the first new chemical entity developed by Recursion, with promising preclinical efficacy data seen in relevant models (superiority versus bezlotoxumab). Full Phase 1 data from our healthy volunteers study will be presented at the World Congress on Infectious Diseases in Paris in June 2024. We expect to initiate a randomized Phase 2 study in patients at high risk for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C. difficile</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> infection recurrence in 2024.  </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Advanced HR-Proficient Cancers (RBM39):</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> RBM39 is a novel CDK12-adjacent target identified by the Recursion OS. We intend to position our lead candidate as a single agent for the potential treatment of advanced HR-proficient cancers including ovarian and other solid tumors.We expect to submit an IND in H2 2024 and anticipate initiating a Phase 1 open label study of our lead candidate in participants with relapsed/refractory cancer. The primary endpoint of the study will be safety and tolerability. Secondary endpoints will explore pharmacokinetics and preliminary signs of anti-tumor activity. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Undisclosed Indication in Fibrosis (Target Epsilon):</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> This program originated under our initial fibrosis collaboration with Bayer and we have since in-licensed from Bayer all rights to this program. We are advancing our lead candidate through IND-enabling studies with IND submission expected in the near-term. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Platform</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Supercomputer Expansion: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We worked with our partner NVIDIA to design and build BioHive-2, our next generation supercomputer with over 500 H100 GPUs. We have nearly completed the build out of BioHive-2 and began performance benchmarking tests. We believe that the performance of our supercomputer may place BioHive-2 in the top 50 of the next TOP500 list, making it one of the most powerful supercomputers in the world across any industry and the most powerful supercomputer owned and operated by any biopharma company. These computational resources, paired with Recursion&#8217;s vast datasets and data generation capabilities, enable the construction of Recursion&#8217;s large foundation models for biology, chemistry and causal patient outcomes. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Whole-Genome Transcriptomics Map: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to focus on key technologies that enhance our ability to generate, extract and validate novel insights for therapeutic advancements. Over the past year, we have scaled our transcriptomics technology in order to validate phenotypic-insights and relate to patient-derived RNA sequencing data. In April, we announced sequencing our 1 millionth transcriptome. We believe that we are one of the largest transcriptomics sequencers in the world and are advancing the development of a whole-genome knockout transcriptomics map, which we expect to complete in the coming quarters. Such platform capabilities are important for curating scaled datasets that are relatable and provide a more complete understanding of biology, chemistry and patient outcomes. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i575b7c0e32c142cfa1b028ec4e7e1359_7">Table of Contents</a></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Active Learning: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been applying active learning approaches to predict where our OS should generate and enrich biological and chemical datasets via phenotypic and ADME compound profiling across existing and new cellular contexts. These capabilities enable Recursion to rapidly construct multiomics maps that are enriched for areas of biology and chemistry that may be of high value for translating insights into therapeutic programs. We believe that such approaches enable Recursion to more rapidly expand its data moat and see active learning capabilities as an important step towards autonomous drug discovery.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Partnerships</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Helix Collaboration: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recursion entered into a multi-year agreement with Helix to access hundreds of thousands of de-identified records including Helix&#8217;s Exome+(R) genomic data and data from longitudinal health records. Recursion plans to use this data to train causal AI models and design biomarker and patient stratification strategies across broad disease areas. The Helix dataset expands Recursion&#8217;s integration of real-world patient data and complements Recursion&#8217;s access to Tempus&#8217; oncology data. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Transformational Collaborations: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to advance efforts to discover potential new therapeutics with our strategic partners in the areas of undruggable oncology (Bayer) as well as neuroscience and a single indication in gastrointestinal oncology (Roche-Genentech). In the near-term, there is the potential for option exercises associated with partnership programs, option exercises associated with map building initiatives or data sharing and additional partnerships in large, intractable areas of biology or technological innovation. </span></div><div><span><br/></span></div><div id="i575b7c0e32c142cfa1b028ec4e7e1359_88"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financing and Operations</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were incorporated in November 2013. In </span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">April 2021</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we closed our Initial Public Offering (IPO) and issued </span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27.9&#160;million</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shares of Class A common stock at a price of $18.00 per share, raising net proceeds of </span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$462.4 million.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Prior to our IPO, we had raised </span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$448.9 million</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in equity financing from investors in addition to </span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$30.0 million </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in an upfront payment from our collaboration with Bayer AG (Bayer). In </span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">January 2022</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we received an upfront payment of </span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$150.0 million</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> from our collaboration with Roche. </span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 9, &#8220;Collaborative Development Contracts&#8221; to the Condensed Consolidated Financial Statements for additional information on the collaboration with Roche. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In </span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">October 2022</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we issued </span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.3&#160;million</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shares of our Class A common stock at a purchase price of $9.80 per share in the 2022 private placement to qualified institutional buyers and </span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">institutional accredited investors for net proceeds of $143.7 million, after deducting fees and offering costs of $6.6 million. In July 2023, we issued an aggregate of 7.7&#160;million shares of our Class A common stock at a purchase price of $6.49 per share in the 2023 Private Placement with NVIDIA Corporation for net proceeds of approximately $49.9 million. In August 2023, we entered into an O</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pen Market Sales Agreement with Jefferies LLC to provide for the offering, issuance and sale of up to an aggregate amount of </span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$300.0 million</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of its Class A common stock of which </span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$208.2 million</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> remain available for future sales. The Company has sold </span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.9&#160;million</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shares and received net proceeds of </span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$89.1 million</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> under the agreement. </span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 8, &#8220;Common Stock&#8221; to the Condensed Consolidated Financial Statements for additional information on the Sales Agreement.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the capital we have raised to fund operating and investing activities across platform research operations, drug discovery, clinical development, digital and other infrastructure, creation of our portfolio of intellectual property and administrative support. We do not have any products approved for commercial sale and have not generated any revenues from product sales. </span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had cash and cash equivalents of $296.3 million as of March&#160;31, 2024.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Based on our current operating plan, we believe that our cash and cash equivalents will be sufficient to fund our operations for at least the next twelve months. </span></div><div><span><br/></span></div><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, we have incurred significant operating losses. Our net losses were $91.4 million and $65.3 million during the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended March 31, 2024 and 2023</span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively. As of March&#160;31, 2024, our accumulated deficit was $1.1 billion. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that we will need to raise additional financing in the future to fund our operations, including the potential commercialization of any approved product candidates. Until such time, if ever, as we can generate significant product revenue, we expect to finance our operations with our existing cash and cash equivalents, any future equity or debt financings and upfront, milestone and royalty payments, if any, received under current or future license or collaboration agreements. We may not be able to raise additional capital on terms acceptable to us or at all. If we are unable to raise additional capital when desired, our business, results of operations and financial condition may be adversely affected.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><div id="i575b7c0e32c142cfa1b028ec4e7e1359_94"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i575b7c0e32c142cfa1b028ec4e7e1359_7">Table of Contents</a></span></div></div><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations </span></div><div><span><br/></span></div><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our results of operations: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.697%"/><td style="width:0.1%"/></tr><tr style="height:21pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except percentages)</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended March 31,</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Change</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">%</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,491&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,134&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,356&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Grant revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">303&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">303&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">n/m</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,794&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,134&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,659&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating costs and expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,166&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,448&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,282)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67,560&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,677&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,883&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,408&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,874&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,534&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total operating costs and expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110,134&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81,999&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,135&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(96,340)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(69,865)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26,476)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,538&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(351)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Loss before income tax benefit</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(92,152)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(65,327)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26,827)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">779&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">779&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">n/m</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(91,373)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(65,327)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26,048)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary</span></div><div><span><br/></span></div><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial performance during the three months ended March 31, 2024</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> compared to the prior period included an increase in research and development costs across all development stages as we continue to expand and upgrade our platform, advance our preclinical pipeline and progress through our various clinical trials. </span></div><div><span><br/></span></div><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue </span></div><div><span><br/></span></div><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our components of revenue:</span></div><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.697%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended March 31,</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except percentages)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$ </span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">% </span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,491&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,134&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,356&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Grant revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">303&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">303&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">n/m</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,794&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,134&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,659&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating revenue is generated through research and development agreements derived from strategic alliances. We are entitled to receive variable consideration as certain milestones are achieved. The timing of revenue recognition is not directly correlated to the timing of cash receipts.</span></div><div><span><br/></span></div><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2024, the increase in revenue compared to prior period was due to revenue recognized from our partnership with Roche, as our mix of work on the three performance obligations shifted towards higher cost processes including the progression of work related to one of our </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">neuroscience</span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> performance obligations.  </span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i575b7c0e32c142cfa1b028ec4e7e1359_7">Table of Contents</a></span></div></div><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Revenue</span></div><div><span><br/></span></div><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cost of revenue: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.697%"/><td style="width:0.1%"/></tr><tr style="height:21pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except percentages)</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended March 31,</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Change</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$ </span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">% </span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cost of revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,166&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,448&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,282)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of revenue consists of the Company&#8217;s costs to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">provide services for drug discovery required under performance obligations with partnership customers. These primarily include materials costs, service hours performed by our employees and depreciation of property and equipment.</span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2024, the decrease in cost of revenue compared to prior period was due to our strategic partnership with Bayer which was completed in 2023.</span></div><div><span><br/></span></div><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development </span></div><div><span><br/></span></div><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our components of research and development expense: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.697%"/><td style="width:0.1%"/></tr><tr style="height:21pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except percentages)</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended March 31,</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Change</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$ </span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">% </span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Platform</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,914&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,492&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,422&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discovery</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,642&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,505&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Clinical</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,597&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,522&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,075&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,995&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,833&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,162&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&gt;100%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">412&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">325&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total research and development expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67,560&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,677&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,883&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses account for a significant portion of our operating expenses. We recognize research and development expenses as they are incurred. Research and development expenses consist of costs incurred in performing activities including: </span></div><div><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.2pt">costs to develop and operate our platform; </span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.2pt">costs of discovery efforts which may lead to development candidates, including research materials and external research; </span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.2pt">costs for clinical development of our investigational products; </span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.2pt">costs for materials and supplies associated with the manufacture of active pharmaceutical ingredients, investigational products for preclinical testing and clinical trials; </span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.2pt">personnel-related expenses, including salaries, benefits, bonuses and stock-based compensation for employees engaged in research and development functions; </span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.2pt">costs associated with operating our digital infrastructure; and </span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.2pt">other direct and allocated expenses incurred as a result of research and development activities, including those for facilities, depreciation, amortization and insurance. </span></div><div><span><br/></span></div><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize expenses associated with third-party contracted services as they are incurred. Upon termination of contracts with third parties, our financial obligations are generally limited to costs incurred or committed to date. Any advance payments for goods or services to be used or rendered in future research and product development activities pursuant to a contractual arrangement are classified as prepaid expenses until such goods or services are rendered. </span></div><div><span><br/></span></div><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of research and development expense include the following allocated by development phase: Platform, which refers primarily to expenses related to screening of product candidates through hit </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i575b7c0e32c142cfa1b028ec4e7e1359_7">Table of Contents</a></span></div></div><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">identification; Discovery, which refers primarily to expenses related to hit identification through development of candidates; and Clinical, which refers primarily to expenses related to development of candidates and beyond.</span></div><div><span><br/></span></div><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2024, the increase in research and development expenses compared to the prior period was </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">across all development phases as we continue to expand and upgrade our platform,</span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> including our chemical technology, machine learning and transcriptomics platform. Our discovery costs increased as we</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> advanced our preclinical pipeline including our work on Target Epsilon. Our clinical costs grew as we continued to progress through our various clinical trials. </span></div><div style="margin-bottom:3pt"><span><br/></span></div><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expense</span></div><div><span><br/></span></div><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our general and administrative expense: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.697%"/><td style="width:0.1%"/></tr><tr style="height:23pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except percentages)</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended March 31,</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Change</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$ </span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">% </span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total general and administrative expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,408&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,874&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,534&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expense general and administrative costs as incurred. General and administrative expenses consist primarily of salaries; including employee benefits and stock-based compensation. General and administrative expenses also include facilities, depreciation, information technology, professional fees for auditing and tax, legal fees for corporate and patent matters and insurance costs.  </span></div><div><span><br/></span></div><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2024, the increase in general and administrative expense compared to prior period was primarily driven by an increase in salaries and wages of $3.9 million and increases in software and depreciation expense.</span></div><div><span><br/></span></div><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income, Net </span></div><div><span><br/></span></div><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our components of other income, net: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.697%"/><td style="width:0.1%"/></tr><tr style="height:21pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except percentages)</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended March 31,</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Change</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$ </span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">% </span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,048&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,660&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(612)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(103)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">263&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">256.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,188&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,538&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(350)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7.7)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">n/m = Not meaningful</span></div><div><span><br/></span></div><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2024, the</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">decrease</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in interest income compared to prior period related to a decrease in earnings on cash and cash equivalents in money market funds.</span></div><div style="margin-bottom:3pt"><span><br/></span></div><div id="i575b7c0e32c142cfa1b028ec4e7e1359_97"></div><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources </span></div><div><span><br/></span></div><div id="i575b7c0e32c142cfa1b028ec4e7e1359_100"></div><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sources of Liquidity </span></div><div><span><br/></span></div><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not yet commercialized any products and do not expect to generate revenue from the sales of any product candidates for at least several years. Cash and cash equivalents totaled $296.3 million and $391.6 million as of March&#160;31, 2024 and December&#160;31, 2023, respectively. </span></div><div><span><br/></span></div><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred operating losses and experienced negative operating cash flows and we anticipate that the Company will continue to incur losses for at least the foreseeable future. Our net loss was $91.4 million and $65.3 million during the three months ended March 31, 2024 and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively. As of March&#160;31, 2024 and December&#160;31, 2023, we had an accumulated deficit of $1.1 billion and $967.6 million, respectively. </span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i575b7c0e32c142cfa1b028ec4e7e1359_7">Table of Contents</a></span></div></div><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have financed our operations through the private placements of preferred stock and Class A common stock issuances. As of March&#160;31, 2024, we have received net proceeds of $448.9 million from the sale of preferred stock and $745.0 million from Class A common stock issuances. See Note 8, &#8220;Common Stock&#8221; to the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Condensed </span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Financial Statements for additional details on Class A common stock issuances. Additionally, as of March&#160;31, 2024, we have received proceeds of $183.0 million from our strategic partnerships. See Note 9, &#8220;Collaborative Development Contracts&#8221; to the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Condensed </span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Financial Statements for additional details on the Roche partnership. </span></div><div style="margin-bottom:3pt"><span><br/></span></div><div id="i575b7c0e32c142cfa1b028ec4e7e1359_103"></div><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div><span><br/></span></div><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Condensed </span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Statements of Cash Flows for each of the periods presented below: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.274%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.275%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three months ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash used in operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(102,300)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73,316)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,653)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,340)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,897&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,922&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Operating Activities </span></div><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used by operating activities increased during the three months ended March 31, 2024 as a result of higher costs incurred for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">research and development and general and administrative due to the Company&#8217;s </span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expansion and upgraded capabilities. </span></div><div><span><br/></span></div><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used by operating activities increased during the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended March 31, 2023</span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as a result of an upfront payment of $150.0 million from our strategic partnership with Roche received during the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended March 31, 2022</span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div><span><br/></span></div><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Investing Activities</span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used by investing activities during the three months ended March 31, 2024 consisted primarily of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">property and equipment purchases of </span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$6.7&#160;million, which included $2.9&#160;million for a project to upgrade the BioHive supercomputer and $2.7&#160;million</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for lab equipment purchases.</span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used by investing activities during the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended March 31, 2023</span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> consisted primarily of property and equipment purchases of $5.2&#160;million, which included $1.7&#160;million for a project to upgrade the BioHive supercomputer and $2.3&#160;million for lab equipment purchases.</span></div><div><span><br/></span></div><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Financing Activities </span></div><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by financing activities during the three months ended March 31, 2024 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">primarily included proceeds of </span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$10.9 million from common stock issuances. Financing inflows also included proceeds from equity incentive plans of $3.0 million.</span></div><div><span><br/></span></div><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">provided by financing activities during the three months ended March 31, 2023 primarily included proceeds from equity incentive plans of </span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.9 million.</span></div><div><span><br/></span></div><div id="i575b7c0e32c142cfa1b028ec4e7e1359_106"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Estimates and Policies </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s significant accounting estimates and policies is included in Note 2, &#8220;Summary of Significant Accounting Policies&#8221; in our 2023 Annual Report. There were no significant changes in the Company&#8217;s application of its critical accounting policies during the </span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended March 31, 2024</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div><span><br/></span></div><div id="i575b7c0e32c142cfa1b028ec4e7e1359_109"></div><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued and Adopted Accounting Pronouncements </span></div><div><span><br/></span></div><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 2, &#8220;Basis of Presentation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; in Item 1 of this Quarterly Report on Form 10-Q</span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for information regarding recently issued and adopted accounting pronouncements. </span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><div id="i575b7c0e32c142cfa1b028ec4e7e1359_112"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i575b7c0e32c142cfa1b028ec4e7e1359_7">Table of Contents</a></span></div></div><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Quantitative and Qualitative Disclosures About Market Risk.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Risk</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to market risk related to changes in interest rates of our cash and cash equivalents. As of March&#160;31, 2024, our cash and cash equivalents primarily consisted of money market funds. Our primary exposure to market risk is interest income sensitivity, which is affected by changes in U.S. interest rates. A hypothetical 100 basis point decrease in interest rates as of</span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2024</span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">would have an insignificant effect on net loss in the ensuring year.  </span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Exchange Risk</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our employees and our operations are primarily located in the United States and Canada and our expenses are generally denominated in U.S. and Canadian dollars. We also have entered into a limited number of contracts with vendors for research and development services that have underlying payment obligations denominated in foreign currencies. We are subject to foreign currency transaction gains or losses on our contracts denominated in foreign currencies. To date, foreign currency transaction gains and losses have not been material to our financial statements, and we do not have a formal hedging program with respect to foreign currency. A 10% increase or decrease in current exchange rates would have an insignificant effect on our financial results during the </span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended March 31, 2024</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 2023.</span></div><div><span><br/></span></div><div id="i575b7c0e32c142cfa1b028ec4e7e1359_115"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Controls and Procedures.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has established disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the Exchange Act) designed to ensure that information required to be disclosed in the reports that the Company files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms and is accumulated and communicated to management, including the principal executive officer (our Chief Executive Officer) and principal financial officer (our Chief Financial Officer), to allow timely decisions regarding required disclosure. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management has evaluated, with the participation of our Chief Executive Officer and Chief Financial Officer, the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this report. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives as management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our disclosure controls and procedures have been designed to provide reasonable assurance of achieving their objectives. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of March&#160;31, 2024, our disclosure controls and procedures were ineffective due to the material weakness in internal controls related to our revenue and unearned revenue process including the operating effectiveness of management review controls over the estimated costs and time to completion and controls to validate the completeness and accuracy of information used to calculate revenue and unearned revenue related to its license agreement disclosed in Part II, Item 9A of our Annual Report on Form 10-K for the year ended December 31, 2023. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Remediation of Material Weakness</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following remediation actions have been taken as of March&#160;31, 2024:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Improvement of documentation procedures regarding specific inquiries related to the cost model used for revenue recognition and the resulting responses</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Improvement of documentation for the review of changes in cost model due to responses from inquiries</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Provided additional documentation for internal reports to validate and support completeness and accuracy of reports</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i575b7c0e32c142cfa1b028ec4e7e1359_7">Table of Contents</a></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Improvement of documentation of these processes was done with the input of our third-party consultants who continue to be involved in the design and enhancement of the revenue recognition policies and procedures</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While significant progress has been made to enhance our internal controls over financial reporting, we are still in the process of implementing and testing these remediated processes, procedures and controls. We believe the above actions will be effective in remediating the material weakness described above. However, the material weakness cannot be considered remediated until controls operate for a sufficient period of time and management has concluded, through testing, that these controls are operating effectively. As such, we were unable to conclude that the material weakness has been remediated as of March&#160;31, 2024.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2024, management is in the process of integrating the internal controls of the acquired businesses into Recursion's existing operations as part of planned integration activities. With the exception of the steps taken to remediate the material weakness as described above, there were no other changes in financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the quarter ended March&#160;31, 2024 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><div id="i575b7c0e32c142cfa1b028ec4e7e1359_118"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i575b7c0e32c142cfa1b028ec4e7e1359_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II - OTHER INFORMATION</span></div><div><span><br/></span></div><div id="i575b7c0e32c142cfa1b028ec4e7e1359_121"></div><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Legal Proceedings. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may, from time to time, be involved in various legal proceedings arising in the normal course of business. An unfavorable resolution of any such matter could materially affect the Company&#8217;s future financial position, results of operations or cash flows. For more information pertaining to legal proceedings, see Part I, Item 1, Note 7, &#8220;Commitments and Contingencies,&#8221; which is incorporated herein by reference.</span></div><div><span><br/></span></div><div id="i575b7c0e32c142cfa1b028ec4e7e1359_124"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors.</span></div><div style="padding-right:5.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investing in our common stock involves a high degree of risk. For a detailed discussion of the risks that affect our business. Please refer to the sections titled &#8220;Risk Factors&#8221; in Part I, Item 1A. of our 2023 Annual Report.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risk factors set forth below represent new risk factors or those containing changes to the similarly titled risk factor included in the sections titled &#8220;Risk Factors&#8221; in Part I, Item 1A. of our 2023 Annual Report.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISKS RELATED TO OUR RELIANCE ON THIRD PARTIES</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third parties that perform some of our research and preclinical testing or conduct our clinical trials may not perform satisfactorily or their agreements may be terminated.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently rely, and expect to continue to rely, on third parties to conduct some aspects of research and preclinical testing and clinical trials. The third parties include CROs, clinical data management organizations, medical institutions, and principal investigators. Any of these third parties may fail to fulfill their contractual obligations, including by not meeting deadlines for the completion of research, testing, or trials, or we or they may terminate their engagements with us. If any of our relationships with these third parties terminate, we may not be able to enter into arrangements with alternative third parties on commercially reasonable terms, or at all. If we need to enter into alternative arrangements, such negotiations could delay product development activities.  Termination of our relationships with foreign third parties can also occur if U.S. legislation, sanctions, trade restrictions, or other U.S. and foreign regulatory requirements, prohibitions or restrictions, limit or prevent our ability to enter into arrangements with such foreign third parties.  For example, we currently rely on foreign CROs and CDMOs, including an affiliate/subsidiary of WuXi AppTec Co., Ltd. (WuXi AppTec) in China that has been listed as a biotechnology company &#8220;of concern&#8221; in proposed U.S. legislation known as the BIOSECURE Act (recently introduced in the U.S. House of Representatives as H.R. 7085 and in the U.S. Senate as S.3558).  While the BIOSECURE Act as currently proposed would restrict purchasing of services or products from WuXI AppTec and other companies of concern in China, it would only impact U.S. companies that contract with or receive funding from the U.S. government, which means that our company would not be directly impacted by the BIOSECURE Act.  However, passage of the BIOSECURE Act could potentially lead the way for further legislation, sanctions, or restrictions that could potentially impact our third-party arrangements with companies such as WuXi AppTec which could delay or impact clinical trials and consequently delay or obstruct regulatory approval of our drug candidates.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our reliance on third parties for research and development activities reduces our control over these activities, but does not relieve us of our responsibilities. For example, we remain responsible for ensuring that each of our respective clinical trials is conducted in accordance with the general investigational plan and protocols for the trial, as well as applicable legal, regulatory, and scientific standards. We also are required to register ongoing clinical trials and post the results of completed clinical trials on a government-sponsored database within certain timeframes. In addition, the FDA and comparable foreign regulatory authorities require compliance with good clinical practices (GCP) guidelines for conducting, recording, and reporting the results of clinical trials to assure that data and reported results are credible, reproducible, and accurate, and that the rights, integrity, and confidentiality of trial participants are protected. Regulatory authorities enforce GCP compliance through periodic inspections of trial sponsors, principal investigators, and trial sites. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or any of the third parties fail to comply with applicable GCP regulations, some or all of the clinical data generated in our clinical trials may be deemed unreliable, and the FDA or comparable foreign regulatory authorities may require us to perform additional nonclinical or clinical trials or to enroll additional patients before approving our marketing applications. In addition, if we or the third parties fail to comply with our stated protocols or applicable laws and regulations during the conduct of clinical trials, we or the third parties could be subject to warning letters or </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i575b7c0e32c142cfa1b028ec4e7e1359_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">enforcement actions by the FDA and comparable foreign regulatory authorities, which could result in civil penalties or criminal prosecution, as well as adverse publicity that harms our business. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also will not be able to obtain, or may be delayed in obtaining, marketing approvals for any drug candidates we may develop if these third parties do not successfully carry out their contractual duties, meet expected deadlines, or conduct clinical trials in accordance with our stated protocols or regulatory requirements. As a result, we may be delayed or unable to successfully commercialize our drug candidates.</span></div><div><span><br/></span></div><div id="i575b7c0e32c142cfa1b028ec4e7e1359_127"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.</span></div><div><span><br/></span></div><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(a) Sales of Unregistered Securities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Stock Option Exercises</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the </span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended March 31, 2024</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we issued 38 thousand shares of our Class A common stock to our employees, directors, advisors and consultants upon the exercise of stock options under our Key Personnel Incentive Stock Plan for aggregate consideration of approximately $10 thousand. The shares of Class A common stock issued upon the exercise of stock options were issued pursuant to written compensatory plans or arrangements with our employees, directors, advisors and consultants, in reliance on the exemption provided by Rule 701 promulgated under the Securities Act of 1933, as amended, or pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended, relative to transactions by an issuer not involving any public offering, to the extent an exemption from such registration was required. All recipients either received adequate information about our company or had access, through employment or other relationships, to such information.</span></div><div><span><br/></span></div><div id="i575b7c0e32c142cfa1b028ec4e7e1359_130"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. <ix:nonNumeric contextRef="c-1" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-583"><ix:nonNumeric contextRef="c-1" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-584"><ix:nonNumeric contextRef="c-1" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-585">Other Information</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric>.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-145" name="ecd:MtrlTermsOfTrdArrTextBlock" id="f-586" escape="true"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On <ix:nonNumeric contextRef="c-145" name="ecd:TrdArrAdoptionDate" id="f-587">March 1, 2024</ix:nonNumeric>, <ix:nonNumeric contextRef="c-145" name="ecd:TrdArrIndName" id="f-588">Terry-Ann Burrell</ix:nonNumeric>, a <ix:nonNumeric contextRef="c-145" name="ecd:TrdArrIndTitle" id="f-589">member of our Board of Directors</ix:nonNumeric>, <ix:nonNumeric contextRef="c-145" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-590">adopted</ix:nonNumeric> a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to <ix:nonFraction unitRef="shares" contextRef="c-146" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" id="f-591">211,290</ix:nonFraction> shares of the Company&#8217;s Class A common stock until May&#160;30, 2025.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="c-147" name="ecd:MtrlTermsOfTrdArrTextBlock" id="f-592" escape="true"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On <ix:nonNumeric contextRef="c-147" name="ecd:TrdArrAdoptionDate" id="f-593">March 1, 2024</ix:nonNumeric>, <ix:nonNumeric contextRef="c-147" name="ecd:TrdArrIndName" id="f-594">Tina Marriott</ix:nonNumeric>, <ix:nonNumeric contextRef="c-147" name="ecd:TrdArrIndTitle" id="f-595">President and Chief Operating Officer</ix:nonNumeric>, <ix:nonNumeric contextRef="c-147" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-596">adopted</ix:nonNumeric> a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to <ix:nonFraction unitRef="shares" contextRef="c-148" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" id="f-597">672,000</ix:nonFraction> shares of the Company&#8217;s Class A common stock until June&#160;27, 2025.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="c-149" name="ecd:MtrlTermsOfTrdArrTextBlock" id="f-598" escape="true"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On <ix:nonNumeric contextRef="c-149" name="ecd:TrdArrAdoptionDate" id="f-599">March 1, 2024</ix:nonNumeric>, <ix:nonNumeric contextRef="c-149" name="ecd:TrdArrIndName" id="f-600">Michael Secora</ix:nonNumeric>, <ix:nonNumeric contextRef="c-149" name="ecd:TrdArrIndTitle" id="f-601">Chief Financial Officer</ix:nonNumeric>, <ix:nonNumeric contextRef="c-149" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-602">adopted</ix:nonNumeric> a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to <ix:nonFraction unitRef="shares" contextRef="c-150" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" id="f-603">1,259,955</ix:nonFraction> shares of the Company&#8217;s Class A common stock until June&#160;10, 2025.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><div id="i575b7c0e32c142cfa1b028ec4e7e1359_136"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i575b7c0e32c142cfa1b028ec4e7e1359_7">Table of Contents</a></span></div></div><div style="-sec-extract:summary"><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. Exhibits.</span></div><div><span><br/></span></div><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit Index:</span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.332%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.259%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated by Reference</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit number</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">File No.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit No. </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filing Date</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filed / Furnished Herewith</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001601830/000119312521123764/d149444dex31.htm">Amended and Restated Certificate of Incorporation of Recursion Pharmaceuticals, Inc.</a></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-40323</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 21, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601830/000160183024000009/a1-25x24amendedbylaws.htm">Amended and Restated Bylaws of Recursion Pharmaceuticals, Inc.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-40323</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 31, 2024</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001601830/000119312521089610/d89478dex41.htm">Amended and Restated Investors&#8217; Rights Agreement by and among the Registrant and certain of its stockholders, dated September 1, 2020.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">333-254576</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 15, 2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001601830/000119312521089610/d89478dex42.htm">Specimen Class A common stock certificate of the Registrant.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">333-254576</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 15, 2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">+</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit101-viraniadvisorya.htm">Advisory Agreement between the Registrant and Shafique Virani</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">+</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit102-viranitransitio.htm">Transition Agreement between the Registrant and Shafique Virani</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit311-q0124.htm">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit312-q0124.htm">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.1*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit321-q0124.htm">Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Instance Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;101.PRE</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></td><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indicates a management contract or compensatory plan.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The certifications furnished in Exhibit 32.1 hereto are deemed to accompany this Quarterly Report on Form 10-Q and will not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. Such certifications will not be deemed to be incorporated by reference into any filings under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that the Registrant specifically incorporates it by reference. </span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="18" style="padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><div id="i575b7c0e32c142cfa1b028ec4e7e1359_139"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i575b7c0e32c142cfa1b028ec4e7e1359_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized on May&#160;9, 2024. </span></div><div><span><br/></span></div><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.736%"><tr><td style="width:1.0%"/><td style="width:8.377%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.107%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.116%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">RECURSION PHARMACEUTICALS, INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">/s/ Christopher Gibson</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Christopher Gibson</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Chief Executive Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(Principal Executive Officer)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">/s/ Michael Secora</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Michael Secora</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(Principal Financial and Accounting Officer)</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:12pt;text-indent:30.6pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>exhibit101-viraniadvisorya.htm
<DESCRIPTION>EX-10.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i3750bbaf08de455b80ac011e6289f298_4"></div><div style="min-height:36pt;width:100%"><div style="margin-top:12pt;text-align:right;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXHIBIT 10.1</font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:12pt;text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ADVISORY AGREEMENT</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">This Advisory Agreement (this &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8221;) is made and entered into as of February 6, 2024 (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Effective Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8221;) by and between Recursion Pharmaceuticals, Inc., (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Company</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8221;), and Shafique Virani (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Advisor</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8221;) (each herein referred to individually as a &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Party</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">,&#8221; or collectively as the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Parties</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8221;). </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:29.34pt">SERVICES AND COMPENSATION</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Advisor shall perform the services described in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exhibit&#160;1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">Services</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;) for the Company (or its designee), and the Company agrees to pay Advisor the compensation described in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exhibit&#160;1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> for Advisor&#8217;s performance of the Services.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:29.34pt">CONFIDENTIALITY</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">A.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;padding-left:10.45pt">Definition of Confidential Information</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">Confidential Information</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; means any information (including any and all combinations of individual items of information) that relates to the actual or anticipated business and&#47;or products, research or development of the Company, its affiliates or subsidiaries, or to the Company&#8217;s, its affiliates&#8217; or subsidiaries&#8217; technical data, trade secrets, or know-how, including, but not limited to, research, product plans, or other information regarding the Company&#8217;s, its affiliates&#8217; or subsidiaries&#8217; products or services and markets therefor, customer lists and customers, software, developments, inventions, discoveries, ideas, processes, formulas, technology, designs, drawings, engineering, hardware configuration information, marketing, finances, and other business information disclosed by the Company, its affiliates or subsidiaries, either directly or indirectly, in writing, orally or by drawings or inspection of premises, parts, equipment, or other property of Company, its affiliates or subsidiaries. Notwithstanding the foregoing, Confidential Information shall not include any such information which Advisor can establish (i) was publicly known or made generally available prior to the time of disclosure to Advisor&#59; (ii) becomes publicly known or made generally available after disclosure to Advisor through no wrongful action or inaction of Advisor&#59; or (iii) is in the rightful possession of Advisor, without confidentiality obligations, at the time of disclosure as shown by Advisor&#8217;s then-contemporaneous written records&#59; provided that any combination of individual items of information shall not be deemed to be within any of the foregoing exceptions merely because one or more of the individual items are within such exception, unless the combination as a whole is within such exception. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">B.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;padding-left:10.45pt">Nonuse and Nondisclosure</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> During and after the term of this Agreement, Advisor will hold in the strictest confidence, and take all reasonable precautions to prevent any unauthorized use or disclosure of Confidential Information, and Advisor will not (i)&#160;use the Confidential Information for any purpose whatsoever other than as necessary for the performance of the Services on behalf of the Company, or (ii)&#160;subject to Advisor&#8217;s right to engage in Protected Activity (as defined below), disclose the Confidential Information to any third party without the prior written consent of an authorized representative of the Company, except that Advisor may disclose Confidential Information to the extent compelled by applicable law&#59; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">provided however</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, prior to such disclosure, Advisor shall provide prior written notice to Company and seek a protective order or such similar confidential protection as may be available under applicable law. Advisor agrees that no ownership of Confidential Information is conveyed to the Advisor. Without limiting the foregoing, Advisor shall not use or disclose any Company property, intellectual property rights, trade secrets or other proprietary know-how of the Company to invent, author, make, develop, design, or otherwise enable others to invent, author, make, develop, or design identical or substantially similar designs as those developed under this Agreement for any third party. Advisor agrees that Advisor&#8217;s obligations under this Section&#160;2.B shall continue after the termination of this Agreement. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">C.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;padding-left:10.01pt">Other Client Confidential Information</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Advisor agrees that Advisor will not improperly use, disclose, or induce the Company to use any proprietary information or trade secrets of any former or current employer of Advisor or other person or entity with which Advisor has an obligation to keep in confidence. Advisor also agrees that Advisor will not bring onto the Company&#8217;s premises or transfer onto the Company&#8217;s technology systems any unpublished document, proprietary information, or trade secrets belonging to any third party unless disclosure to, and use by, the Company has been consented to in writing by such third party. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">D.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;padding-left:10.01pt">Third Party Confidential Information</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Advisor recognizes that the Company has received and in the future will receive from third parties their confidential or proprietary information subject to a duty on the Company&#8217;s part to maintain the confidentiality of such information and to use it only for certain limited purposes. Advisor agrees that at all times during the term of this Agreement and thereafter, Advisor owes the Company and such third parties a duty to hold all such confidential or proprietary information in the strictest confidence and not to use it or to disclose it to any person, firm, corporation, or other third party except as necessary in carrying out the Services for the Company consistent with the Company&#8217;s agreement with such third party.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:29.34pt">OWNERSHIP</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">A.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;padding-left:10.45pt">Assignment of Inventions</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Advisor agrees that all right, title, and interest in and to any copyrightable material, notes, records, drawings, designs, inventions, improvements, developments, discoveries, ideas and trade secrets conceived, discovered, authored, invented, developed or reduced to practice by Advisor, solely or in collaboration with others, during the term of this Agreement and arising out of, or in connection with, performing the Services under this Agreement and any copyrights, patents, trade secrets, mask work rights or other intellectual property rights relating to the foregoing (collectively, &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">Inventions</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;), are the sole property of the Company. Advisor also agrees to promptly make full written disclosure to the Company of any Inventions and to deliver and assign (or cause to be assigned) and hereby irrevocably assigns fully to the Company all right, title and interest in and to the Inventions.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">B.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;padding-left:10.45pt">Pre-Existing Material</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">s.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Subject to Section&#160;3.A, Advisor will provide the Company with prior written notice if, in the course of performing the Services, Advisor incorporates into any Invention or utilizes in the performance of the Services any invention, discovery, idea, original works of authorship, development, improvements, trade secret, concept, or other proprietary information or intellectual property right owned by Advisor or in which Advisor has an interest, prior to, or separate from, performing the Services under this Agreement (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">Prior Invention</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">s</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;), and the Company is hereby granted a nonexclusive, royalty-free, perpetual, irrevocable, transferable, worldwide license (with the right to grant and authorize sublicenses) to make, </font></div><div style="height:60.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">have made, use, import, offer for sale, sell, reproduce, distribute, modify, adapt, prepare derivative works of, display, perform, and otherwise exploit such Prior Inventions, without restriction, including, without limitation, as part of or in connection with such Invention, and to practice any method related thereto. Advisor will not incorporate any invention, discovery, idea, original works of authorship, development, improvements, trade secret, concept, or other proprietary information or intellectual property right owned by any third party into any Invention without Company&#8217;s prior written permission.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">C.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;padding-left:10.01pt">Further Assurances</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Advisor agrees to assist Company, or its designee, at the Company&#8217;s expense, in every proper way to secure the Company&#8217;s rights in Inventions in any and all countries, including the disclosure to the Company of all pertinent information and data with respect thereto, the execution of all applications, specifications, oaths, assignments and all other instruments that the Company may deem necessary in order to apply for, register, obtain, maintain, defend, and enforce such rights, and in order to deliver, assign and convey to the Company, its successors, assigns and nominees the sole and exclusive right, title, and interest in and to all Inventions and testifying in a suit or other proceeding relating to such Inventions. Advisor further agrees that Advisor&#8217;s obligations under this Section&#160;3.C shall continue after the termination of this Agreement.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:29.34pt">CONFLICTING OBLIGATIONS</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">A.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10.45pt">Advisor represents and warrants that Advisor has no agreements, relationships, or commitments to any other person or entity that conflict with the provisions of this Agreement, Advisor&#8217;s obligations to the Company under this Agreement, and&#47;or Advisor&#8217;s ability to perform the Services. Advisor will not enter into any such conflicting agreement during the term of this Agreement.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">B.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10.45pt">In light of the unique and specialized nature of Advisor&#8217;s services, Advisor shall have the right to subcontract or delegate the performance of any Services only with the prior written permission of the Company.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:29.34pt">RETURN OF COMPANY MATERIALS </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Upon the termination of this Agreement, or upon Company&#8217;s earlier request, Advisor will immediately deliver to the Company, and will not keep in Advisor&#8217;s possession, recreate, or deliver to anyone else, any and all Company property, including, but not limited to, Confidential Information, tangible embodiments of the Inventions, all devices and equipment belonging to the Company, all electronically-stored information and passwords to access such property, and any reproductions of any of the foregoing items that Advisor may have in Advisor&#8217;s possession or control.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">6.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:29.34pt">TERM AND TERMINATION</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">A.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;padding-left:10.45pt">Term</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> The term of this Agreement will begin on the Effective Date and will continue until the earlier of i) December 31, 2024, or ii)&#160;termination as provided in Section&#160;6.B.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">B.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;padding-left:10.45pt">Termination</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Advisor may terminate this Agreement upon giving the Company seven (7) days prior written notice of such termination pursuant to Section&#160;8.G of this Agreement. The Company may terminate this Agreement immediately and without prior notice for any or no reason.  For the avoidance of doubt, this Agreement will terminate immediately if Advisor fails to execute, by the deadline specified therein, the Separation Agreement and Release to which this Agreement is attached (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">Separation Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">) or if Advisor revokes the Separation Agreement.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">C.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;padding-left:10.01pt">Survival</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Upon any termination, all rights and duties of the Company and Advisor toward each other shall cease except&#58;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.24pt">The Company will pay, within thirty (30) days after the effective date of termination, all amounts owing to Advisor for Services completed and accepted by the Company prior to the termination date&#59; and</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.24pt">the sections entitled Confidentiality, Ownership, Conflicting Obligations, Return of Company Materials, Term and Termination, Independent Contractor&#59; Benefits, and Miscellaneous will survive termination or expiration of this Agreement in accordance with their terms.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">7.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:29.34pt">INDEPENDENT CONTRACTOR&#59; BENEFITS</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">A.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;padding-left:10.45pt">Independent Contractor.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">It is the express intention of the Company and Advisor that Advisor perform the Services as an independent contractor to the Company. Nothing in this Agreement shall in any way be construed to constitute Advisor as an agent, employee or representative of the Company. Without limiting the generality of the foregoing, Advisor is not authorized to bind the Company to any liability or obligation or to represent that Advisor has any such authority. Advisor agrees to furnish (or reimburse the Company for) all tools and materials necessary to accomplish this Agreement and shall incur all expenses associated with performance. Advisor acknowledges and agrees that Advisor is obligated to report as income all compensation received by Advisor pursuant to this Agreement. Advisor agrees to and acknowledges the obligation to pay all self-employment and other taxes on such income.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">B.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;padding-left:10.45pt">Benefits</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> The Company and Advisor agree that Advisor will receive no Company-sponsored benefits from the Company where benefits include, but are not limited to, paid vacation, sick leave, medical insurance and 401k participation. If Advisor is reclassified by a state or federal agency or court as the Company&#8217;s employee, Advisor will become a reclassified employee and will receive no benefits from the Company, except those mandated by state or federal law, even if by the terms of the Company&#8217;s benefit plans or programs of the Company in effect at the time of such reclassification, Advisor would otherwise be eligible for such benefits.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">8.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:29.34pt">MISCELLANEOUS</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">A.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;padding-left:10.45pt">Governing Law&#59; Consent to Personal Jurisdiction</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> This Agreement shall be governed by the laws of the State of Florida, without regard to the conflicts of law provisions of any jurisdiction.</font></div><div style="height:60.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">B.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;padding-left:10.45pt">Assignability</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> This Agreement will be binding upon Advisor&#8217;s heirs, executors, assigns, administrators, and other legal representatives, and will be for the benefit of the Company, its successors, and its assigns. There are no intended third-party beneficiaries to this Agreement, except as expressly stated. Except as may otherwise be provided in this Agreement, Advisor may not sell, assign or delegate any rights or obligations under this Agreement. Notwithstanding anything to the contrary herein, Company may assign this Agreement and its rights and obligations under this Agreement to any successor to all or substantially all of Company&#8217;s relevant assets, whether by merger, consolidation, reorganization, reincorporation, sale of assets or stock, change of control or otherwise.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">C.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;padding-left:10.01pt">Entire Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> This Agreement constitutes the entire agreement and understanding between the Parties with respect to the subject matter herein and supersedes all prior written and oral agreements, discussions, or representations between the Parties (for the avoidance of doubt, the Separation Agreement and Release between Advisor and the Company and any surviving documents therein will continue in full force and effect). Advisor represents and warrants that Advisor is not relying on any statement or representation not contained in this Agreement. To the extent any terms set forth in any exhibit or schedule conflict with the terms set forth in this Agreement, the terms of this Agreement shall control unless otherwise expressly agreed by the Parties in such exhibit or schedule.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">D.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;padding-left:10.01pt">Headings</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Headings are used in this Agreement for reference only and shall not be considered when interpreting this Agreement.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">E.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;padding-left:10.45pt">Severability</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> If a court or other body of competent jurisdiction finds, or the Parties mutually believe, any provision of this Agreement, or portion thereof, to be invalid or unenforceable, such provision will be enforced to the maximum extent permissible so as to effect the intent of the Parties, and the remainder of this Agreement will continue in full force and effect. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">F.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;padding-left:10.9pt">Modification, Waiver.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">No modification of or amendment to this Agreement, nor any waiver of any rights under this Agreement, will be effective unless in a writing signed by the Parties. Waiver by the Company of a breach of any provision of this Agreement will not operate as a waiver of any other or subsequent breach.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">G.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;padding-left:9.56pt">Notices</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Any notice or other communication required or permitted by this Agreement to be given to a Party shall be in writing and shall be deemed given (i)&#160;if delivered personally or by commercial messenger or courier service, (ii)&#160;when sent by confirmed facsimile or email, or (iii)&#160;if mailed by U.S. registered or certified mail (return receipt requested), to the Party at the Party&#8217;s address written below or at such other address as the Party may have previously specified by like notice. If by mail, delivery shall be deemed effective three business days after mailing in accordance with this Section&#160;8.G.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.24pt">If to the Company, to&#58;</font></div><div style="padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Recursion Pharmaceuticals, Inc.</font></div><div style="padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">41 S Rio Grande Street</font></div><div style="padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Salt Lake City, UT 84101</font></div><div style="padding-left:54pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Attention&#58; Chief Legal Officer</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.24pt">If to Advisor, to the address for notice on the signature page to this Agreement or, if no such address is provided, to the last address of Advisor provided by Advisor to the Company.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">H.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;padding-left:10.01pt">Attorneys&#8217; Fees</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> In any court action at law or equity that is brought by one of the Parties to this Agreement to enforce or interpret the provisions of this Agreement, the prevailing Party will be entitled to reasonable attorneys&#8217; fees, in addition to any other relief to which that Party may be entitled.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">I.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;padding-left:13.56pt">Signatures.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">This Agreement may be signed in two counterparts, each of which shall be deemed an original, with the same force and effectiveness as though executed in a single document.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">J.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;padding-left:11.78pt">Protected Activity Not Prohibited.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Advisor understands that nothing in this Agreement shall in any way limit or prohibit Advisor from engaging in any Protected Activity. For purposes of this Agreement, &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">Protected Activity</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; shall mean filing and&#47;or pursuing a charge, complaint, or report with, or otherwise communicating, cooperating, or participating in any investigation or proceeding that may be conducted by, any federal, state or local government agency or commission, including the Securities and Exchange Commission (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">Government Agencies</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;).  Notwithstanding the foregoing, Advisor agrees to take all reasonable precautions to prevent any unauthorized use or disclosure of any information that may constitute Confidential Information to any parties other than the Government Agencies. Advisor further understands that &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">Protected Activity</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; does not include the disclosure of any Company attorney-client privileged communications or privileged attorney work product. Pursuant to the Defend Trade Secrets Act of 2016, Advisor is notified that an individual will not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that (i) is made in confidence to a federal, state, or local government official (directly or indirectly) or to an attorney </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">solely</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> for the purpose of reporting or investigating a suspected violation of law, or (ii) is made in a complaint or other document filed in a lawsuit or other proceeding, if (and only if) such filing is made under seal. In addition, an individual who files a lawsuit for retaliation by an employer for reporting a suspected violation of law may disclose the trade secret to the individual&#8217;s attorney and use the trade secret information in the court proceeding, if the individual files any document containing the trade secret under seal and does not disclose the trade secret, except pursuant to court order. Advisor understands that nothing in this Agreement, including its definition of Confidential Information, limits Advisor&#8217;s rights to discuss or disclose Advisor&#8217;s compensation or the terms or conditions of Advisor&#8217;s service relationship with the Company to the extent protected by applicable law, or otherwise impairs Advisor from assisting other Company current or former service providers in the exercise of their rights under applicable law.. </font></div><div style="height:60.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><div id="i3750bbaf08de455b80ac011e6289f298_7"></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:24pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">ADVISOR&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Recursion Pharmaceuticals, Inc.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Shafique Virani&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Christopher Gibson&#160;&#160;&#160;&#160;</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Name&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Shafique Virani&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Name&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Christopher Gibson&#160;&#160;&#160;&#160;</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Title&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">CEO&#160;&#160;&#160;&#160;</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Address for Notice&#58;</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-top:6pt;text-align:justify"><font><br></font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Email Address for Notice</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="height:60.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font><br></font></div></div></div><div id="i3750bbaf08de455b80ac011e6289f298_10"></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font><br></font></div></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">EXHIBIT&#160;1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SERVICES AND COMPENSATION</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;padding-left:29.34pt">Contact</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Advisor&#8217;s principal Company contact&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> </font></div><div style="margin-top:12pt;padding-left:90pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Name&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Christopher Gibson&#160;&#160;&#160;&#160;</font></div><div style="margin-top:12pt;padding-left:90pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Title&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">CEO&#160;&#160;&#160;&#160;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;padding-left:29.34pt">Services</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. The Services will include, but will not be limited to, the following&#58;  Advisor will provide strategic and operational support to the Company's business development function and any other mutually agreed upon transition assistance.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;padding-left:29.34pt">Compensation</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">A.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:28.45pt">During the period that Advisor provides Services under this Agreement (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Advisory Period</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;), the Company will pay Advisor the following advisory fees to Advisor&#58; (i) for each month that Advisor provides Services under this Agreement from February 2024 through July&#160;2024, a total of $25,000 (which constitutes the full advisory fee for the first twenty-five (25) hours of Service performed by Advisor during such month) plus $1,000 for each hour of Services performed during such month in excess of twenty-five (25) hours if Advisor receives written consent from an authorized agent of the Company prior to performing such Services, and (ii) for each month that Advisor provides Services under this Agreement from August 2024 through December 2024, a total of $15,000 (which constitutes the full advisory fee for the first fifteen (15) hours of Service performed by Advisor during such month) plus $1,000 for each hour of Services performed during such month in excess of fifteen (15) hours if Advisor receives written consent from an authorized agent of the Company prior to performing such Services.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">B.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:28.45pt">During the Advisory Period, each outstanding equity award previously granted to Advisor by the Company (each, an &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Equity Award</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;) shall continue to vest in accordance with the terms and conditions of the equity plan under which such Equity Award was granted and the award agreement between the Company and Employee evidencing such Equity Award.  In addition, every three months during the period that Advisor provides Services under this Agreement, the Company&#8217;s Board of Directors (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Board</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;) will review Advisor&#8217;s contributions towards the completion of transformative transactions, and based on such assessment, the Board will consider whether to accelerate the vesting of a portion of Advisor&#8217;s outstanding Equity Awards, as determined by the Board in its discretion.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">C.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:28.01pt">If Advisor elects continuation coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">COBRA</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;), within the time period prescribed pursuant to COBRA for Advisor and Advisor&#8217;s eligible dependents, if applicable, the Company will pay, by remitting payment directly to the COBRA administrator, the premiums necessary to continue group health insurance benefits for Advisor and Advisor&#8217;s eligible dependents until the earlier of (i) the date Advisor ceases providing Services under this Agreement or (ii) the date upon which Advisor and&#47;or Advisor&#8217;s eligible dependents cease(s) to be eligible for coverage under COBRA (such payments, the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">COBRA Payments</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;). Notwithstanding anything in this Agreement to the contrary, if the Company determines in its sole discretion that it cannot provide the COBRA Payments without potentially violating, or being subject to an excise tax under, applicable law (including, without limitation, Section 2716 of the Public Health Service Act), the Company will in lieu thereof provide to Advisor a taxable monthly payment, payable on the last day of a given month (except as provided by the last sentence of this Section&#160;3.C.), in an amount equal to the monthly COBRA premium that Advisor would be required to pay to continue the group health coverage for Advisor and&#47;or Advisor&#8217;s eligible dependents in effect on the date of the termination of Advisor&#8217;s employment with the Company (which amount will be based on the premium for the first month of COBRA continuation coverage) (each, a &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">COBRA Replacement Payment</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;),  which  COBRA Replacement  Payments  will  be made  regardless  of whether Advisor and&#47;or Advisor&#8217;s eligible dependents elect COBRA continuation coverage and will commence on the month following the Separation Date and will end on the earlier of (x) the date upon which Advisor obtains health insurance through other employment or (y) the date Advisor ceases providing Services under this Agreement.  For the avoidance of doubt, the COBRA Replacement Payments may be used for any purpose, including, but not limited to continuation coverage under COBRA, and will be subject to all applicable tax withholdings. Notwithstanding anything to the contrary under this Agreement, if the Company determines in its sole discretion at any time that it cannot provide the COBRA Replacement Payments without violating applicable law (including, without limitation, Section 2716 of the Public Health Service Act), Advisor will not receive any further COBRA Replacement Payments or COBRA Payments.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">D.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:28.01pt">The Company will reimburse Advisor, in accordance with Company policy, for all reasonable travel expenses incurred by Advisor in performing the Services pursuant to this Agreement, if Advisor receives written consent from an authorized agent of the Company prior to incurring such expenses and submits receipts for such expenses to the Company in accordance with Company policy.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;padding-left:29.34pt">Invoices and Payments</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Every two weeks, Advisor shall submit to the Company a written invoice for Services and expenses within thirty (30) days after such Services are performed or such expenses are incurred, and such statement shall be subject to the approval of the contact person listed above or other designated agent of the Company. The Company will remit payment for properly submitted and approved invoices within thirty (30) days following invoice submission. In order to help prevent adverse tax consequences to Advisor under Section&#160;409A (as defined below), in no event will any payment under Section&#160;3.A. of this Exhibit be made later than the later of (1)&#160;March 15</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> of the calendar year following the calendar year in which such payment was earned, or (2)&#160;the 15th day of the third (3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">rd</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">) month following the end of the Company&#8217;s fiscal year in which such payment was earned.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In addition, any reimbursement under Section&#160;3.D. of this Exhibit shall be subject to Advisor continuing to provide Services to the Company pursuant to this Agreement through the date that the expense to be reimbursed is incurred, and in no event shall any such reimbursement be made later than the later of (i) March 15th of the calendar year following the calendar year in which such expense was approved by the Company&#59; or (ii) the 15th day of the third (3rd) month following the end of the Company&#8217;s tax year in which such expense was approved by the Company. </font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In addition, to the extent necessary to comply with Section 409A with respect to any reimbursements under Section&#160;3.D. of this Exhibit that constitute &#8220;deferred compensation&#8221; within the meaning of Section 409A,  the following provisions will apply&#58; (i) the amount eligible for reimbursement in one calendar year may not affect the amount eligible for reimbursement in any other calendar year&#59; (ii) the right to the applicable reimbursement is not subject to liquidation or exchange for another benefit or payment&#59; (iii) to the extent there is any reimbursement of an expense, subject to any shorter time periods provided in this Agreement or in the applicable reimbursement arrangement, any such reimbursement of an expense must be made on or before the last day of Advisor&#8217;s taxable year following the taxable year of Advisor in which the expense was incurred&#59; and (iv) except as specifically provided herein or in the applicable reimbursement arrangement, reimbursements will be made for expenses incurred only during Advisor&#8217;s lifetime.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">All payments and benefits provided for under this Agreement are intended to be exempt from or otherwise comply with the requirements of Section&#160;409A of the Internal Revenue Code of 1986, as amended, and the regulations and guidance thereunder (together, &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Section&#160;409A</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;),</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> so that none of the payments and benefits to be provided hereunder will be subject to the additional tax imposed under Section&#160;409A</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, and any ambiguities or ambiguous terms herein will be interpreted to be exempt or so comply. Each payment and benefit payable under this Agreement is intended to constitute a separate payment for purposes of Section&#160;1.409A-2(b)(2) of the Treasury Regulations. In no event will the Company (or any of its subsidiaries or affiliates) have any liability, responsibility or obligation to reimburse, indemnify or hold harmless Advisor for any taxes imposed, or other costs incurred, as a result of Section 409A.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">This </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exhibit 1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> is accepted and agreed upon as of February 6, 2024.</font></div><div style="margin-bottom:12pt;margin-top:24pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">ADVISOR&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;RECURSION PHARMACEUTICALS, INC.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Shafique Virani&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Christopher Gibson&#160;&#160;&#160;&#160;</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Name&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Shafique Virani&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Name&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Christopher Gibson&#160;&#160;&#160;&#160;</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Title&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">CEO&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;-2-</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>exhibit102-viranitransitio.htm
<DESCRIPTION>EX-10.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i69b8215cb41a45bf88703976ebb065f9_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXHIBIT 10.2</font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">TRANSITION AGREEMENT AND RELEASE </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This Transition Agreement and Release (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) is made by and between Shafique Virani (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) and Recursion Pharmaceuticals, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) (collectively referred to as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; or individually referred to as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">RECITALS</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">WHEREAS, Employee was employed by the Company&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">WHEREAS, Employee signed a confirmatory employment letter with the Company dated March 21, 2021 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Employment Letter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">WHEREAS, Employee signed a participation agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Participation Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), pursuant to which Employee was a participant in the Company&#8217;s Executive Change in Control and Severance Plan (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Severance Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">WHEREAS, Employee signed an At-Will Employment, Confidential Information, Invention Assignment, and Arbitration Agreement with the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Confidentiality Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">WHEREAS, the Company granted Employee the options to purchase shares of the Company&#8217;s common stock (each, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) and&#47;or awards of restricted stock units (each, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">RSU Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) listed in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (such Options and&#47;or RSU Awards, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Equity Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), each subject to the terms and conditions of the Key Personnel Incentive Plan, the Company&#8217;s 2016 Equity Incentive Plan or the 2021 Equity Incentive Plan (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Plans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) and the applicable award agreement between the Company and Employee applicable to each Option (each, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Equity Award Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) (the Plans together with the Equity Award Agreements, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Stock Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">WHEREAS, Employee separated from employment with the Company effective February 6, 2024 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Separation Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)&#59; and</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">WHEREAS, the Parties wish to resolve any and all disputes, claims, complaints, grievances, charges, actions, petitions, and demands that the Employee may have against the Company and any of the Releasees as defined below, including, but not limited to, any and all claims arising out of or in any way related to Employee&#8217;s employment with or separation from the Company.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">NOW, THEREFORE, in consideration of the mutual promises made herein, the Company and Employee hereby agree as follows&#58;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">COVENANTS</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.75pt;text-decoration:underline">Consideration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  In consideration of and contingent on Employee&#8217;s execution of this Agreement, this Agreement going into effect, and Employee&#8217;s fulfillment of all of its terms and conditions, the Company agrees as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:28.37pt;text-decoration:underline">Advisory Services Opportunity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Company agrees to enter into an Advisory Agreement with Employee, attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Advisory Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), pursuant to which Employee will provide advisory services to the Company as an independent contractor immediately following the end of Employee&#8217;s employment with the Company pursuant to the terms and conditions set forth in the Advisory Agreement (the period that Employee actually provides such services, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Advisory Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), and will be eligible for the compensation set forth therein. Nothing in this Agreement or the </font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">4875-9998-4802.5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Advisory Agreement pertaining to Employee&#8217;s anticipated role as an advisor shall in any way be construed to constitute Employee as agent, officer, employee, or representative of the Company. Notwithstanding anything to the contrary in the Advisory Agreement, the Parties agree that the Advisory Agreement and the related advisory services opportunity shall terminate immediately and without penalty to the Company in the event that Employee (i)&#160;does not execute this Agreement within the time period specified herein, or (ii) revokes this Agreement under Sections 6 and 28 below.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.75pt;text-decoration:underline">Supplemental Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Employee agrees to execute, within twenty-one (21) calendar days after the date the Advisory Period ends, the Supplemental Release attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit&#160;C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Supplemental Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), in exchange for the consideration set forth therein&#59; provided, however, that the Company may modify the Supplemental Release pursuant to or otherwise as may be required by applicable law.  Subject to Employee executing the Supplemental Release (along with this Agreement), the Company agrees to provide to Employee the consideration set forth in the Supplemental Release. </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Employee&#8217;s failure to sign the Supplemental Release in the specified time period will constitute a material breach of this Agreement.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:28.37pt;text-decoration:underline">General</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Employee acknowledges that without this Agreement, Employee is otherwise not entitled to the consideration listed above and that without the Supplemental Release, Employee is not entitled to the consideration set forth in the Supplemental Release. </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.75pt;text-decoration:underline">Equity Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  During the Advisory Period, the Equity Awards will continue to vest and otherwise continue in accordance with their terms and conditions.  In addition, every three months during the Advisory Period, the Company&#8217;s Board of Directors (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) will review Employee&#8217;s contributions towards the completion of transformative transactions, and based on such assessment, the Board will consider whether to accelerate the vesting of a portion of Employee&#8217;s outstanding Equity Awards, as determined by the Board in its discretion.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.75pt;text-decoration:underline">Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Employee&#8217;s Company-sponsored health insurance benefits shall cease on February 29, 2024 (or such earlier date as may be required by applicable plan terms and conditions), subject to Employee&#8217;s right to continue Employee&#8217;s health insurance under COBRA.  Employee&#8217;s participation in all benefits and incidents of employment, including, but not limited to, the accrual of bonuses, vacation, and paid time off, ceased as of the Separation Date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.75pt;text-decoration:underline">Payment of Salary and Receipt of All Benefits and Reimbursements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Employee acknowledges and represents that, other than the consideration set forth in this Agreement, the Company has (as applicable) paid or provided all salary, wages, bonuses, vacation&#47;paid time off, premiums, leaves, housing allowances, relocation costs, interest, severance, outplacement costs, fees, reimbursable expenses, commissions, stock, equity awards, vesting, and any and all other benefits and compensation due to Employee.  Employee also affirms that Employee has submitted all expense reports in compliance with Employer&#8217;s policies and procedures and been reimbursed for all expenses necessarily incurred by Employee in following Employer&#8217;s directions or incurred in performing Employee&#8217;s duties during Employee&#8217;s employment with Employer.  For the avoidance of doubt, Employee acknowledges and agrees that Employee is not entitled to receive any payments or benefits under the Severance Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.75pt;text-decoration:underline">Release of Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Employee agrees that the foregoing consideration represents settlement in full of all outstanding obligations owed to Employee by the Company, its parents, subsidiaries, affiliates, and each of their respective current and former officers, directors, employees, agents, investors, attorneys, shareholders, administrators, benefit plans, plan administrators, professional employer organizations or co-employers,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">insurers, trustees, divisions,  predecessor and successor corporations, and assigns (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Releasees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). Employee, on Employee&#8217;s own behalf and on behalf of Employee&#8217;s respective heirs, family members, executors, agents, and assigns, hereby and forever releases the Releasees from, and agrees </font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">not to sue concerning, or in any manner to institute, prosecute, or pursue, any claim, complaint, charge, duty, obligation, demand, or cause of action relating to any matters of any kind, whether presently known or unknown, suspected or unsuspected, that Employee may possess against any of the Releasees arising from any omissions, acts, facts, or damages that have occurred up until and including the date Employee signs this Agreement, including, without limitation&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;any and all claims relating to or arising from Employee&#8217;s employment relationship with the Company and the termination of that relationship&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;any and all claims relating to, or arising from, Employee&#8217;s right to purchase, or actual purchase of shares of stock of the Company, including, without limitation, any claims for fraud, misrepresentation, breach of fiduciary duty, breach of duty under applicable state corporate law, and securities fraud under any state or federal law&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">c.&#160;&#160;&#160;&#160;any and all claims under the law of any jurisdiction, including, but not limited to, wrongful discharge of employment&#59; constructive discharge from employment&#59; termination in violation of public policy&#59; discrimination&#59; harassment&#59; retaliation&#59; breach of contract, both express and implied&#59; breach of covenant of good faith and fair dealing, both express and implied&#59; promissory estoppel&#59; negligent or intentional infliction of emotional distress&#59; fraud&#59; negligent or intentional misrepresentation&#59; negligent or intentional interference with contract or prospective economic advantage&#59; unfair business practices&#59; defamation&#59; libel&#59; slander&#59; negligence&#59; personal injury&#59; assault&#59; battery&#59; invasion of privacy&#59; false imprisonment&#59; conversion&#59; and disability benefits&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">d.&#160;&#160;&#160;&#160;any and all claims for violation of any federal, state, or municipal statute, including, but not limited to, the following, each as may be amended, and except as prohibited by law&#58; Title&#160;VII of the Civil Rights Act of 1964&#59; the Civil Rights Act of 1991&#59; the Rehabilitation Act of 1973&#59; the Americans with Disabilities Act of 1990&#59; the Equal Pay Act&#59; the Fair Labor Standards Act&#59; the Fair Credit Reporting Act&#59; the Age Discrimination in Employment Act of 1967&#59; the Older Workers Benefit Protection Act&#59;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">the Employee Retirement Income Security Act of 1974&#59; the Worker Adjustment and Retraining Notification Act&#59; the Family and Medical Leave Act&#59; the Uniformed Services Employment and Reemployment Rights Act&#59; the Immigration Reform and Control Act&#59; the Florida Civil Rights Act of 1992, the Florida Workers&#8217; Compensation Retaliation provision, the Florida Minimum Wage Act, the Florida Equal Pay Law, and the Florida Whistleblower Protection Act&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">e.&#160;&#160;&#160;&#160;any and all claims for violation of the federal or any state constitution&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">f.&#160;&#160;&#160;&#160;any and all claims arising out of any other laws and regulations relating to employment or employment discrimination&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">g.&#160;&#160;&#160;&#160;any claim for any loss, cost, damage, or expense arising out of any dispute over the nonwithholding or other tax treatment of any of the proceeds received by Employee from the Company&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">h.&#160;&#160;&#160;&#160;any and all claims for attorneys&#8217; fees and costs.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Employee agrees that the release set forth in this section shall be and remain in effect in all respects as a complete general release as to the matters released. This release does not extend to any obligations incurred under this Agreement. This release does not release claims that cannot be released as a matter of law. Any and all disputed wage claims that are released herein shall be subject to binding arbitration in accordance with the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Arbitration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; section below, except as required by applicable law. This release does not extend to any right Employee may have to unemployment compensation benefits or workers&#8217; compensation benefits. </font></div><div style="text-align:justify"><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.75pt;text-decoration:underline">Acknowledgment of Waiver of Claims under ADEA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Employee acknowledges that Employee is waiving and releasing any rights Employee may have under the Age Discrimination in Employment Act of 1967 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">ADEA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), and that this waiver and release is knowing and voluntary. Employee agrees that this waiver and release does not apply to any rights or claims that may arise under the ADEA after the date Employee signs this Agreement. Employee acknowledges that the consideration given for this waiver and release is in addition to anything of value to which Employee was already entitled. Employee further acknowledges that Employee has been advised by this writing that&#58; (a) Employee should consult with an attorney prior to executing this Agreement&#59; (b) Employee has twenty-one (21) days within which to consider this Agreement&#59; (c) Employee has seven (7) days following Employee&#8217;s execution of this Agreement to revoke this Agreement&#59; (d) this Agreement shall not be effective until after the revocation period has expired&#59; and (e) nothing in this Agreement prevents or precludes Employee from challenging or seeking a determination in good faith of the validity of this waiver under the ADEA, nor does it impose any condition precedent, penalties, or costs for doing so, unless specifically authorized by federal law. In the event Employee signs this Agreement and returns it to the Company in less than the twenty-one (21)-day period identified above, Employee hereby acknowledges that Employee has knowingly and voluntarily chosen to waive the time period allotted for considering this Agreement. Employee acknowledges and understands that revocation must be accomplished by a written notification to the person executing this Agreement on the Company&#8217;s behalf that is received prior to the Effective Date. The Parties agree that changes, whether material or immaterial, do not restart the running of the 21-day period.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.75pt;text-decoration:underline">Unknown Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Employee acknowledges that Employee has been advised to consult with legal counsel and that Employee is familiar with the principle that a general release does not extend to claims that the releaser does not know or suspect to exist in Employee&#8217;s favor at the time of executing the release, which, if known by Employee, must have materially affected Employee&#8217;s settlement with the Releasees.  Employee, being aware of said principle, agrees to expressly waive any rights Employee may have to that effect, as well as under any other statute or common law principles of similar effect.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.75pt;text-decoration:underline">No Pending or Future Lawsuits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Employee represents that Employee has no lawsuits, claims, or actions pending in Employee&#8217;s name, or on behalf of any other person or entity, against the Company or any of the other Releasees.  Employee also represents that Employee does not intend to bring any claims on Employee&#8217;s own behalf or on behalf of any other person or entity against the Company or any of the other Releasees.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.75pt;text-decoration:underline">No Right to Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Employee understands and agrees that, as a condition of this Agreement, Employee shall not be entitled to any employment with the Company, and Employee hereby waives any right, or alleged right, of employment or re-employment with the Company. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.25pt;text-decoration:underline">Confidentiality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Subject to the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Protected Activity Not Prohibited</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; section below (and as applicable, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Protected Activity Not Prohibted</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; section in the Advisory Agreement), Employee agrees to maintain in complete confidence the existence of this Agreement and the Supplemental Release, the contents and terms of this Agreement and the Supplemental Release, and the consideration for this Agreement and the Supplemental Release (hereinafter collectively referred to as &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Separation Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), and Employee agrees that Employee will not publicize, directly or indirectly, any Separation Information. If, however, Employee becomes an advisor to the Company pursuant to the Advisory Agreement, Employee may disclose that he is an advisor to the Company for the time period Employee is a service provider to the Company under such Advisory Agreement.  Except as required by law, and subject to the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Protected Activity Not Prohibited</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; section below, Employee may disclose Separation Information only to Employee&#8217;s immediate family members, the Court in any proceedings to enforce the terms of this Agreement or the Supplemental Release, Employee&#8217;s counsel, and Employee&#8217;s accountant and any professional tax advisor to the extent that they need to know the Separation Information in order to provide advice on tax treatment or to prepare tax returns, and must prevent disclosure of any Separation Information to all other third parties. </font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.25pt;text-decoration:underline">Trade Secrets and Confidential Information&#47;Company Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Employee reaffirms and agrees to observe and abide by the terms of the Confidentiality Agreement, specifically including the provisions therein regarding nondisclosure of the Company&#8217;s trade secrets and confidential and proprietary information, and all restrictive covenants.&#160; During the Advisory Period, Employee may continue to use his Company-provided laptop computer (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Laptop</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), although the Company may require the earlier return of the Laptop in its discretion.  Employee&#8217;s signature below constitutes his certification under penalty of perjury that, other than the Laptop, Employee does not have in his possession, custody, or control, and has returned to the Company, all devices, records, data, notes, reports, proposals, lists, correspondence, specifications, drawings, blueprints, sketches, materials, equipment, any other documents, items, or property,  or reproductions of any and all aforementioned items (whether in physical or electronic form) provided to him by the Company (with the exception of personnel documents specifically relating to Employee), developed or obtained by Employee in connection with his relationship with the Company or otherwise belonging to the Company, including, but not limited to, all passwords to any software or other programs or data that Employee used in performing services for the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.25pt;text-decoration:underline">No Cooperation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Subject to the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Protected Activity Not Prohibited</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; section below, Employee agrees that Employee will not knowingly encourage, counsel, or assist any attorneys or their clients in the presentation or prosecution of any disputes, differences, grievances, claims, charges, or complaints by any third party against any of the Releasees, unless under a subpoena or other court order to do so or upon </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">written request from an administrative agency or the legislature</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> or as related directly to the ADEA waiver in this Agreement or the Supplemental Release. Employee agrees both to immediately notify the Company upon receipt of any such subpoena or court order or </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">written request from an administrative agency or the legislature</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, and to furnish, within three (3) business days of its receipt, a copy of such subpoena or other court order or </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">written request from an administrative agency or the legislature</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Subject to the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Protected Activity Not Prohibited</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; section below, if approached by anyone for counsel or assistance in the presentation or prosecution of any disputes, differences, grievances, claims, charges, or complaints against any of the Releasees, Employee shall state no more than that Employee cannot provide counsel or assistance.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.25pt;text-decoration:underline">Nondisparagement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Subject to the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Protected Activity Not Prohibited</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; section below, Employee agrees to refrain from any disparagement, defamation, libel, or slander of any of the Releasees, and agrees to refrain from any tortious interference with the contracts and relationships of any of the Releasees.  Employee shall direct any inquiries by potential future employers to the Company&#8217;s human resources department.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.25pt;text-decoration:underline">Protected Activity Not Prohibited</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Employee understands that nothing in this Agreement or the Supplemental Release shall in any way limit or prohibit Employee from engaging in any &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Protected Activity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">,&#8221; which means filing a charge, complaint, or report with, or otherwise communicating, cooperating, or participating in any investigation or proceeding that may be conducted by, any federal, state or local government agency or commission, including the Securities and Exchange Commission, the Equal Employment Opportunity Commission, the Occupational Safety and Health Administration, and the National Labor Relations Board (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Government Agencies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). Additionally, nothing in this Agreement or the Supplemental Release constitutes a waiver of any rights Employee may have under the Sarbanes-Oxley Act or Section 7 of the National Labor Relations Act (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">NLRA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).  For purposes of clarity, nothing in this Agreement or the Supplemental Release shall be interpreted to impair or limit Employee&#8217;s participation in any legally protected activities, such as (i) forming, joining, or supporting labor unions, (ii) bargaining collectively through representatives of employees&#8217; choosing, (iii) discussing wages, benefits, or terms and conditions of employment, and (iv) discussing, or raising complaints about, working conditions for the purpose of mutual aid or protection of Employee or the Company&#8217;s other current or former employees, to the extent such activities are protected by Section 7 of the NLRA.  When engaging in any of the protected conduct described in this section, Employee agrees to take all reasonable precautions to prevent any unauthorized use or disclosure of any Company confidential information&#59; provided, however, that such </font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">disclosures may be made to Government Agencies in connection with Protected Activity.  For the sake of clarity, Company confidential information does not include information regarding working conditions, wages, benefits, or other terms and conditions of employment.  Additionally, Employee understands that the protected conduct described herein does not include the disclosure of any Company attorney-client privileged communications or privileged attorney work product.  Employee understands that nothing in the Confidentiality Agreement shall limit or prohibit Employee from engaging in any protected conduct set forth in this section.  Finally</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">pursuant to the Defend Trade Secrets Act of 2016, Employee is notified that an individual will not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that (a) is made in confidence to a federal, state, or local government official (directly or indirectly) or to an attorney </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">solely</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> for the purpose of reporting or investigating a suspected violation of law, or (b) is made in a complaint or other document filed in a lawsuit or other proceeding, if (and only if) such filing is made under seal. In addition, an individual who files a lawsuit for retaliation by an employer for reporting a suspected violation of law may disclose the trade secret to the individual&#8217;s attorney and use the trade secret information in the court proceeding, if the individual files any document containing the trade secret under seal and does not disclose the trade secret, except pursuant to court order.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.25pt;text-decoration:underline">Breach</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. In addition to the rights provided in the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Attorneys&#8217; Fees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; section below, Employee acknowledges and agrees that any material breach of this Agreement, unless such breach constitutes a legal action by Employee challenging or seeking a determination in good faith of the validity of the waiver in this Agreement or the Supplemental Release under the ADEA, or of any provision of the Confidentiality Agreement or the Advisory Agreement shall entitle the Company immediately to recover and&#47;or cease providing the consideration provided to Employee under this Agreement and the Supplemental Release and to obtain damages, except as provided by law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.25pt;text-decoration:underline">No Admission of Liability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Employee understands and acknowledges that with respect to all claims released in this Agreement and the Supplemental Release, this Agreement and the Supplemental Release constitute a compromise and settlement of any and all actual or potential disputed claims by Employee. No action taken by the Company hereto, either previously or in connection with this Agreement and the Supplemental Release, shall be deemed or construed to be (a)&#160;an admission of the truth or falsity of any actual or potential claims or (b)&#160;an acknowledgment or admission by the Company of any fault or liability whatsoever to Employee or to any third party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.25pt;text-decoration:underline">Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Parties shall each bear their own costs, attorneys&#8217; fees, and other fees incurred in connection with the preparation of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">18.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.25pt;text-decoration:underline">ARBITRATION</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. EXCEPT AS PROHIBITED BY LAW, THE PARTIES AGREE THAT ANY AND ALL DISPUTES ARISING OUT OF THE TERMS OF THIS AGREEMENT OR THE SUPPLEMENTAL RELEASE, THEIR INTERPRETATION, EMPLOYEE&#8217;S EMPLOYMENT WITH THE COMPANY OR THE TERMS THEREOF, OR ANY OF THE MATTERS HEREIN RELEASED, SHALL BE SUBJECT TO BINDING ARBITRATION UNDER THE FEDERAL ARBITRATION ACT (THE &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">FAA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) AND THAT THE FAA SHALL GOVERN AND APPLY TO THIS ARBITRATION AGREEMENT WITH FULL FORCE AND EFFECT&#59; HOWEVER, WITHOUT LIMITING ANY PROVISIONS OF THE FAA, A MOTION OR PETITION OR ACTION TO COMPEL ARBITRATION MAY ALSO BE BROUGHT IN STATE COURT UNDER THE PROCEDURAL PROVISIONS OF SUCH STATE&#8217;S LAWS RELATING TO MOTIONS OR PETITIONS OR ACTIONS TO COMPEL ARBITRATION. EMPLOYEE AGREES THAT, TO THE FULLEST EXTENT PERMITTED BY LAW, EMPLOYEE MAY BRING ANY SUCH ARBITRATION PROCEEDING ONLY IN EMPLOYEE&#8217;S INDIVIDUAL CAPACITY. ANY ARBITRATION WILL OCCUR IN FLORIDA BEFORE JAMS, PURSUANT TO ITS EMPLOYMENT ARBITRATION RULES &#38; PROCEDURES (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">JAMS RULES</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), EXCEPT AS EXPRESSLY PROVIDED IN THIS SECTION. THE PARTIES AGREE THAT THE ARBITRATOR SHALL HAVE THE POWER TO DECIDE ANY MOTIONS BROUGHT BY ANY </font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">PARTY TO THE ARBITRATION, INCLUDING MOTIONS FOR SUMMARY JUDGMENT AND&#47;OR ADJUDICATION, AND MOTIONS TO DISMISS AND DEMURRERS, APPLYING THE STANDARDS SET FORTH UNDER FLORIDA&#8217;S RULES OF CIVIL PROCEDURE. THE PARTIES AGREE THAT THE ARBITRATOR SHALL ISSUE A WRITTEN DECISION ON THE MERITS. THE PARTIES ALSO AGREE THAT THE ARBITRATOR SHALL HAVE THE POWER TO AWARD ANY REMEDIES AVAILABLE UNDER APPLICABLE LAW, AND THAT THE ARBITRATOR MAY AWARD ATTORNEYS&#8217; FEES AND COSTS TO THE PREVAILING PARTY, WHERE PERMITTED BY APPLICABLE LAW. &#160;THE ARBITRATOR MAY GRANT INJUNCTIONS AND OTHER RELIEF IN SUCH DISPUTES. THE ARBITRATOR SHALL APPLY SUBSTANTIVE FLORIDA LAW TO ANY DISPUTE OR CLAIM, WITHOUT REFERENCE TO ANY CONFLICT OF LAW PROVISIONS OF ANY JURISDICTION.  THE DECISION OF THE ARBITRATOR SHALL BE FINAL, CONCLUSIVE, AND BINDING ON THE PARTIES TO THE ARBITRATION. THE PARTIES AGREE THAT THE PREVAILING PARTY IN ANY ARBITRATION SHALL BE ENTITLED TO INJUNCTIVE RELIEF IN ANY COURT OF COMPETENT JURISDICTION TO ENFORCE THE ARBITRATION AWARD. EMPLOYEE UNDERSTANDS THAT THE PARTIES TO THE ARBITRATION SHALL EACH PAY AN EQUAL SHARE OF THE COSTS AND EXPENSES OF SUCH ARBITRATION, AND EACH PARTY SHALL SEPARATELY PAY FOR ITS RESPECTIVE COUNSEL FEES AND EXPENSES&#59; PROVIDED, HOWEVER, THAT THE ARBITRATOR SHALL AWARD ATTORNEYS&#8217; FEES AND COSTS TO THE PREVAILING PARTY, EXCEPT AS PROHIBITED BY LAW.&#160; THE PARTIES HEREBY AGREE TO WAIVE THEIR RIGHT TO HAVE ANY DISPUTE BETWEEN THEM RESOLVED IN A COURT OF LAW BY A JUDGE OR JURY. NOTWITHSTANDING THE FOREGOING, THIS SECTION WILL NOT PREVENT EITHER PARTY FROM SEEKING INJUNCTIVE RELIEF (OR ANY OTHER PROVISIONAL REMEDY) FROM ANY COURT HAVING JURISDICTION OVER THE PARTIES AND THE SUBJECT MATTER OF THEIR DISPUTE RELATING TO THIS AGREEMENT, THE AGREEMENTS INCORPORATED HEREIN BY REFERENCE, AND THE SUPPLEMENTAL RELEASE. SHOULD ANY PART OF THE ARBITRATION AGREEMENT CONTAINED IN THIS SECTION CONFLICT WITH ANY OTHER ARBITRATION AGREEMENT BETWEEN THE PARTIES, THE PARTIES AGREE THAT THIS ARBITRATION AGREEMENT SHALL GOVERN.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">19.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.25pt;text-decoration:underline">Tax Consequences</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The Company makes no representations or warranties with respect to the tax consequences of the consideration provided to Employee or made on Employee&#8217;s behalf under the terms of this Agreement or the Supplemental Release.  Employee agrees and understands that Employee is responsible for payment, if any, of local, state, and&#47;or federal taxes on the consideration provided under this Agreement or the Supplemental Release by the Company and any penalties or assessments thereon.  Employee further agrees to indemnify and hold the Releasees harmless from any claims, demands, deficiencies, penalties, interest, assessments, executions, judgments, or recoveries by any government agency against the Company for any amounts claimed due on account of (a) Employee&#8217;s failure to pay or delayed payment of, federal or state taxes, or (b) damages sustained by the Company by reason of any such claims, including attorneys&#8217; fees and costs.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">20.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.25pt;text-decoration:underline">No Representations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Employee represents that Employee has had an opportunity to consult with an attorney, and has carefully read and understands the scope and effect of the provisions of this Agreement and the Supplemental Release.  Employee has not relied upon any representations or statements made by the Company that are not specifically set forth in this Agreement or the Supplemental Release.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">21.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.25pt;text-decoration:underline">Section 409A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  It is intended that this Agreement and the Supplemental Release comply with, or be exempt from, Code Section 409A and the final regulations and official guidance thereunder (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) and any ambiguities in this Agreement and the Supplemental Release will be interpreted to so comply and&#47;or be exempt from Section 409A. Each payment and benefit to be paid or provided under this Agreement or the Supplemental Release is intended to constitute a series of separate payments for purposes of Section 1.409A-2(b)(2) of the Treasury Regulations.&#160; The Company and Employee will work together in </font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">good faith to consider either (i) amendments to this Agreement or the Supplemental Release&#59; or (ii) revisions to this Agreement or the Supplemental Release with respect to the payment of any awards, which are necessary or appropriate to avoid the imposition of any additional tax or income recognition prior to the actual payment to Employee under Section 409A. In no event will the Releasees reimburse Employee for any taxes that may be imposed on Employee as a result of Section 409A.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">22.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.25pt;text-decoration:underline">Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The Company represents and warrants that the undersigned has the authority to act on behalf of the Company and to bind the Company and all who may claim through it to the terms and conditions of this Agreement and the Supplemental Release.  Employee represents and warrants that Employee has the capacity to act on Employee&#8217;s own behalf and on behalf of all who might claim through Employee to bind them to the terms and conditions of this Agreement and the Supplemental Release.  Each Party warrants and represents that there are no liens or claims of lien or assignments in law or equity or otherwise of or against any of the claims or causes of action released in this Agreement or the Supplemental Release.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">23.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.25pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  In the event that any provision or any portion of any provision hereof (or the Supplemental Release) or any surviving agreement made a part hereof becomes or is declared by a court of competent jurisdiction or arbitrator to be illegal, unenforceable, or void, this Agreement and the Supplemental Release shall continue in full force and effect without said provision or portion of provision.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">24.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.25pt;text-decoration:underline">Attorneys&#8217; Fees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Except with regard to a legal action challenging or seeking a determination in good faith of the validity of the waiver in this Agreement or the Supplemental Release under the ADEA, in the event that either Party brings an action to enforce or effect its rights under this Agreement or the Supplemental Release, the prevailing Party shall be entitled to recover its costs and expenses, including the costs of mediation, arbitration, litigation, court fees, and reasonable attorneys&#8217; fees incurred in connection with such an action.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">25.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.25pt;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. This Agreement (and the Supplemental Release, when entered into and effective) represents the entire agreement and understanding between the Company and Employee concerning the subject matter of this Agreement and the Supplemental Release and Employee&#8217;s employment with and separation from the Company and the events leading thereto and associated therewith, and supersedes and replaces any and all prior agreements and understandings concerning the subject matter of this Agreement and Employee&#8217;s relationship with the Company, with the exception of the Confidentiality Agreement and the Stock Agreements. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">26.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.25pt;text-decoration:underline">No Oral Modification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  This Agreement and the Supplemental Release may only be amended in a writing signed by Employee and the Company&#8217;s Chief Executive Officer.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">27.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.25pt;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  This Agreement and the Supplemental Release shall be governed by the laws of the State of Florida, without regard for choice-of-law provisions, except that any dispute regarding the enforceability of the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Arbitration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; section of this Agreement shall be governed by the FAA.  Employee consents to personal and exclusive jurisdiction and venue in the State of Florida.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">28.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.25pt;text-decoration:underline">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Employee understands that this Agreement shall be null and void if not executed by Employee within twenty-one (21) days. Each Party has seven (7) days after that Party signs this Agreement to revoke it. This Agreement will become effective on the eighth (8th) day after Employee signed this Agreement, so long as it has been signed by the Parties and has not been revoked by either Party before that date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">29.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.25pt;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. This Agreement may be executed in counterparts and each counterpart shall be deemed an original and all of which counterparts taken together shall have the same force and effect as an </font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">original and shall constitute an effective, binding agreement on the part of each of the undersigned.&#160; The counterparts of this Agreement may be executed and delivered by facsimile, photo, email PDF, or other electronic transmission or signature.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">30.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.25pt;text-decoration:underline">Voluntary Execution of Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Employee understands and agrees that Employee executed this Agreement voluntarily and without any duress or undue influence on the part or behalf of the Company or any third party, with the full intent of releasing all of Employee&#8217;s claims against the Company and any of the other Releasees. Employee acknowledges that&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Employee has read this Agreement&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Employee has had a reasonable period of at least twenty-one (21) days in which to consult with an attorney regarding this Agreement, and has been represented in the preparation, negotiation, and execution of this Agreement by an attorney of Employee&#8217;s own choice or has elected not to retain an attorney&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Employee understands the terms and consequences of this Agreement and of the releases it contains&#59; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Employee is fully aware of the legal and binding effect of this Agreement&#59; and</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;Employee has not relied upon any representations or statements made by the Company that are not specifically set forth in this Agreement.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">The remainder of this page is intentionally left blank&#59; signature page follows</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#93;</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9</font></div></div></div><div id="i69b8215cb41a45bf88703976ebb065f9_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:24pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, the Parties have executed this Agreement on the respective dates set forth below.</font></div><div style="margin-bottom:36pt;margin-top:12pt;padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SHAFIQUE VIRANI, an individual</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Dated&#58;  2&#47;6&#47;2024&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Shafique Virani</font></div><div style="margin-bottom:36pt;padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Shafique Virani</font></div><div style="margin-bottom:36pt;margin-top:12pt;padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">RECURSION PHARMACEUTICALS, INC.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Dated&#58;  2&#47;6&#47;2024&#160;&#160;&#160;&#160;By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Christopher Gibson</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Christopher Gibson</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;CEO</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="height:49.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><div id="i69b8215cb41a45bf88703976ebb065f9_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit A</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Equity Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">)</font></div><div style="padding-left:20.7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.728%"><tr><td style="width:1.0%"></td><td style="width:28.052%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.950%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.137%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.919%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#aeaaaa;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Grant ID</font></td><td colspan="3" style="background-color:#aeaaaa;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Grant Date</font></td><td colspan="3" style="background-color:#aeaaaa;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Type of Equity Award*</font></td><td colspan="3" style="background-color:#aeaaaa;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exercise Price Per Share</font></td><td colspan="3" style="background-color:#aeaaaa;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Original Number of Shares Subject to Equity Award</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ES-411</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">March 4, 2020</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ISO</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$2.22</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">45,045</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ES-411N</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">March 4, 2020</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NSO</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$2.22</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">704,955</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">FIDLU76EF9O31</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">February 4, 2022</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ISO</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$11.40</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">38,438</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">FIDLU76EF9O31</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">February 4, 2022</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NSO</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$11.40</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">42,012</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">FIDLP7EHG7CZS</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">February 4, 2022</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NSO</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$11.40</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5,436</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">FIDLP7EHG7DEO</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">February 4, 2022</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">RSU</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">n&#47;a</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">40,225</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">FIDLP7EHG7DFH</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">February 4, 2022</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">RSU</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">n&#47;a</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2,718</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">FIDMOFZXOSSEI</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">February 1, 2023</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ISO</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$8.55</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16,082</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">FIDMOFZXOSSEI</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">February 1, 2023</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NSO</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$8.55</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">196,425</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">FIDMOFZXOSS2G</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">February 1, 2023</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">RSU</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">n&#47;a</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">106,253</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">FIDMOFZXOSS3A</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">February 1, 2023</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">RSU</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">n&#47;a</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10,837</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Annual Bonus RSUs (yet to be granted)</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Yet to be granted Feb. 2024</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">RSU</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">n&#47;a</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">TBD (dollar grant value of $104,000)</font></td></tr><tr><td colspan="12" style="background-color:#aeaaaa;border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Total&#58;</font></td><td colspan="3" style="background-color:#aeaaaa;border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1,208,426 (prior to Feb. 2024 grant)</font></td></tr></table></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:47.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit B</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Advisory Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">)</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div><font><br></font></div><div style="height:47.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit C</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">SUPPLEMENTAL RELEASE</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This Supplemental Release (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Supplemental Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) is made by and between Shafique Virani (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Advisor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) and Recursion Pharmaceuticals, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) (collectively referred to as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; or individually referred to as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). Capitalized terms used, but not defined herein, shall have the meanings assigned to such terms in the Transition Agreement and Release to which this Supplemental Release was attached as an exhibit (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Transition Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.75pt;text-decoration:underline">Consideration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  In consideration for the Company&#8217;s payment to Advisor of the amount(s) set forth below in Sections 1.a. and&#47;or 1.b. (as applicable), Advisor hereby extends Advisor&#8217;s release and waiver of claims in Section 5 of the Transition Agreement to any claims that may have arisen between the date Advisor signed the Transition Agreement and the date Advisor signs this Supplemental Release. Advisor acknowledges that without this Supplemental Release, Advisor is not entitled to such consideration.  </font></div><div style="margin-top:12pt;padding-left:90pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.37pt">The Company shall pay to Advisor a lump sum cash payment of $2,500 within ten (10) business days after the Supplemental Release Effective Date (as defined below).</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.75pt">If, prior to August 1, 2024, the Company terminates the Advisory Agreement for any reason other than for Cause (as defined below), the Company shall pay Advisor a lump sum cash payment equal to the following amount within ten (10) business days after the Supplemental Release Effective Date&#58; (a)&#160;$390,000 if such termination occurs in February 2024, (b) $325,000 if such termination occurs in March 2024, (c) $260,000 if such termination occurs in April 2024, (d) $195,000 if such termination occurs in May 2024, (e) $130,000 if such termination occurs in June 2024, or (f) $65,000 if such termination occurs in July 2024.  For the avoidance of doubt, if the Company terminates the Advisory Agreement after July 2024 for any reason, Advisor will not receive any payment pursuant to this Section 1.b.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For purposes of this Supplemental Release, &#8220;Cause&#8221; means the following&#58; (i) an act of dishonesty made by Advisor in connection with Advisor&#8217;s performance of Services under the Advisory Agreement, (ii) Advisor&#8217;s conviction of, or plea of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">nolo contendere</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> to, a felony or any crime involving fraud, embezzlement or any other act of moral turpitude, (iii) Advisor&#8217;s gross misconduct, (iv) Advisor&#8217;s unauthorized use or disclosure of any proprietary information or trade secrets of the Company or any other party to whom Advisor owes an obligation of nondisclosure as a result of Advisor&#8217;s relationship with the Company&#59; (v) Advisor&#8217;s willful breach of any obligations under any written agreement or covenant with the Company&#59; or (vi) Advisor&#8217;s failure to provide Services under the Advisory Agreement after Advisor has received a written demand of performance from the Company with specifically sets forth the factual basis for the Company&#8217;s belief that Advisor has not substantially performed Services under the Advisory Agreement and has failed to cure such non-performance to the Company&#8217;s satisfaction within 10 business days after receiving such notice.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.75pt;text-decoration:underline">Acknowledgment of Receipt of All Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Advisor acknowledges and represents that the Company and its agents have paid or provided all compensation, including, without limitation, all advisory fees, stock, stock options, vesting, and any and all other benefits and compensation due to Advisor.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.75pt;text-decoration:underline">Incorporation of Terms of Transition Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The Parties further acknowledge that the terms of the Transition Agreement shall apply to this Supplemental Release and are incorporated herein to the extent that they are not inconsistent with the express terms of this Supplemental Release.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.75pt;text-decoration:underline">Equity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The Parties agree that for purposes of determining the number of shares of the Company&#8217;s common stock that Advisor could otherwise be entitled to purchase from the Company, pursuant to the exercise of outstanding Options, and vesting of RSU Awards, Advisor will be considered to have vested only up to the last day of the Advisory Period. Advisor acknowledges that as of the last day of the </font></div><div style="height:47.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Advisory Period, Advisor has vested in &#91;# OF OPTIONS&#93; and received &#91;# OF SHARES&#93; of the Company&#8217;s common stock pursuant to any vested RSU Awards (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Vested Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). Advisor acknowledges that the total amount of Vested Securities is inclusive of all shares previously acquired by exercising a vested Option and all shares received in settlement of any vested RSU Awards. In addition to the limitations of the Vested Securities, Advisor acknowledges and agrees that Advisor holds no other interest in the Company&#8217;s equity pursuant to any additional agreements similar to the Stock Agreements nor is Advisor entitled to any further vesting of the Equity Awards pursuant to the Stock Agreements.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.75pt;text-decoration:underline">Company Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Advisor&#8217;s signature below constitutes his certification under penalty of perjury that Advisor does not have in his possession, custody, or control, and has returned to the Company, all devices, records, data, notes, reports, proposals, lists, correspondence, specifications, drawings, blueprints, sketches, materials, equipment, any other documents, items, or property,  or reproductions of any and all aforementioned items (whether in physical or electronic form) provided to him by the Company (with the exception of personnel documents specifically relating to Advisor), developed or obtained by Advisor in connection with his relationship with the Company or otherwise belonging to the Company, including, but not limited to, the Laptop and all passwords to any software or other programs or data that Advisor used in performing services for the Company.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.75pt;text-decoration:underline">Acknowledgment of Waiver of Claims under ADEA</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Advisor understands and acknowledges that, to the extent applicable, Advisor</font><font style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> is waiving and releasing any rights or claims </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Advisor may have under the Age Discrimination in Employment Act of 1967 (&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">ADEA</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), and that this waiver and release is knowing and voluntary. Advisor understands and agrees that this waiver and release does not apply to any rights or claims that may arise under the ADEA after the date Advisor signs this Supplemental Release. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Advisor</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> understands and acknowledges that the consideration given for this waiver and release is in addition to anything of value to which Advisor was already entitled. Advisor further understands and acknowledges that Advisor has been advised by this writing that&#58; (a) Advisor should consult with an attorney prior to executing this Supplemental Release&#59; (b) Advisor has had more than twenty-one (21) days within which to consider this Supplemental Release&#59; (c) Advisor has seven (7) days following Advisor&#8217;s execution of this Supplemental Release to revoke this Supplemental Release&#59; (d)&#160;this Supplemental Release shall not be effective until after the revocation period has expired&#59; and (e)&#160;nothing in this Supplemental Release or the Transition Agreement prevents or precludes Advisor from challenging or seeking a determination in good faith of the validity of this waiver under the ADEA, nor does it impose any condition precedent, penalties, or costs for doing so, unless specifically authorized by federal law. Advisor acknowledges and understands that any revocation of this Supplemental Release must be accomplished by a written notification to the person executing this Supplemental Release on the Company&#8217;s behalf that is received prior to the Supplemental Release Effective Date. The Parties agree that changes, whether material or immaterial, do not restart the running of the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">twenty-one (21)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-day period.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.75pt;text-decoration:underline">Supplemental Release Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.   Advisor understands that this Supplemental Release shall be null and void (i) if executed by Advisor before the&#160;termination or expiration of the Advisory Agreement,&#160; or (ii)&#160;if not executed by Advisor within twenty-one (21) days following termination or expiration of the Advisory Agreement.&#160;Each Party has seven (7) days after that Party signs this Supplemental Release to revoke it. This Supplemental Release will become effective on the eighth (8th) day after Advisor signed this Supplemental Release, so long as it has been signed by the Parties on or after the&#160;Separation&#160;Date and has not been revoked by either Party before that date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Supplemental Release Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).&#160;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.75pt;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  This Supplemental Release and the Transition Agreement represent the entire agreement and understanding between the Company and Advisor concerning the subject matter of this Supplemental Release and the Transition Agreement and Advisor&#8217;s relationship with and separation from </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Company and the events leading thereto and associated therewith, and supersedes and replaces any and all prior agreements and understandings concerning Advisor&#8217;s relationship with the Company, with the </font></div><div style="height:47.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">exception of the Confidentiality Agreement, and provisions in the Advisory Agreement that survive its termination (as set forth in Section 6(C)(2) therein).</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.75pt;text-decoration:underline">Voluntary Execution of Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Advisor understands and agrees that Advisor executed this Supplemental Release voluntarily, without any duress or undue </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">influence</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> on the part or behalf of the Company or any third party, with the full intent of releasing all of Advisor&#8217;s claims against any of the Releasees.  Advisor acknowledges that&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Advisor has read this Supplemental Release&#59;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Advisor has been represented in the preparation, negotiation, and execution of this Supplemental Release by legal counsel of Advisor&#8217;s own choice or has elected not to retain legal counsel&#59;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Advisor understands the terms and consequences of this Supplemental Release and of the releases it contains&#59; </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Advisor has not relied upon any representations or statements made by the Company that are not specifically set forth in this Supplemental Release or in the Transition Agreement&#59; and</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;Advisor is fully aware of the legal and binding effect of this Supplemental Release.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">The remainder of this page is intentionally left blank&#59; signature page follows</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#93;</font></div><div><font><br></font></div><div style="height:47.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, the Parties have executed this Supplemental Release on the respective dates set forth below.</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;SHAFIQUE VIRANI, an individual</font></div><div style="margin-top:12pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Dated&#58;  ________________&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Shafique Virani</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;RECURSION PHARMACEUTICALS, INC.</font></div><div style="margin-top:12pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Dated&#58;  ________________&#160;&#160;&#160;&#160;By </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div><font><br></font></div><div style="height:47.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>exhibit311-q0124.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ica5ee512f2dc4ab48a7d91d1af7bf6df_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of Principal Executive Officer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to Rules 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Christopher Gibson, certify that&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.  I have reviewed this Quarterly Report on Form 10-Q of Recursion Pharmaceuticals, Inc.&#59;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Christopher Gibson</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Christopher Gibson, Chief Executive Officer (principal executive officer)&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May&#160;9, 2024</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>exhibit312-q0124.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i500f1e9d4a5c47198c4ae61b51efb772_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of Principal Financial Officer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to Rules 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Michael Secora, certify that&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Quarterly Report on Form 10-Q of Recursion Pharmaceuticals, Inc.&#59;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Michael Secora</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Michael Secora, Chief Financial Officer (principal financial officer)&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May&#160;9, 2024</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>exhibit321-q0124.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i38bbe48bc32343548a0344648f970d73_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certifications of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of Recursion Pharmaceuticals, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended March&#160;31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), The undersigned certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Christopher Gibson</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Christopher Gibson, Chief Executive Officer (principal executive officer)</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Michael Secora</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Michael Secora, Chief Financial Officer (principal financial officer)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May&#160;9, 2024</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>rxrx-20240331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:3e558803-1e4e-49a0-9bef-dda845cc7d19,g:dd7baf31-0188-4ca9-9996-087ebdfea724-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:rxrx="http://www.recursion.com/20240331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.recursion.com/20240331">
  <xs:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2023" schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rxrx-20240331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rxrx-20240331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rxrx-20240331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rxrx-20240331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.recursion.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsunaudited" roleURI="http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited">
        <link:definition>0000002 - Statement - Condensed Consolidated Balance Sheets (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsunauditedParenthetical" roleURI="http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical">
        <link:definition>0000003 - Statement - Condensed Consolidated Balance Sheets (unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited" roleURI="http://www.recursion.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited">
        <link:definition>0000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquityunaudited" roleURI="http://www.recursion.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited">
        <link:definition>0000005 - Statement - Condensed Consolidated Statements of Stockholders&#8217; Equity (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlowsunaudited" roleURI="http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited">
        <link:definition>0000006 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionoftheBusiness" roleURI="http://www.recursion.com/role/DescriptionoftheBusiness">
        <link:definition>0000007 - Disclosure - Description of the Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentation" roleURI="http://www.recursion.com/role/BasisofPresentation">
        <link:definition>0000008 - Disclosure - Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalFinancialInformation" roleURI="http://www.recursion.com/role/SupplementalFinancialInformation">
        <link:definition>0000009 - Disclosure - Supplemental Financial Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Acquisitions" roleURI="http://www.recursion.com/role/Acquisitions">
        <link:definition>0000010 - Disclosure - Acquisitions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.recursion.com/role/Leases">
        <link:definition>0000011 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssets" roleURI="http://www.recursion.com/role/GoodwillandIntangibleAssets">
        <link:definition>0000012 - Disclosure - Goodwill and Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.recursion.com/role/CommitmentsandContingencies">
        <link:definition>0000013 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStock" roleURI="http://www.recursion.com/role/CommonStock">
        <link:definition>0000014 - Disclosure - Common Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeDevelopmentContracts" roleURI="http://www.recursion.com/role/CollaborativeDevelopmentContracts">
        <link:definition>0000015 - Disclosure - Collaborative Development Contracts</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.recursion.com/role/StockBasedCompensation">
        <link:definition>0000016 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.recursion.com/role/IncomeTaxes">
        <link:definition>0000017 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShare" roleURI="http://www.recursion.com/role/NetLossPerShare">
        <link:definition>0000018 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.recursion.com/role/FairValueMeasurements">
        <link:definition>0000019 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationPolicies" roleURI="http://www.recursion.com/role/BasisofPresentationPolicies">
        <link:definition>9954471 - Disclosure - Basis of Presentation (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalFinancialInformationTables" roleURI="http://www.recursion.com/role/SupplementalFinancialInformationTables">
        <link:definition>9954472 - Disclosure - Supplemental Financial Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsTables" roleURI="http://www.recursion.com/role/AcquisitionsTables">
        <link:definition>9954473 - Disclosure - Acquisitions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.recursion.com/role/LeasesTables">
        <link:definition>9954474 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsTables" roleURI="http://www.recursion.com/role/GoodwillandIntangibleAssetsTables">
        <link:definition>9954475 - Disclosure - Goodwill and Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.recursion.com/role/StockBasedCompensationTables">
        <link:definition>9954476 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareTables" roleURI="http://www.recursion.com/role/NetLossPerShareTables">
        <link:definition>9954477 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.recursion.com/role/FairValueMeasurementsTables">
        <link:definition>9954478 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionoftheBusinessDetails" roleURI="http://www.recursion.com/role/DescriptionoftheBusinessDetails">
        <link:definition>9954479 - Disclosure - Description of the Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalFinancialInformationNarrativeDetails" roleURI="http://www.recursion.com/role/SupplementalFinancialInformationNarrativeDetails">
        <link:definition>9954480 - Disclosure - Supplemental Financial Information - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalFinancialInformationScheduleofPropertyandEquipmentDetails" roleURI="http://www.recursion.com/role/SupplementalFinancialInformationScheduleofPropertyandEquipmentDetails">
        <link:definition>9954481 - Disclosure - Supplemental Financial Information - Schedule of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalFinancialInformationScheduleofAccruedExpensesandOtherLiabilitiesDetails" roleURI="http://www.recursion.com/role/SupplementalFinancialInformationScheduleofAccruedExpensesandOtherLiabilitiesDetails">
        <link:definition>9954482 - Disclosure - Supplemental Financial Information - Schedule of Accrued Expenses and Other Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalFinancialInformationScheduleofInterestIncomeandExpenseDisclosureDetails" roleURI="http://www.recursion.com/role/SupplementalFinancialInformationScheduleofInterestIncomeandExpenseDisclosureDetails">
        <link:definition>9954483 - Disclosure - Supplemental Financial Information - Schedule of Interest Income and Expense Disclosure (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsNarrativeDetails" roleURI="http://www.recursion.com/role/AcquisitionsNarrativeDetails">
        <link:definition>9954484 - Disclosure - Acquisitions - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails" roleURI="http://www.recursion.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails">
        <link:definition>9954485 - Disclosure - Acquisitions - Schedule of Business Acquisitions, by Acquisition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" roleURI="http://www.recursion.com/role/AcquisitionsScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails">
        <link:definition>9954486 - Disclosure - Acquisitions - Schedule of Fair Value of Assets Acquired and Liabilities Assumed (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsScheduleofBusinessAcquisitionsProFormaInformationDetails" roleURI="http://www.recursion.com/role/AcquisitionsScheduleofBusinessAcquisitionsProFormaInformationDetails">
        <link:definition>9954487 - Disclosure - Acquisitions - Schedule of Business Acquisitions, Pro Forma Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.recursion.com/role/LeasesNarrativeDetails">
        <link:definition>9954488 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesComponentsofLeaseCostDetails" roleURI="http://www.recursion.com/role/LeasesComponentsofLeaseCostDetails">
        <link:definition>9954489 - Disclosure - Leases - Components of Lease Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLeaseTermandDiscountRatesDetails" roleURI="http://www.recursion.com/role/LeasesLeaseTermandDiscountRatesDetails">
        <link:definition>9954490 - Disclosure - Leases - Lease Term and Discount Rates (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" roleURI="http://www.recursion.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails">
        <link:definition>9954491 - Disclosure - Leases - Maturities of Operating Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1" roleURI="http://www.recursion.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1">
        <link:definition>9954491 - Disclosure - Leases - Maturities of Operating Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsDetails" roleURI="http://www.recursion.com/role/GoodwillandIntangibleAssetsDetails">
        <link:definition>9954492 - Disclosure - Goodwill and Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsDetails_1" roleURI="http://www.recursion.com/role/GoodwillandIntangibleAssetsDetails_1">
        <link:definition>9954492 - Disclosure - Goodwill and Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesDetails" roleURI="http://www.recursion.com/role/CommitmentsandContingenciesDetails">
        <link:definition>9954493 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockDetails" roleURI="http://www.recursion.com/role/CommonStockDetails">
        <link:definition>9954494 - Disclosure - Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeDevelopmentContractsDetails" roleURI="http://www.recursion.com/role/CollaborativeDevelopmentContractsDetails">
        <link:definition>9954495 - Disclosure - Collaborative Development Contracts (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationNarrativeDetails" roleURI="http://www.recursion.com/role/StockBasedCompensationNarrativeDetails">
        <link:definition>9954496 - Disclosure - Stock-Based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofStockbasedCompensationExpensesDetails" roleURI="http://www.recursion.com/role/StockBasedCompensationSummaryofStockbasedCompensationExpensesDetails">
        <link:definition>9954497 - Disclosure - Stock-Based Compensation - Summary of Stock-based Compensation Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofSharebasedPaymentArrangementOptionActivityDetails" roleURI="http://www.recursion.com/role/StockBasedCompensationScheduleofSharebasedPaymentArrangementOptionActivityDetails">
        <link:definition>9954498 - Disclosure - Stock-Based Compensation - Schedule of Share-based Payment Arrangement, Option, Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionDetails" roleURI="http://www.recursion.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionDetails">
        <link:definition>9954499 - Disclosure - Stock-Based Compensation - Schedule of Share-based Payment Award, Stock Options, Valuation Assumption (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofRSUActivityDetails" roleURI="http://www.recursion.com/role/StockBasedCompensationScheduleofRSUActivityDetails">
        <link:definition>9954500 - Disclosure - Stock-Based Compensation - Schedule of RSU Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.recursion.com/role/IncomeTaxesDetails">
        <link:definition>9954501 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareScheduleofBasicandDilutedNetLossperShareDetails" roleURI="http://www.recursion.com/role/NetLossPerShareScheduleofBasicandDilutedNetLossperShareDetails">
        <link:definition>9954502 - Disclosure - Net Loss Per Share - Schedule of Basic and Diluted Net Loss per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossPerShareDetails" roleURI="http://www.recursion.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossPerShareDetails">
        <link:definition>9954503 - Disclosure - Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails" roleURI="http://www.recursion.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails">
        <link:definition>9954504 - Disclosure - Fair Value Measurements - Assets and Liabilities Measured on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsAssetandLiabilityNotMeasuredatFairValueDetails" roleURI="http://www.recursion.com/role/FairValueMeasurementsAssetandLiabilityNotMeasuredatFairValueDetails">
        <link:definition>9954505 - Disclosure - Fair Value Measurements - Asset and Liability Not Measured at Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="rxrx_NumberOfClassesOfCommonStockAuthorized" abstract="false" name="NumberOfClassesOfCommonStockAuthorized" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="rxrx_LicenseAgreementTradingPeriodUsedForEquityValueDetermination" abstract="false" name="LicenseAgreementTradingPeriodUsedForEquityValueDetermination" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="rxrx_ValenceDiscoveryIncMember" abstract="true" name="ValenceDiscoveryIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rxrx_RevenueRemainingPerformanceObligationVariableConsiderationAmount" abstract="false" name="RevenueRemainingPerformanceObligationVariableConsiderationAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rxrx_NeuroscienceMember" abstract="true" name="NeuroscienceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rxrx_SupplementalBalanceSheetAndIncomeStatementInformationTextBlock" abstract="false" name="SupplementalBalanceSheetAndIncomeStatementInformationTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="rxrx_LesseeOperatingLeaseSquareFootageOfLeasedSpace" abstract="false" name="LesseeOperatingLeaseSquareFootageOfLeasedSpace" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:areaItemType"/>
  <xs:element id="rxrx_MichaelSecoraMember" abstract="true" name="MichaelSecoraMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rxrx_BioHiveSupercomputerMember" abstract="true" name="BioHiveSupercomputerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rxrx_SaleOfStockValueAuthorized" abstract="false" name="SaleOfStockValueAuthorized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rxrx_SaleOfStockValueRemainingAuthorized" abstract="false" name="SaleOfStockValueRemainingAuthorized" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rxrx_AtTheMarketOfferingProgramMember" abstract="true" name="AtTheMarketOfferingProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rxrx_RegistrationRightsAgreementTerm" abstract="false" name="RegistrationRightsAgreementTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="rxrx_FinancedEquipmentPurchase" abstract="false" name="FinancedEquipmentPurchase" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rxrx_GastrointestinalCancerMember" abstract="true" name="GastrointestinalCancerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rxrx_ExchangeableStockMember" abstract="true" name="ExchangeableStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rxrx_LeaseDescriptionDomain" abstract="true" name="LeaseDescriptionDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rxrx_CyclicaIncMember" abstract="true" name="CyclicaIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rxrx_Station41LeaseMember" abstract="true" name="Station41LeaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rxrx_AffiliatedHoldersOwnershipPercentage" abstract="false" name="AffiliatedHoldersOwnershipPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="rxrx_RevenueRemainingPerformanceObligationNumberOfProjectsThatMayBeInitiated" abstract="false" name="RevenueRemainingPerformanceObligationNumberOfProjectsThatMayBeInitiated" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="rxrx_LondonLeaseMember" abstract="true" name="LondonLeaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rxrx_LesseeOperatingLeaseIncreaseDecreaseInOperatingLeaseLiabilityDueToLeaseModifications" abstract="false" name="LesseeOperatingLeaseIncreaseDecreaseInOperatingLeaseLiabilityDueToLeaseModifications" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rxrx_DataCenterLeaseMember" abstract="true" name="DataCenterLeaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rxrx_RocheAndGenentechMember" abstract="true" name="RocheAndGenentechMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rxrx_IncreaseDecreaseInAccruedDevelopmentExpense" abstract="false" name="IncreaseDecreaseInAccruedDevelopmentExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rxrx_LicenseAgreementAnnualPayments" abstract="false" name="LicenseAgreementAnnualPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rxrx_RecursionValenceAndCyclicaMember" abstract="true" name="RecursionValenceAndCyclicaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rxrx_BusinessCombinationConsiderationTransferredEquityInterestsIssuable" abstract="false" name="BusinessCombinationConsiderationTransferredEquityInterestsIssuable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rxrx_RevenueRemainingPerformanceObligationAxis" abstract="true" name="RevenueRemainingPerformanceObligationAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="rxrx_LaboratoryEquipmentMember" abstract="true" name="LaboratoryEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rxrx_RevenueRemainingPerformanceObligationDomain" abstract="true" name="RevenueRemainingPerformanceObligationDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rxrx_NVDIAPrivatePlacementMember" abstract="true" name="NVDIAPrivatePlacementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rxrx_AccruedEarlyDiscoveryExpensesCurrent" abstract="false" name="AccruedEarlyDiscoveryExpensesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rxrx_ContractWithCustomerMaximumAcceptedProduct" abstract="false" name="ContractWithCustomerMaximumAcceptedProduct" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="rxrx_RegistrationRightsAgreementAccruedLiability" abstract="false" name="RegistrationRightsAgreementAccruedLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rxrx_LicenseAgreementAggregatePayments" abstract="false" name="LicenseAgreementAggregatePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rxrx_SupplementalFinancialInformationAbstract" abstract="true" name="SupplementalFinancialInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilitiesCurrent" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilitiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rxrx_TerryAnnBurrellMember" abstract="true" name="TerryAnnBurrellMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rxrx_AccruedDevelopmentCostsCurrent" abstract="false" name="AccruedDevelopmentCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rxrx_AffiliatedHoldersPotentialOwnershipPercentageWhenOutstandingEquityAwardsVest" abstract="false" name="AffiliatedHoldersPotentialOwnershipPercentageWhenOutstandingEquityAwardsVest" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="rxrx_SaleOfStockPercentageOfCommission" abstract="false" name="SaleOfStockPercentageOfCommission" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="rxrx_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour" abstract="false" name="LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rxrx_CommonStockConversionRatio" abstract="false" name="CommonStockConversionRatio" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="rxrx_RevenuePerformanceObligationNumberOfObligations" abstract="false" name="RevenuePerformanceObligationNumberOfObligations" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="rxrx_CommonStockVotePerShare" abstract="false" name="CommonStockVotePerShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="rxrx_A2021EquityIncentivePlanMember" abstract="true" name="A2021EquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInvestments" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInvestments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rxrx_MaterialsReceivedNotInvoiced" abstract="false" name="MaterialsReceivedNotInvoiced" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rxrx_LicenseAgreementTerm" abstract="false" name="LicenseAgreementTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherReceivables" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherReceivables" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rxrx_BusinessAcquisitionContingentConsiderationEquityInterestsIssuableNumberOfShares" abstract="false" name="BusinessAcquisitionContingentConsiderationEquityInterestsIssuableNumberOfShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="rxrx_TempusAgreementMember" abstract="true" name="TempusAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rxrx_PercentOfAggregatePurchasePricePaidByTheHolderDueIfAgreementIsBroken" abstract="false" name="PercentOfAggregatePurchasePricePaidByTheHolderDueIfAgreementIsBroken" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="rxrx_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" abstract="false" name="IncreaseDecreaseInOperatingLeaseRightOfUseAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rxrx_PhenomapsRawImagesMember" abstract="true" name="PhenomapsRawImagesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rxrx_TempusLabsIncMember" abstract="true" name="TempusLabsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rxrx_LicenseAgreementPrepaidExpenses" abstract="false" name="LicenseAgreementPrepaidExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rxrx_PhenomapsCreationMember" abstract="true" name="PhenomapsCreationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rxrx_DevelopedAndCommercializedProgramsMember" abstract="true" name="DevelopedAndCommercializedProgramsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rxrx_LeaseDescriptionAxis" abstract="true" name="LeaseDescriptionAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="rxrx_ChristopherGibsonAndAffiliatesMember" abstract="true" name="ChristopherGibsonAndAffiliatesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rxrx_TinaMarriottMember" abstract="true" name="TinaMarriottMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rxrx_RestrictedCashAndCashEquivalentsFairValueDisclosure" abstract="false" name="RestrictedCashAndCashEquivalentsFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>rxrx-20240331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:3e558803-1e4e-49a0-9bef-dda845cc7d19,g:dd7baf31-0188-4ca9-9996-087ebdfea724-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited" xlink:type="simple" xlink:href="rxrx-20240331.xsd#CondensedConsolidatedBalanceSheetsunaudited"/>
  <link:calculationLink xlink:role="http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_ef9442e9-4d8d-474d-9b8b-b66a1735a5b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_70dc2bd2-5085-423c-9d82-105d1bd78a83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_ef9442e9-4d8d-474d-9b8b-b66a1735a5b0" xlink:to="loc_us-gaap_Liabilities_70dc2bd2-5085-423c-9d82-105d1bd78a83" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_deb4f515-2ac7-4dab-8b6b-9eb9bc11ec1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_ef9442e9-4d8d-474d-9b8b-b66a1735a5b0" xlink:to="loc_us-gaap_CommitmentsAndContingencies_deb4f515-2ac7-4dab-8b6b-9eb9bc11ec1f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_bb5cab66-b47c-4eec-94af-2e42f0021628" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_ef9442e9-4d8d-474d-9b8b-b66a1735a5b0" xlink:to="loc_us-gaap_StockholdersEquity_bb5cab66-b47c-4eec-94af-2e42f0021628" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_0c4abc9f-0aab-452f-a89f-26ca6839b0e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_885e5d31-2ef6-4632-b648-0ca87d3ec49a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_0c4abc9f-0aab-452f-a89f-26ca6839b0e8" xlink:to="loc_us-gaap_LiabilitiesCurrent_885e5d31-2ef6-4632-b648-0ca87d3ec49a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_ef550918-fb04-491c-9733-f7d89ec74999" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_0c4abc9f-0aab-452f-a89f-26ca6839b0e8" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_ef550918-fb04-491c-9733-f7d89ec74999" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermNotesPayable_b8c0fa41-ff42-4525-aafe-9169f154d0af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermNotesPayable"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_0c4abc9f-0aab-452f-a89f-26ca6839b0e8" xlink:to="loc_us-gaap_LongTermNotesPayable_b8c0fa41-ff42-4525-aafe-9169f154d0af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1093c3ed-baf5-47f6-9e17-665a72541a4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_0c4abc9f-0aab-452f-a89f-26ca6839b0e8" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1093c3ed-baf5-47f6-9e17-665a72541a4f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_d7ea6a50-b1b6-416f-acce-934cee0b8cf5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_0c4abc9f-0aab-452f-a89f-26ca6839b0e8" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_d7ea6a50-b1b6-416f-acce-934cee0b8cf5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_135eb45e-5a92-4b76-99fd-8ef1ec71fd44" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_5b7ed560-3db0-4713-8870-e40fd87e1532" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_135eb45e-5a92-4b76-99fd-8ef1ec71fd44" xlink:to="loc_us-gaap_AccountsPayableCurrent_5b7ed560-3db0-4713-8870-e40fd87e1532" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_2f86d34a-9c54-4c2e-ba9d-96880e7adebb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_135eb45e-5a92-4b76-99fd-8ef1ec71fd44" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_2f86d34a-9c54-4c2e-ba9d-96880e7adebb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_e06df585-1b5b-4408-94e1-905e9ae4d5e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_135eb45e-5a92-4b76-99fd-8ef1ec71fd44" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_e06df585-1b5b-4408-94e1-905e9ae4d5e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_686221d8-8469-4cd7-81e6-556c425cc844" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_135eb45e-5a92-4b76-99fd-8ef1ec71fd44" xlink:to="loc_us-gaap_NotesPayableCurrent_686221d8-8469-4cd7-81e6-556c425cc844" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_54394315-92cc-49bc-bef5-5644b58f7f51" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_135eb45e-5a92-4b76-99fd-8ef1ec71fd44" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_54394315-92cc-49bc-bef5-5644b58f7f51" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_e1d9dd0b-2a00-4169-86cc-2cc77dbd3fae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_809b8f4e-2bc4-4c93-bbac-3796c38db45f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e1d9dd0b-2a00-4169-86cc-2cc77dbd3fae" xlink:to="loc_us-gaap_AssetsCurrent_809b8f4e-2bc4-4c93-bbac-3796c38db45f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_a43aa2e1-76f7-4e41-9574-bafec8f7017c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e1d9dd0b-2a00-4169-86cc-2cc77dbd3fae" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_a43aa2e1-76f7-4e41-9574-bafec8f7017c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_193a229b-28e7-425c-bcf0-6ce3a9db8281" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e1d9dd0b-2a00-4169-86cc-2cc77dbd3fae" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_193a229b-28e7-425c-bcf0-6ce3a9db8281" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_78e1d3c0-c1c1-4f40-9867-9dfefa658c03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e1d9dd0b-2a00-4169-86cc-2cc77dbd3fae" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_78e1d3c0-c1c1-4f40-9867-9dfefa658c03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_90e809b5-39bf-4cac-a8e8-b004889b106b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e1d9dd0b-2a00-4169-86cc-2cc77dbd3fae" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_90e809b5-39bf-4cac-a8e8-b004889b106b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_0c6372e4-a823-4f1c-9128-150b7ff95ff2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e1d9dd0b-2a00-4169-86cc-2cc77dbd3fae" xlink:to="loc_us-gaap_Goodwill_0c6372e4-a823-4f1c-9128-150b7ff95ff2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_6ba4fed3-9915-4d82-b5de-e2e30d5bd974" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e1d9dd0b-2a00-4169-86cc-2cc77dbd3fae" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_6ba4fed3-9915-4d82-b5de-e2e30d5bd974" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_e9e46f45-5e9b-4315-92c1-9ce8fe04a122" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d73b4214-37c5-405d-a4a1-07b9d52aacc9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_e9e46f45-5e9b-4315-92c1-9ce8fe04a122" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d73b4214-37c5-405d-a4a1-07b9d52aacc9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_a61578e7-8788-432e-9146-339e3391c66b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_e9e46f45-5e9b-4315-92c1-9ce8fe04a122" xlink:to="loc_us-gaap_RestrictedCashCurrent_a61578e7-8788-432e-9146-339e3391c66b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_32fb2df0-8020-44e1-9566-3909c14235e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_e9e46f45-5e9b-4315-92c1-9ce8fe04a122" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_32fb2df0-8020-44e1-9566-3909c14235e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_e8c043fc-2819-444d-9e4d-ccecd8de8099" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_e9e46f45-5e9b-4315-92c1-9ce8fe04a122" xlink:to="loc_us-gaap_OtherAssetsCurrent_e8c043fc-2819-444d-9e4d-ccecd8de8099" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_4cf6574c-7848-4378-8aec-8f8cd46415e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_fde63055-ce57-48e8-bd08-fa74bed6541d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4cf6574c-7848-4378-8aec-8f8cd46415e6" xlink:to="loc_us-gaap_CommonStockValue_fde63055-ce57-48e8-bd08-fa74bed6541d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_c468c331-ba52-4f91-acea-938cdbae9826" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4cf6574c-7848-4378-8aec-8f8cd46415e6" xlink:to="loc_us-gaap_AdditionalPaidInCapital_c468c331-ba52-4f91-acea-938cdbae9826" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ed624bcd-74c5-488f-af87-5d1c51d47bb8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4cf6574c-7848-4378-8aec-8f8cd46415e6" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ed624bcd-74c5-488f-af87-5d1c51d47bb8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited" xlink:type="simple" xlink:href="rxrx-20240331.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"/>
  <link:calculationLink xlink:role="http://www.recursion.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_3da11925-84e2-4530-898b-90d7e553023c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_72f0320d-3725-47dc-aca4-ead49f54a7f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_3da11925-84e2-4530-898b-90d7e553023c" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_72f0320d-3725-47dc-aca4-ead49f54a7f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_894cecc0-4311-480e-ab1b-a439473b9048" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_3da11925-84e2-4530-898b-90d7e553023c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_894cecc0-4311-480e-ab1b-a439473b9048" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_7428e9a8-f674-4492-a5a9-bd729d33467f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_3da11925-84e2-4530-898b-90d7e553023c" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_7428e9a8-f674-4492-a5a9-bd729d33467f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_fd49ee22-ffb1-4791-b0c9-4d0f3b73001d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_c87c0904-69da-4a73-920e-36db17a970db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_fd49ee22-ffb1-4791-b0c9-4d0f3b73001d" xlink:to="loc_us-gaap_OperatingIncomeLoss_c87c0904-69da-4a73-920e-36db17a970db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_9a317974-3ccf-4d79-8ba6-4a0523d7a17b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_fd49ee22-ffb1-4791-b0c9-4d0f3b73001d" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_9a317974-3ccf-4d79-8ba6-4a0523d7a17b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ccca7e39-aceb-4b24-941b-3f306c6de9c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9c0e2b2b-6b52-4dc4-84b7-026cea960ecb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_ccca7e39-aceb-4b24-941b-3f306c6de9c2" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9c0e2b2b-6b52-4dc4-84b7-026cea960ecb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_3a804f11-961e-4c2f-9553-b659e1bbb360" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_ccca7e39-aceb-4b24-941b-3f306c6de9c2" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_3a804f11-961e-4c2f-9553-b659e1bbb360" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_1c7991df-3b77-4fc9-ba58-fc8e7d38c196" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3eed0750-c4ef-44fd-8145-7372d355b80d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_1c7991df-3b77-4fc9-ba58-fc8e7d38c196" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3eed0750-c4ef-44fd-8145-7372d355b80d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_fc22dde1-cac5-4f7d-aff9-6a202476efc5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_1c7991df-3b77-4fc9-ba58-fc8e7d38c196" xlink:to="loc_us-gaap_CostsAndExpenses_fc22dde1-cac5-4f7d-aff9-6a202476efc5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_39b5754c-e00c-4f95-80af-9edb8d478c2b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_611c7c4e-e34e-4de4-aea1-1450d751d6e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_39b5754c-e00c-4f95-80af-9edb8d478c2b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_611c7c4e-e34e-4de4-aea1-1450d751d6e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_73d4188c-af40-4b5d-8c26-8d100874c8ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_39b5754c-e00c-4f95-80af-9edb8d478c2b" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_73d4188c-af40-4b5d-8c26-8d100874c8ff" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" xlink:type="simple" xlink:href="rxrx-20240331.xsd#CondensedConsolidatedStatementsofCashFlowsunaudited"/>
  <link:calculationLink xlink:role="http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9286b8f8-a543-42e4-ab15-328f2efa91ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_a87bbfed-e609-4767-8aef-fd4ae503039d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9286b8f8-a543-42e4-ab15-328f2efa91ce" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_a87bbfed-e609-4767-8aef-fd4ae503039d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_35b59e13-cb5b-4a3c-9a56-5a0d94fe3538" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9286b8f8-a543-42e4-ab15-328f2efa91ce" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_35b59e13-cb5b-4a3c-9a56-5a0d94fe3538" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_500eb776-7ba3-4f33-8f27-813f8587ca6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9286b8f8-a543-42e4-ab15-328f2efa91ce" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_500eb776-7ba3-4f33-8f27-813f8587ca6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d5d59324-48c5-418a-b8a1-df1f7cb1c486" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2fd28814-7062-4bf2-becb-27f88c59f8f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d5d59324-48c5-418a-b8a1-df1f7cb1c486" xlink:to="loc_us-gaap_NetIncomeLoss_2fd28814-7062-4bf2-becb-27f88c59f8f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_c790db67-ddd8-4462-aef0-253d2c428041" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d5d59324-48c5-418a-b8a1-df1f7cb1c486" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_c790db67-ddd8-4462-aef0-253d2c428041" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_46078046-7a5e-4964-bc72-83905e457db8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d5d59324-48c5-418a-b8a1-df1f7cb1c486" xlink:to="loc_us-gaap_ShareBasedCompensation_46078046-7a5e-4964-bc72-83905e457db8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TangibleAssetImpairmentCharges_5b6056f8-5149-4da7-9dda-b0f211abe23f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TangibleAssetImpairmentCharges"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d5d59324-48c5-418a-b8a1-df1f7cb1c486" xlink:to="loc_us-gaap_TangibleAssetImpairmentCharges_5b6056f8-5149-4da7-9dda-b0f211abe23f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_2313c800-3daf-4af3-b752-d363cf823025" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d5d59324-48c5-418a-b8a1-df1f7cb1c486" xlink:to="loc_us-gaap_OperatingLeaseExpense_2313c800-3daf-4af3-b752-d363cf823025" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_fc3d09c3-9eb9-4409-955c-031d47066831" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d5d59324-48c5-418a-b8a1-df1f7cb1c486" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_fc3d09c3-9eb9-4409-955c-031d47066831" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_40dd0cf0-e413-417e-8a77-17ae49908cd2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d5d59324-48c5-418a-b8a1-df1f7cb1c486" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_40dd0cf0-e413-417e-8a77-17ae49908cd2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_0dc2ad9f-16ea-4703-bc9c-dc34b61f757b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d5d59324-48c5-418a-b8a1-df1f7cb1c486" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_0dc2ad9f-16ea-4703-bc9c-dc34b61f757b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_dcf65926-63f3-41a1-8648-db47548c31c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d5d59324-48c5-418a-b8a1-df1f7cb1c486" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_dcf65926-63f3-41a1-8648-db47548c31c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_IncreaseDecreaseInAccruedDevelopmentExpense_5daff6e5-3140-4aab-8377-acbb66756145" xlink:href="rxrx-20240331.xsd#rxrx_IncreaseDecreaseInAccruedDevelopmentExpense"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d5d59324-48c5-418a-b8a1-df1f7cb1c486" xlink:to="loc_rxrx_IncreaseDecreaseInAccruedDevelopmentExpense_5daff6e5-3140-4aab-8377-acbb66756145" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_0ac7ebd4-7510-462d-8fdf-b53f479fde19" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d5d59324-48c5-418a-b8a1-df1f7cb1c486" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_0ac7ebd4-7510-462d-8fdf-b53f479fde19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_56006dfb-6846-4446-8e21-9f86374606f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d5d59324-48c5-418a-b8a1-df1f7cb1c486" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_56006dfb-6846-4446-8e21-9f86374606f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a629664a-94ef-4a87-a998-a5a66fd39e63" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_cf26d4c5-bfe1-4800-949d-f3645e1ccacc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a629664a-94ef-4a87-a998-a5a66fd39e63" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_cf26d4c5-bfe1-4800-949d-f3645e1ccacc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_abad57cc-4397-4a5f-a3e5-15946a78f9b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a629664a-94ef-4a87-a998-a5a66fd39e63" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_abad57cc-4397-4a5f-a3e5-15946a78f9b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3f82b463-96ef-4594-ab8b-354b64487064" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c726ba1b-25cf-4e83-a245-32e08d5f00e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3f82b463-96ef-4594-ab8b-354b64487064" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c726ba1b-25cf-4e83-a245-32e08d5f00e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_dc768f5b-d24b-48cb-86a7-52baf4d9fc66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3f82b463-96ef-4594-ab8b-354b64487064" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_dc768f5b-d24b-48cb-86a7-52baf4d9fc66" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1c3641c3-c447-474a-b793-bdbe54e0bbc1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3f82b463-96ef-4594-ab8b-354b64487064" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1c3641c3-c447-474a-b793-bdbe54e0bbc1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d267c738-6fb7-4eb2-8038-d739bc4e4c29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3f82b463-96ef-4594-ab8b-354b64487064" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d267c738-6fb7-4eb2-8038-d739bc4e4c29" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/SupplementalFinancialInformationScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="rxrx-20240331.xsd#SupplementalFinancialInformationScheduleofPropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.recursion.com/role/SupplementalFinancialInformationScheduleofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_2da15212-2a4e-4fea-90d9-a727afbb42dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_81cee267-c9d4-496f-9db0-ba24dadab3e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_2da15212-2a4e-4fea-90d9-a727afbb42dd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_81cee267-c9d4-496f-9db0-ba24dadab3e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_855bb855-0c52-4df7-80d9-35a6e4cd130b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_2da15212-2a4e-4fea-90d9-a727afbb42dd" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_855bb855-0c52-4df7-80d9-35a6e4cd130b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/SupplementalFinancialInformationScheduleofAccruedExpensesandOtherLiabilitiesDetails" xlink:type="simple" xlink:href="rxrx-20240331.xsd#SupplementalFinancialInformationScheduleofAccruedExpensesandOtherLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.recursion.com/role/SupplementalFinancialInformationScheduleofAccruedExpensesandOtherLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_c6cd0f1b-2b03-48ea-806e-f6a11699dc7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionPayableCurrent_663f6857-92c4-4dda-80e2-c6c3a5b672a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_c6cd0f1b-2b03-48ea-806e-f6a11699dc7b" xlink:to="loc_us-gaap_ConstructionPayableCurrent_663f6857-92c4-4dda-80e2-c6c3a5b672a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_MaterialsReceivedNotInvoiced_a2faaaed-c5a5-4127-ba56-ae69f7ea14c4" xlink:href="rxrx-20240331.xsd#rxrx_MaterialsReceivedNotInvoiced"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_c6cd0f1b-2b03-48ea-806e-f6a11699dc7b" xlink:to="loc_rxrx_MaterialsReceivedNotInvoiced_a2faaaed-c5a5-4127-ba56-ae69f7ea14c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_AccruedEarlyDiscoveryExpensesCurrent_11febb66-9746-4dd7-af4a-9d959467b77a" xlink:href="rxrx-20240331.xsd#rxrx_AccruedEarlyDiscoveryExpensesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_c6cd0f1b-2b03-48ea-806e-f6a11699dc7b" xlink:to="loc_rxrx_AccruedEarlyDiscoveryExpensesCurrent_11febb66-9746-4dd7-af4a-9d959467b77a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_83e17b16-3312-4451-9d47-fe04271b6042" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_c6cd0f1b-2b03-48ea-806e-f6a11699dc7b" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_83e17b16-3312-4451-9d47-fe04271b6042" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_AccruedDevelopmentCostsCurrent_8d79d302-af81-4aac-8c5b-fc734cfbc14c" xlink:href="rxrx-20240331.xsd#rxrx_AccruedDevelopmentCostsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_c6cd0f1b-2b03-48ea-806e-f6a11699dc7b" xlink:to="loc_rxrx_AccruedDevelopmentCostsCurrent_8d79d302-af81-4aac-8c5b-fc734cfbc14c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_86117e0b-caa1-4ea1-8cfe-431402b69d33" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_c6cd0f1b-2b03-48ea-806e-f6a11699dc7b" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_86117e0b-caa1-4ea1-8cfe-431402b69d33" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/SupplementalFinancialInformationScheduleofInterestIncomeandExpenseDisclosureDetails" xlink:type="simple" xlink:href="rxrx-20240331.xsd#SupplementalFinancialInformationScheduleofInterestIncomeandExpenseDisclosureDetails"/>
  <link:calculationLink xlink:role="http://www.recursion.com/role/SupplementalFinancialInformationScheduleofInterestIncomeandExpenseDisclosureDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRevenueExpenseNet_659a3e9c-200a-4a65-9f02-2943ab450667" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestRevenueExpenseNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_047a53b3-d638-40ba-a8af-2c3ffd22929f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestRevenueExpenseNet_659a3e9c-200a-4a65-9f02-2943ab450667" xlink:to="loc_us-gaap_InterestExpense_047a53b3-d638-40ba-a8af-2c3ffd22929f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNonoperating_9fbd61ce-2263-4138-9608-a75d2ede6505" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeNonoperating"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestRevenueExpenseNet_659a3e9c-200a-4a65-9f02-2943ab450667" xlink:to="loc_us-gaap_InvestmentIncomeNonoperating_9fbd61ce-2263-4138-9608-a75d2ede6505" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails" xlink:type="simple" xlink:href="rxrx-20240331.xsd#AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails"/>
  <link:calculationLink xlink:role="http://www.recursion.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_8d4f45b7-7cb6-4c24-8e73-c42579c72334" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_0a7e6ee2-7db2-44d4-bd10-1b60ccb62517" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_8d4f45b7-7cb6-4c24-8e73-c42579c72334" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_0a7e6ee2-7db2-44d4-bd10-1b60ccb62517" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_1a50bd77-6855-4caa-92b3-f7057eabd83e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_8d4f45b7-7cb6-4c24-8e73-c42579c72334" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_1a50bd77-6855-4caa-92b3-f7057eabd83e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_BusinessCombinationConsiderationTransferredEquityInterestsIssuable_b3037c7e-22b9-4aa7-86b0-9cf652f2b526" xlink:href="rxrx-20240331.xsd#rxrx_BusinessCombinationConsiderationTransferredEquityInterestsIssuable"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_8d4f45b7-7cb6-4c24-8e73-c42579c72334" xlink:to="loc_rxrx_BusinessCombinationConsiderationTransferredEquityInterestsIssuable_b3037c7e-22b9-4aa7-86b0-9cf652f2b526" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/AcquisitionsScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="rxrx-20240331.xsd#AcquisitionsScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:calculationLink xlink:role="http://www.recursion.com/role/AcquisitionsScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_05cf33d2-0cb0-46b0-bfda-e14286db44ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_42241160-a832-462c-9eae-1fbe1625fe2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_05cf33d2-0cb0-46b0-bfda-e14286db44ec" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_42241160-a832-462c-9eae-1fbe1625fe2c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_7039002c-4418-477a-a700-77d4e9c200a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_05cf33d2-0cb0-46b0-bfda-e14286db44ec" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_7039002c-4418-477a-a700-77d4e9c200a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_2ffd3058-931c-4dcd-b623-fb4350fccb62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_05cf33d2-0cb0-46b0-bfda-e14286db44ec" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_2ffd3058-931c-4dcd-b623-fb4350fccb62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_f29395f5-d2c5-47d6-815e-b9b2395b26a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_05cf33d2-0cb0-46b0-bfda-e14286db44ec" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_f29395f5-d2c5-47d6-815e-b9b2395b26a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInvestments_1b4f9ef7-343a-4d39-91e9-3531fbeecfc7" xlink:href="rxrx-20240331.xsd#rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInvestments"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_05cf33d2-0cb0-46b0-bfda-e14286db44ec" xlink:to="loc_rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInvestments_1b4f9ef7-343a-4d39-91e9-3531fbeecfc7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilitiesCurrent_092c433a-303a-44da-95b2-65953d6fee5f" xlink:href="rxrx-20240331.xsd#rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilitiesCurrent"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_05cf33d2-0cb0-46b0-bfda-e14286db44ec" xlink:to="loc_rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilitiesCurrent_092c433a-303a-44da-95b2-65953d6fee5f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_7944f247-86b6-4871-8386-c23c2ca38ed3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_05cf33d2-0cb0-46b0-bfda-e14286db44ec" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_7944f247-86b6-4871-8386-c23c2ca38ed3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherReceivables_911b4077-419a-4d03-a4a8-6de6283462ea" xlink:href="rxrx-20240331.xsd#rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherReceivables"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_05cf33d2-0cb0-46b0-bfda-e14286db44ec" xlink:to="loc_rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherReceivables_911b4077-419a-4d03-a4a8-6de6283462ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_31e2d7b0-78aa-4263-8fff-cdf3c80e6cfc" xlink:href="rxrx-20240331.xsd#rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_05cf33d2-0cb0-46b0-bfda-e14286db44ec" xlink:to="loc_rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_31e2d7b0-78aa-4263-8fff-cdf3c80e6cfc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_5a66b665-da57-4b28-ae6f-3eb7d7336d00" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_05cf33d2-0cb0-46b0-bfda-e14286db44ec" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_5a66b665-da57-4b28-ae6f-3eb7d7336d00" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_57aedae4-48f3-49a5-8ca7-d4055781291a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_05cf33d2-0cb0-46b0-bfda-e14286db44ec" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_57aedae4-48f3-49a5-8ca7-d4055781291a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_c46a8979-acb8-426f-8349-8dda5ca6836d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_92be8137-8074-49eb-aa78-41223b252833" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_c46a8979-acb8-426f-8349-8dda5ca6836d" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_92be8137-8074-49eb-aa78-41223b252833" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_da16b622-afad-4182-a396-e92146319e10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_c46a8979-acb8-426f-8349-8dda5ca6836d" xlink:to="loc_us-gaap_Goodwill_da16b622-afad-4182-a396-e92146319e10" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/LeasesComponentsofLeaseCostDetails" xlink:type="simple" xlink:href="rxrx-20240331.xsd#LeasesComponentsofLeaseCostDetails"/>
  <link:calculationLink xlink:role="http://www.recursion.com/role/LeasesComponentsofLeaseCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_9e804913-5a63-4f09-97bf-13714e10d976" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_36d5707f-4da5-449e-a7d1-ae985bddbc74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_9e804913-5a63-4f09-97bf-13714e10d976" xlink:to="loc_us-gaap_OperatingLeaseCost_36d5707f-4da5-449e-a7d1-ae985bddbc74" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_8d1b1b58-f26d-49b7-bb47-2dc8badb7210" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_9e804913-5a63-4f09-97bf-13714e10d976" xlink:to="loc_us-gaap_VariableLeaseCost_8d1b1b58-f26d-49b7-bb47-2dc8badb7210" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_dfca42dc-7826-40c5-a0cb-8aebbad03f19" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_9e804913-5a63-4f09-97bf-13714e10d976" xlink:to="loc_us-gaap_ShortTermLeaseCost_dfca42dc-7826-40c5-a0cb-8aebbad03f19" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="rxrx-20240331.xsd#LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.recursion.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c81d07a4-f4c4-4e8f-91bc-ec3285276167" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_abdd0c29-faad-42cb-ab5e-794102d1f43c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c81d07a4-f4c4-4e8f-91bc-ec3285276167" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_abdd0c29-faad-42cb-ab5e-794102d1f43c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_8ed0a6a2-7097-4494-a660-00f843e238d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c81d07a4-f4c4-4e8f-91bc-ec3285276167" xlink:to="loc_us-gaap_OperatingLeaseLiability_8ed0a6a2-7097-4494-a660-00f843e238d5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="rxrx-20240331.xsd#LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1"/>
  <link:calculationLink xlink:role="http://www.recursion.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ec6ee2e1-04c5-4f1b-af70-e422a2307c37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_99ba4975-50af-45e3-952e-b6df9acacd38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ec6ee2e1-04c5-4f1b-af70-e422a2307c37" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_99ba4975-50af-45e3-952e-b6df9acacd38" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_702f51c4-cb8b-4c2c-a48e-b54bfde02e28" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ec6ee2e1-04c5-4f1b-af70-e422a2307c37" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_702f51c4-cb8b-4c2c-a48e-b54bfde02e28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_10ef972a-7bbe-4117-8fb6-fc5d59329b36" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ec6ee2e1-04c5-4f1b-af70-e422a2307c37" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_10ef972a-7bbe-4117-8fb6-fc5d59329b36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_238285f8-3ecf-42ae-a17b-933a4f5a8588" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ec6ee2e1-04c5-4f1b-af70-e422a2307c37" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_238285f8-3ecf-42ae-a17b-933a4f5a8588" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1cad2a0e-fb5c-44df-b675-dd82626b2858" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ec6ee2e1-04c5-4f1b-af70-e422a2307c37" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1cad2a0e-fb5c-44df-b675-dd82626b2858" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour_999cd45b-27c8-4e44-8ef5-e82ab18bdd89" xlink:href="rxrx-20240331.xsd#rxrx_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ec6ee2e1-04c5-4f1b-af70-e422a2307c37" xlink:to="loc_rxrx_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour_999cd45b-27c8-4e44-8ef5-e82ab18bdd89" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/GoodwillandIntangibleAssetsDetails" xlink:type="simple" xlink:href="rxrx-20240331.xsd#GoodwillandIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.recursion.com/role/GoodwillandIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_06a2f4db-3dc5-4162-a3cc-456eaf4d060e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_fbc9d239-5e9d-4a1f-ab12-d294120f1028" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_06a2f4db-3dc5-4162-a3cc-456eaf4d060e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_fbc9d239-5e9d-4a1f-ab12-d294120f1028" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_910a8b92-1f43-487e-8eae-22b02007090a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_06a2f4db-3dc5-4162-a3cc-456eaf4d060e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_910a8b92-1f43-487e-8eae-22b02007090a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_c769289e-a830-47e7-8c32-e8b1fc6d895e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_659261c0-d822-4da6-b625-1644c1eb5683" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_c769289e-a830-47e7-8c32-e8b1fc6d895e" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_659261c0-d822-4da6-b625-1644c1eb5683" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_15262105-b0e4-4225-aa1d-88155c546f47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_c769289e-a830-47e7-8c32-e8b1fc6d895e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_15262105-b0e4-4225-aa1d-88155c546f47" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8d5c8e9d-f654-4c9d-8cea-8af477abff15" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_e56b2a71-3c44-4421-ad60-3080424c4e2d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8d5c8e9d-f654-4c9d-8cea-8af477abff15" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_e56b2a71-3c44-4421-ad60-3080424c4e2d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_f49c908e-1261-4fbd-b9b1-2b84d699dc55" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8d5c8e9d-f654-4c9d-8cea-8af477abff15" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_f49c908e-1261-4fbd-b9b1-2b84d699dc55" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/GoodwillandIntangibleAssetsDetails_1" xlink:type="simple" xlink:href="rxrx-20240331.xsd#GoodwillandIntangibleAssetsDetails_1"/>
  <link:calculationLink xlink:role="http://www.recursion.com/role/GoodwillandIntangibleAssetsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_b37923f7-1c17-48f6-97b6-c2b8cbd22d54" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_5814bd66-ad45-4fa7-9ea4-528e1f83efef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_b37923f7-1c17-48f6-97b6-c2b8cbd22d54" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_5814bd66-ad45-4fa7-9ea4-528e1f83efef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_000a89be-675d-4d11-b0d8-353d8edad26a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_b37923f7-1c17-48f6-97b6-c2b8cbd22d54" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_000a89be-675d-4d11-b0d8-353d8edad26a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails" xlink:type="simple" xlink:href="rxrx-20240331.xsd#FairValueMeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.recursion.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_b52f0420-6329-4251-a497-926c29bedf46" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a437cbc5-384c-4865-82ed-9fafc4c2580e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_b52f0420-6329-4251-a497-926c29bedf46" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a437cbc5-384c-4865-82ed-9fafc4c2580e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_RestrictedCashAndCashEquivalentsFairValueDisclosure_452fd71a-e45d-4f14-8c10-c39dc75a5dc0" xlink:href="rxrx-20240331.xsd#rxrx_RestrictedCashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_b52f0420-6329-4251-a497-926c29bedf46" xlink:to="loc_rxrx_RestrictedCashAndCashEquivalentsFairValueDisclosure_452fd71a-e45d-4f14-8c10-c39dc75a5dc0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/FairValueMeasurementsAssetandLiabilityNotMeasuredatFairValueDetails" xlink:type="simple" xlink:href="rxrx-20240331.xsd#FairValueMeasurementsAssetandLiabilityNotMeasuredatFairValueDetails"/>
  <link:calculationLink xlink:role="http://www.recursion.com/role/FairValueMeasurementsAssetandLiabilityNotMeasuredatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_24bf12f0-2989-4eec-8b17-37cd0a7b5e11" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_2b8f531f-c90a-4728-bacf-a72d1736a60d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtFairValue_24bf12f0-2989-4eec-8b17-37cd0a7b5e11" xlink:to="loc_us-gaap_LongTermDebtCurrent_2b8f531f-c90a-4728-bacf-a72d1736a60d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_0e6eecfd-d18d-4b24-93f8-1a3031399efd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtFairValue_24bf12f0-2989-4eec-8b17-37cd0a7b5e11" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_0e6eecfd-d18d-4b24-93f8-1a3031399efd" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>rxrx-20240331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:3e558803-1e4e-49a0-9bef-dda845cc7d19,g:dd7baf31-0188-4ca9-9996-087ebdfea724-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.recursion.com/role/Cover" xlink:type="simple" xlink:href="rxrx-20240331.xsd#Cover"/>
  <link:definitionLink xlink:role="http://www.recursion.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_1c55dfd2-80a6-42a5-b88b-b04bb3b24dd1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_6946bc76-55cc-4862-81d4-9202e52b78c3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_1c55dfd2-80a6-42a5-b88b-b04bb3b24dd1" xlink:to="loc_dei_DocumentInformationTable_6946bc76-55cc-4862-81d4-9202e52b78c3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_0b33eda9-f264-4043-bdc0-894419bc348f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_6946bc76-55cc-4862-81d4-9202e52b78c3" xlink:to="loc_us-gaap_StatementClassOfStockAxis_0b33eda9-f264-4043-bdc0-894419bc348f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_0b33eda9-f264-4043-bdc0-894419bc348f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_0b33eda9-f264-4043-bdc0-894419bc348f" xlink:to="loc_us-gaap_ClassOfStockDomain_0b33eda9-f264-4043-bdc0-894419bc348f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_9f1f9e2e-4716-4164-abc5-8a06288b6d72" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_0b33eda9-f264-4043-bdc0-894419bc348f" xlink:to="loc_us-gaap_ClassOfStockDomain_9f1f9e2e-4716-4164-abc5-8a06288b6d72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_7e34b52a-e388-443a-b724-f9a28441e64a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_9f1f9e2e-4716-4164-abc5-8a06288b6d72" xlink:to="loc_us-gaap_CommonClassAMember_7e34b52a-e388-443a-b724-f9a28441e64a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_ab6bf645-09ba-46cf-90c2-1928156e11a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_9f1f9e2e-4716-4164-abc5-8a06288b6d72" xlink:to="loc_us-gaap_CommonClassBMember_ab6bf645-09ba-46cf-90c2-1928156e11a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_51a03ba6-45c7-4688-9907-8c4cae217826" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1c55dfd2-80a6-42a5-b88b-b04bb3b24dd1" xlink:to="loc_dei_DocumentType_51a03ba6-45c7-4688-9907-8c4cae217826" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_b870de5c-fd85-4895-a5b6-d532a3694aef" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1c55dfd2-80a6-42a5-b88b-b04bb3b24dd1" xlink:to="loc_dei_DocumentQuarterlyReport_b870de5c-fd85-4895-a5b6-d532a3694aef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_c3e18045-be77-491c-809f-cc4b921066f9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1c55dfd2-80a6-42a5-b88b-b04bb3b24dd1" xlink:to="loc_dei_DocumentPeriodEndDate_c3e18045-be77-491c-809f-cc4b921066f9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_f49d147d-106e-4ee9-8c27-0f67cc40ac4e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1c55dfd2-80a6-42a5-b88b-b04bb3b24dd1" xlink:to="loc_dei_DocumentTransitionReport_f49d147d-106e-4ee9-8c27-0f67cc40ac4e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_2a6848c0-795d-4314-93a6-c84671510630" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1c55dfd2-80a6-42a5-b88b-b04bb3b24dd1" xlink:to="loc_dei_EntityFileNumber_2a6848c0-795d-4314-93a6-c84671510630" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_5225480b-93aa-4c48-8330-f3ae62e8f681" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1c55dfd2-80a6-42a5-b88b-b04bb3b24dd1" xlink:to="loc_dei_EntityRegistrantName_5225480b-93aa-4c48-8330-f3ae62e8f681" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_222ae878-617f-4bfa-b6d1-77a2f38ada16" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1c55dfd2-80a6-42a5-b88b-b04bb3b24dd1" xlink:to="loc_dei_EntityIncorporationStateCountryCode_222ae878-617f-4bfa-b6d1-77a2f38ada16" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_c3ff7faa-a57b-4394-8f60-d7756085c13c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1c55dfd2-80a6-42a5-b88b-b04bb3b24dd1" xlink:to="loc_dei_EntityTaxIdentificationNumber_c3ff7faa-a57b-4394-8f60-d7756085c13c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_bd3c7243-8c6a-4f6f-a78d-74520bf7bed8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1c55dfd2-80a6-42a5-b88b-b04bb3b24dd1" xlink:to="loc_dei_EntityAddressAddressLine1_bd3c7243-8c6a-4f6f-a78d-74520bf7bed8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_23cd4110-17bc-4bf4-9f88-0676bd8630b6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1c55dfd2-80a6-42a5-b88b-b04bb3b24dd1" xlink:to="loc_dei_EntityAddressCityOrTown_23cd4110-17bc-4bf4-9f88-0676bd8630b6" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_6bf4bdc2-7e05-49c9-8be6-75ddb0bdf7e2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1c55dfd2-80a6-42a5-b88b-b04bb3b24dd1" xlink:to="loc_dei_EntityAddressStateOrProvince_6bf4bdc2-7e05-49c9-8be6-75ddb0bdf7e2" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_28fbc844-7f2b-4eca-952e-f557a4fc700a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1c55dfd2-80a6-42a5-b88b-b04bb3b24dd1" xlink:to="loc_dei_EntityAddressPostalZipCode_28fbc844-7f2b-4eca-952e-f557a4fc700a" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_17bb9fbf-02cf-4089-aa8a-253915761c37" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1c55dfd2-80a6-42a5-b88b-b04bb3b24dd1" xlink:to="loc_dei_CityAreaCode_17bb9fbf-02cf-4089-aa8a-253915761c37" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_9577eeb4-7e1e-4c70-a6b9-7ef43190f699" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1c55dfd2-80a6-42a5-b88b-b04bb3b24dd1" xlink:to="loc_dei_LocalPhoneNumber_9577eeb4-7e1e-4c70-a6b9-7ef43190f699" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_538f6b4e-7f87-4f1f-b269-3bd73c743714" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1c55dfd2-80a6-42a5-b88b-b04bb3b24dd1" xlink:to="loc_dei_Security12bTitle_538f6b4e-7f87-4f1f-b269-3bd73c743714" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_066eff4b-256f-477c-8d1c-2aa1fe15655a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1c55dfd2-80a6-42a5-b88b-b04bb3b24dd1" xlink:to="loc_dei_TradingSymbol_066eff4b-256f-477c-8d1c-2aa1fe15655a" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_0ebd0e92-fcd9-4994-8724-3c1d6cb27bc0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1c55dfd2-80a6-42a5-b88b-b04bb3b24dd1" xlink:to="loc_dei_SecurityExchangeName_0ebd0e92-fcd9-4994-8724-3c1d6cb27bc0" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_053747bc-b6c5-48dd-b87c-96a587295f63" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1c55dfd2-80a6-42a5-b88b-b04bb3b24dd1" xlink:to="loc_dei_EntityCurrentReportingStatus_053747bc-b6c5-48dd-b87c-96a587295f63" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_3c3f42f5-cfaa-4055-9505-400ea5b52fe8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1c55dfd2-80a6-42a5-b88b-b04bb3b24dd1" xlink:to="loc_dei_EntityInteractiveDataCurrent_3c3f42f5-cfaa-4055-9505-400ea5b52fe8" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_36e3ce89-1232-4b33-b324-24f8cf7b1534" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1c55dfd2-80a6-42a5-b88b-b04bb3b24dd1" xlink:to="loc_dei_EntityFilerCategory_36e3ce89-1232-4b33-b324-24f8cf7b1534" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_2c06bdcc-d324-49f2-9835-5baff28c835d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1c55dfd2-80a6-42a5-b88b-b04bb3b24dd1" xlink:to="loc_dei_EntitySmallBusiness_2c06bdcc-d324-49f2-9835-5baff28c835d" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_d7779d79-9bfe-410f-a573-f5f595c3e864" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1c55dfd2-80a6-42a5-b88b-b04bb3b24dd1" xlink:to="loc_dei_EntityEmergingGrowthCompany_d7779d79-9bfe-410f-a573-f5f595c3e864" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_1a0339a4-5edc-4647-a4a7-855f56ce3618" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1c55dfd2-80a6-42a5-b88b-b04bb3b24dd1" xlink:to="loc_dei_EntityShellCompany_1a0339a4-5edc-4647-a4a7-855f56ce3618" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_0ed6fff2-e866-40c5-b655-33cb7ec0346d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1c55dfd2-80a6-42a5-b88b-b04bb3b24dd1" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_0ed6fff2-e866-40c5-b655-33cb7ec0346d" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_8cb78aef-2ef3-4ef4-bf41-06890fc25509" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1c55dfd2-80a6-42a5-b88b-b04bb3b24dd1" xlink:to="loc_dei_EntityCentralIndexKey_8cb78aef-2ef3-4ef4-bf41-06890fc25509" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_a8a6237e-9b2c-4453-9df2-2cd76f3d799f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1c55dfd2-80a6-42a5-b88b-b04bb3b24dd1" xlink:to="loc_dei_AmendmentFlag_a8a6237e-9b2c-4453-9df2-2cd76f3d799f" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_ced5310b-6e95-4e20-ac31-afc387cd495a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1c55dfd2-80a6-42a5-b88b-b04bb3b24dd1" xlink:to="loc_dei_DocumentFiscalYearFocus_ced5310b-6e95-4e20-ac31-afc387cd495a" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_a7209ef6-82e8-4c95-9a7e-bfdc8057a5b6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1c55dfd2-80a6-42a5-b88b-b04bb3b24dd1" xlink:to="loc_dei_DocumentFiscalPeriodFocus_a7209ef6-82e8-4c95-9a7e-bfdc8057a5b6" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_37c3479b-0774-484c-89fb-4bcc01590c55" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1c55dfd2-80a6-42a5-b88b-b04bb3b24dd1" xlink:to="loc_dei_CurrentFiscalYearEndDate_37c3479b-0774-484c-89fb-4bcc01590c55" xlink:type="arc" order="28"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical" xlink:type="simple" xlink:href="rxrx-20240331.xsd#CondensedConsolidatedBalanceSheetsunauditedParenthetical"/>
  <link:definitionLink xlink:role="http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_36b026d6-1c45-4855-8a34-f6d8bc988918" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_4b1be05b-9a98-4531-a714-a89a1a843433" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_36b026d6-1c45-4855-8a34-f6d8bc988918" xlink:to="loc_us-gaap_StatementTable_4b1be05b-9a98-4531-a714-a89a1a843433" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_9b0a8208-3b1b-4010-bfed-97e9a5e4675e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4b1be05b-9a98-4531-a714-a89a1a843433" xlink:to="loc_us-gaap_StatementClassOfStockAxis_9b0a8208-3b1b-4010-bfed-97e9a5e4675e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_9b0a8208-3b1b-4010-bfed-97e9a5e4675e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9b0a8208-3b1b-4010-bfed-97e9a5e4675e" xlink:to="loc_us-gaap_ClassOfStockDomain_9b0a8208-3b1b-4010-bfed-97e9a5e4675e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4bc330ba-2e35-4383-a867-5f104963e2cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9b0a8208-3b1b-4010-bfed-97e9a5e4675e" xlink:to="loc_us-gaap_ClassOfStockDomain_4bc330ba-2e35-4383-a867-5f104963e2cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_eae7eb69-8006-41b8-b7fe-2471325b8fb7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_4bc330ba-2e35-4383-a867-5f104963e2cc" xlink:to="loc_us-gaap_CommonClassAMember_eae7eb69-8006-41b8-b7fe-2471325b8fb7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_f9d79776-1ee5-4c30-b976-4f72643f5891" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_4bc330ba-2e35-4383-a867-5f104963e2cc" xlink:to="loc_us-gaap_CommonClassBMember_f9d79776-1ee5-4c30-b976-4f72643f5891" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_ExchangeableStockMember_c0e9fe1f-7807-4da5-b2bf-b9966d7c485a" xlink:href="rxrx-20240331.xsd#rxrx_ExchangeableStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_4bc330ba-2e35-4383-a867-5f104963e2cc" xlink:to="loc_rxrx_ExchangeableStockMember_c0e9fe1f-7807-4da5-b2bf-b9966d7c485a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_0eced7a9-722b-4385-a8b6-5830f919b6af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_36b026d6-1c45-4855-8a34-f6d8bc988918" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_0eced7a9-722b-4385-a8b6-5830f919b6af" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_a91ecc29-ed59-4e7f-8713-7e4c358db493" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_36b026d6-1c45-4855-8a34-f6d8bc988918" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_a91ecc29-ed59-4e7f-8713-7e4c358db493" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_bd9a5427-3fb4-4f32-b50d-557f5c1a1d02" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_36b026d6-1c45-4855-8a34-f6d8bc988918" xlink:to="loc_us-gaap_CommonStockSharesIssued_bd9a5427-3fb4-4f32-b50d-557f5c1a1d02" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_f6bee11f-9c0b-48c1-b417-153476f6f03b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_36b026d6-1c45-4855-8a34-f6d8bc988918" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_f6bee11f-9c0b-48c1-b417-153476f6f03b" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.recursion.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited" xlink:type="simple" xlink:href="rxrx-20240331.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"/>
  <link:definitionLink xlink:role="http://www.recursion.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_7c7c754f-16a8-436d-8a7a-42cc7174a81f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_5afafebc-990d-4fad-b4fa-3ae27f279d12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_7c7c754f-16a8-436d-8a7a-42cc7174a81f" xlink:to="loc_us-gaap_StatementTable_5afafebc-990d-4fad-b4fa-3ae27f279d12" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ce45d234-f659-4872-aabc-65e68a97c466" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_5afafebc-990d-4fad-b4fa-3ae27f279d12" xlink:to="loc_srt_ProductOrServiceAxis_ce45d234-f659-4872-aabc-65e68a97c466" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ce45d234-f659-4872-aabc-65e68a97c466_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_ce45d234-f659-4872-aabc-65e68a97c466" xlink:to="loc_srt_ProductsAndServicesDomain_ce45d234-f659-4872-aabc-65e68a97c466_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a31b65d7-bda1-4ddd-be47-8c6f73365ca8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_ce45d234-f659-4872-aabc-65e68a97c466" xlink:to="loc_srt_ProductsAndServicesDomain_a31b65d7-bda1-4ddd-be47-8c6f73365ca8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAndServiceMember_1b27560c-cf9b-4567-bc65-711fb640f493" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseAndServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a31b65d7-bda1-4ddd-be47-8c6f73365ca8" xlink:to="loc_us-gaap_LicenseAndServiceMember_1b27560c-cf9b-4567-bc65-711fb640f493" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_bec997bf-a793-4ea7-8aba-1631fa2ff026" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a31b65d7-bda1-4ddd-be47-8c6f73365ca8" xlink:to="loc_us-gaap_GrantMember_bec997bf-a793-4ea7-8aba-1631fa2ff026" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_9c49f215-0585-4177-b556-c0cac847250b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7c7c754f-16a8-436d-8a7a-42cc7174a81f" xlink:to="loc_us-gaap_RevenuesAbstract_9c49f215-0585-4177-b556-c0cac847250b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c8a4014b-1147-4b51-805d-3894214ac49a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_9c49f215-0585-4177-b556-c0cac847250b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c8a4014b-1147-4b51-805d-3894214ac49a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_2017fb6e-e63c-43a0-998d-e2384aca06d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7c7c754f-16a8-436d-8a7a-42cc7174a81f" xlink:to="loc_us-gaap_OperatingExpensesAbstract_2017fb6e-e63c-43a0-998d-e2384aca06d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_5e3bc9f3-5d58-4b7e-a6a2-ea56c077d86c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2017fb6e-e63c-43a0-998d-e2384aca06d6" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_5e3bc9f3-5d58-4b7e-a6a2-ea56c077d86c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_108a1b00-d9c1-4673-8533-44278c327c43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2017fb6e-e63c-43a0-998d-e2384aca06d6" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_108a1b00-d9c1-4673-8533-44278c327c43" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_e6debde4-d75b-4312-a0c5-9dd0e45b6c81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2017fb6e-e63c-43a0-998d-e2384aca06d6" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_e6debde4-d75b-4312-a0c5-9dd0e45b6c81" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_9a9fc799-3db8-4004-9805-5ef0a8954892" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2017fb6e-e63c-43a0-998d-e2384aca06d6" xlink:to="loc_us-gaap_CostsAndExpenses_9a9fc799-3db8-4004-9805-5ef0a8954892" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_a4bee4a4-aa40-4d83-829e-89e40e40bddd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7c7c754f-16a8-436d-8a7a-42cc7174a81f" xlink:to="loc_us-gaap_OperatingIncomeLoss_a4bee4a4-aa40-4d83-829e-89e40e40bddd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_651fc6f5-b590-440a-b007-6c23dfebe503" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7c7c754f-16a8-436d-8a7a-42cc7174a81f" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_651fc6f5-b590-440a-b007-6c23dfebe503" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5a0ecc34-e820-4607-a1e8-6e6baa63f17b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7c7c754f-16a8-436d-8a7a-42cc7174a81f" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5a0ecc34-e820-4607-a1e8-6e6baa63f17b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_e99c5e78-b613-49c9-89ff-908b6756a444" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7c7c754f-16a8-436d-8a7a-42cc7174a81f" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_e99c5e78-b613-49c9-89ff-908b6756a444" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_e0e4ff62-ddfe-4665-a46f-883d4bc90247" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7c7c754f-16a8-436d-8a7a-42cc7174a81f" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_e0e4ff62-ddfe-4665-a46f-883d4bc90247" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9ee40a40-f511-42a2-a75a-3abc12264231" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7c7c754f-16a8-436d-8a7a-42cc7174a81f" xlink:to="loc_us-gaap_NetIncomeLoss_9ee40a40-f511-42a2-a75a-3abc12264231" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_c273f3be-abbd-4d7f-9ede-d6c80cf333d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7c7c754f-16a8-436d-8a7a-42cc7174a81f" xlink:to="loc_us-gaap_EarningsPerShareAbstract_c273f3be-abbd-4d7f-9ede-d6c80cf333d9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_15200b44-0786-4a4e-9130-c8f8b57c6949" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c273f3be-abbd-4d7f-9ede-d6c80cf333d9" xlink:to="loc_us-gaap_EarningsPerShareBasic_15200b44-0786-4a4e-9130-c8f8b57c6949" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_dfe38768-b6e7-415f-a079-63e988f50be5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c273f3be-abbd-4d7f-9ede-d6c80cf333d9" xlink:to="loc_us-gaap_EarningsPerShareDiluted_dfe38768-b6e7-415f-a079-63e988f50be5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b377e26e-3a4f-459e-a47c-e9565e089a80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c273f3be-abbd-4d7f-9ede-d6c80cf333d9" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b377e26e-3a4f-459e-a47c-e9565e089a80" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9f1f8ff0-8fcd-4140-9dfe-b30c520246c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c273f3be-abbd-4d7f-9ede-d6c80cf333d9" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9f1f8ff0-8fcd-4140-9dfe-b30c520246c8" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.recursion.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited" xlink:type="simple" xlink:href="rxrx-20240331.xsd#CondensedConsolidatedStatementsofStockholdersEquityunaudited"/>
  <link:definitionLink xlink:role="http://www.recursion.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_fa77925c-83b7-44bc-8b03-ef22cfd047a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_a7ca7c32-d687-4f1b-82f3-67744aa3b469" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_fa77925c-83b7-44bc-8b03-ef22cfd047a1" xlink:to="loc_us-gaap_StatementTable_a7ca7c32-d687-4f1b-82f3-67744aa3b469" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1e0b1f7f-c5d1-4f9d-a760-2fad3e20d3c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_a7ca7c32-d687-4f1b-82f3-67744aa3b469" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1e0b1f7f-c5d1-4f9d-a760-2fad3e20d3c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1e0b1f7f-c5d1-4f9d-a760-2fad3e20d3c3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1e0b1f7f-c5d1-4f9d-a760-2fad3e20d3c3" xlink:to="loc_us-gaap_EquityComponentDomain_1e0b1f7f-c5d1-4f9d-a760-2fad3e20d3c3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c33fcdd3-a8ab-4695-8e4a-59a1b2177fde" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1e0b1f7f-c5d1-4f9d-a760-2fad3e20d3c3" xlink:to="loc_us-gaap_EquityComponentDomain_c33fcdd3-a8ab-4695-8e4a-59a1b2177fde" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_6c3b028c-a4c0-487a-bb7d-1999ba51e474" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c33fcdd3-a8ab-4695-8e4a-59a1b2177fde" xlink:to="loc_us-gaap_CommonStockMember_6c3b028c-a4c0-487a-bb7d-1999ba51e474" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_22a603ea-6dc7-40cd-b168-e75e051de757" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c33fcdd3-a8ab-4695-8e4a-59a1b2177fde" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_22a603ea-6dc7-40cd-b168-e75e051de757" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_9c26cc38-ebaa-4917-98ea-652982ef0d88" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c33fcdd3-a8ab-4695-8e4a-59a1b2177fde" xlink:to="loc_us-gaap_RetainedEarningsMember_9c26cc38-ebaa-4917-98ea-652982ef0d88" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_962930f9-83f7-4fa4-a354-0ce0a68b37b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_fa77925c-83b7-44bc-8b03-ef22cfd047a1" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_962930f9-83f7-4fa4-a354-0ce0a68b37b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_9807e812-80d4-41f1-a790-f3552ca91ded" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_962930f9-83f7-4fa4-a354-0ce0a68b37b4" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_9807e812-80d4-41f1-a790-f3552ca91ded" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f0308797-c45b-4326-83cb-6a73fdd3dd69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_962930f9-83f7-4fa4-a354-0ce0a68b37b4" xlink:to="loc_us-gaap_StockholdersEquity_f0308797-c45b-4326-83cb-6a73fdd3dd69" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_389b6938-6e17-47e1-afd9-7f0146c95d5b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_962930f9-83f7-4fa4-a354-0ce0a68b37b4" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_389b6938-6e17-47e1-afd9-7f0146c95d5b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f1d073d5-3361-440e-ab80-d6af39f66efc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_962930f9-83f7-4fa4-a354-0ce0a68b37b4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f1d073d5-3361-440e-ab80-d6af39f66efc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_c3b1be21-c3cb-44b4-a6af-819b204806ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_962930f9-83f7-4fa4-a354-0ce0a68b37b4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_c3b1be21-c3cb-44b4-a6af-819b204806ba" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_72cacfbb-2b62-496f-b96a-05ac2864a81b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_962930f9-83f7-4fa4-a354-0ce0a68b37b4" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_72cacfbb-2b62-496f-b96a-05ac2864a81b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7c2111f9-891f-44b8-ad29-7305710c46d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_962930f9-83f7-4fa4-a354-0ce0a68b37b4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7c2111f9-891f-44b8-ad29-7305710c46d9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_f015e047-f0c0-4869-8f51-e5c5d2cb763f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_962930f9-83f7-4fa4-a354-0ce0a68b37b4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_f015e047-f0c0-4869-8f51-e5c5d2cb763f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_7475809c-9941-496d-82a7-457e951c8dc5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2349881b-ac9c-4d2d-81bb-856422e02c41" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.recursion.com/role/SupplementalFinancialInformationNarrativeDetails" xlink:type="simple" xlink:href="rxrx-20240331.xsd#SupplementalFinancialInformationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.recursion.com/role/SupplementalFinancialInformationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_997e73af-c51f-496d-8e63-52a31bb7f11e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_25548654-bbc3-4598-a3b7-68f0f560c0f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_997e73af-c51f-496d-8e63-52a31bb7f11e" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_25548654-bbc3-4598-a3b7-68f0f560c0f0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_95d1207c-0d55-44d2-9e5d-f60aff629fbe" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_25548654-bbc3-4598-a3b7-68f0f560c0f0" xlink:to="loc_srt_CounterpartyNameAxis_95d1207c-0d55-44d2-9e5d-f60aff629fbe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_95d1207c-0d55-44d2-9e5d-f60aff629fbe_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_95d1207c-0d55-44d2-9e5d-f60aff629fbe" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_95d1207c-0d55-44d2-9e5d-f60aff629fbe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_26b48f56-eea6-4430-8f31-cdd58af8c827" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_95d1207c-0d55-44d2-9e5d-f60aff629fbe" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_26b48f56-eea6-4430-8f31-cdd58af8c827" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_TempusLabsIncMember_bf357833-3225-4732-b7b7-ab2235a2c99e" xlink:href="rxrx-20240331.xsd#rxrx_TempusLabsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_26b48f56-eea6-4430-8f31-cdd58af8c827" xlink:to="loc_rxrx_TempusLabsIncMember_bf357833-3225-4732-b7b7-ab2235a2c99e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a7e61279-bb93-4aa4-9703-5ff9f243672a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_25548654-bbc3-4598-a3b7-68f0f560c0f0" xlink:to="loc_srt_RangeAxis_a7e61279-bb93-4aa4-9703-5ff9f243672a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a7e61279-bb93-4aa4-9703-5ff9f243672a_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_a7e61279-bb93-4aa4-9703-5ff9f243672a" xlink:to="loc_srt_RangeMember_a7e61279-bb93-4aa4-9703-5ff9f243672a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5a63a0cd-f8f2-49f6-844a-de4b0828d45a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_a7e61279-bb93-4aa4-9703-5ff9f243672a" xlink:to="loc_srt_RangeMember_5a63a0cd-f8f2-49f6-844a-de4b0828d45a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_63f341d9-4e3a-4508-a279-6ea8d9caa743" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5a63a0cd-f8f2-49f6-844a-de4b0828d45a" xlink:to="loc_srt_MinimumMember_63f341d9-4e3a-4508-a279-6ea8d9caa743" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ab9053a3-3f5e-4688-8a8d-4fbcd361d841" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5a63a0cd-f8f2-49f6-844a-de4b0828d45a" xlink:to="loc_srt_MaximumMember_ab9053a3-3f5e-4688-8a8d-4fbcd361d841" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_c3561e46-8ee7-4ef9-acb0-d73774071a3e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_25548654-bbc3-4598-a3b7-68f0f560c0f0" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_c3561e46-8ee7-4ef9-acb0-d73774071a3e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_c3561e46-8ee7-4ef9-acb0-d73774071a3e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_c3561e46-8ee7-4ef9-acb0-d73774071a3e" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_c3561e46-8ee7-4ef9-acb0-d73774071a3e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_7c66b1d6-58b5-4108-9d98-f4abc1fa7112" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_c3561e46-8ee7-4ef9-acb0-d73774071a3e" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_7c66b1d6-58b5-4108-9d98-f4abc1fa7112" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_3e61d9b5-4f6c-4c43-9f4a-fa4d8bb942dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7c66b1d6-58b5-4108-9d98-f4abc1fa7112" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_3e61d9b5-4f6c-4c43-9f4a-fa4d8bb942dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0753d7a4-0071-4d00-ab40-708472ed71f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_25548654-bbc3-4598-a3b7-68f0f560c0f0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0753d7a4-0071-4d00-ab40-708472ed71f2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0753d7a4-0071-4d00-ab40-708472ed71f2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0753d7a4-0071-4d00-ab40-708472ed71f2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0753d7a4-0071-4d00-ab40-708472ed71f2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_358838ad-2e5d-4d76-af1f-a6cbf2e062b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0753d7a4-0071-4d00-ab40-708472ed71f2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_358838ad-2e5d-4d76-af1f-a6cbf2e062b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_BioHiveSupercomputerMember_a6f49fdf-e515-4f7a-9ba7-2e88af9c2f83" xlink:href="rxrx-20240331.xsd#rxrx_BioHiveSupercomputerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_358838ad-2e5d-4d76-af1f-a6cbf2e062b0" xlink:to="loc_rxrx_BioHiveSupercomputerMember_a6f49fdf-e515-4f7a-9ba7-2e88af9c2f83" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_cb485182-ca62-4bef-b21d-f8fde256b1da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_25548654-bbc3-4598-a3b7-68f0f560c0f0" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_cb485182-ca62-4bef-b21d-f8fde256b1da" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_cb485182-ca62-4bef-b21d-f8fde256b1da_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_cb485182-ca62-4bef-b21d-f8fde256b1da" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_cb485182-ca62-4bef-b21d-f8fde256b1da_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ba771cfd-3983-440f-bbc9-6640d290e667" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_cb485182-ca62-4bef-b21d-f8fde256b1da" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ba771cfd-3983-440f-bbc9-6640d290e667" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_3b348d36-f0e6-4f5d-ab4e-e7d750c287ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_ba771cfd-3983-440f-bbc9-6640d290e667" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_3b348d36-f0e6-4f5d-ab4e-e7d750c287ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_dabb95c2-be14-4a7e-b701-f94f3cdc6800" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_25548654-bbc3-4598-a3b7-68f0f560c0f0" xlink:to="loc_us-gaap_DebtInstrumentAxis_dabb95c2-be14-4a7e-b701-f94f3cdc6800" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_dabb95c2-be14-4a7e-b701-f94f3cdc6800_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_dabb95c2-be14-4a7e-b701-f94f3cdc6800" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_dabb95c2-be14-4a7e-b701-f94f3cdc6800_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5a198f70-5f96-4212-8dc5-564dcb8854e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_dabb95c2-be14-4a7e-b701-f94f3cdc6800" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5a198f70-5f96-4212-8dc5-564dcb8854e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_Station41LeaseMember_a41aec1b-1e6f-467b-8209-8af17525a7b6" xlink:href="rxrx-20240331.xsd#rxrx_Station41LeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5a198f70-5f96-4212-8dc5-564dcb8854e9" xlink:to="loc_rxrx_Station41LeaseMember_a41aec1b-1e6f-467b-8209-8af17525a7b6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_LicenseAgreementTerm_a8e3c33b-4ec9-44ea-8d42-1f74d5084f37" xlink:href="rxrx-20240331.xsd#rxrx_LicenseAgreementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_997e73af-c51f-496d-8e63-52a31bb7f11e" xlink:to="loc_rxrx_LicenseAgreementTerm_a8e3c33b-4ec9-44ea-8d42-1f74d5084f37" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_LicenseAgreementAnnualPayments_82589c1a-4831-4753-9fe2-14f96e465ede" xlink:href="rxrx-20240331.xsd#rxrx_LicenseAgreementAnnualPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_997e73af-c51f-496d-8e63-52a31bb7f11e" xlink:to="loc_rxrx_LicenseAgreementAnnualPayments_82589c1a-4831-4753-9fe2-14f96e465ede" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_LicenseAgreementAggregatePayments_5a976444-9a87-4b5c-bbe1-f123f8e8b0fd" xlink:href="rxrx-20240331.xsd#rxrx_LicenseAgreementAggregatePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_997e73af-c51f-496d-8e63-52a31bb7f11e" xlink:to="loc_rxrx_LicenseAgreementAggregatePayments_5a976444-9a87-4b5c-bbe1-f123f8e8b0fd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_LicenseAgreementTradingPeriodUsedForEquityValueDetermination_1d6a33ac-068d-49f2-aa2e-31501e6b1ef5" xlink:href="rxrx-20240331.xsd#rxrx_LicenseAgreementTradingPeriodUsedForEquityValueDetermination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_997e73af-c51f-496d-8e63-52a31bb7f11e" xlink:to="loc_rxrx_LicenseAgreementTradingPeriodUsedForEquityValueDetermination_1d6a33ac-068d-49f2-aa2e-31501e6b1ef5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_LicenseAgreementPrepaidExpenses_30a29211-c141-4979-b931-af54c2c1a685" xlink:href="rxrx-20240331.xsd#rxrx_LicenseAgreementPrepaidExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_997e73af-c51f-496d-8e63-52a31bb7f11e" xlink:to="loc_rxrx_LicenseAgreementPrepaidExpenses_30a29211-c141-4979-b931-af54c2c1a685" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_de81f353-d77f-4259-a40b-165c6a9ca336" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_997e73af-c51f-496d-8e63-52a31bb7f11e" xlink:to="loc_us-gaap_Depreciation_de81f353-d77f-4259-a40b-165c6a9ca336" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLeasehold_91c6de18-c39d-499f-9c13-77a8bb2d06bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLeasehold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_997e73af-c51f-496d-8e63-52a31bb7f11e" xlink:to="loc_us-gaap_ImpairmentOfLeasehold_91c6de18-c39d-499f-9c13-77a8bb2d06bc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_03c4b7c3-6dbd-4303-908b-c3a41e2fd80b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_997e73af-c51f-496d-8e63-52a31bb7f11e" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_03c4b7c3-6dbd-4303-908b-c3a41e2fd80b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_4fcb373b-664e-48ca-b90b-6cc93247ca81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_997e73af-c51f-496d-8e63-52a31bb7f11e" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_4fcb373b-664e-48ca-b90b-6cc93247ca81" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_fea8bb38-8898-49c2-8819-43f4c63e7cb7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_997e73af-c51f-496d-8e63-52a31bb7f11e" xlink:to="loc_us-gaap_DebtInstrumentTerm_fea8bb38-8898-49c2-8819-43f4c63e7cb7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7001bb08-13c2-49bc-b6e7-a4c182b0608f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_997e73af-c51f-496d-8e63-52a31bb7f11e" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7001bb08-13c2-49bc-b6e7-a4c182b0608f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable_f64304ec-4cf9-4cc9-9b3c-61d4902d2236" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_997e73af-c51f-496d-8e63-52a31bb7f11e" xlink:to="loc_us-gaap_NotesPayable_f64304ec-4cf9-4cc9-9b3c-61d4902d2236" xlink:type="arc" order="11"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.recursion.com/role/SupplementalFinancialInformationScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="rxrx-20240331.xsd#SupplementalFinancialInformationScheduleofPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.recursion.com/role/SupplementalFinancialInformationScheduleofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9b056f80-5bac-4b0b-8cb5-548332532765" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0b1c9725-ce23-4609-b1b0-185a3e6c91a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9b056f80-5bac-4b0b-8cb5-548332532765" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0b1c9725-ce23-4609-b1b0-185a3e6c91a5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_27b5a3a1-fb49-41d0-9141-7d38e97dcf5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0b1c9725-ce23-4609-b1b0-185a3e6c91a5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_27b5a3a1-fb49-41d0-9141-7d38e97dcf5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_27b5a3a1-fb49-41d0-9141-7d38e97dcf5a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_27b5a3a1-fb49-41d0-9141-7d38e97dcf5a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_27b5a3a1-fb49-41d0-9141-7d38e97dcf5a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_eef1a5c0-b99e-4a7e-bb89-e7432bfb213b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_27b5a3a1-fb49-41d0-9141-7d38e97dcf5a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_eef1a5c0-b99e-4a7e-bb89-e7432bfb213b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_LaboratoryEquipmentMember_d6881de3-c5bb-493e-93a2-f7521078a570" xlink:href="rxrx-20240331.xsd#rxrx_LaboratoryEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_eef1a5c0-b99e-4a7e-bb89-e7432bfb213b" xlink:to="loc_rxrx_LaboratoryEquipmentMember_d6881de3-c5bb-493e-93a2-f7521078a570" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_f43564dd-0348-41c4-bbac-0aba9791963a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_eef1a5c0-b99e-4a7e-bb89-e7432bfb213b" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_f43564dd-0348-41c4-bbac-0aba9791963a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_a932b98d-4f4f-4796-818b-0163295e16af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_eef1a5c0-b99e-4a7e-bb89-e7432bfb213b" xlink:to="loc_us-gaap_OfficeEquipmentMember_a932b98d-4f4f-4796-818b-0163295e16af" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetUnderConstructionMember_56663ef2-94b5-435e-8b48-466ca5fab92d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetUnderConstructionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_eef1a5c0-b99e-4a7e-bb89-e7432bfb213b" xlink:to="loc_us-gaap_AssetUnderConstructionMember_56663ef2-94b5-435e-8b48-466ca5fab92d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_8a512f7c-0100-4ce9-98a6-b39714038a67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9b056f80-5bac-4b0b-8cb5-548332532765" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_8a512f7c-0100-4ce9-98a6-b39714038a67" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_21cb0404-8edf-4d61-82f5-bc110422fda1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9b056f80-5bac-4b0b-8cb5-548332532765" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_21cb0404-8edf-4d61-82f5-bc110422fda1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_a46b4a0f-968e-4697-bde9-a25accaa907e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9b056f80-5bac-4b0b-8cb5-548332532765" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_a46b4a0f-968e-4697-bde9-a25accaa907e" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.recursion.com/role/AcquisitionsNarrativeDetails" xlink:type="simple" xlink:href="rxrx-20240331.xsd#AcquisitionsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.recursion.com/role/AcquisitionsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_a878aaed-96fd-4ca1-a526-8befce75c2e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e39be7d7-9499-4abf-9b19-fc854da1fc75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a878aaed-96fd-4ca1-a526-8befce75c2e1" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e39be7d7-9499-4abf-9b19-fc854da1fc75" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_b02d9822-220f-4500-9f66-30db3c9f5a89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e39be7d7-9499-4abf-9b19-fc854da1fc75" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_b02d9822-220f-4500-9f66-30db3c9f5a89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b02d9822-220f-4500-9f66-30db3c9f5a89_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b02d9822-220f-4500-9f66-30db3c9f5a89" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b02d9822-220f-4500-9f66-30db3c9f5a89_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dcb6cd84-2222-498b-81cb-988151bf4681" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b02d9822-220f-4500-9f66-30db3c9f5a89" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dcb6cd84-2222-498b-81cb-988151bf4681" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_ValenceDiscoveryIncMember_7588e6d3-2458-431d-a679-7d27effe4f64" xlink:href="rxrx-20240331.xsd#rxrx_ValenceDiscoveryIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dcb6cd84-2222-498b-81cb-988151bf4681" xlink:to="loc_rxrx_ValenceDiscoveryIncMember_7588e6d3-2458-431d-a679-7d27effe4f64" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_CyclicaIncMember_3293145f-5e47-413d-a26c-bf05c5f906d9" xlink:href="rxrx-20240331.xsd#rxrx_CyclicaIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dcb6cd84-2222-498b-81cb-988151bf4681" xlink:to="loc_rxrx_CyclicaIncMember_3293145f-5e47-413d-a26c-bf05c5f906d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_587d1d60-e792-41e8-b657-3674fa5787cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e39be7d7-9499-4abf-9b19-fc854da1fc75" xlink:to="loc_us-gaap_StatementClassOfStockAxis_587d1d60-e792-41e8-b657-3674fa5787cf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_587d1d60-e792-41e8-b657-3674fa5787cf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_587d1d60-e792-41e8-b657-3674fa5787cf" xlink:to="loc_us-gaap_ClassOfStockDomain_587d1d60-e792-41e8-b657-3674fa5787cf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_0d419164-08a1-4036-a9de-8cc82ee9e5c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_587d1d60-e792-41e8-b657-3674fa5787cf" xlink:to="loc_us-gaap_ClassOfStockDomain_0d419164-08a1-4036-a9de-8cc82ee9e5c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_f79eefaf-94df-41eb-8dd9-2d9b98e9c466" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_0d419164-08a1-4036-a9de-8cc82ee9e5c3" xlink:to="loc_us-gaap_CommonClassAMember_f79eefaf-94df-41eb-8dd9-2d9b98e9c466" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_ExchangeableStockMember_63bf0ad5-c303-4b24-bff4-209b4b1d9c3d" xlink:href="rxrx-20240331.xsd#rxrx_ExchangeableStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_0d419164-08a1-4036-a9de-8cc82ee9e5c3" xlink:to="loc_rxrx_ExchangeableStockMember_63bf0ad5-c303-4b24-bff4-209b4b1d9c3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_bb5e754e-f0d1-4efb-8481-ca764bdfb471" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e39be7d7-9499-4abf-9b19-fc854da1fc75" xlink:to="loc_us-gaap_AwardTypeAxis_bb5e754e-f0d1-4efb-8481-ca764bdfb471" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bb5e754e-f0d1-4efb-8481-ca764bdfb471_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_bb5e754e-f0d1-4efb-8481-ca764bdfb471" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bb5e754e-f0d1-4efb-8481-ca764bdfb471_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c056d1a7-5cf9-406c-bffa-39690193d848" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_bb5e754e-f0d1-4efb-8481-ca764bdfb471" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c056d1a7-5cf9-406c-bffa-39690193d848" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_ef878181-1cca-4a98-9b05-bfc44c4c395d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c056d1a7-5cf9-406c-bffa-39690193d848" xlink:to="loc_us-gaap_EmployeeStockOptionMember_ef878181-1cca-4a98-9b05-bfc44c4c395d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f5522afe-7b32-4884-85d5-b58b392f4001" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e39be7d7-9499-4abf-9b19-fc854da1fc75" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f5522afe-7b32-4884-85d5-b58b392f4001" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f5522afe-7b32-4884-85d5-b58b392f4001_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f5522afe-7b32-4884-85d5-b58b392f4001" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f5522afe-7b32-4884-85d5-b58b392f4001_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_390ea392-b597-4bf4-b1b0-758b1503bb4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f5522afe-7b32-4884-85d5-b58b392f4001" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_390ea392-b597-4bf4-b1b0-758b1503bb4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_248b23c4-41bf-41d1-b76e-062d4c95ec21" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_390ea392-b597-4bf4-b1b0-758b1503bb4e" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_248b23c4-41bf-41d1-b76e-062d4c95ec21" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_718d4dde-adc8-444a-8e8d-33adf51e0f9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a878aaed-96fd-4ca1-a526-8befce75c2e1" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_718d4dde-adc8-444a-8e8d-33adf51e0f9c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_6f9c407f-083c-4670-b077-055456907306" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a878aaed-96fd-4ca1-a526-8befce75c2e1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_6f9c407f-083c-4670-b077-055456907306" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_b13769b1-b513-4933-b8cb-3d94c67c33f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a878aaed-96fd-4ca1-a526-8befce75c2e1" xlink:to="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_b13769b1-b513-4933-b8cb-3d94c67c33f5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_a69b6ad2-c172-4e4f-a492-dc905a9693d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a878aaed-96fd-4ca1-a526-8befce75c2e1" xlink:to="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_a69b6ad2-c172-4e4f-a492-dc905a9693d4" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.recursion.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails" xlink:type="simple" xlink:href="rxrx-20240331.xsd#AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails"/>
  <link:definitionLink xlink:role="http://www.recursion.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_78576679-672c-439d-b804-0af81ac5e089" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d6af3e9f-b156-4c62-9b74-bb8f46253f21" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_78576679-672c-439d-b804-0af81ac5e089" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d6af3e9f-b156-4c62-9b74-bb8f46253f21" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_febf126e-8c88-4830-b7f3-d032c966e833" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d6af3e9f-b156-4c62-9b74-bb8f46253f21" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_febf126e-8c88-4830-b7f3-d032c966e833" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_febf126e-8c88-4830-b7f3-d032c966e833_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_febf126e-8c88-4830-b7f3-d032c966e833" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_febf126e-8c88-4830-b7f3-d032c966e833_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bbb6dd71-a636-483a-9421-a46768c7868e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_febf126e-8c88-4830-b7f3-d032c966e833" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bbb6dd71-a636-483a-9421-a46768c7868e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_ValenceDiscoveryIncMember_b343415f-c739-4163-a8bd-b9856ad1ea62" xlink:href="rxrx-20240331.xsd#rxrx_ValenceDiscoveryIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bbb6dd71-a636-483a-9421-a46768c7868e" xlink:to="loc_rxrx_ValenceDiscoveryIncMember_b343415f-c739-4163-a8bd-b9856ad1ea62" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_CyclicaIncMember_1691fb04-6470-46c1-863a-01f9b211db57" xlink:href="rxrx-20240331.xsd#rxrx_CyclicaIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bbb6dd71-a636-483a-9421-a46768c7868e" xlink:to="loc_rxrx_CyclicaIncMember_1691fb04-6470-46c1-863a-01f9b211db57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_b564e6b1-7645-461e-bd3b-de1e683bf1ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d6af3e9f-b156-4c62-9b74-bb8f46253f21" xlink:to="loc_us-gaap_StatementClassOfStockAxis_b564e6b1-7645-461e-bd3b-de1e683bf1ff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_b564e6b1-7645-461e-bd3b-de1e683bf1ff_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_b564e6b1-7645-461e-bd3b-de1e683bf1ff" xlink:to="loc_us-gaap_ClassOfStockDomain_b564e6b1-7645-461e-bd3b-de1e683bf1ff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_2ca74160-f94c-433e-a4fe-422f9b5a18fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_b564e6b1-7645-461e-bd3b-de1e683bf1ff" xlink:to="loc_us-gaap_ClassOfStockDomain_2ca74160-f94c-433e-a4fe-422f9b5a18fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_ba997ae1-0a62-4461-8536-8445023af7ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_2ca74160-f94c-433e-a4fe-422f9b5a18fa" xlink:to="loc_us-gaap_CommonClassAMember_ba997ae1-0a62-4461-8536-8445023af7ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_ExchangeableStockMember_c2a09031-2e56-44c7-b326-ce2225eeecb5" xlink:href="rxrx-20240331.xsd#rxrx_ExchangeableStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_2ca74160-f94c-433e-a4fe-422f9b5a18fa" xlink:to="loc_rxrx_ExchangeableStockMember_c2a09031-2e56-44c7-b326-ce2225eeecb5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_cfbcf733-6401-4914-8db4-cbee81f11e04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d6af3e9f-b156-4c62-9b74-bb8f46253f21" xlink:to="loc_us-gaap_AwardTypeAxis_cfbcf733-6401-4914-8db4-cbee81f11e04" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cfbcf733-6401-4914-8db4-cbee81f11e04_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_cfbcf733-6401-4914-8db4-cbee81f11e04" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cfbcf733-6401-4914-8db4-cbee81f11e04_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1aa9e925-30c6-4c4e-a4d4-5b8a2ffb5b64" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_cfbcf733-6401-4914-8db4-cbee81f11e04" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1aa9e925-30c6-4c4e-a4d4-5b8a2ffb5b64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_2c3f4602-9722-4c8d-b0d3-599ebe572a6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1aa9e925-30c6-4c4e-a4d4-5b8a2ffb5b64" xlink:to="loc_us-gaap_EmployeeStockMember_2c3f4602-9722-4c8d-b0d3-599ebe572a6b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_BusinessCombinationConsiderationTransferredEquityInterestsIssuable_12e120e0-211e-4e08-ab3a-ac41783381df" xlink:href="rxrx-20240331.xsd#rxrx_BusinessCombinationConsiderationTransferredEquityInterestsIssuable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_78576679-672c-439d-b804-0af81ac5e089" xlink:to="loc_rxrx_BusinessCombinationConsiderationTransferredEquityInterestsIssuable_12e120e0-211e-4e08-ab3a-ac41783381df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_71df390c-7b3f-4ceb-875e-ad64cec1a03c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_78576679-672c-439d-b804-0af81ac5e089" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_71df390c-7b3f-4ceb-875e-ad64cec1a03c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_37fee5a0-aab1-46d2-ae3a-175aac30a86e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_78576679-672c-439d-b804-0af81ac5e089" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_37fee5a0-aab1-46d2-ae3a-175aac30a86e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_1d93c8e2-7197-4150-91b4-41097f939802" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_78576679-672c-439d-b804-0af81ac5e089" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_1d93c8e2-7197-4150-91b4-41097f939802" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.recursion.com/role/AcquisitionsScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="rxrx-20240331.xsd#AcquisitionsScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:definitionLink xlink:role="http://www.recursion.com/role/AcquisitionsScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_70cac2d7-bcd0-45e3-a08b-6e256f0b8897" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_59e9162b-3509-4f5d-be3a-ffbb9d7e6729" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_70cac2d7-bcd0-45e3-a08b-6e256f0b8897" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_59e9162b-3509-4f5d-be3a-ffbb9d7e6729" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_8579f34a-ccb1-4994-a9b9-cf39d90168f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_59e9162b-3509-4f5d-be3a-ffbb9d7e6729" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_8579f34a-ccb1-4994-a9b9-cf39d90168f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8579f34a-ccb1-4994-a9b9-cf39d90168f7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8579f34a-ccb1-4994-a9b9-cf39d90168f7" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8579f34a-ccb1-4994-a9b9-cf39d90168f7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ae97e7fc-cc84-4f6e-8a3a-c70758efc865" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8579f34a-ccb1-4994-a9b9-cf39d90168f7" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ae97e7fc-cc84-4f6e-8a3a-c70758efc865" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_ValenceDiscoveryIncMember_e110d171-920e-4d0c-922e-f50c0b6c0f89" xlink:href="rxrx-20240331.xsd#rxrx_ValenceDiscoveryIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ae97e7fc-cc84-4f6e-8a3a-c70758efc865" xlink:to="loc_rxrx_ValenceDiscoveryIncMember_e110d171-920e-4d0c-922e-f50c0b6c0f89" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_CyclicaIncMember_fe796747-263c-4859-ad36-d560444a0f9b" xlink:href="rxrx-20240331.xsd#rxrx_CyclicaIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ae97e7fc-cc84-4f6e-8a3a-c70758efc865" xlink:to="loc_rxrx_CyclicaIncMember_fe796747-263c-4859-ad36-d560444a0f9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_e5c0db03-8201-4feb-9868-7a5beffff554" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_70cac2d7-bcd0-45e3-a08b-6e256f0b8897" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_e5c0db03-8201-4feb-9868-7a5beffff554" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_479dfe44-10d5-4648-a7ec-a346940d8d47" xlink:href="rxrx-20240331.xsd#rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_70cac2d7-bcd0-45e3-a08b-6e256f0b8897" xlink:to="loc_rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_479dfe44-10d5-4648-a7ec-a346940d8d47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherReceivables_79996c78-cc12-4820-9735-2146ad9da2a7" xlink:href="rxrx-20240331.xsd#rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_70cac2d7-bcd0-45e3-a08b-6e256f0b8897" xlink:to="loc_rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherReceivables_79996c78-cc12-4820-9735-2146ad9da2a7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInvestments_0bcdcc5e-a872-487e-a773-955cd8a67de5" xlink:href="rxrx-20240331.xsd#rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_70cac2d7-bcd0-45e3-a08b-6e256f0b8897" xlink:to="loc_rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInvestments_0bcdcc5e-a872-487e-a773-955cd8a67de5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_702db540-47d1-4eb1-b45c-27466e3a673b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_70cac2d7-bcd0-45e3-a08b-6e256f0b8897" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_702db540-47d1-4eb1-b45c-27466e3a673b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_d4b4567e-7ca1-47fe-8937-2cafdb40574c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_70cac2d7-bcd0-45e3-a08b-6e256f0b8897" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_d4b4567e-7ca1-47fe-8937-2cafdb40574c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_acb224b7-7e70-48b7-be42-f3e988e82f30" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_70cac2d7-bcd0-45e3-a08b-6e256f0b8897" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_acb224b7-7e70-48b7-be42-f3e988e82f30" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_cd5320c0-5e1c-417c-9aac-4ac469b88952" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_70cac2d7-bcd0-45e3-a08b-6e256f0b8897" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_cd5320c0-5e1c-417c-9aac-4ac469b88952" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_0e60bbb9-abaf-41ee-a4a6-9f2c979a87e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_70cac2d7-bcd0-45e3-a08b-6e256f0b8897" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_0e60bbb9-abaf-41ee-a4a6-9f2c979a87e3" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilitiesCurrent_ded667b6-a111-4665-8467-8ff887270d86" xlink:href="rxrx-20240331.xsd#rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_70cac2d7-bcd0-45e3-a08b-6e256f0b8897" xlink:to="loc_rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilitiesCurrent_ded667b6-a111-4665-8467-8ff887270d86" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_fc781c30-de37-4fd7-88c0-5f8af2dc5d4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_70cac2d7-bcd0-45e3-a08b-6e256f0b8897" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_fc781c30-de37-4fd7-88c0-5f8af2dc5d4e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_8a74e3a2-dc49-489d-862a-3a740d827a02" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_70cac2d7-bcd0-45e3-a08b-6e256f0b8897" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_8a74e3a2-dc49-489d-862a-3a740d827a02" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_d65ecbea-fc93-4d3a-bf15-6599518c002f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_70cac2d7-bcd0-45e3-a08b-6e256f0b8897" xlink:to="loc_us-gaap_Goodwill_d65ecbea-fc93-4d3a-bf15-6599518c002f" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_b0dbf25a-281b-48f9-b268-ea2fc5bf4a9f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_70cac2d7-bcd0-45e3-a08b-6e256f0b8897" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_b0dbf25a-281b-48f9-b268-ea2fc5bf4a9f" xlink:type="arc" order="13"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.recursion.com/role/AcquisitionsScheduleofBusinessAcquisitionsProFormaInformationDetails" xlink:type="simple" xlink:href="rxrx-20240331.xsd#AcquisitionsScheduleofBusinessAcquisitionsProFormaInformationDetails"/>
  <link:definitionLink xlink:role="http://www.recursion.com/role/AcquisitionsScheduleofBusinessAcquisitionsProFormaInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_f3373a70-9e5b-46bf-8bb1-7efcd6284459" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2774c8ef-923d-4ed7-85c7-093cc57d41b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f3373a70-9e5b-46bf-8bb1-7efcd6284459" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2774c8ef-923d-4ed7-85c7-093cc57d41b5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_f2a5ad9d-d0d0-4adf-81de-44bb6dd602a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2774c8ef-923d-4ed7-85c7-093cc57d41b5" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_f2a5ad9d-d0d0-4adf-81de-44bb6dd602a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f2a5ad9d-d0d0-4adf-81de-44bb6dd602a9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f2a5ad9d-d0d0-4adf-81de-44bb6dd602a9" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f2a5ad9d-d0d0-4adf-81de-44bb6dd602a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7508f245-e193-44a1-871a-81b13db3f2cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f2a5ad9d-d0d0-4adf-81de-44bb6dd602a9" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7508f245-e193-44a1-871a-81b13db3f2cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_RecursionValenceAndCyclicaMember_6826806d-c806-4bbe-849a-e98f47645dbf" xlink:href="rxrx-20240331.xsd#rxrx_RecursionValenceAndCyclicaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7508f245-e193-44a1-871a-81b13db3f2cf" xlink:to="loc_rxrx_RecursionValenceAndCyclicaMember_6826806d-c806-4bbe-849a-e98f47645dbf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_58a4d389-d11e-424e-859f-87daee55650a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f3373a70-9e5b-46bf-8bb1-7efcd6284459" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_58a4d389-d11e-424e-859f-87daee55650a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_7ae3ebca-ada7-4326-a948-164a1d289364" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f3373a70-9e5b-46bf-8bb1-7efcd6284459" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_7ae3ebca-ada7-4326-a948-164a1d289364" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.recursion.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="rxrx-20240331.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.recursion.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_fa53d88e-651d-4723-ad16-6aad5356ffbc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_e0498a31-7fb1-4507-a20b-a6f3fffad392" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fa53d88e-651d-4723-ad16-6aad5356ffbc" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_e0498a31-7fb1-4507-a20b-a6f3fffad392" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3ab07d62-035f-4e26-beeb-bb1776db48a8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_e0498a31-7fb1-4507-a20b-a6f3fffad392" xlink:to="loc_srt_RangeAxis_3ab07d62-035f-4e26-beeb-bb1776db48a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3ab07d62-035f-4e26-beeb-bb1776db48a8_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_3ab07d62-035f-4e26-beeb-bb1776db48a8" xlink:to="loc_srt_RangeMember_3ab07d62-035f-4e26-beeb-bb1776db48a8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2b84119e-efe2-414a-9076-27f6a7680585" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_3ab07d62-035f-4e26-beeb-bb1776db48a8" xlink:to="loc_srt_RangeMember_2b84119e-efe2-414a-9076-27f6a7680585" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ac5b02de-9885-43a6-a05b-b0d347df1d44" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2b84119e-efe2-414a-9076-27f6a7680585" xlink:to="loc_srt_MinimumMember_ac5b02de-9885-43a6-a05b-b0d347df1d44" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a087bccc-f412-4322-a6dc-a93e2167d86b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2b84119e-efe2-414a-9076-27f6a7680585" xlink:to="loc_srt_MaximumMember_a087bccc-f412-4322-a6dc-a93e2167d86b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_LeaseDescriptionAxis_9af96d2c-e8b7-4905-b415-9c011c649501" xlink:href="rxrx-20240331.xsd#rxrx_LeaseDescriptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_e0498a31-7fb1-4507-a20b-a6f3fffad392" xlink:to="loc_rxrx_LeaseDescriptionAxis_9af96d2c-e8b7-4905-b415-9c011c649501" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_LeaseDescriptionDomain_9af96d2c-e8b7-4905-b415-9c011c649501_default" xlink:href="rxrx-20240331.xsd#rxrx_LeaseDescriptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_rxrx_LeaseDescriptionAxis_9af96d2c-e8b7-4905-b415-9c011c649501" xlink:to="loc_rxrx_LeaseDescriptionDomain_9af96d2c-e8b7-4905-b415-9c011c649501_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_LeaseDescriptionDomain_a71e2e59-3021-4662-b2dc-6a0d44834d61" xlink:href="rxrx-20240331.xsd#rxrx_LeaseDescriptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_rxrx_LeaseDescriptionAxis_9af96d2c-e8b7-4905-b415-9c011c649501" xlink:to="loc_rxrx_LeaseDescriptionDomain_a71e2e59-3021-4662-b2dc-6a0d44834d61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_LondonLeaseMember_0bc957e7-4580-41d1-9e9c-1d2fe48851e6" xlink:href="rxrx-20240331.xsd#rxrx_LondonLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rxrx_LeaseDescriptionDomain_a71e2e59-3021-4662-b2dc-6a0d44834d61" xlink:to="loc_rxrx_LondonLeaseMember_0bc957e7-4580-41d1-9e9c-1d2fe48851e6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_DataCenterLeaseMember_a69c1965-cb34-432f-a9d1-2b2d7f8130ee" xlink:href="rxrx-20240331.xsd#rxrx_DataCenterLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rxrx_LeaseDescriptionDomain_a71e2e59-3021-4662-b2dc-6a0d44834d61" xlink:to="loc_rxrx_DataCenterLeaseMember_a69c1965-cb34-432f-a9d1-2b2d7f8130ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_b7eee4fb-8b1a-48d2-89bd-19a25049556e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fa53d88e-651d-4723-ad16-6aad5356ffbc" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_b7eee4fb-8b1a-48d2-89bd-19a25049556e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_a066626a-b7ac-43b8-bc16-66159c492263" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fa53d88e-651d-4723-ad16-6aad5356ffbc" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_a066626a-b7ac-43b8-bc16-66159c492263" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_f1466601-2c3f-4d3d-b2dc-7aac03746e68" xlink:href="rxrx-20240331.xsd#rxrx_IncreaseDecreaseInOperatingLeaseRightOfUseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fa53d88e-651d-4723-ad16-6aad5356ffbc" xlink:to="loc_rxrx_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_f1466601-2c3f-4d3d-b2dc-7aac03746e68" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_LesseeOperatingLeaseIncreaseDecreaseInOperatingLeaseLiabilityDueToLeaseModifications_b25aa820-a7d4-4819-b0e2-7867bf2d3d11" xlink:href="rxrx-20240331.xsd#rxrx_LesseeOperatingLeaseIncreaseDecreaseInOperatingLeaseLiabilityDueToLeaseModifications"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fa53d88e-651d-4723-ad16-6aad5356ffbc" xlink:to="loc_rxrx_LesseeOperatingLeaseIncreaseDecreaseInOperatingLeaseLiabilityDueToLeaseModifications_b25aa820-a7d4-4819-b0e2-7867bf2d3d11" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_LesseeOperatingLeaseSquareFootageOfLeasedSpace_6e8b9a8e-4e2c-41da-819e-06ec617d5c24" xlink:href="rxrx-20240331.xsd#rxrx_LesseeOperatingLeaseSquareFootageOfLeasedSpace"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fa53d88e-651d-4723-ad16-6aad5356ffbc" xlink:to="loc_rxrx_LesseeOperatingLeaseSquareFootageOfLeasedSpace_6e8b9a8e-4e2c-41da-819e-06ec617d5c24" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_c6ece238-f1ca-43e3-a76a-5c38d196953c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fa53d88e-651d-4723-ad16-6aad5356ffbc" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_c6ece238-f1ca-43e3-a76a-5c38d196953c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_96329908-7b3f-4fc1-95ea-3f2405f2de22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fa53d88e-651d-4723-ad16-6aad5356ffbc" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_96329908-7b3f-4fc1-95ea-3f2405f2de22" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.recursion.com/role/CommonStockDetails" xlink:type="simple" xlink:href="rxrx-20240331.xsd#CommonStockDetails"/>
  <link:definitionLink xlink:role="http://www.recursion.com/role/CommonStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_eae82d41-c8f4-4ccd-83c9-7cd5a7bf883b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_fb945117-1563-4241-a2c5-7f28e529010d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_eae82d41-c8f4-4ccd-83c9-7cd5a7bf883b" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_fb945117-1563-4241-a2c5-7f28e529010d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_eabf216e-fd6d-45bc-a3ec-8ea18a0a4bdf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_fb945117-1563-4241-a2c5-7f28e529010d" xlink:to="loc_us-gaap_StatementClassOfStockAxis_eabf216e-fd6d-45bc-a3ec-8ea18a0a4bdf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_eabf216e-fd6d-45bc-a3ec-8ea18a0a4bdf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_eabf216e-fd6d-45bc-a3ec-8ea18a0a4bdf" xlink:to="loc_us-gaap_ClassOfStockDomain_eabf216e-fd6d-45bc-a3ec-8ea18a0a4bdf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_14e8a563-4e48-461f-8769-586e4acb64cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_eabf216e-fd6d-45bc-a3ec-8ea18a0a4bdf" xlink:to="loc_us-gaap_ClassOfStockDomain_14e8a563-4e48-461f-8769-586e4acb64cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_d52b5643-cb1f-422c-b454-7b23c8885eac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_14e8a563-4e48-461f-8769-586e4acb64cf" xlink:to="loc_us-gaap_CommonClassAMember_d52b5643-cb1f-422c-b454-7b23c8885eac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_007cfa69-88d1-4976-8851-d906f9eb0485" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_14e8a563-4e48-461f-8769-586e4acb64cf" xlink:to="loc_us-gaap_CommonClassBMember_007cfa69-88d1-4976-8851-d906f9eb0485" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_ExchangeableStockMember_12197ccb-cd0a-4e56-b42c-6d93232450e8" xlink:href="rxrx-20240331.xsd#rxrx_ExchangeableStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_14e8a563-4e48-461f-8769-586e4acb64cf" xlink:to="loc_rxrx_ExchangeableStockMember_12197ccb-cd0a-4e56-b42c-6d93232450e8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_6b6b4939-e803-4168-8a3e-a3e2c8c825a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_fb945117-1563-4241-a2c5-7f28e529010d" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_6b6b4939-e803-4168-8a3e-a3e2c8c825a4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6b6b4939-e803-4168-8a3e-a3e2c8c825a4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_6b6b4939-e803-4168-8a3e-a3e2c8c825a4" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6b6b4939-e803-4168-8a3e-a3e2c8c825a4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d739d0c3-bc20-4a8a-a7dd-ace88e431266" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_6b6b4939-e803-4168-8a3e-a3e2c8c825a4" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d739d0c3-bc20-4a8a-a7dd-ace88e431266" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_AtTheMarketOfferingProgramMember_139857dd-4453-44f8-a48d-eb4613126e7b" xlink:href="rxrx-20240331.xsd#rxrx_AtTheMarketOfferingProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d739d0c3-bc20-4a8a-a7dd-ace88e431266" xlink:to="loc_rxrx_AtTheMarketOfferingProgramMember_139857dd-4453-44f8-a48d-eb4613126e7b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_NVDIAPrivatePlacementMember_c7678bc2-f14a-4270-bf50-387248fa2d1c" xlink:href="rxrx-20240331.xsd#rxrx_NVDIAPrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d739d0c3-bc20-4a8a-a7dd-ace88e431266" xlink:to="loc_rxrx_NVDIAPrivatePlacementMember_c7678bc2-f14a-4270-bf50-387248fa2d1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_5a4ecfcf-9cc9-4eb4-9545-62cf93239bb4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_fb945117-1563-4241-a2c5-7f28e529010d" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_5a4ecfcf-9cc9-4eb4-9545-62cf93239bb4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5a4ecfcf-9cc9-4eb4-9545-62cf93239bb4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_5a4ecfcf-9cc9-4eb4-9545-62cf93239bb4" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5a4ecfcf-9cc9-4eb4-9545-62cf93239bb4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_36da7113-00be-4231-993c-a4402fa1c511" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_5a4ecfcf-9cc9-4eb4-9545-62cf93239bb4" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_36da7113-00be-4231-993c-a4402fa1c511" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_ValenceDiscoveryIncMember_2ad64345-b08d-46fc-833d-1b749859e397" xlink:href="rxrx-20240331.xsd#rxrx_ValenceDiscoveryIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_36da7113-00be-4231-993c-a4402fa1c511" xlink:to="loc_rxrx_ValenceDiscoveryIncMember_2ad64345-b08d-46fc-833d-1b749859e397" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_cff20487-e69e-448c-b613-043de16a32b9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_fb945117-1563-4241-a2c5-7f28e529010d" xlink:to="loc_srt_RangeAxis_cff20487-e69e-448c-b613-043de16a32b9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_cff20487-e69e-448c-b613-043de16a32b9_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_cff20487-e69e-448c-b613-043de16a32b9" xlink:to="loc_srt_RangeMember_cff20487-e69e-448c-b613-043de16a32b9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_92b86ab0-868b-4b86-bc48-d17450f1ff9c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_cff20487-e69e-448c-b613-043de16a32b9" xlink:to="loc_srt_RangeMember_92b86ab0-868b-4b86-bc48-d17450f1ff9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e76f1cc3-356d-47d6-b6c6-087c16294d7f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_92b86ab0-868b-4b86-bc48-d17450f1ff9c" xlink:to="loc_srt_MaximumMember_e76f1cc3-356d-47d6-b6c6-087c16294d7f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3836f680-304c-4b7e-b359-03172a47cc18" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_fb945117-1563-4241-a2c5-7f28e529010d" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3836f680-304c-4b7e-b359-03172a47cc18" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_3836f680-304c-4b7e-b359-03172a47cc18_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3836f680-304c-4b7e-b359-03172a47cc18" xlink:to="loc_us-gaap_RelatedPartyDomain_3836f680-304c-4b7e-b359-03172a47cc18_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_29af5997-c43f-4c35-bbb9-247707624054" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3836f680-304c-4b7e-b359-03172a47cc18" xlink:to="loc_us-gaap_RelatedPartyDomain_29af5997-c43f-4c35-bbb9-247707624054" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_ChristopherGibsonAndAffiliatesMember_48055370-cf9a-4753-90fc-d8d3ac9a6b08" xlink:href="rxrx-20240331.xsd#rxrx_ChristopherGibsonAndAffiliatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_29af5997-c43f-4c35-bbb9-247707624054" xlink:to="loc_rxrx_ChristopherGibsonAndAffiliatesMember_48055370-cf9a-4753-90fc-d8d3ac9a6b08" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_CommonStockVotePerShare_157fe40b-5ca0-4406-8afa-81e7652637b0" xlink:href="rxrx-20240331.xsd#rxrx_CommonStockVotePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_eae82d41-c8f4-4ccd-83c9-7cd5a7bf883b" xlink:to="loc_rxrx_CommonStockVotePerShare_157fe40b-5ca0-4406-8afa-81e7652637b0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsStock_8b67ef57-cf2d-438a-8347-3c92eb8fa3c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_eae82d41-c8f4-4ccd-83c9-7cd5a7bf883b" xlink:to="loc_us-gaap_DividendsStock_8b67ef57-cf2d-438a-8347-3c92eb8fa3c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_SaleOfStockValueAuthorized_5bda42f5-4da9-4a17-95ac-66c95ad732ba" xlink:href="rxrx-20240331.xsd#rxrx_SaleOfStockValueAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_eae82d41-c8f4-4ccd-83c9-7cd5a7bf883b" xlink:to="loc_rxrx_SaleOfStockValueAuthorized_5bda42f5-4da9-4a17-95ac-66c95ad732ba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_SaleOfStockValueRemainingAuthorized_d3859a8e-b9b8-4e88-ad0d-ebeac18a263a" xlink:href="rxrx-20240331.xsd#rxrx_SaleOfStockValueRemainingAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_eae82d41-c8f4-4ccd-83c9-7cd5a7bf883b" xlink:to="loc_rxrx_SaleOfStockValueRemainingAuthorized_d3859a8e-b9b8-4e88-ad0d-ebeac18a263a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_8de5f3bd-0304-470c-8e0b-31d38b10021f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_eae82d41-c8f4-4ccd-83c9-7cd5a7bf883b" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_8de5f3bd-0304-470c-8e0b-31d38b10021f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_ba81f2d1-b7c6-4d5f-89f3-0d7380b41e04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_eae82d41-c8f4-4ccd-83c9-7cd5a7bf883b" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_ba81f2d1-b7c6-4d5f-89f3-0d7380b41e04" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_SaleOfStockPercentageOfCommission_d16fbae3-6969-40e8-8f8e-6846e6dbf52a" xlink:href="rxrx-20240331.xsd#rxrx_SaleOfStockPercentageOfCommission"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_eae82d41-c8f4-4ccd-83c9-7cd5a7bf883b" xlink:to="loc_rxrx_SaleOfStockPercentageOfCommission_d16fbae3-6969-40e8-8f8e-6846e6dbf52a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_ec73e28a-b627-41b1-95f9-7491829f9fb4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_eae82d41-c8f4-4ccd-83c9-7cd5a7bf883b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_ec73e28a-b627-41b1-95f9-7491829f9fb4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_4b8fe4f8-7253-4710-a2e7-fc36599b6447" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_eae82d41-c8f4-4ccd-83c9-7cd5a7bf883b" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_4b8fe4f8-7253-4710-a2e7-fc36599b6447" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_ee2f65d6-7b8f-412e-99ea-35b33a94f81d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_eae82d41-c8f4-4ccd-83c9-7cd5a7bf883b" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_ee2f65d6-7b8f-412e-99ea-35b33a94f81d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_BusinessAcquisitionContingentConsiderationEquityInterestsIssuableNumberOfShares_154a1af7-7b6d-41e9-8652-5c878d3d93ee" xlink:href="rxrx-20240331.xsd#rxrx_BusinessAcquisitionContingentConsiderationEquityInterestsIssuableNumberOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_eae82d41-c8f4-4ccd-83c9-7cd5a7bf883b" xlink:to="loc_rxrx_BusinessAcquisitionContingentConsiderationEquityInterestsIssuableNumberOfShares_154a1af7-7b6d-41e9-8652-5c878d3d93ee" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_CommonStockConversionRatio_e35ec2af-0e56-4527-abe4-92832d94b754" xlink:href="rxrx-20240331.xsd#rxrx_CommonStockConversionRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_eae82d41-c8f4-4ccd-83c9-7cd5a7bf883b" xlink:to="loc_rxrx_CommonStockConversionRatio_e35ec2af-0e56-4527-abe4-92832d94b754" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_b890adf3-bd9e-4061-a694-8afd99833c5e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_eae82d41-c8f4-4ccd-83c9-7cd5a7bf883b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_b890adf3-bd9e-4061-a694-8afd99833c5e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_PercentOfAggregatePurchasePricePaidByTheHolderDueIfAgreementIsBroken_5f0ddd6e-507c-49f6-8267-75f75c8bd6cb" xlink:href="rxrx-20240331.xsd#rxrx_PercentOfAggregatePurchasePricePaidByTheHolderDueIfAgreementIsBroken"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_eae82d41-c8f4-4ccd-83c9-7cd5a7bf883b" xlink:to="loc_rxrx_PercentOfAggregatePurchasePricePaidByTheHolderDueIfAgreementIsBroken_5f0ddd6e-507c-49f6-8267-75f75c8bd6cb" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_RegistrationRightsAgreementAccruedLiability_a8774571-a5bf-4006-acde-7ff96edb5c64" xlink:href="rxrx-20240331.xsd#rxrx_RegistrationRightsAgreementAccruedLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_eae82d41-c8f4-4ccd-83c9-7cd5a7bf883b" xlink:to="loc_rxrx_RegistrationRightsAgreementAccruedLiability_a8774571-a5bf-4006-acde-7ff96edb5c64" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_RegistrationRightsAgreementTerm_f0b7298d-3562-4ee1-a29d-dbafc339b06b" xlink:href="rxrx-20240331.xsd#rxrx_RegistrationRightsAgreementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_eae82d41-c8f4-4ccd-83c9-7cd5a7bf883b" xlink:to="loc_rxrx_RegistrationRightsAgreementTerm_f0b7298d-3562-4ee1-a29d-dbafc339b06b" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_NumberOfClassesOfCommonStockAuthorized_e0254c24-3e91-4e77-9ad6-74044769b93d" xlink:href="rxrx-20240331.xsd#rxrx_NumberOfClassesOfCommonStockAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_eae82d41-c8f4-4ccd-83c9-7cd5a7bf883b" xlink:to="loc_rxrx_NumberOfClassesOfCommonStockAuthorized_e0254c24-3e91-4e77-9ad6-74044769b93d" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_AffiliatedHoldersOwnershipPercentage_854212da-df41-43b2-ad7a-6ca60a75632c" xlink:href="rxrx-20240331.xsd#rxrx_AffiliatedHoldersOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_eae82d41-c8f4-4ccd-83c9-7cd5a7bf883b" xlink:to="loc_rxrx_AffiliatedHoldersOwnershipPercentage_854212da-df41-43b2-ad7a-6ca60a75632c" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_AffiliatedHoldersPotentialOwnershipPercentageWhenOutstandingEquityAwardsVest_f5256b8b-a8a5-428f-8003-2160f942091c" xlink:href="rxrx-20240331.xsd#rxrx_AffiliatedHoldersPotentialOwnershipPercentageWhenOutstandingEquityAwardsVest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_eae82d41-c8f4-4ccd-83c9-7cd5a7bf883b" xlink:to="loc_rxrx_AffiliatedHoldersPotentialOwnershipPercentageWhenOutstandingEquityAwardsVest_f5256b8b-a8a5-428f-8003-2160f942091c" xlink:type="arc" order="18"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.recursion.com/role/CollaborativeDevelopmentContractsDetails" xlink:type="simple" xlink:href="rxrx-20240331.xsd#CollaborativeDevelopmentContractsDetails"/>
  <link:definitionLink xlink:role="http://www.recursion.com/role/CollaborativeDevelopmentContractsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d5f309b1-284e-42a2-89cb-13e593b2a15c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_65be20c9-36d7-42af-ae7c-04cc3a408891" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d5f309b1-284e-42a2-89cb-13e593b2a15c" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_65be20c9-36d7-42af-ae7c-04cc3a408891" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_f171e844-ab15-4b0e-9100-b501593f7a1b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_65be20c9-36d7-42af-ae7c-04cc3a408891" xlink:to="loc_srt_CounterpartyNameAxis_f171e844-ab15-4b0e-9100-b501593f7a1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f171e844-ab15-4b0e-9100-b501593f7a1b_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_f171e844-ab15-4b0e-9100-b501593f7a1b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f171e844-ab15-4b0e-9100-b501593f7a1b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6fceed55-3226-4012-950b-f1f380bf0fe9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_f171e844-ab15-4b0e-9100-b501593f7a1b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6fceed55-3226-4012-950b-f1f380bf0fe9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_RocheAndGenentechMember_a3fb5279-b8de-427b-a476-ca62f37a8742" xlink:href="rxrx-20240331.xsd#rxrx_RocheAndGenentechMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6fceed55-3226-4012-950b-f1f380bf0fe9" xlink:to="loc_rxrx_RocheAndGenentechMember_a3fb5279-b8de-427b-a476-ca62f37a8742" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_6c6a71b2-46bd-4cb7-a01e-6bdebe9ac949" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_65be20c9-36d7-42af-ae7c-04cc3a408891" xlink:to="loc_us-gaap_TypeOfArrangementAxis_6c6a71b2-46bd-4cb7-a01e-6bdebe9ac949" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6c6a71b2-46bd-4cb7-a01e-6bdebe9ac949_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6c6a71b2-46bd-4cb7-a01e-6bdebe9ac949" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6c6a71b2-46bd-4cb7-a01e-6bdebe9ac949_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_91f2036f-a58d-4edc-ba58-a5deab6d0ee5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6c6a71b2-46bd-4cb7-a01e-6bdebe9ac949" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_91f2036f-a58d-4edc-ba58-a5deab6d0ee5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_4ff8ddcc-3571-4784-a384-663a4481a5d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_91f2036f-a58d-4edc-ba58-a5deab6d0ee5" xlink:to="loc_us-gaap_CollaborativeArrangementMember_4ff8ddcc-3571-4784-a384-663a4481a5d2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_RevenueRemainingPerformanceObligationAxis_e0891ab6-9bbe-45dd-a396-a47b32b63408" xlink:href="rxrx-20240331.xsd#rxrx_RevenueRemainingPerformanceObligationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_65be20c9-36d7-42af-ae7c-04cc3a408891" xlink:to="loc_rxrx_RevenueRemainingPerformanceObligationAxis_e0891ab6-9bbe-45dd-a396-a47b32b63408" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_RevenueRemainingPerformanceObligationDomain_e0891ab6-9bbe-45dd-a396-a47b32b63408_default" xlink:href="rxrx-20240331.xsd#rxrx_RevenueRemainingPerformanceObligationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_rxrx_RevenueRemainingPerformanceObligationAxis_e0891ab6-9bbe-45dd-a396-a47b32b63408" xlink:to="loc_rxrx_RevenueRemainingPerformanceObligationDomain_e0891ab6-9bbe-45dd-a396-a47b32b63408_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_RevenueRemainingPerformanceObligationDomain_1eab405d-42d4-4683-8c45-b8f99ffe3d81" xlink:href="rxrx-20240331.xsd#rxrx_RevenueRemainingPerformanceObligationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_rxrx_RevenueRemainingPerformanceObligationAxis_e0891ab6-9bbe-45dd-a396-a47b32b63408" xlink:to="loc_rxrx_RevenueRemainingPerformanceObligationDomain_1eab405d-42d4-4683-8c45-b8f99ffe3d81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_PhenomapsCreationMember_4ffcceda-eda1-4f4c-be22-d2c84f378d18" xlink:href="rxrx-20240331.xsd#rxrx_PhenomapsCreationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rxrx_RevenueRemainingPerformanceObligationDomain_1eab405d-42d4-4683-8c45-b8f99ffe3d81" xlink:to="loc_rxrx_PhenomapsCreationMember_4ffcceda-eda1-4f4c-be22-d2c84f378d18" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_PhenomapsRawImagesMember_f77a03cf-bbbc-4641-9b71-8a10bc92eaf0" xlink:href="rxrx-20240331.xsd#rxrx_PhenomapsRawImagesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rxrx_RevenueRemainingPerformanceObligationDomain_1eab405d-42d4-4683-8c45-b8f99ffe3d81" xlink:to="loc_rxrx_PhenomapsRawImagesMember_f77a03cf-bbbc-4641-9b71-8a10bc92eaf0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_DevelopedAndCommercializedProgramsMember_84a5f6cf-8930-4467-b44d-4e3cf470c446" xlink:href="rxrx-20240331.xsd#rxrx_DevelopedAndCommercializedProgramsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rxrx_RevenueRemainingPerformanceObligationDomain_1eab405d-42d4-4683-8c45-b8f99ffe3d81" xlink:to="loc_rxrx_DevelopedAndCommercializedProgramsMember_84a5f6cf-8930-4467-b44d-4e3cf470c446" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_GastrointestinalCancerMember_f8fda4b3-79f6-44c6-85e7-cc65e22c378e" xlink:href="rxrx-20240331.xsd#rxrx_GastrointestinalCancerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rxrx_RevenueRemainingPerformanceObligationDomain_1eab405d-42d4-4683-8c45-b8f99ffe3d81" xlink:to="loc_rxrx_GastrointestinalCancerMember_f8fda4b3-79f6-44c6-85e7-cc65e22c378e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_NeuroscienceMember_62d40d2f-7922-4152-bcc4-0062a7840b1f" xlink:href="rxrx-20240331.xsd#rxrx_NeuroscienceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rxrx_RevenueRemainingPerformanceObligationDomain_1eab405d-42d4-4683-8c45-b8f99ffe3d81" xlink:to="loc_rxrx_NeuroscienceMember_62d40d2f-7922-4152-bcc4-0062a7840b1f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_fd9fe85d-3246-4999-a0fd-178c7cc0e36c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d5f309b1-284e-42a2-89cb-13e593b2a15c" xlink:to="loc_us-gaap_ContractWithCustomerLiability_fd9fe85d-3246-4999-a0fd-178c7cc0e36c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_RevenueRemainingPerformanceObligationVariableConsiderationAmount_d6afc3d8-122a-4cd8-bcd1-4570aeb9c5f6" xlink:href="rxrx-20240331.xsd#rxrx_RevenueRemainingPerformanceObligationVariableConsiderationAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d5f309b1-284e-42a2-89cb-13e593b2a15c" xlink:to="loc_rxrx_RevenueRemainingPerformanceObligationVariableConsiderationAmount_d6afc3d8-122a-4cd8-bcd1-4570aeb9c5f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_ContractWithCustomerMaximumAcceptedProduct_725c3864-b388-4377-94ed-133321ef938e" xlink:href="rxrx-20240331.xsd#rxrx_ContractWithCustomerMaximumAcceptedProduct"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d5f309b1-284e-42a2-89cb-13e593b2a15c" xlink:to="loc_rxrx_ContractWithCustomerMaximumAcceptedProduct_725c3864-b388-4377-94ed-133321ef938e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_RevenueRemainingPerformanceObligationNumberOfProjectsThatMayBeInitiated_d90dbfcc-1dca-4145-98be-eb14ddf59549" xlink:href="rxrx-20240331.xsd#rxrx_RevenueRemainingPerformanceObligationNumberOfProjectsThatMayBeInitiated"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d5f309b1-284e-42a2-89cb-13e593b2a15c" xlink:to="loc_rxrx_RevenueRemainingPerformanceObligationNumberOfProjectsThatMayBeInitiated_d90dbfcc-1dca-4145-98be-eb14ddf59549" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_RevenuePerformanceObligationNumberOfObligations_97af19b8-13e9-49a3-a38f-bc750459d4fb" xlink:href="rxrx-20240331.xsd#rxrx_RevenuePerformanceObligationNumberOfObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d5f309b1-284e-42a2-89cb-13e593b2a15c" xlink:to="loc_rxrx_RevenuePerformanceObligationNumberOfObligations_97af19b8-13e9-49a3-a38f-bc750459d4fb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_845cccb1-857b-4e09-b717-8c50c1b67693" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d5f309b1-284e-42a2-89cb-13e593b2a15c" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_845cccb1-857b-4e09-b717-8c50c1b67693" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_1a115b37-1ab4-47f3-9643-32846055cd22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d5f309b1-284e-42a2-89cb-13e593b2a15c" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_1a115b37-1ab4-47f3-9643-32846055cd22" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.recursion.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="rxrx-20240331.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.recursion.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8951b432-e440-4664-995f-ed6f7c2c4672" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7d3df568-f2e5-475f-9496-362ca87448b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8951b432-e440-4664-995f-ed6f7c2c4672" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7d3df568-f2e5-475f-9496-362ca87448b3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_1a5100f6-d9d2-4b41-9f49-34a71d62b956" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7d3df568-f2e5-475f-9496-362ca87448b3" xlink:to="loc_us-gaap_PlanNameAxis_1a5100f6-d9d2-4b41-9f49-34a71d62b956" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_1a5100f6-d9d2-4b41-9f49-34a71d62b956_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_1a5100f6-d9d2-4b41-9f49-34a71d62b956" xlink:to="loc_us-gaap_PlanNameDomain_1a5100f6-d9d2-4b41-9f49-34a71d62b956_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_5a8cd375-bf87-4079-93ee-4a5df38fe5d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_1a5100f6-d9d2-4b41-9f49-34a71d62b956" xlink:to="loc_us-gaap_PlanNameDomain_5a8cd375-bf87-4079-93ee-4a5df38fe5d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_A2021EquityIncentivePlanMember_8ff0de38-96dd-4edd-84d0-ada420e9084e" xlink:href="rxrx-20240331.xsd#rxrx_A2021EquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_5a8cd375-bf87-4079-93ee-4a5df38fe5d0" xlink:to="loc_rxrx_A2021EquityIncentivePlanMember_8ff0de38-96dd-4edd-84d0-ada420e9084e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7fe264de-5eb6-41ef-98ff-b206a4804042" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7d3df568-f2e5-475f-9496-362ca87448b3" xlink:to="loc_us-gaap_AwardTypeAxis_7fe264de-5eb6-41ef-98ff-b206a4804042" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7fe264de-5eb6-41ef-98ff-b206a4804042_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_7fe264de-5eb6-41ef-98ff-b206a4804042" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7fe264de-5eb6-41ef-98ff-b206a4804042_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_42cdfa3f-045b-4ddb-a6e8-36c534885061" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_7fe264de-5eb6-41ef-98ff-b206a4804042" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_42cdfa3f-045b-4ddb-a6e8-36c534885061" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_da852d2c-0567-43d4-a98a-2c336488209f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_42cdfa3f-045b-4ddb-a6e8-36c534885061" xlink:to="loc_us-gaap_EmployeeStockOptionMember_da852d2c-0567-43d4-a98a-2c336488209f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_7d70250d-b5b5-4b43-92a4-d432c647b4d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_42cdfa3f-045b-4ddb-a6e8-36c534885061" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_7d70250d-b5b5-4b43-92a4-d432c647b4d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_b8da9e87-1cd1-4f37-a8dc-bbbca8ac06a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_42cdfa3f-045b-4ddb-a6e8-36c534885061" xlink:to="loc_us-gaap_RestrictedStockMember_b8da9e87-1cd1-4f37-a8dc-bbbca8ac06a8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_5e97a401-a5fb-4c62-a820-ad488acab919" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8951b432-e440-4664-995f-ed6f7c2c4672" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_5e97a401-a5fb-4c62-a820-ad488acab919" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_31a091de-a3e7-4b00-8c11-1b2f13dda3c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8951b432-e440-4664-995f-ed6f7c2c4672" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_31a091de-a3e7-4b00-8c11-1b2f13dda3c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_b0f31643-5556-4c2a-be6d-4004bc3854c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8951b432-e440-4664-995f-ed6f7c2c4672" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_b0f31643-5556-4c2a-be6d-4004bc3854c9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a8be056d-2e4f-45e9-9f27-7ec6c62ccbe6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8951b432-e440-4664-995f-ed6f7c2c4672" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a8be056d-2e4f-45e9-9f27-7ec6c62ccbe6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_b0af742c-4783-4f8f-9702-399c30b6271c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8951b432-e440-4664-995f-ed6f7c2c4672" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_b0af742c-4783-4f8f-9702-399c30b6271c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_76b24c1c-3e05-463c-a122-4291faf6a6a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8951b432-e440-4664-995f-ed6f7c2c4672" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_76b24c1c-3e05-463c-a122-4291faf6a6a2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_ab3addac-dff5-4cba-908e-a701791feecf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8951b432-e440-4664-995f-ed6f7c2c4672" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_ab3addac-dff5-4cba-908e-a701791feecf" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_15e24adc-43f6-47b1-8437-39c92058a845" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8951b432-e440-4664-995f-ed6f7c2c4672" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_15e24adc-43f6-47b1-8437-39c92058a845" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.recursion.com/role/StockBasedCompensationSummaryofStockbasedCompensationExpensesDetails" xlink:type="simple" xlink:href="rxrx-20240331.xsd#StockBasedCompensationSummaryofStockbasedCompensationExpensesDetails"/>
  <link:definitionLink xlink:role="http://www.recursion.com/role/StockBasedCompensationSummaryofStockbasedCompensationExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ef559bfa-d169-43c4-8fa8-05cd20ce78c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e1b158d1-cc92-459c-b53a-707c755d480d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ef559bfa-d169-43c4-8fa8-05cd20ce78c0" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e1b158d1-cc92-459c-b53a-707c755d480d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_ce558b9b-20a5-427a-84b3-d367b08d74c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e1b158d1-cc92-459c-b53a-707c755d480d" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_ce558b9b-20a5-427a-84b3-d367b08d74c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ce558b9b-20a5-427a-84b3-d367b08d74c4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_ce558b9b-20a5-427a-84b3-d367b08d74c4" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ce558b9b-20a5-427a-84b3-d367b08d74c4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_5c084c0b-8990-4bfa-bb3c-30f14e0efaf0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_ce558b9b-20a5-427a-84b3-d367b08d74c4" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_5c084c0b-8990-4bfa-bb3c-30f14e0efaf0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_3bf49748-1dd6-40f0-91fb-7a75da01461f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5c084c0b-8990-4bfa-bb3c-30f14e0efaf0" xlink:to="loc_us-gaap_CostOfSalesMember_3bf49748-1dd6-40f0-91fb-7a75da01461f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_237c1da7-9f42-4ce5-b164-1ea009ecad36" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5c084c0b-8990-4bfa-bb3c-30f14e0efaf0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_237c1da7-9f42-4ce5-b164-1ea009ecad36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_da2bd741-7c6d-424f-b39e-9175d5775472" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5c084c0b-8990-4bfa-bb3c-30f14e0efaf0" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_da2bd741-7c6d-424f-b39e-9175d5775472" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_50b432a4-bea4-4448-8344-c5805d9cdc16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ef559bfa-d169-43c4-8fa8-05cd20ce78c0" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_50b432a4-bea4-4448-8344-c5805d9cdc16" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.recursion.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionDetails" xlink:type="simple" xlink:href="rxrx-20240331.xsd#StockBasedCompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionDetails"/>
  <link:definitionLink xlink:role="http://www.recursion.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_62f1bd30-1150-4019-bd48-5deeedeeeb5c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1df40097-cf1f-4fa9-9b36-44a9432ea0b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_62f1bd30-1150-4019-bd48-5deeedeeeb5c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1df40097-cf1f-4fa9-9b36-44a9432ea0b2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_056d7d10-8148-4d0d-be6b-062158ce3827" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1df40097-cf1f-4fa9-9b36-44a9432ea0b2" xlink:to="loc_us-gaap_AwardTypeAxis_056d7d10-8148-4d0d-be6b-062158ce3827" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_056d7d10-8148-4d0d-be6b-062158ce3827_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_056d7d10-8148-4d0d-be6b-062158ce3827" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_056d7d10-8148-4d0d-be6b-062158ce3827_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_26f5f211-7a6e-4869-b083-b30f69fc9d30" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_056d7d10-8148-4d0d-be6b-062158ce3827" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_26f5f211-7a6e-4869-b083-b30f69fc9d30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_8ead21f3-e1b1-40ae-80b7-9df2abad1b77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_26f5f211-7a6e-4869-b083-b30f69fc9d30" xlink:to="loc_us-gaap_EmployeeStockOptionMember_8ead21f3-e1b1-40ae-80b7-9df2abad1b77" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_a611beeb-ecc8-488b-adcc-00955c226c05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_62f1bd30-1150-4019-bd48-5deeedeeeb5c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_a611beeb-ecc8-488b-adcc-00955c226c05" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_237d1017-b862-48b4-aa3f-e04d97a52bc0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_62f1bd30-1150-4019-bd48-5deeedeeeb5c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_237d1017-b862-48b4-aa3f-e04d97a52bc0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_d30a5f12-ba42-4153-af44-90dffaa6f527" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_62f1bd30-1150-4019-bd48-5deeedeeeb5c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_d30a5f12-ba42-4153-af44-90dffaa6f527" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_acb495fd-fc18-4e0e-baca-725c3f8a8dcc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_62f1bd30-1150-4019-bd48-5deeedeeeb5c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_acb495fd-fc18-4e0e-baca-725c3f8a8dcc" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.recursion.com/role/StockBasedCompensationScheduleofRSUActivityDetails" xlink:type="simple" xlink:href="rxrx-20240331.xsd#StockBasedCompensationScheduleofRSUActivityDetails"/>
  <link:definitionLink xlink:role="http://www.recursion.com/role/StockBasedCompensationScheduleofRSUActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cef4e98f-ab5b-444b-9d1a-2ef7dc5646dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ee43a11c-019e-4f84-abac-5a34d7789161" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cef4e98f-ab5b-444b-9d1a-2ef7dc5646dc" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ee43a11c-019e-4f84-abac-5a34d7789161" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0f6a25e6-a023-4992-bb62-33761b045ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ee43a11c-019e-4f84-abac-5a34d7789161" xlink:to="loc_us-gaap_AwardTypeAxis_0f6a25e6-a023-4992-bb62-33761b045ec8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0f6a25e6-a023-4992-bb62-33761b045ec8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_0f6a25e6-a023-4992-bb62-33761b045ec8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0f6a25e6-a023-4992-bb62-33761b045ec8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a7e9ea58-5ec3-4294-b32c-28d772ae6a37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_0f6a25e6-a023-4992-bb62-33761b045ec8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a7e9ea58-5ec3-4294-b32c-28d772ae6a37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_19c5465d-6ffe-4113-b723-8640175a12ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a7e9ea58-5ec3-4294-b32c-28d772ae6a37" xlink:to="loc_us-gaap_RestrictedStockMember_19c5465d-6ffe-4113-b723-8640175a12ab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_7547e3fe-61b7-4947-995e-dcb21684f871" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cef4e98f-ab5b-444b-9d1a-2ef7dc5646dc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_7547e3fe-61b7-4947-995e-dcb21684f871" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ae0cf362-0d1a-4b67-88d8-e21d6c72c897" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_7547e3fe-61b7-4947-995e-dcb21684f871" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ae0cf362-0d1a-4b67-88d8-e21d6c72c897" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_61fd619e-522b-4c0d-bb9f-3090f6d92b11" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_7547e3fe-61b7-4947-995e-dcb21684f871" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_61fd619e-522b-4c0d-bb9f-3090f6d92b11" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_22c624b1-fd94-4ec6-9e05-fdefc093146c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_7547e3fe-61b7-4947-995e-dcb21684f871" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_22c624b1-fd94-4ec6-9e05-fdefc093146c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_8d5de2d1-d55c-409a-95cb-44844426dde3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_7547e3fe-61b7-4947-995e-dcb21684f871" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_8d5de2d1-d55c-409a-95cb-44844426dde3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c08134bd-b853-4c2a-8c79-8b95d70c19cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_13778042-9304-4250-9857-897121bd0dae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cef4e98f-ab5b-444b-9d1a-2ef7dc5646dc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_13778042-9304-4250-9857-897121bd0dae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6bfa58f0-cbb7-4970-89b9-51a2b8956969" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_13778042-9304-4250-9857-897121bd0dae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6bfa58f0-cbb7-4970-89b9-51a2b8956969" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_92b6edd8-295e-4736-b651-f9d4aeca61f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_13778042-9304-4250-9857-897121bd0dae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_92b6edd8-295e-4736-b651-f9d4aeca61f1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_b82c7558-cfc5-46e6-a580-409f44413859" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_13778042-9304-4250-9857-897121bd0dae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_b82c7558-cfc5-46e6-a580-409f44413859" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_fa218da2-e42a-44dd-8163-33b04726174f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_13778042-9304-4250-9857-897121bd0dae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_fa218da2-e42a-44dd-8163-33b04726174f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_ed29d508-a855-402d-b196-069b48ff69c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.recursion.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossPerShareDetails" xlink:type="simple" xlink:href="rxrx-20240331.xsd#NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossPerShareDetails"/>
  <link:definitionLink xlink:role="http://www.recursion.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_deb6ebc1-9a77-4549-bb73-ebd6f9e918f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_23344f30-d178-4dbc-b20b-76e8a1b0c77f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_deb6ebc1-9a77-4549-bb73-ebd6f9e918f0" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_23344f30-d178-4dbc-b20b-76e8a1b0c77f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cb349cca-62ad-4464-8776-95965f67f1c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_23344f30-d178-4dbc-b20b-76e8a1b0c77f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cb349cca-62ad-4464-8776-95965f67f1c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_cb349cca-62ad-4464-8776-95965f67f1c8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cb349cca-62ad-4464-8776-95965f67f1c8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_cb349cca-62ad-4464-8776-95965f67f1c8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9274a02d-a181-4548-8a5d-f8630e55a173" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cb349cca-62ad-4464-8776-95965f67f1c8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9274a02d-a181-4548-8a5d-f8630e55a173" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_cb7395dd-5113-4e26-b166-8d45b6673516" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9274a02d-a181-4548-8a5d-f8630e55a173" xlink:to="loc_us-gaap_EmployeeStockOptionMember_cb7395dd-5113-4e26-b166-8d45b6673516" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_TempusAgreementMember_2f5171ec-0833-4e9c-b9eb-36ed68e3f329" xlink:href="rxrx-20240331.xsd#rxrx_TempusAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9274a02d-a181-4548-8a5d-f8630e55a173" xlink:to="loc_rxrx_TempusAgreementMember_2f5171ec-0833-4e9c-b9eb-36ed68e3f329" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_62d87f9e-c5e9-43b2-8f5a-f0260e6bff76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_deb6ebc1-9a77-4549-bb73-ebd6f9e918f0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_62d87f9e-c5e9-43b2-8f5a-f0260e6bff76" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.recursion.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails" xlink:type="simple" xlink:href="rxrx-20240331.xsd#FairValueMeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.recursion.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_028ee393-f7e3-4f71-ace4-1522ec8871a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_986c1f71-9160-4455-80ae-b49ba9ff249d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_028ee393-f7e3-4f71-ace4-1522ec8871a2" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_986c1f71-9160-4455-80ae-b49ba9ff249d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e39f3620-d4fb-4c52-a3c4-e2b6133c5354" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_986c1f71-9160-4455-80ae-b49ba9ff249d" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e39f3620-d4fb-4c52-a3c4-e2b6133c5354" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_e39f3620-d4fb-4c52-a3c4-e2b6133c5354_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e39f3620-d4fb-4c52-a3c4-e2b6133c5354" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_e39f3620-d4fb-4c52-a3c4-e2b6133c5354_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_c951075e-1a5d-49ac-bbbd-09132c7b532a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e39f3620-d4fb-4c52-a3c4-e2b6133c5354" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_c951075e-1a5d-49ac-bbbd-09132c7b532a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_aed68790-edeb-4ecc-aa4d-2effb453956b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_c951075e-1a5d-49ac-bbbd-09132c7b532a" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_aed68790-edeb-4ecc-aa4d-2effb453956b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_85544c83-ceba-47e4-917a-bd89e25309b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_986c1f71-9160-4455-80ae-b49ba9ff249d" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_85544c83-ceba-47e4-917a-bd89e25309b3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_85544c83-ceba-47e4-917a-bd89e25309b3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_85544c83-ceba-47e4-917a-bd89e25309b3" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_85544c83-ceba-47e4-917a-bd89e25309b3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f0e19a2c-02ba-4b63-a37f-bdeb1d859911" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_85544c83-ceba-47e4-917a-bd89e25309b3" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f0e19a2c-02ba-4b63-a37f-bdeb1d859911" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_b9883d1b-b080-4ed3-855e-5f1275fb89fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f0e19a2c-02ba-4b63-a37f-bdeb1d859911" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_b9883d1b-b080-4ed3-855e-5f1275fb89fc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_d807c912-fcac-44ca-9e00-8909c81f459a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f0e19a2c-02ba-4b63-a37f-bdeb1d859911" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_d807c912-fcac-44ca-9e00-8909c81f459a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_94667603-5663-4440-a713-e2a30d29f7cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f0e19a2c-02ba-4b63-a37f-bdeb1d859911" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_94667603-5663-4440-a713-e2a30d29f7cf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_6f66013a-f795-4590-b551-4f47c4540b60" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_986c1f71-9160-4455-80ae-b49ba9ff249d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_6f66013a-f795-4590-b551-4f47c4540b60" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_6f66013a-f795-4590-b551-4f47c4540b60_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_6f66013a-f795-4590-b551-4f47c4540b60" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_6f66013a-f795-4590-b551-4f47c4540b60_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_74427d49-3dbf-4abe-b23f-680427211da1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_6f66013a-f795-4590-b551-4f47c4540b60" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_74427d49-3dbf-4abe-b23f-680427211da1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_c9a99c86-7276-495e-8c7e-a4f84c59b84c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_74427d49-3dbf-4abe-b23f-680427211da1" xlink:to="loc_us-gaap_MoneyMarketFundsMember_c9a99c86-7276-495e-8c7e-a4f84c59b84c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_282cbb5a-084f-4b4c-bcc1-373904d75be3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_028ee393-f7e3-4f71-ace4-1522ec8871a2" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_282cbb5a-084f-4b4c-bcc1-373904d75be3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_RestrictedCashAndCashEquivalentsFairValueDisclosure_8e1f9268-23a3-4454-807e-b50f02d4b23a" xlink:href="rxrx-20240331.xsd#rxrx_RestrictedCashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_028ee393-f7e3-4f71-ace4-1522ec8871a2" xlink:to="loc_rxrx_RestrictedCashAndCashEquivalentsFairValueDisclosure_8e1f9268-23a3-4454-807e-b50f02d4b23a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_5be95925-e777-4a6c-8010-556647c55818" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_028ee393-f7e3-4f71-ace4-1522ec8871a2" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_5be95925-e777-4a6c-8010-556647c55818" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.recursion.com/role/FairValueMeasurementsAssetandLiabilityNotMeasuredatFairValueDetails" xlink:type="simple" xlink:href="rxrx-20240331.xsd#FairValueMeasurementsAssetandLiabilityNotMeasuredatFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.recursion.com/role/FairValueMeasurementsAssetandLiabilityNotMeasuredatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems_15c58993-e4a6-4a7a-99b5-9a6ed73f034a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable_cdb46468-ae3d-474d-8ce9-507033387eb1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems_15c58993-e4a6-4a7a-99b5-9a6ed73f034a" xlink:to="loc_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable_cdb46468-ae3d-474d-8ce9-507033387eb1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_64e5bcac-e5f6-4f05-a996-a364a823d8f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable_cdb46468-ae3d-474d-8ce9-507033387eb1" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_64e5bcac-e5f6-4f05-a996-a364a823d8f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_64e5bcac-e5f6-4f05-a996-a364a823d8f2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_64e5bcac-e5f6-4f05-a996-a364a823d8f2" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_64e5bcac-e5f6-4f05-a996-a364a823d8f2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_f63e66d4-5351-4511-81e9-0311cfd359e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_64e5bcac-e5f6-4f05-a996-a364a823d8f2" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_f63e66d4-5351-4511-81e9-0311cfd359e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_d9b4c11d-4831-46dd-9208-d31dce35e34d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_f63e66d4-5351-4511-81e9-0311cfd359e8" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_d9b4c11d-4831-46dd-9208-d31dce35e34d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember_bcbce117-3f85-4641-bc71-62310058249a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_d9b4c11d-4831-46dd-9208-d31dce35e34d" xlink:to="loc_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember_bcbce117-3f85-4641-bc71-62310058249a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_aec9cb48-37b8-43db-80ac-d54cc883fc43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_d9b4c11d-4831-46dd-9208-d31dce35e34d" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_aec9cb48-37b8-43db-80ac-d54cc883fc43" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_38c3275e-7eb9-4c77-b724-0a3908650a6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable_cdb46468-ae3d-474d-8ce9-507033387eb1" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_38c3275e-7eb9-4c77-b724-0a3908650a6f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_38c3275e-7eb9-4c77-b724-0a3908650a6f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_38c3275e-7eb9-4c77-b724-0a3908650a6f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_38c3275e-7eb9-4c77-b724-0a3908650a6f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_0718d136-9819-40c8-a547-8254955dce1a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_38c3275e-7eb9-4c77-b724-0a3908650a6f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_0718d136-9819-40c8-a547-8254955dce1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_08a35c19-dd77-492b-bf5c-dfa249bf87ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_0718d136-9819-40c8-a547-8254955dce1a" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_08a35c19-dd77-492b-bf5c-dfa249bf87ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_df193b35-e87d-4779-aefd-78d45531f98b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems_15c58993-e4a6-4a7a-99b5-9a6ed73f034a" xlink:to="loc_us-gaap_LongTermDebtCurrent_df193b35-e87d-4779-aefd-78d45531f98b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_0fa8e9cf-422e-4b37-91f3-ca9fb8091a06" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems_15c58993-e4a6-4a7a-99b5-9a6ed73f034a" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_0fa8e9cf-422e-4b37-91f3-ca9fb8091a06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_98cf318d-f761-4b10-8fbc-f19f1cf43fe5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems_15c58993-e4a6-4a7a-99b5-9a6ed73f034a" xlink:to="loc_us-gaap_LongTermDebtFairValue_98cf318d-f761-4b10-8fbc-f19f1cf43fe5" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#AwardTypeOnly"/>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockMember" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_RestrictedStockMember" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#IndividualsOnly"/>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_TerryAnnBurrellMember_79349401-53d5-4253-9467-91cc461c36cc" xlink:href="rxrx-20240331.xsd#rxrx_TerryAnnBurrellMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_rxrx_TerryAnnBurrellMember_79349401-53d5-4253-9467-91cc461c36cc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_TinaMarriottMember_e231bae9-6fd7-415b-9659-f6d14b295b7e" xlink:href="rxrx-20240331.xsd#rxrx_TinaMarriottMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_rxrx_TinaMarriottMember_e231bae9-6fd7-415b-9659-f6d14b295b7e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_MichaelSecoraMember_44f7871d-b310-4c9f-ad3d-22456f2bad33" xlink:href="rxrx-20240331.xsd#rxrx_MichaelSecoraMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_rxrx_MichaelSecoraMember_44f7871d-b310-4c9f-ad3d-22456f2bad33" xlink:type="arc" order="4"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>rxrx-20240331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:3e558803-1e4e-49a0-9bef-dda845cc7d19,g:dd7baf31-0188-4ca9-9996-087ebdfea724-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_AffiliatedHoldersOwnershipPercentage_ccd4c8b0-18b7-4bf1-88ca-ed9713810ff2_terseLabel_en-US" xlink:label="lab_rxrx_AffiliatedHoldersOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Affiliated holders, ownership percentage</link:label>
    <link:label id="lab_rxrx_AffiliatedHoldersOwnershipPercentage_label_en-US" xlink:label="lab_rxrx_AffiliatedHoldersOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Affiliated Holders, Ownership Percentage</link:label>
    <link:label id="lab_rxrx_AffiliatedHoldersOwnershipPercentage_documentation_en-US" xlink:label="lab_rxrx_AffiliatedHoldersOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Affiliated Holders, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_AffiliatedHoldersOwnershipPercentage" xlink:href="rxrx-20240331.xsd#rxrx_AffiliatedHoldersOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_AffiliatedHoldersOwnershipPercentage" xlink:to="lab_rxrx_AffiliatedHoldersOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_155a88ca-c395-48d0-b37f-91d58f7dfcbf_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_bcc70a70-2c63-4395-8ee2-816b42477d53_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Accrued expense and other liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_8b8c7913-6100-4fd0-bc07-4aa1b9a1edcc_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock_fbc70a21-d15d-45ea-a030-a811c717ff71_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value Disclosure of Asset and Liability Not Measured at Fair Value</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosure of Asset and Liability Not Measured at Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock" xlink:to="lab_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_1c5b6372-6d90-4a97-8f98-4fdc8f390a39_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_748f5ab8-22f6-41e2-8f6b-5d76e822ded5_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_eed98b35-3f06-44ad-b3c4-064c6d01889b_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options, expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_473a4bec-1d2a-4f80-b5f6-4a49090d2baf_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_BusinessAcquisitionContingentConsiderationEquityInterestsIssuableNumberOfShares_b6686c7d-0d21-4e46-964f-407a6f356323_terseLabel_en-US" xlink:label="lab_rxrx_BusinessAcquisitionContingentConsiderationEquityInterestsIssuableNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration, equity interests issuable (in shares)</link:label>
    <link:label id="lab_rxrx_BusinessAcquisitionContingentConsiderationEquityInterestsIssuableNumberOfShares_label_en-US" xlink:label="lab_rxrx_BusinessAcquisitionContingentConsiderationEquityInterestsIssuableNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition , Contingent Consideration, Equity Interests Issuable, Number Of Shares</link:label>
    <link:label id="lab_rxrx_BusinessAcquisitionContingentConsiderationEquityInterestsIssuableNumberOfShares_documentation_en-US" xlink:label="lab_rxrx_BusinessAcquisitionContingentConsiderationEquityInterestsIssuableNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Acquisition , Contingent Consideration, Equity Interests Issuable, Number Of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_BusinessAcquisitionContingentConsiderationEquityInterestsIssuableNumberOfShares" xlink:href="rxrx-20240331.xsd#rxrx_BusinessAcquisitionContingentConsiderationEquityInterestsIssuableNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_BusinessAcquisitionContingentConsiderationEquityInterestsIssuableNumberOfShares" xlink:to="lab_rxrx_BusinessAcquisitionContingentConsiderationEquityInterestsIssuableNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bb45b250-6a1b-4f8b-9e06-1fad5f194018_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c31e10fc-1cdd-4ec6-a8ba-a2c48b6e1060_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a1b5878d-b515-4708-bcea-e230436b3941_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_PhenomapsRawImagesMember_1641816d-4f7e-4c8e-9545-9d7c6e0fb5a1_terseLabel_en-US" xlink:label="lab_rxrx_PhenomapsRawImagesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Phenomaps raw images</link:label>
    <link:label id="lab_rxrx_PhenomapsRawImagesMember_label_en-US" xlink:label="lab_rxrx_PhenomapsRawImagesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Phenomaps Raw Images [Member]</link:label>
    <link:label id="lab_rxrx_PhenomapsRawImagesMember_documentation_en-US" xlink:label="lab_rxrx_PhenomapsRawImagesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Phenomaps Raw Images</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_PhenomapsRawImagesMember" xlink:href="rxrx-20240331.xsd#rxrx_PhenomapsRawImagesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_PhenomapsRawImagesMember" xlink:to="lab_rxrx_PhenomapsRawImagesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_8bea7b39-ae6b-4705-9dc7-d02b7f07423b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining operating lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_67af80c4-ab75-4757-80ed-9e45c8e95dd3_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_d658c772-eace-4940-b116-de534e732b29_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value of Assets Acquired and Liabilities Assumed</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a828e77f-1c7c-4e6d-a726-ec7250e6c6c2_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of exchange rate changes on cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_b9449428-a0cf-47f2-9196-74c52488a7ca_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_710e256b-829d-4d91-a9be-4f074e8680ce_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_e581fe5b-2338-41a4-87e6-8d0ed3507c29_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options, exercisable, weighted average remaining contractual life</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_9f02fe36-059b-45f3-94ef-3d2a75e75b69_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_05e3e252-c98f-427d-97e3-36c46809a540_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:to="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_25a2d9c1-8c67-4ca4-817f-08830d5fb16c_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_633fa6dc-f2d6-4475-b594-e20257e9e00b_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of pending claims</link:label>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Pending Claims, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:to="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_dc39a057-35d3-4e01-b029-7504821f4b79_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies (Note&#160;7)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_121cb8fd-5cf1-4bb0-a64d-59d55f8a1efb_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of indefinite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_LicenseAgreementTerm_30f43a07-3c40-4958-9cc9-bd451fa5d633_terseLabel_en-US" xlink:label="lab_rxrx_LicenseAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License agreement, term</link:label>
    <link:label id="lab_rxrx_LicenseAgreementTerm_label_en-US" xlink:label="lab_rxrx_LicenseAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Agreement, Term</link:label>
    <link:label id="lab_rxrx_LicenseAgreementTerm_documentation_en-US" xlink:label="lab_rxrx_LicenseAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License Agreement, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_LicenseAgreementTerm" xlink:href="rxrx-20240331.xsd#rxrx_LicenseAgreementTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_LicenseAgreementTerm" xlink:to="lab_rxrx_LicenseAgreementTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_9a6e1016-3c27-44a0-84f7-0306cd54a852_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable, (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_7a71d332-7d5f-4c7c-832c-82f79a986183_terseLabel_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued, price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_label_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare" xlink:to="lab_us-gaap_SharesIssuedPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_f4a38513-0a2e-4e5d-a3be-7fac0ddca7e2_terseLabel_en-US" xlink:label="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Nonvested RSU Activity</link:label>
    <link:label id="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonvested Restricted Stock Shares Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:to="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_80550fa0-f8b8-4627-a3c4-882e80e9f0c0_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_77906e38-d1d5-4568-82f6-9fede64c8f97_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common shares, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_b1eee586-9be8-4218-b8ad-31bd5d5fbbbf_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_33d38042-8820-44b8-ba31-eb102617e65e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_edce4d61-2ad2-4978-9281-e28decb9e17d_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unearned revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dfcc30e1-1026-450d-af6b-8e2882e3ec0d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_ffe8d82e-7237-487d-a328-fd66f53f5d5c_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_6a17ddb2-edbd-4147-9c95-716a1c1f5537_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_37e44d5c-5f4b-4116-8b3e-c0ba8624c127_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average grant date fair value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_ffb00b40-42ec-426d-accc-b29d47589e98_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share of Class A, B and Exchangeable common stock, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_f69d5f34-775a-418c-a316-ce59ff05d977_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share, diluted (in dollars per shares)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseAndServiceMember_749ea976-688c-4537-89eb-54f3748a4d26_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseAndServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating revenue</link:label>
    <link:label id="lab_us-gaap_LicenseAndServiceMember_label_en-US" xlink:label="lab_us-gaap_LicenseAndServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License and Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAndServiceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseAndServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseAndServiceMember" xlink:to="lab_us-gaap_LicenseAndServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_RegistrationRightsAgreementAccruedLiability_3728d44c-8dfd-41ae-94d3-4cc75951f545_terseLabel_en-US" xlink:label="lab_rxrx_RegistrationRightsAgreementAccruedLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Registration rights agreement, accrued liability</link:label>
    <link:label id="lab_rxrx_RegistrationRightsAgreementAccruedLiability_label_en-US" xlink:label="lab_rxrx_RegistrationRightsAgreementAccruedLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Registration Rights Agreement, Accrued Liability</link:label>
    <link:label id="lab_rxrx_RegistrationRightsAgreementAccruedLiability_documentation_en-US" xlink:label="lab_rxrx_RegistrationRightsAgreementAccruedLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Registration Rights Agreement, Accrued Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_RegistrationRightsAgreementAccruedLiability" xlink:href="rxrx-20240331.xsd#rxrx_RegistrationRightsAgreementAccruedLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_RegistrationRightsAgreementAccruedLiability" xlink:to="lab_rxrx_RegistrationRightsAgreementAccruedLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_SaleOfStockValueAuthorized_ce65619c-86b5-48fd-8e55-379965086f89_terseLabel_en-US" xlink:label="lab_rxrx_SaleOfStockValueAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, value authorized</link:label>
    <link:label id="lab_rxrx_SaleOfStockValueAuthorized_label_en-US" xlink:label="lab_rxrx_SaleOfStockValueAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Value, Authorized</link:label>
    <link:label id="lab_rxrx_SaleOfStockValueAuthorized_documentation_en-US" xlink:label="lab_rxrx_SaleOfStockValueAuthorized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale of Stock, Value, Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_SaleOfStockValueAuthorized" xlink:href="rxrx-20240331.xsd#rxrx_SaleOfStockValueAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_SaleOfStockValueAuthorized" xlink:to="lab_rxrx_SaleOfStockValueAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6f9c874b-8bde-4ffc-8ce4-c73c0baa6aba_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_ea769efc-9b8d-40d4-93d9-c462ac19f416_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6b971d10-6f6f-4bf0-b573-2fc78da78f87_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Options, outstanding, number at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_18049f45-043b-4a84-9673-33c5b720af29_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Options, outstanding, number at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_MaterialsReceivedNotInvoiced_f8f87598-854c-49eb-b1c7-8c6fc1ab795a_terseLabel_en-US" xlink:label="lab_rxrx_MaterialsReceivedNotInvoiced" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Materials received not invoiced</link:label>
    <link:label id="lab_rxrx_MaterialsReceivedNotInvoiced_label_en-US" xlink:label="lab_rxrx_MaterialsReceivedNotInvoiced" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Materials Received Not Invoiced</link:label>
    <link:label id="lab_rxrx_MaterialsReceivedNotInvoiced_documentation_en-US" xlink:label="lab_rxrx_MaterialsReceivedNotInvoiced" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Materials Received Not Invoiced</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_MaterialsReceivedNotInvoiced" xlink:href="rxrx-20240331.xsd#rxrx_MaterialsReceivedNotInvoiced"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_MaterialsReceivedNotInvoiced" xlink:to="lab_rxrx_MaterialsReceivedNotInvoiced" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_e2e9ebe0-107c-4f83-94ec-d5c1322a283b_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock option exercises and other</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_23c0d97b-619c-4271-90c3-35a678a25a9a_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1b4b17b4-7a92-4180-ae22-f7366fd30cc6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_5a74e796-1986-4d8b-9ce4-5a10885f8c6c_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_label_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtFairValue" xlink:to="lab_us-gaap_LongTermDebtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_10ac2f9b-455c-41c8-993c-0109b18554a5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options granted in period, weighted average grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c0c8715b-a98b-49c1-9e4f-2fa892f512a4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_8fba700f-6ef7-4918-99ae-782063461225_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss and comprehensive loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_687273c3-da76-4c79-92c9-995145a597a9_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Income (Loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_c6c4f9dc-ac06-4bbc-bab1-d75ae76dddc8_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_bcc3a9b6-4f9d-492e-a26b-fa296f243fd7_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_6212d128-fedb-43dc-b4d8-185da1448126_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, gross</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d3ed9fcf-7ca1-435b-8cd4-2f680d2242c0_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_063944d9-7253-478f-884d-480dd373202d_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_AccruedDevelopmentCostsCurrent_64070af2-319b-484b-a076-ab4cd17b59ee_terseLabel_en-US" xlink:label="lab_rxrx_AccruedDevelopmentCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued development expenses</link:label>
    <link:label id="lab_rxrx_AccruedDevelopmentCostsCurrent_label_en-US" xlink:label="lab_rxrx_AccruedDevelopmentCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Development Costs, Current</link:label>
    <link:label id="lab_rxrx_AccruedDevelopmentCostsCurrent_documentation_en-US" xlink:label="lab_rxrx_AccruedDevelopmentCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Development Costs, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_AccruedDevelopmentCostsCurrent" xlink:href="rxrx-20240331.xsd#rxrx_AccruedDevelopmentCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_AccruedDevelopmentCostsCurrent" xlink:to="lab_rxrx_AccruedDevelopmentCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_90633323-9ad6-4b01-bd3e-920f04054793_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_5b252616-d5a1-4294-82e6-16dfdcbc9ea4_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_095c13c3-bcd6-437a-83aa-8ca391166313_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining unearned revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9c8e2238-1e48-4720-9065-a80811d65244_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock option exercises and other (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a10804b5-b553-46a3-b06f-3485b7134fd8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_3411c6d6-5a75-4b5d-bd90-d808f35a3903_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Basic and Diluted Net Loss per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_dd7795b9-4ba8-493e-b286-14a9dc38ebbb_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of revenue</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_da12eb4e-3ca4-4a2e-97b6-825ff22b7d47_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options, vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_787f92ab-c17d-41a1-92ae-468cf5b7a1a6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonClassBMember_32c2eb20-bf2d-4639-9caa-55648a0e8e07_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonClassBMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Class B</link:label>
    <link:label id="lab_us-gaap_CommonClassBMember_ab0b70e6-18d3-4a8b-b1a3-7382bd6ced1b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonClassBMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class B</link:label>
    <link:label id="lab_us-gaap_CommonClassBMember_label_en-US" xlink:label="lab_us-gaap_CommonClassBMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Class B [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassBMember" xlink:to="lab_us-gaap_CommonClassBMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermNotesPayable_20d2d44b-bc2a-48e8-9113-8b60c79e12ba_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes payable, non-current</link:label>
    <link:label id="lab_us-gaap_LongTermNotesPayable_label_en-US" xlink:label="lab_us-gaap_LongTermNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermNotesPayable" xlink:to="lab_us-gaap_LongTermNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_0ec26379-c4c8-471c-9122-346dec88f008_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_baa7e93d-ee88-42cf-b638-89a4172f6aa7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_c98511dc-0c9d-482c-9cd9-361ab31f5526_verboseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_b52e55e9-dc28-40f6-8cd7-f5c0149b121e_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_2dc8254b-617d-4b37-aaa7-001d5a9cb148_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_c9bc4d51-5f3c-4b73-bbf9-a5aeeaa10122_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_da367773-e77e-4596-b8ca-26c8da7ed080_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares available for grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_LicenseAgreementAnnualPayments_a29bed3a-c68e-4e7c-8b7b-242759bf6bf0_terseLabel_en-US" xlink:label="lab_rxrx_LicenseAgreementAnnualPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual payments</link:label>
    <link:label id="lab_rxrx_LicenseAgreementAnnualPayments_label_en-US" xlink:label="lab_rxrx_LicenseAgreementAnnualPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Agreement, Annual Payments</link:label>
    <link:label id="lab_rxrx_LicenseAgreementAnnualPayments_documentation_en-US" xlink:label="lab_rxrx_LicenseAgreementAnnualPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License Agreement, Annual Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_LicenseAgreementAnnualPayments" xlink:href="rxrx-20240331.xsd#rxrx_LicenseAgreementAnnualPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_LicenseAgreementAnnualPayments" xlink:to="lab_rxrx_LicenseAgreementAnnualPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_RevenueRemainingPerformanceObligationVariableConsiderationAmount_897ec8f8-6656-4485-9c2d-fec245e6bb0a_terseLabel_en-US" xlink:label="lab_rxrx_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research project, fees and milestones payments receivable for an option on a lead series</link:label>
    <link:label id="lab_rxrx_RevenueRemainingPerformanceObligationVariableConsiderationAmount_label_en-US" xlink:label="lab_rxrx_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Variable Consideration Amount</link:label>
    <link:label id="lab_rxrx_RevenueRemainingPerformanceObligationVariableConsiderationAmount_documentation_en-US" xlink:label="lab_rxrx_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Variable Consideration Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:href="rxrx-20240331.xsd#rxrx_RevenueRemainingPerformanceObligationVariableConsiderationAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:to="lab_rxrx_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_71782a53-1072-4a2a-9593-fb09d8222c1b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_a5073857-faf6-496a-8dbd-42b8dcc5fcda_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_f3c67695-0a41-42ef-a451-5f0fa2ec269a_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_cafbcabc-af5d-4b93-80bc-fe0948803779_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_a43ec8ad-03da-4901-87a5-70f3dc05a626_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_f39b7c4a-da1b-4750-b0f0-22f9348e40a8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_506eaa89-3da1-40d1-a2bb-5efa7ba30a86_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_b1a80a88-57b2-452b-89cc-fd5f6ea050a7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities, non-current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_d9097a59-5161-48ac-9f71-08ebe1458e1f_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_3aae3b80-af69-4eb7-8cb7-b56b178ed5b7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_f07a3008-e82c-4d27-8be6-fe6018d6f588_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_823814cc-22cb-47a2-914f-e243a7df0c8a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_LicenseAgreementAggregatePayments_bd42a5b3-f946-4473-83bb-39c04d5526e7_terseLabel_en-US" xlink:label="lab_rxrx_LicenseAgreementAggregatePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate amount payable in cash or equity</link:label>
    <link:label id="lab_rxrx_LicenseAgreementAggregatePayments_label_en-US" xlink:label="lab_rxrx_LicenseAgreementAggregatePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Agreement, Aggregate Payments</link:label>
    <link:label id="lab_rxrx_LicenseAgreementAggregatePayments_documentation_en-US" xlink:label="lab_rxrx_LicenseAgreementAggregatePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License Agreement, Aggregate Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_LicenseAgreementAggregatePayments" xlink:href="rxrx-20240331.xsd#rxrx_LicenseAgreementAggregatePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_LicenseAgreementAggregatePayments" xlink:to="lab_rxrx_LicenseAgreementAggregatePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_AccruedEarlyDiscoveryExpensesCurrent_b6711ae1-8664-404b-bda3-b76d0aa53afd_terseLabel_en-US" xlink:label="lab_rxrx_AccruedEarlyDiscoveryExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued early discovery expenses</link:label>
    <link:label id="lab_rxrx_AccruedEarlyDiscoveryExpensesCurrent_label_en-US" xlink:label="lab_rxrx_AccruedEarlyDiscoveryExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Early Discovery Expenses, Current</link:label>
    <link:label id="lab_rxrx_AccruedEarlyDiscoveryExpensesCurrent_documentation_en-US" xlink:label="lab_rxrx_AccruedEarlyDiscoveryExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Early Discovery Expenses, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_AccruedEarlyDiscoveryExpensesCurrent" xlink:href="rxrx-20240331.xsd#rxrx_AccruedEarlyDiscoveryExpensesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_AccruedEarlyDiscoveryExpensesCurrent" xlink:to="lab_rxrx_AccruedEarlyDiscoveryExpensesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_529f9392-58f6-46ab-b0de-04f537c94811_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Portion at Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_8776c1e5-3511-4a36-b871-b3e7503876cc_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0e8559fc-6a72-4dce-91e4-69765f2df465_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_RevenueRemainingPerformanceObligationAxis_bc67befa-3eaa-435d-8499-3ac358eed268_terseLabel_en-US" xlink:label="lab_rxrx_RevenueRemainingPerformanceObligationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation [Axis]</link:label>
    <link:label id="lab_rxrx_RevenueRemainingPerformanceObligationAxis_label_en-US" xlink:label="lab_rxrx_RevenueRemainingPerformanceObligationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation [Axis]</link:label>
    <link:label id="lab_rxrx_RevenueRemainingPerformanceObligationAxis_documentation_en-US" xlink:label="lab_rxrx_RevenueRemainingPerformanceObligationAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_RevenueRemainingPerformanceObligationAxis" xlink:href="rxrx-20240331.xsd#rxrx_RevenueRemainingPerformanceObligationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_RevenueRemainingPerformanceObligationAxis" xlink:to="lab_rxrx_RevenueRemainingPerformanceObligationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_f7d2a401-bcc3-4d06-8af6-ec3e6906a776_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Maturities of Operating Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_80394c60-e2f2-4eda-ad75-41a7e37ad960_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_58ba02ae-9c0a-47b7-bf11-45fe8bb69315_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">IPO, number of shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_b32ae894-206c-4acf-bd25-47913797ae67_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Net Loss per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_fe19789f-1cba-4aa1-a0a3-b0caed0052f6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Expenses and Other Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_5f0803ef-5ec4-46d0-9524-b9cd342b0a7c_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_f937fe3b-7d31-438e-9862-84805985aa13_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Components of Lease Cost, Supplemental Cash Flow Information Related to Leases, Lease Term and Discount Rates</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_96bb9ea8-605b-4dcb-b93c-297eb7a50f52_terseLabel_en-US" xlink:label="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal Income Tax Expense (Benefit), Continuing Operations</link:label>
    <link:label id="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_label_en-US" xlink:label="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Federal Income Tax Expense (Benefit), Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:to="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_3de50665-c231-47ee-ac20-cdfee99fa46d_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_516e1487-39c8-4f8b-8df6-83da341ed1a1_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_RevenuePerformanceObligationNumberOfObligations_79f4a5f5-f056-4920-83af-3cf7ca87ea2d_terseLabel_en-US" xlink:label="lab_rxrx_RevenuePerformanceObligationNumberOfObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of performance obligations under the agreement (in performance obligations)</link:label>
    <link:label id="lab_rxrx_RevenuePerformanceObligationNumberOfObligations_label_en-US" xlink:label="lab_rxrx_RevenuePerformanceObligationNumberOfObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Performance Obligation, Number Of Obligations</link:label>
    <link:label id="lab_rxrx_RevenuePerformanceObligationNumberOfObligations_documentation_en-US" xlink:label="lab_rxrx_RevenuePerformanceObligationNumberOfObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue, Performance Obligation, Number Of Obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_RevenuePerformanceObligationNumberOfObligations" xlink:href="rxrx-20240331.xsd#rxrx_RevenuePerformanceObligationNumberOfObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_RevenuePerformanceObligationNumberOfObligations" xlink:to="lab_rxrx_RevenuePerformanceObligationNumberOfObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_4a240e1e-c7a2-47da-816c-deb5c9ca7dd4_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive securities excluded from computation of loss per share, amount (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_7261369a-06d7-4da6-b99a-cf83753da5e9_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5d90467e-7132-4c7b-b2e7-feb46b2f4523_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_92de2520-94d9-40a5-9251-331a8aaf304b_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_6cadb38e-1195-4fc5-9916-aa66f67b4927_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_RestrictedCashAndCashEquivalentsFairValueDisclosure_c22d120a-6540-48aa-80ed-69825907b6a7_terseLabel_en-US" xlink:label="lab_rxrx_RestrictedCashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_rxrx_RestrictedCashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_rxrx_RestrictedCashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:label id="lab_rxrx_RestrictedCashAndCashEquivalentsFairValueDisclosure_documentation_en-US" xlink:label="lab_rxrx_RestrictedCashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_RestrictedCashAndCashEquivalentsFairValueDisclosure" xlink:href="rxrx-20240331.xsd#rxrx_RestrictedCashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_RestrictedCashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_rxrx_RestrictedCashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_8a66aefa-1f90-4924-9aa5-b422e7b76f28_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental schedule of non-cash investing and financing activities</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_59101e79-f4d6-4083-b67a-9963017d8e21_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_de9d12e5-4857-4596-bad7-77e5206ae4b2_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_a10e5d40-b0a7-4185-abf6-efa3def9f297_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued property and equipment</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e200160e-b7db-4b9f-bf43-4d5008e93190_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_87dd3899-28ea-40ca-9a20-0f4c99b9f234_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_96f1efda-7b5e-4f35-ae1e-708e90fd350b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableOtherPayablesMember_43bcb1fd-b6d4-4681-82ed-dfcd4e5fc79a_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes payable</link:label>
    <link:label id="lab_us-gaap_NotesPayableOtherPayablesMember_label_en-US" xlink:label="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable, Other Payables [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableOtherPayablesMember" xlink:to="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_ed07f464-1329-41a7-a028-6ed95ad2729b_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options, outstanding, weighted average remaining contractual life</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_6995fcd6-7dab-4de8-bd2a-360c52a54203_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use asset additions and modifications</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_881c1312-0420-426a-aa5d-cdc76fe8698f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_c6b52f73-0149-433e-96bb-0d111c6b7c26_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Interest Income and Expense Disclosure</link:label>
    <link:label id="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Income and Interest Expense Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:to="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_a1b2e688-341d-4b5e-90bd-b7fcd9575740_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_a419c8e8-e614-45c2-9b99-88d296b8809b_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_3d43bc71-f119-4295-8767-35cd284ef3d1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsStock_0eb8d176-be0f-44f6-a141-57c5203d2aed_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends, stock</link:label>
    <link:label id="lab_us-gaap_DividendsStock_label_en-US" xlink:label="lab_us-gaap_DividendsStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends, Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsStock" xlink:to="lab_us-gaap_DividendsStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_a3e4b79d-6f88-4939-800a-488b358462f1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInvestments_8430886d-4e77-4e0b-920c-2487e31623ac_terseLabel_en-US" xlink:label="lab_rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInvestments_label_en-US" xlink:label="lab_rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Investments</link:label>
    <link:label id="lab_rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInvestments_documentation_en-US" xlink:label="lab_rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInvestments" xlink:href="rxrx-20240331.xsd#rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInvestments" xlink:to="lab_rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_0c847ede-2933-4155-aa4f-7cf0e669822f_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_d6d916db-2404-46e6-9ecd-5b55f8c54d7c_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_51fa9322-1302-4dc5-890c-31cbba9678a8_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_7fdb9864-b43b-435d-acb1-4ca4af2aa2ae_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_c3ce0f3a-34a7-403e-8dc5-be8d3565ef3d_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net carrying amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_dae43eea-5326-46d0-888a-5f7928dd7964_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_998f303c-45e8-4f1d-99ea-9a5f4e13872f_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_24e26eaf-c297-4b3e-9da8-95abc8f591fe_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_db88954d-0c05-4bdd-ac86-4c09bf22e231_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ccba1a28-ee1d-40d5-b17b-47f05fed8b67_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_e3091ffd-7baf-4799-b623-459225365e57_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_e2be9da1-ba31-473f-a008-9e2948c16d9f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_PercentOfAggregatePurchasePricePaidByTheHolderDueIfAgreementIsBroken_8ce3e4ce-eb51-4753-a67c-d805526f1d00_terseLabel_en-US" xlink:label="lab_rxrx_PercentOfAggregatePurchasePricePaidByTheHolderDueIfAgreementIsBroken" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percent of aggregate purchase price paid by the holder due if agreement is broken</link:label>
    <link:label id="lab_rxrx_PercentOfAggregatePurchasePricePaidByTheHolderDueIfAgreementIsBroken_label_en-US" xlink:label="lab_rxrx_PercentOfAggregatePurchasePricePaidByTheHolderDueIfAgreementIsBroken" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percent of Aggregate Purchase Price Paid By The Holder Due If Agreement is Broken</link:label>
    <link:label id="lab_rxrx_PercentOfAggregatePurchasePricePaidByTheHolderDueIfAgreementIsBroken_documentation_en-US" xlink:label="lab_rxrx_PercentOfAggregatePurchasePricePaidByTheHolderDueIfAgreementIsBroken" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percent of Aggregate Purchase Price Paid By The Holder Due If Agreement is Broken</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_PercentOfAggregatePurchasePricePaidByTheHolderDueIfAgreementIsBroken" xlink:href="rxrx-20240331.xsd#rxrx_PercentOfAggregatePurchasePricePaidByTheHolderDueIfAgreementIsBroken"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_PercentOfAggregatePurchasePricePaidByTheHolderDueIfAgreementIsBroken" xlink:to="lab_rxrx_PercentOfAggregatePurchasePricePaidByTheHolderDueIfAgreementIsBroken" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_e72f53c6-9c3e-41e5-969f-e8ae8659ee13_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable lease cost</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_SupplementalBalanceSheetAndIncomeStatementInformationTextBlock_63a0c408-4a43-4d9f-920d-227c533decf3_terseLabel_en-US" xlink:label="lab_rxrx_SupplementalBalanceSheetAndIncomeStatementInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental Financial Information</link:label>
    <link:label id="lab_rxrx_SupplementalBalanceSheetAndIncomeStatementInformationTextBlock_label_en-US" xlink:label="lab_rxrx_SupplementalBalanceSheetAndIncomeStatementInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Balance Sheet And Income Statement Information [Text Block]</link:label>
    <link:label id="lab_rxrx_SupplementalBalanceSheetAndIncomeStatementInformationTextBlock_documentation_en-US" xlink:label="lab_rxrx_SupplementalBalanceSheetAndIncomeStatementInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Supplemental Balance Sheet And Income Statement Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_SupplementalBalanceSheetAndIncomeStatementInformationTextBlock" xlink:href="rxrx-20240331.xsd#rxrx_SupplementalBalanceSheetAndIncomeStatementInformationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_SupplementalBalanceSheetAndIncomeStatementInformationTextBlock" xlink:to="lab_rxrx_SupplementalBalanceSheetAndIncomeStatementInformationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_6269ee87-1670-46c7-933a-a4764af6671d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_d864c66e-d622-42dc-9b29-9190e7b71ca5_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_4f6c4b57-a222-49b3-9f2d-08c67d794c65_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_0ee07df9-3a81-41a8-93b1-ee9716fae7b6_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_c11a28ea-64e2-4155-8fd5-704050c8f035_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unearned revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_fb3d3146-ab39-46b7-95a5-ac40ee28478f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_717c1672-1857-4e9c-af42-af312fdb7f1f_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_d68c7595-ef0a-4a7e-a90f-a2d46a05c7bd_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_2941eeee-1808-483f-ae0e-9197e08c5646_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">IPO, net proceeds received</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_e0158bce-d6e2-4b77-9553-cfc19e0ac0d3_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Development Contracts</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_53d73a70-63e6-49b4-97af-836e12400d37_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock based compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_356e9c18-8e74-4913-a26a-1f1b75f19e2c_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_RecursionValenceAndCyclicaMember_17a4cd6d-f46d-42f0-b661-5df2af4610cf_terseLabel_en-US" xlink:label="lab_rxrx_RecursionValenceAndCyclicaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recursion, Valence and Cyclica</link:label>
    <link:label id="lab_rxrx_RecursionValenceAndCyclicaMember_label_en-US" xlink:label="lab_rxrx_RecursionValenceAndCyclicaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recursion, Valence And Cyclica [Member]</link:label>
    <link:label id="lab_rxrx_RecursionValenceAndCyclicaMember_documentation_en-US" xlink:label="lab_rxrx_RecursionValenceAndCyclicaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Recursion, Valence And Cyclica</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_RecursionValenceAndCyclicaMember" xlink:href="rxrx-20240331.xsd#rxrx_RecursionValenceAndCyclicaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_RecursionValenceAndCyclicaMember" xlink:to="lab_rxrx_RecursionValenceAndCyclicaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonClassAMember_58a1b6c3-a870-42c8-939d-9a2f486a6444_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Class A</link:label>
    <link:label id="lab_us-gaap_CommonClassAMember_283790cb-61f2-41e7-9691-c63a3f4cb086_terseLabel_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class A</link:label>
    <link:label id="lab_us-gaap_CommonClassAMember_label_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Class A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassAMember" xlink:to="lab_us-gaap_CommonClassAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_2d42b31e-964b-40a1-9e17-6d55a5138c09_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unvested stock options, unamortized stock-based compensation cost, weighted average period recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_28a5dd59-cb56-4ead-a685-a30f790b5ebb_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating costs and expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_03104c9a-c2bc-4d0a-8ca8-fc6c29a9fd94_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_0ca8111b-6ef6-46df-a887-eb533f8e842d_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss and comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_f735dc0c-1865-42e9-8cb9-f2eddbb1cab9_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_9b84963c-209c-4a20-bdaf-67023fe890a5_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_8c74d23e-c3e5-4476-a287-13691c114eef_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term lease cost</link:label>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_label_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-Term Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeaseCost" xlink:to="lab_us-gaap_ShortTermLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_3a59b477-5da3-4e71-b019-4834d51928ec_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_SaleOfStockValueRemainingAuthorized_730d5bfc-f40a-4188-b3fc-2192b9063665_terseLabel_en-US" xlink:label="lab_rxrx_SaleOfStockValueRemainingAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock value remaining authorized</link:label>
    <link:label id="lab_rxrx_SaleOfStockValueRemainingAuthorized_label_en-US" xlink:label="lab_rxrx_SaleOfStockValueRemainingAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock Value Remaining Authorized</link:label>
    <link:label id="lab_rxrx_SaleOfStockValueRemainingAuthorized_documentation_en-US" xlink:label="lab_rxrx_SaleOfStockValueRemainingAuthorized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale of Stock Value Remaining Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_SaleOfStockValueRemainingAuthorized" xlink:href="rxrx-20240331.xsd#rxrx_SaleOfStockValueRemainingAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_SaleOfStockValueRemainingAuthorized" xlink:to="lab_rxrx_SaleOfStockValueRemainingAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_638df30c-49dd-407f-af21-42714db35921_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_dbdf7899-637f-45d9-9b84-a5489d65575c_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_02dced88-4837-4a8c-a408-dc3be25fee45_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_8cc6d0c7-ecd9-4b6a-a288-98dfec7b9f3c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_795b6702-3b02-48a7-8b41-637441939352_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember_6762324c-0e16-4e4a-8eb5-a68668534e87_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Book values</link:label>
    <link:label id="lab_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Portion at Other than Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_f498dd49-2376-4d40-b972-ff503ee91bc9_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_2d702ce0-541f-4921-81fb-4def86cd27ad_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_NeuroscienceMember_32d72188-e5b0-467f-b39f-70de5e166324_terseLabel_en-US" xlink:label="lab_rxrx_NeuroscienceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Neuroscience</link:label>
    <link:label id="lab_rxrx_NeuroscienceMember_label_en-US" xlink:label="lab_rxrx_NeuroscienceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Neuroscience [Member]</link:label>
    <link:label id="lab_rxrx_NeuroscienceMember_documentation_en-US" xlink:label="lab_rxrx_NeuroscienceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Neuroscience</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_NeuroscienceMember" xlink:href="rxrx-20240331.xsd#rxrx_NeuroscienceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_NeuroscienceMember" xlink:to="lab_rxrx_NeuroscienceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_da5a1cd6-ca64-4c72-9c08-483ca9e5bb01_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash, non-current</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_dc5397cb-b66b-4408-9c53-78798269dd11_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_70c81455-3384-403f-a3b5-40dce415823b_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock sales issuances, net of issuance costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_4a79c579-b474-4e43-8e3c-81e8149ebf0a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cancelled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_a06ac4d7-c6b4-47cc-8286-2778a939f79f_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_635e2a48-efa3-4c5d-886a-53c4ed7f39ca_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities, non-current</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_2a86787a-1635-4ee6-a0bb-9153143b53a3_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_e52a4077-ac82-42da-9c76-a6b98c71e819_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_b91cfe04-0409-40b0-97ef-7214316a350c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_1fbc4cff-d711-48ec-bd3b-6e72696b972c_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_999e0b6b-11bc-4026-b16c-95817ef782a1_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Pro Forma Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_29815163-a5f5-42c3-9495-24e413b973f9_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance, outstanding (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c322c294-02d0-4d0b-865c-ae5653e0da2e_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance, outstanding (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_b64a5638-b7be-4203-8138-15b2c765993e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_23ec5675-1e7f-42b4-befd-d74a16606c7a_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_440840fd-5a95-44e4-ac7d-c06d696ebd76_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_ContractWithCustomerMaximumAcceptedProduct_00de2717-7e98-430b-b05a-5519bf2eb314_terseLabel_en-US" xlink:label="lab_rxrx_ContractWithCustomerMaximumAcceptedProduct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of eligible phenomaps (in phenomaps)</link:label>
    <link:label id="lab_rxrx_ContractWithCustomerMaximumAcceptedProduct_label_en-US" xlink:label="lab_rxrx_ContractWithCustomerMaximumAcceptedProduct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract With Customer, Maximum Accepted Product</link:label>
    <link:label id="lab_rxrx_ContractWithCustomerMaximumAcceptedProduct_documentation_en-US" xlink:label="lab_rxrx_ContractWithCustomerMaximumAcceptedProduct" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract With Customer, Maximum Accepted Product</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_ContractWithCustomerMaximumAcceptedProduct" xlink:href="rxrx-20240331.xsd#rxrx_ContractWithCustomerMaximumAcceptedProduct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_ContractWithCustomerMaximumAcceptedProduct" xlink:to="lab_rxrx_ContractWithCustomerMaximumAcceptedProduct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_74405261-2534-43b4-b2fb-d5b6b283da26_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common shares, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Private Placement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_f4f5c0e6-aa19-41de-bb30-ed1fe418f547_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_72c87797-7a24-4b02-bf34-74aeb780a693_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_87efc961-81c5-49cd-a029-d3e5ae3ea2c1_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_95c4d4ee-f71d-4678-8519-77ab908c3993_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_GastrointestinalCancerMember_5e8aa503-59f0-4c03-bcde-1bb21f3852a3_terseLabel_en-US" xlink:label="lab_rxrx_GastrointestinalCancerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gastrointestinal cancer</link:label>
    <link:label id="lab_rxrx_GastrointestinalCancerMember_label_en-US" xlink:label="lab_rxrx_GastrointestinalCancerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gastrointestinal Cancer [Member]</link:label>
    <link:label id="lab_rxrx_GastrointestinalCancerMember_documentation_en-US" xlink:label="lab_rxrx_GastrointestinalCancerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gastrointestinal Cancer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_GastrointestinalCancerMember" xlink:href="rxrx-20240331.xsd#rxrx_GastrointestinalCancerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_GastrointestinalCancerMember" xlink:to="lab_rxrx_GastrointestinalCancerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_RocheAndGenentechMember_75180afb-a49d-4631-a242-39754f650f01_terseLabel_en-US" xlink:label="lab_rxrx_RocheAndGenentechMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Roche and Genentech</link:label>
    <link:label id="lab_rxrx_RocheAndGenentechMember_label_en-US" xlink:label="lab_rxrx_RocheAndGenentechMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Roche and Genentech [Member]</link:label>
    <link:label id="lab_rxrx_RocheAndGenentechMember_documentation_en-US" xlink:label="lab_rxrx_RocheAndGenentechMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Roche and Genentech</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_RocheAndGenentechMember" xlink:href="rxrx-20240331.xsd#rxrx_RocheAndGenentechMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_RocheAndGenentechMember" xlink:to="lab_rxrx_RocheAndGenentechMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_a2770687-b7ee-4353-bd14-f3627a660800_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_25eb4e6f-e0a0-4e84-8070-38a0eaabc6cb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b5a51220-8794-4621-9e3e-4bc13818dd40_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_097d0f42-c15d-455a-b004-53a87dc20875_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_3dc5ef01-7ade-45db-93df-6ca2bd1f3caf_negatedLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_81821080-8c3d-4a03-a34f-b2172db18097_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_3a01a24c-defd-4051-bb51-9116f06aa9c1_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_f9b126a1-2b73-49f4-a3c2-977d14fa0212_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_913dbb7a-c190-47ab-a0c1-3b2d0256507c_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ff668386-959c-40d0-8726-1fea95f2db19_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_e21651c7-a00e-4e39-ba48-d3561af7eb91_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_de92b595-a281-4654-a460-76a0a8da1d02_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common sock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_3450ec1b-9f66-4b2c-8132-0372ccb228de_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_9c7f2e31-048f-4398-9dee-e1705e168140_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_LesseeOperatingLeaseIncreaseDecreaseInOperatingLeaseLiabilityDueToLeaseModifications_71bf7fe2-1cf1-47d6-92f3-04df31c19356_terseLabel_en-US" xlink:label="lab_rxrx_LesseeOperatingLeaseIncreaseDecreaseInOperatingLeaseLiabilityDueToLeaseModifications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (decrease) in lease liability</link:label>
    <link:label id="lab_rxrx_LesseeOperatingLeaseIncreaseDecreaseInOperatingLeaseLiabilityDueToLeaseModifications_label_en-US" xlink:label="lab_rxrx_LesseeOperatingLeaseIncreaseDecreaseInOperatingLeaseLiabilityDueToLeaseModifications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Increase (Decrease) In Operating Lease Liability Due To Lease Modifications</link:label>
    <link:label id="lab_rxrx_LesseeOperatingLeaseIncreaseDecreaseInOperatingLeaseLiabilityDueToLeaseModifications_documentation_en-US" xlink:label="lab_rxrx_LesseeOperatingLeaseIncreaseDecreaseInOperatingLeaseLiabilityDueToLeaseModifications" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Increase (Decrease) In Operating Lease Liability Due To Lease Modifications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_LesseeOperatingLeaseIncreaseDecreaseInOperatingLeaseLiabilityDueToLeaseModifications" xlink:href="rxrx-20240331.xsd#rxrx_LesseeOperatingLeaseIncreaseDecreaseInOperatingLeaseLiabilityDueToLeaseModifications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_LesseeOperatingLeaseIncreaseDecreaseInOperatingLeaseLiabilityDueToLeaseModifications" xlink:to="lab_rxrx_LesseeOperatingLeaseIncreaseDecreaseInOperatingLeaseLiabilityDueToLeaseModifications" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayable_905d71ff-145a-4114-aa07-e717a17fd300_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes payable</link:label>
    <link:label id="lab_us-gaap_NotesPayable_label_en-US" xlink:label="lab_us-gaap_NotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayable" xlink:to="lab_us-gaap_NotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_IncreaseDecreaseInAccruedDevelopmentExpense_13414e5d-eddf-40cb-9144-195ada187db8_terseLabel_en-US" xlink:label="lab_rxrx_IncreaseDecreaseInAccruedDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued development expense</link:label>
    <link:label id="lab_rxrx_IncreaseDecreaseInAccruedDevelopmentExpense_label_en-US" xlink:label="lab_rxrx_IncreaseDecreaseInAccruedDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Accrued Development Expense</link:label>
    <link:label id="lab_rxrx_IncreaseDecreaseInAccruedDevelopmentExpense_documentation_en-US" xlink:label="lab_rxrx_IncreaseDecreaseInAccruedDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Accrued Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_IncreaseDecreaseInAccruedDevelopmentExpense" xlink:href="rxrx-20240331.xsd#rxrx_IncreaseDecreaseInAccruedDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_IncreaseDecreaseInAccruedDevelopmentExpense" xlink:to="lab_rxrx_IncreaseDecreaseInAccruedDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_AffiliatedHoldersPotentialOwnershipPercentageWhenOutstandingEquityAwardsVest_3cf98938-e6a1-47f2-b266-183203e8467b_terseLabel_en-US" xlink:label="lab_rxrx_AffiliatedHoldersPotentialOwnershipPercentageWhenOutstandingEquityAwardsVest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Affiliated holders, potential ownership percentage when outstanding equity awards vest</link:label>
    <link:label id="lab_rxrx_AffiliatedHoldersPotentialOwnershipPercentageWhenOutstandingEquityAwardsVest_label_en-US" xlink:label="lab_rxrx_AffiliatedHoldersPotentialOwnershipPercentageWhenOutstandingEquityAwardsVest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Affiliated Holders, Potential Ownership Percentage When Outstanding Equity Awards Vest</link:label>
    <link:label id="lab_rxrx_AffiliatedHoldersPotentialOwnershipPercentageWhenOutstandingEquityAwardsVest_documentation_en-US" xlink:label="lab_rxrx_AffiliatedHoldersPotentialOwnershipPercentageWhenOutstandingEquityAwardsVest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Affiliated Holders, Potential Ownership Percentage When Outstanding Equity Awards Vest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_AffiliatedHoldersPotentialOwnershipPercentageWhenOutstandingEquityAwardsVest" xlink:href="rxrx-20240331.xsd#rxrx_AffiliatedHoldersPotentialOwnershipPercentageWhenOutstandingEquityAwardsVest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_AffiliatedHoldersPotentialOwnershipPercentageWhenOutstandingEquityAwardsVest" xlink:to="lab_rxrx_AffiliatedHoldersPotentialOwnershipPercentageWhenOutstandingEquityAwardsVest" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_TinaMarriottMember_label_en-US" xlink:label="lab_rxrx_TinaMarriottMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tina Marriott [Member]</link:label>
    <link:label id="lab_rxrx_TinaMarriottMember_documentation_en-US" xlink:label="lab_rxrx_TinaMarriottMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tina Marriott</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_TinaMarriottMember" xlink:href="rxrx-20240331.xsd#rxrx_TinaMarriottMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_TinaMarriottMember" xlink:to="lab_rxrx_TinaMarriottMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_a880fbfd-1031-41f6-89de-3e7306d92ca0_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_feab5b6f-a76c-4f67-8f2f-48ba3db40a86_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_f5fb583b-00d9-467e-8470-d5b592441414_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_d8f352d6-03d6-4490-8278-94c38c725f54_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour_33f81ca7-1adf-4822-8a57-0e4dbd799234_terseLabel_en-US" xlink:label="lab_rxrx_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_rxrx_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour_label_en-US" xlink:label="lab_rxrx_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Due after Year Four</link:label>
    <link:label id="lab_rxrx_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour_documentation_en-US" xlink:label="lab_rxrx_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Due after Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour" xlink:href="rxrx-20240331.xsd#rxrx_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour" xlink:to="lab_rxrx_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9f0769e4-1d88-459c-8374-2a977ab678eb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares&#160;</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_0906de60-4afc-4666-b21e-e49c10701a1e_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_7b58008c-4605-4453-9d3d-d24715f28e4a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_6f88f0d9-d61b-4e61-9a00-c393cb9ab2d9_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net revenues</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:to="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillPeriodIncreaseDecrease_cd2b8871-4830-4bac-b1de-63d7d5356609_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in carrying amount of goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_GoodwillPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillPeriodIncreaseDecrease" xlink:to="lab_us-gaap_GoodwillPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_828fe62f-d5d8-4443-af45-a4c332d521d6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Present value of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_d693077a-b377-43f1-93b3-587e571093cb_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_b234ba69-da2b-4065-90c3-73d921b8a18b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_9b377b9e-87e2-4eb6-aae9-fe7b2479cc12_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_30f10f8f-57c6-43f0-bf3e-d60f77eddac5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_1500af56-5b10-4c28-b8ce-96e6e6aca75e_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unearned revenue, non-current</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_0b9e2014-b957-4273-a6f8-33bb7b170496_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_964c49e0-722e-48e9-a784-0e4931364ce3_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_6188f8ee-03c6-4ac7-a052-d1ef3b810a3e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Per share data</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_1d99e2e7-074f-41a1-8009-0eff4b1f9c13_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock units</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_0c7b7ae0-3500-4d9a-89ca-c7ba0a2bcdcc_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.00001 par value; 2,000,000,000 shares (Class A 1,989,032,117 and Class B 10,967,883) authorized as of March&#160;31, 2024 and December&#160;31, 2023; 237,508,682 shares (Class A 230,043,061, Class B 7,464,871 and Exchangeable 750) and 234,270,384 shares (Class A 226,264,764, Class B 7,544,871 and Exchangeable 460,749) issued and outstanding as of March&#160;31, 2024 and December&#160;31, 2023, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_ValenceDiscoveryIncMember_a7356f2b-b6ba-4174-a59d-3f9253f8fa6d_terseLabel_en-US" xlink:label="lab_rxrx_ValenceDiscoveryIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valence Discovery Inc</link:label>
    <link:label id="lab_rxrx_ValenceDiscoveryIncMember_label_en-US" xlink:label="lab_rxrx_ValenceDiscoveryIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valence Discovery Inc [Member]</link:label>
    <link:label id="lab_rxrx_ValenceDiscoveryIncMember_documentation_en-US" xlink:label="lab_rxrx_ValenceDiscoveryIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Valence Discovery Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_ValenceDiscoveryIncMember" xlink:href="rxrx-20240331.xsd#rxrx_ValenceDiscoveryIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_ValenceDiscoveryIncMember" xlink:to="lab_rxrx_ValenceDiscoveryIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_704a7e27-2417-447b-b2f7-e7ebc347e163_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ae1a3886-e21c-4824-ab62-7bf7c030d504_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_LeaseDescriptionAxis_a40b6d68-512f-48ac-814c-75bb445850d7_terseLabel_en-US" xlink:label="lab_rxrx_LeaseDescriptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Description [Axis]</link:label>
    <link:label id="lab_rxrx_LeaseDescriptionAxis_label_en-US" xlink:label="lab_rxrx_LeaseDescriptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Description [Axis]</link:label>
    <link:label id="lab_rxrx_LeaseDescriptionAxis_documentation_en-US" xlink:label="lab_rxrx_LeaseDescriptionAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lease Description</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_LeaseDescriptionAxis" xlink:href="rxrx-20240331.xsd#rxrx_LeaseDescriptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_LeaseDescriptionAxis" xlink:to="lab_rxrx_LeaseDescriptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilitiesCurrent_36a81d7d-0289-4c67-a5bd-03486c29294f_negatedTerseLabel_en-US" xlink:label="lab_rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities, current</link:label>
    <link:label id="lab_rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilitiesCurrent_label_en-US" xlink:label="lab_rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Liabilities, Current</link:label>
    <link:label id="lab_rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilitiesCurrent_documentation_en-US" xlink:label="lab_rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilitiesCurrent" xlink:href="rxrx-20240331.xsd#rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilitiesCurrent" xlink:to="lab_rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_a35e783a-6a71-420c-b634-93509bf09a8a_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_CommonStockConversionRatio_1e452537-fca2-40d4-bd26-949a2a29ac6d_terseLabel_en-US" xlink:label="lab_rxrx_CommonStockConversionRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, conversion ratio</link:label>
    <link:label id="lab_rxrx_CommonStockConversionRatio_label_en-US" xlink:label="lab_rxrx_CommonStockConversionRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Conversion Ratio</link:label>
    <link:label id="lab_rxrx_CommonStockConversionRatio_documentation_en-US" xlink:label="lab_rxrx_CommonStockConversionRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_CommonStockConversionRatio" xlink:href="rxrx-20240331.xsd#rxrx_CommonStockConversionRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_CommonStockConversionRatio" xlink:to="lab_rxrx_CommonStockConversionRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_a6c365e9-4ca1-40e9-b110-3e1f74e9328e_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental schedule of cash flow information</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_8f79f1a0-cd07-4746-97dd-f10bbbbe24d0_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_d258dbb7-c78c-4d89-b0c8-00c0622f46cf_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_13548408-2fdf-46d3-a97f-53dcb32bc505_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_31a0de7f-a803-4249-a5f2-988fc75d32dc_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_Station41LeaseMember_d52584eb-f469-4d73-ae9e-e871e119a57f_terseLabel_en-US" xlink:label="lab_rxrx_Station41LeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Station 41 lease</link:label>
    <link:label id="lab_rxrx_Station41LeaseMember_label_en-US" xlink:label="lab_rxrx_Station41LeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Station 41 Lease [Member]</link:label>
    <link:label id="lab_rxrx_Station41LeaseMember_documentation_en-US" xlink:label="lab_rxrx_Station41LeaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Station 41 Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_Station41LeaseMember" xlink:href="rxrx-20240331.xsd#rxrx_Station41LeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_Station41LeaseMember" xlink:to="lab_rxrx_Station41LeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_3799e4b5-012d-4015-860f-8320c77dc926_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9142fefc-4e10-42de-b51d-218beea6afac_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_b48957ff-050b-42f6-98ab-eb3ed03e2319_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent" xlink:to="lab_us-gaap_RestrictedCashCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_bad6b0f8-875a-440f-884f-6bc7ca85e727_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_6567c89b-f778-470b-a21b-7627cac13790_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable, intrinsic value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_65c7406d-ad89-4356-b858-22886e9305dc_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_d07415ec-dcc1-485b-81c6-66f60e51449f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued other expenses</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_630dfdde-05cd-4830-8573-29608d73e50f_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Description of the Business</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_ff72e694-d421-4b5e-b626-7e48ea002aa6_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_7c3d637e-af52-40c9-a18f-5deacd928ec5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, interest rate (as percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_906ee75e-bebc-4ac9-9f5e-416875301397_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_b94c130c-af5f-4e9f-8a1d-959751960083_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_b41665b4-05fe-47b6-99b0-73bbefba25e6_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_ExchangeableStockMember_6ed9d2a2-f5da-4389-a433-ada098aa81b9_terseLabel_en-US" xlink:label="lab_rxrx_ExchangeableStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exchangeable Stock</link:label>
    <link:label id="lab_rxrx_ExchangeableStockMember_label_en-US" xlink:label="lab_rxrx_ExchangeableStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exchangeable Stock [Member]</link:label>
    <link:label id="lab_rxrx_ExchangeableStockMember_documentation_en-US" xlink:label="lab_rxrx_ExchangeableStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exchangeable Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_ExchangeableStockMember" xlink:href="rxrx-20240331.xsd#rxrx_ExchangeableStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_ExchangeableStockMember" xlink:to="lab_rxrx_ExchangeableStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_MichaelSecoraMember_label_en-US" xlink:label="lab_rxrx_MichaelSecoraMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Michael Secora [Member]</link:label>
    <link:label id="lab_rxrx_MichaelSecoraMember_documentation_en-US" xlink:label="lab_rxrx_MichaelSecoraMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Michael Secora</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_MichaelSecoraMember" xlink:href="rxrx-20240331.xsd#rxrx_MichaelSecoraMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_MichaelSecoraMember" xlink:to="lab_rxrx_MichaelSecoraMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_06fdbd53-db50-4fdd-894f-384724cd43d5_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net revenue</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Pro Forma Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_d381e7bf-edd1-404b-9cee-df0d4b697eb3_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill impairment</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_38c1c8ae-a0fa-48b7-8f44-2c2b2d0adbe5_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ae3c4aa3-5c05-44d7-826f-af3fcdacf12c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b5c21e5b-1a45-4807-98fa-86244af6c895_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_d55c6e3b-918d-4df7-8453-dcdab3861dfd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_TempusAgreementMember_9b6bf80e-1fbc-45ce-b125-0224421052db_terseLabel_en-US" xlink:label="lab_rxrx_TempusAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tempus agreement</link:label>
    <link:label id="lab_rxrx_TempusAgreementMember_label_en-US" xlink:label="lab_rxrx_TempusAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tempus Agreement [Member]</link:label>
    <link:label id="lab_rxrx_TempusAgreementMember_documentation_en-US" xlink:label="lab_rxrx_TempusAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tempus Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_TempusAgreementMember" xlink:href="rxrx-20240331.xsd#rxrx_TempusAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_TempusAgreementMember" xlink:to="lab_rxrx_TempusAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1c7017bc-bb8a-428c-93ef-89cdcaf09aa5_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_99a47e86-059f-4712-8776-143a3af9780a_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss before income tax benefit</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_b09b1ac7-f550-4cb2-bd82-c894ddf50f0a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_CyclicaIncMember_8a616e23-6ea4-4cf0-a3c8-171a43f46060_terseLabel_en-US" xlink:label="lab_rxrx_CyclicaIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cyclica Inc</link:label>
    <link:label id="lab_rxrx_CyclicaIncMember_label_en-US" xlink:label="lab_rxrx_CyclicaIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cyclica Inc [Member]</link:label>
    <link:label id="lab_rxrx_CyclicaIncMember_documentation_en-US" xlink:label="lab_rxrx_CyclicaIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cyclica Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_CyclicaIncMember" xlink:href="rxrx-20240331.xsd#rxrx_CyclicaIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_CyclicaIncMember" xlink:to="lab_rxrx_CyclicaIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_c04fb6e9-f439-4484-9c7e-52a1a7d73d0b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchase of an intangible asset</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TangibleAssetImpairmentCharges_b2c3527e-6a2a-4ada-a76e-33be420d2e93_terseLabel_en-US" xlink:label="lab_us-gaap_TangibleAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset impairment</link:label>
    <link:label id="lab_us-gaap_TangibleAssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_TangibleAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tangible Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TangibleAssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TangibleAssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TangibleAssetImpairmentCharges" xlink:to="lab_us-gaap_TangibleAssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_LeaseDescriptionDomain_b1dbd106-79ed-4f79-bea7-d484d395e2c0_terseLabel_en-US" xlink:label="lab_rxrx_LeaseDescriptionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Description [Domain]</link:label>
    <link:label id="lab_rxrx_LeaseDescriptionDomain_label_en-US" xlink:label="lab_rxrx_LeaseDescriptionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Description [Domain]</link:label>
    <link:label id="lab_rxrx_LeaseDescriptionDomain_documentation_en-US" xlink:label="lab_rxrx_LeaseDescriptionDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lease Description [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_LeaseDescriptionDomain" xlink:href="rxrx-20240331.xsd#rxrx_LeaseDescriptionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_LeaseDescriptionDomain" xlink:to="lab_rxrx_LeaseDescriptionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f7659be5-b208-4bed-a2cf-abd3658312af_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_799760cb-a506-4efa-8e7a-682b6d4b55ac_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued in the period, upon conversion (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_2c3b119f-325c-4c37-bb5a-cf08301333e8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_4e0fce72-74e2-4e8d-969f-fe103594ab67_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_7e6a5493-db82-4016-9421-c9f0988b63c1_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_768aec0d-8692-43b0-b519-008902b471d7_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_3b795041-041a-4d68-8568-14b1b9a92d77_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total identifiable net assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3e03d8c8-add8-4e6c-aee9-572a06ba6ac7_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_052dfcec-bbc8-41ab-8a2d-0532b243a5b7_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets - technology</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_4d137553-7462-4095-934c-84b28dfc4204_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_8b2fc4be-8da6-4cd4-a03b-1eac6448bd42_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_a2ce5c7b-0e62-44e2-ae2f-cbc15667eb04_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Useful life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a1152bd2-5f3c-4928-8329-5882fef528bf_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1c49df50-3a75-4a2d-84f1-20dd64a58de3_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_796f0932-1d19-4f68-a908-76f6ff644b78_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Options, outstanding, at beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3a8879e4-e133-40f9-8429-efd8af92b35c_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Options, outstanding, at end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_62b8113a-1c15-49d1-b9f7-a986e23df24d_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_546cdb43-ed9a-45b5-a502-3942ea058530_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_1e47786e-1b50-4444-9b3c-f99d5d6ff5ab_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock (Class A, B and Exchangeable)</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_TerryAnnBurrellMember_label_en-US" xlink:label="lab_rxrx_TerryAnnBurrellMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Terry-Ann Burrell [Member]</link:label>
    <link:label id="lab_rxrx_TerryAnnBurrellMember_documentation_en-US" xlink:label="lab_rxrx_TerryAnnBurrellMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Terry-Ann Burrell</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_TerryAnnBurrellMember" xlink:href="rxrx-20240331.xsd#rxrx_TerryAnnBurrellMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_TerryAnnBurrellMember" xlink:to="lab_rxrx_TerryAnnBurrellMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_7f7b0a29-f1de-4a38-bd85-ad5ed4129dea_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_06546d21-7896-4955-ad19-e421e21ec85a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_bfb8c22f-e132-412b-afcd-3dcf2ba49ae3_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_9fee5958-7975-4055-8a38-ade91669ea92_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_e13743b7-741a-41dd-98e8-8cda3aa33864_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_867ec056-e1f1-42c2-bfb7-60e9c7b9ce55_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_6f6d8e0e-6b4f-4f48-9fa8-3f71a8919340_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_744b5b87-fc31-4315-8576-29e295acef4f_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_bee5e26e-6a8f-410f-9014-a129f56f81ea_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_1780d756-65be-4b0e-8756-66e5f9a16d58_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_CommonStockVotePerShare_2be6036b-f22a-4538-bda4-887eeb016cf9_terseLabel_en-US" xlink:label="lab_rxrx_CommonStockVotePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vote per share of common stock (in votes)</link:label>
    <link:label id="lab_rxrx_CommonStockVotePerShare_label_en-US" xlink:label="lab_rxrx_CommonStockVotePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Vote Per Share</link:label>
    <link:label id="lab_rxrx_CommonStockVotePerShare_documentation_en-US" xlink:label="lab_rxrx_CommonStockVotePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock, Vote Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_CommonStockVotePerShare" xlink:href="rxrx-20240331.xsd#rxrx_CommonStockVotePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_CommonStockVotePerShare" xlink:to="lab_rxrx_CommonStockVotePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherReceivables_807bd5de-cb78-4b9e-aa50-e2b30a31a011_terseLabel_en-US" xlink:label="lab_rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherReceivables_label_en-US" xlink:label="lab_rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Receivables</link:label>
    <link:label id="lab_rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherReceivables_documentation_en-US" xlink:label="lab_rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherReceivables" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherReceivables" xlink:href="rxrx-20240331.xsd#rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherReceivables" xlink:to="lab_rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_b5a39ffe-95ad-4857-ba44-baff9a1195b6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Arrangement, Option, Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3e01c917-6f48-4f33-bb3b-b828d695145f_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems_8977dc8a-f64d-49dc-be2d-76a7d9200140_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems" xlink:to="lab_us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_6ac7ee90-be0e-4ff0-ab48-f962b00fe8c2_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_9022f729-25b3-4222-81d2-3898ffc7f5d5_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of long-term debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable_37b480fa-2c5b-4869-96e6-e47b4b184caa_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Disclosure of Asset and Liability Not Measured at Fair Value [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosure of Asset and Liability Not Measured at Fair Value [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable" xlink:to="lab_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_76fd5ec1-e962-416a-a04f-1a3945fd1500_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_74bd870a-07bc-4f2c-8058-fb407d2bc335_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Current Assets</link:label>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Current Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentAssetsMember" xlink:to="lab_us-gaap_OtherCurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_12ca2192-297f-4c39-80ba-cd5f7dfb739e_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_a30acd9d-0aef-4943-b8f3-faa65f8bebdc_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_11202fa5-5aeb-40ca-9b8d-d2a1b4fa29b9_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_b07b0917-01b2-4dfe-b250-ea95b1e9fda5_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_55b35b06-df58-428f-8aa2-29555fb3a6be_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion of notes payable</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_25394707-5e34-40d7-800b-2667f00cecf9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock-based Compensation Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_fddd1034-c39c-4035-ac7d-735dc196ab2c_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_760de2a6-4354-4c3b-86d4-8bba2b40a3ef_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_c72528a0-e255-4220-b60f-45990752897f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets, non-current</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_ChristopherGibsonAndAffiliatesMember_0d6e80ef-8198-4c1b-887f-f9396923234c_terseLabel_en-US" xlink:label="lab_rxrx_ChristopherGibsonAndAffiliatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Christopher Gibson and Affiliates</link:label>
    <link:label id="lab_rxrx_ChristopherGibsonAndAffiliatesMember_label_en-US" xlink:label="lab_rxrx_ChristopherGibsonAndAffiliatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Christopher Gibson And Affiliates [Member]</link:label>
    <link:label id="lab_rxrx_ChristopherGibsonAndAffiliatesMember_documentation_en-US" xlink:label="lab_rxrx_ChristopherGibsonAndAffiliatesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Christopher Gibson And Affiliates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_ChristopherGibsonAndAffiliatesMember" xlink:href="rxrx-20240331.xsd#rxrx_ChristopherGibsonAndAffiliatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_ChristopherGibsonAndAffiliatesMember" xlink:to="lab_rxrx_ChristopherGibsonAndAffiliatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_TempusLabsIncMember_7e687ecc-bfb2-4108-ac9a-9fac5b40ebc5_terseLabel_en-US" xlink:label="lab_rxrx_TempusLabsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tempus Labs, Inc</link:label>
    <link:label id="lab_rxrx_TempusLabsIncMember_label_en-US" xlink:label="lab_rxrx_TempusLabsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tempus Labs, Inc [Member]</link:label>
    <link:label id="lab_rxrx_TempusLabsIncMember_documentation_en-US" xlink:label="lab_rxrx_TempusLabsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tempus Labs, Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_TempusLabsIncMember" xlink:href="rxrx-20240331.xsd#rxrx_TempusLabsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_TempusLabsIncMember" xlink:to="lab_rxrx_TempusLabsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_897331af-8d80-4084-9203-be44d4d08f55_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_c595eb1e-4bab-4246-a3a8-66f77f1605f0_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share of Class A, B and Exchangeable common stock, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_b37eccfa-b861-4977-90a8-4dd48ca32bdb_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share, basic (in dollars per shares)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_199e3add-b4fa-4c9e-b1d1-5db0e8fb67e8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRevenueExpenseNet_da782dbf-a2f8-4cb4-b931-1f58bd24d278_totalLabel_en-US" xlink:label="lab_us-gaap_InterestRevenueExpenseNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Interest income, net</link:label>
    <link:label id="lab_us-gaap_InterestRevenueExpenseNet_label_en-US" xlink:label="lab_us-gaap_InterestRevenueExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Revenue (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRevenueExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestRevenueExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRevenueExpenseNet" xlink:to="lab_us-gaap_InterestRevenueExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_897ff39e-1e33-44cb-9d9d-20ec78fb465f_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unvested stock options, unamortized stock-based compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionPayableCurrent_f1f3a9e0-70e9-482f-99fe-85cbdc4f9c8e_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued construction</link:label>
    <link:label id="lab_us-gaap_ConstructionPayableCurrent_label_en-US" xlink:label="lab_us-gaap_ConstructionPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionPayableCurrent" xlink:to="lab_us-gaap_ConstructionPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_3eb59ddc-ee79-40cc-9787-8d13f54ce4c1_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_eab15a9f-e422-4066-8040-e233f2feb92b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise, intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_69fab5f5-e408-4da7-930f-444b8e7c6513_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remainder of 2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_9a9e9f7f-8f80-4ae5-873f-9bc01ae4666b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_SaleOfStockPercentageOfCommission_39610381-1653-409a-a962-118df6bed3ea_terseLabel_en-US" xlink:label="lab_rxrx_SaleOfStockPercentageOfCommission" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock, percentage of commission</link:label>
    <link:label id="lab_rxrx_SaleOfStockPercentageOfCommission_label_en-US" xlink:label="lab_rxrx_SaleOfStockPercentageOfCommission" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Percentage of Commission</link:label>
    <link:label id="lab_rxrx_SaleOfStockPercentageOfCommission_documentation_en-US" xlink:label="lab_rxrx_SaleOfStockPercentageOfCommission" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale of Stock, Percentage of Commission</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_SaleOfStockPercentageOfCommission" xlink:href="rxrx-20240331.xsd#rxrx_SaleOfStockPercentageOfCommission"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_SaleOfStockPercentageOfCommission" xlink:to="lab_rxrx_SaleOfStockPercentageOfCommission" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_51ca58da-00a0-443d-8a22-a41af6209427_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_4274b5d2-2d9b-4b30-ae81-a3f053480ad7_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_501af2bc-d8e5-44f5-b144-030764de389e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TechnologyBasedIntangibleAssetsMember_7eadc7db-e89f-474f-bbeb-7d37e5168050_terseLabel_en-US" xlink:label="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Technology Intangible Assets</link:label>
    <link:label id="lab_us-gaap_TechnologyBasedIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Technology-Based Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:to="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_959b82af-52f8-4b4d-80b5-c7b224145505_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_f2259c89-62e1-4e87-8248-30edb62fed4b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationTable_cb057283-6256-4d24-9963-5a12c14c067d_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:label id="lab_dei_DocumentInformationTable_label_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_f6c1106a-1658-4b12-a5e5-7b9c1adc1ea5_terseLabel_en-US" xlink:label="lab_rxrx_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (decrease) in operating lease right-of-use assets</link:label>
    <link:label id="lab_rxrx_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_label_en-US" xlink:label="lab_rxrx_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Lease Right-Of-Use Assets</link:label>
    <link:label id="lab_rxrx_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_documentation_en-US" xlink:label="lab_rxrx_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Lease Right-Of-Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" xlink:href="rxrx-20240331.xsd#rxrx_IncreaseDecreaseInOperatingLeaseRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" xlink:to="lab_rxrx_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_BusinessCombinationConsiderationTransferredEquityInterestsIssuable_87cc9d66-1d2e-4481-b965-2c29b99300a0_terseLabel_en-US" xlink:label="lab_rxrx_BusinessCombinationConsiderationTransferredEquityInterestsIssuable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of equity interests issued, value</link:label>
    <link:label id="lab_rxrx_BusinessCombinationConsiderationTransferredEquityInterestsIssuable_label_en-US" xlink:label="lab_rxrx_BusinessCombinationConsiderationTransferredEquityInterestsIssuable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Interests Issuable</link:label>
    <link:label id="lab_rxrx_BusinessCombinationConsiderationTransferredEquityInterestsIssuable_documentation_en-US" xlink:label="lab_rxrx_BusinessCombinationConsiderationTransferredEquityInterestsIssuable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Interests Issuable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_BusinessCombinationConsiderationTransferredEquityInterestsIssuable" xlink:href="rxrx-20240331.xsd#rxrx_BusinessCombinationConsiderationTransferredEquityInterestsIssuable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_BusinessCombinationConsiderationTransferredEquityInterestsIssuable" xlink:to="lab_rxrx_BusinessCombinationConsiderationTransferredEquityInterestsIssuable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetUnderConstructionMember_218ef953-8470-42ae-9aed-c5ab5f103a4c_terseLabel_en-US" xlink:label="lab_us-gaap_AssetUnderConstructionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_AssetUnderConstructionMember_label_en-US" xlink:label="lab_us-gaap_AssetUnderConstructionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset under Construction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetUnderConstructionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetUnderConstructionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetUnderConstructionMember" xlink:to="lab_us-gaap_AssetUnderConstructionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_13a7dff4-199f-4855-8475-9e42b92ff047_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableCurrent_62829b80-4127-427b-bd21-6dd260b5ec40_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes payable</link:label>
    <link:label id="lab_us-gaap_NotesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableCurrent" xlink:to="lab_us-gaap_NotesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_DevelopedAndCommercializedProgramsMember_0f11c0f7-3e07-4037-b5a6-b8da3b8f27e9_terseLabel_en-US" xlink:label="lab_rxrx_DevelopedAndCommercializedProgramsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Developed and commercialized programs</link:label>
    <link:label id="lab_rxrx_DevelopedAndCommercializedProgramsMember_label_en-US" xlink:label="lab_rxrx_DevelopedAndCommercializedProgramsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Developed And Commercialized Programs [Member]</link:label>
    <link:label id="lab_rxrx_DevelopedAndCommercializedProgramsMember_documentation_en-US" xlink:label="lab_rxrx_DevelopedAndCommercializedProgramsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Developed And Commercialized Programs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_DevelopedAndCommercializedProgramsMember" xlink:href="rxrx-20240331.xsd#rxrx_DevelopedAndCommercializedProgramsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_DevelopedAndCommercializedProgramsMember" xlink:to="lab_rxrx_DevelopedAndCommercializedProgramsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_9b2aa8f8-eced-4ab4-8173-98c0548827f4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair market value of vested shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_bc5beb48-2147-4300-88b5-88b77d51e1bf_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_LicenseAgreementPrepaidExpenses_8614d877-88fb-4ec1-b925-920036948894_terseLabel_en-US" xlink:label="lab_rxrx_LicenseAgreementPrepaidExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License agreement, prepaid expenses</link:label>
    <link:label id="lab_rxrx_LicenseAgreementPrepaidExpenses_label_en-US" xlink:label="lab_rxrx_LicenseAgreementPrepaidExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Agreement, Prepaid Expenses</link:label>
    <link:label id="lab_rxrx_LicenseAgreementPrepaidExpenses_documentation_en-US" xlink:label="lab_rxrx_LicenseAgreementPrepaidExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License Agreement, Prepaid Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_LicenseAgreementPrepaidExpenses" xlink:href="rxrx-20240331.xsd#rxrx_LicenseAgreementPrepaidExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_LicenseAgreementPrepaidExpenses" xlink:to="lab_rxrx_LicenseAgreementPrepaidExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_e8179d68-81c0-4b40-9021-2f83b8d6d9c7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_PhenomapsCreationMember_1d8d7d89-7989-4e6d-9aec-9740c38eebd8_terseLabel_en-US" xlink:label="lab_rxrx_PhenomapsCreationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Phenomaps creation</link:label>
    <link:label id="lab_rxrx_PhenomapsCreationMember_label_en-US" xlink:label="lab_rxrx_PhenomapsCreationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Phenomaps Creation [Member]</link:label>
    <link:label id="lab_rxrx_PhenomapsCreationMember_documentation_en-US" xlink:label="lab_rxrx_PhenomapsCreationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Phenomaps Creation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_PhenomapsCreationMember" xlink:href="rxrx-20240331.xsd#rxrx_PhenomapsCreationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_PhenomapsCreationMember" xlink:to="lab_rxrx_PhenomapsCreationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_RegistrationRightsAgreementTerm_824e8a1f-45cc-48e6-ada3-ee1593ca32f2_terseLabel_en-US" xlink:label="lab_rxrx_RegistrationRightsAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Registration rights agreement, term</link:label>
    <link:label id="lab_rxrx_RegistrationRightsAgreementTerm_label_en-US" xlink:label="lab_rxrx_RegistrationRightsAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Registration Rights Agreement, Term</link:label>
    <link:label id="lab_rxrx_RegistrationRightsAgreementTerm_documentation_en-US" xlink:label="lab_rxrx_RegistrationRightsAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Registration Rights Agreement, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_RegistrationRightsAgreementTerm" xlink:href="rxrx-20240331.xsd#rxrx_RegistrationRightsAgreementTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_RegistrationRightsAgreementTerm" xlink:to="lab_rxrx_RegistrationRightsAgreementTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationLineItems_ed98b1b3-3346-45a0-86d8-8b6489a199fe_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:label id="lab_dei_DocumentInformationLineItems_label_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_715df554-c893-44ea-8af2-0b1c0227a0de_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred liabilities for additional consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred, Liabilities Incurred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_36091c99-35a0-4a05-9b95-5e57dc5f9a9f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_7a48bfc0-5ba2-4bd3-a377-7b2d878597ed_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cancelled (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_3aed3df7-97f6-4f6d-915c-53e25b147de0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_721fcbff-d0a8-4aa7-8794-3f1c3909a459_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity interest issued or issuable (in shares)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Equity Interest Issued or Issuable, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1497178a-9bf8-48de-9046-26a0e78a093c_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_f032575d-9232-45ad-9c5a-617c13a12b2f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options, outstanding, intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_9cad695b-2417-4a51-a9b6-11c0c83ae266_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_37f13d69-565e-47a1-8a6d-6fc7de64e121_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other receivables and assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_fc85f83f-49a5-417f-8f87-d6e927556bfb_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of revenue</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_710c5061-539a-46c0-9406-81764f177b55_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_09753cd2-5bdc-473b-813d-471ca9e1ec66_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Unearned revenue</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_de211638-05e5-4b84-9708-dad24d73dd44_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: Accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_68426785-fd89-40cb-b7fc-133dc69961f5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_edb60a2b-5b53-4b09-9f13-6877d3bc0d91_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_6b58ea77-4559-44fd-950f-3c9b68ba03a8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repayment of long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_a2f5aba1-26fa-4ac1-ae7d-811a292fbdfa_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, Pro Forma Information</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Pro Forma Information [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_787eae0d-073b-4563-98f2-5bdd6ea967c5_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_73108cb7-2af2-4116-8842-5d8f41c9f767_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss contingency accrual</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_74c2fed9-0ac8-406e-bce0-c582a6ada4e5_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_29e41376-de1b-4ab1-a651-06dbf9f0fd93_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based payment arrangement, expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_NVDIAPrivatePlacementMember_065a3255-7c56-4bed-927e-8234e8f8adc5_terseLabel_en-US" xlink:label="lab_rxrx_NVDIAPrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NVDIA Private Placement</link:label>
    <link:label id="lab_rxrx_NVDIAPrivatePlacementMember_label_en-US" xlink:label="lab_rxrx_NVDIAPrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">NVDIA Private Placement [Member]</link:label>
    <link:label id="lab_rxrx_NVDIAPrivatePlacementMember_documentation_en-US" xlink:label="lab_rxrx_NVDIAPrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">NVDIA Private Placement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_NVDIAPrivatePlacementMember" xlink:href="rxrx-20240331.xsd#rxrx_NVDIAPrivatePlacementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_NVDIAPrivatePlacementMember" xlink:to="lab_rxrx_NVDIAPrivatePlacementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_c9465811-75a2-489c-a2ae-506c7d2cc29d_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross carrying amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_ee17003b-3793-4398-8649-f29d0ff1a9d1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Income tax benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_73169429-682c-4f37-8894-64a1ceeb4569_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfLeasehold_ab8db771-c091-455b-977d-e5eec6f10d35_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLeasehold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of leasehold improvements</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLeasehold_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfLeasehold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment of Leasehold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLeasehold" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLeasehold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLeasehold" xlink:to="lab_us-gaap_ImpairmentOfLeasehold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_2cc1339d-5b4f-45a2-9287-c91cd3d98643_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_4b711bb5-1018-43f9-ad44-6eacadfed4a6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_LondonLeaseMember_ac3e6a3c-8b57-4257-948a-cff92d0c748c_terseLabel_en-US" xlink:label="lab_rxrx_LondonLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">London Lease</link:label>
    <link:label id="lab_rxrx_LondonLeaseMember_label_en-US" xlink:label="lab_rxrx_LondonLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">London Lease [Member]</link:label>
    <link:label id="lab_rxrx_LondonLeaseMember_documentation_en-US" xlink:label="lab_rxrx_LondonLeaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">London Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_LondonLeaseMember" xlink:href="rxrx-20240331.xsd#rxrx_LondonLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_LondonLeaseMember" xlink:to="lab_rxrx_LondonLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_dd042f0a-eda4-48b8-9a39-47da13eb2d2d_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock sales issuances, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePaymentsUse_45e9181c-7fa4-45a6-b4c6-a5317e0d14cf_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePaymentsUse" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePaymentsUse_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePaymentsUse" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Payments, Use</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePaymentsUse" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePaymentsUse"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePaymentsUse" xlink:to="lab_us-gaap_OperatingLeasePaymentsUse" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_d08140f3-2d98-4d4b-809e-6cb2e24b1fe8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average remaining lease term (years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_8bf0edcc-de8f-4a3e-93ee-8876c35bd3af_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets acquired and liabilities assumed</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fea48fc1-acf3-4cb5-ad67-c46968af3f59_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_4eaf4ab4-e2ac-4419-987d-695cf944efa0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherReceivablesNetCurrent" xlink:to="lab_us-gaap_OtherReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_LicenseAgreementTradingPeriodUsedForEquityValueDetermination_9b62dde7-2c70-4011-9435-3ee4f4228f26_terseLabel_en-US" xlink:label="lab_rxrx_LicenseAgreementTradingPeriodUsedForEquityValueDetermination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License agreement, trading period</link:label>
    <link:label id="lab_rxrx_LicenseAgreementTradingPeriodUsedForEquityValueDetermination_label_en-US" xlink:label="lab_rxrx_LicenseAgreementTradingPeriodUsedForEquityValueDetermination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Agreement, Trading Period Used For Equity Value Determination</link:label>
    <link:label id="lab_rxrx_LicenseAgreementTradingPeriodUsedForEquityValueDetermination_documentation_en-US" xlink:label="lab_rxrx_LicenseAgreementTradingPeriodUsedForEquityValueDetermination" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License Agreement, Trading Period Used For Equity Value Determination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_LicenseAgreementTradingPeriodUsedForEquityValueDetermination" xlink:href="rxrx-20240331.xsd#rxrx_LicenseAgreementTradingPeriodUsedForEquityValueDetermination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_LicenseAgreementTradingPeriodUsedForEquityValueDetermination" xlink:to="lab_rxrx_LicenseAgreementTradingPeriodUsedForEquityValueDetermination" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_da7d5145-9a46-490e-9979-8af157a2e0c7_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_1b65a1d3-d0d9-45d0-ab71-57ca50ba1376_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_80b98d2c-0017-4a59-a9b7-4c9cbdeeaa8a_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_87ef9a85-2125-48a5-bcfe-3518c64d9f3f_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_f23b2c10-aba5-48ba-8765-e8109758181f_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_354a5806-be02-4360-b4c0-4abf98ed8e49_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_AtTheMarketOfferingProgramMember_a6e1929a-e100-4753-836d-242dfd494f75_terseLabel_en-US" xlink:label="lab_rxrx_AtTheMarketOfferingProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">At-the-Market offering program</link:label>
    <link:label id="lab_rxrx_AtTheMarketOfferingProgramMember_label_en-US" xlink:label="lab_rxrx_AtTheMarketOfferingProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">At-The-Market Offering Program [Member]</link:label>
    <link:label id="lab_rxrx_AtTheMarketOfferingProgramMember_documentation_en-US" xlink:label="lab_rxrx_AtTheMarketOfferingProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">At-The-Market Offering Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_AtTheMarketOfferingProgramMember" xlink:href="rxrx-20240331.xsd#rxrx_AtTheMarketOfferingProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_AtTheMarketOfferingProgramMember" xlink:to="lab_rxrx_AtTheMarketOfferingProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_efc414da-6e71-47f3-aa4a-e25d0009c82e_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes payable, net of current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_8c6503f1-2443-46e4-a412-6e81bf4c675c_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_RevenueRemainingPerformanceObligationNumberOfProjectsThatMayBeInitiated_70a78c4d-1614-44c7-98af-f82c5936a23c_terseLabel_en-US" xlink:label="lab_rxrx_RevenueRemainingPerformanceObligationNumberOfProjectsThatMayBeInitiated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of projects that may be initiated (in projects)</link:label>
    <link:label id="lab_rxrx_RevenueRemainingPerformanceObligationNumberOfProjectsThatMayBeInitiated_label_en-US" xlink:label="lab_rxrx_RevenueRemainingPerformanceObligationNumberOfProjectsThatMayBeInitiated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Number Of Projects That May Be Initiated</link:label>
    <link:label id="lab_rxrx_RevenueRemainingPerformanceObligationNumberOfProjectsThatMayBeInitiated_documentation_en-US" xlink:label="lab_rxrx_RevenueRemainingPerformanceObligationNumberOfProjectsThatMayBeInitiated" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Number Of Projects That May Be Initiated</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_RevenueRemainingPerformanceObligationNumberOfProjectsThatMayBeInitiated" xlink:href="rxrx-20240331.xsd#rxrx_RevenueRemainingPerformanceObligationNumberOfProjectsThatMayBeInitiated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_RevenueRemainingPerformanceObligationNumberOfProjectsThatMayBeInitiated" xlink:to="lab_rxrx_RevenueRemainingPerformanceObligationNumberOfProjectsThatMayBeInitiated" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_DataCenterLeaseMember_714a2c62-ba1e-4256-90e3-f651730e17a0_terseLabel_en-US" xlink:label="lab_rxrx_DataCenterLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Data Center Lease</link:label>
    <link:label id="lab_rxrx_DataCenterLeaseMember_label_en-US" xlink:label="lab_rxrx_DataCenterLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Data Center Lease [Member]</link:label>
    <link:label id="lab_rxrx_DataCenterLeaseMember_documentation_en-US" xlink:label="lab_rxrx_DataCenterLeaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Data Center Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_DataCenterLeaseMember" xlink:href="rxrx-20240331.xsd#rxrx_DataCenterLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_DataCenterLeaseMember" xlink:to="lab_rxrx_DataCenterLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ddb0fccb-4ab8-41a1-ad58-c034ae18a393_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average shares (Class A, B and Exchangeable) outstanding, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b0b93c0f-a5a0-4bd5-91d3-d6a10e1a9ad7_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average common shares outstanding, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_794699f8-5ecb-424e-8cf5-099441a42632_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_8fe66440-45f7-42e0-8639-db5d2515049f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating costs and expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_c91b7288-b3ef-4dfc-9df9-d313de323277_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ad944c80-f6d8-411c-8e22-f32a75c80796_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_0d5d651a-2726-4380-9f89-d3566b2437fe_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-in-Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_NumberOfClassesOfCommonStockAuthorized_d86667b6-11b8-4b71-918b-8206e0c8398f_terseLabel_en-US" xlink:label="lab_rxrx_NumberOfClassesOfCommonStockAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of classes of common stock authorized</link:label>
    <link:label id="lab_rxrx_NumberOfClassesOfCommonStockAuthorized_label_en-US" xlink:label="lab_rxrx_NumberOfClassesOfCommonStockAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Classes Of Common Stock Authorized</link:label>
    <link:label id="lab_rxrx_NumberOfClassesOfCommonStockAuthorized_documentation_en-US" xlink:label="lab_rxrx_NumberOfClassesOfCommonStockAuthorized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Classes Of Common Stock Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_NumberOfClassesOfCommonStockAuthorized" xlink:href="rxrx-20240331.xsd#rxrx_NumberOfClassesOfCommonStockAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_NumberOfClassesOfCommonStockAuthorized" xlink:to="lab_rxrx_NumberOfClassesOfCommonStockAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_b72309cd-57c9-4cf3-a51c-3cad813962e3_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_0f7fbd5c-902a-402e-8d87-3ffc098735b9_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeNonoperating_55520f0b-1d4c-49cb-ac64-1e288b1099b6_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNonoperating" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNonoperating_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNonoperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeNonoperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNonoperating" xlink:to="lab_us-gaap_InvestmentIncomeNonoperating" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_22ce4f73-52a3-4770-9502-ad41bc188004_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_9ed17ac2-9ac7-4748-935c-23ac4bc2597f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_RevenueRemainingPerformanceObligationDomain_01b459fe-4b68-4ce5-b35e-f447c79d448c_terseLabel_en-US" xlink:label="lab_rxrx_RevenueRemainingPerformanceObligationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation [Domain]</link:label>
    <link:label id="lab_rxrx_RevenueRemainingPerformanceObligationDomain_label_en-US" xlink:label="lab_rxrx_RevenueRemainingPerformanceObligationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation [Domain]</link:label>
    <link:label id="lab_rxrx_RevenueRemainingPerformanceObligationDomain_documentation_en-US" xlink:label="lab_rxrx_RevenueRemainingPerformanceObligationDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_RevenueRemainingPerformanceObligationDomain" xlink:href="rxrx-20240331.xsd#rxrx_RevenueRemainingPerformanceObligationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_RevenueRemainingPerformanceObligationDomain" xlink:to="lab_rxrx_RevenueRemainingPerformanceObligationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrantMember_59e9f19f-1155-463c-95c2-bac1d320c0ad_terseLabel_en-US" xlink:label="lab_us-gaap_GrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grant revenue</link:label>
    <link:label id="lab_us-gaap_GrantMember_label_en-US" xlink:label="lab_us-gaap_GrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Grant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrantMember" xlink:to="lab_us-gaap_GrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_cbb86b98-1faa-4f78-9d44-7c534ed23bec_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_903ebe84-58a1-46a7-a516-15e0f43170b1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, operating lease, liability, to be paid</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a5a2219b-a27b-4958-afcd-86283375a468_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_7b566464-14d9-41e3-b921-7ce1878c4a6e_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining performance obligation revenue</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_LesseeOperatingLeaseSquareFootageOfLeasedSpace_7194d034-53b1-4729-bdf5-1c7c268bf011_terseLabel_en-US" xlink:label="lab_rxrx_LesseeOperatingLeaseSquareFootageOfLeasedSpace" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Square footage of leased space (in square feet)</link:label>
    <link:label id="lab_rxrx_LesseeOperatingLeaseSquareFootageOfLeasedSpace_label_en-US" xlink:label="lab_rxrx_LesseeOperatingLeaseSquareFootageOfLeasedSpace" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Square Footage Of Leased Space</link:label>
    <link:label id="lab_rxrx_LesseeOperatingLeaseSquareFootageOfLeasedSpace_documentation_en-US" xlink:label="lab_rxrx_LesseeOperatingLeaseSquareFootageOfLeasedSpace" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Square Footage Of Leased Space</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_LesseeOperatingLeaseSquareFootageOfLeasedSpace" xlink:href="rxrx-20240331.xsd#rxrx_LesseeOperatingLeaseSquareFootageOfLeasedSpace"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_LesseeOperatingLeaseSquareFootageOfLeasedSpace" xlink:to="lab_rxrx_LesseeOperatingLeaseSquareFootageOfLeasedSpace" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_LaboratoryEquipmentMember_3cada03f-841d-4319-bd3c-eeb74b646b54_terseLabel_en-US" xlink:label="lab_rxrx_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lab equipment</link:label>
    <link:label id="lab_rxrx_LaboratoryEquipmentMember_label_en-US" xlink:label="lab_rxrx_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
    <link:label id="lab_rxrx_LaboratoryEquipmentMember_documentation_en-US" xlink:label="lab_rxrx_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Laboratory Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_LaboratoryEquipmentMember" xlink:href="rxrx-20240331.xsd#rxrx_LaboratoryEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_LaboratoryEquipmentMember" xlink:to="lab_rxrx_LaboratoryEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3d3ccf97-4578-41ec-948c-769e6765a07a_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net change in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0a6d7166-adda-48be-b56e-62827a7436be_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_BioHiveSupercomputerMember_77d09283-70f1-432a-a061-6adf86ef4d7b_terseLabel_en-US" xlink:label="lab_rxrx_BioHiveSupercomputerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BioHive Supercomputer</link:label>
    <link:label id="lab_rxrx_BioHiveSupercomputerMember_label_en-US" xlink:label="lab_rxrx_BioHiveSupercomputerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BioHive Supercomputer [Member]</link:label>
    <link:label id="lab_rxrx_BioHiveSupercomputerMember_documentation_en-US" xlink:label="lab_rxrx_BioHiveSupercomputerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BioHive Supercomputer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_BioHiveSupercomputerMember" xlink:href="rxrx-20240331.xsd#rxrx_BioHiveSupercomputerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_BioHiveSupercomputerMember" xlink:to="lab_rxrx_BioHiveSupercomputerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_98bae1f6-df7f-46c9-b0f1-1a0d797bae84_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease, renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_63cd820d-66a4-4943-9224-9dfe03bf8861_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6615e010-aab7-457d-b4c2-015b6029a889_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average shares (Class A, B and Exchangeable) outstanding, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8d91e199-29c2-407e-8046-f01b58727073_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average common shares outstanding, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_5005fa21-e0ff-4a6d-9904-5dbd3afe4b15_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_407da0ed-3c2b-4ffc-84c9-3dd02efc1837_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_A2021EquityIncentivePlanMember_2722a96c-067f-47a9-9a20-c0176ff26d1f_terseLabel_en-US" xlink:label="lab_rxrx_A2021EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021 Equity Incentive Plan</link:label>
    <link:label id="lab_rxrx_A2021EquityIncentivePlanMember_label_en-US" xlink:label="lab_rxrx_A2021EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2021 Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_rxrx_A2021EquityIncentivePlanMember_documentation_en-US" xlink:label="lab_rxrx_A2021EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2021 Equity Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_A2021EquityIncentivePlanMember" xlink:href="rxrx-20240331.xsd#rxrx_A2021EquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_A2021EquityIncentivePlanMember" xlink:to="lab_rxrx_A2021EquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_a9424c55-3443-4a2a-ad91-50ce4d773291_terseLabel_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Office equipment</link:label>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_label_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Office Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OfficeEquipmentMember" xlink:to="lab_us-gaap_OfficeEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_209ffa56-e833-4adb-8493-11f66d65129f_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_FinancedEquipmentPurchase_ae4c2b01-beef-4e83-bbf3-a4c81043f233_terseLabel_en-US" xlink:label="lab_rxrx_FinancedEquipmentPurchase" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financed equipment purchase</link:label>
    <link:label id="lab_rxrx_FinancedEquipmentPurchase_label_en-US" xlink:label="lab_rxrx_FinancedEquipmentPurchase" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financed Equipment Purchase</link:label>
    <link:label id="lab_rxrx_FinancedEquipmentPurchase_documentation_en-US" xlink:label="lab_rxrx_FinancedEquipmentPurchase" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Financed Equipment Purchase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_FinancedEquipmentPurchase" xlink:href="rxrx-20240331.xsd#rxrx_FinancedEquipmentPurchase"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_FinancedEquipmentPurchase" xlink:to="lab_rxrx_FinancedEquipmentPurchase" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_772c51c4-3198-4bce-b027-cf92d17ea997_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from equity incentive plans</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b5a2bb04-d776-403a-a063-4cf494d82d66_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_73dda828-77cc-4a3e-ade3-abc2a24875e6_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_5b9292bb-a946-4e15-924a-e30e36633b61_terseLabel_en-US" xlink:label="lab_rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_label_en-US" xlink:label="lab_rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Restricted Cash</link:label>
    <link:label id="lab_rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_documentation_en-US" xlink:label="lab_rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Restricted Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" xlink:href="rxrx-20240331.xsd#rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" xlink:to="lab_rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_3e0ee5f3-f079-49bb-b992-30fd6a189382_terseLabel_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair values</link:label>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_SupplementalFinancialInformationAbstract_label_en-US" xlink:label="lab_rxrx_SupplementalFinancialInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Financial Information [Abstract]</link:label>
    <link:label id="lab_rxrx_SupplementalFinancialInformationAbstract_documentation_en-US" xlink:label="lab_rxrx_SupplementalFinancialInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Supplemental Financial Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_SupplementalFinancialInformationAbstract" xlink:href="rxrx-20240331.xsd#rxrx_SupplementalFinancialInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_SupplementalFinancialInformationAbstract" xlink:to="lab_rxrx_SupplementalFinancialInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>rxrx-20240331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:3e558803-1e4e-49a0-9bef-dda845cc7d19,g:dd7baf31-0188-4ca9-9996-087ebdfea724-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.recursion.com/role/Cover" xlink:type="simple" xlink:href="rxrx-20240331.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_add21146-b291-405d-824c-05046b7f0355" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_6946bc76-55cc-4862-81d4-9202e52b78c3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_add21146-b291-405d-824c-05046b7f0355" xlink:to="loc_dei_DocumentInformationTable_6946bc76-55cc-4862-81d4-9202e52b78c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_0b33eda9-f264-4043-bdc0-894419bc348f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_6946bc76-55cc-4862-81d4-9202e52b78c3" xlink:to="loc_us-gaap_StatementClassOfStockAxis_0b33eda9-f264-4043-bdc0-894419bc348f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_9f1f9e2e-4716-4164-abc5-8a06288b6d72" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_0b33eda9-f264-4043-bdc0-894419bc348f" xlink:to="loc_us-gaap_ClassOfStockDomain_9f1f9e2e-4716-4164-abc5-8a06288b6d72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_7e34b52a-e388-443a-b724-f9a28441e64a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_9f1f9e2e-4716-4164-abc5-8a06288b6d72" xlink:to="loc_us-gaap_CommonClassAMember_7e34b52a-e388-443a-b724-f9a28441e64a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_ab6bf645-09ba-46cf-90c2-1928156e11a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_9f1f9e2e-4716-4164-abc5-8a06288b6d72" xlink:to="loc_us-gaap_CommonClassBMember_ab6bf645-09ba-46cf-90c2-1928156e11a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_1c55dfd2-80a6-42a5-b88b-b04bb3b24dd1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_6946bc76-55cc-4862-81d4-9202e52b78c3" xlink:to="loc_dei_DocumentInformationLineItems_1c55dfd2-80a6-42a5-b88b-b04bb3b24dd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_51a03ba6-45c7-4688-9907-8c4cae217826" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1c55dfd2-80a6-42a5-b88b-b04bb3b24dd1" xlink:to="loc_dei_DocumentType_51a03ba6-45c7-4688-9907-8c4cae217826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_b870de5c-fd85-4895-a5b6-d532a3694aef" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1c55dfd2-80a6-42a5-b88b-b04bb3b24dd1" xlink:to="loc_dei_DocumentQuarterlyReport_b870de5c-fd85-4895-a5b6-d532a3694aef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_c3e18045-be77-491c-809f-cc4b921066f9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1c55dfd2-80a6-42a5-b88b-b04bb3b24dd1" xlink:to="loc_dei_DocumentPeriodEndDate_c3e18045-be77-491c-809f-cc4b921066f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_f49d147d-106e-4ee9-8c27-0f67cc40ac4e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1c55dfd2-80a6-42a5-b88b-b04bb3b24dd1" xlink:to="loc_dei_DocumentTransitionReport_f49d147d-106e-4ee9-8c27-0f67cc40ac4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_2a6848c0-795d-4314-93a6-c84671510630" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1c55dfd2-80a6-42a5-b88b-b04bb3b24dd1" xlink:to="loc_dei_EntityFileNumber_2a6848c0-795d-4314-93a6-c84671510630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_5225480b-93aa-4c48-8330-f3ae62e8f681" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1c55dfd2-80a6-42a5-b88b-b04bb3b24dd1" xlink:to="loc_dei_EntityRegistrantName_5225480b-93aa-4c48-8330-f3ae62e8f681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_222ae878-617f-4bfa-b6d1-77a2f38ada16" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1c55dfd2-80a6-42a5-b88b-b04bb3b24dd1" xlink:to="loc_dei_EntityIncorporationStateCountryCode_222ae878-617f-4bfa-b6d1-77a2f38ada16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_c3ff7faa-a57b-4394-8f60-d7756085c13c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1c55dfd2-80a6-42a5-b88b-b04bb3b24dd1" xlink:to="loc_dei_EntityTaxIdentificationNumber_c3ff7faa-a57b-4394-8f60-d7756085c13c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_bd3c7243-8c6a-4f6f-a78d-74520bf7bed8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1c55dfd2-80a6-42a5-b88b-b04bb3b24dd1" xlink:to="loc_dei_EntityAddressAddressLine1_bd3c7243-8c6a-4f6f-a78d-74520bf7bed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_23cd4110-17bc-4bf4-9f88-0676bd8630b6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1c55dfd2-80a6-42a5-b88b-b04bb3b24dd1" xlink:to="loc_dei_EntityAddressCityOrTown_23cd4110-17bc-4bf4-9f88-0676bd8630b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_6bf4bdc2-7e05-49c9-8be6-75ddb0bdf7e2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1c55dfd2-80a6-42a5-b88b-b04bb3b24dd1" xlink:to="loc_dei_EntityAddressStateOrProvince_6bf4bdc2-7e05-49c9-8be6-75ddb0bdf7e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_28fbc844-7f2b-4eca-952e-f557a4fc700a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1c55dfd2-80a6-42a5-b88b-b04bb3b24dd1" xlink:to="loc_dei_EntityAddressPostalZipCode_28fbc844-7f2b-4eca-952e-f557a4fc700a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_17bb9fbf-02cf-4089-aa8a-253915761c37" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1c55dfd2-80a6-42a5-b88b-b04bb3b24dd1" xlink:to="loc_dei_CityAreaCode_17bb9fbf-02cf-4089-aa8a-253915761c37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_9577eeb4-7e1e-4c70-a6b9-7ef43190f699" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1c55dfd2-80a6-42a5-b88b-b04bb3b24dd1" xlink:to="loc_dei_LocalPhoneNumber_9577eeb4-7e1e-4c70-a6b9-7ef43190f699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_538f6b4e-7f87-4f1f-b269-3bd73c743714" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1c55dfd2-80a6-42a5-b88b-b04bb3b24dd1" xlink:to="loc_dei_Security12bTitle_538f6b4e-7f87-4f1f-b269-3bd73c743714" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_066eff4b-256f-477c-8d1c-2aa1fe15655a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1c55dfd2-80a6-42a5-b88b-b04bb3b24dd1" xlink:to="loc_dei_TradingSymbol_066eff4b-256f-477c-8d1c-2aa1fe15655a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_0ebd0e92-fcd9-4994-8724-3c1d6cb27bc0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1c55dfd2-80a6-42a5-b88b-b04bb3b24dd1" xlink:to="loc_dei_SecurityExchangeName_0ebd0e92-fcd9-4994-8724-3c1d6cb27bc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_053747bc-b6c5-48dd-b87c-96a587295f63" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1c55dfd2-80a6-42a5-b88b-b04bb3b24dd1" xlink:to="loc_dei_EntityCurrentReportingStatus_053747bc-b6c5-48dd-b87c-96a587295f63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_3c3f42f5-cfaa-4055-9505-400ea5b52fe8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1c55dfd2-80a6-42a5-b88b-b04bb3b24dd1" xlink:to="loc_dei_EntityInteractiveDataCurrent_3c3f42f5-cfaa-4055-9505-400ea5b52fe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_36e3ce89-1232-4b33-b324-24f8cf7b1534" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1c55dfd2-80a6-42a5-b88b-b04bb3b24dd1" xlink:to="loc_dei_EntityFilerCategory_36e3ce89-1232-4b33-b324-24f8cf7b1534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_2c06bdcc-d324-49f2-9835-5baff28c835d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1c55dfd2-80a6-42a5-b88b-b04bb3b24dd1" xlink:to="loc_dei_EntitySmallBusiness_2c06bdcc-d324-49f2-9835-5baff28c835d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_d7779d79-9bfe-410f-a573-f5f595c3e864" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1c55dfd2-80a6-42a5-b88b-b04bb3b24dd1" xlink:to="loc_dei_EntityEmergingGrowthCompany_d7779d79-9bfe-410f-a573-f5f595c3e864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_1a0339a4-5edc-4647-a4a7-855f56ce3618" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1c55dfd2-80a6-42a5-b88b-b04bb3b24dd1" xlink:to="loc_dei_EntityShellCompany_1a0339a4-5edc-4647-a4a7-855f56ce3618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_0ed6fff2-e866-40c5-b655-33cb7ec0346d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1c55dfd2-80a6-42a5-b88b-b04bb3b24dd1" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_0ed6fff2-e866-40c5-b655-33cb7ec0346d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_8cb78aef-2ef3-4ef4-bf41-06890fc25509" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1c55dfd2-80a6-42a5-b88b-b04bb3b24dd1" xlink:to="loc_dei_EntityCentralIndexKey_8cb78aef-2ef3-4ef4-bf41-06890fc25509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_a8a6237e-9b2c-4453-9df2-2cd76f3d799f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1c55dfd2-80a6-42a5-b88b-b04bb3b24dd1" xlink:to="loc_dei_AmendmentFlag_a8a6237e-9b2c-4453-9df2-2cd76f3d799f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_ced5310b-6e95-4e20-ac31-afc387cd495a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1c55dfd2-80a6-42a5-b88b-b04bb3b24dd1" xlink:to="loc_dei_DocumentFiscalYearFocus_ced5310b-6e95-4e20-ac31-afc387cd495a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_a7209ef6-82e8-4c95-9a7e-bfdc8057a5b6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1c55dfd2-80a6-42a5-b88b-b04bb3b24dd1" xlink:to="loc_dei_DocumentFiscalPeriodFocus_a7209ef6-82e8-4c95-9a7e-bfdc8057a5b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_37c3479b-0774-484c-89fb-4bcc01590c55" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1c55dfd2-80a6-42a5-b88b-b04bb3b24dd1" xlink:to="loc_dei_CurrentFiscalYearEndDate_37c3479b-0774-484c-89fb-4bcc01590c55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited" xlink:type="simple" xlink:href="rxrx-20240331.xsd#CondensedConsolidatedBalanceSheetsunaudited"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_09560aa9-43c0-4aaf-8346-f502a85fe433" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_42082818-4975-4498-af53-8f18624bc6ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_09560aa9-43c0-4aaf-8346-f502a85fe433" xlink:to="loc_us-gaap_AssetsAbstract_42082818-4975-4498-af53-8f18624bc6ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_076766f6-bee7-4fe6-b306-d6e65f0c614b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_42082818-4975-4498-af53-8f18624bc6ba" xlink:to="loc_us-gaap_AssetsCurrentAbstract_076766f6-bee7-4fe6-b306-d6e65f0c614b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2915f957-28c9-4fd7-9dcb-9d3c2c775cf8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_076766f6-bee7-4fe6-b306-d6e65f0c614b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2915f957-28c9-4fd7-9dcb-9d3c2c775cf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_37df4a75-fb89-4523-b288-3777bedaab09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_076766f6-bee7-4fe6-b306-d6e65f0c614b" xlink:to="loc_us-gaap_RestrictedCashCurrent_37df4a75-fb89-4523-b288-3777bedaab09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_6e19c625-8a9d-46c4-b40d-2e8ffccc310e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_076766f6-bee7-4fe6-b306-d6e65f0c614b" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_6e19c625-8a9d-46c4-b40d-2e8ffccc310e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_35c8c0ec-7f39-41ba-91d9-c71c9707cb3a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_076766f6-bee7-4fe6-b306-d6e65f0c614b" xlink:to="loc_us-gaap_OtherAssetsCurrent_35c8c0ec-7f39-41ba-91d9-c71c9707cb3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_115ecc3b-f170-4a7f-a650-68334469e1b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_076766f6-bee7-4fe6-b306-d6e65f0c614b" xlink:to="loc_us-gaap_AssetsCurrent_115ecc3b-f170-4a7f-a650-68334469e1b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_d25d4453-054f-4881-bb1b-5bc1feab4e6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_42082818-4975-4498-af53-8f18624bc6ba" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_d25d4453-054f-4881-bb1b-5bc1feab4e6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_7e377337-81f7-4db6-b9bd-93f6bbee7acf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_42082818-4975-4498-af53-8f18624bc6ba" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_7e377337-81f7-4db6-b9bd-93f6bbee7acf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_346f1006-5099-489f-a7b7-ac0d5c4ab83d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_42082818-4975-4498-af53-8f18624bc6ba" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_346f1006-5099-489f-a7b7-ac0d5c4ab83d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_27564411-fd2c-4fb8-98cd-0301688054bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_42082818-4975-4498-af53-8f18624bc6ba" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_27564411-fd2c-4fb8-98cd-0301688054bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_71394b80-3504-4d20-92fa-cc892286b1a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_42082818-4975-4498-af53-8f18624bc6ba" xlink:to="loc_us-gaap_Goodwill_71394b80-3504-4d20-92fa-cc892286b1a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_633b34dc-9465-49ad-bded-fa578428bccf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_42082818-4975-4498-af53-8f18624bc6ba" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_633b34dc-9465-49ad-bded-fa578428bccf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_5919d5d7-b191-461f-b03c-d734749e297c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_42082818-4975-4498-af53-8f18624bc6ba" xlink:to="loc_us-gaap_Assets_5919d5d7-b191-461f-b03c-d734749e297c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_527a3eae-0d5c-470a-ac3f-325136ee6177" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_09560aa9-43c0-4aaf-8346-f502a85fe433" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_527a3eae-0d5c-470a-ac3f-325136ee6177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_744b0749-30d4-4b33-9a96-c8b96ca6d81b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_527a3eae-0d5c-470a-ac3f-325136ee6177" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_744b0749-30d4-4b33-9a96-c8b96ca6d81b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_8ddb9e1f-d97c-41cf-aa34-9812fdce573a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_744b0749-30d4-4b33-9a96-c8b96ca6d81b" xlink:to="loc_us-gaap_AccountsPayableCurrent_8ddb9e1f-d97c-41cf-aa34-9812fdce573a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_a1c9faaf-3b1a-4928-b1e3-4949d479f641" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_744b0749-30d4-4b33-9a96-c8b96ca6d81b" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_a1c9faaf-3b1a-4928-b1e3-4949d479f641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_79588158-e048-4d46-831b-69d8edab2020" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_744b0749-30d4-4b33-9a96-c8b96ca6d81b" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_79588158-e048-4d46-831b-69d8edab2020" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_a50abb72-2e9c-4b02-9cc9-cb56eb369cdb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_744b0749-30d4-4b33-9a96-c8b96ca6d81b" xlink:to="loc_us-gaap_NotesPayableCurrent_a50abb72-2e9c-4b02-9cc9-cb56eb369cdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_e69f94d8-e5bd-41bd-9fe3-234157882449" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_744b0749-30d4-4b33-9a96-c8b96ca6d81b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_e69f94d8-e5bd-41bd-9fe3-234157882449" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_e753ee12-2a98-40c0-96dd-7784ad23369d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_744b0749-30d4-4b33-9a96-c8b96ca6d81b" xlink:to="loc_us-gaap_LiabilitiesCurrent_e753ee12-2a98-40c0-96dd-7784ad23369d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_10ee3403-ac7c-4277-9a10-01bdfa849356" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_527a3eae-0d5c-470a-ac3f-325136ee6177" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_10ee3403-ac7c-4277-9a10-01bdfa849356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermNotesPayable_557f09ca-2cca-4995-b289-71a33662419e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermNotesPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_527a3eae-0d5c-470a-ac3f-325136ee6177" xlink:to="loc_us-gaap_LongTermNotesPayable_557f09ca-2cca-4995-b289-71a33662419e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_8d6c0622-9020-491e-b8b9-236b660c0a00" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_527a3eae-0d5c-470a-ac3f-325136ee6177" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_8d6c0622-9020-491e-b8b9-236b660c0a00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_e981e7c5-f652-4ad6-8687-1e03bd10347b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_527a3eae-0d5c-470a-ac3f-325136ee6177" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_e981e7c5-f652-4ad6-8687-1e03bd10347b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_e7bcdb68-18f7-495b-b0fa-fb5298ada310" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_527a3eae-0d5c-470a-ac3f-325136ee6177" xlink:to="loc_us-gaap_Liabilities_e7bcdb68-18f7-495b-b0fa-fb5298ada310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_973e5e39-6034-434e-b9d1-c182b4d73861" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_527a3eae-0d5c-470a-ac3f-325136ee6177" xlink:to="loc_us-gaap_CommitmentsAndContingencies_973e5e39-6034-434e-b9d1-c182b4d73861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_50643b19-a19f-415a-80ea-5305f61c66ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_527a3eae-0d5c-470a-ac3f-325136ee6177" xlink:to="loc_us-gaap_StockholdersEquityAbstract_50643b19-a19f-415a-80ea-5305f61c66ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_2a41b09f-102a-45d7-8c7e-06502d342281" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_50643b19-a19f-415a-80ea-5305f61c66ec" xlink:to="loc_us-gaap_CommonStockValue_2a41b09f-102a-45d7-8c7e-06502d342281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_db2f1113-0faf-4f08-b400-94708da31cba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_50643b19-a19f-415a-80ea-5305f61c66ec" xlink:to="loc_us-gaap_AdditionalPaidInCapital_db2f1113-0faf-4f08-b400-94708da31cba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ac5da776-3392-4434-bf45-8ca69bde3b98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_50643b19-a19f-415a-80ea-5305f61c66ec" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ac5da776-3392-4434-bf45-8ca69bde3b98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e73430fd-aed9-438a-843c-8b7edfe5ac56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_50643b19-a19f-415a-80ea-5305f61c66ec" xlink:to="loc_us-gaap_StockholdersEquity_e73430fd-aed9-438a-843c-8b7edfe5ac56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_5c9cb2fa-6aa5-46df-a75b-d558d019f59c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_527a3eae-0d5c-470a-ac3f-325136ee6177" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_5c9cb2fa-6aa5-46df-a75b-d558d019f59c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical" xlink:type="simple" xlink:href="rxrx-20240331.xsd#CondensedConsolidatedBalanceSheetsunauditedParenthetical"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_4266d5bd-63b3-46f2-8377-4a9839296e96" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_4b1be05b-9a98-4531-a714-a89a1a843433" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4266d5bd-63b3-46f2-8377-4a9839296e96" xlink:to="loc_us-gaap_StatementTable_4b1be05b-9a98-4531-a714-a89a1a843433" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_9b0a8208-3b1b-4010-bfed-97e9a5e4675e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4b1be05b-9a98-4531-a714-a89a1a843433" xlink:to="loc_us-gaap_StatementClassOfStockAxis_9b0a8208-3b1b-4010-bfed-97e9a5e4675e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4bc330ba-2e35-4383-a867-5f104963e2cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9b0a8208-3b1b-4010-bfed-97e9a5e4675e" xlink:to="loc_us-gaap_ClassOfStockDomain_4bc330ba-2e35-4383-a867-5f104963e2cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_eae7eb69-8006-41b8-b7fe-2471325b8fb7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4bc330ba-2e35-4383-a867-5f104963e2cc" xlink:to="loc_us-gaap_CommonClassAMember_eae7eb69-8006-41b8-b7fe-2471325b8fb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_f9d79776-1ee5-4c30-b976-4f72643f5891" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4bc330ba-2e35-4383-a867-5f104963e2cc" xlink:to="loc_us-gaap_CommonClassBMember_f9d79776-1ee5-4c30-b976-4f72643f5891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_ExchangeableStockMember_c0e9fe1f-7807-4da5-b2bf-b9966d7c485a" xlink:href="rxrx-20240331.xsd#rxrx_ExchangeableStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4bc330ba-2e35-4383-a867-5f104963e2cc" xlink:to="loc_rxrx_ExchangeableStockMember_c0e9fe1f-7807-4da5-b2bf-b9966d7c485a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_36b026d6-1c45-4855-8a34-f6d8bc988918" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4b1be05b-9a98-4531-a714-a89a1a843433" xlink:to="loc_us-gaap_StatementLineItems_36b026d6-1c45-4855-8a34-f6d8bc988918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_0eced7a9-722b-4385-a8b6-5830f919b6af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_36b026d6-1c45-4855-8a34-f6d8bc988918" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_0eced7a9-722b-4385-a8b6-5830f919b6af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_a91ecc29-ed59-4e7f-8713-7e4c358db493" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_36b026d6-1c45-4855-8a34-f6d8bc988918" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_a91ecc29-ed59-4e7f-8713-7e4c358db493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_bd9a5427-3fb4-4f32-b50d-557f5c1a1d02" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_36b026d6-1c45-4855-8a34-f6d8bc988918" xlink:to="loc_us-gaap_CommonStockSharesIssued_bd9a5427-3fb4-4f32-b50d-557f5c1a1d02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_f6bee11f-9c0b-48c1-b417-153476f6f03b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_36b026d6-1c45-4855-8a34-f6d8bc988918" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_f6bee11f-9c0b-48c1-b417-153476f6f03b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited" xlink:type="simple" xlink:href="rxrx-20240331.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_834ba1e1-66a9-4ac8-aad9-2542e5b7ca68" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_5afafebc-990d-4fad-b4fa-3ae27f279d12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_834ba1e1-66a9-4ac8-aad9-2542e5b7ca68" xlink:to="loc_us-gaap_StatementTable_5afafebc-990d-4fad-b4fa-3ae27f279d12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ce45d234-f659-4872-aabc-65e68a97c466" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_5afafebc-990d-4fad-b4fa-3ae27f279d12" xlink:to="loc_srt_ProductOrServiceAxis_ce45d234-f659-4872-aabc-65e68a97c466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a31b65d7-bda1-4ddd-be47-8c6f73365ca8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_ce45d234-f659-4872-aabc-65e68a97c466" xlink:to="loc_srt_ProductsAndServicesDomain_a31b65d7-bda1-4ddd-be47-8c6f73365ca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAndServiceMember_1b27560c-cf9b-4567-bc65-711fb640f493" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseAndServiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a31b65d7-bda1-4ddd-be47-8c6f73365ca8" xlink:to="loc_us-gaap_LicenseAndServiceMember_1b27560c-cf9b-4567-bc65-711fb640f493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_bec997bf-a793-4ea7-8aba-1631fa2ff026" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a31b65d7-bda1-4ddd-be47-8c6f73365ca8" xlink:to="loc_us-gaap_GrantMember_bec997bf-a793-4ea7-8aba-1631fa2ff026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_7c7c754f-16a8-436d-8a7a-42cc7174a81f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_5afafebc-990d-4fad-b4fa-3ae27f279d12" xlink:to="loc_us-gaap_StatementLineItems_7c7c754f-16a8-436d-8a7a-42cc7174a81f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_9c49f215-0585-4177-b556-c0cac847250b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7c7c754f-16a8-436d-8a7a-42cc7174a81f" xlink:to="loc_us-gaap_RevenuesAbstract_9c49f215-0585-4177-b556-c0cac847250b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c8a4014b-1147-4b51-805d-3894214ac49a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_9c49f215-0585-4177-b556-c0cac847250b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c8a4014b-1147-4b51-805d-3894214ac49a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_2017fb6e-e63c-43a0-998d-e2384aca06d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7c7c754f-16a8-436d-8a7a-42cc7174a81f" xlink:to="loc_us-gaap_OperatingExpensesAbstract_2017fb6e-e63c-43a0-998d-e2384aca06d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_5e3bc9f3-5d58-4b7e-a6a2-ea56c077d86c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2017fb6e-e63c-43a0-998d-e2384aca06d6" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_5e3bc9f3-5d58-4b7e-a6a2-ea56c077d86c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_108a1b00-d9c1-4673-8533-44278c327c43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2017fb6e-e63c-43a0-998d-e2384aca06d6" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_108a1b00-d9c1-4673-8533-44278c327c43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_e6debde4-d75b-4312-a0c5-9dd0e45b6c81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2017fb6e-e63c-43a0-998d-e2384aca06d6" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_e6debde4-d75b-4312-a0c5-9dd0e45b6c81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_9a9fc799-3db8-4004-9805-5ef0a8954892" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2017fb6e-e63c-43a0-998d-e2384aca06d6" xlink:to="loc_us-gaap_CostsAndExpenses_9a9fc799-3db8-4004-9805-5ef0a8954892" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_a4bee4a4-aa40-4d83-829e-89e40e40bddd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7c7c754f-16a8-436d-8a7a-42cc7174a81f" xlink:to="loc_us-gaap_OperatingIncomeLoss_a4bee4a4-aa40-4d83-829e-89e40e40bddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_651fc6f5-b590-440a-b007-6c23dfebe503" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7c7c754f-16a8-436d-8a7a-42cc7174a81f" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_651fc6f5-b590-440a-b007-6c23dfebe503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5a0ecc34-e820-4607-a1e8-6e6baa63f17b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7c7c754f-16a8-436d-8a7a-42cc7174a81f" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5a0ecc34-e820-4607-a1e8-6e6baa63f17b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_e99c5e78-b613-49c9-89ff-908b6756a444" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7c7c754f-16a8-436d-8a7a-42cc7174a81f" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_e99c5e78-b613-49c9-89ff-908b6756a444" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_e0e4ff62-ddfe-4665-a46f-883d4bc90247" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7c7c754f-16a8-436d-8a7a-42cc7174a81f" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_e0e4ff62-ddfe-4665-a46f-883d4bc90247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9ee40a40-f511-42a2-a75a-3abc12264231" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7c7c754f-16a8-436d-8a7a-42cc7174a81f" xlink:to="loc_us-gaap_NetIncomeLoss_9ee40a40-f511-42a2-a75a-3abc12264231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_c273f3be-abbd-4d7f-9ede-d6c80cf333d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7c7c754f-16a8-436d-8a7a-42cc7174a81f" xlink:to="loc_us-gaap_EarningsPerShareAbstract_c273f3be-abbd-4d7f-9ede-d6c80cf333d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_15200b44-0786-4a4e-9130-c8f8b57c6949" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c273f3be-abbd-4d7f-9ede-d6c80cf333d9" xlink:to="loc_us-gaap_EarningsPerShareBasic_15200b44-0786-4a4e-9130-c8f8b57c6949" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_dfe38768-b6e7-415f-a079-63e988f50be5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c273f3be-abbd-4d7f-9ede-d6c80cf333d9" xlink:to="loc_us-gaap_EarningsPerShareDiluted_dfe38768-b6e7-415f-a079-63e988f50be5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b377e26e-3a4f-459e-a47c-e9565e089a80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c273f3be-abbd-4d7f-9ede-d6c80cf333d9" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b377e26e-3a4f-459e-a47c-e9565e089a80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9f1f8ff0-8fcd-4140-9dfe-b30c520246c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c273f3be-abbd-4d7f-9ede-d6c80cf333d9" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9f1f8ff0-8fcd-4140-9dfe-b30c520246c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited" xlink:type="simple" xlink:href="rxrx-20240331.xsd#CondensedConsolidatedStatementsofStockholdersEquityunaudited"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_c57f03c8-060d-47f9-942b-27a33697d091" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_a7ca7c32-d687-4f1b-82f3-67744aa3b469" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_c57f03c8-060d-47f9-942b-27a33697d091" xlink:to="loc_us-gaap_StatementTable_a7ca7c32-d687-4f1b-82f3-67744aa3b469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1e0b1f7f-c5d1-4f9d-a760-2fad3e20d3c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_a7ca7c32-d687-4f1b-82f3-67744aa3b469" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1e0b1f7f-c5d1-4f9d-a760-2fad3e20d3c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c33fcdd3-a8ab-4695-8e4a-59a1b2177fde" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1e0b1f7f-c5d1-4f9d-a760-2fad3e20d3c3" xlink:to="loc_us-gaap_EquityComponentDomain_c33fcdd3-a8ab-4695-8e4a-59a1b2177fde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_6c3b028c-a4c0-487a-bb7d-1999ba51e474" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c33fcdd3-a8ab-4695-8e4a-59a1b2177fde" xlink:to="loc_us-gaap_CommonStockMember_6c3b028c-a4c0-487a-bb7d-1999ba51e474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_22a603ea-6dc7-40cd-b168-e75e051de757" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c33fcdd3-a8ab-4695-8e4a-59a1b2177fde" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_22a603ea-6dc7-40cd-b168-e75e051de757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_9c26cc38-ebaa-4917-98ea-652982ef0d88" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c33fcdd3-a8ab-4695-8e4a-59a1b2177fde" xlink:to="loc_us-gaap_RetainedEarningsMember_9c26cc38-ebaa-4917-98ea-652982ef0d88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_fa77925c-83b7-44bc-8b03-ef22cfd047a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_a7ca7c32-d687-4f1b-82f3-67744aa3b469" xlink:to="loc_us-gaap_StatementLineItems_fa77925c-83b7-44bc-8b03-ef22cfd047a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_962930f9-83f7-4fa4-a354-0ce0a68b37b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_fa77925c-83b7-44bc-8b03-ef22cfd047a1" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_962930f9-83f7-4fa4-a354-0ce0a68b37b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_9807e812-80d4-41f1-a790-f3552ca91ded" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_962930f9-83f7-4fa4-a354-0ce0a68b37b4" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_9807e812-80d4-41f1-a790-f3552ca91ded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f0308797-c45b-4326-83cb-6a73fdd3dd69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_962930f9-83f7-4fa4-a354-0ce0a68b37b4" xlink:to="loc_us-gaap_StockholdersEquity_f0308797-c45b-4326-83cb-6a73fdd3dd69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_389b6938-6e17-47e1-afd9-7f0146c95d5b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_962930f9-83f7-4fa4-a354-0ce0a68b37b4" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_389b6938-6e17-47e1-afd9-7f0146c95d5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f1d073d5-3361-440e-ab80-d6af39f66efc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_962930f9-83f7-4fa4-a354-0ce0a68b37b4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f1d073d5-3361-440e-ab80-d6af39f66efc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_c3b1be21-c3cb-44b4-a6af-819b204806ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_962930f9-83f7-4fa4-a354-0ce0a68b37b4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_c3b1be21-c3cb-44b4-a6af-819b204806ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_72cacfbb-2b62-496f-b96a-05ac2864a81b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_962930f9-83f7-4fa4-a354-0ce0a68b37b4" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_72cacfbb-2b62-496f-b96a-05ac2864a81b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7c2111f9-891f-44b8-ad29-7305710c46d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_962930f9-83f7-4fa4-a354-0ce0a68b37b4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7c2111f9-891f-44b8-ad29-7305710c46d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_f015e047-f0c0-4869-8f51-e5c5d2cb763f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_962930f9-83f7-4fa4-a354-0ce0a68b37b4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_f015e047-f0c0-4869-8f51-e5c5d2cb763f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_7475809c-9941-496d-82a7-457e951c8dc5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_962930f9-83f7-4fa4-a354-0ce0a68b37b4" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_7475809c-9941-496d-82a7-457e951c8dc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2349881b-ac9c-4d2d-81bb-856422e02c41" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_962930f9-83f7-4fa4-a354-0ce0a68b37b4" xlink:to="loc_us-gaap_StockholdersEquity_2349881b-ac9c-4d2d-81bb-856422e02c41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" xlink:type="simple" xlink:href="rxrx-20240331.xsd#CondensedConsolidatedStatementsofCashFlowsunaudited"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_ef2d8f69-8095-4dd0-8159-8a832181234f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5861bf06-ff87-4a85-afb6-16d39303291d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ef2d8f69-8095-4dd0-8159-8a832181234f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5861bf06-ff87-4a85-afb6-16d39303291d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_69ca261d-11b0-4565-8fe0-22dd3cad822e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5861bf06-ff87-4a85-afb6-16d39303291d" xlink:to="loc_us-gaap_NetIncomeLoss_69ca261d-11b0-4565-8fe0-22dd3cad822e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_71492e5e-047d-453b-9ac6-a16ed2531ac1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5861bf06-ff87-4a85-afb6-16d39303291d" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_71492e5e-047d-453b-9ac6-a16ed2531ac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_3c34ee2d-6554-4a47-93e1-f8ba2e3779ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_71492e5e-047d-453b-9ac6-a16ed2531ac1" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_3c34ee2d-6554-4a47-93e1-f8ba2e3779ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_f6bb8c30-d853-41a5-b0f3-0a561930798d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_71492e5e-047d-453b-9ac6-a16ed2531ac1" xlink:to="loc_us-gaap_ShareBasedCompensation_f6bb8c30-d853-41a5-b0f3-0a561930798d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TangibleAssetImpairmentCharges_0dc75be0-4486-4db2-9cef-2b126dfb6b7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TangibleAssetImpairmentCharges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_71492e5e-047d-453b-9ac6-a16ed2531ac1" xlink:to="loc_us-gaap_TangibleAssetImpairmentCharges_0dc75be0-4486-4db2-9cef-2b126dfb6b7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_efe02f06-fce6-4d8d-a904-55cbc29e6f32" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_71492e5e-047d-453b-9ac6-a16ed2531ac1" xlink:to="loc_us-gaap_OperatingLeaseExpense_efe02f06-fce6-4d8d-a904-55cbc29e6f32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_8441eb49-1cee-421a-a610-9567576920e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_71492e5e-047d-453b-9ac6-a16ed2531ac1" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_8441eb49-1cee-421a-a610-9567576920e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_99a3f2a3-58ff-422c-85e1-660e5b3f8262" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_71492e5e-047d-453b-9ac6-a16ed2531ac1" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_99a3f2a3-58ff-422c-85e1-660e5b3f8262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_08e8106c-c2f7-4261-83cc-3e4f4208fbaa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_99a3f2a3-58ff-422c-85e1-660e5b3f8262" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_08e8106c-c2f7-4261-83cc-3e4f4208fbaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_d0078f9e-fc9b-4e8f-b305-77efe896b171" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_99a3f2a3-58ff-422c-85e1-660e5b3f8262" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_d0078f9e-fc9b-4e8f-b305-77efe896b171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_bfc8acc4-c6d0-44fc-93be-8b761d02524d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_99a3f2a3-58ff-422c-85e1-660e5b3f8262" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_bfc8acc4-c6d0-44fc-93be-8b761d02524d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_IncreaseDecreaseInAccruedDevelopmentExpense_291b179f-6a8d-4607-94d7-19882c864aff" xlink:href="rxrx-20240331.xsd#rxrx_IncreaseDecreaseInAccruedDevelopmentExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_99a3f2a3-58ff-422c-85e1-660e5b3f8262" xlink:to="loc_rxrx_IncreaseDecreaseInAccruedDevelopmentExpense_291b179f-6a8d-4607-94d7-19882c864aff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_c6388bfe-4946-403e-9074-405d15bc107a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_99a3f2a3-58ff-422c-85e1-660e5b3f8262" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_c6388bfe-4946-403e-9074-405d15bc107a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_96503795-a9b7-41ca-8570-12f016cb017f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_99a3f2a3-58ff-422c-85e1-660e5b3f8262" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_96503795-a9b7-41ca-8570-12f016cb017f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_35eae762-66ae-46a3-af7d-55cadd7b51b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5861bf06-ff87-4a85-afb6-16d39303291d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_35eae762-66ae-46a3-af7d-55cadd7b51b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5acb3d7f-1773-49ea-9569-2803b389f83b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ef2d8f69-8095-4dd0-8159-8a832181234f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5acb3d7f-1773-49ea-9569-2803b389f83b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_127240c5-cca5-40b8-a55a-3accd8bcc3e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5acb3d7f-1773-49ea-9569-2803b389f83b" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_127240c5-cca5-40b8-a55a-3accd8bcc3e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_f7955b16-964d-428d-b42f-3004e7645b66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5acb3d7f-1773-49ea-9569-2803b389f83b" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_f7955b16-964d-428d-b42f-3004e7645b66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f1d3118c-8212-4ec5-8b89-bb0947ec6a74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5acb3d7f-1773-49ea-9569-2803b389f83b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f1d3118c-8212-4ec5-8b89-bb0947ec6a74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_93103a42-2c23-47d2-8f93-4cbf7a0f9483" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ef2d8f69-8095-4dd0-8159-8a832181234f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_93103a42-2c23-47d2-8f93-4cbf7a0f9483" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_ef0e7b39-32eb-4c94-a847-f075a0b3d9c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_93103a42-2c23-47d2-8f93-4cbf7a0f9483" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_ef0e7b39-32eb-4c94-a847-f075a0b3d9c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_8d859e91-b684-4e8b-acaf-6385eff47e43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_93103a42-2c23-47d2-8f93-4cbf7a0f9483" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_8d859e91-b684-4e8b-acaf-6385eff47e43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_14972ef4-705d-4f24-87c3-56f798956998" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_93103a42-2c23-47d2-8f93-4cbf7a0f9483" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_14972ef4-705d-4f24-87c3-56f798956998" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_35fd66ab-d778-4463-84eb-27a1788f6cd0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_93103a42-2c23-47d2-8f93-4cbf7a0f9483" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_35fd66ab-d778-4463-84eb-27a1788f6cd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ae66cc26-50fd-409f-a8af-1d424b82abde" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ef2d8f69-8095-4dd0-8159-8a832181234f" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ae66cc26-50fd-409f-a8af-1d424b82abde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_fd3bacc8-b747-4aa6-b973-c7c5a71e9c5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ef2d8f69-8095-4dd0-8159-8a832181234f" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_fd3bacc8-b747-4aa6-b973-c7c5a71e9c5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e5b83210-97d0-4d34-b9ea-4d09510f9147" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ef2d8f69-8095-4dd0-8159-8a832181234f" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e5b83210-97d0-4d34-b9ea-4d09510f9147" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d7da377f-d070-4e76-8670-48bcc07947f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ef2d8f69-8095-4dd0-8159-8a832181234f" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d7da377f-d070-4e76-8670-48bcc07947f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_43f6fc0e-88eb-4650-af9f-a53ad649105c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ef2d8f69-8095-4dd0-8159-8a832181234f" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_43f6fc0e-88eb-4650-af9f-a53ad649105c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_527f900c-807d-428d-91d5-e54b80e2b6db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_43f6fc0e-88eb-4650-af9f-a53ad649105c" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_527f900c-807d-428d-91d5-e54b80e2b6db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_1c6a6095-5b08-4534-a855-2f63c9d7a891" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_43f6fc0e-88eb-4650-af9f-a53ad649105c" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_1c6a6095-5b08-4534-a855-2f63c9d7a891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_FinancedEquipmentPurchase_4b01de41-98bb-47ea-8344-eef89bf5ac5d" xlink:href="rxrx-20240331.xsd#rxrx_FinancedEquipmentPurchase"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_43f6fc0e-88eb-4650-af9f-a53ad649105c" xlink:to="loc_rxrx_FinancedEquipmentPurchase_4b01de41-98bb-47ea-8344-eef89bf5ac5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_0064f765-9e9b-4985-b438-7bf92ac18b2d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ef2d8f69-8095-4dd0-8159-8a832181234f" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_0064f765-9e9b-4985-b438-7bf92ac18b2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePaymentsUse_83c573bd-91bc-4d1c-a22b-6e3e1348db8d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePaymentsUse"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_0064f765-9e9b-4985-b438-7bf92ac18b2d" xlink:to="loc_us-gaap_OperatingLeasePaymentsUse_83c573bd-91bc-4d1c-a22b-6e3e1348db8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/DescriptionoftheBusiness" xlink:type="simple" xlink:href="rxrx-20240331.xsd#DescriptionoftheBusiness"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/DescriptionoftheBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bbd9cf67-239d-450c-ad62-3907719da450" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_f1f4edf0-c2e1-4a56-a33d-2de3c2700124" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bbd9cf67-239d-450c-ad62-3907719da450" xlink:to="loc_us-gaap_NatureOfOperations_f1f4edf0-c2e1-4a56-a33d-2de3c2700124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/BasisofPresentation" xlink:type="simple" xlink:href="rxrx-20240331.xsd#BasisofPresentation"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/BasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_565814d7-affd-40d5-87b7-49e259c0c45b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_9f385c32-3c4e-4abb-b9da-6abfab66cf6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_565814d7-affd-40d5-87b7-49e259c0c45b" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_9f385c32-3c4e-4abb-b9da-6abfab66cf6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/SupplementalFinancialInformation" xlink:type="simple" xlink:href="rxrx-20240331.xsd#SupplementalFinancialInformation"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/SupplementalFinancialInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_SupplementalFinancialInformationAbstract_9e57bfdb-87b4-4ac9-9362-7671d8d6565a" xlink:href="rxrx-20240331.xsd#rxrx_SupplementalFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_SupplementalBalanceSheetAndIncomeStatementInformationTextBlock_54265fa9-e07b-437a-9123-c4bcab4c94dc" xlink:href="rxrx-20240331.xsd#rxrx_SupplementalBalanceSheetAndIncomeStatementInformationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rxrx_SupplementalFinancialInformationAbstract_9e57bfdb-87b4-4ac9-9362-7671d8d6565a" xlink:to="loc_rxrx_SupplementalBalanceSheetAndIncomeStatementInformationTextBlock_54265fa9-e07b-437a-9123-c4bcab4c94dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/Acquisitions" xlink:type="simple" xlink:href="rxrx-20240331.xsd#Acquisitions"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/Acquisitions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_78de8851-28a4-4067-8c76-d72feaf870be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_eac739a1-50e3-4433-84c1-500d5d60f9be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_78de8851-28a4-4067-8c76-d72feaf870be" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_eac739a1-50e3-4433-84c1-500d5d60f9be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/Leases" xlink:type="simple" xlink:href="rxrx-20240331.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_903d9558-9c79-4c34-ab4a-2122f1cb6a98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_2c23e720-6096-441b-9113-968c2c5bcf11" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_903d9558-9c79-4c34-ab4a-2122f1cb6a98" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_2c23e720-6096-441b-9113-968c2c5bcf11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/GoodwillandIntangibleAssets" xlink:type="simple" xlink:href="rxrx-20240331.xsd#GoodwillandIntangibleAssets"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/GoodwillandIntangibleAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1f2ef93a-2210-4826-b00e-3fbf6e739b30" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_c478fb13-49fc-4f83-b44b-5bf0ef7ce630" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1f2ef93a-2210-4826-b00e-3fbf6e739b30" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_c478fb13-49fc-4f83-b44b-5bf0ef7ce630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="rxrx-20240331.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_189d0d26-375d-43fa-9ddb-6f063738eb7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_947edec5-9286-494f-90d0-69ad18adc99f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_189d0d26-375d-43fa-9ddb-6f063738eb7e" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_947edec5-9286-494f-90d0-69ad18adc99f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/CommonStock" xlink:type="simple" xlink:href="rxrx-20240331.xsd#CommonStock"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/CommonStock" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_a0755f32-8809-4e97-97e0-16dd1f206fb4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_258a6ee7-fc48-420a-91f4-e3c1d837cab3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a0755f32-8809-4e97-97e0-16dd1f206fb4" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_258a6ee7-fc48-420a-91f4-e3c1d837cab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/CollaborativeDevelopmentContracts" xlink:type="simple" xlink:href="rxrx-20240331.xsd#CollaborativeDevelopmentContracts"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/CollaborativeDevelopmentContracts" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ab15f8e5-a1ce-4663-b1f0-51074b918224" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_595bcb8a-c0cb-494e-8ec1-9024595a48f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ab15f8e5-a1ce-4663-b1f0-51074b918224" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_595bcb8a-c0cb-494e-8ec1-9024595a48f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="rxrx-20240331.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e7bd8378-a1e0-43ee-b72d-5ad09f62992b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_29672640-12e8-4366-8ece-03f23324d9c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e7bd8378-a1e0-43ee-b72d-5ad09f62992b" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_29672640-12e8-4366-8ece-03f23324d9c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/IncomeTaxes" xlink:type="simple" xlink:href="rxrx-20240331.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_9bdaad21-fd13-452b-8071-f8fe988056ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_a451b7c4-e434-4184-86a9-af63e4fef476" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9bdaad21-fd13-452b-8071-f8fe988056ed" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_a451b7c4-e434-4184-86a9-af63e4fef476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/NetLossPerShare" xlink:type="simple" xlink:href="rxrx-20240331.xsd#NetLossPerShare"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/NetLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_e368c900-b229-4953-9ee0-59941584d2b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_1c6f0232-d2af-407b-a139-19383bb53df6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_e368c900-b229-4953-9ee0-59941584d2b2" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_1c6f0232-d2af-407b-a139-19383bb53df6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="rxrx-20240331.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_c7e5eba5-6456-4f76-bfc9-1d023674d5ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_22d817c5-aee9-4211-a566-faf7607907da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_c7e5eba5-6456-4f76-bfc9-1d023674d5ce" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_22d817c5-aee9-4211-a566-faf7607907da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/BasisofPresentationPolicies" xlink:type="simple" xlink:href="rxrx-20240331.xsd#BasisofPresentationPolicies"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/BasisofPresentationPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_a4a4be3d-dadd-4e0b-b195-87f715c9141b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_f28a8759-ca87-40ab-9a86-3686099f64fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a4a4be3d-dadd-4e0b-b195-87f715c9141b" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_f28a8759-ca87-40ab-9a86-3686099f64fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_8f083f01-e6b3-4677-a4ae-89fa59bc5d8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a4a4be3d-dadd-4e0b-b195-87f715c9141b" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_8f083f01-e6b3-4677-a4ae-89fa59bc5d8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/SupplementalFinancialInformationTables" xlink:type="simple" xlink:href="rxrx-20240331.xsd#SupplementalFinancialInformationTables"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/SupplementalFinancialInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_SupplementalFinancialInformationAbstract_900c32c7-f55a-4013-814a-744761ef0df7" xlink:href="rxrx-20240331.xsd#rxrx_SupplementalFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_04604136-7a5f-422f-8447-1c2bf24cbb22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rxrx_SupplementalFinancialInformationAbstract_900c32c7-f55a-4013-814a-744761ef0df7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_04604136-7a5f-422f-8447-1c2bf24cbb22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_34e4a60b-de1a-4a40-b63f-8fb61811c373" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rxrx_SupplementalFinancialInformationAbstract_900c32c7-f55a-4013-814a-744761ef0df7" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_34e4a60b-de1a-4a40-b63f-8fb61811c373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_5192581e-c575-4ba0-9db8-4390de829b5b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rxrx_SupplementalFinancialInformationAbstract_900c32c7-f55a-4013-814a-744761ef0df7" xlink:to="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_5192581e-c575-4ba0-9db8-4390de829b5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/AcquisitionsTables" xlink:type="simple" xlink:href="rxrx-20240331.xsd#AcquisitionsTables"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/AcquisitionsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_9f13feae-c3dc-4278-82b9-2e652ad0fa51" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_c21dc03e-7991-4563-a2ee-4cee53706a9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_9f13feae-c3dc-4278-82b9-2e652ad0fa51" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_c21dc03e-7991-4563-a2ee-4cee53706a9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_5e56ddb3-bd16-461f-a680-4ac544ec9413" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_9f13feae-c3dc-4278-82b9-2e652ad0fa51" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_5e56ddb3-bd16-461f-a680-4ac544ec9413" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_d5b09198-9011-4b8c-8be8-54d00ae439d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_9f13feae-c3dc-4278-82b9-2e652ad0fa51" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_d5b09198-9011-4b8c-8be8-54d00ae439d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/LeasesTables" xlink:type="simple" xlink:href="rxrx-20240331.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_1b46cdbc-608d-4e0c-8865-abf05c217094" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_0d5064b3-aea9-4623-a2ec-2c393f1438de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1b46cdbc-608d-4e0c-8865-abf05c217094" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_0d5064b3-aea9-4623-a2ec-2c393f1438de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_84a7d112-6012-4600-b2cb-aa890a63ea39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1b46cdbc-608d-4e0c-8865-abf05c217094" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_84a7d112-6012-4600-b2cb-aa890a63ea39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/GoodwillandIntangibleAssetsTables" xlink:type="simple" xlink:href="rxrx-20240331.xsd#GoodwillandIntangibleAssetsTables"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/GoodwillandIntangibleAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1682d227-43da-4e52-91e8-ec009d53b866" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_9b4a977f-891a-4c6e-ac07-196c95079e27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1682d227-43da-4e52-91e8-ec009d53b866" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_9b4a977f-891a-4c6e-ac07-196c95079e27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_af8a7a3c-8d03-4c53-999d-3ec95ab88464" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1682d227-43da-4e52-91e8-ec009d53b866" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_af8a7a3c-8d03-4c53-999d-3ec95ab88464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="rxrx-20240331.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6381eada-3707-469c-a195-a49d6678b4af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_b4d20a0c-f9a7-42b7-a8f6-1918325d9347" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6381eada-3707-469c-a195-a49d6678b4af" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_b4d20a0c-f9a7-42b7-a8f6-1918325d9347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_d2060943-b897-4433-8c26-554687fc8871" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6381eada-3707-469c-a195-a49d6678b4af" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_d2060943-b897-4433-8c26-554687fc8871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_6f3bea8b-6782-4bf6-9cf4-8f3677edab80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6381eada-3707-469c-a195-a49d6678b4af" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_6f3bea8b-6782-4bf6-9cf4-8f3677edab80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_acd597b3-646b-451a-872d-23326d414db4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6381eada-3707-469c-a195-a49d6678b4af" xlink:to="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_acd597b3-646b-451a-872d-23326d414db4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/NetLossPerShareTables" xlink:type="simple" xlink:href="rxrx-20240331.xsd#NetLossPerShareTables"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/NetLossPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_12b927bb-158d-448d-a724-8dd9e9505eb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_e6923784-e700-4443-b5ca-83956508f786" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_12b927bb-158d-448d-a724-8dd9e9505eb0" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_e6923784-e700-4443-b5ca-83956508f786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_751ed7c3-806e-4ea0-9e31-625bdf3d2352" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_12b927bb-158d-448d-a724-8dd9e9505eb0" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_751ed7c3-806e-4ea0-9e31-625bdf3d2352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="rxrx-20240331.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_97e6103c-08e7-4f95-becf-c8d30a3789ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_e768e2d5-69f8-4445-9767-6b57d8476885" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_97e6103c-08e7-4f95-becf-c8d30a3789ec" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_e768e2d5-69f8-4445-9767-6b57d8476885" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock_58138ecb-aeb3-4eda-a5cd-a4ccad50317b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_97e6103c-08e7-4f95-becf-c8d30a3789ec" xlink:to="loc_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock_58138ecb-aeb3-4eda-a5cd-a4ccad50317b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/DescriptionoftheBusinessDetails" xlink:type="simple" xlink:href="rxrx-20240331.xsd#DescriptionoftheBusinessDetails"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/DescriptionoftheBusinessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5839acd8-efe0-4a3c-9aa8-667e7ca25569" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ed13f70d-83b0-4be6-8a2e-bbf31dc3d499" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5839acd8-efe0-4a3c-9aa8-667e7ca25569" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ed13f70d-83b0-4be6-8a2e-bbf31dc3d499" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/SupplementalFinancialInformationNarrativeDetails" xlink:type="simple" xlink:href="rxrx-20240331.xsd#SupplementalFinancialInformationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/SupplementalFinancialInformationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_SupplementalFinancialInformationAbstract_6f539f84-03a6-469a-a0cd-c09ed10855cd" xlink:href="rxrx-20240331.xsd#rxrx_SupplementalFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_25548654-bbc3-4598-a3b7-68f0f560c0f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rxrx_SupplementalFinancialInformationAbstract_6f539f84-03a6-469a-a0cd-c09ed10855cd" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_25548654-bbc3-4598-a3b7-68f0f560c0f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_95d1207c-0d55-44d2-9e5d-f60aff629fbe" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_25548654-bbc3-4598-a3b7-68f0f560c0f0" xlink:to="loc_srt_CounterpartyNameAxis_95d1207c-0d55-44d2-9e5d-f60aff629fbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_26b48f56-eea6-4430-8f31-cdd58af8c827" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_95d1207c-0d55-44d2-9e5d-f60aff629fbe" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_26b48f56-eea6-4430-8f31-cdd58af8c827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_TempusLabsIncMember_bf357833-3225-4732-b7b7-ab2235a2c99e" xlink:href="rxrx-20240331.xsd#rxrx_TempusLabsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_26b48f56-eea6-4430-8f31-cdd58af8c827" xlink:to="loc_rxrx_TempusLabsIncMember_bf357833-3225-4732-b7b7-ab2235a2c99e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a7e61279-bb93-4aa4-9703-5ff9f243672a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_25548654-bbc3-4598-a3b7-68f0f560c0f0" xlink:to="loc_srt_RangeAxis_a7e61279-bb93-4aa4-9703-5ff9f243672a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5a63a0cd-f8f2-49f6-844a-de4b0828d45a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_a7e61279-bb93-4aa4-9703-5ff9f243672a" xlink:to="loc_srt_RangeMember_5a63a0cd-f8f2-49f6-844a-de4b0828d45a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_63f341d9-4e3a-4508-a279-6ea8d9caa743" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5a63a0cd-f8f2-49f6-844a-de4b0828d45a" xlink:to="loc_srt_MinimumMember_63f341d9-4e3a-4508-a279-6ea8d9caa743" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ab9053a3-3f5e-4688-8a8d-4fbcd361d841" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5a63a0cd-f8f2-49f6-844a-de4b0828d45a" xlink:to="loc_srt_MaximumMember_ab9053a3-3f5e-4688-8a8d-4fbcd361d841" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_c3561e46-8ee7-4ef9-acb0-d73774071a3e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_25548654-bbc3-4598-a3b7-68f0f560c0f0" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_c3561e46-8ee7-4ef9-acb0-d73774071a3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_7c66b1d6-58b5-4108-9d98-f4abc1fa7112" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_c3561e46-8ee7-4ef9-acb0-d73774071a3e" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_7c66b1d6-58b5-4108-9d98-f4abc1fa7112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_3e61d9b5-4f6c-4c43-9f4a-fa4d8bb942dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7c66b1d6-58b5-4108-9d98-f4abc1fa7112" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_3e61d9b5-4f6c-4c43-9f4a-fa4d8bb942dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0753d7a4-0071-4d00-ab40-708472ed71f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_25548654-bbc3-4598-a3b7-68f0f560c0f0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0753d7a4-0071-4d00-ab40-708472ed71f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_358838ad-2e5d-4d76-af1f-a6cbf2e062b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0753d7a4-0071-4d00-ab40-708472ed71f2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_358838ad-2e5d-4d76-af1f-a6cbf2e062b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_BioHiveSupercomputerMember_a6f49fdf-e515-4f7a-9ba7-2e88af9c2f83" xlink:href="rxrx-20240331.xsd#rxrx_BioHiveSupercomputerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_358838ad-2e5d-4d76-af1f-a6cbf2e062b0" xlink:to="loc_rxrx_BioHiveSupercomputerMember_a6f49fdf-e515-4f7a-9ba7-2e88af9c2f83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_cb485182-ca62-4bef-b21d-f8fde256b1da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_25548654-bbc3-4598-a3b7-68f0f560c0f0" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_cb485182-ca62-4bef-b21d-f8fde256b1da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ba771cfd-3983-440f-bbc9-6640d290e667" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_cb485182-ca62-4bef-b21d-f8fde256b1da" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ba771cfd-3983-440f-bbc9-6640d290e667" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_3b348d36-f0e6-4f5d-ab4e-e7d750c287ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_ba771cfd-3983-440f-bbc9-6640d290e667" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_3b348d36-f0e6-4f5d-ab4e-e7d750c287ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_dabb95c2-be14-4a7e-b701-f94f3cdc6800" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_25548654-bbc3-4598-a3b7-68f0f560c0f0" xlink:to="loc_us-gaap_DebtInstrumentAxis_dabb95c2-be14-4a7e-b701-f94f3cdc6800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5a198f70-5f96-4212-8dc5-564dcb8854e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_dabb95c2-be14-4a7e-b701-f94f3cdc6800" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5a198f70-5f96-4212-8dc5-564dcb8854e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_Station41LeaseMember_a41aec1b-1e6f-467b-8209-8af17525a7b6" xlink:href="rxrx-20240331.xsd#rxrx_Station41LeaseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5a198f70-5f96-4212-8dc5-564dcb8854e9" xlink:to="loc_rxrx_Station41LeaseMember_a41aec1b-1e6f-467b-8209-8af17525a7b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_997e73af-c51f-496d-8e63-52a31bb7f11e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_25548654-bbc3-4598-a3b7-68f0f560c0f0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_997e73af-c51f-496d-8e63-52a31bb7f11e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_LicenseAgreementTerm_a8e3c33b-4ec9-44ea-8d42-1f74d5084f37" xlink:href="rxrx-20240331.xsd#rxrx_LicenseAgreementTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_997e73af-c51f-496d-8e63-52a31bb7f11e" xlink:to="loc_rxrx_LicenseAgreementTerm_a8e3c33b-4ec9-44ea-8d42-1f74d5084f37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_LicenseAgreementAnnualPayments_82589c1a-4831-4753-9fe2-14f96e465ede" xlink:href="rxrx-20240331.xsd#rxrx_LicenseAgreementAnnualPayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_997e73af-c51f-496d-8e63-52a31bb7f11e" xlink:to="loc_rxrx_LicenseAgreementAnnualPayments_82589c1a-4831-4753-9fe2-14f96e465ede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_LicenseAgreementAggregatePayments_5a976444-9a87-4b5c-bbe1-f123f8e8b0fd" xlink:href="rxrx-20240331.xsd#rxrx_LicenseAgreementAggregatePayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_997e73af-c51f-496d-8e63-52a31bb7f11e" xlink:to="loc_rxrx_LicenseAgreementAggregatePayments_5a976444-9a87-4b5c-bbe1-f123f8e8b0fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_LicenseAgreementTradingPeriodUsedForEquityValueDetermination_1d6a33ac-068d-49f2-aa2e-31501e6b1ef5" xlink:href="rxrx-20240331.xsd#rxrx_LicenseAgreementTradingPeriodUsedForEquityValueDetermination"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_997e73af-c51f-496d-8e63-52a31bb7f11e" xlink:to="loc_rxrx_LicenseAgreementTradingPeriodUsedForEquityValueDetermination_1d6a33ac-068d-49f2-aa2e-31501e6b1ef5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_LicenseAgreementPrepaidExpenses_30a29211-c141-4979-b931-af54c2c1a685" xlink:href="rxrx-20240331.xsd#rxrx_LicenseAgreementPrepaidExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_997e73af-c51f-496d-8e63-52a31bb7f11e" xlink:to="loc_rxrx_LicenseAgreementPrepaidExpenses_30a29211-c141-4979-b931-af54c2c1a685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_de81f353-d77f-4259-a40b-165c6a9ca336" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_997e73af-c51f-496d-8e63-52a31bb7f11e" xlink:to="loc_us-gaap_Depreciation_de81f353-d77f-4259-a40b-165c6a9ca336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLeasehold_91c6de18-c39d-499f-9c13-77a8bb2d06bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLeasehold"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_997e73af-c51f-496d-8e63-52a31bb7f11e" xlink:to="loc_us-gaap_ImpairmentOfLeasehold_91c6de18-c39d-499f-9c13-77a8bb2d06bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_03c4b7c3-6dbd-4303-908b-c3a41e2fd80b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_997e73af-c51f-496d-8e63-52a31bb7f11e" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_03c4b7c3-6dbd-4303-908b-c3a41e2fd80b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_4fcb373b-664e-48ca-b90b-6cc93247ca81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_997e73af-c51f-496d-8e63-52a31bb7f11e" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_4fcb373b-664e-48ca-b90b-6cc93247ca81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_fea8bb38-8898-49c2-8819-43f4c63e7cb7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_997e73af-c51f-496d-8e63-52a31bb7f11e" xlink:to="loc_us-gaap_DebtInstrumentTerm_fea8bb38-8898-49c2-8819-43f4c63e7cb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7001bb08-13c2-49bc-b6e7-a4c182b0608f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_997e73af-c51f-496d-8e63-52a31bb7f11e" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7001bb08-13c2-49bc-b6e7-a4c182b0608f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable_f64304ec-4cf9-4cc9-9b3c-61d4902d2236" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayable"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_997e73af-c51f-496d-8e63-52a31bb7f11e" xlink:to="loc_us-gaap_NotesPayable_f64304ec-4cf9-4cc9-9b3c-61d4902d2236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/SupplementalFinancialInformationScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="rxrx-20240331.xsd#SupplementalFinancialInformationScheduleofPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/SupplementalFinancialInformationScheduleofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_SupplementalFinancialInformationAbstract_b411b670-16fb-434c-bbce-c8d1809506af" xlink:href="rxrx-20240331.xsd#rxrx_SupplementalFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0b1c9725-ce23-4609-b1b0-185a3e6c91a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rxrx_SupplementalFinancialInformationAbstract_b411b670-16fb-434c-bbce-c8d1809506af" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0b1c9725-ce23-4609-b1b0-185a3e6c91a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_27b5a3a1-fb49-41d0-9141-7d38e97dcf5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0b1c9725-ce23-4609-b1b0-185a3e6c91a5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_27b5a3a1-fb49-41d0-9141-7d38e97dcf5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_eef1a5c0-b99e-4a7e-bb89-e7432bfb213b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_27b5a3a1-fb49-41d0-9141-7d38e97dcf5a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_eef1a5c0-b99e-4a7e-bb89-e7432bfb213b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_LaboratoryEquipmentMember_d6881de3-c5bb-493e-93a2-f7521078a570" xlink:href="rxrx-20240331.xsd#rxrx_LaboratoryEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_eef1a5c0-b99e-4a7e-bb89-e7432bfb213b" xlink:to="loc_rxrx_LaboratoryEquipmentMember_d6881de3-c5bb-493e-93a2-f7521078a570" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_f43564dd-0348-41c4-bbac-0aba9791963a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_eef1a5c0-b99e-4a7e-bb89-e7432bfb213b" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_f43564dd-0348-41c4-bbac-0aba9791963a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_a932b98d-4f4f-4796-818b-0163295e16af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_eef1a5c0-b99e-4a7e-bb89-e7432bfb213b" xlink:to="loc_us-gaap_OfficeEquipmentMember_a932b98d-4f4f-4796-818b-0163295e16af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetUnderConstructionMember_56663ef2-94b5-435e-8b48-466ca5fab92d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetUnderConstructionMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_eef1a5c0-b99e-4a7e-bb89-e7432bfb213b" xlink:to="loc_us-gaap_AssetUnderConstructionMember_56663ef2-94b5-435e-8b48-466ca5fab92d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9b056f80-5bac-4b0b-8cb5-548332532765" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0b1c9725-ce23-4609-b1b0-185a3e6c91a5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9b056f80-5bac-4b0b-8cb5-548332532765" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_8a512f7c-0100-4ce9-98a6-b39714038a67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9b056f80-5bac-4b0b-8cb5-548332532765" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_8a512f7c-0100-4ce9-98a6-b39714038a67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_21cb0404-8edf-4d61-82f5-bc110422fda1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9b056f80-5bac-4b0b-8cb5-548332532765" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_21cb0404-8edf-4d61-82f5-bc110422fda1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_a46b4a0f-968e-4697-bde9-a25accaa907e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9b056f80-5bac-4b0b-8cb5-548332532765" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_a46b4a0f-968e-4697-bde9-a25accaa907e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/SupplementalFinancialInformationScheduleofAccruedExpensesandOtherLiabilitiesDetails" xlink:type="simple" xlink:href="rxrx-20240331.xsd#SupplementalFinancialInformationScheduleofAccruedExpensesandOtherLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/SupplementalFinancialInformationScheduleofAccruedExpensesandOtherLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_SupplementalFinancialInformationAbstract_b64c6a0e-3dde-43b3-a730-f6f0228be6ce" xlink:href="rxrx-20240331.xsd#rxrx_SupplementalFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_137fae60-64dc-44ab-a456-a5c98bca1d6a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rxrx_SupplementalFinancialInformationAbstract_b64c6a0e-3dde-43b3-a730-f6f0228be6ce" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_137fae60-64dc-44ab-a456-a5c98bca1d6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_AccruedDevelopmentCostsCurrent_82b04fb5-e178-4f05-aef6-dbc27828060a" xlink:href="rxrx-20240331.xsd#rxrx_AccruedDevelopmentCostsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rxrx_SupplementalFinancialInformationAbstract_b64c6a0e-3dde-43b3-a730-f6f0228be6ce" xlink:to="loc_rxrx_AccruedDevelopmentCostsCurrent_82b04fb5-e178-4f05-aef6-dbc27828060a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_AccruedEarlyDiscoveryExpensesCurrent_74e89296-dd36-4a89-909a-ebeea027c9fe" xlink:href="rxrx-20240331.xsd#rxrx_AccruedEarlyDiscoveryExpensesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rxrx_SupplementalFinancialInformationAbstract_b64c6a0e-3dde-43b3-a730-f6f0228be6ce" xlink:to="loc_rxrx_AccruedEarlyDiscoveryExpensesCurrent_74e89296-dd36-4a89-909a-ebeea027c9fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionPayableCurrent_68d3d554-6504-4a65-9e8a-eb453955a81c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionPayableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rxrx_SupplementalFinancialInformationAbstract_b64c6a0e-3dde-43b3-a730-f6f0228be6ce" xlink:to="loc_us-gaap_ConstructionPayableCurrent_68d3d554-6504-4a65-9e8a-eb453955a81c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_MaterialsReceivedNotInvoiced_6397b877-ccf0-44c8-bddd-6024ae386933" xlink:href="rxrx-20240331.xsd#rxrx_MaterialsReceivedNotInvoiced"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rxrx_SupplementalFinancialInformationAbstract_b64c6a0e-3dde-43b3-a730-f6f0228be6ce" xlink:to="loc_rxrx_MaterialsReceivedNotInvoiced_6397b877-ccf0-44c8-bddd-6024ae386933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_0dafd94c-ec37-43a2-aeb6-548116efc08b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rxrx_SupplementalFinancialInformationAbstract_b64c6a0e-3dde-43b3-a730-f6f0228be6ce" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_0dafd94c-ec37-43a2-aeb6-548116efc08b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_fc8b3d5e-0a39-40e9-9977-aaca6a324be0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rxrx_SupplementalFinancialInformationAbstract_b64c6a0e-3dde-43b3-a730-f6f0228be6ce" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_fc8b3d5e-0a39-40e9-9977-aaca6a324be0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/SupplementalFinancialInformationScheduleofInterestIncomeandExpenseDisclosureDetails" xlink:type="simple" xlink:href="rxrx-20240331.xsd#SupplementalFinancialInformationScheduleofInterestIncomeandExpenseDisclosureDetails"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/SupplementalFinancialInformationScheduleofInterestIncomeandExpenseDisclosureDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_SupplementalFinancialInformationAbstract_1cab316d-7ea9-4db1-a404-6e650fc1571b" xlink:href="rxrx-20240331.xsd#rxrx_SupplementalFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNonoperating_776b9f82-5217-49ac-b984-448b6b787ada" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeNonoperating"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rxrx_SupplementalFinancialInformationAbstract_1cab316d-7ea9-4db1-a404-6e650fc1571b" xlink:to="loc_us-gaap_InvestmentIncomeNonoperating_776b9f82-5217-49ac-b984-448b6b787ada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_93d3ec4d-4b93-43ca-99a8-c280b9048b43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rxrx_SupplementalFinancialInformationAbstract_1cab316d-7ea9-4db1-a404-6e650fc1571b" xlink:to="loc_us-gaap_InterestExpense_93d3ec4d-4b93-43ca-99a8-c280b9048b43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRevenueExpenseNet_a3493516-4d65-4729-b171-15734d5c3531" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestRevenueExpenseNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rxrx_SupplementalFinancialInformationAbstract_1cab316d-7ea9-4db1-a404-6e650fc1571b" xlink:to="loc_us-gaap_InterestRevenueExpenseNet_a3493516-4d65-4729-b171-15734d5c3531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/AcquisitionsNarrativeDetails" xlink:type="simple" xlink:href="rxrx-20240331.xsd#AcquisitionsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/AcquisitionsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_7ad054ae-8ff9-4514-ab8e-0cb30d3a7c30" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e39be7d7-9499-4abf-9b19-fc854da1fc75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_7ad054ae-8ff9-4514-ab8e-0cb30d3a7c30" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e39be7d7-9499-4abf-9b19-fc854da1fc75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_b02d9822-220f-4500-9f66-30db3c9f5a89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e39be7d7-9499-4abf-9b19-fc854da1fc75" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_b02d9822-220f-4500-9f66-30db3c9f5a89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dcb6cd84-2222-498b-81cb-988151bf4681" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b02d9822-220f-4500-9f66-30db3c9f5a89" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dcb6cd84-2222-498b-81cb-988151bf4681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_ValenceDiscoveryIncMember_7588e6d3-2458-431d-a679-7d27effe4f64" xlink:href="rxrx-20240331.xsd#rxrx_ValenceDiscoveryIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dcb6cd84-2222-498b-81cb-988151bf4681" xlink:to="loc_rxrx_ValenceDiscoveryIncMember_7588e6d3-2458-431d-a679-7d27effe4f64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_CyclicaIncMember_3293145f-5e47-413d-a26c-bf05c5f906d9" xlink:href="rxrx-20240331.xsd#rxrx_CyclicaIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dcb6cd84-2222-498b-81cb-988151bf4681" xlink:to="loc_rxrx_CyclicaIncMember_3293145f-5e47-413d-a26c-bf05c5f906d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_587d1d60-e792-41e8-b657-3674fa5787cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e39be7d7-9499-4abf-9b19-fc854da1fc75" xlink:to="loc_us-gaap_StatementClassOfStockAxis_587d1d60-e792-41e8-b657-3674fa5787cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_0d419164-08a1-4036-a9de-8cc82ee9e5c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_587d1d60-e792-41e8-b657-3674fa5787cf" xlink:to="loc_us-gaap_ClassOfStockDomain_0d419164-08a1-4036-a9de-8cc82ee9e5c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_f79eefaf-94df-41eb-8dd9-2d9b98e9c466" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_0d419164-08a1-4036-a9de-8cc82ee9e5c3" xlink:to="loc_us-gaap_CommonClassAMember_f79eefaf-94df-41eb-8dd9-2d9b98e9c466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_ExchangeableStockMember_63bf0ad5-c303-4b24-bff4-209b4b1d9c3d" xlink:href="rxrx-20240331.xsd#rxrx_ExchangeableStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_0d419164-08a1-4036-a9de-8cc82ee9e5c3" xlink:to="loc_rxrx_ExchangeableStockMember_63bf0ad5-c303-4b24-bff4-209b4b1d9c3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_bb5e754e-f0d1-4efb-8481-ca764bdfb471" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e39be7d7-9499-4abf-9b19-fc854da1fc75" xlink:to="loc_us-gaap_AwardTypeAxis_bb5e754e-f0d1-4efb-8481-ca764bdfb471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c056d1a7-5cf9-406c-bffa-39690193d848" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_bb5e754e-f0d1-4efb-8481-ca764bdfb471" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c056d1a7-5cf9-406c-bffa-39690193d848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_ef878181-1cca-4a98-9b05-bfc44c4c395d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c056d1a7-5cf9-406c-bffa-39690193d848" xlink:to="loc_us-gaap_EmployeeStockOptionMember_ef878181-1cca-4a98-9b05-bfc44c4c395d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f5522afe-7b32-4884-85d5-b58b392f4001" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e39be7d7-9499-4abf-9b19-fc854da1fc75" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f5522afe-7b32-4884-85d5-b58b392f4001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_390ea392-b597-4bf4-b1b0-758b1503bb4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f5522afe-7b32-4884-85d5-b58b392f4001" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_390ea392-b597-4bf4-b1b0-758b1503bb4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_248b23c4-41bf-41d1-b76e-062d4c95ec21" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_390ea392-b597-4bf4-b1b0-758b1503bb4e" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_248b23c4-41bf-41d1-b76e-062d4c95ec21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_a878aaed-96fd-4ca1-a526-8befce75c2e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e39be7d7-9499-4abf-9b19-fc854da1fc75" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_a878aaed-96fd-4ca1-a526-8befce75c2e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_718d4dde-adc8-444a-8e8d-33adf51e0f9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a878aaed-96fd-4ca1-a526-8befce75c2e1" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_718d4dde-adc8-444a-8e8d-33adf51e0f9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_6f9c407f-083c-4670-b077-055456907306" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a878aaed-96fd-4ca1-a526-8befce75c2e1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_6f9c407f-083c-4670-b077-055456907306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_b13769b1-b513-4933-b8cb-3d94c67c33f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a878aaed-96fd-4ca1-a526-8befce75c2e1" xlink:to="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_b13769b1-b513-4933-b8cb-3d94c67c33f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_a69b6ad2-c172-4e4f-a492-dc905a9693d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a878aaed-96fd-4ca1-a526-8befce75c2e1" xlink:to="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_a69b6ad2-c172-4e4f-a492-dc905a9693d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails" xlink:type="simple" xlink:href="rxrx-20240331.xsd#AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_beb9553b-1a57-4e9a-ac4c-9c7991015a1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d6af3e9f-b156-4c62-9b74-bb8f46253f21" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_beb9553b-1a57-4e9a-ac4c-9c7991015a1c" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d6af3e9f-b156-4c62-9b74-bb8f46253f21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_febf126e-8c88-4830-b7f3-d032c966e833" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d6af3e9f-b156-4c62-9b74-bb8f46253f21" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_febf126e-8c88-4830-b7f3-d032c966e833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bbb6dd71-a636-483a-9421-a46768c7868e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_febf126e-8c88-4830-b7f3-d032c966e833" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bbb6dd71-a636-483a-9421-a46768c7868e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_ValenceDiscoveryIncMember_b343415f-c739-4163-a8bd-b9856ad1ea62" xlink:href="rxrx-20240331.xsd#rxrx_ValenceDiscoveryIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bbb6dd71-a636-483a-9421-a46768c7868e" xlink:to="loc_rxrx_ValenceDiscoveryIncMember_b343415f-c739-4163-a8bd-b9856ad1ea62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_CyclicaIncMember_1691fb04-6470-46c1-863a-01f9b211db57" xlink:href="rxrx-20240331.xsd#rxrx_CyclicaIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bbb6dd71-a636-483a-9421-a46768c7868e" xlink:to="loc_rxrx_CyclicaIncMember_1691fb04-6470-46c1-863a-01f9b211db57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_b564e6b1-7645-461e-bd3b-de1e683bf1ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d6af3e9f-b156-4c62-9b74-bb8f46253f21" xlink:to="loc_us-gaap_StatementClassOfStockAxis_b564e6b1-7645-461e-bd3b-de1e683bf1ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_2ca74160-f94c-433e-a4fe-422f9b5a18fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_b564e6b1-7645-461e-bd3b-de1e683bf1ff" xlink:to="loc_us-gaap_ClassOfStockDomain_2ca74160-f94c-433e-a4fe-422f9b5a18fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_ba997ae1-0a62-4461-8536-8445023af7ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_2ca74160-f94c-433e-a4fe-422f9b5a18fa" xlink:to="loc_us-gaap_CommonClassAMember_ba997ae1-0a62-4461-8536-8445023af7ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_ExchangeableStockMember_c2a09031-2e56-44c7-b326-ce2225eeecb5" xlink:href="rxrx-20240331.xsd#rxrx_ExchangeableStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_2ca74160-f94c-433e-a4fe-422f9b5a18fa" xlink:to="loc_rxrx_ExchangeableStockMember_c2a09031-2e56-44c7-b326-ce2225eeecb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_cfbcf733-6401-4914-8db4-cbee81f11e04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d6af3e9f-b156-4c62-9b74-bb8f46253f21" xlink:to="loc_us-gaap_AwardTypeAxis_cfbcf733-6401-4914-8db4-cbee81f11e04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1aa9e925-30c6-4c4e-a4d4-5b8a2ffb5b64" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_cfbcf733-6401-4914-8db4-cbee81f11e04" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1aa9e925-30c6-4c4e-a4d4-5b8a2ffb5b64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_2c3f4602-9722-4c8d-b0d3-599ebe572a6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1aa9e925-30c6-4c4e-a4d4-5b8a2ffb5b64" xlink:to="loc_us-gaap_EmployeeStockMember_2c3f4602-9722-4c8d-b0d3-599ebe572a6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_78576679-672c-439d-b804-0af81ac5e089" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d6af3e9f-b156-4c62-9b74-bb8f46253f21" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_78576679-672c-439d-b804-0af81ac5e089" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_BusinessCombinationConsiderationTransferredEquityInterestsIssuable_12e120e0-211e-4e08-ab3a-ac41783381df" xlink:href="rxrx-20240331.xsd#rxrx_BusinessCombinationConsiderationTransferredEquityInterestsIssuable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_78576679-672c-439d-b804-0af81ac5e089" xlink:to="loc_rxrx_BusinessCombinationConsiderationTransferredEquityInterestsIssuable_12e120e0-211e-4e08-ab3a-ac41783381df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_71df390c-7b3f-4ceb-875e-ad64cec1a03c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_78576679-672c-439d-b804-0af81ac5e089" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_71df390c-7b3f-4ceb-875e-ad64cec1a03c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_37fee5a0-aab1-46d2-ae3a-175aac30a86e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_78576679-672c-439d-b804-0af81ac5e089" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_37fee5a0-aab1-46d2-ae3a-175aac30a86e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_1d93c8e2-7197-4150-91b4-41097f939802" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_78576679-672c-439d-b804-0af81ac5e089" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_1d93c8e2-7197-4150-91b4-41097f939802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/AcquisitionsScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="rxrx-20240331.xsd#AcquisitionsScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/AcquisitionsScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_6cdf1a05-96c7-4d61-9ec7-930a3bc356f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_59e9162b-3509-4f5d-be3a-ffbb9d7e6729" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_6cdf1a05-96c7-4d61-9ec7-930a3bc356f0" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_59e9162b-3509-4f5d-be3a-ffbb9d7e6729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_8579f34a-ccb1-4994-a9b9-cf39d90168f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_59e9162b-3509-4f5d-be3a-ffbb9d7e6729" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_8579f34a-ccb1-4994-a9b9-cf39d90168f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ae97e7fc-cc84-4f6e-8a3a-c70758efc865" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8579f34a-ccb1-4994-a9b9-cf39d90168f7" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ae97e7fc-cc84-4f6e-8a3a-c70758efc865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_ValenceDiscoveryIncMember_e110d171-920e-4d0c-922e-f50c0b6c0f89" xlink:href="rxrx-20240331.xsd#rxrx_ValenceDiscoveryIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ae97e7fc-cc84-4f6e-8a3a-c70758efc865" xlink:to="loc_rxrx_ValenceDiscoveryIncMember_e110d171-920e-4d0c-922e-f50c0b6c0f89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_CyclicaIncMember_fe796747-263c-4859-ad36-d560444a0f9b" xlink:href="rxrx-20240331.xsd#rxrx_CyclicaIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ae97e7fc-cc84-4f6e-8a3a-c70758efc865" xlink:to="loc_rxrx_CyclicaIncMember_fe796747-263c-4859-ad36-d560444a0f9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_70cac2d7-bcd0-45e3-a08b-6e256f0b8897" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_59e9162b-3509-4f5d-be3a-ffbb9d7e6729" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_70cac2d7-bcd0-45e3-a08b-6e256f0b8897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_e5c0db03-8201-4feb-9868-7a5beffff554" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_70cac2d7-bcd0-45e3-a08b-6e256f0b8897" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_e5c0db03-8201-4feb-9868-7a5beffff554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_479dfe44-10d5-4648-a7ec-a346940d8d47" xlink:href="rxrx-20240331.xsd#rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_70cac2d7-bcd0-45e3-a08b-6e256f0b8897" xlink:to="loc_rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_479dfe44-10d5-4648-a7ec-a346940d8d47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherReceivables_79996c78-cc12-4820-9735-2146ad9da2a7" xlink:href="rxrx-20240331.xsd#rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherReceivables"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_70cac2d7-bcd0-45e3-a08b-6e256f0b8897" xlink:to="loc_rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherReceivables_79996c78-cc12-4820-9735-2146ad9da2a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInvestments_0bcdcc5e-a872-487e-a773-955cd8a67de5" xlink:href="rxrx-20240331.xsd#rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_70cac2d7-bcd0-45e3-a08b-6e256f0b8897" xlink:to="loc_rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInvestments_0bcdcc5e-a872-487e-a773-955cd8a67de5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_702db540-47d1-4eb1-b45c-27466e3a673b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_70cac2d7-bcd0-45e3-a08b-6e256f0b8897" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_702db540-47d1-4eb1-b45c-27466e3a673b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_d4b4567e-7ca1-47fe-8937-2cafdb40574c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_70cac2d7-bcd0-45e3-a08b-6e256f0b8897" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_d4b4567e-7ca1-47fe-8937-2cafdb40574c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_acb224b7-7e70-48b7-be42-f3e988e82f30" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_70cac2d7-bcd0-45e3-a08b-6e256f0b8897" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_acb224b7-7e70-48b7-be42-f3e988e82f30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_cd5320c0-5e1c-417c-9aac-4ac469b88952" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_70cac2d7-bcd0-45e3-a08b-6e256f0b8897" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_cd5320c0-5e1c-417c-9aac-4ac469b88952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_0e60bbb9-abaf-41ee-a4a6-9f2c979a87e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_70cac2d7-bcd0-45e3-a08b-6e256f0b8897" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_0e60bbb9-abaf-41ee-a4a6-9f2c979a87e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilitiesCurrent_ded667b6-a111-4665-8467-8ff887270d86" xlink:href="rxrx-20240331.xsd#rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilitiesCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_70cac2d7-bcd0-45e3-a08b-6e256f0b8897" xlink:to="loc_rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilitiesCurrent_ded667b6-a111-4665-8467-8ff887270d86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_fc781c30-de37-4fd7-88c0-5f8af2dc5d4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_70cac2d7-bcd0-45e3-a08b-6e256f0b8897" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_fc781c30-de37-4fd7-88c0-5f8af2dc5d4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_8a74e3a2-dc49-489d-862a-3a740d827a02" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_70cac2d7-bcd0-45e3-a08b-6e256f0b8897" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_8a74e3a2-dc49-489d-862a-3a740d827a02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_d65ecbea-fc93-4d3a-bf15-6599518c002f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_70cac2d7-bcd0-45e3-a08b-6e256f0b8897" xlink:to="loc_us-gaap_Goodwill_d65ecbea-fc93-4d3a-bf15-6599518c002f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_b0dbf25a-281b-48f9-b268-ea2fc5bf4a9f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_70cac2d7-bcd0-45e3-a08b-6e256f0b8897" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_b0dbf25a-281b-48f9-b268-ea2fc5bf4a9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/AcquisitionsScheduleofBusinessAcquisitionsProFormaInformationDetails" xlink:type="simple" xlink:href="rxrx-20240331.xsd#AcquisitionsScheduleofBusinessAcquisitionsProFormaInformationDetails"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/AcquisitionsScheduleofBusinessAcquisitionsProFormaInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_653aff68-ef8a-409c-b508-30b4c4ccdf7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2774c8ef-923d-4ed7-85c7-093cc57d41b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_653aff68-ef8a-409c-b508-30b4c4ccdf7c" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2774c8ef-923d-4ed7-85c7-093cc57d41b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_f2a5ad9d-d0d0-4adf-81de-44bb6dd602a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2774c8ef-923d-4ed7-85c7-093cc57d41b5" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_f2a5ad9d-d0d0-4adf-81de-44bb6dd602a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7508f245-e193-44a1-871a-81b13db3f2cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f2a5ad9d-d0d0-4adf-81de-44bb6dd602a9" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7508f245-e193-44a1-871a-81b13db3f2cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_RecursionValenceAndCyclicaMember_6826806d-c806-4bbe-849a-e98f47645dbf" xlink:href="rxrx-20240331.xsd#rxrx_RecursionValenceAndCyclicaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7508f245-e193-44a1-871a-81b13db3f2cf" xlink:to="loc_rxrx_RecursionValenceAndCyclicaMember_6826806d-c806-4bbe-849a-e98f47645dbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_f3373a70-9e5b-46bf-8bb1-7efcd6284459" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2774c8ef-923d-4ed7-85c7-093cc57d41b5" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_f3373a70-9e5b-46bf-8bb1-7efcd6284459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_58a4d389-d11e-424e-859f-87daee55650a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f3373a70-9e5b-46bf-8bb1-7efcd6284459" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_58a4d389-d11e-424e-859f-87daee55650a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_7ae3ebca-ada7-4326-a948-164a1d289364" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f3373a70-9e5b-46bf-8bb1-7efcd6284459" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_7ae3ebca-ada7-4326-a948-164a1d289364" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="rxrx-20240331.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_4a3db43e-68ea-4bc9-ae48-80561ee2d1c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_e0498a31-7fb1-4507-a20b-a6f3fffad392" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4a3db43e-68ea-4bc9-ae48-80561ee2d1c5" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_e0498a31-7fb1-4507-a20b-a6f3fffad392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3ab07d62-035f-4e26-beeb-bb1776db48a8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_e0498a31-7fb1-4507-a20b-a6f3fffad392" xlink:to="loc_srt_RangeAxis_3ab07d62-035f-4e26-beeb-bb1776db48a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2b84119e-efe2-414a-9076-27f6a7680585" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_3ab07d62-035f-4e26-beeb-bb1776db48a8" xlink:to="loc_srt_RangeMember_2b84119e-efe2-414a-9076-27f6a7680585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ac5b02de-9885-43a6-a05b-b0d347df1d44" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2b84119e-efe2-414a-9076-27f6a7680585" xlink:to="loc_srt_MinimumMember_ac5b02de-9885-43a6-a05b-b0d347df1d44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a087bccc-f412-4322-a6dc-a93e2167d86b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2b84119e-efe2-414a-9076-27f6a7680585" xlink:to="loc_srt_MaximumMember_a087bccc-f412-4322-a6dc-a93e2167d86b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_LeaseDescriptionAxis_9af96d2c-e8b7-4905-b415-9c011c649501" xlink:href="rxrx-20240331.xsd#rxrx_LeaseDescriptionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_e0498a31-7fb1-4507-a20b-a6f3fffad392" xlink:to="loc_rxrx_LeaseDescriptionAxis_9af96d2c-e8b7-4905-b415-9c011c649501" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_LeaseDescriptionDomain_a71e2e59-3021-4662-b2dc-6a0d44834d61" xlink:href="rxrx-20240331.xsd#rxrx_LeaseDescriptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rxrx_LeaseDescriptionAxis_9af96d2c-e8b7-4905-b415-9c011c649501" xlink:to="loc_rxrx_LeaseDescriptionDomain_a71e2e59-3021-4662-b2dc-6a0d44834d61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_LondonLeaseMember_0bc957e7-4580-41d1-9e9c-1d2fe48851e6" xlink:href="rxrx-20240331.xsd#rxrx_LondonLeaseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rxrx_LeaseDescriptionDomain_a71e2e59-3021-4662-b2dc-6a0d44834d61" xlink:to="loc_rxrx_LondonLeaseMember_0bc957e7-4580-41d1-9e9c-1d2fe48851e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_DataCenterLeaseMember_a69c1965-cb34-432f-a9d1-2b2d7f8130ee" xlink:href="rxrx-20240331.xsd#rxrx_DataCenterLeaseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rxrx_LeaseDescriptionDomain_a71e2e59-3021-4662-b2dc-6a0d44834d61" xlink:to="loc_rxrx_DataCenterLeaseMember_a69c1965-cb34-432f-a9d1-2b2d7f8130ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_fa53d88e-651d-4723-ad16-6aad5356ffbc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_e0498a31-7fb1-4507-a20b-a6f3fffad392" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_fa53d88e-651d-4723-ad16-6aad5356ffbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_b7eee4fb-8b1a-48d2-89bd-19a25049556e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fa53d88e-651d-4723-ad16-6aad5356ffbc" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_b7eee4fb-8b1a-48d2-89bd-19a25049556e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_a066626a-b7ac-43b8-bc16-66159c492263" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fa53d88e-651d-4723-ad16-6aad5356ffbc" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_a066626a-b7ac-43b8-bc16-66159c492263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_f1466601-2c3f-4d3d-b2dc-7aac03746e68" xlink:href="rxrx-20240331.xsd#rxrx_IncreaseDecreaseInOperatingLeaseRightOfUseAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fa53d88e-651d-4723-ad16-6aad5356ffbc" xlink:to="loc_rxrx_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_f1466601-2c3f-4d3d-b2dc-7aac03746e68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_LesseeOperatingLeaseIncreaseDecreaseInOperatingLeaseLiabilityDueToLeaseModifications_b25aa820-a7d4-4819-b0e2-7867bf2d3d11" xlink:href="rxrx-20240331.xsd#rxrx_LesseeOperatingLeaseIncreaseDecreaseInOperatingLeaseLiabilityDueToLeaseModifications"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fa53d88e-651d-4723-ad16-6aad5356ffbc" xlink:to="loc_rxrx_LesseeOperatingLeaseIncreaseDecreaseInOperatingLeaseLiabilityDueToLeaseModifications_b25aa820-a7d4-4819-b0e2-7867bf2d3d11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_LesseeOperatingLeaseSquareFootageOfLeasedSpace_6e8b9a8e-4e2c-41da-819e-06ec617d5c24" xlink:href="rxrx-20240331.xsd#rxrx_LesseeOperatingLeaseSquareFootageOfLeasedSpace"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fa53d88e-651d-4723-ad16-6aad5356ffbc" xlink:to="loc_rxrx_LesseeOperatingLeaseSquareFootageOfLeasedSpace_6e8b9a8e-4e2c-41da-819e-06ec617d5c24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_c6ece238-f1ca-43e3-a76a-5c38d196953c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fa53d88e-651d-4723-ad16-6aad5356ffbc" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_c6ece238-f1ca-43e3-a76a-5c38d196953c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_96329908-7b3f-4fc1-95ea-3f2405f2de22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fa53d88e-651d-4723-ad16-6aad5356ffbc" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_96329908-7b3f-4fc1-95ea-3f2405f2de22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/LeasesComponentsofLeaseCostDetails" xlink:type="simple" xlink:href="rxrx-20240331.xsd#LeasesComponentsofLeaseCostDetails"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/LeasesComponentsofLeaseCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_ea71cbd9-f2a9-4f7a-8df5-dfe3050af83d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_bb895c0a-744a-44a5-b5a7-5fb8e679a7b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ea71cbd9-f2a9-4f7a-8df5-dfe3050af83d" xlink:to="loc_us-gaap_OperatingLeaseCost_bb895c0a-744a-44a5-b5a7-5fb8e679a7b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_055d5196-8a6c-4258-84d4-5e708795d96a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ea71cbd9-f2a9-4f7a-8df5-dfe3050af83d" xlink:to="loc_us-gaap_VariableLeaseCost_055d5196-8a6c-4258-84d4-5e708795d96a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_e9ef6f5a-5387-4c08-9693-ab4214bba7e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ea71cbd9-f2a9-4f7a-8df5-dfe3050af83d" xlink:to="loc_us-gaap_ShortTermLeaseCost_e9ef6f5a-5387-4c08-9693-ab4214bba7e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_91629d2a-5014-4d57-a8a0-6231ba1f3752" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ea71cbd9-f2a9-4f7a-8df5-dfe3050af83d" xlink:to="loc_us-gaap_LeaseCost_91629d2a-5014-4d57-a8a0-6231ba1f3752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/LeasesLeaseTermandDiscountRatesDetails" xlink:type="simple" xlink:href="rxrx-20240331.xsd#LeasesLeaseTermandDiscountRatesDetails"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/LeasesLeaseTermandDiscountRatesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_9f310777-f55e-4a22-8218-e3e2b5f1f488" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_1e9195f5-29a9-4bec-8423-d7bdf9327747" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9f310777-f55e-4a22-8218-e3e2b5f1f488" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_1e9195f5-29a9-4bec-8423-d7bdf9327747" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_bbae13d2-ab8a-4884-9e8c-9ecb1e0e469b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9f310777-f55e-4a22-8218-e3e2b5f1f488" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_bbae13d2-ab8a-4884-9e8c-9ecb1e0e469b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="rxrx-20240331.xsd#LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_e1ac087c-1531-47bb-a720-3b7a11262267" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_c21632b1-9773-45d5-9a23-d325eb5178ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e1ac087c-1531-47bb-a720-3b7a11262267" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_c21632b1-9773-45d5-9a23-d325eb5178ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_297b3281-af06-402c-82a9-bb1ed033dfd2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e1ac087c-1531-47bb-a720-3b7a11262267" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_297b3281-af06-402c-82a9-bb1ed033dfd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2da56ce9-0dbb-48d2-9a31-d2245120941c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e1ac087c-1531-47bb-a720-3b7a11262267" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2da56ce9-0dbb-48d2-9a31-d2245120941c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_c9154846-3986-4971-a411-3e8210ee08fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e1ac087c-1531-47bb-a720-3b7a11262267" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_c9154846-3986-4971-a411-3e8210ee08fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_d6495321-9ebf-421e-a484-9c0053b85a73" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e1ac087c-1531-47bb-a720-3b7a11262267" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_d6495321-9ebf-421e-a484-9c0053b85a73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour_48227853-4f52-4a04-9272-28c812db8143" xlink:href="rxrx-20240331.xsd#rxrx_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e1ac087c-1531-47bb-a720-3b7a11262267" xlink:to="loc_rxrx_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour_48227853-4f52-4a04-9272-28c812db8143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_eea8abb7-d6e6-4a13-a11b-4a56d87b781c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e1ac087c-1531-47bb-a720-3b7a11262267" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_eea8abb7-d6e6-4a13-a11b-4a56d87b781c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1c9e157c-a5e0-4122-8910-7c9fadb88f86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e1ac087c-1531-47bb-a720-3b7a11262267" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1c9e157c-a5e0-4122-8910-7c9fadb88f86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_c265317d-6ed3-418f-8ff9-42bc980921ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e1ac087c-1531-47bb-a720-3b7a11262267" xlink:to="loc_us-gaap_OperatingLeaseLiability_c265317d-6ed3-418f-8ff9-42bc980921ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/GoodwillandIntangibleAssetsDetails" xlink:type="simple" xlink:href="rxrx-20240331.xsd#GoodwillandIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/GoodwillandIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0dc79975-12e6-4507-bfa0-ef144d272abf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPeriodIncreaseDecrease_49eb56d4-c27a-4e32-a0a6-62a920cf4a50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillPeriodIncreaseDecrease"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0dc79975-12e6-4507-bfa0-ef144d272abf" xlink:to="loc_us-gaap_GoodwillPeriodIncreaseDecrease_49eb56d4-c27a-4e32-a0a6-62a920cf4a50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_eee56e1e-b198-4196-9867-76b6f801d4ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0dc79975-12e6-4507-bfa0-ef144d272abf" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_eee56e1e-b198-4196-9867-76b6f801d4ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_46e15a9f-75c0-4dda-83a0-2dc83c7d0440" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0dc79975-12e6-4507-bfa0-ef144d272abf" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_46e15a9f-75c0-4dda-83a0-2dc83c7d0440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_a682f23a-7be4-4c5b-b775-d03d4b2b2d48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_46e15a9f-75c0-4dda-83a0-2dc83c7d0440" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_a682f23a-7be4-4c5b-b775-d03d4b2b2d48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_eb67f588-f29e-4dc9-b1f1-5e9f1c565726" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_46e15a9f-75c0-4dda-83a0-2dc83c7d0440" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_eb67f588-f29e-4dc9-b1f1-5e9f1c565726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_cfb42a99-72a2-4b37-898d-0b630a19a910" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_46e15a9f-75c0-4dda-83a0-2dc83c7d0440" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_cfb42a99-72a2-4b37-898d-0b630a19a910" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_c1545e41-7694-4caa-9612-3524e4fa2aa3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_46e15a9f-75c0-4dda-83a0-2dc83c7d0440" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_c1545e41-7694-4caa-9612-3524e4fa2aa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_c480434f-e326-4792-b801-04d458723117" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_46e15a9f-75c0-4dda-83a0-2dc83c7d0440" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_c480434f-e326-4792-b801-04d458723117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_053e5e53-eaa5-4398-97d1-94e43cbedc7d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_46e15a9f-75c0-4dda-83a0-2dc83c7d0440" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_053e5e53-eaa5-4398-97d1-94e43cbedc7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_06b4792d-6faa-4c5a-a251-6f67dce27d86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0dc79975-12e6-4507-bfa0-ef144d272abf" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_06b4792d-6faa-4c5a-a251-6f67dce27d86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_42554335-7618-40e5-a511-0e8bf3020b61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0dc79975-12e6-4507-bfa0-ef144d272abf" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_42554335-7618-40e5-a511-0e8bf3020b61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="rxrx-20240331.xsd#CommitmentsandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b4d6160a-df05-4f37-8496-ffeb02207de5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_0c0f0c38-90e9-4f60-887c-f35c4d3ce659" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b4d6160a-df05-4f37-8496-ffeb02207de5" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_0c0f0c38-90e9-4f60-887c-f35c4d3ce659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_398320f0-ba84-469c-9a5e-c58841ce9fdd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b4d6160a-df05-4f37-8496-ffeb02207de5" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_398320f0-ba84-469c-9a5e-c58841ce9fdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/CommonStockDetails" xlink:type="simple" xlink:href="rxrx-20240331.xsd#CommonStockDetails"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/CommonStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_05ffe721-fc7f-4c4d-b848-19cad0a46578" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_fb945117-1563-4241-a2c5-7f28e529010d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_05ffe721-fc7f-4c4d-b848-19cad0a46578" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_fb945117-1563-4241-a2c5-7f28e529010d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_eabf216e-fd6d-45bc-a3ec-8ea18a0a4bdf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_fb945117-1563-4241-a2c5-7f28e529010d" xlink:to="loc_us-gaap_StatementClassOfStockAxis_eabf216e-fd6d-45bc-a3ec-8ea18a0a4bdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_14e8a563-4e48-461f-8769-586e4acb64cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_eabf216e-fd6d-45bc-a3ec-8ea18a0a4bdf" xlink:to="loc_us-gaap_ClassOfStockDomain_14e8a563-4e48-461f-8769-586e4acb64cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_d52b5643-cb1f-422c-b454-7b23c8885eac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_14e8a563-4e48-461f-8769-586e4acb64cf" xlink:to="loc_us-gaap_CommonClassAMember_d52b5643-cb1f-422c-b454-7b23c8885eac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_007cfa69-88d1-4976-8851-d906f9eb0485" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_14e8a563-4e48-461f-8769-586e4acb64cf" xlink:to="loc_us-gaap_CommonClassBMember_007cfa69-88d1-4976-8851-d906f9eb0485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_ExchangeableStockMember_12197ccb-cd0a-4e56-b42c-6d93232450e8" xlink:href="rxrx-20240331.xsd#rxrx_ExchangeableStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_14e8a563-4e48-461f-8769-586e4acb64cf" xlink:to="loc_rxrx_ExchangeableStockMember_12197ccb-cd0a-4e56-b42c-6d93232450e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_6b6b4939-e803-4168-8a3e-a3e2c8c825a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_fb945117-1563-4241-a2c5-7f28e529010d" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_6b6b4939-e803-4168-8a3e-a3e2c8c825a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d739d0c3-bc20-4a8a-a7dd-ace88e431266" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_6b6b4939-e803-4168-8a3e-a3e2c8c825a4" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d739d0c3-bc20-4a8a-a7dd-ace88e431266" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_AtTheMarketOfferingProgramMember_139857dd-4453-44f8-a48d-eb4613126e7b" xlink:href="rxrx-20240331.xsd#rxrx_AtTheMarketOfferingProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d739d0c3-bc20-4a8a-a7dd-ace88e431266" xlink:to="loc_rxrx_AtTheMarketOfferingProgramMember_139857dd-4453-44f8-a48d-eb4613126e7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_NVDIAPrivatePlacementMember_c7678bc2-f14a-4270-bf50-387248fa2d1c" xlink:href="rxrx-20240331.xsd#rxrx_NVDIAPrivatePlacementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d739d0c3-bc20-4a8a-a7dd-ace88e431266" xlink:to="loc_rxrx_NVDIAPrivatePlacementMember_c7678bc2-f14a-4270-bf50-387248fa2d1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_5a4ecfcf-9cc9-4eb4-9545-62cf93239bb4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_fb945117-1563-4241-a2c5-7f28e529010d" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_5a4ecfcf-9cc9-4eb4-9545-62cf93239bb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_36da7113-00be-4231-993c-a4402fa1c511" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_5a4ecfcf-9cc9-4eb4-9545-62cf93239bb4" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_36da7113-00be-4231-993c-a4402fa1c511" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_ValenceDiscoveryIncMember_2ad64345-b08d-46fc-833d-1b749859e397" xlink:href="rxrx-20240331.xsd#rxrx_ValenceDiscoveryIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_36da7113-00be-4231-993c-a4402fa1c511" xlink:to="loc_rxrx_ValenceDiscoveryIncMember_2ad64345-b08d-46fc-833d-1b749859e397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_cff20487-e69e-448c-b613-043de16a32b9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_fb945117-1563-4241-a2c5-7f28e529010d" xlink:to="loc_srt_RangeAxis_cff20487-e69e-448c-b613-043de16a32b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_92b86ab0-868b-4b86-bc48-d17450f1ff9c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_cff20487-e69e-448c-b613-043de16a32b9" xlink:to="loc_srt_RangeMember_92b86ab0-868b-4b86-bc48-d17450f1ff9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e76f1cc3-356d-47d6-b6c6-087c16294d7f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_92b86ab0-868b-4b86-bc48-d17450f1ff9c" xlink:to="loc_srt_MaximumMember_e76f1cc3-356d-47d6-b6c6-087c16294d7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3836f680-304c-4b7e-b359-03172a47cc18" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_fb945117-1563-4241-a2c5-7f28e529010d" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3836f680-304c-4b7e-b359-03172a47cc18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_29af5997-c43f-4c35-bbb9-247707624054" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3836f680-304c-4b7e-b359-03172a47cc18" xlink:to="loc_us-gaap_RelatedPartyDomain_29af5997-c43f-4c35-bbb9-247707624054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_ChristopherGibsonAndAffiliatesMember_48055370-cf9a-4753-90fc-d8d3ac9a6b08" xlink:href="rxrx-20240331.xsd#rxrx_ChristopherGibsonAndAffiliatesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_29af5997-c43f-4c35-bbb9-247707624054" xlink:to="loc_rxrx_ChristopherGibsonAndAffiliatesMember_48055370-cf9a-4753-90fc-d8d3ac9a6b08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_eae82d41-c8f4-4ccd-83c9-7cd5a7bf883b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_fb945117-1563-4241-a2c5-7f28e529010d" xlink:to="loc_us-gaap_ClassOfStockLineItems_eae82d41-c8f4-4ccd-83c9-7cd5a7bf883b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_CommonStockVotePerShare_157fe40b-5ca0-4406-8afa-81e7652637b0" xlink:href="rxrx-20240331.xsd#rxrx_CommonStockVotePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_eae82d41-c8f4-4ccd-83c9-7cd5a7bf883b" xlink:to="loc_rxrx_CommonStockVotePerShare_157fe40b-5ca0-4406-8afa-81e7652637b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsStock_8b67ef57-cf2d-438a-8347-3c92eb8fa3c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_eae82d41-c8f4-4ccd-83c9-7cd5a7bf883b" xlink:to="loc_us-gaap_DividendsStock_8b67ef57-cf2d-438a-8347-3c92eb8fa3c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_SaleOfStockValueAuthorized_5bda42f5-4da9-4a17-95ac-66c95ad732ba" xlink:href="rxrx-20240331.xsd#rxrx_SaleOfStockValueAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_eae82d41-c8f4-4ccd-83c9-7cd5a7bf883b" xlink:to="loc_rxrx_SaleOfStockValueAuthorized_5bda42f5-4da9-4a17-95ac-66c95ad732ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_SaleOfStockValueRemainingAuthorized_d3859a8e-b9b8-4e88-ad0d-ebeac18a263a" xlink:href="rxrx-20240331.xsd#rxrx_SaleOfStockValueRemainingAuthorized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_eae82d41-c8f4-4ccd-83c9-7cd5a7bf883b" xlink:to="loc_rxrx_SaleOfStockValueRemainingAuthorized_d3859a8e-b9b8-4e88-ad0d-ebeac18a263a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_8de5f3bd-0304-470c-8e0b-31d38b10021f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_eae82d41-c8f4-4ccd-83c9-7cd5a7bf883b" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_8de5f3bd-0304-470c-8e0b-31d38b10021f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_ba81f2d1-b7c6-4d5f-89f3-0d7380b41e04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_eae82d41-c8f4-4ccd-83c9-7cd5a7bf883b" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_ba81f2d1-b7c6-4d5f-89f3-0d7380b41e04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_SaleOfStockPercentageOfCommission_d16fbae3-6969-40e8-8f8e-6846e6dbf52a" xlink:href="rxrx-20240331.xsd#rxrx_SaleOfStockPercentageOfCommission"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_eae82d41-c8f4-4ccd-83c9-7cd5a7bf883b" xlink:to="loc_rxrx_SaleOfStockPercentageOfCommission_d16fbae3-6969-40e8-8f8e-6846e6dbf52a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_ec73e28a-b627-41b1-95f9-7491829f9fb4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_eae82d41-c8f4-4ccd-83c9-7cd5a7bf883b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_ec73e28a-b627-41b1-95f9-7491829f9fb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_4b8fe4f8-7253-4710-a2e7-fc36599b6447" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_eae82d41-c8f4-4ccd-83c9-7cd5a7bf883b" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_4b8fe4f8-7253-4710-a2e7-fc36599b6447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_ee2f65d6-7b8f-412e-99ea-35b33a94f81d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_eae82d41-c8f4-4ccd-83c9-7cd5a7bf883b" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_ee2f65d6-7b8f-412e-99ea-35b33a94f81d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_BusinessAcquisitionContingentConsiderationEquityInterestsIssuableNumberOfShares_154a1af7-7b6d-41e9-8652-5c878d3d93ee" xlink:href="rxrx-20240331.xsd#rxrx_BusinessAcquisitionContingentConsiderationEquityInterestsIssuableNumberOfShares"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_eae82d41-c8f4-4ccd-83c9-7cd5a7bf883b" xlink:to="loc_rxrx_BusinessAcquisitionContingentConsiderationEquityInterestsIssuableNumberOfShares_154a1af7-7b6d-41e9-8652-5c878d3d93ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_CommonStockConversionRatio_e35ec2af-0e56-4527-abe4-92832d94b754" xlink:href="rxrx-20240331.xsd#rxrx_CommonStockConversionRatio"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_eae82d41-c8f4-4ccd-83c9-7cd5a7bf883b" xlink:to="loc_rxrx_CommonStockConversionRatio_e35ec2af-0e56-4527-abe4-92832d94b754" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_b890adf3-bd9e-4061-a694-8afd99833c5e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_eae82d41-c8f4-4ccd-83c9-7cd5a7bf883b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_b890adf3-bd9e-4061-a694-8afd99833c5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_PercentOfAggregatePurchasePricePaidByTheHolderDueIfAgreementIsBroken_5f0ddd6e-507c-49f6-8267-75f75c8bd6cb" xlink:href="rxrx-20240331.xsd#rxrx_PercentOfAggregatePurchasePricePaidByTheHolderDueIfAgreementIsBroken"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_eae82d41-c8f4-4ccd-83c9-7cd5a7bf883b" xlink:to="loc_rxrx_PercentOfAggregatePurchasePricePaidByTheHolderDueIfAgreementIsBroken_5f0ddd6e-507c-49f6-8267-75f75c8bd6cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_RegistrationRightsAgreementAccruedLiability_a8774571-a5bf-4006-acde-7ff96edb5c64" xlink:href="rxrx-20240331.xsd#rxrx_RegistrationRightsAgreementAccruedLiability"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_eae82d41-c8f4-4ccd-83c9-7cd5a7bf883b" xlink:to="loc_rxrx_RegistrationRightsAgreementAccruedLiability_a8774571-a5bf-4006-acde-7ff96edb5c64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_RegistrationRightsAgreementTerm_f0b7298d-3562-4ee1-a29d-dbafc339b06b" xlink:href="rxrx-20240331.xsd#rxrx_RegistrationRightsAgreementTerm"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_eae82d41-c8f4-4ccd-83c9-7cd5a7bf883b" xlink:to="loc_rxrx_RegistrationRightsAgreementTerm_f0b7298d-3562-4ee1-a29d-dbafc339b06b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_NumberOfClassesOfCommonStockAuthorized_e0254c24-3e91-4e77-9ad6-74044769b93d" xlink:href="rxrx-20240331.xsd#rxrx_NumberOfClassesOfCommonStockAuthorized"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_eae82d41-c8f4-4ccd-83c9-7cd5a7bf883b" xlink:to="loc_rxrx_NumberOfClassesOfCommonStockAuthorized_e0254c24-3e91-4e77-9ad6-74044769b93d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_AffiliatedHoldersOwnershipPercentage_854212da-df41-43b2-ad7a-6ca60a75632c" xlink:href="rxrx-20240331.xsd#rxrx_AffiliatedHoldersOwnershipPercentage"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_eae82d41-c8f4-4ccd-83c9-7cd5a7bf883b" xlink:to="loc_rxrx_AffiliatedHoldersOwnershipPercentage_854212da-df41-43b2-ad7a-6ca60a75632c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_AffiliatedHoldersPotentialOwnershipPercentageWhenOutstandingEquityAwardsVest_f5256b8b-a8a5-428f-8003-2160f942091c" xlink:href="rxrx-20240331.xsd#rxrx_AffiliatedHoldersPotentialOwnershipPercentageWhenOutstandingEquityAwardsVest"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_eae82d41-c8f4-4ccd-83c9-7cd5a7bf883b" xlink:to="loc_rxrx_AffiliatedHoldersPotentialOwnershipPercentageWhenOutstandingEquityAwardsVest_f5256b8b-a8a5-428f-8003-2160f942091c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/CollaborativeDevelopmentContractsDetails" xlink:type="simple" xlink:href="rxrx-20240331.xsd#CollaborativeDevelopmentContractsDetails"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/CollaborativeDevelopmentContractsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f035c9b4-5a30-4516-9ff1-a7807c886257" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_65be20c9-36d7-42af-ae7c-04cc3a408891" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f035c9b4-5a30-4516-9ff1-a7807c886257" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_65be20c9-36d7-42af-ae7c-04cc3a408891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_f171e844-ab15-4b0e-9100-b501593f7a1b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_65be20c9-36d7-42af-ae7c-04cc3a408891" xlink:to="loc_srt_CounterpartyNameAxis_f171e844-ab15-4b0e-9100-b501593f7a1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6fceed55-3226-4012-950b-f1f380bf0fe9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_f171e844-ab15-4b0e-9100-b501593f7a1b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6fceed55-3226-4012-950b-f1f380bf0fe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_RocheAndGenentechMember_a3fb5279-b8de-427b-a476-ca62f37a8742" xlink:href="rxrx-20240331.xsd#rxrx_RocheAndGenentechMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6fceed55-3226-4012-950b-f1f380bf0fe9" xlink:to="loc_rxrx_RocheAndGenentechMember_a3fb5279-b8de-427b-a476-ca62f37a8742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_6c6a71b2-46bd-4cb7-a01e-6bdebe9ac949" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_65be20c9-36d7-42af-ae7c-04cc3a408891" xlink:to="loc_us-gaap_TypeOfArrangementAxis_6c6a71b2-46bd-4cb7-a01e-6bdebe9ac949" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_91f2036f-a58d-4edc-ba58-a5deab6d0ee5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6c6a71b2-46bd-4cb7-a01e-6bdebe9ac949" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_91f2036f-a58d-4edc-ba58-a5deab6d0ee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_4ff8ddcc-3571-4784-a384-663a4481a5d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_91f2036f-a58d-4edc-ba58-a5deab6d0ee5" xlink:to="loc_us-gaap_CollaborativeArrangementMember_4ff8ddcc-3571-4784-a384-663a4481a5d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_RevenueRemainingPerformanceObligationAxis_e0891ab6-9bbe-45dd-a396-a47b32b63408" xlink:href="rxrx-20240331.xsd#rxrx_RevenueRemainingPerformanceObligationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_65be20c9-36d7-42af-ae7c-04cc3a408891" xlink:to="loc_rxrx_RevenueRemainingPerformanceObligationAxis_e0891ab6-9bbe-45dd-a396-a47b32b63408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_RevenueRemainingPerformanceObligationDomain_1eab405d-42d4-4683-8c45-b8f99ffe3d81" xlink:href="rxrx-20240331.xsd#rxrx_RevenueRemainingPerformanceObligationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rxrx_RevenueRemainingPerformanceObligationAxis_e0891ab6-9bbe-45dd-a396-a47b32b63408" xlink:to="loc_rxrx_RevenueRemainingPerformanceObligationDomain_1eab405d-42d4-4683-8c45-b8f99ffe3d81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_PhenomapsCreationMember_4ffcceda-eda1-4f4c-be22-d2c84f378d18" xlink:href="rxrx-20240331.xsd#rxrx_PhenomapsCreationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rxrx_RevenueRemainingPerformanceObligationDomain_1eab405d-42d4-4683-8c45-b8f99ffe3d81" xlink:to="loc_rxrx_PhenomapsCreationMember_4ffcceda-eda1-4f4c-be22-d2c84f378d18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_PhenomapsRawImagesMember_f77a03cf-bbbc-4641-9b71-8a10bc92eaf0" xlink:href="rxrx-20240331.xsd#rxrx_PhenomapsRawImagesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rxrx_RevenueRemainingPerformanceObligationDomain_1eab405d-42d4-4683-8c45-b8f99ffe3d81" xlink:to="loc_rxrx_PhenomapsRawImagesMember_f77a03cf-bbbc-4641-9b71-8a10bc92eaf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_DevelopedAndCommercializedProgramsMember_84a5f6cf-8930-4467-b44d-4e3cf470c446" xlink:href="rxrx-20240331.xsd#rxrx_DevelopedAndCommercializedProgramsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rxrx_RevenueRemainingPerformanceObligationDomain_1eab405d-42d4-4683-8c45-b8f99ffe3d81" xlink:to="loc_rxrx_DevelopedAndCommercializedProgramsMember_84a5f6cf-8930-4467-b44d-4e3cf470c446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_GastrointestinalCancerMember_f8fda4b3-79f6-44c6-85e7-cc65e22c378e" xlink:href="rxrx-20240331.xsd#rxrx_GastrointestinalCancerMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rxrx_RevenueRemainingPerformanceObligationDomain_1eab405d-42d4-4683-8c45-b8f99ffe3d81" xlink:to="loc_rxrx_GastrointestinalCancerMember_f8fda4b3-79f6-44c6-85e7-cc65e22c378e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_NeuroscienceMember_62d40d2f-7922-4152-bcc4-0062a7840b1f" xlink:href="rxrx-20240331.xsd#rxrx_NeuroscienceMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rxrx_RevenueRemainingPerformanceObligationDomain_1eab405d-42d4-4683-8c45-b8f99ffe3d81" xlink:to="loc_rxrx_NeuroscienceMember_62d40d2f-7922-4152-bcc4-0062a7840b1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d5f309b1-284e-42a2-89cb-13e593b2a15c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_65be20c9-36d7-42af-ae7c-04cc3a408891" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d5f309b1-284e-42a2-89cb-13e593b2a15c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_fd9fe85d-3246-4999-a0fd-178c7cc0e36c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d5f309b1-284e-42a2-89cb-13e593b2a15c" xlink:to="loc_us-gaap_ContractWithCustomerLiability_fd9fe85d-3246-4999-a0fd-178c7cc0e36c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_RevenueRemainingPerformanceObligationVariableConsiderationAmount_d6afc3d8-122a-4cd8-bcd1-4570aeb9c5f6" xlink:href="rxrx-20240331.xsd#rxrx_RevenueRemainingPerformanceObligationVariableConsiderationAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d5f309b1-284e-42a2-89cb-13e593b2a15c" xlink:to="loc_rxrx_RevenueRemainingPerformanceObligationVariableConsiderationAmount_d6afc3d8-122a-4cd8-bcd1-4570aeb9c5f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_ContractWithCustomerMaximumAcceptedProduct_725c3864-b388-4377-94ed-133321ef938e" xlink:href="rxrx-20240331.xsd#rxrx_ContractWithCustomerMaximumAcceptedProduct"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d5f309b1-284e-42a2-89cb-13e593b2a15c" xlink:to="loc_rxrx_ContractWithCustomerMaximumAcceptedProduct_725c3864-b388-4377-94ed-133321ef938e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_RevenueRemainingPerformanceObligationNumberOfProjectsThatMayBeInitiated_d90dbfcc-1dca-4145-98be-eb14ddf59549" xlink:href="rxrx-20240331.xsd#rxrx_RevenueRemainingPerformanceObligationNumberOfProjectsThatMayBeInitiated"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d5f309b1-284e-42a2-89cb-13e593b2a15c" xlink:to="loc_rxrx_RevenueRemainingPerformanceObligationNumberOfProjectsThatMayBeInitiated_d90dbfcc-1dca-4145-98be-eb14ddf59549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_RevenuePerformanceObligationNumberOfObligations_97af19b8-13e9-49a3-a38f-bc750459d4fb" xlink:href="rxrx-20240331.xsd#rxrx_RevenuePerformanceObligationNumberOfObligations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d5f309b1-284e-42a2-89cb-13e593b2a15c" xlink:to="loc_rxrx_RevenuePerformanceObligationNumberOfObligations_97af19b8-13e9-49a3-a38f-bc750459d4fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_845cccb1-857b-4e09-b717-8c50c1b67693" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d5f309b1-284e-42a2-89cb-13e593b2a15c" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_845cccb1-857b-4e09-b717-8c50c1b67693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_1a115b37-1ab4-47f3-9643-32846055cd22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d5f309b1-284e-42a2-89cb-13e593b2a15c" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_1a115b37-1ab4-47f3-9643-32846055cd22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="rxrx-20240331.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_585974bf-56bb-41bd-8b9c-0bac92fdbf9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7d3df568-f2e5-475f-9496-362ca87448b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_585974bf-56bb-41bd-8b9c-0bac92fdbf9e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7d3df568-f2e5-475f-9496-362ca87448b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_1a5100f6-d9d2-4b41-9f49-34a71d62b956" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7d3df568-f2e5-475f-9496-362ca87448b3" xlink:to="loc_us-gaap_PlanNameAxis_1a5100f6-d9d2-4b41-9f49-34a71d62b956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_5a8cd375-bf87-4079-93ee-4a5df38fe5d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_1a5100f6-d9d2-4b41-9f49-34a71d62b956" xlink:to="loc_us-gaap_PlanNameDomain_5a8cd375-bf87-4079-93ee-4a5df38fe5d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_A2021EquityIncentivePlanMember_8ff0de38-96dd-4edd-84d0-ada420e9084e" xlink:href="rxrx-20240331.xsd#rxrx_A2021EquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_5a8cd375-bf87-4079-93ee-4a5df38fe5d0" xlink:to="loc_rxrx_A2021EquityIncentivePlanMember_8ff0de38-96dd-4edd-84d0-ada420e9084e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7fe264de-5eb6-41ef-98ff-b206a4804042" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7d3df568-f2e5-475f-9496-362ca87448b3" xlink:to="loc_us-gaap_AwardTypeAxis_7fe264de-5eb6-41ef-98ff-b206a4804042" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_42cdfa3f-045b-4ddb-a6e8-36c534885061" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_7fe264de-5eb6-41ef-98ff-b206a4804042" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_42cdfa3f-045b-4ddb-a6e8-36c534885061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_da852d2c-0567-43d4-a98a-2c336488209f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_42cdfa3f-045b-4ddb-a6e8-36c534885061" xlink:to="loc_us-gaap_EmployeeStockOptionMember_da852d2c-0567-43d4-a98a-2c336488209f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_7d70250d-b5b5-4b43-92a4-d432c647b4d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_42cdfa3f-045b-4ddb-a6e8-36c534885061" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_7d70250d-b5b5-4b43-92a4-d432c647b4d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_b8da9e87-1cd1-4f37-a8dc-bbbca8ac06a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_42cdfa3f-045b-4ddb-a6e8-36c534885061" xlink:to="loc_us-gaap_RestrictedStockMember_b8da9e87-1cd1-4f37-a8dc-bbbca8ac06a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8951b432-e440-4664-995f-ed6f7c2c4672" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7d3df568-f2e5-475f-9496-362ca87448b3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8951b432-e440-4664-995f-ed6f7c2c4672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_5e97a401-a5fb-4c62-a820-ad488acab919" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8951b432-e440-4664-995f-ed6f7c2c4672" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_5e97a401-a5fb-4c62-a820-ad488acab919" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_31a091de-a3e7-4b00-8c11-1b2f13dda3c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8951b432-e440-4664-995f-ed6f7c2c4672" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_31a091de-a3e7-4b00-8c11-1b2f13dda3c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_b0f31643-5556-4c2a-be6d-4004bc3854c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8951b432-e440-4664-995f-ed6f7c2c4672" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_b0f31643-5556-4c2a-be6d-4004bc3854c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a8be056d-2e4f-45e9-9f27-7ec6c62ccbe6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8951b432-e440-4664-995f-ed6f7c2c4672" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a8be056d-2e4f-45e9-9f27-7ec6c62ccbe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_b0af742c-4783-4f8f-9702-399c30b6271c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8951b432-e440-4664-995f-ed6f7c2c4672" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_b0af742c-4783-4f8f-9702-399c30b6271c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_76b24c1c-3e05-463c-a122-4291faf6a6a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8951b432-e440-4664-995f-ed6f7c2c4672" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_76b24c1c-3e05-463c-a122-4291faf6a6a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_ab3addac-dff5-4cba-908e-a701791feecf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8951b432-e440-4664-995f-ed6f7c2c4672" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_ab3addac-dff5-4cba-908e-a701791feecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_15e24adc-43f6-47b1-8437-39c92058a845" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8951b432-e440-4664-995f-ed6f7c2c4672" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_15e24adc-43f6-47b1-8437-39c92058a845" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/StockBasedCompensationSummaryofStockbasedCompensationExpensesDetails" xlink:type="simple" xlink:href="rxrx-20240331.xsd#StockBasedCompensationSummaryofStockbasedCompensationExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/StockBasedCompensationSummaryofStockbasedCompensationExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_53318ed3-17d3-4fe8-b0d5-0847fc45125d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e1b158d1-cc92-459c-b53a-707c755d480d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_53318ed3-17d3-4fe8-b0d5-0847fc45125d" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e1b158d1-cc92-459c-b53a-707c755d480d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_ce558b9b-20a5-427a-84b3-d367b08d74c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e1b158d1-cc92-459c-b53a-707c755d480d" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_ce558b9b-20a5-427a-84b3-d367b08d74c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_5c084c0b-8990-4bfa-bb3c-30f14e0efaf0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_ce558b9b-20a5-427a-84b3-d367b08d74c4" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_5c084c0b-8990-4bfa-bb3c-30f14e0efaf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_3bf49748-1dd6-40f0-91fb-7a75da01461f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5c084c0b-8990-4bfa-bb3c-30f14e0efaf0" xlink:to="loc_us-gaap_CostOfSalesMember_3bf49748-1dd6-40f0-91fb-7a75da01461f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_237c1da7-9f42-4ce5-b164-1ea009ecad36" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5c084c0b-8990-4bfa-bb3c-30f14e0efaf0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_237c1da7-9f42-4ce5-b164-1ea009ecad36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_da2bd741-7c6d-424f-b39e-9175d5775472" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5c084c0b-8990-4bfa-bb3c-30f14e0efaf0" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_da2bd741-7c6d-424f-b39e-9175d5775472" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ef559bfa-d169-43c4-8fa8-05cd20ce78c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e1b158d1-cc92-459c-b53a-707c755d480d" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ef559bfa-d169-43c4-8fa8-05cd20ce78c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_50b432a4-bea4-4448-8344-c5805d9cdc16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ef559bfa-d169-43c4-8fa8-05cd20ce78c0" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_50b432a4-bea4-4448-8344-c5805d9cdc16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/StockBasedCompensationScheduleofSharebasedPaymentArrangementOptionActivityDetails" xlink:type="simple" xlink:href="rxrx-20240331.xsd#StockBasedCompensationScheduleofSharebasedPaymentArrangementOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/StockBasedCompensationScheduleofSharebasedPaymentArrangementOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e62864ce-74f4-4f77-9afd-e6e41caacabd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4ad34f61-e6ad-43f5-9d72-52ee09416e13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e62864ce-74f4-4f77-9afd-e6e41caacabd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4ad34f61-e6ad-43f5-9d72-52ee09416e13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_426c2c88-162b-470b-bb98-e7beb31b9865" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4ad34f61-e6ad-43f5-9d72-52ee09416e13" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_426c2c88-162b-470b-bb98-e7beb31b9865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_81daa48b-7db7-4f09-b8d6-12dd3b878e78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4ad34f61-e6ad-43f5-9d72-52ee09416e13" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_81daa48b-7db7-4f09-b8d6-12dd3b878e78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_06b8c4d7-78a3-471d-9e0b-cead2244d0ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4ad34f61-e6ad-43f5-9d72-52ee09416e13" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_06b8c4d7-78a3-471d-9e0b-cead2244d0ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_56f56214-2574-4f81-b5ea-06efaf4445a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4ad34f61-e6ad-43f5-9d72-52ee09416e13" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_56f56214-2574-4f81-b5ea-06efaf4445a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6530fbf1-2e2a-4cd7-8390-beed20bae458" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4ad34f61-e6ad-43f5-9d72-52ee09416e13" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6530fbf1-2e2a-4cd7-8390-beed20bae458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_01a9fa7a-c605-4bf3-a72f-7c83d4ec6fed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e62864ce-74f4-4f77-9afd-e6e41caacabd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_01a9fa7a-c605-4bf3-a72f-7c83d4ec6fed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e640c953-09c3-4b12-b5de-1d6e819cd332" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e62864ce-74f4-4f77-9afd-e6e41caacabd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e640c953-09c3-4b12-b5de-1d6e819cd332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b5617a58-db7a-46d0-a83a-cb009f3d9593" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e640c953-09c3-4b12-b5de-1d6e819cd332" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b5617a58-db7a-46d0-a83a-cb009f3d9593" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_60be5db0-a38c-43bb-a7a6-a7b1a6c30def" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e640c953-09c3-4b12-b5de-1d6e819cd332" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_60be5db0-a38c-43bb-a7a6-a7b1a6c30def" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_02b6a7a8-2faa-4364-a73f-823abbaaad2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e640c953-09c3-4b12-b5de-1d6e819cd332" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_02b6a7a8-2faa-4364-a73f-823abbaaad2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2384594d-13a3-44bd-88de-8c145ffaa249" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e640c953-09c3-4b12-b5de-1d6e819cd332" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2384594d-13a3-44bd-88de-8c145ffaa249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_10a7d2f3-05fe-48ba-92cb-ba6bc587dd47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e640c953-09c3-4b12-b5de-1d6e819cd332" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_10a7d2f3-05fe-48ba-92cb-ba6bc587dd47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2111a3b3-829f-42c0-ba61-adadd6802eee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e62864ce-74f4-4f77-9afd-e6e41caacabd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2111a3b3-829f-42c0-ba61-adadd6802eee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_daa944fc-5632-4ab2-83fb-1494db660210" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e62864ce-74f4-4f77-9afd-e6e41caacabd" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_daa944fc-5632-4ab2-83fb-1494db660210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_08c65f18-087b-4195-89e3-9afce7f351a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e62864ce-74f4-4f77-9afd-e6e41caacabd" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_08c65f18-087b-4195-89e3-9afce7f351a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_ef524866-6379-4931-bff3-d3b2324d2298" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e62864ce-74f4-4f77-9afd-e6e41caacabd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_ef524866-6379-4931-bff3-d3b2324d2298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_4e9c54d3-d083-4d85-9bc6-5739330a3706" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e62864ce-74f4-4f77-9afd-e6e41caacabd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_4e9c54d3-d083-4d85-9bc6-5739330a3706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2c7ceace-7f4e-433a-a4cd-50a049a3e65e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e62864ce-74f4-4f77-9afd-e6e41caacabd" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2c7ceace-7f4e-433a-a4cd-50a049a3e65e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionDetails" xlink:type="simple" xlink:href="rxrx-20240331.xsd#StockBasedCompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionDetails"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_74e21374-4911-48b8-b70d-e2ec6a49a505" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1df40097-cf1f-4fa9-9b36-44a9432ea0b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_74e21374-4911-48b8-b70d-e2ec6a49a505" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1df40097-cf1f-4fa9-9b36-44a9432ea0b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_056d7d10-8148-4d0d-be6b-062158ce3827" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1df40097-cf1f-4fa9-9b36-44a9432ea0b2" xlink:to="loc_us-gaap_AwardTypeAxis_056d7d10-8148-4d0d-be6b-062158ce3827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_26f5f211-7a6e-4869-b083-b30f69fc9d30" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_056d7d10-8148-4d0d-be6b-062158ce3827" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_26f5f211-7a6e-4869-b083-b30f69fc9d30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_8ead21f3-e1b1-40ae-80b7-9df2abad1b77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_26f5f211-7a6e-4869-b083-b30f69fc9d30" xlink:to="loc_us-gaap_EmployeeStockOptionMember_8ead21f3-e1b1-40ae-80b7-9df2abad1b77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_62f1bd30-1150-4019-bd48-5deeedeeeb5c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1df40097-cf1f-4fa9-9b36-44a9432ea0b2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_62f1bd30-1150-4019-bd48-5deeedeeeb5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_a611beeb-ecc8-488b-adcc-00955c226c05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_62f1bd30-1150-4019-bd48-5deeedeeeb5c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_a611beeb-ecc8-488b-adcc-00955c226c05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_237d1017-b862-48b4-aa3f-e04d97a52bc0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_62f1bd30-1150-4019-bd48-5deeedeeeb5c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_237d1017-b862-48b4-aa3f-e04d97a52bc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_d30a5f12-ba42-4153-af44-90dffaa6f527" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_62f1bd30-1150-4019-bd48-5deeedeeeb5c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_d30a5f12-ba42-4153-af44-90dffaa6f527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_acb495fd-fc18-4e0e-baca-725c3f8a8dcc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_62f1bd30-1150-4019-bd48-5deeedeeeb5c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_acb495fd-fc18-4e0e-baca-725c3f8a8dcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/StockBasedCompensationScheduleofRSUActivityDetails" xlink:type="simple" xlink:href="rxrx-20240331.xsd#StockBasedCompensationScheduleofRSUActivityDetails"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/StockBasedCompensationScheduleofRSUActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_70536999-cc9e-40d2-8d20-f19d5c5372d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ee43a11c-019e-4f84-abac-5a34d7789161" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_70536999-cc9e-40d2-8d20-f19d5c5372d8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ee43a11c-019e-4f84-abac-5a34d7789161" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0f6a25e6-a023-4992-bb62-33761b045ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ee43a11c-019e-4f84-abac-5a34d7789161" xlink:to="loc_us-gaap_AwardTypeAxis_0f6a25e6-a023-4992-bb62-33761b045ec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a7e9ea58-5ec3-4294-b32c-28d772ae6a37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_0f6a25e6-a023-4992-bb62-33761b045ec8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a7e9ea58-5ec3-4294-b32c-28d772ae6a37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_19c5465d-6ffe-4113-b723-8640175a12ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a7e9ea58-5ec3-4294-b32c-28d772ae6a37" xlink:to="loc_us-gaap_RestrictedStockMember_19c5465d-6ffe-4113-b723-8640175a12ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cef4e98f-ab5b-444b-9d1a-2ef7dc5646dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ee43a11c-019e-4f84-abac-5a34d7789161" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cef4e98f-ab5b-444b-9d1a-2ef7dc5646dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_7547e3fe-61b7-4947-995e-dcb21684f871" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cef4e98f-ab5b-444b-9d1a-2ef7dc5646dc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_7547e3fe-61b7-4947-995e-dcb21684f871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ae0cf362-0d1a-4b67-88d8-e21d6c72c897" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_7547e3fe-61b7-4947-995e-dcb21684f871" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ae0cf362-0d1a-4b67-88d8-e21d6c72c897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_61fd619e-522b-4c0d-bb9f-3090f6d92b11" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_7547e3fe-61b7-4947-995e-dcb21684f871" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_61fd619e-522b-4c0d-bb9f-3090f6d92b11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_22c624b1-fd94-4ec6-9e05-fdefc093146c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_7547e3fe-61b7-4947-995e-dcb21684f871" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_22c624b1-fd94-4ec6-9e05-fdefc093146c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_8d5de2d1-d55c-409a-95cb-44844426dde3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_7547e3fe-61b7-4947-995e-dcb21684f871" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_8d5de2d1-d55c-409a-95cb-44844426dde3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c08134bd-b853-4c2a-8c79-8b95d70c19cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_7547e3fe-61b7-4947-995e-dcb21684f871" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c08134bd-b853-4c2a-8c79-8b95d70c19cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_13778042-9304-4250-9857-897121bd0dae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cef4e98f-ab5b-444b-9d1a-2ef7dc5646dc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_13778042-9304-4250-9857-897121bd0dae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6bfa58f0-cbb7-4970-89b9-51a2b8956969" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_13778042-9304-4250-9857-897121bd0dae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6bfa58f0-cbb7-4970-89b9-51a2b8956969" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_92b6edd8-295e-4736-b651-f9d4aeca61f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_13778042-9304-4250-9857-897121bd0dae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_92b6edd8-295e-4736-b651-f9d4aeca61f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_b82c7558-cfc5-46e6-a580-409f44413859" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_13778042-9304-4250-9857-897121bd0dae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_b82c7558-cfc5-46e6-a580-409f44413859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_fa218da2-e42a-44dd-8163-33b04726174f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_13778042-9304-4250-9857-897121bd0dae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_fa218da2-e42a-44dd-8163-33b04726174f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_ed29d508-a855-402d-b196-069b48ff69c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_13778042-9304-4250-9857-897121bd0dae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_ed29d508-a855-402d-b196-069b48ff69c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="rxrx-20240331.xsd#IncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_d957926a-073b-441c-bf2b-6cb9fb728350" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_58e75262-4b65-45ee-8028-2282bcd6a9f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d957926a-073b-441c-bf2b-6cb9fb728350" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_58e75262-4b65-45ee-8028-2282bcd6a9f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_84833177-cd5b-4227-acc3-f2d076865ec9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d957926a-073b-441c-bf2b-6cb9fb728350" xlink:to="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_84833177-cd5b-4227-acc3-f2d076865ec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/NetLossPerShareScheduleofBasicandDilutedNetLossperShareDetails" xlink:type="simple" xlink:href="rxrx-20240331.xsd#NetLossPerShareScheduleofBasicandDilutedNetLossperShareDetails"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/NetLossPerShareScheduleofBasicandDilutedNetLossperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_f99ac0e5-c782-4976-868d-e82d2da82ac8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2305d61e-b9d5-4b40-a010-a986ec2b2658" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f99ac0e5-c782-4976-868d-e82d2da82ac8" xlink:to="loc_us-gaap_NetIncomeLoss_2305d61e-b9d5-4b40-a010-a986ec2b2658" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ffebcfdc-1ebf-42e3-9d2c-67ceede88d49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f99ac0e5-c782-4976-868d-e82d2da82ac8" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ffebcfdc-1ebf-42e3-9d2c-67ceede88d49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b3ad5a3f-98a6-4621-8e6d-bbd027163d14" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f99ac0e5-c782-4976-868d-e82d2da82ac8" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b3ad5a3f-98a6-4621-8e6d-bbd027163d14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_2e614137-7bb7-4ad5-beb3-59e1feb10516" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f99ac0e5-c782-4976-868d-e82d2da82ac8" xlink:to="loc_us-gaap_EarningsPerShareBasic_2e614137-7bb7-4ad5-beb3-59e1feb10516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_079881ad-98ee-4688-bb87-f395d2f60a8d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f99ac0e5-c782-4976-868d-e82d2da82ac8" xlink:to="loc_us-gaap_EarningsPerShareDiluted_079881ad-98ee-4688-bb87-f395d2f60a8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossPerShareDetails" xlink:type="simple" xlink:href="rxrx-20240331.xsd#NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0d3437ea-f997-4768-bc5e-d7f52f93f827" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_23344f30-d178-4dbc-b20b-76e8a1b0c77f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0d3437ea-f997-4768-bc5e-d7f52f93f827" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_23344f30-d178-4dbc-b20b-76e8a1b0c77f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cb349cca-62ad-4464-8776-95965f67f1c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_23344f30-d178-4dbc-b20b-76e8a1b0c77f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cb349cca-62ad-4464-8776-95965f67f1c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9274a02d-a181-4548-8a5d-f8630e55a173" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cb349cca-62ad-4464-8776-95965f67f1c8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9274a02d-a181-4548-8a5d-f8630e55a173" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_cb7395dd-5113-4e26-b166-8d45b6673516" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9274a02d-a181-4548-8a5d-f8630e55a173" xlink:to="loc_us-gaap_EmployeeStockOptionMember_cb7395dd-5113-4e26-b166-8d45b6673516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_TempusAgreementMember_2f5171ec-0833-4e9c-b9eb-36ed68e3f329" xlink:href="rxrx-20240331.xsd#rxrx_TempusAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9274a02d-a181-4548-8a5d-f8630e55a173" xlink:to="loc_rxrx_TempusAgreementMember_2f5171ec-0833-4e9c-b9eb-36ed68e3f329" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_deb6ebc1-9a77-4549-bb73-ebd6f9e918f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_23344f30-d178-4dbc-b20b-76e8a1b0c77f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_deb6ebc1-9a77-4549-bb73-ebd6f9e918f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_62d87f9e-c5e9-43b2-8f5a-f0260e6bff76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_deb6ebc1-9a77-4549-bb73-ebd6f9e918f0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_62d87f9e-c5e9-43b2-8f5a-f0260e6bff76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails" xlink:type="simple" xlink:href="rxrx-20240331.xsd#FairValueMeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_460ad4df-de87-4309-9bb4-d00f15b107a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_986c1f71-9160-4455-80ae-b49ba9ff249d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_460ad4df-de87-4309-9bb4-d00f15b107a6" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_986c1f71-9160-4455-80ae-b49ba9ff249d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e39f3620-d4fb-4c52-a3c4-e2b6133c5354" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_986c1f71-9160-4455-80ae-b49ba9ff249d" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e39f3620-d4fb-4c52-a3c4-e2b6133c5354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_c951075e-1a5d-49ac-bbbd-09132c7b532a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e39f3620-d4fb-4c52-a3c4-e2b6133c5354" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_c951075e-1a5d-49ac-bbbd-09132c7b532a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_aed68790-edeb-4ecc-aa4d-2effb453956b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_c951075e-1a5d-49ac-bbbd-09132c7b532a" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_aed68790-edeb-4ecc-aa4d-2effb453956b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_85544c83-ceba-47e4-917a-bd89e25309b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_986c1f71-9160-4455-80ae-b49ba9ff249d" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_85544c83-ceba-47e4-917a-bd89e25309b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f0e19a2c-02ba-4b63-a37f-bdeb1d859911" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_85544c83-ceba-47e4-917a-bd89e25309b3" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f0e19a2c-02ba-4b63-a37f-bdeb1d859911" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_b9883d1b-b080-4ed3-855e-5f1275fb89fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f0e19a2c-02ba-4b63-a37f-bdeb1d859911" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_b9883d1b-b080-4ed3-855e-5f1275fb89fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_d807c912-fcac-44ca-9e00-8909c81f459a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f0e19a2c-02ba-4b63-a37f-bdeb1d859911" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_d807c912-fcac-44ca-9e00-8909c81f459a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_94667603-5663-4440-a713-e2a30d29f7cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f0e19a2c-02ba-4b63-a37f-bdeb1d859911" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_94667603-5663-4440-a713-e2a30d29f7cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_6f66013a-f795-4590-b551-4f47c4540b60" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_986c1f71-9160-4455-80ae-b49ba9ff249d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_6f66013a-f795-4590-b551-4f47c4540b60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_74427d49-3dbf-4abe-b23f-680427211da1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_6f66013a-f795-4590-b551-4f47c4540b60" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_74427d49-3dbf-4abe-b23f-680427211da1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_c9a99c86-7276-495e-8c7e-a4f84c59b84c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_74427d49-3dbf-4abe-b23f-680427211da1" xlink:to="loc_us-gaap_MoneyMarketFundsMember_c9a99c86-7276-495e-8c7e-a4f84c59b84c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_028ee393-f7e3-4f71-ace4-1522ec8871a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_986c1f71-9160-4455-80ae-b49ba9ff249d" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_028ee393-f7e3-4f71-ace4-1522ec8871a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_282cbb5a-084f-4b4c-bcc1-373904d75be3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_028ee393-f7e3-4f71-ace4-1522ec8871a2" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_282cbb5a-084f-4b4c-bcc1-373904d75be3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_RestrictedCashAndCashEquivalentsFairValueDisclosure_8e1f9268-23a3-4454-807e-b50f02d4b23a" xlink:href="rxrx-20240331.xsd#rxrx_RestrictedCashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_028ee393-f7e3-4f71-ace4-1522ec8871a2" xlink:to="loc_rxrx_RestrictedCashAndCashEquivalentsFairValueDisclosure_8e1f9268-23a3-4454-807e-b50f02d4b23a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_5be95925-e777-4a6c-8010-556647c55818" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_028ee393-f7e3-4f71-ace4-1522ec8871a2" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_5be95925-e777-4a6c-8010-556647c55818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/FairValueMeasurementsAssetandLiabilityNotMeasuredatFairValueDetails" xlink:type="simple" xlink:href="rxrx-20240331.xsd#FairValueMeasurementsAssetandLiabilityNotMeasuredatFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/FairValueMeasurementsAssetandLiabilityNotMeasuredatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_32de0163-9fb7-48f3-a223-2c32ad546866" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable_cdb46468-ae3d-474d-8ce9-507033387eb1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_32de0163-9fb7-48f3-a223-2c32ad546866" xlink:to="loc_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable_cdb46468-ae3d-474d-8ce9-507033387eb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_64e5bcac-e5f6-4f05-a996-a364a823d8f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable_cdb46468-ae3d-474d-8ce9-507033387eb1" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_64e5bcac-e5f6-4f05-a996-a364a823d8f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_f63e66d4-5351-4511-81e9-0311cfd359e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_64e5bcac-e5f6-4f05-a996-a364a823d8f2" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_f63e66d4-5351-4511-81e9-0311cfd359e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_d9b4c11d-4831-46dd-9208-d31dce35e34d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_f63e66d4-5351-4511-81e9-0311cfd359e8" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_d9b4c11d-4831-46dd-9208-d31dce35e34d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember_bcbce117-3f85-4641-bc71-62310058249a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_d9b4c11d-4831-46dd-9208-d31dce35e34d" xlink:to="loc_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember_bcbce117-3f85-4641-bc71-62310058249a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_aec9cb48-37b8-43db-80ac-d54cc883fc43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_d9b4c11d-4831-46dd-9208-d31dce35e34d" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_aec9cb48-37b8-43db-80ac-d54cc883fc43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_38c3275e-7eb9-4c77-b724-0a3908650a6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable_cdb46468-ae3d-474d-8ce9-507033387eb1" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_38c3275e-7eb9-4c77-b724-0a3908650a6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_0718d136-9819-40c8-a547-8254955dce1a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_38c3275e-7eb9-4c77-b724-0a3908650a6f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_0718d136-9819-40c8-a547-8254955dce1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_08a35c19-dd77-492b-bf5c-dfa249bf87ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_0718d136-9819-40c8-a547-8254955dce1a" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_08a35c19-dd77-492b-bf5c-dfa249bf87ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems_15c58993-e4a6-4a7a-99b5-9a6ed73f034a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable_cdb46468-ae3d-474d-8ce9-507033387eb1" xlink:to="loc_us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems_15c58993-e4a6-4a7a-99b5-9a6ed73f034a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_df193b35-e87d-4779-aefd-78d45531f98b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems_15c58993-e4a6-4a7a-99b5-9a6ed73f034a" xlink:to="loc_us-gaap_LongTermDebtCurrent_df193b35-e87d-4779-aefd-78d45531f98b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_0fa8e9cf-422e-4b37-91f3-ca9fb8091a06" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems_15c58993-e4a6-4a7a-99b5-9a6ed73f034a" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_0fa8e9cf-422e-4b37-91f3-ca9fb8091a06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_98cf318d-f761-4b10-8fbc-f19f1cf43fe5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems_15c58993-e4a6-4a7a-99b5-9a6ed73f034a" xlink:to="loc_us-gaap_LongTermDebtFairValue_98cf318d-f761-4b10-8fbc-f19f1cf43fe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_RestrictedStockMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_TerryAnnBurrellMember" xlink:href="rxrx-20240331.xsd#rxrx_TerryAnnBurrellMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_rxrx_TerryAnnBurrellMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_TinaMarriottMember" xlink:href="rxrx-20240331.xsd#rxrx_TinaMarriottMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_rxrx_TinaMarriottMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_MichaelSecoraMember" xlink:href="rxrx-20240331.xsd#rxrx_MichaelSecoraMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_rxrx_MichaelSecoraMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_us-gaap_NetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>rxrx-20240331_g1.jpg
<TEXT>
begin 644 rxrx-20240331_g1.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (%!&4# 2(  A$! Q$!_\0
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M:V\OF>1E>>87 X!4:R<YQDI07*O<?,FVIWOJE9Q:LWJ?'=]ILGA/]E'P7?\
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M 649*,OTZ$5]=5=:C.A+EF=.;Y/B\CQ/U7&1M*UU9W37=,**^2OVTOC7\0/
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MF$;#*[E!.,CGKWH ZNBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4X]5=;2VFMEFBCC6$BX0NY8#@!0:\R;P#\+N?^+IW!)/W5T63.2>@_&O88?
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MKE<C'L: /@3XH?#/3?''B+]K#Q)K%SJLNM^%8K>XT:2"]EBCLKA+!9/-B0'
M8NHY].*T?#.@^"[W]KOP#XH\9)'!KVN_#VQU"RO;J5X_MFJ!D!*=B^W/R_C7
MWPVB:<_VW=86K?;>+K,*_O\ C'S\?-QQSVJ"Z\*Z+?36$MSH]A<2Z><V;RVR
M,UL1P#&2/D_#% 'YPV/C'1KSX(?"_P .^+-(MO$-SJ^N^()(K[Q1JD]GI=JL
M5U)N\]D.9'P1L7V.*L_ S6[W7/"_[+K7E[+J M?'.L6EO*SO(%@2.01JK/\
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M86BBB@84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MJ_A;]B;QZWPY^('AS6+'X;Z%>:UX<DT2RU+PWI\\=Q)(Q7,LSN3A2%Y51UH
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M5;."X]-W:-?UKLPN$KXRJJ.'@Y2?1?U^)%W)\L%=GT/XJ^,EY>1S+IFW3;-
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MMSP;R89D/^ZO0?C32;,Y3C'<]J\8?$+1/ ]J9=3O%20CY+=/FD?Z+7SMX_\
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MSQ-@<GO";YZG\J_5]/S\C*MBH4?=W?8^(/A7^R%XX^)$<-[=6Z^&]&?D7FH
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MP"J#Z?WC7M_@7]G?1]!\NZUIO[7OEYV,,0H?8=_QKUF*%+>-8XD6.-1A548
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M\J>TQE2Z6T5I%>B_5W?F%%%%<Y\Z%%%% !1110 4444 %%%% !1110 4444
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MF4*BL"_\?>)=4W?:==OI W51*5'Z4<K%[>/1'V3J7B/2]'C,E[J%M;*.IDE
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\#W_ ,*GD8^='0?\/>O@#_S^:Y_X+&_QH_X>]? '_G\US_P6-_C7-R_\$O\
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M[L^5]!_9Y\6:MM:Z2#2HCU,[;F'_  $5Z7X=_9IT'3]LFJW5QJL@Y*9\N/\
M(=:]AHJ>9FJI11F:+X9TKP["(M-T^WLT'_/) #^=:=%%2;!1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P (OIO]]_\ ONC_ (1?3?[[_P#?=344>WJ_S,7LX]B'_A%]-_OO_P!]TO\
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M7"BBBD4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MR\:>)[?XQ? _7F\,/-XG>WNR/#]K>!U>0_*,2CY2N,-GTK2\9?M +\3/V?\
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M^/GAR\@UFWM_A?>?#F7Q3>P&-2UM<QR[90S]<I@C;_C7(<1]IT5\N?#7]O\
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M94H+9/3TW7X'[;E.*6+PL*E_^'V?XEJBBBO*/8"BBB@ HHHH **** "BBB@
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M)_CKQ3XX^(%U:QZ!K=IXF&;/5=9DD-QI2X_U<2#@>F:^S**[HXVM&I*KU?\
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M]EC_ +#<G_H25]S5\,_MN?\ )X7[+'_8;D_]"2@#[=OO]3^-4*OWW^I_&J%
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M ")N@_\ 7A!_Z+6OD#_@JRULW[*TWV8H?^*AL#)L_O>:.M?7_@G_ )$W0?\
MKP@_]%K5RJ2J/FD[LSITX4H\L%9&U7EG[1&@_P!I>!Q?(N9M/F$N0/X3PW]*
M]3K)\6:8NM>&=3LG&5FMW7'OCC]:E;E27-%H_*3XX> [.;Q@VH9DB:]C#DH>
M"PX/]*\XC\"Q)<(S7+20@Y9"N"?;-?0_QFTXMHMI<$?/;3&)C['C^8KR"OUW
M)\=5J8*"YMM/N_X!_-_$LJ^"S.K"$O=EJOFO\[G6_"N^73_%$-N,)#/&8=HZ
M=,C^5?H_\!=9.K_#?3U9MTEH6MF_X">/TQ7Y@:'>&PUJQN <>7,I_#-?67@W
MXCZWX%F9M+N1]FD.^2UE&Z-_?V/TKY#B*C:O&HNJ_+_AS[K@/%WPE2C+[,OS
M7^:9]HT5XSX7_:6T>_"1:U:2Z9-T,J?O(B?YBO4-&\5Z/XAC5].U*VNPW01R
M#=^76OD;-'ZK&49;,UJ***184444 %%%% !1110 4444 %%%% !17/\ C'QO
MIO@6TM;K5&DCMIYA#YB+NV$CJ?:M32M8LM<LTN]/NHKNW<9$D39'_P!:@5U>
MQ<HHHH&%%%% !1110 445'<7$=I;RSS.(XHU+NS= H&2: /E#]OSXX2>"O!E
MOX*TBX,6L:\I-S)&V&AM1PWT+'C\Z_.E5"*%48 X KO/CM\2)OBQ\6?$/B.1
MV:WEN&@M%)R$@0[4 _ 9KA*_1,#AUAJ"AU>K]3]5RW"K!X>,.KU?K_P HHHK
MO/3"O>OV=OAR5M[7QC/I\&J:O>7;6'AC3;P9@>X49EO9A_SRA7YO0G%>!M&T
MN(T^_(0B_4G _G7UY\3KW_A6OPY\1#3SY4FC:78^$=/9./+DN$\^\D'^TP(7
M-<.*D[*G'>7]?K]USS<;.5HTH[R_X"_-J_E<X?QG\9)IO%Q\)^"=>-O-J5TM
MKK/CR\.+O492<.5?_EC;J<A57' K#\)_"+3;/]IS3O"6N:[8^)+*UG^U37RS
M;HKW:GF"'<QZL0%//>M[X9?"3PAI'P[L_$/BA)/%S^(I8H-!TC0E9;_[5$VZ
M6(AAMV8&&/-:VL>!?A]\8-(\6?\ ",Z:WPZ\6Z1='4=7L=:W'[+:HFTI;A!T
MW8R,9R:Y?:0IWA"Z6S=NNU^^FW8X_:0I7A3NE:S=NNU^^FVUNAP?Q&^"NO>#
M;+6_',>IZ/8&#4@+C2]#O<S:896)B0LAQG&.!TKI_A+\<[KQ9K6FZ5XHU4:?
MXGCQ#H?C3:!)'(>%MKWM- _W3NY&:YWX:_$SPM%\/=/\"ZMX/N?$5^VMF\M8
MTN_(M;V:3"(;C W$+V -6_CO\$=4A\;^)[[PEX.OK/PKI2HES-#&P@CF5!YQ
MBW'<R!L\C/2M':3]E7WUL]/)=_\ A]C5VF_88C1ZVEHM-%W_  >^SN0_M!_#
MN*QV^,M,TI=$CFO'TW7M$C^YIFI+R=G_ $RE'SI]:\7KZ[TNX/Q8^&$4UT?-
MG\4^%;B"Z8_Q:CIIW13?[QC&":^08G\R-6[D9K?"S;BX2WC_ %_FCHP524H.
MG/>.G]?--?(?1117:>B%>]?L:_&Z3X1?%.WL+V<IX<U]UM;M6/RQ2DXCE_,[
M3[&O!::REEX)5NH8=0>QK&M2C6ING/9F%>C'$4Y4I[,_<D$, 0<@TM>.?LF_
M%%OBM\$]$U&XDWZG9K]@O>>?,CXR?J,&O8Z_-ZE.5*;IRW1^25J4J-25.6Z=
M@JIJ^I1:-I-[J$X8PVD#SN%&3M52QQ^ JW6#X]!;P+XB 4L?[-N?E7J?W3<5
MD8GAGPS_ &X/#OQ UOPG9WWA3Q'X5L/%SO'X?U?5;8"TU"1<_NU=2=K$*2 >
MM>_V/B32-3OI[*SU2RN[R#_6V\%PCR1_[R@Y'XU\2_LH?L_:QXC^#?PI\;^,
MO$]]KND^%;.;5-"\(6]BML(;C]ZJF1\[I' )"YQR:\K^"/B:R\2?M(?!C6=
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M1_=4Y=F_R_X!IP)-_6*]/ND_N?\ P22EAD>VD$D,CPR#HT;%3^E;>O>!]?\
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M%Q??!]D;P%=+%XM>+6$:."-L%6M3LS,=AW$$+C% 'V!<:99W<D4D]I!,\/\
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MR.D6BBB@ IT?^M3ZTVG1_P"L3ZT ?(O_  5F_P"351_V'M/_ /1HKZV\$_\
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M[70](%K&%D&!/(<Y=^YS7UY',DN[8ZOM.UMIS@^AI%GC9BJR*S X*AAD'TH
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MXN-9O(=[)*+FW/R1PDCA3T&,5^E^A^'=*\,V(LM'TVTTJS4Y%O90+#&#Z[5
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M[V&UAMU\,:4T"+M">8I"\]!D=*NPW&L6:K';:)90QDY98YU4 ]^ /I7P"/\
M@LI\/%Z?#KQ!C_KI'2C_ (+*_#Q3_P DZ\0>O^LCH _0/^TM?VO_ ,2NV!!^
M7_2A@CUI#J7B#Y<:5;'Y<G_2AU]*_/T_\%E_AZ<Y^'7B#G_II'1_P^5^'H7;
M_P *Z\0 >GF1T ?H(-0UXALZ;:@]O])J%;OQ&MQ))_9L+HP&U/M0P/6O@ _\
M%E/AX>/^%<^(,?\ 72.I8_\ @L_X"A7;'\/O$2+Z"6.@#] #?^(=Z@:3;E=N
M2?M/(/I2)J'B$QY;2;</_=^U5\!_\/I/ W_0@>(_^_L='_#Z3P-_T('B/_O[
M'0!]_)?>(#&2VE6ZOG[OVFA[[Q '<+I5N5 ^4FYZFO@'_A])X&_Z$#Q'_P!_
M8Z/^'TG@;_H0/$?_ ']CH ^]=4\1ZEHMI)=7]K96=LI4>=-=A5R?<U)HOB*#
MQ-I9N(;BUG,<I1_LDPE53Z$COBOSO\5?\%>?AGXTT=]+U;X=^)9K-W60JD\:
ML&4Y!S]:I>%?^"LGPM\%65U:Z1\/?$\,=U-]HF:6XC=F?&,Y/TH _2FBOSRC
M_P""RG@'<-W@/Q(1[215:'_!9?X<?]"%XF_[[BH _0.G1_ZQ/K7Y]?\ #YCX
M;_\ 0A>)O^^XJ5?^"S'PW5@?^$"\3<'/WXJ /2O^"LW_ ":K_P!Q[3__ $;7
MUMX)_P"1-T'_ *\(/_1:U^27[9?_  4;\(_M/_".'P3H?A76M+OI=5M+G[1?
M%/+58Y 2..YK];?!/_(FZ#_UX0?^BUH VJXCXS:Y_87P\U20'$LR"WCY[MQ_
M+-=O7@/[2WB)9KS2]#C?_5@W4P!Z=E!_G36YG4?+%GQQ\:-0'VC3M/4\1H96
M'N>!_6O-*WO'6K_VUXHOKA3F,/Y:?[J\5@U^N9?1^KX6G![V_/4_EG/<6L;F
M5:LMKV7HM%^1N^!K'^T/%6GQ8RJR>8WT7FOO#]F"Q9KCQ!?*H) CA4GIZFOC
M7X.Z;YFH7M^PXA3RU/N?_K"OO/\ 9KTLV?@.6Z(P;RY=Q[@?*/Y5\5G];VF)
MY%]E?\$_7N!\*Z. ]J]YMOY+1?J>M4445\N?I@4444 %%%% !1110 4444 %
M%%% !1110 PPH9!(44R 8#XY ],T^BB@ HHHH **** "BBB@ HHHH _-G]OS
MX0MX*^)D7B^RAVZ3XB_UQ4?+'=*/FS_O#GZU\Z>"_P#D=?#G_82M_P#T8M?K
MS\9_A7IWQD^'FJ>&-1 7[0FZWGQS!,.4<?0_IFOR(\5>%]7^'OBR_P!"U:)[
M/6-+GV/C(Y!RKJ?0\$&OM\LQ*Q%'V4G[T?R/T7)\8L5A_8R?O1T^73_(^S?V
MB/CGX3^"/QF\47VE>$+J]^(MUI,5JVKW%P!;)$T8QM3KD#'UQ73?L]Z'XFT#
M2?AA)>^)?$.L66K0R3C3]'LHAI5O&V6874G4DEOKFOS^U;6-0\07SWNJ7UQJ
M5ZX >XNI#([ < $GTK4TWXB>+-%TE-+T_P 3:M8Z:CB1+2WNW2-6!R" #QS5
MRR_]RJ<7KU;UZ6T[&DLK_<*E&6O5O7I;3M;R/K^W\8:G\)/@O\;M6\,>187U
MIXQEAMI#$&$ 8J"5![X/%4IOB%\3/'/[$+ZMI.H7>K:V=3N(-3FMXU+K9;&,
M@88X7!Y/O7R!-XHUJXL;RREU:]EL[V;[1=6[S,4GE_ON,\M[FI-*\7:]H.FW
MFGZ9K5]I^GW@*W-K;SLD<P(P0R@X.16GU%;Z-W3U796L:?V:OBT<N9.[71*U
MC[N;XF^(?"?B[]G#PSI%U';:-KFGPKJ$(A4M<+M"A2W7 Z_6H_ .EZ?HNE?'
M2308-5M]?C\2,DG_  B\<9U**#Y2!"&Z#)8G'O7PG)XKUR2XTV=]9OGGTQ0E
MC*T[%K51T$9S\H^E2Z7XV\1Z'K4^KZ=KVHV.JW!)FO(+EEEE)[L0>?QK)Y>[
M637^?O7U_(R>5OEM&2O^?O7U^6A]Z>#?%PUSX_-J9\,:MH6J6W@F7SG\06Z1
MW%_L;*2NJ_3G-><_LY_&3Q?\1)/%;^(-/UV^DURXAL%\6>&;=?/TL@G9&0!E
M4&<Y],YKY5G\?^*;K5IM5F\1ZI+J<T1@DO&NG,KQGJA;/W?:F>&_&_B/P;Y_
M]@:]J&BBX&)A8W#1"3Z@'FJ^H>ZUI=I?*Q7]F+DDM+M)+?2Q]HS:IXG^"7PY
M_:"O;7Q$NL^(['4;9TUJ2%"[%HP S*/EW@'GWK8M;Z;Q/\8_V</$6HK'-K.I
M:+<M=W00 S'RLY/YD_C7P9_PDFL&RO[,ZK>M::@_FWD+3L4N7_O2#/S'W-6(
M_&?B&&;3IH]=U".;35,=C(MPP:U4]5C.?E'TH> ;N[J[OK;O&WYZB>6-IOF7
M,[ZV[QY?SU/LOX?S>.+7X!?%*7X=6QN/%4?C"Z^SB*)7E5/, <Q@_P 6/ZUT
MGC3Q'?\ A'XV> M9N/"=QXF\5CPDP\00:.BM>6N2O[]5[L&W#UP>*^4/#G[0
M&H>%_@MJG@NP%]::W>:N-577;>Y*.AR"0<<DGUS7!0^._$UMXB?7XO$.I1ZZ
MXPVI+<OY[#T+9SCVJ%@92G)RM;7U=TEOV,UETYSG*5DKOU=TEJUT_4]E_;(\
M*:CX=\6>&;J^\3:CXC@U'3VGM(]:0+?6<98'RY<#)Z\9YXKQ[P#X'O\ XE>-
M-'\,::A:ZU*=8MP'^KC_ (W/L%R:S-<\0:EXBOY-1UG4KK5+UQ\]S>2F1R/3
M)K] _P!@W]GN3P3X??QYKUKY>MZO%MLH9%^:VM3SG'9GZ_3%;UJWU##>\[RV
M7J=->O\ V;@USN\EHNEW_P  ^H?!_A>R\%>%]+T+3XQ%9Z?;I;QJ!V48S^/7
M\:V***^!;<G=GYE)N3;>X445SGQ(OKC3/AWXIO+25K>ZM]*NI8I4^\CK"Q5A
M[@@&D(Z.BOD+]EG]H>?PS^P/IWQ3^(.J7NN2Z?9W%S=W,K;YY]LC!4!/4DX
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M /I2BOC?XL?MZ^)/!?Q&^(WA/PQ\)+[Q?_P@T45[JFH0Z@D44=H8P[N05SN
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MN1RN.%&2>QXJ&T_X*&6^M_![P=K^B>!;[4O'?BG6)M L?"8ND4B\A.)=TQ&
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M%>I_';]L[QO\#["#4=0^%4":=:Z;#?ZHU[XBMX959@/,AMH_O3,F2"0,''%
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MTW^-?5G_  SW\-O^A*T?_P !5H_X9[^&W_0E:/\ ^ JT7"Q\I_\ "&_LF_\
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MJ8ZKSSVZ+L%%%%<1YP5D^+M#/B;PKK6CB7R#J%E-:"7&=GF1LF['?&<UK44
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MH/B9\;/%GAOXE?$31[&\ABL-'\,C4K-6@5BDV0-Q/<<GBJAEU6I)1A).ZO\
M*]NW<[WG5",92G"2<7RM-*Z?+S=^Q],5ROCSXG>&_AG'IDGB/4ETY-2N5L[8
MLK-OE;HO XKY1UKXR?&[1OAGH_CV]U'3XM#UT0Q'[+8^<VF1'K<L!U+<\=!5
M_P ;?%/7++P/X&O(O%VA?$*WU'Q3;VT>IG34!BB;&59#G9(#GG@UZ-/)9\T>
M>2:;:T;W6^O*TK>>_0YWGE.<7R0<6DG[R6SV=N:[OY;=3[(5@R@@Y!Y%+7R=
M8?$+XM?''7_'5]X(\0Z;X6\/>&KI[*TMY[,3R7LB+DEV/W0?:N7LOVJOB-XV
MM?AE!X?73;+6]<GNM-OXKJ+,!GC( E!Z@ 9.!WKD>4UEIS*ZW5]M+ZZ=ETN>
MS2QE.KLG9[/OK;0^V:P?&'CSP]X TX7WB+6+/1[4G:LEW*$W'T'J?I7B?P'^
M)'CR/XQ^+OAQX[U"SURYTVUCOK?4K6 0Y5S]TJ.U<A<:'9?%S]N#5],\40KJ
M.E>&]*22QT^X&Z'>VTERIX/+']*X_JO)-QF]$KZ=5Y'LT*4:DFYO1*[/HOP1
M\6O!WQ(,J^&O$5AJ\D0R\5O*"ZCU*]<5GWOQZ^'NG>)O^$?N?%VEQ:OY@B-L
MTXR')P%)Z Y[5\]?M >$-+^&?[0'PLU?PC:0Z#J&L7,FGW26""-9488R4'!Q
MFN,\*M;?LVZA>>%_BQ\/(-4T*^U-IX/%J0+-DLX*L[$9&",]01SUK&5.-N:+
MW/J\'DN'Q4%4@Y2YE>,%RJ3U:=KZ.UMEJ[GWJ"& (Y%+4%C<0W5G!-;,KV\D
M:O&R]"I&01^%3US'Q;5G8****!!5/5]5MM#TRYO[N016]NA=V/H*N5\X?'KX
MF1ZS=2:)9SA=,LB6NY@?ED<=L^@_G5)<SL9U)J$;L\A^,7Q,EN9M2\07)Q/.
M?*LX2?NC^$?@.37R]+*\\KR2,7D<EF8]2372>/O%S>*]:9XR18P92!?;NWU-
M<S7ZAE.!^IT+R7O2W_1'\V<3YQ_:N,Y:;_=PT7F^K^?3R"O6?A+X>^R:?-JT
MRXDN/W<6?[@ZG\37G?A?09?$FM6]C'D*QS(W]U!U-?;?PA^$$>O>#=7O)(=D
M)MFM=.4CHRC[X_$8KS\^QBITUAXO66_I_P $]W@K*98C$/'37NPT7K_P%^+/
M)ZZ3X;^(O^$6\<:3J!;;$)1%+SCY&X/]*YQHWA=HY!MD0E&7T(.#36&Y2*^%
M/V5.SN??"L&4,IR",@BEKA_@WXL'BWP)83.^Z[ME^S3C/.Y> ?Q&*[BL#U$[
MJZ"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ KE?B)\+_#'Q4T1]*\3Z1!J=JP^5I%Q)&?5&ZJ?I754549.#YHNS*C
M*4&I1=FC\^?BU_P3MUW19)[[P!J::S9\L-,U!@DZ#T5^C?C@U\L>+/ OB3P'
M>-:>(]!O]&F4X/VJ!@I^C=#7[6U3U31['6K5K;4+*WOK=N#%<1+(I_ BO>H9
MQ5IZ55S?@SZ;#9]7IKEK+F7W,_$%9%;HP/XTZOUD\4?L@_";Q6[R7/A"UM9G
MY,EBS0'\E('Z5P%]_P $[/A?<L3!-K5G_LQW>X?J#7K1SG#R^)-'MPS_  LE
M[R:^7_!/S:I"P7J<5^CT'_!.7X:QOF34-<F']TW*C^2UU?A_]A?X1:$ZN^@2
MZFX[WUT[C\@0*<LXPRVN_D5+/L)':[^7_!/R[L;6XU2Z6VL;::^N&.%BMHS(
MQ_ 5[Y\+_P!B'XD_$1XI]0LU\):4V";C4A^^(_V8AS^=?I-X7^'?ACP3"L6@
MZ!I^DJ!C-K;JC?B0,FNBKS:V=3EI1C;UU/(Q'$-22M0A;S>IXM\$_P!DWP-\
M%%CN[2T.L:]CY]6U !Y ?]@=$'T_.O::**^?J59UI<U1W9\O5K5*\N>K*["B
MBBLC$**** "N/^,6I:UHWPG\8W_AQ&DUZVTFZFL51=S><L3%,#N<XP*["B@#
M\X-!L?A6O[)OBC6]!\8W6M_$C5_ MS<:W;W.JR3RSR%09WG@8D(R294<#'2K
M/C[Q)JMCI_Q3BMM5O;:&U^#ND3VZ13.JP2%R#(@!X;W'-?>%C\,O"&ES:G+9
M^%]'M9=3!6^>&QB4W(/4287Y@?>K\WA'0KCSQ+HUA(+BW6TEW6R'S(5^[&W'
M*#LIXH ^&-'\&P_!;XE^!HO#FLZT5\7?#K4KS6OMVH2W!N[B*WC>.<[B=K@L
M>5QQ7*>&]1T'QO)\#-#^+OBB]L/A_-\/FU&W>ZU*2UAO=2$I5VEF# LZ1X*@
MGWK]&)?#FE3S6\TFFVDDUO"UO#(T"EHXF&&13CA2  0..*S=8^'/A3Q!H]GI
M6I^&])U#3+,@VUG<V4;Q0D=-BD87\* /SR_:D\5>"-0.MZ7X>\R\N?#/A&"[
MT[Q3KGBB>U(5MQ@>QB7F>7*\L00?E%>U? O5[O7_ -JGPYJ=_.]S?WOPGTV>
M>>0?-)(T[%F/N37U%JOPU\):[<6=QJ/AG2+^>SC\FVDN+*-VACQC8I*\+CL.
M*U+7P[I=C>1W=MIMI;W4<"VJ310JKK"#D1@@9"@_P]* /B7]H)O"7BK]J#Q?
MI/Q;\47OAWPWHWA&*]\-1)J#V<33NSB>>,J1YDRD* O/7I7AGAJ_O-3^'?[-
M_A?4IK%O E[X?U"Y-OKVJ3Z997M\LS!%EFB^8N$PRH<9))K]0O$'@?P[XLN+
M.XUO0M.U>>R;?;27UJDS0MZJ6!Q^%0ZG\/?"^M:'%HM_X=TN\TB([H[&>SC>
M%#ZJA& ?I0!\'_V]KW[-'P_^%OQ9USQ?%XST+0+[4-#U230[V2\MSIUQDVJ%
MC_K'AE54WD9P:Y'7M.\4V/\ PIO1/&][!/H_C"WU/Q/JEOXDU>XT^QN-1F??
M#;O/'\P,<3+LCX&<U^D@\$>'E\.KH T+3?[#4 #3?LJ?9Q@Y'[O&WKSTI_B'
MP?H7B[2UTW6]&L-7T]2"MK>VR2Q@CH0K @8H ^%/"&EZUX>U+]FVQU/Q1IOC
M*>#Q/K7]GW>F7C7<,<'V24Q6QF89<I]W<?05YKI>L:3-\-?#7CRR\7:I<?M)
MW?C".VN=/.H2&Y,ANRDMFUIG @6$'^' &#FOTSL/!?A_2[?3H+/1-/M8=-8M
M91PVJ*ML2,$Q@#Y203T]:@A^'OA>W\32>(XO#NEQZ_)P^J+9QBY;US)C=^M
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M?:?'#*+5Y?[_ ,H&"?0&ONC6OAKX2\16T=OJOAG2-1@CB6!([JQCD5(U.50
MKPH[#I6G_P ([I6ZP;^S;3=8*5M#Y"YMP5VD1\?*,<<=J /S]^!]Q)=:1^S/
MH_VNXCTS5=4\66]Y;0RO&EPGF-PP!&<9./3M7#?#O2O#'P__ &)?B3+X7U";
M3/%\'B(VNI0P7\GVFVB74E6,,F[*97'./FSWK]-K7PGHEE]B^SZ18P?86=[7
MR[=%\AG^^4P/E+=\=:J#X=^%EN-3G'AS2A-J;*]\_P!CCS=,IRIDX^8@\\T
M?GE\:%U[X@_'?XN:=K6O:'X>U?1ULT\,7WB#7[C33I<)A1UNK:-!MER^=Q.<
MG(KI_B]?P>!OCAX<\7>+];T_XDH8]%TV72]+UF2VU+1KT[1]IM[=2%FBF9@[
M \XSVK[D\1?#GPIXOO+:[USPWI.L75MQ#-?6<<SQ]_E+ D4ZX^'GA>Z\10:_
M-X=TN76[=0D6HO9QF>, 8 5\9&.W/% '0*VY0?44M%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MF]%5\)/F77NO)KI_5CTFBF13)/&LD;K(C#(93D&GUS'MA1110 4444 %%%%
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M_LK[U]56K4\/!U*CLD?FN%PM;'5HT*$>:3'^ ?!$GBF\\Z<-'ID)S))_?/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MF*7L*\6^S=G]SLSZCHKQK3_C],RC[5I22C^];2_XYK;M?COHDF//M;RW/?Y
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M7'3O/1+9=C^C<ER'#9/2Y::O)[M[O_)>0BJ$4*H"J!@ #@4M%%>4?4!1110
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M4MY/$%K MU/IZM^]CB;[KD>AH47*]EL!N4445(!1110 4444 %%%% !1110
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MR.NAF&,PW\"M*/I)K\F=8OQ/UY<?Z1&WUC%.;XI:Z1_K(1](Q7(T5C]3P_\
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M6=_(@+FXY&1N[],5].ZY^QW\+M>\476NS:+<6]U=S?:+F"SO988)Y,YW-&K
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MUW7[%M0@M3I4+J&\LLYQ+* <[4H ^LZ*\ST[]H#PSJWP!'Q=M/M5QX8.D/K
M2.(F<QJI+)M_O J1]17GMK^V#)!\)5\?ZSX%N].TFYOK&UL!;ZE#="[2Z<*L
M@9.%*;AN0\B@#Z.HKYU_:&^."PZ9\6_ 6G17FG:WHW@F;7DU>*3:JA@Z*$QR
M&!&<US'P3_:[GBTOP)H/C3P3X@\.IK'A]KS2M;U!TF_M1K> 22J47YD=E&Y0
M<ELT ?6-%?-OA']M+3]:^$VN?$W6?"MWH/@>SM!>66HB]AN7O-S[%B,:<Q2E
MB!L;INYK"NOVUM0U'P_XSTVV\%2Z7X\T_P .2>(=+TTZE;WD=U; $%R\?RJR
M'EHSSQUH ^KZ*^2/"O[:/B"Q^$7PTU+Q-X$G;QEXRVPZ?:?;X;:WO2(!*T_F
ML-L08'Y4/))Q7T-JOQ*M/"7PMN?&_BRTF\-VEC8&_O[2<B22V"C+(2O#'/ Q
MUR* .QHKYQ\&_M?7>M^(_#VE>(/AMK?A%?%=K-<^&+B^N(W74F2/S!"VW_4R
M,F& ;/6N,_8'UCQ-\0+CQWXV\66.O0:I>ZO=VPGO]5\ZS\N.8A8(8!Q&8\;2
MW>@#[!HKX;_:F_:VU?Q!\+?']IX)\*>(8]"TO5(=%?QU97"Q10W:7,0E 3[Y
MC&=A<'&6Q7K/Q/\ VJKSX*2VSZUX&U"Y\)VR6D=UXC_M"!"WFA09(K<GS)55
MF^8C% 'T717S)X8_:*\?ZI^U=XT\!R>"IKKPAI>GVMS!=P3QB2)761O.(QEQ
M)M"JO4$5N>!OVJYM=^+NE_#_ ,3>![WP?J6LP7%QIDDVH071D\GETF2,YA?;
MR V: /?Z*\S^,WQ6UWX96]D^B^";GQ9YRN\TPU"&RM[<*,X:24XW-SA0.<5Y
ME<?MP:9>^$OAKJ_AOP7K7B6^\=M<PV&EVKHDL,\ /F)(QX !!RW3 S0!],T5
M\UC]MC3C\.4U<>#-8;QE)XB;PHG@U70W3:DO+1^9]W8%^8OTQVK+_95^)7B/
MXA?'SXW?V_8:KX?^PR:;%'X?U.<2_8F\EMQC*_*5?@Y'6@#ZHHKXQT7]HV;X
M>?M(?&'PY,NJ>,-?U#7=.M-!\+6DNZ18S:QF:4;N(H4R69CQGZUU6N_MZ>']
M$\1:C_Q3T]QX,TK5TT+4?$JZA ODW194;9;$^9)&CL%+C\J /J2BOGO4_P!L
MC0='\%>.=9N]"U"+5/"NOIX=DT3>OGW5Q(Z" QG&-LBN''L#7O\ :RO/:PR2
M1&"1T5FB8Y*$CE<^U $M%%% !1110 4444 %>;_'#X^>%?@#X<AU7Q+/*7N7
M\JULK5=\UPP&2%'H!U)XKTBODK]O7]G7Q/\ &32_#^M^$X1J.H:-YL<NF[PK
M2QO@[DSQN!'3N#7=@:=&MB(PKRM%E12;LST?X!_M<>"_V@+ZZTS21=:7K5NG
MFG3[]0'>/^\A!(8#OW%>W5^?W[#_ .RIXY\(?%!/&WBS39/#MG86TD-O:SL/
M.N'<8)('10/7K7Z UOF5'#T,0X8:5X_?KZE323LCYM_:*^./BGX<?M"_ GPC
MHL]M'HWBW59K75$EA#N\:KD!6S\M6?''Q9G\,_M=>'_#EUXT?3=!/ABZU6ZT
M)K$&%Q&6W3M/U7:!T]O>N:_;&^"OQ,\=?$SX1^.?AKINCZOJ'@R^FO)+/6+P
MVT<FY0%&0,XZ]*Y?6/V=?BQ\:/C!I/C#QUIFB>&ENO!>I>'-2CTF^,ZV\TQ8
M1,@(RPPP)Y[8KRC,[OP?_P %!OAKXNMM<U/[%XATGPSIME-?IXBU'3'BL;R*
M(X?R9/XFSP!U-6/!W[>7@3Q5!XA%WI'B+PW?Z1HC>(ET_6; P37NGJ,^? ,_
M,.GIUKPK1OV8?C]XN_9MU#X!^*+#PKHGAC2M,>UTS7[2Z>6>_E23? '0<(I_
MB/6HOAO^QYXVC\,^+[74_A?H?AKQ'-X0N="M-?7Q-/?R75PZ!0JH^5BB;!)]
M,\4 >X_"K_@H1\,OBUXWTKPWI]OKVF/J]I)=Z;?ZKIS6]M>"-2TBQN>I4 ^V
M>E06/[:.@?%[P/XYNO!UKXCT;3].TB^N[/QC<:26L', (9HSGYF!Y"G&<5PF
MB_LF_$#2Y/V7I#:Z4S?#W3)[;6E:Y!02-#M55X^=2>#7&_#_ /9!^+%GXF^(
M]U:^']*^''AG7?#=]I\GA?3=;DN['4-1E!"3HC#$"\CZ4 >G:%^W;X7^&?PS
M^&,'BN[\0>-O$OB?P_\ VM:W.EZ03+?@,0?W2GY6X^F!FNR_X;R^'-U\,/"_
MC'2[?6]:D\27TFFZ;H.GV+2:C-<QY\V/RL\%0,GGN*\V^#_[)_CWP7\1OV?=
M8U.#3A8^"_!%UH6K&.Y#LEU)OVA!CYE^8?-]:^5?CA\)?%OP3T/X5>#]=O[+
MPUJUUXQUK6XM8^VR6]I;0R >66O(QF)R/X1US0!^E?[._P"T?X>_:4\.ZKK/
MAS3M6L+33KPV$W]K6OD,9E'SJO)SM/!]#7K%?)O_  3;\86/B+X'ZAIFF>$C
MX:L]&U:>V^UQW$EQ!JTA.Y[J.63YGW'J37UE0 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 8/BWP3H_C:Q-KJMHLW'R2CB2,^JM7SIX\^ >M>%3)=:9NUC31S\@_
M?(/=>_U%?5-%4I-&<J<9;GP/R&*D$,#@J1@BBOL#QM\'_#WC96DGMOL=\>EW
M; *^??L?QKP;QA\!_$GA<R36L8UBQ7GS+<?O /=/\*T4DSCE2E$\W*@XR.G2
MNN\+?%;Q/X195M-2>>V7_EVNOWB?AGD5R3JT4C1R*T<B\%'!##\#15&:;6Q]
M$^&_VG-/N-D>MZ=+9/T,UN?,3ZXZBO3M%^('A_Q%"7T[5K:X;&?+WA7Z?W3S
M7Q12+\K;E)5O53@U'*C:-:2W+^O7AU#7M2N2<F:YD?/U8U0]#T(.01P12T59
M@>M_#CX_:AX;\JPUWS-2TT?*L_6:(>_]X?K7T9H7B#3_ !-I\=[IEU'=VS]&
MC/3V([&OABMGPKXPU;P7J(O-)NF@;/SQ-S'(/1A4./8WA5<='L?;]%>;?#GX
MW:1XV6.TNBNF:OC!@D/R2'U0]_I7I-9[':I*2N@HHHI#"OG3]OCQD_A/]G/6
MH8GV3ZM+%IZX/.&;+?\ CJFOHNOB#_@J%K#1>$O!.F!L)/?RSLOKMCP/_0J]
M3*Z?M<;2B^]_NU+@KR1^>JC:H'IQ2T45^LGH!1110 R1?,79_>(7\R!7U'^U
MSXFN/ 7Q0^%7]G#;'X7T#3[JVCZ*6R&;\]M?+DV?+;;]X#(^HYKZY^-6CV'Q
M/U3]GCQI=NO]@:[;VFBZC+GY4DBD 96/;/S5YF*:C6I2GM[WY?Y)D2W1ZGJO
MPB^'L_CG2?COKMKJ.IZ9XKN+%[#P^+=@(;Z7 ,LQ[(",C/%?.W[;GQ"\0^*/
MCMXHT'4-6N9M#TFX6"TT[>5AC&Q23M'!))ZFO1/B9^TQXT^"_P"UAK]M?0!_
M"0N+?3X]#ODQ;&S7"QS19& PZY'XUT'[3W[*9^*7Q/US7_ /B"UU'Q)=01:A
M>^&[MO+E,;( LD+XP00.A[UXN%E]7K4ZF)?NN/NO=+;3RLMWU,HZ-.1\;>!_
M&VO?#CQ#::OX9U6XT:_25,O;/M5QN *LO1@1ZBOT(^,'P)\'_M.?$.VT\BZT
M+QO8Z;8:C?:G%"6M[VTDQNC8C@.,''?FOF[X?_L5Z^T]AJGQ-OX? &@R7<<$
M<,Y\R]NY2PVQQH,XR1U-=W^U]^TMXHT/XI)\._ DATZ+19+199K!2UW?S(%*
M1,1SM' QWKHQ4OK6)@L'+WTG>71;=>OH.7O-<IQOB'XL?\)%^V_X5U+2X);/
M3M#U.VT*S@E4J_DQ_(VX=MWI7EO[2VDQ:)^T#X^M(%"1+JLD@5>@WX8_J37T
MKXK^'L/B3]OCPA/';I:S'3K;Q%KL*\+;RQQ[G+>A)KY/^,'BE/&_Q8\7Z]$=
MT%]J<TD1]4#%5/Y 5U8)QE4@X*R5-?GI^3*CNK=CD:***]LU"BBB@#ZW_P""
M:OC!]'^,FL^'V?$&L:<9%4GCS(CG/_?.:_3&OQ[_ &.M6?1_VF/ TB-M\^Y:
MU;W#H1BOV$K\YX@IJ.+4E]I+_(XZR]X*Q_&&AOXF\(ZWH\<JP2:A8SVBRL,A
M#)&R GZ9K8IDTR6\,DLK!(XU+,S=  ,DU\P8'PAX%_8O^.OAOX":Y\&]0\>^
M#[KP1=:1=6%JL.GS+<I+(249I".5#'GCI6W??L:_%3P'XH\&^+_A9XVT'2O$
M]EX3M?"NLKK-I)-;3K$H43Q!>=PP, ^GO7V)X;\2:7XPT.TUC1;^'4]+NU+P
M7=NVZ.0 D$@]^01^%:= 'PK\1/V"?&%[\6M5\=Z%>>"/%%[XAL;>+6+?QIID
MLT<=W&@5KBW$9X#8^Z:])\/_ +)NMZ1\;&\;'5=(M[%_ H\+'3]/MVA1+C&#
M(B=%CST7.:^BO&'B:T\%^%=8\07XD:RTNTEO)Q$NYRD:EFP.YP*K^ ?&=C\1
M?!.A^*-,65-.UBSBOK=9UVN(Y%#+N'8X- 'Q'K7[ OQ"D_9Q\*?"JVU/P1JU
MO8QW2W5YK%C,TUK-++O2XM)5^9&4$Y4\$XJ/Q%_P3E\3Z+XHTGQ#X:UCPMXR
MOCH-KH^J1>/[*6Y226% HN(RAR"0!P?2OO\ HH \[T'P+KOAGX)6OA?33H%M
MX@MM.^SQ^58E-+$ISD>3G(C))XZ\U\WZ?^PWXIO/ WQ&M+G5] \+:EXBN[#4
M=-T?P_',VD6%U:N'\[8^"#*P^<* ,=*^U** /DR#]F'XG>+M;^)GB'QQXF\/
MR:OXN\(GPU;V^DP2K!8G)(;+#+C+$D]><4>#?V9?BK-XD\"W?CCQ=X>U"R^'
MVG30^'QIMI(K75V\(B6:Z#8PJJ -JGGDU]9T4 ?%$/["7B'QE:_$C_A*-2\/
M>&1XJTV&U&E^$8918->13"9;Z6*3 WEE *J/ND\UW?PP_9M\2Z7I?B;3O$FC
M^ -$34M%ETA+_P )V,J74C.I4R.S@;5P<[!GGO7TY10!\AS?LW_%>\^ .A?#
M?6%^'?B:WTJ(Z<@U*VN-IMT0)#<*P&Z.=<9.WCWKU2T_9U:]_98'P>\0>(KK
M5I)=&_LN?6GR92V,AQDY(4XQGL*]HHH ^7_ O[//Q-UCQQ\/-2^)_B30;_2?
MA\CG28="@D26^N#%Y*SW!<87"9^5<C)->F?LX_"*_P#@MX%U#0M2O[?4;BYU
MF^U,2VRD*$GE+JO/< \UZI10!\7>+/V._BE<>&/&OP\\-^,M L_ASXAUIM<!
MO;:5M0B+SI-);9 V["Z9#=>V*H?&C]A;QI\2/%OC*YM=:\-W=AXB:RE@U'6X
MIY;[2%@5 ;>V4?($8J2&ZC/-?<%% 'SMK'P!\;6WQPUKQ7X<\0Z;9:'XG\/0
MZ'JXF23[;:/#'(L<]LP&TG,@.&Q]VO-_@3^Q-XN^&_Q2\!>)M8O_  O]G\*P
M7EM+<:9%.U]JYF0J)[B23^/)!*CCKS7VC10!\Z?M,?L[>)OBYXX\)>(M%N]$
MU"STBWN+:;P_XF69K%FEQBY"Q_>D3! #<$&N?^$?[(.O_#B#X*QW.O:=<_\
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M29,^N&!%:%% %>PT^UTJTCM;*VAL[:,82&WC"(H] H&!5BBB@ HHHH ****
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M45\__L=^+O$OC;P5J&J:W\4= ^*VGS2QM8:IHMD+22$%3OBGC'1@<8]J^@*
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M**0G R>E  JA!A0%'H!2/&DGWE5O]X9IOG1Y W@$],\5)3 C\B-0=L:J<=E
MK[P^"?[07P?L?@IX'T'Q9KLEAK&APW$4D!LVD_UH=2,[2",.#]17PDS!1DD
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MBSV-[;F<I+&@QF-@OW2#VKU35_VGK#X9ZI\:?%OV+Q%KR:''HLS:3->J8/\
M2HH]JVJ$?NS\XW9ZF@#ZXHKYA\0_M?:]X7L/"VEZK\/XM(\?>)C<7%AH.I:W
M#!##91 'SY[AAM0G(&S&<FHK/]N2T\3>"O"<_A7PA=:[XW\1ZK=:+!X;6[C1
M(;BVS]H=[C!7REX(<#G(H ^HZ*^0=9_:2^,R?M!?#GPQ'\-%TVPU?3;R:_TF
MZU.$R.\3H&E64+PJ Y _CW>U>X?'CXU?\*9\/Z+-;Z-)K^N:[J<.CZ7IRSK
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MA=I6M?$'2;_P=\.M46[TNU@T]DNKN%4=(Q.Y. Z*P P,'DFLGPG^PGXH\/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MK N[WQ/H>HS+<ZS9#'[BXM?N&0XP7H ^XZ*** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 1M;Q.Q+1HQ.,
MDJ.<=*;)9V\R[9((Y%W;\,@(W>OUHHH 22QMI54/;Q.%.X!D!P?7ZTIL[<S+
M*8(S*HP'V#<!Z9HHH 8VFVC>;FUA/F_ZS,8^?Z\<U*UO$T/DM$AAQM\LJ-N/
M3%%% #?L<'D&#R(_)/!CV#:?PH6S@50H@C"@;0H08 '(%%% &=KWA>R\10K%
M<^8D88L1"VW=GKGUJ[#I=I!9K:I;1_9U18Q&5!&T= <]:** )?LT/V?R/*3R
M<;?+VC;CTQ0EK!&BHD,:HH*JJJ  #U HHH 3['!YJ2>1'YB#:K[!E1Z ]A21
MV5O"NV."*-=V_:J #=Z_6BB@"*ZTFVNH;F/RQ$;A=LDD0"NWXBLFU\!Z1:VL
M5N(G>-;@7+!VSYD@& 6]<>GM110!T#QI)C>BMCD;AG%,:UA92IAC*E=A4J,;
M?3Z444 )'9P1*%2&-%7H%0 #/6F?V;:>2L7V6'RE.X)Y8V@^N,=:** 'M9V[
MLK-!&S*-H)09 ]/I1]C@\YIO(C\UEVF38-Q'IGTHHH ;<6,<]O)$ 8?,3R]\
M7RL!['M4.DZ+::+8P6EK%MBA!"%N6YZG/J:** )UL;=6D86\0:3[Y"#+_7UI
M_P!GBR3Y:9R&^Z.HZ&BB@!)+6&:6.22&-Y(^4=E!*_0]J;]BM_,>3R(O,?AG
MV#)^IHHH D:)&CV%%*?W2./RIDUG!<*ZRP1R*^-P= 0V.F?6BB@ >SMY&C+P
M1L8_N%D!V_3TI?LT.W'E)C;LQM'W?3Z444 $-K#;P^5%#'%%_<10%_(4V*QM
MX5"QV\4:J<@*@ !]:** "2QMI-F^WB?9DKN0';GKCTJ22&.:,QR(LD;#!1@"
M#^%%% $+:=:- L#6L+0J<K&8QM'T&*E%O$,8B0<[ONCKZT44 1I86T;.R6T*
MLYW,50 L?4^M/>U@DQOAC;#;QN4'YO7Z^]%% #/L%KNE;[-#NE&)#L&7^OK3
MDL[>./8L$:IC&U4 &!T%%% "SVL-TH6:&.95.0)%# 'UYI/L=OYKR^1'YCC:
MS[!EAZ$]Q110 /9V\D91X(V0D$JR @XZ<4UK"V9D+6T),?W"4'R_3THHH =]
MC@\YIO)C\YAM,FP;B/3/I1)9V\RH)((W"?=#(#M^GI110 -9P-(9#!&7P!N*
M#.!T&:!9VXDD<01AY!AVV#+?7UHHH 5K:%F#&)"<@Y*CJ.AJ6BB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
:BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>rxrx-20240331_g2.jpg
<TEXT>
begin 644 rxrx-20240331_g2.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" ,3!>T# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MS=#_ ./>Y_Z^I_\ T8U:59NA_P#'O<_]?4__ *,:@74TJ***!A1110 4444
M%%%% !1110 4444 %%%% !6=9_\ (:U+_=B_D:T:SK/_ )#6I?[L7\C3$:-%
M%?.'PL_;V^&?Q;^/6N_"/2X]:L/%.E3W5L)-2MHH[:[DMW*RK"RRLQ(VLPW*
MN0I-)>]+E6^K^[<;]V/,]O\ ,^CZ*\RA_:!\.3?M"S_!Q;34AXHAT,:^UT8H
M_L9MS((]H??OWY(XV8QWKTVCHI='^C:_-,.MOZ[_ )!1110 445Q'Q@^*/\
MPJ'P>WB#_A$?%7C7$Z0?V7X/TW[??'=GY_*W+\@QR<\9%)R4=6-)O8[>BOC;
M1_\ @IUX7\0^(M5\/Z5\%OC1J>O:3C^T-+L_"L4MU9YZ>=$MR6CS_M 5]>Z+
MJ7]LZ/8ZA]EN;'[5!'/]EO8_+GAW*&V2+D[7&<$=B#5)7CS+8FZYN7J7****
M0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\1-/U'7YG\N"TD@N+<3M_=B>6-4D/'1&)-.S<N7J3=)<SV/=J*^%?&'_  5
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MQ4];)]Q7U:[!1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !116;XDL=0U/P]JEGI.I_V+JEQ:RQ6FI?9
MUG^R3,A"2^6WROM8AMIX.,&DW97L-*[LW8TJ*_-KXF^(/VG?AS^U!\-?@_\
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M:>-#%AO%UN%P _G^8-F/M!XV-G;U&:(Z5:<KV2;_ /26OU-5)*C5B]Y1LO\
MP*+_ "1\Y_#WPCXP\0?M#?&#]IKQ5IM[\#?"C>%9=-TNX\0VD9U"+;%$OVR>
MUR>4\G=L;[Q*J-V":\#^('[17B'X?2>$/'?PZ\>_M :^E[K=M#/K7CRS1/"6
MJP-NWI;)M 5F*\*%SMWX(*YK]6_BG\.-)^+WPY\1>"]=\X:3KEG)97#6S[)5
M5AC<A((# X(R",CD&OC_ %S_ ()L^+/%GP[T#P1XA_: UC5O#?AFZMYO#^FM
MX>MXH+2.(X59MD@>X81[D5V<;=Q(!Z4Z/N58+:,>7[N9N5_OZ+75=$95+RIR
MOJWS??RI1MZ6ZNZW6[/)_P!H_P""/_"4?\%1OASHO_"?^.=)_P"$GT6XU#^T
M=,UGR;S2=L5Y^XL9-A\B$^5RF#GS).?FX] ^&^E>(O@7_P %$++X>_\ "TOB
M%XW\)OX(FUJ6V\8>()-0_?&1UR%PJ<",8^7(R>>:]T_:(_9$O/C!\4?!?Q+\
M(>/[GX<>/O"]O)9V^JQ:5#J,<D#A@5,,K*N0))0"<CYSQT-:EK^R[,/VH]%^
M,][XN;4+NQ\*+X:GTV33E4W3AF9KDRK( I8L?W8CQZ'M2A[M.$8Z./.OOY^5
M_C%>OWCK/VDW*VZA]Z<>;[]?+\C\\])_:-^)_P"T)HOBOQU%<?M##Q%]MN4\
M-6OPQT@2>%[144>3#= '=.P)&_(R >_2O8OCW\<OC1_PH_\ 9<U:\U#6?AQ\
M0M>\2)INL0RP26I=RQA#W%IE0ZMQ+Y3C;\PX%>UZ-^PWXL^%>O:V/@Y\<=6^
M&G@_6KY]0N_#3:#::I'%*X ;[/)-S",  84G &2<"NK^,G['K?%[0_A%I]SX
M\U(S> =9@UB34M5MA>W6JM&02LCAXPC,1]X @#@+4VO3A%*WO4[]U9KF^_KK
M=Z:"G=SD_*=OFGRK7MI;MW/$;F3QW^S?^W#\+O J_%;QAX[\-?$*PN_[4MO%
M-XDYMYDCD(DMMJ*L W*I"JO'();/'G/['_[/OF?MR_&^R_X65\0E_P"$.U+3
M[C[0NO8FUSYF;R]2;R_])3Y<8^7AF'>OL_XH?LPK\2/VD/A?\6/^$D.G-X)C
MN8_[)^P^:+WS59<^;YB^7C=_=;..U<U'^Q[K'AG]IO6/BSX(^)U[X3LO$D]M
M-XE\-G1[>\34A#CY$GD.8 V#DJI8;VPPR %A^>-2G.H[-<Z]$W>&W1:^?D.L
ME*,XQV?(_5KXOF_Z9],44458@HHHH **** ,[4/^0II?^_)_Z+-:-9VH?\A3
M2_\ ?D_]%FM&@045\-_M6?%[XO-^VI\,O@W\//B(OP]TOQ)HKWEQ?#0[34V6
M93<MN*3KDC;;JN R_>)YK3^ _P"TC\1?!W[37CCX'?%W6].\7?V#HIUZT\86
M.GK922VZI&[^=;QDJ#MDZ*,@H?O!@0HM./-)V3YM_P"[>_Y-Z]#2I"5.7+:[
M]W;^]:WYV/M&BO&/ W[9'P:^)7BGPUX;\,^.K/5M=\16TEWIMA%;7"R21H'9
MBX:,>4<1N0LFUB!D C%9>I_MY? '1_'C^#KSXGZ/#KJ3>0ZXE:V20'!5KD(8
M5(/!!<8/6JL[J/5_IH_QT,[JW-T_S/>Z*X3XL?'3P#\#/#46O^.O%-CX=TN9
MML$MPQ=[AL9Q%&@9Y#CG"*>*^5?VV?VI-&\>?L.^)O'7P9\?W.ZWU.QM?[5T
M*YGLKJW9IX]T;?<EC)5AP0,@^E92GRIO>S2?E=I?J:1CS->=_P %<^Y:*^4O
M$&L6US\>/V?3J'QIUKPSJU[HIE3P-#:W,MMXC;R=SR32JWE*5Y/[P$G;\N#7
M;^*OVY?@7X'_ +?&N?$*QTZ;0]3DT>_MI+:X,Z72??1(A&7E"]WC#*/6M96C
M=-[-K[G;\_NV>IE!N:32T:3^]7M]R?KT/=J*^<_VAOB;X/\ B1^R7K?BW0/C
M%-X"\+W2P-'X\\/PSW,MIBX12HCA*RY9OW;*"K#<<XP:[.3XR>!_@G\#_"GB
M'QK\089-%.FVL<7B+5=R3ZJQA4B41 %VDD WE5!(R?2E\*DY:<K2^_\ +Y[]
M"MW'EUO?\+??^AZS17CWA?\ ; ^#7C#X<ZGX\TOX@Z2_A32Y%AO=0N6>V^SR
M-]Q'CE57#-_"-N6[9J#X0_ME?!CX\>(Y- \#>.[+6M:16<6+P3VLLBKRQC6:
M-/, '/R9XR>E.SOR]1<RMS7T/:**^-?V5?B!XG\1_ML?M-Z!JWB+5-3T/1[F
MQ&FZ;>7DDMO9!@^X0QL2L8.!D*!G%?9513DJE*%5;22?WCE[LYP_E=C-\0?\
M@QO^NL/_ *,6M*LWQ!_R#&_ZZP_^C%K2J@"BOC[_ (*2?'/X@?!'P-\/W^'G
MB)?#&IZ[XEBTNXOC8P79$31N<!)D9?O8/ !XQD5S,_QF^-/[+_[3'PP^'GQ'
M\=:=\6_#/Q D>U@U-="ATB]L9U94X2%BC(#)'UR2"V,$<E/]Y)175\J\W9.W
MW/K8F<E33;Z+F?DKM7_![7/N>BOSM_9S_;*\/_"[XH?M''XP_$VXMM,LO&+V
MFBV>K74]X\,0EN 4MH%#N(P%0$(NT<9Q7VDWQ_\ AS'\+8_B0_C+2$\#2('3
M7'N (#EMNW)YW[OEV8W9&,9XH^PI]&D_2Z3M^);3525/JFUZV=CT"BO%_A#^
MV5\&/CQXCDT#P-X[LM:UI%9Q8O!/:RR*O+&-9HT\P <_)GC)Z5#X\_;8^!_P
MQ\>CP9XF^(NEZ7XC#B.6T9)9%@8C.V:5$,<1P1Q(R]:=G=+J]O/T%W?;<]NH
MKS?XQ?M&_#7X :39ZCX_\76/AZWO<_94D#S37 &,F.*)6D<#(R54@9&>HK1^
M$OQL\#?';PVVO> _$MEXETQ'\J22U+*\+XSMDC8!XVQSAE!Q27O7MTW!Z6OU
MV.WHKR7]I#Q+\4_#O@G_ (M1H.C:EK4PE-QJ>O7ABM=,B2,MYIC4%YF.,!5Z
M'DY'%>9_\$W?C9XS^/W[-Z>*O'>L?VYKQU>ZM3="UAM_W:;-J[(D1>-QYQFB
MG^\<TOLI-_-VT)G)4^2_VG9?)-_H?4U%%%!04444 07W_'E<?]<V_D:CTG_D
M%67_ %Q3_P!!%27W_'E<?]<V_D:CTG_D%67_ %Q3_P!!%/H+J6Z*\*_;@^*'
MB/X,_LL^._&/A*^73?$6FP6YM+MX$F$3/<Q1EMC@J3M=L;@1GM7R+XD^/_[1
MG[//P#^''QUU_P")NF_$[PSXB^POJ7A>^\-VNG26L=Q$9/W5Q 0788*Y( !P
M=I&14Q:=[NR32N]KRV-'"7*I+6]]/\*3?YGZ7T5\"^(OVG(?AS_P42U-_&'C
MVZ\._#1? 4-^--U#4)%L5N',95E@R5:8@G[JECSUKZR^&'[1GPU^,O@O4/%G
M@_QAI^J^']-#&^O&+6_V,*I8F9)0C1C:"<N , FE&7-%R[7OY6DXZ_<1U276
MUO.Z3_4](HKY_P##/[?7[/\ XQ\:P>$])^)NEW.MSS+;PQO#/%#-(3A42=XQ
M$Q)( PYR2 *ZCXS?M6?"?]GN]L;+X@>-++P_?7J^9!9F*6XG9,X#F.%'94R"
M-S #@\\&J>B3>SV\PW;2Z;GK%%<#K'QZ^'GA_P"&-O\ $34?%^EVO@FYB66#
M6GG'DS!L[0G=F."-@!;((QQ6-\%?VJ/A3^T/+>0_#[QG9>(+JT7?-9^5+;7"
MIG&_RID1RN<#<!CD<\BG9W<>JW\A75E+H]CU>BN3^)UEXTU+PK):^ M3TC1=
M?FEC0:CK5J]U#;Q$_O'6)&7?(!]T%@N>OI7Q;I?Q_P#C;\ _VW/!WP:\?>-=
M/^*V@>+K=+B*^BT.#3+BRWF8#:D)(PK0G.\ME3G(-*/O34-FW9>;M?\ KH.7
MNP<^B5WY*]C[^HHHH **** "LW0_^/>Y_P"OJ?\ ]&-6E6;H?_'O<_\ 7U/_
M .C&H%U-*BLSQ-?2Z7X;U:\@(6>WM)9HRPR RH2./J*_,GX/_&O]J'QS^REX
MC^/L7QIT^\3P])=22^$=2\)V*PW,5N%9_P#28@C@E2<*%'(QNYR)YE>7:*N_
M1NQ35N7O)V7K:Y^I-%?FW\5OVN]:\6ZI^QSX\7Q#=^ ] \3WMQ-XBLH=2>WL
M76.6".43?,%>($2$>9G ;UK[+^#_ .U;\)OCWK6I:/X"\;6/B'5-/!>>TC26
M&38" 702(OF("0-Z;EY'/-:\CU[IR5O\-KOT,^=>Z^C2?WWT]=#UFBOG[Q5^
MWY^S]X+\7R>&-6^)VEPZQ%,UO+'#%//#%(IPRO-'&T:$'(.YA@@YKO\ XG?M
M!?#KX-^#;/Q7XP\7:=H^@7P4V=X7,WVO<NX>2L89I<K\WR \<UG=<O/T[FEG
MS<G7L>A45YY\/?VA/AQ\4_A]>>./#'B_3=0\*66_[9JDCFWCM-BAW\X2A6BP
MI#'>!P0:Y+X;?MM_ _XN^,AX4\)_$/3=3U]F*16;Q36_GL!DK"TJ*LIP"<(6
MZ55GS<EM>Q-UR\W0]PHK,\3#6&\.ZH/#QLEU[[-)]@;4@YMA<;3Y?F[/FV;L
M9V\XSBO@C]HKXM?M$_LC^(_ .LZK\5-"^)L?B?68]-D\#P^&8+!@&^\;=U=I
MG&?E#,W#.F0<XI1]Z:AW:7S>B'+W8.?:[^2W/T*HI%8LH)&TD=/2EH ****
M"LZS_P"0UJ7^[%_(UHUG6?\ R&M2_P!V+^1IB-&OQT\._"[6]9T7X\_%3P4A
M'CWX7_%34->L/+7YKBU#DW4!QR5*(&V]PC#^*OV+KP_]G']F6+]G^^^)MPWB
M#_A(D\;>([C7WB>Q%N+42DGR/]8_F8W'YOES_=%9VES.479I:/SYHM?D_EIU
M*TLE)75]5Y<LD_S/FOX._%;1_BS_ ,%$K3Q[H[[]*U;X1Q7RJ#N:,_:5+QG'
M\2L&4^ZFOGW2?VC?B?\ M":+XK\=17'[0P\1?;;E/#5K\,=($GA>T5%'DPW0
M!W3L"1OR,@'OTK[2_9V_X)]:-^SG^T%XD^(NC>++B]T;4;*XL;#PS-9!5TZ*
M:=9BBS>8=Z*RMA=B_>Y).28M&_8;\6?"O7M;'P<^..K?#3P?K5\^H7?AIM!M
M-4CBE< -]GDFYA&  ,*3@#).!6CL^6VGNR_[=;FY?D[75_Q8*\;J]]5K_,E&
MWXM7:?Z:\3X\^.NMW/[,WPCN?BMXO\=?"SQQKYEMKWPYX.T<)XBUJ>,F,"%&
M0FVS\DG"C/F*O&0*YC]A_P",WC'_ (:P\4_#*ZU3XG7/@W_A&SJUK8?%^$+K
MMM.LD2EMW4QL)'QV(QP,9/T%\9/V,Y/B;H_PWN],^)&O:'\0? +M)I7C*]AC
MU&>5GV^8UQ$VU)-Q0<< =,$<55^#O[&FK_#C]H:\^+WB+XI:EX]\0:AH+:/?
M+J.F16^^0R(PDB\IPD486-5$(0\DMNYQ1O.<MK\_I\+Y;?.V]K=.K(:M3C%:
MV4?6_-K^'K?J?)_[$]Y\;?BYX5N/BKK7Q=\6:GX5^'NN7@;P;ID,VH:AX@V(
ML\D+L9D\S*RHD:-O Q@!>I^[?@C^T?\ \+LUC4=/_P"%7?$GP%]B@$_VKQOX
M?_LV"?+;=D3>8VYQUQZ5E?L>_LMQ_LF_#S6?"\?B1O%']I:U/K!NVLA:>7YD
M<:"/9YCYP(A\V><]!7NU:-Q2C&.UE]_*KZ^OR[&E:TZLYQZR?_@/,[:=-/GK
MKL? G[)=PMG_ ,%!_P!JZ=\E(A;NV.N <U\Z:3^T;\3_ -H31?%?CJ*X_:&'
MB+[;<IX:M?ACI D\+VBHH\F&Z .Z=@2-^1D ]^E?H;\(_P!E>/X5_M#?%7XH
M_P#"2'5/^$Z,.=):Q$0LMG7][YC>9G_=7'O7G^C?L-^+/A7KVMCX.?''5OAI
MX/UJ^?4+OPTV@VFJ1Q2N &^SR3<PC  &%)P!DG KCHQ<*-&G+>,$O25_\NJO
M;YCDU[2I)=9W]8VV^_H]_D>&_M%?'/XX#X _LRZN;W5?AY\3->\0#3=2M[J.
M2R668DPHUU; #,;';+Y;*1\WW>U3_M3Z3\7OV2?V:?"D<OQKU_Q=XLOOB%;7
M']NRM-;LL+P,?L;+Y[F2 21EMFX*0V-HKZ6^,G['K?%[0_A%I]SX\U(S> =9
M@UB34M5MA>W6JM&02LCAXPC,1]X @#@+6W^UO^S$G[5'@GP_X>?Q&WAD:3KE
MOK/VA;+[5YOEJZ^5M\Q-N=_WLG&.AK=?Q)R>TJB?_;ON-V[:I[69G'W8I=H-
M?]O6G:_?=>1\G_&K2_BW\!/VE_@]X9T#X]>,-4E^)IFL-6GUY8+NWM)%:)6F
MM+78(H?];E5 ^4J,E@2*[KX+:SXS^"_[?NK?!N[^(?B?X@>$-5\,?V[$WBZ\
M%Y=6MP'P=D@50J\/\JJ%PPXR,U[G\:OV74^,7QK^$/Q"/B1M);X?W<UR-/%C
MYPOQ(8SM\SS%\O!B'.UNO2GS?LQ"7]KZ'XZ?\)(08_#W]A?V#]AZ_,3YOG^9
M[_=V?C54W90OO>=_\+3Y?QV[&<U)REVM"W^)/WOP^\]SHHHJ34**** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OS T7P+X\\>_\%._
MCW9> ?B4_P ,K^/3;22ZU"/1+?5&N(?(LP8@LQ C.2#O'(Q7Z?U@Z?X"\,Z1
MXHU+Q-8>'-)LO$>I(L=]K%O8Q1WETJ@!5EF"[W "K@,3C ]*(VC44WM:2^_^
MOF*=Y4^1=T_N9\>?%S]E_P .?LP_L(?&W3])O[_7M9UJPFU'6=>U1PUS?W!8
M98X&%4$L0.?O$DDDFO,M5^!.CZ+_ ,$I#KOP_P#!^GV?C35O"5G/JFJV%DO]
MHWEL\T,UXK3 >8R%49BF=N%P!@8K]']>\/Z7XJT>[TC6M-M-8TJ\C,5S8W\"
MSP3H>JO&X*L/8BG:/HNG^'=)M-+TJPMM,TRTC6&WL[.%8H88P,!$10 J@= !
MBL90E)U'>SDHK_P'FT]-4K=D:PDH2@[7Y6WZWM^.CU\S\Q/VCOB_\&_&G_!-
MGPGX)\(ZOHFJ^*YK/1[72O#.GRQS:G;WJO$)<P*?,1^)06(^8MWW#.)\=OBK
MKG[.?[57@C79M:T'POXOL?AE8:9>7WCRQO[[3KR8L/,2$6,3RJZD,2_0D$'K
MS^F6C?!KP!X<\22^(M)\#>&]+\02DF35K/2+>&Z<GJ3*J!C^=?/'Q)_9P^,V
MA?M-:W\9/A/XD\&:A?:SI4.DRZ1X]M[HQ642;<BWDM\L S)NQP,LV<UT2FY5
M'/;FDY/_ , E%)>M]_3L8Q@HTU#?EBDO/WHMM^B6WKW/"?#.D^#])_X)M_'J
M7PS\0M)^(&HZP]YK>L2Z- UK;V5Q.8_W*6[@21IA.-RKGG  &*W_  OI?A/]
MFS_@FKI?Q1\*_##PUK'B^X\,6;WEU>Z6D[W)N)8C(]R^-\D2MMDV%@H\M<8Q
M7N?[-_['\GP[N?B9X@^)-YHOC+Q)\1KE)];TZTTX+I"1J7(A2&3/F+EVRSC)
MXXSDGZ+L/#FDZ7H,.AV6EV=GHL,'V6/3;>W1+9(<;?+6,#:%QQM QBLZD7>4
MHNSE&"].5.ZOI=:VOY%PE[RYE=)R?K=K6W1Z-_U8_(3XJ^.]8\;?$O\ 9GU'
M6OC[X<^*M_<^*-,O%\.>'-$M;9= WRPED:XA8N><+Y<NUOE)V\<?1OPWTJRU
M'_@L1\59KNT@N9;/PC;SVSS1AC#)Y6GIO0D?*VUV7(YPQ'>OL73_ (#?#/2;
M>W@L?AWX3LH;>]34H8[?1+:-8[I,[+A0$XE7)PX^89.#6]:^!O#=CXLO?%%M
MX?TNW\37L*V]UK45E&MY/$N-L;S!=[*-JX!.!M'I713G&$DTNLW_ .!145YN
MUMWJ_P $E?DE%ZW45]TN;\>R/@O]@SPGHDGQ8_:_D?2+%G3Q%<V*,;=,K;M)
M=%HAQPAP,J.#@>E=K_P1_N))OV.[9'<LL6NWR(#_  KE&P/Q8G\:^OM#\!^&
M?#-YK%WH_AW2=)NM8E\_4Y[&QBA>^D.?GF95!D;D\MD\FG>$/ _ASX?:.-)\
M+:!I?AK2A(THL='LH[2#>WWFV1J%R<<G'-94WR)I_P D8_\ @-M?F15C[2?,
MOYY2^4DU;Y:?<;=%%%(LXKXW?\D9\>_]@"__ /2=Z_*'4_\ E"WI'_8S-_Z7
M2U^QMY9P:A:36MU!'<VTZ-'+#,@=)$(P593P002"#7*M\'/ +^#8_"#>!_#;
M>$XY/.303I-O]A5PVX.(-FP-N).<9SS7-*CS.;OOR?\ DL^;_@&O/I%=G+\8
MV/B#]O'0=-\.:?\ LCII6GVNFK9^+=.@MA:0K'Y,9\DE$V@;1D X'<5%\/?'
M'A+X1_\ !2?X]W_Q7U;3?#=QJ6EVKZ%J?B"9+>"2SV1AXXI),+DA5&T'DQN,
M'!K[V\0^ ?#'BY=+77?#FDZTNE3K=:>NH6,4XLYE^[)%O4^6XP,,N"*A\5?#
M7PAX[NK"Z\2^%=$\0W.GOYEG-JNG0W3VS?WHVD4E#[C%=.JK2JWW<G;RE&*^
M_P!V_P S!1_=*F^BBOG&3?W:GYF?LTW>A:A\*?VZ[SPO;"S\-72WEQI<*P&!
M5M7M[QH=L9 *J4*D# X(KCM<==+_ &5/V*==\1PM-\--,\0RR:_N0M"A-YF-
MI1R-H19^O4;AWK]9H_AUX4A.OF/PQHT9\0#;K&W3XA_:0V%,7'R_OOE)7Y\\
M''2I+7P#X8LO"2^%;?PYI,'AA8_)718K&);(1YSL$(79MSSC&*<7RN+C]GV>
M_P#T[OOZW^14O?;YNKJ;?]/+;>ECYG_:8_:I^'6E_ [XB^)_AR_@_P"*/B;2
M=,M3<V]J(M2MX[>2Y"1M<M'D-'&S,_EEAC;GCK7Q3\5?'>L>-OB7^S/J.M?'
MWPY\5;^Y\4:9>+X<\.:):VRZ!OEA+(UQ"Q<\X7RY=K?*3MXX_6?PM\,_!_@;
M1[C2/#?A30_#^E7((GL=+TZ&V@ER"#NC10K9!/4=ZRM/^ WPSTFWMX+'X=^$
M[*&WO4U*&.WT2VC6.Z3.RX4!.)5R<./F&3@TZ=J=6,WK:47]SO:VVO??M:^B
ME>4'':Z:^]67GIVVMWMK\<_$/QEH/PR_X*Q:3KGB_6;#POHMQX",,6I:Q<I:
MVS/YD@V^8Y"YRI&,]>.]26Z7]_\ \%.OC"FB2@:G-\+\6,B'_EJ?LOED'_>(
MK[7\8_#+P?\ $1K)O%?A/0_$S63^9:G6-.ANS W]Y/,4[3P.1CI5FV\#^&[/
MQ5<>)[?P_I<'B6XMQ:3:S'91K>20 @B)I@N\H"J_*3C@>E8J"Y8Q?15%_P"!
MJ:^]<WX&G-RRE)=>7_R5Q_/E_$_-?]D?XQ?!WX?_ + 7C?PEXYUC1-(\6Q_V
MO#KGA_5Y(TU&]N6WB,"!\22MCRU& =I4\C!QYGXN\'ZOI?["?[*6D>+;%_\
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M3K=I[IM?<[&=J'_(4TO_ 'Y/_19K1K.U#_D*:7_OR?\ HLUHT ?FQ^V3X?\
M$OBC_@IK\%=+\(>*_P#A"/$5QX:D%IKW]G1:A]E(-\6/D2$(^5#+R>-V>U>_
M>#_V1;+X-:9\4_B'XA\6:C\1/B9XBT.Z@O\ Q'J-O';*(A"?W<,$?RQ*=B<9
M/"*!@#%?1=]X"\,ZIXKL/%%YX<TF[\3:?$8+/69[&)[RVC.[*1S%=Z*=S< @
M?,?6MFZM8;VVEM[B*.>WF0QR12J&1U(P5(/!!'&#6-2FY8:5&.C:FK_XF_NW
MUMN=$JG-755[+DT_PI?Y:=C\W_V _@CH5]^P-J?C#PWX3TN3XJWEEKD>G:^U
MHCZ@EQMG@B6*9ANC^7"X4@')R#DUX+\#?#=AX^_9'/@SQ-^UAX8^&OASS+B/
M5/ .M>%=.-[;2I.SD^8\R7,K$A6#J-PSM'W<5^Q'A7PAH/@718=&\-:)IWA[
M2("QBT_2K2.VMXRQ)8K'& HR22<#DFL34/@O\/M6\4+XEOO GAF\\1JP8:Q<
M:/;R78(Z'SBF_/XUO/WY2;V:BO\ P&_39WN_\SGC>,(KJFW]_GY?YGY__$Z/
M2?A!^UA^R;J'CK7?[5^&6E>$DL+#Q-JT1M[9KU87"W$H<GRV;-LWS'*_*2?E
M)KM?^"C7Q&^'OQ(_8O\ B/>^ M;T3Q"8=9TN/4[_ $-XYHWF\V(KNFC^61@F
MT9#' P..E?<OBGP?H/CG1Y-)\2:)IOB#2I""]CJEI'<P,1T)1P5/Y5DR?"'P
M)-X-_P"$1D\$^'9/"FY7_L)M*@-CN4@J?(V;,@@$<<8%35O6CRR_F;^^7,[^
M?3[NQ4/<DI+^51^Z/+I^?W]SX@^*W_)\'[&O_8 F_P#25JL_L$Z'IVH?M;?M
M@7=U86US=1^(OLR330JSK%)<WOF("1PK;$R.AVC/2ON6Z^'_ (7O]<TC6KGP
MWI%QK.CQF'3=1EL(FN+%",%89"NZ,$<84@4_0? OAOPKJ6KZCHOA[2M(U#6)
MOM&I75A9102WLO/SS.J@R-\S<L2>3ZTUI&HOYO:?+GDI?@E9^HEI3Y/^O?\
MY(FOQN?D!\-Y7;_@DK\<H2Q\J#QDJ1)V1?-T\X [#))_&O8?C)J5AX3^*'[$
M7B;QR4A^&MGH4"2W=XN;.VO3:Q['E)^5<'R6R>@1CT!Q^A4/P;\ V_A;4/#,
M7@?PW'X;U&<W-[HZ:1;BSNIB5)DDAV;';*J=S GY1Z5JZMX(\.Z_X:'AW4]
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MOOPGXBO?B)!\!+36/!,!T3Q#KFC6]_:VK;=TUH1<E8HG#,X+Y!'RC^,9]_\
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M5E_UQ3_T$5)??\>5Q_US;^1J/2?^059?]<4_]!%/H+J?-?\ P4R_Y,?^)O\
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M+LWQ]^+?Q3\#W/Q4\3;;3P_X4@\06C/H\#_NXXEB\PL)F4[ @&X!VSEW8#]
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MF<9<RN%%%%06%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MW+_,#I_[=TW_ *"%K_W_ %_QH_MW3?\ H(6O_?\ 7_&N8_X4C\.O^A!\+_\
M@FMO_B*/^%(_#K_H0?"__@FMO_B*.7#?S2^Y?Y@=/_;NF_\ 00M?^_Z_XT?V
M[IO_ $$+7_O^O^-<Q_PI'X=?]"#X7_\ !-;?_$4?\*1^'7_0@^%__!-;?_$4
M<N&_FE]R_P P.G_MW3?^@A:_]_U_QH_MW3?^@A:_]_U_QKF/^%(_#K_H0?"_
M_@FMO_B*/^%(_#K_ *$'PO\ ^":V_P#B*.7#?S2^Y?Y@=/\ V[IO_00M?^_Z
M_P"-']NZ;_T$+7_O^O\ C7,?\*1^'7_0@^%__!-;?_$4?\*1^'7_ $(/A?\
M\$UM_P#$4<N&_FE]R_S Z?\ MW3?^@A:_P#?]?\ &C^W=-_Z"%K_ -_U_P :
MYC_A2/PZ_P"A!\+_ /@FMO\ XBC_ (4C\.O^A!\+_P#@FMO_ (BCEPW\TON7
M^8'3_P!NZ;_T$+7_ +_K_C1_;NF_]!"U_P"_Z_XUS'_"D?AU_P!"#X7_ /!-
M;?\ Q%'_  I'X=?]"#X7_P#!-;?_ !%'+AOYI?<O\P.G_MW3?^@A:_\ ?]?\
M:/[=TW_H(6O_ '_7_&N8_P"%(_#K_H0?"_\ X)K;_P"(H_X4C\.O^A!\+_\
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M]_U_QH_MW3?^@A:_]_U_QKF/^%(_#K_H0?"__@FMO_B*/^%(_#K_ *$'PO\
M^":V_P#B*.7#?S2^Y?Y@=/\ V[IO_00M?^_Z_P"-']NZ;_T$+7_O^O\ C7,?
M\*1^'7_0@^%__!-;?_$4?\*1^'7_ $(/A?\ \$UM_P#$4<N&_FE]R_S Z?\
MMW3?^@A:_P#?]?\ &C^W=-_Z"%K_ -_U_P :YC_A2/PZ_P"A!\+_ /@FMO\
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M_"D?AU_T(/A?_P $UM_\11RX;^:7W+_,#I_[=TW_ *"%K_W_ %_QH_MW3?\
MH(6O_?\ 7_&N8_X4C\.O^A!\+_\ @FMO_B*/^%(_#K_H0?"__@FMO_B*.7#?
MS2^Y?Y@=/_;NF_\ 00M?^_Z_XT?V[IO_ $$+7_O^O^-<Q_PI'X=?]"#X7_\
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MX7_\$UM_\11RX;^:7W+_ #%H=/\ V[IO_00M?^_Z_P"-']NZ;_T$+7_O^O\
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MHY<-_-+[E_F!T_\ ;NF_]!"U_P"_Z_XT?V[IO_00M?\ O^O^-<Q_PI'X=?\
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M-_Z"%K_W_7_&C^W=-_Z"%K_W_7_&N8_X4C\.O^A!\+_^":V_^(H_X4C\.O\
MH0?"_P#X)K;_ .(HY<-_-+[E_F!T_P#;NF_]!"U_[_K_ (T?V[IO_00M?^_Z
M_P"-<Q_PI'X=?]"#X7_\$UM_\11_PI'X=?\ 0@^%_P#P36W_ ,11RX;^:7W+
M_,#I_P"W=-_Z"%K_ -_U_P :/[=TW_H(6O\ W_7_ !KF/^%(_#K_ *$'PO\
M^":V_P#B*/\ A2/PZ_Z$'PO_ .":V_\ B*.7#?S2^Y?Y@=/_ &[IO_00M?\
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MMW3?^@A:_P#?]?\ &N8_X4C\.O\ H0?"_P#X)K;_ .(H_P"%(_#K_H0?"_\
MX)K;_P"(HY<-_-+[E_F!T_\ ;NF_]!"U_P"_Z_XT?V[IO_00M?\ O^O^-<Q_
MPI'X=?\ 0@^%_P#P36W_ ,11_P *1^'7_0@^%_\ P36W_P 11RX;^:7W+_,#
MI_[=TW_H(6O_ '_7_&C^W=-_Z"%K_P!_U_QKF/\ A2/PZ_Z$'PO_ .":V_\
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M:V_^(HY<-_-+[E_F!T_]NZ;_ -!"U_[_ *_XT?V[IO\ T$+7_O\ K_C7,?\
M"D?AU_T(/A?_ ,$UM_\ $4?\*1^'7_0@^%__  36W_Q%'+AOYI?<O\P.G_MW
M3?\ H(6O_?\ 7_&C^W=-_P"@A:_]_P!?\:YC_A2/PZ_Z$'PO_P"":V_^(H_X
M4C\.O^A!\+_^":V_^(HY<-_-+[E_F!T_]NZ;_P!!"U_[_K_C1_;NF_\ 00M?
M^_Z_XUS'_"D?AU_T(/A?_P $UM_\11_PI'X=?]"#X7_\$UM_\11RX;^:7W+_
M # Z?^W=-_Z"%K_W_7_&C^W=-_Z"%K_W_7_&N8_X4C\.O^A!\+_^":V_^(H_
MX4C\.O\ H0?"_P#X)K;_ .(HY<-_-+[E_F!T_P#;NF_]!"U_[_K_ (T?V[IO
M_00M?^_Z_P"-<Q_PI'X=?]"#X7_\$UM_\11_PI'X=?\ 0@^%_P#P36W_ ,11
MRX;^:7W+_,#I_P"W=-_Z"%K_ -_U_P :/[=TW_H(6O\ W_7_ !KF/^%(_#K_
M *$'PO\ ^":V_P#B*/\ A2/PZ_Z$'PO_ .":V_\ B*.7#?S2^Y?Y@=/_ &[I
MO_00M?\ O^O^-']NZ;_T$+7_ +_K_C7,?\*1^'7_ $(/A?\ \$UM_P#$4?\
M"D?AU_T(/A?_ ,$UM_\ $4<N&_FE]R_S Z?^W=-_Z"%K_P!_U_QJ]7&1_!7X
M>1NKIX#\,HZG(9='MP0?4?)79UC45)6]FV_56_5B"BBBL0"BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@#.U#_ )"FE_[\G_HLUHUSGB/6H--U'3&E=4 >3J<?P&J3?$+3E8C[
M0G_?0H$=A17'?\+#T[_GX3_OH4?\+#T[_GX3_OH4#.QHKCO^%AZ=_P _"?\
M?0H_X6'IW_/PG_?0H [&BN._X6'IW_/PG_?0H_X6'IW_ #\)_P!]"@#L:*X[
M_A8>G?\ /PG_ 'T*/^%AZ=_S\)_WT* .QHKCO^%AZ=_S\)_WT*/^%AZ=_P _
M"?\ ?0H [&BN._X6'IW_ #\)_P!]"C_A8>G?\_"?]]"@#L:*X[_A8>G?\_"?
M]]"C_A8>G?\ /PG_ 'T* -_Q!_R#&_ZZP_\ HQ:TJ\^U[X@:>VFD"="?-B_B
M'_/1:T/^%AZ=_P _"?\ ?0H [&BN._X6'IW_ #\)_P!]"C_A8>G?\_"?]]"@
M#L:*X[_A8>G?\_"?]]"C_A8>G?\ /PG_ 'T* .QHKCO^%AZ=_P _"?\ ?0H_
MX6'IW_/PG_?0H [&BN._X6'IW_/PG_?0H_X6'IW_ #\)_P!]"@#L:*X[_A8>
MG?\ /PG_ 'T*/^%AZ=_S\)_WT* .QHKCO^%AZ=_S\)_WT*/^%AZ=_P _"?\
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M*</=4;]+?^DR3?SDU*W2VAG47,FHNW_[46E]R<;];GS%?7OBCXL?\*/U6_\
M&VKZ9J$GCS7M.6;3;6P'EK"-5CBD42VSC>L4*Q<@J59B5+X<?0G[0'BG6/A]
M\%=:UC1M0>'5[);98[V2*-V):>)&8J5V9(9OX<<\ <59_P"&?_ <?@O3?"EI
MH;Z5H>F7TFI:?#I-]<V4EE<2/([O!-#(DD63-*-J,%"N5 "\5T_B7P5H_C#P
MO-X=UFU>_P!(F6-)(9+B0,X1E9<R!@Y.54YW9..<Y-7)IIJ/?\/T]!33DVUV
M?YNWX-'C6O:KXZ\6?$+XKZ7IOCRZ\+:5X9M+.XL$TW3+.6<S26K2$2/<12*T
M6Y<E0@?/20#Y:]3^$/C*X^(GPI\&^*;N".VN]:T>TU&:&$DHCRPJ[*N>< L<
M5H0^!=#M]5\0ZE'9;;WQ D<>I2^:Y\]8XS&@QNPN%8CY0,YYYJUX7\,Z;X+\
M-Z5H&C6WV/2-+M8K*SM][/Y4,:A$7<Q+'"@#)))[FIA:,))[Z6_\FO\ ?=?=
MT'9W3]?TM]UF:E%%%(H**** "BBB@ HHHH **** "BBB@ HHHH **** "OE&
MU_8QN=>O/VE;7Q9<Z7=:)\4+J*?3%MR\DUF8X65)) R *ZR%6&TM]WKVKZNH
MK.4%*]^J<?DVG^B*4G%Q:Z-/YJ_^9\-^)OV6/V@+K0_V>=9TW7/ 5[\0OAA#
M>V]S-K=U?26-ZLB)#"^8X1(S>4GS9V_-R"17<?$S]F_XI?M%_"#28?B'KOA/
MPO\ %;PSKR:YX=UCP9%<RV$#Q >6)4N?G)+;MV.!A" <$'ZLHK9R<FV^KYO1
MW3NOFB5IRI;)6^6NC^]G@/P]^'_QE\:37UA\?)OAIX@\(/:F#_A'= TB>XAO
MI/,1DFN3>9'R;#A%7&6SGY15;XW? /6YO!>C^&?A%X(^#T>@0W,EQ>^'O&WA
MYGTXNVW;-#';@*L@P^<J<Y'(Q7T/14OWK?U]_P#7ILAQO'^OD?+'@O\ 97\7
M_"WX)^,--T&Y\#^(OB'XMU/^U-63Q%HSKX?E! 46BVT1W+"B*%4\G.21S@97
MPE_85MKBX\5:M\7--\'W-SX@T>/P_P#\(SX"L)=*T>PL5E$SI$5*RL[R!6+G
M:1MQTZ?7E%&EWINK?*UK?=I]_=BV22[W^=[_ )Z_\,?%6G_\$R?AWX,_:4\
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MC/Q8\\VIZ'!Y*B.R@@^S.(T617VR1SIM\YI#$[ J_P!ET55_>YWOK^+O^?\
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M_H.WW_?M/\*/^& ;7_H.WW_?M/\ "C_6G*_YW]S#_5/-?Y%_X$CXQK5\*?\
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MCR$_NBI**!D?D)_=%'D)_=%244 1^0G]T4>0G]T5)10!'Y"?W11Y"?W14E%
M$?D)_=%'D)_=%244 1^0G]T4>0G]T5)10!'Y"?W11Y"?W14E% &5X@@3^S&^
M4?ZV'_T8M:/D)_=%4?$'_(,;_KK#_P"C%K2H C\A/[HH\A/[HJ2B@"/R$_NB
MCR$_NBI** (_(3^Z*/(3^Z*DHH C\A/[HH\A/[HJ2B@"/R$_NBCR$_NBI**
M(_(3^Z*/(3^Z*DHH C\A/[HH\A/[HJ2B@"I?0)]BN/E'^K;^51Z3 G]E6?RC
M_4I_Z"*L7W_'E<?]<V_D:CTG_D%67_7%/_013Z"ZD_D)_=%'D)_=%244AD?D
M)_=%'D)_=%244 1^0G]T4>0G]T5)10!'Y"?W12^2GI3Z* $ Q2T44 %%%% !
M1110 5FZ'_Q[W/\ U]3_ /HQJTJS=#_X][G_ *^I_P#T8U NII4444#"BBB@
M HHHH **** "BBB@ HHHH **** "LZS_ .0UJ7^[%_(UHUG6?_(:U+_=B_D:
M8C1HHHI#"BBB@"E<:+I]WJEGJ4]A;3:C9I)';7DD*M- LFWS%1R,J&VKD \[
M1GI5VBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "HY5D;'ER!/7*YJ2B@"OY5Q_SW7_OW_\ 7H\J
MX_Y[K_W[_P#KU8HH K^5<?\ /=?^_?\ ]>CRKC_GNO\ W[_^O5BB@"OY5Q_S
MW7_OW_\ 7H\JX_Y[K_W[_P#KU8HH K^5<?\ /=?^_?\ ]>CRKC_GNO\ W[_^
MO5BB@"OY5Q_SW7_OW_\ 7H\JX_Y[K_W[_P#KU8HH K^5<?\ /=?^_?\ ]>CR
MKC_GNO\ W[_^O5BB@"OY5Q_SW7_OW_\ 7H\JX_Y[K_W[_P#KU8HH K^5<?\
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MKC_GNO\ W[_^O5BB@"OY5Q_SW7_OW_\ 7H\JX_Y[K_W[_P#KU8HH K^5<?\
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MKC_GNO\ W[_^O5BB@"OY5Q_SW7_OW_\ 7H\JX_Y[K_W[_P#KU8HH K^5<?\
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MKC_GNO\ W[_^O5BB@"OY5Q_SW7_OW_\ 7H\JX_Y[K_W[_P#KU8HH K^5<?\
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M_KT>5<?\]U_[]_\ UZL44AE?RKC_ )[K_P!^_P#Z]'E7'_/=?^_?_P!>K%%
M%?RKC_GNO_?O_P"O1Y5Q_P ]U_[]_P#UZL44 5_*N/\ GNO_ '[_ /KT>5<?
M\]U_[]__ %ZL44 5_*N/^>Z_]^__ *]'E7'_ #W7_OW_ /7JQ10!7\JX_P">
MZ_\ ?O\ ^O1Y5Q_SW7_OW_\ 7JQ10!7\JX_Y[K_W[_\ KT>5<?\ /=?^_?\
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M#@1[FV]>#CC/%:U9UG_R&M2_W8OY&F(L^5<?\]U_[]__ %Z/*N/^>Z_]^_\
MZ]6**0ROY5Q_SW7_ +]__7H\JX_Y[K_W[_\ KU8HH K^5<?\]U_[]_\ UZ/*
MN/\ GNO_ '[_ /KU8HH K^5<?\]U_P"_?_UZ/*N/^>Z_]^__ *]6** *_E7'
M_/=?^_?_ ->CRKC_ )[K_P!^_P#Z]6** *_E7'_/=?\ OW_]>CRKC_GNO_?O
M_P"O5BB@"OY5Q_SW7_OW_P#7H\JX_P">Z_\ ?O\ ^O5BB@"OY5Q_SW7_ +]_
M_7H\JX_Y[K_W[_\ KU8HH K^5<?\]U_[]_\ UZ/*N/\ GNO_ '[_ /KU8HH
MK^5<?\]U_P"_?_UZ/*N/^>Z_]^__ *]6** *_E7'_/=?^_?_ ->CRKC_ )[K
M_P!^_P#Z]6** *_EW'_/=?\ OW_]>K%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@\9_] _3_P#Q_P#QH_U5S3^1?>@_ULRK^=_^ L_2C^T(O[XH_M"+^^*_-?\
MX;@\9_\ 0/T__P ?_P :/^&X/&?_ $#]/_\ '_\ &C_57-/Y%]Z#_6S*OYW_
M . L_1?Q!J$7]F-\X_UL7_HQ:T?[0B_OBOS2NOVU_&-Y#Y3Z?8!=RMP7[$$=
M_:I?^&X/&?\ T#]/_P#'_P#&C_57-/Y%]Z#_ %LRK^=_^ L_2C^T(O[XH_M"
M+^^*_-?_ (;@\9_] _3_ /Q__&C_ (;@\9_] _3_ /Q__&C_ %5S3^1?>@_U
MLRK^=_\ @+/TH_M"+^^*/[0B_OBOS7_X;@\9_P#0/T__ ,?_ ,:/^&X/&?\
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MD:8C1HHKS;XN?'[PO\%=2\-6/B%;YI=>N3;V[6< D6(!D#229884&1?N[F]
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MUD"8*R#@UZ5\8_\ DD?C?_L"7O\ Z(>OC_\ :*TR^^&_[/$/CO2XI9M#\3>
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M1116QS!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 <K%\.=-3XG7'CN2:ZN-9?2DT>&.5
MU,%K )3*_E*%!#2-LW$DY\M ,8YE\.^ =/\ #'BKQ7X@M9KF2\\27$%S=QS,
MIC1H8$@41@*" 50$Y)YST'%=+11MI_6KO^>H[ZM]_P#AOT04444""BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"D;[II:* /F#]M#PGJOBCP+]BTBREO[V6=-D,(RQP0Q_0&OAW_A0_C\?\RM?
M?DO^-?K-K5A'=:GI8=01OD_]%FG'PO:'_EDOY5]1EG$&(RNBZ%*":;OK?R\_
M(^4S3AW#YM75>K.2:5M+?JGW/R7_ .%#^/\ _H5[[\E_QH_X4/X__P"A7OOR
M7_&OUG_X1>T_YY+^5'_"+VG_ #R7\J]?_7+&?\^X_C_F>/\ ZDX+_G[/\/\
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M^2[? GQ\JDGPO>@#DG"_XT+\"O'TBJR^&+UE89! 7G]:_6*^\+VGV.?]TO\
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MA(=+"[Y$MPX&/M%R\F2@Y\LR,V-R[LC1]-TK6/@[^T7-XDB@9KK6==BU.2X
MR(880EMECV6!8F7^[GC'0>E:+^S3X'\.:C<WND_\)-IDES?R:G/#9^,-8B@F
MN7?>\CPK="-BS=05P>A&.*O^(?V?_ OBGQ%?:SJ.CSR7&H&,ZC:PZE=0V.HF
M,80W=I'*L%R< +F6-\JJJ<A0!C*+E3<+VYDT_)RY=5Z*-NG?N7&7+.,DOA::
M]%S:?-ROU[=$>3_$;5%\2?L[Z)X$_LZ/5/B1\1O#D%I]E\D,^XVT:37UTW\,
M4&X,78YW!$7+,!5#XYZM'9PCP'K^E^*+WPCX<\."Z:_A\.:AJ,.L:@L3+ ))
M;>"2-4AV><^\K^\:(]$:O8=>_9Z\&>(O&6H>*YTUZRU^_@AMKF[TCQ1JFG>9
M%$"(T*6]S&H5<L0 ,99CU))[6/PW8KX:_L&07%UIIM39L+N[EGFDB*[2'F=C
M([$=69BQZYSS17BZT:EM')O];:^3=[VW]$117LO9INZBDORYOOM;T\V<1^S7
MKEMX@^ O@.>UCO(DCT6SMV%[936CED@120LJ*S+D<. 58<J2.:]+JAH.AV/A
MC0]/T?3(/LVG:?;QVMM#O9_+B10J+N8DG  &22:OUU5IJI4E-=6948.G3C!]
M$D%%%%8FP4444 %%%% !117G?Q?^.WA;X'V^F3>)GNT346D2#[+!YIR@4MGD
M8^\*UI4IUYJG2C>3V2W,ZE2%&#J5':*W;V/GW]I_P;\$+OQU>3Z[X^NO!OB:
M\C1=1M],BDN4G7 *F:.-&VM@+U(S@'!ZUU?[)_\ PJ#2]>U>T\%>+K[QAXNO
M;?[1>WVIVTZ2F%&4$*7C4!=S+D9+$D<D 8\>\(_'/X'VOQ!\=ZGXH\/#Q+#K
M6H?VA9:EJ.E)<O&C*-UN8Y,[-K D,OW@W., 5[]\!?BM\&O&_C&ZL/A]X;L]
M&UM+)YI)H-%BLV: .@9=Z#)&YD./;VK[C%4L10P'L*D:K2BM=.5:)V>E[+:U
M^A\-0K8?$9A[>G.CK)V6KD]6KKWK7:UO;KU/?J***^"/O0HHJ.27R\?*S9_N
MC- $E%0?:A_SRE_[X-'VH?\ /*7_ +X- $]%0?:A_P \I?\ O@T?:A_SRE_[
MX- $]%0?:A_SRE_[X-'VH?\ /*7_ +X- $]%0?:A_P \I?\ O@T?:A_SRE_[
MX- $]%0?:A_SRE_[X-'VH?\ /*7_ +X- $]%0?:A_P \I?\ O@T?:A_SRE_[
MX- $]%0?:A_SRE_[X-'VH?\ /*7_ +X- $]%0?:A_P \I?\ O@T?:A_SRE_[
MX- $]%0?:A_SRE_[X-'VH?\ /*7_ +X- $]%0?:A_P \I?\ O@T?:A_SRE_[
MX- $]%0?:A_SRE_[X-'VH?\ /*7_ +X- $]%0?:A_P \I?\ O@T?:A_SRE_[
MX- $]%0?:A_SRE_[X-'VH?\ /*7_ +X- $]%0?:A_P \I?\ O@T?:A_SRE_[
MX- $]%0?:A_SRE_[X-'VH?\ /*7_ +X- $]%0?:A_P \I?\ O@T?:A_SRE_[
MX- $]%0?:A_SRE_[X-'VH?\ /*7_ +X- $]%0?:A_P \I?\ O@T?:A_SRE_[
MX- $]%0?:A_SRE_[X-'VH?\ /*7_ +X- $]%0?:A_P \I?\ O@T?:A_SRE_[
MX- $]%0?:A_SRE_[X-'VH?\ /*7_ +X- $]%0?:A_P \I?\ O@T?:A_SRE_[
MX- $]%0?:A_SRE_[X-'VH?\ /*7_ +X- $]%0?:A_P \I?\ O@T?:A_SRE_[
MX- $]%0?:A_SRE_[X-'VH?\ /*7_ +X- $]%0?:A_P \I?\ O@T?:A_SRE_[
MX- $]%0?:A_SRE_[X-'VH?\ /*7_ +X- $]%0?:A_P \I?\ O@T?:A_SRE_[
MX- $]%0?:A_SRE_[X-'VH?\ /*7_ +X- $]%0?:A_P \I?\ O@T?:A_SRE_[
MX- $]%0?:A_SRE_[X-'VH?\ /*7_ +X- $]%0?:A_P \I?\ O@T?:A_SRE_[
MX- $]%0?:A_SRE_[X-'VH?\ /*7_ +X- $]%0?:A_P \I?\ O@T?:A_SRE_[
MX- $]%0?:A_SRE_[X-'VH?\ /*7_ +X- $]%0?:A_P \I?\ O@T?:A_SRE_[
MX- $]%0?:A_SRE_[X-'VH?\ /*7_ +X- $]%0?:A_P \I?\ O@T?:A_SRE_[
MX- $]%0?:A_SRE_[X-'VH?\ /*7_ +X- $]%0?:A_P \I?\ O@T?:A_SRE_[
MX- $]%0?:A_SRE_[X-'VH?\ /*7_ +X- $]%0?:A_P \I?\ O@T?:A_SRE_[
MX- $]%0?:A_SRE_[X-'VH?\ /*7_ +X- $]%0?:A_P \I?\ O@T?:A_SRE_[
MX- %74/^0II?^_)_Z+-:-95]-NU+3FV.-KN<%>3\AZ5>^U#_ )Y2_P#?!IB)
MZ*@^U#_GE+_WP:/M0_YY2_\ ?!I#)Z*@^U#_ )Y2_P#?!H^U#_GE+_WP: )Z
M*@^U#_GE+_WP:/M0_P">4O\ WP: )Z*@^U#_ )Y2_P#?!H^U#_GE+_WP: )Z
M*@^U#_GE+_WP:/M0_P">4O\ WP: )Z*@^U#_ )Y2_P#?!H^U#_GE+_WP: )Z
M*@^U#_GE+_WP:/M0_P">4O\ WP: *GB#_D&-_P!=8?\ T8M:59.MS>;IY78Z
M_O(CEEP.)%-7_M0_YY2_]\&@1/14'VH?\\I?^^#1]J'_ #RE_P"^#0,GHJ#[
M4/\ GE+_ -\&C[4/^>4O_?!H GHJ#[4/^>4O_?!H^U#_ )Y2_P#?!H GHJ#[
M4/\ GE+_ -\&C[4/^>4O_?!H GHJ#[4/^>4O_?!H^U#_ )Y2_P#?!H GHJ#[
M4/\ GE+_ -\&C[4/^>4O_?!H GHJ#[4/^>4O_?!H^U#_ )Y2_P#?!H +[_CR
MN/\ KFW\C4>D_P#(*LO^N*?^@BFWEP&M)QY<@RC#)4XZ4S3+@1Z;:+Y<C;8D
M&57(/RCI3$:%%0?:A_SRE_[X-'VH?\\I?^^#2&3T5!]J'_/*7_O@T?:A_P \
MI?\ O@T 3T5!]J'_ #RE_P"^#1]J'_/*7_O@T 3T5!]J'_/*7_O@T?:A_P \
MI?\ O@T 3T5!]J'_ #RE_P"^#1]J'_/*7_O@T 3T5!]J'_/*7_O@T?:A_P \
MI?\ O@T 3T5!]J'_ #RE_P"^#1]J'_/*7_O@T 3UFZ'_ ,>]S_U]3_\ HQJM
M_:A_SRE_[X-4-'F\N"X&QVS<S-\JYZN3CZTQ&M14'VH?\\I?^^#1]J'_ #RE
M_P"^#2&3T5!]J'_/*7_O@T?:A_SRE_[X- $]%0?:A_SRE_[X-'VH?\\I?^^#
M0!/14'VH?\\I?^^#1]J'_/*7_O@T 3T5!]J'_/*7_O@T?:A_SRE_[X- $]%0
M?:A_SRE_[X-'VH?\\I?^^#0!/14'VH?\\I?^^#1]J'_/*7_O@T 3UG6?_(:U
M+_=B_D:M?:A_SRE_[X-4;68+JU^^QSN6/Y0O(P#UIB-6BH/M0_YY2_\ ?!H^
MU#_GE+_WP:0R>BH/M0_YY2_]\&C[4/\ GE+_ -\&@">BH/M0_P">4O\ WP:/
MM0_YY2_]\&@">BH/M0_YY2_]\&C[4/\ GE+_ -\&@">BH/M0_P">4O\ WP:/
MM0_YY2_]\&@">BH/M0_YY2_]\&C[4/\ GE+_ -\&@">BH/M0_P">4O\ WP:/
MM0_YY2_]\&@">BH/M0_YY2_]\&C[4/\ GE+_ -\&@">BH/M0_P">4O\ WP:/
MM0_YY2_]\&@">BH/M0_YY2_]\&C[4/\ GE+_ -\&@">BH/M0_P">4O\ WP:/
MM0_YY2_]\&@">BH/M0_YY2_]\&IZ "BBB@ HHHH *Y?XD>)M!\#^$;_Q%XC@
M$VEZ<H>3]P)F&Y@HVJ?<BNHKE_B9XNT#P+X'U76_$X1]%M8\S1/$)/-R0%0(
M>&);  />M*2YJD8V;NUHMWY+S?0B;Y8MWMIN]EZ^1\Q^#_VV?ARTVOCQ)IR+
M$-2D&E&STA<FRVKY9DR?OYWY_"O0/@O^T!I?Q<^,%_IW@_21'X4M-%\ZXO9+
M 02K=&90J;@?NLA/!&<H2.E>->'_ (V/;M?:GX6_9IOM1T74[I[][N2&:X$S
M, -R-]G=8UPH^5<J.U?2/[/OQH\,?%G0[R+1-*;PWJ6FNJ7^ARPK&]NS9P1M
M #*2",X!XY XK[#,,'3P]*=6.&DM+:SBU'I=J.OWO?[CXW XVIB:L:4L3%ZM
MZ4Y1NKWLI2=MNR>G?<]8HHHKXL^U"BBB@ HHHH **** "BBB@ HHHH ****
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MUHW#UI#%HI-P]:-P]: %HI-P]:-P]: %HI-P]:-P]: %HHHH **** "BBB@
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MWA_]I3P1XJU1+'1U\4:GOOI--%[:^#M8>Q\^.9H9 ;L6GD!5D5E9R^P;3D@
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M5HH_U-P7_/R7X?Y!_KMCO^?</Q_S/TJ_X;,\!?\ 0>B_[]O_ (4?\-F> O\
MH/1?]^W_ ,*_-6BC_4W!?\_)?A_D'^NV._Y]P_'_ #/TJ_X;,\!?]!Z+_OV_
M^%'_  V9X"_Z#T7_ '[?_"OS5HH_U-P7_/R7X?Y!_KMCO^?</Q_S/TJ_X;,\
M!?\ 0>B_[]O_ (4?\-F> O\ H/1?]^W_ ,*_-6BC_4W!?\_)?A_D'^NV._Y]
MP_'_ #/TFNOVRO <EM*@UV(ED('[M_3Z4RP_;(\"6]C;1-KL09(U4CRWZ@ >
ME?FY11_J;@O^?DOP_P A?ZZX[_GW#\?\S]*O^&S/ 7_0>B_[]O\ X4?\-F>
MO^@]%_W[?_"OS5HH_P!3<%_S\E^'^0_]=L=_S[A^/^9^E7_#9G@+_H/1?]^W
M_P */^&S/ 7_ $'HO^_;_P"%?FK11_J;@O\ GY+\/\@_UVQW_/N'X_YGZ5?\
M-F> O^@]%_W[?_"C_ALSP%_T'HO^_;_X5^:M%'^IN"_Y^2_#_(/]=L=_S[A^
M/^9^E7_#9G@+_H/1?]^W_P *M:?^V)X"O+N*!==C:25PB*(I"2Q. /NU^9=:
MOA3_ )&C1_\ K\A_]#%9U.#\'&#DJDM/3_(NGQIC9S473CJ_/_,_9O2M06_M
MUD4Y!&:O5RW@5BVDPD_W174U^2'[$%%%% !1110 5FZ'_P >]S_U]3_^C&K2
MK-T/_CWN?^OJ?_T8U NII4444#"BBB@ HHHH **** "BBB@ HHHH **** "L
MZS_Y#6I?[L7\C6C6=9_\AK4O]V+^1IB-&N1\=?%KPC\,[S1;3Q-K<.DW&L3_
M &:Q25';S7RH.2JD(H++EFPHSR:ZZN1\=?"7PC\3+S1;OQ-HD.K7&CS_ &FQ
M>5W7RGRI.0K .I*KE6RIQR*TI>SYU[:_+UMO\KFD>6_O?UV.NKP_Q)XZ^)&L
M_%KQKX7\(ZGX5TBS\.:+8:BAUS1KF\>ZEN#=?*9([R$1H/LXYV.?F)YQ@^X5
MX/JG[/\ #XZ^/'CK6_%%GJA\,ZCHFEV-J+'7KFS@O6C:[^T13PV\Z>:@$D8Q
M,I4AV SEJRLVG;1_UTZ^C$K)-OR_-?H:7AC]JCP?J7@?P)K.MR7&CZMXNTG^
MU+'0[6TN-0N9@OEB58%@B9IBID4X5=Q3+[0JL5Z;5?CQX*T76WTN[U*[26&2
M.&ZNX]*NY+*RE?:5CN;M8C!;OAT)25T8!T) #+G*U#X>WD/Q]\":YINDPV_A
MC1?#.IZ67@\N..VDDFLC#$D8((!2&3&U=H"X.,C/DDG[/]S:ZEXR\/:WX*\7
M>,=-U_5[Z^AU#3O'-QIVC/!=R-(8KRU6^C9-C.ROY5M*'4!OF9F4:^[*2Z)W
M^7O62_\  ==69OW8/756\_LW;^3TL=IXJ^(NM0Z[\8+*?QI_PB&FZ ^BFRU3
M^RDO?L2S!6F7R@N9/,/R9;.W?D8Q7;>+/VA/ ?@G6-6TK5-8G_M+28TGU&UL
MM,N[R2SA9-XGE6&)]D.WK,V$4\%@>*\S^)7P?\5ZY%\:8]-TGSU\0#0QI6;J
M(?:!;[?.Y9QMVX/W\9[9KKU\ :]_PEGQMO?L'^C>(]/M(-+?SH_](=+.2-AC
M=E,.P'S8ZYZ5QSG*$'**O9-VZO385*\I*,M+O?MJSI/#?QX\#>,/$UMH&C:[
M]NO;V"6YL;B.TG^Q7\<>WS#:W9007)3>NX12,5YR!M;'/>$_C9X;\*_#WPC)
MXG\>'Q1J&L+<I9ZI'HTMO-JTD+L'2*TB0MY@X41J"S[<J#6+:_#'Q+':_LZ(
MVFX;PG_R&AY\7^B_\2B>W_O?/^]=5^3=USTYK*^%_P )/%GAUO@G_:&E?9_^
M$=_MO^U/])B;[/\ :-_D_=<[MV1]W..^*ZZL5"7+!W\_1O\ 0RC.;46UNK^C
M?3Y;GJ]G\:/".H>$6\26]]=R6"W3V)M_[,NA?_:4)#0?8C%]H\T8)\OR]VT;
ML;>:I/\ M"?#^W\&WOBF\U_^R]%L;^/3+Z75+.XLY;*YD=$2.XAFC62')DC.
M9%4;7#D[3FO*M<^'?Q%TG_A/+C2M-U*73]8\?QZI=V&B:I#9ZAJ6CFPMX7%O
M<&5/)<31@G,D3E8F 8;ANYVQ^!/C"3PQXT@B\,:C9IJWCGP_KEG9:UKRZG>?
M8K=[!IVFN)9Y"7002Y3S'^[M0N-I,P2E**>SY?E?DO?TYG\T[[:]$O=O;6W-
M\[<UOF[+Y-6WT^C/"GQ9\-^,]632].FU"'4I+(ZBEIJFDW>GRO;B4Q&0+<11
MDC>,<<X93T92=?PKXOTGQMI+:GHMW]ML%N)K;[1Y3HK/%(T<FW<!N4.C ,,J
M<9!(YKQ/]KX:]X5TOPOX[\&1PS>,K&\;0;6VE8K]KCU$"#R^ <[)Q;3].ENW
M(!->I^'/AK9^$_A+9^!-,FDAM+/2/[+BN"<O_JMGF$]V))8GU-9MOV<IQ5VK
MJW=[_@G'U;TV'ISJ+>^OHMM?5WMY(\R\<?M+Z+J6K>!M/\&Z]-YFJ>*K73I)
MY-+FCM=1MMTBSBUN)HA%<*"HR]NS8&#D YKT%?CIX,/BJV\/'4;N.\NKMM/M
MKN32KM-/N+D!B8(KTQ"WDD^1UV+(6W(RXW*0/'=*\(_$:^\&_"+P?=> #I:^
M"=7TLZEJAU2T-I<0VJM%YUFB.TC(0 Y65864,  YSC&O?A7\1O$GB30)];\/
M^)+_ %W3?&<.IWFN7/BL#19M/CNV,9M=/2YV!EA\K*O;QM\KMO=_OZ12YG"]
MTYO7;W;05]=EN[>3.><I*\TMH+3?6\W;3=[*Z\CUGX??M+Z!XWUSQSI]SI^J
M:!!X7OI;:34-2TR]@M7ACAAD:62:6W2.%LRD")FWE5#C*L*ZWP5\7O#'C[5K
MS2=+GU"WU:U@2ZET_6=(O-+N?)9BJRK%=11N\>Y2N]05!&"<UY5)X5^)'AF7
MXWZ=X8T>XMM3\1WLFMZ!XD6XL_L@D-E:PB!E>0R)+OA<!C"T?0ENU1?!WX:Z
M[I/QN3Q3+X7\3^']"/AJ337/BWQ4VLWANOM,3\ W=R(XRH)!1^2&W*F%W$;2
M<$_Y5?UY6W_Y,K>KTTL:U&X\SCWT].9+\G?Y'T;1114E!1110 4444 %%%%
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M'/[&OA/P];MK>@>,_ EQXI%G/8QZ+/8ZK"-3OW*NDYNY8Y3'-<KE/)3<@/S
MCGZH90ZE6 96&"",@UYGH?[.'@+0=<TW58M.U*_GTN3SM-M]8U[4-1L]/DQA
M7MK6YGDA@95RJM&BE%)52 2*:^--[*WW75U;T5EVZ"E=PDNKN_G9ZW]7?SZG
MG?P-NK5O#?[0LNMK;V]POC+6AJ/F84BW6WB$+2<]#;",CV-?,5Y9_$"^\"_
MQ=#.H2:FGP?FDUFSLRR:M>::+G3#<PV<G/EW+1<(Q4D\J-K,KK]R^,?V=_ /
MCSQ!>ZQK.D74MUJ"11ZE!:ZK>6EIJ:Q\(MY;0RI#=@+\N)T?* (<J *ZH^ ]
M!/C#3_% T]4US3].ETFUN$D=5BM9'CD>,1@[,%H8CDKD;< @$@E.T.6_2,5_
MX#3G!7[IN2NNUUK<<K-RMU<GV^*<967:UFD_1Z'CFL>%=(^*WP@\#'X9>#_
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MFLYK]KTYBB9=_F%%/61>,<8KS/P/\=_&WPY\/R:)X?U6"STN2X-TUO+IUK<
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M!\=5\3>(!XL:==:^RG5[C^S39FZ"?8C8;_L^W[.=F[R]X?Y]^[YJS5M&]O\
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MZ^@Z*/KV+_Y^R_\  G_F'U#"?\^8_P#@*_R/GS_AD7P)_P!"Y9?]^Z/^&1?
MG_0N67_?NOH.BCZ]B_\ G[+_ ,"?^8?4,)_SYC_X"O\ (^?/^&1? G_0N67_
M '[H_P"&1? G_0N67_?NOH.BCZ]B_P#G[+_P)_YA]0PG_/F/_@*_R/GS_AD7
MP)_T+EE_W[H_X9%\"?\ 0N67_?NOH.BCZ]B_^?LO_ G_ )A]0PG_ #YC_P"
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M#!_<_4T?88/[GZF@">BH/L,']S]31]A@_N?J: )Z*@^PP?W/U-'V&#^Y^IH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110!G:A_R%-+_WY/\ T6:T:P];U"*SU+3"[  /)_Z+-(WBNS!QYJ_G
M0(W:*P?^$LL_^>J_G1_PEEG_ ,]5_.@9O45@_P#"66?_ #U7\Z/^$LL_^>J_
MG0!O45@_\)99_P#/5?SH_P"$LL_^>J_G0!O45@_\)99_\]5_.C_A++/_ )ZK
M^= &]16#_P )99_\]5_.C_A++/\ YZK^= &]16#_ ,)99_\ /5?SH_X2RS_Y
MZK^= &]16#_PEEG_ ,]5_.C_ (2RS_YZK^= %SQ!_P @QO\ KK#_ .C%K2KD
M->\56;::1YJ_ZV+O_P!-%K1_X2RS_P">J_G0!O45@_\ "66?_/5?SH_X2RS_
M .>J_G0!O45@_P#"66?_ #U7\Z/^$LL_^>J_G0!O45@_\)99_P#/5?SH_P"$
MLL_^>J_G0!O45@_\)99_\]5_.C_A++/_ )ZK^= &]16#_P )99_\]5_.C_A+
M+/\ YZK^= &]16#_ ,)99_\ /5?SH_X2RS_YZK^= &]16#_PEEG_ ,]5_.C_
M (2RS_YZK^= &O??\>5Q_P!<V_D:CTG_ )!5E_UQ3_T$5D77BBTDM)P)5)\M
MN_M6CH-REQI%D5.?W*?^@BGT%U-&BBBD,**** "BBB@ HHHH **** "BBB@
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M6!!*21LKHV#PRD,#R"",T>@U:^I:HKY.TOX<:%I?[1/Q!TK4_%7CN/PKX?\
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M #ZC_P" K_(/K^+_ .?TO_ G_F=>_P 7O&DB[7\3ZDRYS@SGMS3O^%P^-O\
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M (7#XV_Z&C4__ AJXZBCZCA?^?4?_ 5_D'U_%_\ /Z7_ ($_\SL?^%P^-O\
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MRNWN!'>W$L)D97:&/?&$A"AB%)W'Y17I5%5U3[?_ "/+^7XJ^Y-M&EU_SO\
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MBBD]9*7:WX:HE:7\TU]ZLSPCQO\  C7_ !+K'QQNK6\TV./QSX9M-%TT32R
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M4<T_E7_@2/B:BOMG_A@'2_\ H,:E^4?_ ,31_P , Z7_ -!C4ORC_P#B:/\
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M&Z37O@7XTOOAK\8? 5J-!_LOQ5/J5]I.K3:A.)EFO'$ABG@%N5159G&])')
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MC_C4]% $'^D^L7Y'_&C_ $GUB_(_XU/10!!_I/K%^1_QH_TGUB_(_P"-3T4
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MI/K%^1_QH_TGUB_(_P"-3T4 0?Z3ZQ?D?\:/])]8OR/^-3T4 0?Z3ZQ?D?\
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MTGUB_(_XU/10!!_I/K%^1_QH_P!)]8OR/^-3T4 0?Z3ZQ?D?\:/])]8OR/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/H+J6Z***0PHHHH **** "BBB@ HHHH **** "BBB@ K-T/_ (][G_KZG_\
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M7;I';ZI!>Q/:S.\@C14E#;6+.0@ /+' YKY$\)ZMX7\.S_LGZSXM\B#3=/\
M =Q/'J-Y$3;V$WV?3U6>63&V%0&9?,<A0749!(I/&FFZ9XO^%OQ;OK2""]\
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M104444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!YY\%?BY_PN#X8IXO\ [*_LG==ZA:_8_M/G?\>MW-;[M^Q?O>3NQCC=
MCG&33^%_QZT+QS\(?"OCK7+C3_!\>NZ>^HK9ZAJ4>(DC5GE(D<)N5$4LS;0
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M6M_# ^!/PLU+Q%K7@Z/^S$U2>'PW\1(O^)-JP-X0X21ODCNT4,(W"2LHE?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:-%%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%<[XN\?:-X'^R?VO)>1_:M_E?9
M=/N+K.W;G/DQOM^\/O8SSC.#5PA*I+E@KOR Z*BO//\ A?G@W_GXU?\ \)_4
M/_C%'_"_/!O_ #\:O_X3^H?_ !BNGZGB?^?4ON8[,]#HKSS_ (7YX-_Y^-7_
M /"?U#_XQ1_POSP;_P _&K_^$_J'_P 8H^IXG_GU+[F%F>AT5YY_POSP;_S\
M:O\ ^$_J'_QBC_A?G@W_ )^-7_\ "?U#_P",4?4\3_SZE]S"S/0Z*\\_X7YX
M-_Y^-7_\)_4/_C%'_"_/!O\ S\:O_P"$_J'_ ,8H^IXG_GU+[F%F>AT5YY_P
MOSP;_P _&K_^$_J'_P 8H_X7YX-_Y^-7_P#"?U#_ .,4?4\3_P ^I?<PLST.
MBO//^%^>#?\ GXU?_P )_4/_ (Q1_P +\\&_\_&K_P#A/ZA_\8H^IXG_ )]2
M^YA9GH=%>>?\+\\&_P#/QJ__ (3^H?\ QBC_ (7YX-_Y^-7_ /"?U#_XQ1]3
MQ/\ SZE]S"S/0Z*\\_X7YX-_Y^-7_P#"?U#_ .,4?\+\\&_\_&K_ /A/ZA_\
M8H^IXG_GU+[F%F>AT5YY_P +\\&_\_&K_P#A/ZA_\8H_X7YX-_Y^-7_\)_4/
M_C%'U/$_\^I?<PLST.BO//\ A?G@W_GXU?\ \)_4/_C%'_"_/!O_ #\:O_X3
M^H?_ !BCZGB?^?4ON869Z'17GG_"_/!O_/QJ_P#X3^H?_&*/^%^>#?\ GXU?
M_P )_4/_ (Q1]3Q/_/J7W,+,]#HKSS_A?G@W_GXU?_PG]0_^,4?\+\\&_P#/
MQJ__ (3^H?\ QBCZGB?^?4ON869Z'17GG_"_/!O_ #\:O_X3^H?_ !BC_A?G
M@W_GXU?_ ,)_4/\ XQ1]3Q/_ #ZE]S"S/0Z*\\_X7YX-_P"?C5__  G]0_\
MC%'_  OSP;_S\:O_ .$_J'_QBCZGB?\ GU+[F%F>AT5YY_POSP;_ ,_&K_\
MA/ZA_P#&*/\ A?G@W_GXU?\ \)_4/_C%'U/$_P#/J7W,+,]#HKSS_A?G@W_G
MXU?_ ,)_4/\ XQ1_POSP;_S\:O\ ^$_J'_QBCZGB?^?4ON869Z'17GG_  OS
MP;_S\:O_ .$_J'_QBC_A?G@W_GXU?_PG]0_^,4?4\3_SZE]S"S/0Z*\\_P"%
M^>#?^?C5_P#PG]0_^,4?\+\\&_\ /QJ__A/ZA_\ &*/J>)_Y]2^YA9GH=%>>
M?\+\\&_\_&K_ /A/ZA_\8H_X7YX-_P"?C5__  G]0_\ C%'U/$_\^I?<PLST
M.BO//^%^>#?^?C5__"?U#_XQ1_POSP;_ ,_&K_\ A/ZA_P#&*/J>)_Y]2^YA
M9GH=%>>?\+\\&_\ /QJ__A/ZA_\ &*/^%^>#?^?C5_\ PG]0_P#C%'U/$_\
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MGB?^?4ON869Z'17GG_"_/!O_ #\:O_X3^H?_ !BC_A?G@W_GXU?_ ,)_4/\
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M_"?U#_XQ1_POSP;_ ,_&K_\ A/ZA_P#&*/J>)_Y]2^YA9G9:A_R%-+_WY/\
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M\3_SZE]S%9GH=%>>?\+\\&_\_&K_ /A/ZA_\8H_X7YX-_P"?C5__  G]0_\
MC%'U/$_\^I?<QV9Z'17GG_"_/!O_ #\:O_X3^H?_ !BC_A?G@W_GXU?_ ,)_
M4/\ XQ1]3Q/_ #ZE]S"S/0Z*\\_X7YX-_P"?C5__  G]0_\ C%'_  OSP;_S
M\:O_ .$_J'_QBCZGB?\ GU+[F%F>AT5YY_POSP;_ ,_&K_\ A/ZA_P#&*/\
MA?G@W_GXU?\ \)_4/_C%'U/$_P#/J7W,+,]#HKSS_A?G@W_GXU?_ ,)_4/\
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M?^?C5_\ PG]0_P#C%'_"_/!O_/QJ_P#X3^H?_&*/J>)_Y]2^YA9GH=%>>?\
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M>/\ B0:AG@'MY%/ZGB?^?4ON8K,]2HKSS_A?G@W_ )^-7_\ "?U#_P",4?\
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M\3_SZE]S"S/0Z*\\_P"%^>#?^?C5_P#PG]0_^,4?\+\\&_\ /QJ__A/ZA_\
M&*/J>)_Y]2^YA9GH=%>>K\>O!SL%%QJV2<<Z!J 'Y^17H58U*-6C;VD6K]U8
M04445B 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MM,U&VCN[6?8R>9%(H9&VL PRI!P0#ZT;WMT_6]OOL_N8;6\_T_X=?>:%%%%
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M-T/_ (][G_KZG_\ 1C4"ZFE1110,**** "BBB@ HHHH **** "BBB@ HHHH
M*SK/_D-:E_NQ?R-:-9UG_P AK4O]V+^1IB-&LS6/%&C>'9K&'5=6L=,EOYA;
MVD=Y<I$UQ*2 (XPQ&]CD?*,GFM.O-OBY\ ?"_P :M2\-7WB%KY9=!N3<6ZV<
MXC64%D+1R94Y4F-?N[6]"*TI*G*:55VCUMJS2/+?WF>DUX]XG^,'C./XD>*/
M"GA'P5H^OGP]I=GJ=Q/J?B*33Y)OM!GV11(MG,I(^SMR[J/F'3DU[#7SSJ'P
MIUWQE^T5\1[C_A(?%'A#0;SP_H]H;C18;:.+4<->B6,3S6\C*R!QS Z.OF@Y
MSM(RLVG;?^M_^ )62;?E^:_0]#\/_'WP+K/P_P!"\87GB+3_  WI>KZ<NJ1+
MKUY#:21PED1BX9\ +)+&A8$KN=0"=PSN7WQ2\&:7XET_P[>>+M"M/$&H(DEG
MI,^I0I=W*N2$:.(MN<,0<$ YP<5Y=<_"C3M$_:$^$R:7X9V>&?"_A75;6QF6
MV:2#3Y#)8I$HD((60QB4#)W, _7FO+KOX;:@]Q\1?!_BO7/B9;OXCUZ\O8[+
MPQX>M+FQU*":0-;NNH/I\@@D5%CCS/<QF(PK@J@0UK:,I*VSN_NERI>K6O7;
MYK-WC!MO56_&-[^B>G3?IU]EUSXJ>)?[=^)VE:9<>&-*?PR^D_8K[Q$\L-KM
MN &F\]U;KMW!-H'S%0<UWGB3XI>#/!TACU_Q=H.AR"=+8IJ6IPVY$SKO2/#L
M/F9?F"]2.17S[\5_!?B"^B^/:VFBZI>G41X?%BT=H[F\\K9YACVK\Y7!W;<X
M[XKJ;CP#)>?$#]H'4KCPXT\FK:+:6-G=R6)8WD?V*020QN5_>+OV@H"1G&1F
MN.=1TX.5KV3?K9;?/^NPJ3<Y*#TN_NU?Y?U;<]ALOB#X7U3Q5?>%[+Q+H]WX
MFL8O.NM&AOXGO+=,+\\D(;>J_.G) 'SKZBL#PE\2+>Q^'^E:KXX\4>$+?4);
M>>>YO=)U +IKK$Q\QX7E;)1%V[R3\ISG%>2^'OA]>:!9?LNII_AJ?3O['26/
M4EMK!HOL*RZ1-YJS;5'EAYQ'N#8S)MSEL5D?#'X<ZDW_  ST-8\,71719M=N
M+D7VGMBQE8N8'?<O[MB2"A."<\5UU8^SER)WZ7]&]?Z^\SC5<E&36ZO]_3^O
MN/HV'XD^$;CP<WBZ+Q3HLOA159SKJ:A";$*K%&/GAMF P*GGJ,=:--^)'A+6
MO#MOK^G^*-%O]"N)UM8=4MM0ADM99FD$:QK*K%2YD(0*#DL0.M?.>K6_B[PF
M_CRXL]$U:UTVY^):7#ZE8Z$VHWMA82:=;J]]86[12"1O/RA=8I0 \QVL0V.0
MN/ASK?B?P/\ $FSO=&\4>)=/UOX@^';U'\1Z*D%SJ-D&T[SYI+>*")1&%1]V
M8E*JA$@#!JF"YY16R?+\N;D_+F?;9^=MY>[?RYOPYE_[:OO7E?Z[\+?$CPEX
MY<IX;\4Z+X@<1>>5TO4(;D^7O:/?\C'Y=Z.N>F58=0:UM+UK3]<@EFTV^MM0
MABFDMI)+699526-BDD9*DX96!4KU!!!KP7]JG5M2^$+^&_BEX<TU]2O]-67P
MY/IL!53<Q7NU+8 $@$I>):^N$DEP#FO2? _PYN/A_P#!6P\':=?,VIVFE-;?
MVBW#27;(2\Y]VE9G/N:SE)JG*:5[=.[WT^5K^<K:V95O?46]]?1;:_.]O)&#
MXZ^/VBZ9KF@Z+X7U_P /:YK$GB6TT35]/AO4N+BQCE9U??'')NC<%,#>, @@
M@UVT/Q0\&W'C*3PC%XMT.3Q7'R^A)J4)OEP@<Y@W;Q\I#=.ASTKYAT?3GU+P
M/\!_#%O\-O$%CK_@S7--359;C0I(X=,*!DN)$NG4+.DC@L9;=I 00SE<C-/4
M+/QAXHU[PG%>V/B^VU+2_'T5Y=>&['PM#;:#I]LMY(HNXKLVN^;>C"1WCN7)
M:>1F1$W!=(Q7,Z=[^_:_E:"NO+5O[]4<TYN-YVM:"=O/WW9^>B7W:,^A?A[^
MT7\/_B?XF\1Z!H7B33;C5M#NY+::U%];M).J1QN]Q"J2,S0@RA"Y PZ.#TKI
MO!GQ,\(?$>.ZD\)>*]$\41VI5;A]%U&&[$);.T.8V;:3@XSUP:\'FD\0>$X_
MVA=)LO"5YK/B#5-1FUO2+6]T2>YTS4;<Z?9Q[?-VB!WW1R+Y!D5V*XQ@YIWP
M;T_6-0_:)'B*2\\<:_I4GA)[)]:\7^'HM)Q.MW&_V=$2TMGX#,P\Q"#N;8S8
M?!&TG"/>*;\GRMO\5R]+/[C6I+DYFN]EZ<R7Y._FOO/INBBBI*"BBB@ HHHH
M **** "BBB@ HHHH ^6OC'\1/#/C3Q1J?A;2?A;)XU\16DK03W30>5Y3 XSY
MD7[S;GU9![USOP]_9M^+GAV.ZU72=>M?!5RQ\R'28[MY8V;/W9!\Z8QT)+GU
M]:Z&'QC\5M-UCXC:CX:_LJ]\.Z+K-S+-#J1/FOA0S1QX(P H!ZCECR>E.\5>
M/_B#\0M9U#5_!NN)H&E:#H=IK#V4BAC.TT1E*-E2&^4$<\<#US7MTI3ITE&F
MTDTFVW>UTGMLK^GS/RO$4\+B\5+$XI5)5%*2@H15-M*36DDU*7+:[O-?X=3Z
M/\*C55\,Z4-<,;:T+6,7IAQL,VT;R,<8W9Z5JUB^"?$!\6>#M#ULQB%M1LH;
MHQCHI= Q ^A-;5>1434VFK.Y^F8>49T82@[II6;W:MNPHHHK,Z K\?/C#=/I
MGQ2_:YOI_@AHGQ(TI=2BM[GQ;JLT._PQYD!19TC\I[AE!;>3"5(\O)-?L'7D
MWA_]F7P?H.K?%:^+7^I+\2I ^N6E])&\('E-$4B"H"JE7;[Q8Y[USS@W-R7\
MLEZMN+MW6B>JU-(RMR_XD_DD_EU6CT/A#X[>"Y?"3?L4^'=+T'3_ (\M:Z;?
MI;Z5>SPP6>MJ;6%E&^X5D6,*=R[P>(U'6NT_::L9E^$?P*\#:S\.M.^!?A[Q
MKX^@L_$_A70KFW>W\G>0J//:*D9$H"L2 ",#/W*]OUO_ ()[>#=8\%?#;P[%
MX\^(.CR?#Y;I-$UK2=6@MM1C2<@LK3+;]% "+M"D+P2:Z]OV._".N?!F^^&O
MC37_ !9\2M)NKPWZ:GXPU<WFI6LVT!##<!5*!,$@8_B8'(8BNN4E>3W]_F]5
MS*5OFEK?3T,DO=A&]K0Y;KH[25_Q7F6]5^&OPS_9ET>_^('@_P"$6_5M/LA8
M&R\ :'&VI7D$DL09%AC*><0RHY+$D!&.>N?E_P#:E_;,\*>-M/\  7@CQG9>
M*_@]X,\47$UWXG_X2[1;BVU&33[=P!:)! )7 N'^4OP BM_>Q7U%\%_V6-&^
M#'B&37%\:^//'&I_9GLK:7QGXADU!;.!F5FCA3"HH)C3G!.%QGK7M-1*[<6W
M=+H_OM]^KZ;K5#3]UI*S[_*W_#=3\?O ?C+X?>-OV /B1X+TKQ +34(/'7GZ
M7HT.GS.M^T]SOT^S\O"!EF$#C ;*!,L!C!]&^&6EZ)X>^+/QG'Q&\-6G[-NN
MW/PU>W70/#-O&; Z><^?J:R0';),LF%$84,!QEVR1]<O^P_\.;CX1:E\.[N3
M6KO2;O7YO$T5\UZL=[97\CE_-@EC1=FTDA<@\$YS5?P7^PI\/?#?_"23>(-4
M\5_$K5=?TI]#O-7\;ZT]_>"Q<Y:".0!/+7.#E1D$<&LHQ?LW'^[;5WU]FH;Z
M:WT?3EU24APM"2:_FO\ ^5.;[K:KK?1MH^)OV<_"O_"-_%+]F>?QE\--/^%^
ME0B==!\9Z/8Q"X\6W#P[+=;W8V^W,D9\S$H<L6(!0$X^@?%WPW\-?#__ (*6
M?!Z?0-)AL+K6='UR_P!1N0S237<[*Y+R2.2S8SA03A1A5   KT[X<_L$^!?A
M_P"+O#^O7'B?QSXS'AM_-T#2?%6OO>V&D,%VJ;>':H7:N ,EL8'< UC>,/\
M@GGH'C3XF/X\N_C!\7K77UGGDLY;/Q/&@T^.9BSP6Q-N7BAYV[%;IQS73S)U
M82OHG-OTE%K7SN[NUEHK*Y@X.4)1?51_"5]/+M?75ZV/JVBFHNQ57).!C+=3
M3JS-0HHHH&9WB+7K+PKX?U/6M3G6VT[3;66\N9G.!'%&A=V/T )KX#^"WQP\
M%Z3\0_@WXXM_&OAO4?%?Q*N;W3O%NEVFJVTUY;O>L;K3UDCC?>OV=T2U&X<"
M4@X-?<?Q1^'.G_%KP+JGA+5KJ]M-*U-5BN_L#JDDL(=6>$EE8;) "C#&2K,
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MHJA5!*QB-0JKW5Y\+=)OOBO9?$"6:[.L6FBSZ"EOO3[,UO--%,[,NW<7W1*
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MPWQ2_:6O?#OA^._\)^%-0UV:W\9V_A2]606R@,;B&.39ON8_F<2[8V)P&P9
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MW%M=K?V\T2R1W4;*RS*0"'!7Y2".<CCGBK-#5G8$[JZ"BBBD,**** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I*6B@#B?'7@ZS\476F
MV]Y"LT32.2C=#A"17,M\!]$SQ80C_@->EZA_R%-+_P!^3_T6:T*M3E%63.>>
M'HU7S5()OS29Y'_PH?1/^?&'_OFC_A0^B?\ /C#_ -\UZY13]I/^9F?U/#?\
M^H_<CR/_ (4/HG_/C#_WS1_PH?1/^?&'_OFO7**/:3_F8?4\-_SZC]R/(_\
MA0^B?\^,/_?-'_"A]$_Y\8?^^:]<HH]I/^9A]3PW_/J/W(\C_P"%#Z)_SXP_
M]\T?\*'T3_GQA_[YKURBCVD_YF'U/#?\^H_<CR/_ (4/HG_/C#_WS1_PH?1/
M^?&'_OFO7**/:3_F8?4\-_SZC]R/(_\ A0^B?\^,/_?-'_"A]$_Y\8?^^:]<
MHH]I/^9A]3PW_/J/W(\C_P"%#Z)_SXP_]\T?\*'T3_GQA_[YKURBCVD_YF'U
M/#?\^H_<CQ;6/@?H]M8F1+.%6\R,9"CNZ@_H:N_\*'T3_GQA_P"^:]+\0?\
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ME:ZDN&C+-LW8 E7=A3C!QGO[+14R@III]=!4W[*491WCM\CPGXO?#GXA^)O
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M^QI_?E_[^-_C1]C3^_+_ -_&_P : +%%5_L:?WY?^_C?XT?8T_OR_P#?QO\
M&@"Q15?[&G]^7_OXW^-'V-/[\O\ W\;_ !H L457^QI_?E_[^-_C1]C3^_+_
M -_&_P : +%%5_L:?WY?^_C?XT?8T_OR_P#?QO\ &@"Q15?[&G]^7_OXW^-'
MV-/[\O\ W\;_ !H L457^QI_?E_[^-_C1]C3^_+_ -_&_P : +%%5_L:?WY?
M^_C?XT?8T_OR_P#?QO\ &@"Q15?[&G]^7_OXW^-'V-/[\O\ W\;_ !H L457
M^QI_?E_[^-_C1]C3^_+_ -_&_P : +%%5_L:?WY?^_C?XT?8T_OR_P#?QO\
M&@"Q15?[&G]^7_OXW^-'V-/[\O\ W\;_ !H L457^QI_?E_[^-_C1]C3^_+_
M -_&_P : +%%5_L:?WY?^_C?XT?8T_OR_P#?QO\ &@"Q15?[&G]^7_OXW^-'
MV-/[\O\ W\;_ !H L457^QI_?E_[^-_C1]C3^_+_ -_&_P : +%%5_L:?WY?
M^_C?XT?8T_OR_P#?QO\ &@"Q15?[&G]^7_OXW^-'V-/[\O\ W\;_ !H L457
M^QI_?E_[^-_C1]C3^_+_ -_&_P : +%%5_L:?WY?^_C?XT?8T_OR_P#?QO\
M&@"Q15?[&G]^7_OXW^-'V-/[\O\ W\;_ !H L457^QI_?E_[^-_C1]C3^_+_
M -_&_P : +%%5_L:?WY?^_C?XT?8T_OR_P#?QO\ &@"Q15?[&G]^7_OXW^-'
MV-/[\O\ W\;_ !H L457^QI_?E_[^-_C1]C3^_+_ -_&_P : +%%5_L:?WY?
M^_C?XT?8T_OR_P#?QO\ &@"Q15?[&G]^7_OXW^-'V-/[\O\ W\;_ !H L457
M^QI_?E_[^-_C1]C3^_+_ -_&_P : +%%5_L:?WY?^_C?XT?8T_OR_P#?QO\
M&@"Q15?[&G]^7_OXW^-'V-/[\O\ W\;_ !H L457^QI_?E_[^-_C1]C3^_+_
M -_&_P : +%%5_L:?WY?^_C?XT?8T_OR_P#?QO\ &@"Q15?[&G]^7_OXW^-'
MV-/[\O\ W\;_ !H L457^QI_?E_[^-_C1]C3^_+_ -_&_P : +%%5_L:?WY?
M^_C?XT?8T_OR_P#?QO\ &@"Q15?[&G]^7_OXW^-'V-/[\O\ W\;_ !H L457
M^QI_?E_[^-_C1]C3^_+_ -_&_P : +%%5_L:?WY?^_C?XT?8T_OR_P#?QO\
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M/L:?WY?^_C?XT 6**K_8T_OR_P#?QO\ &C[&G]^7_OXW^- %BBJ_V-/[\O\
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ME_[^-_C0!8HJO]C3^_+_ -_&_P :/L:?WY?^_C?XT 6**K_8T_OR_P#?QO\
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M:1HNM>*=;O-'@UZVCTB*'RI;.25H_,\V:6.-=I4$AV4D.NS><@2M;6Z_\/\
M=9-I[638WI=OI_FE^;2^:/3J*\_\-_&"#Q9XFN=.T[PSK\ND07L^F_\ "2>3
M ;!KF$LLL8 F,X"NCIYC0B,LN YRI/H%'1,3T;3W04444 %%%% !1110 444
M4 %%%% !1110 45\*^'/V@O$^I>&9=6TCXR2^*OB;%XIN[!?A=%;:3<>;:IJ
MLML%:W@MTO(U6V E,S384+O;<N5/??%KXP1:+^T/XG\->(_CL?A#H&G^&=.U
M'3K=9-'B-W<2S7BS-F^MI7EPL,/RQD8SZM2VCS?UHKC^U*/;_.W]>1]645\>
M^/?B]\7M?_9C^$&L^&M6@\.?$'Q;J<5M]HCT^(Q7:M:7DL.89U?REF,,#$?>
M0.0"*].\1_M!7&I_LRZ3XY\+P(OBCQ/;6MAHVGS 2>5JMRRPK%(.XAE9S(,<
M+#(<<8JFG[R6K3Y;=6WM:]M[V\GO:Z$K6@V[*2YK]E=K7[F_3;9GNE%?,7PT
M\>:_KG[-.EZ[XZ^,4?@RXL]<U.PU3QA/;Z;:R3QP:A=6T**9XC:PLWEQ9)B8
MD @ ,VX8%O\ M!^-=$^ /C?Q';Z[;^(]/M?%=OH7AOQYJME&D=W87%Q;0-J$
ML<"QQ2I!)/,JR1K''*(%/<LS<?>E!:M?C=I+\UO;N*^U]-6ONO?\NA]>45X1
MX?\ $GB?X;?M Z#X UOQM>>.])\3Z'>:E:S:Q:V<-]97%I)"' -I!"C0R)/Q
MN3<K1'YB&P/=Z71277]&U^:#JTU_5KA1112&%%%% !1110 445Y7X@^+GB?0
M_%FL(GP\U"^\%Z/-#;7NL6SS27\K/$LC2VE@ENQNH(_,16:.7S-RR!8GV?,K
MKJ/I<]4HKF?AWXKO_&WAI=7O]!NO#GGW$XM;2^#K.]LLK+#-)&Z(\+2(%<Q.
MH9-VUN0:\<^(>I^/_A#XV^&][_PL&\\5Q^*?%,>B7OAJ]TVRAM$AFCFD:2S,
M,(N$,(BW?O9I04#;B3@T]>:,>]E\VTE^?RZB>D92_EN_DDVVNCV^?2Y]$T5\
M^_M07'C[X<_#SQE\2- ^(]WITV@VZWNG^&?[*LGTVZ$90FWN"\37+O,V]-T4
M\6-Z;5!4EKNL^*?%GQ,^,C> ]&\27G@&PT7P]::YJU[I,%K<7\UQ=22QPVR_
M:H)HDC18)68^678M& 4 ;>+WMM_^ WZ='\_57'HKO^M4OS:_I,]UHKY#U+]J
M#6_!_@GPS>^+O$ECHYT/XD7'A'Q-K,EO%#!>V<,%TZRE6W"-I$6V8^60=^X*
M%!VU8\7>*OB1X[\*6NOW+ZAI-MXNURUL/"_P^BOVT2ZN+-1+(TMWJ,0^T6DL
MD2-<LJ,=D<"P[&DD8%+WE>&JT_%1:?HU*_?1Z:%N+B[/S_!R3^YQ=WMJM=3Z
MTHKRK]F35;W5/A#8+JES>S:M9WE[9WMOJ-V;R>QFCNI5-FUR7<W/D<1>>6+2
M",.V&)4>JU<DD]'=$=6GT_3^NNO<****D HHHH *1ONFEI&^Z: / OVCM0GM
M]/MO)E>)A+D,C$'TZBOGW^U[[_G]N/\ OZW^->\_M*?\>-O_ -=/\*^>Z^BR
M^,94FVNI^0<75ZM+'Q5.;2Y5LVNK+?\ :U]_S^7'_?UO\:/[6OO^?RX_[^M_
MC52BO2]G#^5'Q/UO$_\ /R7WLM_VM??\_EQ_W];_ !H_M:^_Y_+C_OZW^-5*
M*/9P_E0?6\3_ ,_)?>RW_:U]_P _EQ_W];_&C^UK[_G\N/\ OZW^-5**/9P_
ME0?6\3_S\E][-"WUB_6>/%]<#YA_RU;U^M?:/@6Z>YTB!F.3M'\J^(K?_7Q_
M[P_G7VM\//\ D"V_^X/Y5XF9147&R[GZ=P;5J585_:2;^'=W[G8T445XQ^CA
M1110 4444 9OB#_D&-_UUA_]&+6E6;X@_P"08W_76'_T8M:5 !1110 4444
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M *ZP_P#HQ:TJS?$'_(,;_KK#_P"C%K2H **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MHT444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5SWBV\\56OV7_A&=+TG4MV_[1_:F
MH26NSIMV;(9-V?FSG&,#KGCH:*N$E&5VK^O_  + >>?VO\5/^A7\)_\ A07/
M_P AT?VO\5/^A7\)_P#A07/_ ,AUZ'173]8A_P ^H_\ DW_R0SSS^U_BI_T*
M_A/_ ,*"Y_\ D.C^U_BI_P!"OX3_ /"@N?\ Y#KT.BCZQ#_GU'_R;_Y(#SS^
MU_BI_P!"OX3_ /"@N?\ Y#H_M?XJ?]"OX3_\*"Y_^0Z]#HH^L0_Y]1_\F_\
MD@///[7^*G_0K^$__"@N?_D.C^U_BI_T*_A/_P *"Y_^0Z]#HH^L0_Y]1_\
M)O\ Y(#SS^U_BI_T*_A/_P *"Y_^0Z/[7^*G_0K^$_\ PH+G_P"0Z]#HH^L0
M_P"?4?\ R;_Y(#SS^U_BI_T*_A/_ ,*"Y_\ D.C^U_BI_P!"OX3_ /"@N?\
MY#KT.BCZQ#_GU'_R;_Y(#SS^U_BI_P!"OX3_ /"@N?\ Y#H_M?XJ?]"OX3_\
M*"Y_^0Z]#HH^L0_Y]1_\F_\ D@///[7^*G_0K^$__"@N?_D.C^U_BI_T*_A/
M_P *"Y_^0Z]#HH^L0_Y]1_\ )O\ Y(#SS^U_BI_T*_A/_P *"Y_^0Z/[7^*G
M_0K^$_\ PH+G_P"0Z]#HH^L0_P"?4?\ R;_Y(#SS^U_BI_T*_A/_ ,*"Y_\
MD.C^U_BI_P!"OX3_ /"@N?\ Y#KT.BCZQ#_GU'_R;_Y(#SS^U_BI_P!"OX3_
M /"@N?\ Y#H_M?XJ?]"OX3_\*"Y_^0Z]#HH^L0_Y]1_\F_\ D@///[7^*G_0
MK^$__"@N?_D.C^U_BI_T*_A/_P *"Y_^0Z]#HH^L0_Y]1_\ )O\ Y(#SS^U_
MBI_T*_A/_P *"Y_^0Z/[7^*G_0K^$_\ PH+G_P"0Z]#HH^L0_P"?4?\ R;_Y
M(#SS^U_BI_T*_A/_ ,*"Y_\ D.C^U_BI_P!"OX3_ /"@N?\ Y#KT.BCZQ#_G
MU'_R;_Y(#SS^U_BI_P!"OX3_ /"@N?\ Y#H_M?XJ?]"OX3_\*"Y_^0Z]#HH^
ML0_Y]1_\F_\ D@///[7^*G_0K^$__"@N?_D.C^U_BI_T*_A/_P *"Y_^0Z]#
MHH^L0_Y]1_\ )O\ Y(#SS^U_BI_T*_A/_P *"Y_^0Z/[7^*G_0K^$_\ PH+G
M_P"0Z]#HH^L0_P"?4?\ R;_Y(#SS^U_BI_T*_A/_ ,*"Y_\ D.C^U_BI_P!"
MOX3_ /"@N?\ Y#KT.BCZQ#_GU'_R;_Y(#SS^U_BI_P!"OX3_ /"@N?\ Y#H_
MM?XJ?]"OX3_\*"Y_^0Z]#HH^L0_Y]1_\F_\ D@///[7^*G_0K^$__"@N?_D.
MC^U_BI_T*_A/_P *"Y_^0Z]#HH^L0_Y]1_\ )O\ Y(#SS^U_BI_T*_A/_P *
M"Y_^0Z/[7^*G_0K^$_\ PH+G_P"0Z]#HH^L0_P"?4?\ R;_Y(#SS^U_BI_T*
M_A/_ ,*"Y_\ D.C^U_BI_P!"OX3_ /"@N?\ Y#KT.BCZQ#_GU'_R;_Y(#SS^
MU_BI_P!"OX3_ /"@N?\ Y#H_M?XJ?]"OX3_\*"Y_^0Z]#HH^L0_Y]1_\F_\
MD@///[7^*G_0K^$__"@N?_D.C^U_BI_T*_A/_P *"Y_^0Z]#HH^L0_Y]1_\
M)O\ Y(#SS^U_BI_T*_A/_P *"Y_^0Z/[7^*G_0K^$_\ PH+G_P"0Z]#HH^L0
M_P"?4?\ R;_Y(#SS^U_BI_T*_A/_ ,*"Y_\ D.C^U_BI_P!"OX3_ /"@N?\
MY#KT.BCZQ#_GU'_R;_Y(#SS^U_BI_P!"OX3_ /"@N?\ Y#H_M?XJ?]"OX3_\
M*"Y_^0Z]#HH^L0_Y]1_\F_\ D@///[7^*G_0K^$__"@N?_D.C^U_BI_T*_A/
M_P *"Y_^0Z]#HH^L0_Y]1_\ )O\ Y(#SS^U_BI_T*_A/_P *"Y_^0Z/[7^*G
M_0K^$_\ PH+G_P"0Z]#HH^L0_P"?4?\ R;_Y(#SS^U_BI_T*_A/_ ,*"Y_\
MD.C^U_BI_P!"OX3_ /"@N?\ Y#KT.BCZQ#_GU'_R;_Y(#SS^U_BI_P!"OX3_
M /"@N?\ Y#H_M?XJ?]"OX3_\*"Y_^0Z]#HH^L0_Y]1_\F_\ D@///[7^*G_0
MK^$__"@N?_D.C^U_BI_T*_A/_P *"Y_^0Z]#HH^L0_Y]1_\ )O\ Y(#SS^U_
MBI_T*_A/_P *"Y_^0Z/[7^*G_0K^$_\ PH+G_P"0Z]#HH^L0_P"?4?\ R;_Y
M(#SS^U_BI_T*_A/_ ,*"Y_\ D.C^U_BI_P!"OX3_ /"@N?\ Y#KT.BCZQ#_G
MU'_R;_Y(#SS^U_BI_P!"OX3_ /"@N?\ Y#H_M?XJ?]"OX3_\*"Y_^0Z]#HH^
ML0_Y]1_\F_\ D@///[7^*G_0K^$__"@N?_D.C^U_BI_T*_A/_P *"Y_^0Z]#
MHH^L0_Y]1_\ )O\ Y(#SS^U_BI_T*_A/_P *"Y_^0Z/[7^*G_0K^$_\ PH+G
M_P"0Z]#HH^L0_P"?4?\ R;_Y(#SS^U_BI_T*_A/_ ,*"Y_\ D.C^U_BI_P!"
MOX3_ /"@N?\ Y#KT.BCZQ#_GU'_R;_Y(#SS^U_BI_P!"OX3_ /"@N?\ Y#H_
MM?XJ?]"OX3_\*"Y_^0Z]#HH^L0_Y]1_\F_\ D@///[7^*G_0K^$__"@N?_D.
MC^U_BI_T*_A/_P *"Y_^0Z]#HH^L0_Y]1_\ )O\ Y(#SS^U_BI_T*_A/_P *
M"Y_^0Z/[7^*G_0K^$_\ PH+G_P"0Z]#HH^L0_P"?4?\ R;_Y(#SS^U_BI_T*
M_A/_ ,*"Y_\ D.C^U_BI_P!"OX3_ /"@N?\ Y#KT.BCZQ#_GU'_R;_Y(#SS^
MU_BI_P!"OX3_ /"@N?\ Y#H_M?XJ?]"OX3_\*"Y_^0Z]#HH^L0_Y]1_\F_\
MD@///[7^*G_0K^$__"@N?_D.C^U_BI_T*_A/_P *"Y_^0Z]#HH^L0_Y]1_\
M)O\ Y(#S2XO/BI/=6LW_  C/A,>2S-C^W[GG*D?\^?O5C^U_BI_T*_A/_P *
M"Y_^0Z]#HH^L0_Y]1_\ )O\ Y(1YY_:_Q4_Z%?PG_P"%!<__ "'1_:_Q4_Z%
M?PG_ .%!<_\ R'7H=%'UB'_/J/\ Y-_\D,\\_M?XJ?\ 0K^$_P#PH+G_ .0Z
M/[7^*G_0K^$__"@N?_D.O0Z*/K$/^?4?_)O_ )(#SS^U_BI_T*_A/_PH+G_Y
M#H_M?XJ?]"OX3_\ "@N?_D.O0Z*/K$/^?4?_ ";_ .2 \\_M?XJ?]"OX3_\
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M#H_M?XJ?]"OX3_\ "@N?_D.O0Z*/K$/^?4?_ ";_ .2 \\_M?XJ?]"OX3_\
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MY_:_Q4_Z%?PG_P"%!<__ "'1_:_Q4_Z%?PG_ .%!<_\ R'7H=%'UB'_/J/\
MY-_\D!YY_:_Q4_Z%?PG_ .%!<_\ R'1_:_Q4_P"A7\)_^%!<_P#R'7H=%'UB
M'_/J/_DW_P D!YY_:_Q4_P"A7\)_^%!<_P#R'1_:_P 5/^A7\)_^%!<__(=>
MAT4?6(?\^H_^3?\ R0'GG]K_ !4_Z%?PG_X4%S_\AU6L;SXJ6<<B_P#",^$V
MWRO+_P A^X'WF)Q_QY^]>F44?6(?\^H_^3?_ "0CSS^U_BI_T*_A/_PH+G_Y
M#H_M?XJ?]"OX3_\ "@N?_D.O0Z*/K$/^?4?_ ";_ .2&>>?VO\5/^A7\)_\
MA07/_P AT?VO\5/^A7\)_P#A07/_ ,AUZ'11]8A_SZC_ .3?_) >>?VO\5/^
MA7\)_P#A07/_ ,AT?VO\5/\ H5_"?_A07/\ \AUZ'11]8A_SZC_Y-_\ ) >>
M?VO\5/\ H5_"?_A07/\ \AT?VO\ %3_H5_"?_A07/_R'7H=%'UB'_/J/_DW_
M ,D!YY_:_P 5/^A7\)_^%!<__(=']K_%3_H5_"?_ (4%S_\ (=>AT4?6(?\
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MG]K_ !4_Z%?PG_X4%S_\AT?VO\5/^A7\)_\ A07/_P AUZ'11]8A_P ^H_\
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M]'JWQ2,BA_#'A14S\Q77[@D#V'V,9KT&BBL:E15+6BH^E_U;$%%%%8@%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/1INZ?0])HKPB/\ :JLKGX(^(?'T'AZX%YH-VEC>Z+<7 C99C+&A E"G('F
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MTG>-^CE9'NM%?.6K_M?7'AVWT+7-5^'>L6/@K666.TUIKF)I9&*Y!%L!NVD
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M=CWH[7[)^6HJV0XOZQ.C0AI'E7O2@KN45))/F<9-WNE%MM6TN?1E%>+?$/\
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MV;M'@TR[U8Z!?E]4N;&!Y8;4M<6TC%W PJC#X+8R%-?8=%:*34U-[W3^Z_\
MF-<23A4YZ5&,;N<FKO64XN#>KT24G9?BSYE_:T^$=_XL\5^#?%2>&[CQGH>E
M[[?5=$LI62X>%B"'C"D,QZ\*<Y"]LD7O@'X'\'6?C@ZKX9^$/B+P4D%I(K:M
MXBFFA?>Q4>4D$DK[@PW'?QC;CO7T914Q]Q67G^)R?V]B'@(X!WM%.*M*25FV
M]8I\K>N[6V]['E_[37@W4_'WP.\4:)HT!NM2FCBEA@7[TGES1R%1[D(0/?%>
M->+FU_QU^QK/X;MO!7B:QUK2;73-/:SO=-=);IHGA#O"@RSH I.<#]*^M:*F
MVC7=I_-&>!SF>!I4J?LU+V=15$]=]+KT?*O0^6?VBO!7B#6_@5\+M/T[0]1O
M[^QO=/:ZM;6U>26 +;,K%U4$J 3@D]#63\8_!^IZE\==4NO&_@OQ5X^\$S64
M:Z)8Z TC003!4#>:$=-AW!\L3W!P>WUY15/63EYM_>DOT.K"\0U<+&$5!>ZI
MJ]VG[[4KIK5-<MKKHVCX6\/_  Q\5:?^RK\5]"/A#5K#4[C787M-)%M)+*T:
MS6Y_=\$RJH5OG7((4G-=A^T-X#\2:U^RC\--&T[0-2O]7L6TW[38VMJ\D\.V
MRD1MR*"1AB <C@FOKFBJ4G'[XO[CJ_UHK_6(8ATU>-1U-WNXQC;T]V_<@F64
MV3K"0D_ED(6Z!L<9_&OSYU3X7:YJG@OQ+9^)OAEXR\2_%/SI9%\0RR2O9)$"
M#F)@^V0X#80*V21@] /T-HK-QNV^YYF39U4R;F]E"]W%WNT_=OI=--Q=]8[/
M0XKX)Z?=:3\'_!=E>VTUG>6^CVL4UO<(4DC<1*"K*>00>H->#^!5\7_L_P#Q
M-^(MD? FN>*[3Q)?G4-)OM)@5H2S-(P2>4D"(?. 2W0J3@@@U]6T5<GS3<^]
M_P ?^&,,/FCHNO&I34X5=T[K52YE9JST?WH^)/"WP-\:>*/V;?B'X=N='GTS
MQ(_B5]0M[.Z5H4NMBQ[A&SX#*?GVM]TD#GN.A^)&L>-/CY\.=&^'EE\./$6@
MZFTMM_:6HZQ:_9[&W6,?,T<A/[P9YQ@''0$U]=45-EMTT_!)+\CUWQ-5E6]O
M.C%RC-SAO[LFDGUU7NIV?7RT/D+XS3ZQJ7QE\-:1K'@?QAKWP^\(Q12(NBZ0
M]RNHW8C4JY.50HN0O4_=<8^8X9\=OA_<?$;QOX,^)EUX!U[Q#X6>P-EJGAEH
MGM]3MPKRE&\I'#9S)NP#_#SC=7V!13[=T[_?N11XCGA_8NA2Y73BX:2:NI7Y
MGI:TFWS<R=[I=%8^;?A'X!\+6H\3ZEX5^$_B#P27TB:U2\UZ65;BX9QDQ);O
M+(0/E4[OPKG_ (=>"/$5E^Q#XAT*XT'4K?7)HKSR],EM)%N7S)D 1$;B2.G'
M-?65%3*/,I+NK?BW^IA+/ZTY-RC?WX3UE*3]Q-)7DV];_P"1X+IOPWUCQ5^Q
MY:>#_LTNGZY-H:1+:WBF%UF4APCA@"N2H!STS7D/BS4/'GBK]F2'X<V_PQ\2
M6^J:5;V]O?75Q:[862"12IMP,M.S%5R%7 !8Y(YK[8HIR]YR?>WX;%87/YX:
M?/*DI6J>U5V])?)ZK;?JOD?,7BWP?KUU\:/@->PZ+J$MEING[+ZY2U<QVK>4
M!B5L80Y[-BN*^,7A6_UCQA?7O@CX;>-?"OQ)-^0NM:60FEW2>9S+),&V?.HW
M$87D_,3SG[2HHZI^;?WNY>'XBJX>=.:II\D>7=V:YI2]Y)VDO>U3[+8^7O%6
MB^+_ (5?M!V7Q&D\-:GXQTO4=$CT[45T&'[1<03A4#%8N"5+1J<\##-R,<GQ
MFTOQA\2(_ /Q&TGP7J=M<^%]6><^'[XH+VXM2T3>9Y8)VMF(C9DL,@\U]0T4
M:Z-='=???_/Y&-//90G1K>RBYPCR7UUA9QLU>VSM=>1\M:]9^(OVC?C%\.]5
MB\&Z_P"$?#OA.Y:^N;OQ%;"UEEDWQN(TC))89A49']XYQ@9XW]I#X?\ CKP[
M\4_%,G@C0-1U72_'FEQ6M[)96KRQ02^8BN6*J0N53JQ Q*Y[5]KT466BZ*_X
M[G3AN)*F$K0E3I1]G"/*H.[7Q<]V]V^;7\+'RA^T!^SS=#PO\,6TG09/%>D>
M$H_LFHZ+;2-'-=0,(][H5()8E&SMYRP/0&MGX&^ _!$?CZTU7PW\&O$O@][.
M&5CK'B.6: Q.R[-D<,DS[]RLPW8&/QKZ6HJDVF_.[^_<YY<0XN>!^I3;M:2N
MI22:DVWS132EJWNO)W1\]_L<>%=9\+>'_&T>LZ3?:3)<>(9IH5OK=X3)&44!
MU# 97KR.*\0_:.\&Z[X9^-NJ^%O#Q$.E_$XVAE51G;*LXWG@]FRQ[8D-?>=<
M%?\ P9T35/BU8?$.\N+^YUFPM?LMI;22I]EA4A@65-F[=\[<EB.>G2H44I0O
MLM/DE_P$=^ XA]CF-?'UH_'%^[:ZYE9P^Z23OY'7:!HMKX;T/3])LHQ%9V-O
M';0H.R(H4#\A7QEXP^'NKZM\1_'J>//A[XK\?:A>7#GPQ<V,\@TVVA)?RPTB
MNJQ  ID'/0Y'<_;E%.2YG=^?XGBY7F]7+)U*D(W<UO=IJSOI)-/7KKJCX>U+
MX=^*Y/V'=)T!?#.L-KL>L-*^F"QE^TJGG2G<8]N[&"#G'0UZC^TKX3US7;CX
M.G3='O\ 41I^M0279M+9Y?LZ Q9:3:#M48/)XXKZ0HJNM_-/[K?Y'H2XBJRK
MQK^S5U.K/K_R]5FOET/EV&W\3_ []HCQMKO_  AFM^+-!\5QQR6MSH5N)WBE
M7'R29($:Y+#)(& I&><:_P"RCX;\3:+XH^*=]XGT"YT&ZU;5UO5BE4F(F0RN
MRQR8VR!2X&Y<BOHNBIC[J2[*WRO<Y\1GDL1AIT94DI3C",I:W?L[<NE[+16?
M??0^<OVG/"6M^(OBW\$KS2](OM1M-.UEI;VXM;=Y([9/.M6W2,!A!A&.3C[I
MJ/\ :]^$FI^.;SP9XBL]"E\5Z=HD\BZEH=O(R37%NY0DQE2&S\A&%Y^8=@:^
MD:*/LI=FW]XL-GM?"2PTJ<5>BI16^JFY-[6:?O.S6VY\S?!/P+X+@\<0:OX8
M^"_B7PI-96\S#5/$<TUN4D*[1''%),^_<&8;L#;^->?MX1U>;XDZ#?\ PT^'
MGC+X=:\VHH^MK=#RM&:'.9,-N*R#V4 8SA<XK[9HJOM*78Z8\1UHU:E647+F
MCR^].<M-?BN_>6MTGL]NM_B'7?@CI_@_XO>-+SQQ\,?$/Q!T/6KU[_2]0\."
M:5X3([NZ2)'*F/O@9;^YQD-75^./ASKEC^SNUI\./!6L>#(KC6!=ZAH<-\\F
MH7-GL*DY+.RLV(\Q@GA>AY!^LZ*A*T5'M;\.YM/BG%5)4IU(\S@XNSE)Q?*K
M+W+\J?5M+?56/B/P/\.(K;]H+X>:WX3^%WBCPAX<B:=;RZUJ.9I'E\ILO(K.
M_E+\P )(#$G XKUCX$^%=9T?]H'XR:E?Z3?66GW]U";2[N+=XXK@!I"3&Q&'
M'(Z9ZU]"45:T:?:_XV_R.?&\0UL;"<)Q^*"A=R<G93Y[W;;;Z?EV/E;PDOB;
M]G?XO?$26[\$^(/%>A^*+[^T+*^\/6@NF5B\C;)/F&T#S2"6(^[D @YK3\7:
M1XE\5?M(?![Q++X7U*PMHK"9K[]V9H[%V67"2RJ-@;D=3WKZ6HJ8^ZX/^7_*
MQG//'.J\0Z2]I*#A)W>MX<E[7LG;7S?8^>]-\+ZS'^VMJNNOI-\NB2>'EA34
MC;O]F:3]U\@DQMW<'C.>*=^W1_R;]J'_ %_6O_H=?05<=\5_A=I7QA\'S>&]
M9N+RVL998YC)8NB2AD.1@LK#'X5$HMQ45T?_ +=<,'FT?[2PF*Q"M&ER)VUT
MAU]3YH^)D?C']H7PSX$\!1> =;T%K6YM[K4]7O8U^PQHL)3=#,"5D!61FQP<
M@#!YQZ'I7A368?VU-5UQM)OET1O#RP)J36[BW:3]T-@DQM+<'C.>#7ONGV<>
MFV-M:1%C%;QK$FXY.%  S[\58K9OWKKNW]ZL.IGTO9/#TJ2C#EG%*[^VTY/5
MM_922Z(^9=9T_P 2?!7]I#Q+XY3PIK'BWPOXDLHXBV@6XN;JVE18QM,>0<9C
M// PPYRI%<9JGAWQ"=(^.'Q5U[2AX3MM=TO[#I^GZT!YI3"1[I(^=KG8@53_
M !-Z $_9M87CCP3I'Q$\+WWA[7;7[7I=XH66,,5.0P96!'((8 CZ5BX^YRKL
MTO1G3AN(.6=-U::O:$925[N$'%V2;M>T4F^MNA\1>$X7^%.G^"?%_C_P+XKN
M?#5F;<Z?<7WB:*\MK.5D#++%9"-6CSMW!6;C [@5[GH_AO5Y/VT=3\1#2KW^
MP9O#JQQZF;=Q;,Y$7RB3&TMP>,YX-;&G?LD>%(;C3AJNN^*O$^F:<ZR6FCZW
MJIFLH"O"[8PJ\ <8SC'!R*]NZ<#@5LW=W[-_BK?>=F:Y]0K2<L.N:4X2A+XE
M%)M-64I2=]'S;)M['R%\7/!NI:E\===N?'7@CQ5\0/"5Q;1KH%KH3R&V@DVJ
M&\S8Z>7\P;+$]\X88QR_AOX9>*]/_9%^)^@/X3U:SU>?7HWMM)%K)),\:RVN
M3&,9E4!&^=<@A2<U]S45G&/+'E_K=/[]#"GQ37ITJ5)4U:FZ;WE;]WM:-[+F
M^TTKMZGR9\</ OB/5?V<_A!I=EH.I7NI:?/IGVNSM[5Y);?9:,KEU4$J W!)
MZ&NN^.'A?6=6_:#^#>HV.DWUYI]A/,UW=V]L[Q6X)3!D<#"9P>I'2OH6BK;O
M/G\[_A8\^&>U8*"Y%[JJK_P:K/[NA\6_&+PK?ZQXPOKWP1\-O&OA7XDF_(76
MM+(32[I/,YEDF#;/G4;B,+R?F)YS]CZ2MW'I=FM^ZR7RPH)WC^ZTFT;B/;.:
MMT5,?=CRG)F&:2Q]*E1E"RIWUNV];:7;;Y5;1=+L^'=,^'/BN/\ 9@^+VE/X
M9U==4OO$*3VED;&7S[B,3VY+QIMW,N%8Y (X/I74_M#> _$FM?LH_#31M.T#
M4K_5[%M-^TV-K:O)/#MLI$;<B@D88@'(X)KZYHIP]R*2Z.+_ / 4E^A[/^M%
M=8B&(]FKQJ.IUW<8QMZ>Z036XN;)X&)421E"1P1D8KY,^$NJ^,_V=?!VN^ [
M_P"'7B+Q%?+=SR:9J6BV?G65PKJ IED!_=C(SSD@'! (KZZHJ7&]_-69X6!S
M!82C/#U*:G"3B[-M:QO9W7JTT?"OCKX!^,/"_P"R=X9\.+HUYJGB&3Q(NHW5
MAIL37+6RM#,H#; > -F3T!;&>]>N?M,>$=<\0?%;X(7NF:/?:C::;K!DO9[6
MW>1+9/.M3ND*@A!A&.3@?*:^CJ*UYGS*79W_  2_0]>7$N)J585ZD$Y1=5]=
M?:JS^[I^)\MZ?'XE^ ?QZ\>:U-X,U[Q9X=\5/'<6]WX?M?M4L4@).QTR-HR[
MC)(Z+C/9?B%IOC"U^+/@/XR0>"M3O+>#3WL=2T"UVW%]:H3,%8(#\S%9<X7H
M5(.,YKZCHK-+E44OL[?U\S'^WG[15I48N3AR3=W[T>7DM:^CM;5=4GW3^:/"
M?A_Q#\7/VEM-^)=UX9U7PEX>T/3#96L6N1""ZNI")0<Q9)4#SWYZ?*O/) \Y
M\-? WQ=XL_9]^)>@C1[S3M9F\2MJ%C:ZA$UM]K5 GW2X ((W8/0D#D=1]NT4
MG&Z2[+]5+\T;0XEQ%*2=*"2C[/E6KLJ;;2\[N3O^%CY%^)&L>-/CY\.=&^'E
ME\./$6@ZFTMM_:6HZQ:_9[&W6,?,T<A/[P9YQ@''0$USWQ/\-^(-=_:.U/3?
M"UAJVM76CZ!:6C2^&-<BT>X@3 R)YGC8,S9^Y_=*^G'VW7DWC+]FWP]XJ\87
M?BBSUOQ)X2UR\14N[KPWJ1M3<@  ;\JW91TQG&3S3>LK]VV_6UON/0RWB"A1
MFX2IJG!1ERKWI+FDXMN7O*5K1LK/UOJ<%\$[3PE\1OA+XU^%]EX=O/"MYIYD
MM-4LKZX%S(MQ)N"S><  [!X\] !L&!C%>:?LA:+KOC;XK0S^)/GB^'>G/H]L
MG4),TLB@>A*J9%SZ*E?5?PY^$/A_X5Z)>Z?H"7,<M\YFN]0N)C-=3RD8\QW8
M8)YSTQDDXY.6?"/X.Z'\%]!NM*T26]NUN[EKNXNM1E62>60@#+,JJ,  =O7N
M35+X^;R7W[?J_P "*F>T(4<=2H7?M6N7FU:NK5'=MOWEI9MNS5WH/^-7@FZ^
M(OPJ\2^';%UCO;ZT9("[;5,@(95)[ E0#]:^<KW7_'.N? &W^$L7PO\ $L'B
M<6D.E27T]LJ::L<;*/,%QNVDE5''3)/)QS]AT5'*G=/9_I_PYX> S=X&G&E*
MDIJ,U.-[JTDK=&KK1:>6Y\KZQ\*]=\-_%GX!64&GWFIV/A_3S:WVI6UL[6\3
M*F"7<#" GIN-?5%%%7?2WFW][N<>.S"ICU2]HM8)KUO*4K_?(^*OV@/A;XRC
M^-6NV7AC1]2N?#_CZVLH-1O;.V>2&U=9XP[.R@A<"/)W$#$K50\:?!'Q/'\9
M;KP#I>@WQ^'.M:[8ZS->16TGV6)$C83(T@&T9+-P3_"GK7W)14P2A:W3_.Z7
MRMH?24N+,31IPIJFO=ARWU^+W5&?^**C%+_@GSCXT\'ZU<_MK> M<MM'OI-!
ML]$DAFU&.W<VT+;;P!&DQM!^=."<_,*H^!;;7_A;^TUX]>^\(:]J>E^++NW-
MGJNF6GFVL*EB2TTF0$5=YSW^4\'(KZ<HIK1Q?:_XNYYG]MSE2]C.FG'V2I;O
M:,N=/UOTVL?./[,WA'7/#_Q4^-U[JFCWVG6FI:UYEE/=6[Q)<IY]TVZ,L '7
M#J<C(^84_P#89\)ZWX-^%.L66O:1?:-=OK<TJP7]N\+LGDP@, P!*Y4C/3@U
M]%T4XOE^Y+[A8S.ZF,C7C*"7M?9W\O9QY5;UZGSE\8O#?B3P7^T%X:^*6E>'
M[[Q5HT.G-INH6.EQB6[A_P!9ATCSEL^8.G]ULXR#4/@?P_XC^*?[1P^)=[X9
MU/PEX>TW2CIUI#K48AN[ESOR3%DE0/,?GIPN,Y./I.BHY5:S\_QO_FP_MNI]
M7]E[-<_)[/FUOR7O:U[7Z7[>>I\4> -/\>_#OX0^._A0WP\US4M7O&O([;5(
M8@NGM#+$$:3SB<%@ 65%R6R%X-5->^&_BN;]DWX5Z,GAG5Y-7L_$#3W-@MC(
M9X(S+<D.Z;<JN&7D@#YA7W%15W?7^[_Y*>H^*JOM%55&*?/[1ZO67+*+ZZ)\
MU[+81?NCZ5\C>.O$VH>$?VV&U.PT"]\2>5X?7[19:;M-SY)!W/&C$;V!Q\H.
M3DU]=5PX^$.C#XN'XB?:+[^VS8_V?Y'F)]F\OUV[-V[_ (%CVJ->:+[7_)H\
M7)\91P,JSKQYE*G**6NK=NVVVYX+X+\$^//&7CKXM?$RST6_\(:AK&D2:;H5
MIJ:B"Z+B.-5D93_JS^X3D\9<\D#->)^*OA3?ZQ\,8([;X3^-I_B%;S*VKZ_J
M"SR++\Y!$*;SYV<KR$^4 G)Y-?H]132M:W2R^YW_ !ZGO8;BW$86K[2%))+E
MLDY*RA'E46T[R5M;/2^OD?-GBCP?KMU^V9\.]<BT:^ET6ST!HKC45MG-O"^R
M[&QI,;0V73@G/S"IOVLO"6O7OB;X7>+=(T2_U^U\-:M]HO;/2X3-<E#) X*H
M.3_J6'U(SBOHVBJN[Q:W3O\ BW^IX]/.ZE/$8>OR)^RA[.VNJ?,GZ.TV?,WQ
M=L=;^('Q2^!7B.P\,:Y;V4-W+/>1W5DPDL5+PD?:-N1&<*3R>U:/B;PEK-W^
MVCX<UN/2KYM#3P\\$FIQV[FWCD/V@;3(!M#?,O!.>17T114V5E'I=_C_ ,.$
M<[G"FJ4::25.=-:O:<G*_JKV/@GPC\"]&^'-SJVA?$#X/^*/&MZMXQT[6O#H
MGD@F@( 4/Y<R*G(SSS\V".*]#^*7PSOH?#OP2LO#G@?4-'L[#75NKG2K<R7Q
MT]&E1V,LHW<=223@<C/%?6=%.[LKO:WX'I5N*L7B*T*]17:NVG*3C=Q<;J+=
MH[MZ+TLM#QC]I/3='UG2=+LO$'P[UOQOI+&5OM7AU/,O+"4;0I5 RL0P)R<X
M^09!XKQW]G7]D70=:TWQ!?\ COP=>Q6DUZ?[&@U6ZFM[U+89QYR1.H#?=ZC.
M0W;%?9-%*/NW\_Z_KR.##<08O!X!X'"R<+OXE*5][Z*]E?9VW73J<5\-_@SX
M.^$8U >$]'_LG[?Y?VG_ $J:;?LW;?\ 6.V,;VZ8ZUY=XB\*ZU-^VKX9UV/2
M;Z31(M :&34EMW-NDG[_ .1I,;0WS+P3GD5]#5Y[)9_%8R,4U;P<J9^56TR[
M) [9/V@9_*JU<E)]/\K&&#QU:56O6K5$Y5(.#<VVWS*U[ZMV2ZGE7A/PCKMM
M^T%\;-1FT;4(M/U#2UCL[M[9Q%<MY2#;&^,.<@C )K3_ &7]!UKPC^S/+9ZG
MX7NIM30WKC0M0B-O)=9+8C(D' ?IDC'->@?8_BQ_T%_!O_@JN_\ Y)H^Q_%C
M_H+^#?\ P57?_P DU$8\L>7R2^[_ (<];$X]XFDZ,IT[7IO>7_+N#@NG6]W^
M!\]_#KPCJ]C\:_#UW\./!WC/P%X>\QW\16?B!3#8.O'$*LS;S]X#DX.T@* :
MZSP+;:_\+?VFO'KWWA#7M3TOQ9=VYL]5TRT\VUA4L26FDR BKO.>_P IX.17
MK'V/XL?]!?P;_P""J[_^2:/L?Q8_Z"_@W_P57?\ \DU4?=:?:_XG1B,T^L\Z
MJ2IM3@H.\IN3M+F3<K7;377IIYE;]IC_ )()XX_[!LG]*^:FUWQA\0/V8?#O
MPUTOX>:Y+?:A!:I%K"QJVG&V242+(9@<*QV %& QD\] ?H+QQX#^)?C_ ,(Z
MKX=U'6_"<-EJ4#6\TEMIETLBJ>ZEIR ?J#2^"/ OQ,\ ^$=*\.Z?K?A.6RTV
M!;>&2YTRZ:1E'=B+@ GZ 5*CJV_+\+E9=C,/E^"A'GA.I&KSJ[G96BDGHE?7
MH>?:U\,]:T'X\? V&VTZ]U#2O#^C?8;K4X;9V@C9(70%W VJ3QC)'45I_&+P
MWXD\%_M!>&OBEI7A^^\5:-#IS:;J%CI<8ENX?]9ATCSEL^8.G]ULXR#7I/V/
MXL?]!?P;_P""J[_^2:/L?Q8_Z"_@W_P57?\ \DU6NGJW]^_YG-',)\\)3J4Y
M)4W3:O+WHR<F]EH_>TMV/'+'3_$'C[XS:M\6-0\/77@OPYHGAZ>TM5\31B&6
M9PDA+2Q9)5!YCD^P&,Y./"_ OAV^TGX8Z5XH\3^!O$VO> K64WDR1^)H8M-D
M;S2/.73_ "PXY./O 'KT-?9>M>&OB7XBT>]TK4=0\%W5A>PO;W$+:7> /&RE
M67BYSR">E>*0_L7>*X[5-,E\<QW/AI7WCPY-)>?V?][=CRQ.#C//WLY[U,4X
MO3R_-M_F?2Y=G&$C3E#$58P7N))>TTA%25HR3B^?WGJ]/(Z+Q1!>_$#]HCX,
M>,]$TG4+KPU)ICW#7RVKF*W5XY&42, 50_,.">M5/VDO"^L:M\7=!N]?\-^)
M?&7PS6P,;Z3X;+NPN\O\TD:,IQRGS$C@=>"#ZSI^A_$_2;"VLK/4/!-M:6T:
MPPPQZ3=A8T4850/M/   %3_8_BQ_T%_!O_@JN_\ Y)JN5:);)M_>?.TLP]A6
MI5*<X6IP<%K).S<G=-1NI+FW1\X_"'X;:WH?A_X_VT/@C5O#5IJ>CE-(TRXC
MDF9PT%QLB1SGS7^=00"2"V#S6E<^ O$O_# L'AT>']3/B .&.E"TD-UC^T2_
M^JQN^X=W3IS7OGV/XL?]!?P;_P""J[_^2:/L?Q8_Z"_@W_P57?\ \DT/6-O3
M\#LJ9W4JUHUY3IW52G4WF]:<.1*[3>N[;NSQWX^>#=?UGX2?!^RT_0]1OKRQ
MOM/:[M[:TDD>W58,,9% )4 \$G&*^E/$NC_\)!X<U72_,,/VZUEMO,'\.]"N
M?PS7&_8_BQ_T%_!O_@JN_P#Y)H^Q_%C_ *"_@W_P57?_ ,DT22FI)]6W]Z2_
M0\'$5G7I4:7M8+V;DT[R^T[_ ,O0\"^'^N>./A3\'=3^&%W\,_$>I:^JW=K8
MW^GVPETZ43%B'><$!0"Y_ #.T].5^+'P_P!8^$?P1^#>AW$4=YKUOKYN6M5D
M 7SG8R"+?TX)"ENF<GI7U/\ 8_BQ_P!!?P;_ ."J[_\ DFN'^)WP5\?_ !8;
M0#J^O^&K?^Q;Y=0M_L>G7";Y%Z!]TS97CM@^]#NW?K>-_1.Y]/A<XI?6U5JR
MIQC*3G.SF^:3C)=5HO>>B[[['(^)K/Q1^T%\;OAW='P3KGA/1_"-P;V^O-:@
M$0>7?&Y2(@D2+F%0&4\[B< #F]X7M]?^%_[4GC:\N_"&O:MI'BJ2V2SU32K3
MSK:'E<M,^0(U7+9SS\O0@BO6/L?Q8_Z"_@W_ ,%5W_\ )-'V/XL?]!?P;_X*
MKO\ ^2:(^ZTUTO\ CN>7+,4Z;PZ=-4N3D4;ST][GO>U[\WRMIYGB7A?X3>(?
M$FJ_M(:7+IUWI8\03JNF75[ \,-RP:X92CD89<E,E<\-6;_PD'CF\^ *?"5?
MA=XEC\4?8UTDWLELJZ8(PV/,^T;MI.T?3/<U[_\ 8_BQ_P!!?P;_ ."J[_\
MDFC['\6/^@OX-_\ !5=__)-3RJW*]K)?<;?VMS3YZCIRM*$HZSTE"$8)Z)73
M44VOQ/$_%_PFU_P[XJ_9TTRVTZ\U:'P\3'J-]9V[R0P$& EG8#"KD-@MC(%=
M1XF\):S=_MH^'-;CTJ^;0T\//!)J<=NYMXY#]H&TR ;0WS+P3GD5Z)]C^+'_
M $%_!O\ X*KO_P"2:/L?Q8_Z"_@W_P %5W_\DU3U5GW;_P# O^'.=YE4E%*5
M2#?).%[R^W)R;^'=-GR;X1^!>C?#FYU;0OB!\'_%'C6]6\8Z=K7AT3R030$
M*'\N9%3D9YY^;!'%>A_%#X2:KH_A;X2^)?"/@FYLX_"-^]Y<>%(9S>7$<<DR
M2MM8EB[93G&2"XQPO'M_V/XL?]!?P;_X*KO_ .2:/L?Q8_Z"_@W_ ,%5W_\
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MN_X=#H_M)5:?LL2Z<TXQC)MS3ER-N+;2W2?*^Z\SYHNOV9?'$W[.-VK62_\
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M,ZDF)+=Y9"!E4.[N<"O4OL?Q8_Z"_@W_ ,%5W_\ )-'V/XL?]!?P;_X*KO\
M^2:)+F4H][_C_P ..KF]>MAHX:5:-HV6DZB5D[ZQ7NM]+M;=+ZGB/@_P/XBM
MOV%=5T";0=2BUV2*YV:7):2+<MFY+ "(C=DCD<=*I_$7P#XH/P1^"&H6?AW4
MM0NO"\UG<:AI5O;L;Q%"H2!$1NR"F",9&1GC->]?8_BQ_P!!?P;_ ."J[_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !153^U(/5ORH_M2#U;\J +=%5/[4@]6_*C^U(/5ORH MT54_M2#
MU;\J/[4@]6_*@"W153^U(/5ORH_M2#U;\J +=%5/[4@]6_*C^U(/5ORH MT5
M4_M2#U;\J/[4@]6_*@"W153^U(/5ORH_M2#U;\J +=%5/[4@]6_*C^U(/5OR
MH MT54_M2#U;\J/[4@]6_*@"W153^U(/5ORH_M2#U;\J +=%5/[4@]6_*C^U
M(/5ORH MT54_M2#U;\J/[4@]6_*@"W153^U(/5ORH_M2#U;\J +=%5/[4@]6
M_*C^U(/5ORH MT54_M2#U;\J/[4@]6_*@"W153^U(/5ORH_M2#U;\J +=%5/
M[4@]6_*C^U(/5ORH MT54_M2#U;\J/[4@]6_*@"W153^U(/5ORH_M2#U;\J
M+=%5/[4@]6_*C^U(/5ORH MT54_M2#U;\J/[4@]6_*@"W153^U(/5ORH_M2#
MU;\J +=%5/[4@]6_*C^U(/5ORH MT54_M2#U;\J/[4@]6_*@"W153^U(/5OR
MH_M2#U;\J +=%5/[4@]6_*C^U(/5ORH MT54_M2#U;\J/[4@]6_*@"W153^U
M(/5ORH_M2#U;\J +=%5/[4@]6_*C^U(/5ORH MT54_M2#U;\J/[4@]6_*@"W
M153^U(/5ORH_M2#U;\J +=%5/[4@]6_*C^U(/5ORH MT54_M2#U;\J/[4@]6
M_*@"W153^U(/5ORH_M2#U;\J +=%5/[4@]6_*C^U(/5ORH MT54_M2#U;\J/
M[4@]6_*@"W153^U(/5ORH_M2#U;\J +=%5/[4@]6_*C^U(/5ORH MT54_M2#
MU;\J/[4@]6_*@"W153^U(/5ORH_M2#U;\J +=%5/[4@]6_*C^U(/5ORH MT5
M4_M2#U;\J/[4@]6_*@"W153^U(/5ORH_M2#U;\J +=%5/[4@]6_*C^U(/5OR
MH MT54_M2#U;\J/[4@]6_*@"W153^U(/5ORH_M2#U;\J +=%5/[4@]6_*C^U
M(/5ORH MT54_M2#U;\J/[4@]6_*@"W153^TX/5ORH_M.#U;\J +=%5/[3@]6
M_*C^TX/5ORH MT54_M.#U;\J/[3@]6_*@"W153^TX/5ORH_M.#U;\J +=%5/
M[4@]6_*C^TX/5ORH MT54_M.#U;\J/[3@]6_*@"W153^TX/5ORH_M2#U;\J
M+=%5/[3@]6_*C^TX/5ORH MT54_M.#U;\J/[4@]6_*@"W153^U(/5ORH_M.#
MU;\J +=%5/[4@]6_*C^TX/5ORH MT54_M2#U;\J/[3@]6_*@"W153^TX/5OR
MH_M2#U;\J +=%5/[4@]6_*C^U(/5ORH MT54_M2#U;\J/[4@]6_*@"W153^U
M(/5ORH_M2#U;\J +=%5/[4@]6_*C^U(/5ORH MT54_M2#U;\J/[4@]6_*@"W
M153^U(/5ORH_M2#U;\J +=%5/[4@]6_*C^U(/5ORH MT54_M2#U;\J/[4@]6
M_*@"W153^U(/5ORH_M2#U;\J +=%5/[4@]6_*C^U(/5ORH MT54_M2#U;\J/
M[4@]6_*@"W153^U(/5ORH_M2#U;\J +=%5/[4@]6_*C^U(/5ORH MT54_M2#
MU;\J/[4@]6_*@"W153^U(/5ORH_M2#U;\J +=%5/[4@]6_*C^U(/5ORH MT5
M4_M2#U;\J/[4@]6_*@"W153^U(/5ORH_M2#U;\J +=%5/[4@]6_*C^U(/5OR
MH MT54_M2#U;\J/[4@]6_*@"W153^U(/5ORH_M2#U;\J +=%5/[4@]6_*C^U
M(/5ORH MT54_M2#U;\J/[4@]6_*@"W153^U(/5ORH_M2#U;\J +=%5/[4@]6
M_*C^U(/5ORH MT54_M.#U;\J/[3@]6_*@"W153^U(/5ORH_M2#U;\J +=%5/
M[3@]6_*C^TX/5ORH MT54_M.#U;\J/[4@]6_*@"W153^U(/5ORH_M.#U;\J
M+=%5/[4@]6_*C^U(/5ORH MT54_M.#U;\J/[3@]6_*@"W153^TX/5ORH_M.#
MU;\J +=%5/[3@]6_*C^TX/5ORH QZ*** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M"X\&37-C\39?A)X+U?PAX2GT2Q@DTZWTJXT&;5+Q+EWN_LUM*L+B8VG[K[0
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MLU+X+:9X^\)W.JZ3I_@*_M=3L=;M'FM$NQ<:?Y45PCL\;. DC(DC/CR]RDE
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M<169,&G/#:(S+=,2#$6(**"#EACBE'5U+].6W_D]_P E==/F92D^>"[IM_\
MDEOS=N_R+_Q.^*D7PUF\-VJ^'=8\4:GX@OVTZQT_13:K*TBV\MPQ9KF>&-5$
M<#GE\YP .:8OQ82TF\&VFM^&=:\.:GXHU&;3;6POC:2R021V\]P6E:"XDC"L
MEN^-C,<LH('.//OVJ-&AU+5OA1=:A8^)[K0M/\1S3ZC-X2AU)[RVC.F7D:.&
MT\?:$4R/&I*X'S8/!-,\50P2Z/\ "?Q;X;TSQ5J?A[PEKTUS>6^IV.I2ZP+9
M[*[M6E\F\7[7,5>X5L;6=D!*!L 5K'D6LG_P/\OGZFDK[+LW\]=/P_JYZ=JW
MQ2TK1_$^OZ%-;WC7>BZ''X@N'C1#&UN[SH%0E@2^;=^" .5YZXK_  Q^)E[\
M2M/BU!_ _B+PMIMQ:Q7=I=ZU+I[+=)( R[%MKN9E.T@_.J]?7BN"TMCXP\=^
M/O'K^'-=E\)3^%;;18K.[TV>RU#46BDO)9UBM9A',HVSJBEE0LV=N1@FA\$=
M)BTWXD1IX$C\<6GP\AT1K>_M?&G]K+''=K(GV5;./5/WRXC\\/Y8$6/*'WAQ
ME33;M/M]VL]_5<MO/3J55M>\'II\W:-[>CYK^7H>UWOB;[%XLTO0O[)U2?[?
M;7%S_:4-MNLK?RC&/+FDS\COYF47!W!'Z8K:KQ[XH:'=WWQI\$WXM]432;?P
MYX@@N]1TNWDD>V:3[%LVLBL1*0CE% +,4. <5S'[(?A^#PC:>(-%TWPK:V&C
M6<=FD'B9?!T_AB[U9PLBLMU;3JLDTL85&:Y 6-S<,%12C40]Z]^G^;7]=RIK
MEC&2ZGLOQ)\8?\*]^'?BCQ3]D^W_ -B:7=:E]D\SR_.\F)I-F_!VYVXS@XST
M-;&D7_\ :FDV5[Y?E?:8$F\O.=NY0<9[]:^1OC]X%M-:U#XSPZ]X UOQ9XSU
M;3&C\&:KI^CSW7D6QT_9Y$-ZB[+0BX^TL\;21F190,2;PISOC%\/M7U/Q[)-
MXDT^&71IO#UA;:)>7GP\U3Q7+ITRHXN3;&QG1M/G#F-C(4#/B,JY\K:D1D]>
MOP_BI-_/1)]F5.*BHKKK?_R2WRU=GU/IG7_B-J-E\1H?"^D:+;:JMMIG]KZK
M-)?M#/! SND0@A6%_/D=HI!M9X@-OWB3BNH\*Z]_PE/AG2=9_LZ_TC^T+2*Z
M_L_58/(N[;>@;RYH\G9(N<,N3@@BOFO5/V>?#WBKXK>)=2\2^!=-\82R> =.
M1=<U;PY&S7FHJ]VKR?O(R5N"BP97.]1Y8/ %3> ?@M9>,-5\&VGCCP>VJZ1:
M_#?3+.6RUNR9[1;M7.Y'BD'EF=!TW#>FYL;=QS2?+%IZN[_#VC_]L2^:?6QE
M.RDGTLG]ZI__ ";^[YGU%17P[K_@_P 6ZQX-^#5QXST8:EHEKX4^RWMEXF\#
MZAXM6#4QY05Y]/@F299C$K@7#JX7]XI*&3Y^SU+P78VFF_"4>/='UCXF> +#
M1[^"2.;PG?70COFD@-I)/I3I-<KL@6XB1Y0Q3/S,#("=+)[/JU]W-ZVO9676
MZ&TXS<'T[?+;:Z5]7Y/KH?0/PP\?_P#"R/#]]J?V#^SOLNKZAI?E>=YN[[+=
M2V_F9VKC=Y6[;CC.,G&:ZZO&_P!D_P /WOAGX2R65]HVJ:!)_;VL316&M,SW
M4<+ZA.\6]V=]Y*,IW[V#9R&;.:\:^.'AO7/%'QBU&XMO!4$>KZ;K6DR:;J@\
M)7^HZC/:)):O+/;:R)TM[&-<S*UJH9CY<K%&,QR2LI)>GZ7_ ,[>KV3:<[1<
M[=&[?>[?\/Z=6?9-</\ $[XJ1?#6;PW:KX=UCQ1J?B"_;3K'3]%-JLK2+;RW
M#%FN9X8U41P.>7SG  YKQ_P[X;M=#_:HO=1TOPVWB:XU:^N)-0US6?!ES:WN
MB*+4)FWUF5%BN+8M''$MO'N8>>S!RB%:[#]H+P?K?C#QA\((]&OM8T;[+XCN
M)[G6=%MH9I;&/^R[U [>?#+$JLS+'ET(S( ,,0:(+FC%OJKDO1R7:_Y?UH>J
M>&=8N]>T2WOK[0[_ ,-W4N[?IFIO;O<0X8@;C;RRQG( 8;7/!&<'(&I7@?CK
MX/IXK^+'PMT[Q3;7WQ T&PTG6Q?WFMVD3P3RL]D85NHX8H[=ONL41HP,Q!@-
MR!AYD?#.M:M^T'I6M1>";71=3T_Q:1<W5KX0OO[0&G!984EDUUYA#/!(A0_9
MHXW$2NB$+Y194FI2C%=7_P"W6_X/DBI1Y:7M+]/\W;\/OLC[)HKY'M_A"^F^
M&]2\6P>$+A_'T/Q,EN+/4Y+*22_AT^37 )/)8@O':O;/*S*F(V621R#N9CU7
M@OPWH-C\9-=G\6>!M4U'XC3>(I[C2O%2Z%<31IIY0>0(]2"F*")(<QO 94+,
M)/W;>:-Y"TE%]U?\(NWK[W_DK?0JK'V;E9W2;7W<VOIHN^Z/HZBOBSX-_#W6
M=-^*6AS^(=FD>-;?5[J;4M2M_AQJIO=21FE_=3Z^MP]K- Z,C*&&U0L2A(WC
M55^L/ 'CJS^(OAXZS86=[9VGVNZM$%]$$:7R9WA,J88AHW*%D;/S*RGC.*4?
M>BI?UT_S,Y>[)Q_KK_D8OC+XO6WAGQ-'X:TGP]K7C7Q+]G6]GTK05MP]K;,S
M*LTTMS-#"@9D954R;VVL54A6*]-X4\0OXGT6*^ETG4M"G9F273]6B5)X'4D%
M3L9D89'#QNR,.58BO'?%4NI_#CXD^-[^]@\26^@^+K6R-GXD\):.^K7FG7,$
M;1M"]LD%PP!4!TD,+1Y:16VMLW^7^-=)^(/C7X7^#KKQ(+[Q'H-OXFU)[]/$
MW@V74Y+K3MTR:=->:-:"UDEQ^Z;9Y>49DD:+Y-RPI.VW]7M^6MGONG;0;[_A
M\KW]/-;7LU<^R:*^1-'^%']O:+\)-'NK.Y\2>%/^$PU"YO-/_P"$4O\ 0K&Q
MLVTV\"VS6-TSR1VOG%5"2'RF\P(!MVK5WXQ? VP\33?&PGP6VH)9^#;./PO%
M'8NT4%Y#;WHC-B@&U9T)B4-$-Z[E (!Q6E3]W#G>NE_P_/\ /N3"]2HH+KI^
M+7W:7\NQ]745\P-\.;KX8>-[;4O!7@J[FDU#X?ZI)JZVKRV\FKZI'):-;+=7
MGWS=-YEUB61C+\TAR<''%?#'P+JMI:_$R;2_"]OINFZMX(EMUAT#P)?>%X+B
M^7SOD:UN9GDFG D $NQ=P8 %\';-:]*+:UTD_NY_SY='YHN%I6Z7:7W\OY<V
MWD^SM]J45\Q6?P%TF'Q%X.TB#PI)9:3XH\$ZEI?BZ[CMY ]Y(4LA$;V;[TDX
MW7&UY6,G,F#]ZLKX0_$+4?[6;Q3XST?5;B^\*3V_PSM%@ME:6^OFND2[OX@7
M&87"VKDCE5BFX.WG7E7/[.^O_!<?SY5_V]Y$7_=JIT>OZZ_+F?I'NSZRKBM/
M^+WAV\MYIII;BP1/$#^&D^T0DF6]5]@5=F["L>C-CWQ7:U\A?$'X5V6L^#I]
M0\3^ '\20:;\39M1>";0&U&X_LV2Z42R10"-Y)(G786$:MN5<X(%<_,_:QCT
M=K_^!P7Y-_GT'.ZIN4=]?_29-:>J2_ ^O:Y'PCX__P"$J\8>.-"^P?9?^$9O
M[>R^T>=O^T^;:0W.[;M&S'G;<9.=N<C.!\M?&KPUJ/BGQY.VB^ K>SGTQ])D
MT"\_X0C4+O46M(V@D9[74A+%#IBQ_O$-IMW_ +N0E&,P4]EX[\$ZNNH?&7Q7
M!IMU%J7A_P 1Z9XIT2:2(H+S[)IEJ)XXG; 998UN+<L,@%V[C%-R47>6BZ^2
MNM?DKW7E;?;2G%3YHK5V5O5]/^#VUL?4-<]X^\=:=\.?"MUKNJ+<2V\+Q0QV
M]I'YDUQ/+(L4,,:D@;WD=$&XA06RQ4 D>2_ ?QC;I)INHZAINI1^(?BI<WGB
MA(FA7-A9110QVRW WDIMMQ:H< KYCD<;AGTKXNV>AZE\/]3L_$OA^^\2Z!<!
M([RQTVVDN9PF\'S4CB/FDQD!P809 5!0%@*N:<+<VFU_+NNVCNK[:7V,X2C)
M\RU7YK_@K;K\S1\%^*KOQ7I\\]]X9UCPG=PR^4]AK0MS*1M#!U>WFEB92#_"
MY((((!%=!7Q7XZ?6XOA%K5M-/XUUWP,GC/PXNA2>(XI[/7)8GU*W^TVZ&40W
M+(K$)')/B4Y8;V4*YVH]"_L?0_BI??#KX<3:;\/[ZSTRU@\.W'A^\TV&XNA*
MZWUV-*$<4\L:P/!OC55-R(&C&[.:OEO!S7>WX1>O;XK=K^1,?B47U_S:T[VM
M?IIYGU!XN\3?\(CHZZA_9.J:UFYM[;[+I%MY\X\V5(_,VY'R)OWNW\**QYQB
MMJOBGP[\/];M/ACX_LM,\--;:;>^)O#E_IMEHGA&ZT"UDC2[L_M$L.G2RRR0
M[1$QD)V$["Y4 AFZ/Q?\))-0M?CQXI?PC<:AXOL_$*7OA2^FLI);F$II^GD2
M6!()7,J.K-#C>8RK$[<!0CS.2>EM?_25;_R9_<.3M34UK=V_!N_X'UG17-Z#
MXZL_$/B[Q)X>M[:[6ZT'[,MW=/&OV=I)H_,$:,&)+JFTLI ($B'D,*^=OVNO
M#NI>-?$4NCCP78ZO'_8,O]E:E?\ A&]\1/+>.9 8;9X9HHM+E7;&?M,K#>7C
MP0(:RE+E5[7_ .&N:0BI;NW_  ;+]3ZMHKYJ3X.V?Q'^*$L_CKPH_B'35^'^
MDP*NN6CSVIOA->&3*2 HUR@8?,1YB"0X*B0YYO3=#_M#3?A7?_%SP1KOBZQ7
MP9;VT5O+H=SJC6.L QF5YK=(W>&=T";;AU4)Y<@+H6^;5JSMYV_]+_/ET[N2
M1+^'F79/[U%_AS:OI9GT;\+/'G_"R_ NG^(_L/\ 9OVIYT^S>=YNWRYY(L[M
MJYSLSTXSCWJMI?Q:TC5O ?B#Q;#;7RZ=HDVHP7$3QH)G:REEBF* /@@M"VW)
M&01G;T'/_LMZ'?\ AKX$^&=-U/3;_1[ZW-T)+'5&+7,6;J8J)&+-N;!!W;FW
M9R&;.3YM'>ZIX-^'/Q&^&TWA7Q'>>*-7U#7&T@V>D7$UA>QWT\TL$AOD1K>!
M1YVUQ-(C*8V.T@H6PJ<RIR4-96=O-Z?CY?Y#H<LH0E4[QOZ6=W^6IZ_=_&_P
MQI=PJZE--I=K_P (Z?$\M]>!$@ALPRJ0YW$AQN' !'OGBNH\(^('\5^&=-UA
M])U#0S>PK.-/U:-([J$'D"149@K8P=N[(S@X.0/F[XH? WQ#XD^(_A*?2HGF
MU'PIX4MY[)KKS!I-_>V]W$XM;G@HP<(64D%HF"2J,IS[AX?^*#:Y;^#FD\)>
M)M/F\11S-+'=:<4&DO$FYDO"2/+R051AN5S@J2"#6RLXMKO)?)2DD_FE\K7^
MTCGC*5[2[+[^6+?W-O[[?99H>._&Z^#5T*"*U6^U'6M5@TRTM7G\D,6R\K[M
MK?ZN&.:3&.=F.,Y&%_POCPS+\8X/AK:KJ%]KK032W%U;VI-C:/&D4A@DG)"^
M<4F1Q&FXA2"VW<N[)^,$,D?Q6^"MZZL]C%KUY ^$#!)9-,NA&Y/;HZ9]9 *P
MOB5X\M-/_: \![M&\574&D1:A#>WEAX4U2[M8VN(H1%B>*W:-P2#DJQ"X.XC
M%3?9;ZO\E^6_S[&TONT3_%Z_I\F>G:#XX_M7QYXG\+7%I':7FD1VMU"RS^8;
MFUG5@LI7:-A$D4Z;<M]P'/S8&%XX^,LGA'Q>/#>G>"/$OC'4ETW^U9AH1L%6
M& R-&,_:;J$LQ93\J!C5"QEEN_VI-76!9!;V/A"U6Z?'[MI);R<Q+U^\JQ2G
MIT>L7QI\.=?\8?M!375AXE\2^#=-'A6.V?4M#M[0K<.;J0F(R7-M,H8*0WR;
M6&<YZ5%Y/V=M+\V_DIVOY/E3]'H4[+G\N7\>2_W7:^6IZMX+\8:3\0?">D^)
M-"N?MFCZI;I=6LY1D+(PR,JP!4]B" 000:VJ\#N_@5X<;XP>!]&D\*+J'@C0
M/"-Q:6EO?0O<V44R7-KY(D\S<KRA59E+Y;(+#G)KR+PQ\.]>A^,$D_B%X])\
M7KXPFO5UZ'X;:I?ZA<6)O&>"#^WHIS;+;O:%(2CH%B0E&0,F:W24Y1MHI-_)
M*7+_ ,'3\3.[2G_=M^,;_)+:_<^V:@U"Z^PV-S<[=_DQM)MSC. 3C-?-7A;X
M?Z_8_$:U\ MI%\/!/A/6K[Q78W3(XM+Q)EWV=F)&&TF*YN;IMH)*"TMR<;A7
M$_ _PKKC_$S3M>'@N'PU)=:!J<&MQ6'@_4-+FCNG\AT@O;^YG;^U9 PDQ<K'
MAF5V#_O,'GG)JDY+M?\ #MWYM'NEIKJK[12YU%]TOQ_RLUU>NUF?5/PK\<?\
M+,^&?A/Q=]B_LW^WM*M=3^Q^;YOD>=$LFS?M7=C=C.!G'05U-?"VH?#O7_\
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MK8N[V\Y?A)K\DG\UW1UM%?*GQ@M?!=Y^TYK">._!>I>-]&7P78-%9VNB3ZU
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M15EYKY_35Q\4M*?P[=:QI%IJGB6&UU;^Q9[?2+)Y)TN%NA;2G8VW*1/N9W'
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M89%.2Y79^AC&7,D^YZ'17$>,?C-X2\"ZA8V.IWMY-=WENUY'%I6EW>HE+<$
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M9;FNB;XO>#H]-T#4'U^U2PUVPDU6PNGW+%)9QPB:2X9B,1Q*C(2[[0"Z@G+
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MG'LVOFK_ .3?HCMZ*\<\0?M/>'-'\4>!]*M]+\0:C;^)_M&+JW\/ZDS6IB#
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M8M-X%L5M=4,,LA6<C3FM?W.4&X>80?F"_*,]>*]+TK_A)?\ A*-<_M+^RO\
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M35;:&.XGL4F4SQ1.6$;LF=RJQ1P"1@E&QT-7:A-QE"2^RDEZ)Q?YQ0_\[_\
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MC^&[_1KI [^8\L[691D&W!0?9GSD@\K@'G'%>!?@OXTTOPG\(=$UG^P8?^$
MU-2;BQOIIOMUHFGW%LDFUH$\N4M,I,>64 '$C'BO?Z*VYY7O_6[?YM_?Z&<6
MXQY%M:WRM;\CYQ\$_ 7QU9?$WP_XC\2:I'?G1]1O;F6^D\4ZG??VBD\-Q&K)
MI\J+:V)3S(QLA#_+D!P%Q)ZU\&?!=]\._ACH/AS4I;>>^L(6CEDM69HR2[-\
MI90>A'4"NTJEHVM:=XCTNVU/2;^UU33;E/,@O+.99H95_O*ZDAA[@UEV7;05
MM7+N<!XF\#^(Y/C1I'BK2HM+O-&ET6;0]3BO+V6VN+=&G2430!89%E;A@48Q
M]CN[5Q?@WX.^.[+1/ ?@G65\.0>$/!=W;SV^L6-[//J&I1VF1:H]L]NB6[,-
MC2.)I<[64#Y]R_0%%.'N)16R=_G=R7W-MKU["DE+FO\ :T?W<K^])+Y=[G&_
M%[PWXA\6_#[5-*\+ZI_9&L3^7LF^TR6OF1B16EA\^-6D@\R,/'YT:EX]^Y1E
M17CFE_LX^*H/"WBK-U8VNM7VK:1KNFVE]KNH:Y%%/8R1R"":\O%,SI(T0&]4
M&P2?+&2GS_2M%"]U\RWNG\UM^2_IN[>MD]M?Q/GG5O@KX^\>ZIX]UG7[CPWH
M=_KNC:99:;9Z=-/?Q6=Q974]PGGR21Q&:-VD0DJD9 9DVG:'>]J'PO\ B'XX
M\0>)-<\11^&='EU'P?=^&[;3M+OKB\$4TCAEE>X>"+<A[@1 IM_Y:;OE]XHJ
M)PC4TDNC7WII_A)E.3;YO-/_ ,!Y;?\ I*/#/BA\"]:\5:#\/)M-F2?5_"L#
M6\MBGB"_T..\22!8G"WUF/.B*LBL/D=6 *E1D,N5JGP-U=OAOI.F6/@;13KT
M.H7.H&>;XC:RMS8SR J9X=5^R-=N[J2'4[!@E<L*^B**N7ON4GN_\T_S7]61
M$5R*,5LO^"OU/G_7/@]X]O-<\&7]M)I(\2:;9Z=:ZMX^AUNZLKR^6*16N4ET
MR*W^SW2./-"+-+B,SNRA2.?==7@:ZTF]A2TM[]Y(706MXVV&8E2-CG:V%/0G
M:W!/!Z5;HIS]]-/JV_O\MOP''W;6Z6_#SW_K0^8[?]FKQ5K'PW\6>%[RXL_"
MFDW+Z;/H7A[3O$>H:K;:?-:3"8E+N6.">WBDV0QB& *L*Q;X\,Q%;7AK]GR\
MU'PSXYT_7]%CT#4M>T^*QAU2'QWJOB><>697B;=?PH8?*D?>H3=DL2<8&?:_
M%WBS2O GA?5?$6N77V'1M+MI+R\N?+>3RHD4LS;4!8X / !/M6LC"1593E6&
M10[M/ST_"WY6&G:W]=NFW]:GS;J_[-WB;Q)X!TZ[U>[L7^(:^)&\3Z@NEZQ?
M:=:W<IADM5MTO8%6XA5;9HU$BIUCY0AB*U=%^!.KIX1@M3I-AH&K-XMT[7KU
MI/%NH^(3=1VSP99KJ\A67S-D018\;0$7YADX]^HIJ3C+F7=/[K6^7NK3;3N1
M)<T>63W37R=[_F_^&/G#]HCX#>._BYJ7B:TT_5(GT+5=%^PV/G>*=2TM-,GV
M2AR]E:)Y=ZLC-'DS/\HR-C ;6]6\+^!;_1/BEXN\23S6[V.KZ?IMK!'&S&56
MM_/WE@5  /FKC!/0YQW[FBE'W8\JVU?WE2]ZU^G_  /\CA?B7X%O_&6M?#^\
MLIK:*+P_XA75KH7#,"\0M+F':F%.6W3H<' P&YZ \3I'P/\ $&F_#?2/#YO=
M/%]9^-Y?$LDD<LGEFU?6);W8#LSYGE2!2,;=V1NQS7N%%$6X;?S*7S5K?D@J
M?O(\LMK6^7O?_),^<]<^"/Q!N- U;P3ITGAE?"D_B=/$<.KW5U<?;F0ZE'?R
M6S6RP[%(?S%6;S6RJH#&"25T]6^!OB9=0\5ZWIEUI,FK2^-[;Q;I%K=S2I;S
M)'I]O:/!<LL9,981SX95D"$QOAB"M>\UE^*/$VF^"_#>J:_K-S]CTG3+:2\N
M[CRV?RXD4L[;5!8X )P 3[4HWCJGKI^#BT_OC'[M=V:-RJ/EWNWIWNFG]]W^
MFR/(/B#X%^*/Q M_#=S='3;06\ES_:/AS1?%^IZ1"=VP03#4;6!9YC&JR9B,
M<2,9AGF)6:GX8^"7C'P'_P *DN-.FT76KOPI9W^E:E'>WUS;K-!=20L9XI#'
M,[2)Y _=R?>WG,HQN/OD$R7,,<T;;HY%#JV,9!&0:?1:SVM;^OZZ^>ULU+[2
M?3\SP"U^"?C'PJ^GZYHKZ'J6OZ9XIUS6(M/U"[FM[6YL]0FE;8TZPR-#,BO&
MVX1.,JZ=&W"W_P *3\2ZKI]UJ.I7&DVWB+5_&.F^)[^TM)I'M+6*U-N@ABE,
M2O*_E6RG>R(&9CPHKW2BB'[NSCTM_P"2\K7XQ7],*G[QSO\ :O?_ +>O?\W_
M $D>,^-/A'JVM:C\1KEM&T7Q39>(AIGV/2]2U:XTX1/;JP:;[1#!*\,JML>-
MX@6#(I#(0#6KX2\-?$?PG\'I-.BU#2=0\:I--)9#6;VZOK.VA:X+1V\ETRK<
M7'EPG9YKJ'<J"W>O4:*F*Y;VZ_U_77Y"MLOZ_KRV^:1G^(-)77O#^I:9-PE[
M:R6SX..'0J?YUX]\*=4\<V_P-^'T/A;2_#NL:CI5@NC:U8:QJ4^GB*YM5%O(
M(Y8[><@K+%(I1H^000PQAO<:*I:<UNMOPO;\V/M?I?\ &U_R7W'S;XN^'M]X
M3^!D7@JXGTU?$/C3Q1&SV=B&6S@:YOA=745N#M9DC@2=MY"ERC/M3=M'TBRB
M12K ,K#!!Z&J>DZWIVO6\L^F7]KJ,,4TEM)):3+*J2QL4DC)4G#*P*E>H((/
M-7:-+6M_PUDDO3_,/M-]>OK=M_GMT/F3PO\ LQ>*='^&?Q!T.ZU/1)-;GEB@
M\(7<:R-%9V=E(T^EK<ADR&25VWB,$8QMYJ]XA_9MUV[^'OP^AM[N"\\4^';J
MYU#4(+?7-0T2#4+B\$ANRE[:YN(1YLK.ORN&"[&7YMR_1M%)ZJS\OPZ^KZ@]
M?Q_'_+H<'\&? \O@/PE-:76D0Z/?W5Y)=W447B.]U[S)&"KYC7=XB3.Q5%&"
MN!C S3%^'^HK\9=?\6^=:_V;J'ANTT>*+<WG":*XNI&9AMQL(G3!!)R&X'&>
M_HHDE.U^FGX./Y,<'R)Q77_Y)2_-'S'<?L]_$!/!/P\\-KJ\-Y8Z-X;CT6]M
M[3Q7J>B16]T BF[0V:*]Z-J[1#*T2@+P07)70U[]F?6M2T'P'I<%_IZ6\7A^
MT\+>+HV=PM]I\+PR$18C)9B8YX@&*#9=RG.0 ?HRBM.9\SEU;O\ /WO_ ))K
MT=MDA2]_5]K?E^L4_57W;O\ -'Q$_9JU?5?'?C'5+#38?$^B>*VBEO-/NO'V
ML^&XX2MLEM)$T%E'+%<(Z1J<NJL,LIW+C'TG;PK;V\42+L2-0BJ"3@ 8QDU)
M14IVBHC?O.[/%-+^"VOZ?\/_  AH?VVP6]TCQ:VNW$D<LFQ[<WL\Y13LR7*2
M@8( SD9QR<:+X,^.X="O?A\@\.?\(+=:]-JK:^UY,=36WEOFOF@^Q_9_+,F]
MC$)C<=,2%"WR'Z$HI1]VZZ-W^=DO_;5^/<CE7X6^[F_^2?X=D>:^#_!?B3PK
M\8/'6K&+2[KPMXFEM[\7'VN5+VVN(K6&V,7D>24="(0_F>:I!.-AZUH?$OP+
M?^,M:^']Y936T47A_P 0KJUT+AF!>(6ES#M3"G+;IT.#@8#<] >ZHI6MR^5O
MP=T:\SU\TU\FK?D>*M\%-<;7KB]^U:?Y4GCV/Q2%\R3=]E6S2 I]S_6;E)Q]
MW'\6>*K>+OA!XVNG^)%SH.KV]M)XBUW3M2@MH]4N=.>>UAM;:">W>ZAC:2U9
MS"^)(0S8V\C)Q[G14J*24?3\%%?E!76SUON2G9M][_BW+Y:MZK5=#YR\)_LZ
M^)M'\.W]K<W5DES>>-],\4^5-K5]JC0P01V8EA-W=*9IG!MY K-@$%>(Q\JS
M>-O@QX]NO NL^'=%&@:A9:[XLNM4U>SOM4GL1=:7*YD^RB9+:8HTA"))\A'E
MF10P+!A]#T5;UM_7\B^?P1WWU[BW=_Z^U_\ )/\ "VQ\V^.?@+XL\0>.(_&5
MMIEC)>ZCHEKI6H:#8^/M8T"WLVMY)F1HKFQ@!ND87#+MEA39L!4_.PKHK#X4
M^+/A[XATS4? FF>'([.;PU8^';O3=5U2Z*Z6MHTAADMY1 [W:@7$JE)#"7\M
M#O4DX]PHIMMIQZ/_ (/^;\UT8[_DOPM;\EY/JGJ</\#_  +??#'X1>$O">I7
M-O>7^CZ=%9SW%J&$4C(,%E#<@'WKRGXM? ;QW\0_&FM3KJ\<^BW4UG/I\LOB
M?4[*/3XX3&SVS:9;J+>YWNDC>=,Y8>: 481J#]'44MWS/^OZ_P"!M<'>2:?4
MI:UIW]L:-?V'F>5]JMY(/,QG;N4KG'?&:^?V^$OQ2G^%'P^\.W!TI+CPW&ME
M?Z;HOC'4M(AU.*.V6**?[=;VHN(B&#,;<*4.X9D.T5]&T4=_.WX7M^;^_P!
M[/M?\=_R7W=KW\/^&GP*UOP1-\._M5_9W:>''ULW4@N)Y9)?MDYDB*M+N=R
M?F,CEL_Q.>:\#/C*'1?C?XDCN-9@U33W\<K=MX D\26]MJLMTLD,4=S#I*V,
MEQ(B[$N%S>(DBIYS(@8J/NRBB.E7VO\ 6Z?_ +;IYZ]"'&+I.E;^K-?K]VA\
MRV/[,NK:+XUN@^F0^)O#-SXC;7A<77Q UK3OLYDN_M6/[*BC>TE:*3++ED$A
M5=P4Y8^I?#CP?XF\&^//'SWD6DW'AG7=5.L65[!=RB\1VM[>)H9;<P[  8G(
MD64D@J-@Y->D44XMQ5EVM\M/_D5KOIK<J7OMN7>_SUU_%^6NEM#QW]J+[>?!
M?AC^RS;KJ/\ PENBF#[8&,)?[;'@/M.<'ID=,YP>E<WKGP-\:>/(_&&N:X^A
MZ5XDUZZT".+3;"^FNK.ULM-OA='-PUO&\DKF2X_Y9*H_=KV+GZ&HI1]V+7=W
M_"/_ ,B&O.IKLE]S;_7\#R[QIX1\8Z;\3H?&W@RTT/6IKC2/['OM,U[4I]/5
M528RQ3131V]QSEY%9#&-V4.X;,'D-%^"/C+X;W'A+7O#DF@^(_$%C#K$.JV6
MJ3R:;:RMJ5XE[*]O+'!.Z".9-JHR'<C?,P9<GZ HIQ;@K1\_QO?[^9^>NFRL
MY/FO?K;\%9?=8^=M%^"/C[PGX=\*7MK<>&];\6:'XHU?7);::>XL;&\AOGNL
MJL@CF>%E%PK8*2#*E<G.^BQ^"'C[38;?Q#Y_AN^\86/C.[\3P:?Y\\&GSPW-
MHUJ\#3&*22)U21B)!&^2@^50Y"_1-%%WS<ZWM;Y>Z[?^2HF:4Y<TN[?S?,O_
M &Y[?H>1^*O"/Q US5/AWXHCL_#<GB'0KR[>_P!*;4KB*T\BXA>+$5S]G=G>
M,%.6A0.=W^KX%>N444M-02L[A1110,**** "O(OVA_&&M^%Q\/++1?$D/A4^
M(/%,.BW6H36\4V(I;6Y(5!+\HE,B1["<C?LRKJ2C>NUP_P 4?A79?%1O"T6I
M/;R:?H^K?VC<6-U:+<17T9M;BW:!U8@!2+@DDAA\N,<Y"UO'U5_2ZO\ @:4V
MES7[2^_E=OQL>,ZG\1O&^CVOB7PS8^,Y-5O-)\:Z-H,7B:^TVV:<Q78MWGAE
M2*..!Y(Q,0&1$P&3<"02W27C>+=9^)&K>!4^*&L^&[?PWX>M-3&KI9:8U[JD
MEQ+<J\T_FVAA$40MT7$,<9R[;C]VO6M(^'GA7P_H-EH>E^&='TW1;*=;JUTV
MSL(HK:"8/Y@DCC50JN'^8, #GGK5?QK\+/!?Q):S/B[PAH/BDV>[[,=:TR"\
M\C=C=L\Q6VYVKG'7 ]*I6M;SW_[=2V];NWGJ[ZF:^)R\O_;FW]ZLO+TT/F[2
MV\3_ !A^)GP9\02>.M8\,WFJ>"]4N';P];6/V<E9[$&6%;JVG(28,C_,6P$C
MVD?,7N?"G4+EW^"-W,([J[2U\3;C;VD-J)V24#=Y<$:1JS;<G:@R23C)KZAD
MT73YM4MM2>QMGU&UB>""\:%3-%&Y4NB/C*JQ1"0#@[%ST%5K'PGH>FM8FST;
M3[4V'FBT,%K&GV?S3F7R\#Y-YY;&,]\UG43G%1B[;_BV_P!?0/M1;Z*WY'SA
M^SK\2/BQ\0IO _B?4-,\377A_P 1VS76K-J0T*/2+!7A:2,V(MIC>_+*$BVW
M =BK,7V,M=K^U-HFH:UIWP^CL/$NJ>'"WB_38FDTQ+5BQ:3Y6(GAE&4(W*,8
MS]X-P*] TWX/> M%\73>*]/\$>'+'Q1-))+)K=MI-O'>N\F?,9IU0.2V3DD\
MY.:Z34-)L=7%N+ZRM[T6\Z7,(N(ED\J5#E)%R/E93T8<BM)VE*#BK6E%_=).
MU_32^A,DY*HE]I-?>FKVZ>BT/F?Q7\0/&UKX-^(_CJT\>W%A<^"]5FTVU\*2
M6-D]K?>08Q'%='R3<&>[W@IY,D8 N(-L9((?T?POJ'BGQ5\;O&4$WBFZL/#G
MAV6R%OHEK9VV+@S6BO(L\KQM(4#$,HC,; ELLRD*O:WWPM\&:GXPMO%MYX1T
M&[\56P40:Y/ID+WT6T$+MG*[UP"0,'N:W;;2;&RO;R\M[.W@N[PJUS<1Q*LD
MY5=JEV RV%X&>@XI*_+%/=?CHE?Y[VV5_F6]W;9W_P" OEM?=]3ROX[^,M4T
MW4/#WASP_>^*(M;U%+F\%KX0M=+:]>" ('D:74V%M'$K2H&7!D8NFW 5\['P
M$\9:O\0/@?X5\0ZC/#=:S?:>'DN-B(DL@)4.1$S(-VT$[&*\G:<8KI_%WP_\
M+_$"WM+?Q1X;TCQ)!:3"XMXM7L8KI890,!T$BD*V">1SS6I;Z38V>GFP@LK>
M&Q(93:QQ*L6&)+#:!C!).?7)J;/E:[_U\OZ?DB_O)]$?*EU\5/'W@#X8^-5\
M5>*=4TSXDZ3::=>W"Z[;:7+H]M%+>>2]U9FU1':U<I,-MTXF"(,[#\YZ+Q=\
M4?%WP=F^)5M%XBE^(CZ/X)D\5VS:G9VZ-9W"M*J0G[+'$&@D"%E5OWF(I/WC
M Y7T76OV>?!X\!:MX8\(Z#H?@6#4Y[:XN)-%TB&!9&AF20%TC"!CA"N2>-WX
M5U_@_P"'OA;X>V=S:>%?#6C^&;6ZE\^>#1["*T260@ NZQJ S8 &3SQ2LW*[
M[?HU\K73ONVNSLFG;[U^:;Z=;-6MHGU:N_G6T^)GQ:\"^"?&'B6]TSQ-JVCV
M7A2ZU>#4?&0T+:E]&JM$L*Z3*6>!T:1V#J6 B7:Y+8K=^(BZQX1\#Z)]M\>_
M\+ N+GQ)X8D0ZUIFFN]NDVIPQM)$L,"*$<$^6Y0NC*S+(2!M]=\(_!SP#\/]
M0NK[POX'\-^&[ZZC,-Q<Z1I-O:R3(2"5=HT!89 .#QD4_0?A#X$\*Z=+I^B^
M"?#NCV$MW%?R6MAI4$$3W,3!HIBJ( 9$9597Z@J"",5TQG&,X2MLT_6TKV^[
M2^G9F;7NN-][_BDK^7I>VM_7Y5\9>'=?TV#]HK6H_'NM3P6/B.U+Z/>:=I-U
M8W:M9V!"3)+9,Q55<(-K*=L:DDMN9O:]/USQ%XN^*WC7?XXG\(Z3X2U*QL(=
M#2ULVM[Z.2"*8S7#RQ--B5IFA3RI(P##_$<UZM<>$="O(=4AGT73IH=4D6:_
MCDM(V6\=555:4$?O"%1 "V2 BCL*I:O\-O"/B#Q1IWB75/"VBZEXCTX*MEK%
MYIT,MW:@$L!%,RETP68C:1R3ZUBM''LDE\TEKY[;/34J7O2E+O\ \'[O5:Z'
M(?M+:E)I/PK:ZABM995UK14"WEK%<H-^J6J$[)%9=P#'#8RIPRD$ CS3Q3\0
M/'-O_P +B\3P^,;FRTWP#KJ0V6AVVGVAAO(!96-Q)%<R/$TA!,T@4Q/$R[B2
MSC:%^D=5T>PUVS-IJ5C;:C:>9'+Y%U$LJ;T<.C;6!&5=58'L5!'(JK-X1T*X
MM=6MI=$TZ6WU>3S=1A>TC*7K[%3=,",2'8B+EL\(HZ 4Z=HN3EK?;UO']$U\
MQS]ZFHK1W_"S7_!/F7]H+Q%K_BCP;^T%))XY;PMI'A72)-/AT)K6U:VODFTX
M2F:X>6/SLR/.T4?E2QJ&A'#G<IF\0_$;5O 6I?$N^TL:=:7&G^"_#$D6H36,
M/^BM//>PO<SR *\L4* 2;'?:H1]N-S9^A->^%_@WQ3KUMKFM>$M"U?6K:!K6
M#4K_ $V&>YBA8,&C61E+*A#N"H.#O;U-::^%]&6:\F&D6(FO+:.RN9!;)NGM
MTW[(7./F1?,DPIX&]L#DU,?=C-=TOPOK?SOTVZ%RES**[?JX]/\ MWYWU/'?
M'&KZU\-_#<.ACXA^)_%OB#6=3@MK#[!IVCMK8+122-%$7C@LHU*022![B,_*
MDJ@LS)M\@O=3\5?%#2?A5+JOC7Q#HFH:?\2;W11<"#1S>?);7HC>?RXI[8W"
M!3$?*_=G>V4W;2OT];_ _P"'-IX3N?"T'@#PO#X8NIQ=3Z+'HULME+,-N)'A
M";&<;5^8C/RCT%:&H?"_P;JWA=_#=]X2T*]\.NR.VD7&FPR6C,F-A,)782NU
M<<<;1Z4_M<WFG]SB_P!&OG?<E2M'E79K[U)?JG;R:ZZ?/'_"5>)/AG;_ !<L
MX?$;7^H)XNT/1QXHU33;&.XMX[V"PC>YF^S6\,<KQB<[&D0@;8PV44BM/Q[X
MZ\;?"O3_ (H:-:>.9O%5YH_AF'7++5-6L+0W>G7$DLD8BF6VAAA>-Q'O0&,/
M\LGS,,;?H*3P9X?EL]5M'T+37M=601ZC UG&4O%$8B"S+C$@\M53#9^50.@Q
M6=H/PJ\%>%O#=YX>T7P?H.D:!>NTEUI5AID$%K.Q 4L\2J%8D*H)(Z*/2B.B
ML_\ A]$K>5G[UUK?38*CYE:.FWWWNWYWVMLMUJ<AX,U/Q%X=^,E]X3UGQ1>>
M*;2^T-=;@:]L[: V4BW!BDBC,$:9B(>/:)-[C8<R-FO2=&U[3/$5K)<Z3J-I
MJ=O'/);/-9SK,B2QN4DC)4D!E92K+U!!!Y%2?V18?VJ-3^Q6_P#:2P?9A>>4
MOG"$L&,>_&=NX [<XR,U'HV@Z9X=M9+;2=.M-,MY)Y+EX;.!84>61R\DA"@
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M1G&<$^M-U3X>>%=<\(Q^%=1\,Z/J'A>*..%-$NK"*2R1(\>6@@92@5-J[1C
MVC'2HIQY(VZJ]OG-3OZIKY[F<USRN^MG]T'"WH[W?W>9R?P*\;:IXNTOQ%:>
M(='TO2O%.AZJ=,UB30Y6EL+RZ$$,C3PLRJ^"LB@H^60J5);:&/ENJ_$;QI)X
M2\1_$:+QK-ILNC^)I]&A\$O96CV,Z17PM4MY&,1NC<3J5D0I, &EBQ&RY5OH
MSP[X:TCP?HMMH^@Z59:)I-J"L%AIUNEO!$"22$C0!5&23P.I-9,GPK\%3>-%
M\8OX/T%_%RXVZ^VF0&_&$\L8N-OF?<^7[W3CI6EUS)OHE]ZMK;;6STV5^VC)
M*\)):-M_KI^*UWT\[KPKQ3\0/'-O_P +B\3P^,;FRTWP#KJ0V6AVVGVAAO(!
M96-Q)%<R/$TA!,T@4Q/$R[B2SC:%L>*->U_PKXG^,OB3P]<-')HNIZ)J5];+
M LIN]/CM8VNX0""0Q@\PJ5PVY5'<U[_-X1T*XM=6MI=$TZ6WU>3S=1A>TC*7
MK[%3=,",2'8B+EL\(HZ 5!KGA6*\T?Q#%I2V>DZMJ]J\+ZE]C64F3RC'')*H
M*F4(,?*6' QD5E4ORQ=-:Q2^;27YM==-=2H13J/F?NMOY)M_DGT^1P7PR^+,
M'BC3_%_CG4_$>G0?#Z355L_#][--%%;-;QJD+3^<<;O-NC*JY8@A8]OWN8_V
MH[F>+X;Z5;QAOL][XIT"SNV5MN+>35+99,^Q'RGV8YXKKO"_PH\->&_ACH?@
M)M*L]3\.Z596]G'9WUNDL4@A"E'9&!!;<@?)_BYZ\U<^(W@J#XB>"]4T":?[
M(;I%:"Z$8D-M.CK)#,%/!*2(C@>JUM+EA-<NJBU_V\DUO_BL[]-2*;DU>6C=
M_E?_ "_0XO\ :%U>XOM$T;P#ID\UMK/CB\_LE9[?A[:S"&2]GS_#M@1U4]GE
MCJK\3$M_"WQ(^!EMID<=J#J]WI,=O'E1]D_LNY=D !QM#6\)QC^ 8KU(:%8R
MZE9ZK=65G<:U:V[VT>H_9U$J(Y4R(C'+*C,B$J#@[5SG K&U3P0=6^(VA>)[
MB\5K?1[*Z@MM/\@9$\YC#3F3=U$<;(%"])'))X F-HOO=Z_+;_@:7O)[+5-^
M\OEIZO=^NWE[JZF5\6/&^C_#ZWL-3?2%UWQA=>;IWA_2[>-&O;V:0!FAB8_<
MC/EJ\KDA$6/>Y 6O*YO <_PQTO\ 9Q\,W4\-Q=V'B219VM4*0B1M,U!W2)3R
M(U9BJ@\A56O:O&WPK\%?$O[)_P )?X/T'Q5]CW?9O[;TR"\\C=C=L\Q6VYVK
MG'7 ]*IW7P3^'=]X3M/"USX"\,7'ABSF-Q;:++H]NUE!*=Q+I"4V*QWMR!GY
MCZFB/NOF>]U]W]7_ *O?2_Y27WIK\/\ /RMP_P"TAXE^(7A^ST'_ (132M'E
MT^36])B>\N?$-Q87#2/?1J8#''9R@PN"%9O,SM=OW;8PWI#ZUKNG> [S5=5T
MFS@UZVLYKA]-TV\DO(#(BL51)6AB9\X'_+-3DXP>IO\ A?PGH?@?18-'\.:-
MI^@:1 6,6GZ7:QVUO&68LQ6- %&223@<DDUJU,DW2E3B]6V[]KI+\+?UK>(_
MQ%-K2R5O1M_C?^M+?*/A_4-8U+XA?L]:OK'Q&C\7S>(DO-7%@]K:PK$6TR1B
MUGY*H_V=3+L(F\U_FCS(#D/=C\?>.['X'ZA\0;OQK<S7;Z_'IZ68T^SCL[2T
M775MG<_NBY<VX96=GV@?,%5ANKWG0OA7X*\+ZE/J.C>#]!TC4)[EKV6[L=,@
M@EDN&5U,K.J@ERLD@+$YP[#/)K3/A/1&T&YT,Z-IYT2Z65)]-^RI]FE64L90
M\>-K!RS%LCDL<YS6E22D^:*MY?/;S[7^?D94HN$DY.^WSM_6VW0\$^+OQTUS
MPIXH^+%CH>K0W+>'O#NCRVUC!;I<S6U]=W5Q&V(U&^29H_(*0L<,=F!\_.W\
M']8\91MXTURYU3QSX]T"%8(]$T_Q!HMCHU_<2!,S[(I+:R/WB 'E*(>0,[=S
M=)XN_9[\+ZE\.]3\+^%=*T?P0MY'#%OTO2HXX'BCG,WV>>&(Q^;;NS2B2+<H
M99I1D;R:I? _X!1_"'6-<U02>';675(8+=M,\'>'AH6EJL1D82FV\Z8O.3*R
MF0ORJHNT;<F+:O7I_GTU-ZEI6E'RT]$E^:;..^*=OK7CCXF?!&_DU/Q/\-KF
MXU/4(1I$@TF6:-EL;EMY(2Z0LZ*1@2,-C'Y5<9$EU\0O&MG-\=/%"Z]<7UEX
M#NKF'2?#,-E;B"ZVZ3;7(%Q)Y9F?$DI*B-XR,L&+@@+[CXL\$^'?'EA#8^)M
M TOQ%90SK<Q6VK6<=U''*H(615D4@, 3AAR,FKUAHNGZ5-?365A;6<U]-]IN
MY+>%4:XEV*GF2$#YVV(B[CDX11T IZ6DNZ:7DVUK]R:\KZ$I)3C)ZZIOIM?3
M3Y'SEX!^(WQ#T#3]2\2^*CXG7P4OAN?5KG7/%4&ARPVEPBH\;6<6E3&66%T:
M5BDNYL1QXDR6SS^G^+?&_B:U^)/A+6==\9:7$_@T:Q;R^(X- _M*!F:56\H6
M(DB$,BKMVSQ[QAMK9Y7Z'\-_!?X?>#M4O=3T#P)X:T/4KV)X+J\TW2+>WFGC
M<AG1W1 65B 2"2"0,U>\)?#/PAX!MFM_#'A31/#ENP8&+2=.AM4(8@L"(U Y
M*KGUP/2LJT?;1<=KIKONI??:ZUTVM8JG)T^5[M-._HX^MKI-6\[^OS]I>NZ[
MX7^$/PI\,Z3XK\;:YKFK:,NIQCP_9:']O%K%;P!@);Q(K1+>,RHN&5IF+IAL
M*Y.'I?BC7OBIXB_9SO[GQB/#6NZYX=UQ9=6L[:T:YN&4V186ZOYMN)6$6\X6
M5-HDVCHZ_1+? OX;/H-KHC?#WPJVBVMT;ZWTXZ+;&WAN",&9(]FU9"/X@,^]
M:6N_##P;XHTV/3M9\):'J^GQQO$EI?:;#-$J.ZR.H1E( 9XT8C'+(I/(%;U)
M<]1S[MO\'_GKWM?K91AU[&,8=DU_P;?U;;I<\"\.^,M5\5>(_A7/J=__ &_<
M:5XM\0Z3%JP@6$ZC';6MW$LI5 $WG858Q@(65BJJ#M"? /XD?%CXA:AX/\3W
M>E^)YM UWS7U:+4!H4>C6$120J;/R)C?;TE2.+;/N)#2%E1@ OT=9^$="TVW
MT>WM-%TZU@T9=FF10VD:+8KL,>(0!B,;"5^7'RDCI6-:_![P%8>,F\76W@CP
MY;^*VD>5M=BTFW6^+NI5V,X3?EE)!.>02*46E*[UT_3>VVOX=!6TEYO[NROY
M?CU,7]HSQGJ?P]^#NO>(-'U.UT;4+,VQ2_O8EE@@5KF)':16(!3:S9^93C.&
M4\CR_P 9_%'Q=\(;WQYI\?BP^-18^%XO$$5_K%E;JNDRR7+0@R?98XE:WV!I
M0K?O,6\G[Q@?E]O^*'@7_A9'@J]\/F]_L_[3+;R?:/)\W;Y4\<N-NY<YV8Z\
M9SSTJ?PK\-_"7@73;W3_  UX6T7P]87KF6ZM=*T^&VBG<C:6=8U 8D #)'05
MCROF;_K9KY6;O==BWK&RT>GYI_DK?/[_ !?Q%XH\8?"S6M7T5?'M]XW2X\&:
MGKT=UJME8K<Z9<6WEB&1?LMO%&8I3*V%D1CF$X8C<*;X2\>>*['7OA^\WCO_
M (36+QIX?N]3FM([&UCM[$Q6\4JW%H84WB$O((R)I)LF1,.",-Z>/@CX/T7P
M/XG\->$?#FB>"H->LYK6X?1=+AME+/&T8D=(PF\J&.,GVR*N_#WX3>%OAK T
MFB>']'T[5KF"*+4=4L-.BMI]0=!_K)F0;G))9OF)Y8\TW%R<E>VBL_\ P.^G
ME>*OY:>1LH6Z-W_\EM]]GIYZ^?D_@'XS:SKF@_LWI>:_;SZOXQTLWFL0[(%E
MO-NF-+(X0*-@6<IG8% )"]#BN0\+^--6T[X.?##PWX=U#Q1#K%[IE]J+6OA&
MTTMKQH(9E5I7FU-A;)"K3*&0 R,SH5*JC[OH[0_A1X(\+ZI-J>C>#O#^DZE-
M<-=RWECI<$,SSLK*TK.J ER'<%B<D.P[FEUCX4^"?$6FZ9IVJ^#M U/3]+D\
MZPM+S2X)8K23KOB1E(C;W4 UI5:J5'-*U[Z+I?MY+\;=+W44[T[]?7]?7\/.
MVOS)HDGB3XP>-OV?O$EQ\0-9\/ZEK7@W4YI)-%M],*^8OV$R.@FMYUS+N!8!
MG4>6OE[1N+:W@/Q)XDCTK0?!=MXI?0I-8\;>(]-N/$]OIFGQ7LHM9[AT1$6W
M%M]HF\LL[M VY4E.-Q##Z,U;X<^$]>M-*M=3\,:-J-MI,ZW6GPW>GQ2I9S+]
MV2%64B-QV9<$4FL?#?PEXAT&[T/5?"VBZGHEW<M>7&FWFGPRVTT[.9&E>-E*
MLY<EBQ&2QSG-0KWOZ_C)/_-&LI)TU#JK:_*2_5?\.>%/\1/',,;>&;;Q<+RX
MLO'T'AD>)Y=/@>:[M)+,3R*Z(BP^?&SM'OC55#1*60_,C>C_  =\1:Q_;'Q"
M\,Z]KUQXB;POJT5M!K&H06\%Q+!+96]SB80)'$2K3.NY8T&T+D$@L>VT[P/X
M<T?2-+TJP\/Z79:7I4@ET^QM[*.."S<;L-$@7;&1N;E0/O'UJ];Z'IUI<:A<
M0:?:PSZBXDO98X55KE@@C#2$#+D(JKEL\*!T%-7BI=;_ .45\M8MZ?S"T;5U
MT_&[?ST=OELM#+U'Q-;ZIX!O=>\.7=MK4$NG27=A<V,ZRPW/[LLA2120P)Q@
M@XKYEAM]3NOAK^S)8>";BQ_X3D:;'J6F:AKP,VF^4-/5+QY@A#R2-'<DHL;(
MQ;)+J@<'ZMT?0M-\/Z/:Z1I>GVNF:5:Q""WL;.%8H(8P,!$10%50., 8KB='
M^!WAG_A7.G>"?$^D:/XRT'3)G:PM-7TN*:&"(._V=/+DWJ6BB<1[Q@D G R1
M3V<K=>7\.;\[K[B=TK^?XV_*WXG@EC>?8OV0_&QOH5@\4Z!XDN;G4IHY0UI-
MK<>II<M):NH7]P9V54# ,H&Q\LK$_4'CC4_#NB>%[K5?%ALHM$T\QWLTE^BO
M'$\;J\;@$'+JX0K@;MP7;SBL/Q)\(])U;PKX?\+Z5;V'A[PSIFIVE\^E6-BJ
M0R1V\HG2"-4*K$#,D3$[6!"L,?-N'2^*?".A>.=%GT?Q)HNG^(-(G*M+I^J6
ML=S;R%6#*6C<%3A@",C@@&AMVO'1Z>FB6J73R72R5[6!7YKR=[W?WMZ7ZON[
M:[^2^:/B3H>J2?LT_M#>--6TQM!F\7:7=WMOH\J;)[>VBLA!"UP,\3R)&'9?
MX RH>4)/M7QDU;Q9HOPOU2Y\):=IM]>)I\[32:AJTNGFW00,?,B:.WF+R @8
M4[!_M"K^@_!+X=^%=*U?3-%\ ^&-'TW6(A!J5G8:-;00WT8# ),B(!(N'888
M$?,?4U<\$_"OP5\,_MG_  B'@_0?"GVS9]I_L33(+/S]F=F_RE7=C<V,]-Q]
M:5:*J471B[::/Y6\OOZ^149.,XS>MF_QM_EYF7\%M6\6ZQX"TJX\7:9I>GW3
M6=NT,FFZO-J)N$,2DR2M);0E')ZJ-_\ O5\]_'7Q#KWBCX9_%/6;WQ\NE6&E
MZ\- C\+-:VOV78DUN$$CL@N#<RA_,0K*$VR1_NVP2WV!7+ZI\*_!6N>(I-?U
M'P?H.H:[)!]E?5+K3()+IX<8\LRLI8ICC;G%7-\]1SZ.^GS3O^#7;6_2QSNF
M_8^R3U[_ ":_X/RMUN<%8:GXL\0?%[X@1CQ9=6.@^&/LWV31K.RMB+AY;,.P
MGEDC=R@;#*(RC ELLRD*O,>!_C9K&J^'?V<FO?$%K+JWB[2FOM8B80(]YLTM
MI9)-H7Y%6?9N*!0"0IX.*^@K;2;&RO;R\M[.W@N[PJUS<1Q*LDY5=JEV RV%
MX&>@XKF=/^#_ ()T2XO;O1O">B:#J5Y))<2:EI6FP6]SY[HZ-/YBH#YF)'&\
M\_,?4UFKQIRCNWMWNK_G?\%\MI>];I_EI_E^)X-^SMXW^(7Q3\1^$-?O/$_C
M)M(N=*N-1U[2-1\,6^FZ7#<2&/[-#:3RV:2SPX:4@QS2DA$9I!G:^U^TMK&N
M>.OV=_&ANM'\4?#7["8)/,O)-)F-\GF@%1Y<MT%0$ACGRVR%P<;A4_PJ_9,_
MX5WXT\/Z_-J/AKS=%24?;/#_ (7.F:KJS/$8B=3O6NIFNP=QE8;4WS*DA/R[
M3[]JNE66NZ9=:=J5G;ZAI]W$T%Q:742RQ31L,,CHP(92"001@@UI42<;1\_E
MJ_O_ !T"3YV[Z7_K;8\>U9/&'_"V?"W@>V^(.K0:;_PCUUJ=[J1L=/>_O)8K
MJ!4RWV?R4!65E8+",CIM;YJX#P3\3OBUXW\8W&KZ=I/B>ZTRW\6W6C7&G@:%
M'H,%A!>O;22$M,-1\]8D\[)&&?@1["M?1^@^!_#GA6.QCT7P_I>D)8V[6=HM
MA91P"W@9@[11A5&Q"P#%1@$@'&:R[_X/> M5\81^++WP1X<O/%4;QRIKEQI-
MN]\KH $83E-X*@  YX &*(M1<;ZVO?SO*^WI96T\B+/EDN]OPC9Z^;UO]_EX
M5'\8_$]]\7O#<FFZQXEN/"FL>*+WP]ON['1X-&D\F.Z5DM5\PZCYT<EO@R2
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MTE-.A%I,JHL:J\078P"1HH!'"HHZ 44KT]7K:UODXOY?"U?L]M'?64U*2?\
M6S7Z_AN[KE^=?$WB/Q)\%_%WQ6G7Q/+XGO[/PSHMQ%K?B+3=.26T$U[=PO),
M]I;VQD@A4&78Y.,28(W&M;Q[XT\:_"&X\:Z/!X[O?&)B\ ZIXE@O=6L;(7>D
MW=OM6!C]FMXHFBFWN562,G=;/AF&X+[YIO@7PWH]NUO8>'M*L8&LH]-,5M91
M1J;2/<([? 4#REWOA/NC>V!R:H>'?A+X'\'Z'J6BZ#X,\/Z)HVIAEOM.T[2X
M+>WNPR[&$L:(%<%?E.X'(XIRN[I=FOO32]+73\[6",H*HI..ET[>G+?UO9Z>
M?R//? ^O^*]!^*/AC1=>\67/BB#Q1X<NM7DBGL;:WAL+F"2U!6V$4:N(F%TW
MRS/,X\M/G/S$[WQR\3:UI/\ PA6B:-JTGAMO$VO1Z5<:]###++8Q^1--^[69
M'C\R1H5A4NC &7[I.*]!_L'3/[0L[[^SK3[;9P/;6USY"^9!$Y4O&C8RJMY:
M94<'8OH*B\2>&-&\9:+<Z/X@TFQUS2+H*)]/U*V2XMY0&# -&X*MA@",CJ :
MN<E)JRV?_MS?Y:&,=%KO;\;6O;UUMH>.:QJ7B>X\=>#_ (<VWQ(OK9+FQU2_
MN?%%I9V!U*[DM9H(UM</ ]LK*+AFDVPJQ\M=H7YZYW2OB%XX\2IX'T"W\9+&
MU[XEUG0+KQ+8Z?;M+?V]I!<%)T5T:%)@\0#,J&/>C_N]IV#VG4O@]X"UGPI8
M>%]0\$>'+[PS8,'M-%N=)MY+.W8;L-'"R%$/S-R /O'UK:M?">B6-OH\%MHV
MGV\.C)Y>F1Q6J*MBOEF/;" /W8V$IA<?*<=*G2UG_P /K>_E9:66CW>I,KM)
M+3_AGIY][O7HM#YDT7QU\2-)\-V?BC4_']QK,>G>/AX/;2SI5G!#?V;:M]@\
MZY98M_V@"0/NA:&/]VH\K[Q:;QK\3_&FGZ7\8_%5IX^,)\!ZU]GT[PO;6%HT
M=[F"V>.UNF:-IF,SR&.,Q-$X+]9. /I)O!V@-9FS.AZ:;1KW^TC;FTC\LW?F
M^=]HVXQYOF@2;_O;ANSGFN-\/_ /PMIOC#6?%&K:1I'B#7+K67U?3]0O-+B:
MYTPM##'LBE;<PYAW;E*_>Z<9-4VE;G5[+?S_ '?3Y3?;4=9*4KP6E]K]/?Z_
M.*OO=7.8T/5/%7B[XH?%)+SQ3<6_AOPS<P6]IX?@L+4QSB72X)I%N))(F=T#
MR;E5#&02P9G4JB>>:)XP\::9\&?@]XIEU+5=#\ KX1T^YUBZ\&VFDQM;3M'"
M6>>WN82HM0A.$LU\Q?F 0C;CZGM]#TZTN-0N(-/M89]1<27LL<*JURP01AI"
M!ER$55RV>% Z"N9O/@M\/=0OM$O;KP)X9N;W0XHK?2KB;1[=Y-/CB.8D@8IF
M)4/*A,!3TQ1"7*K/^[^"DGZWYE]Q53WUIVM_Z3]VSU\SQ.^\<>(M)O/B,F@7
MMCHUV_Q/TK1UNH]+@.8+BTTWS3( JF5R)7_>.2X^49VJ #QM\3O&7PU\/_$'
M05\3:KXCU+2M5T2VM-:DTJWGU2.VOWC2;RK>V@6.>:("=XP(.?E#+)@Y^B&\
M'Z#))<.VB:<SW%['J,S&TC)ENHPBQSL<<RJ(XP'/S (N#P*Y+XN_!^U^)?AF
M_L+-]/TK4+RYM;BZGN].%W;:@L#Y%O>PJ\;7,!4LIC,@'/ID'.3?+%16JY;^
MBC!/TUBWIKJ39NHY7TU^^\G^J7R,/]GF3Q=?KXNU#Q#XC\3Z_HDNI)%X?;Q5
MH]MI=U]E2"/S)&@CM;>129VG7,J#*QH54 [GC\7:IXC\8?&+4_!EAXRO_ .G
MZ5H%OJZ7>EVUE+<7\DTT\;Y-W#,@BA$*9"JK9F7+ 8!T?@;\$(_@ZNNR++HD
M,FK2Q.^G>%=#&C:5!Y:E0\=J)92)7S\\AD.X*@P-M=9XV^%_@WXE+9KXN\(Z
M%XJ6S+&V&MZ;#>" MC<4\Q6VYVKG'7 ]*NI:35MK+\K7TW=]7W\NCB]'=6O_
M )W_ !6GE?Y'@FF_M#^)_#OA_P +>,?$5Q!JFAZ_X:OA;P6-LL4-QJUJ[/ T
M!.7*WL =D1G8#REVGYB3G?&#XF^/_!?A>:RB\2^)+GQ=X8\)Q:WKLWA_3M%C
ML8;AUF/F7KW[KN@9H'58[4+(JQR%G8NF/J#6/"^C>(K6TMM5TBQU.WLYX[JV
MAO+9)4@FC.8Y$# A74\JPY':L[Q'\-?"'C#5['5=>\*Z)K>J6"LEI?:EIT-Q
M/;JWWA&[J60'O@BLY7LU'^MW^;M;:R5@A[J5]=/OV^[1;KJVW<\T\/\ B3Q9
MXX^.6I:4?%$^C>'M)\/:)K)TVPL[8FZGN7O!)&\LL;L(2(%RJ;7R 0Z_,&\^
MT;X@ZS_PJ?X9Z'H%UKUCK6H:9>Z@;#P)I6C03?9X)4C,FZ_V6<,"&5 R*GF,
MSH5*A7W?4-GH&F:?J$U_:Z;:6U]/!%;2W,,"I+)#$6,4;,!DJGF/M4\#>V,9
M-8NL?"GP3XBTW3-.U7P=H&IZ?I<GG6%I>:7!+%:2==\2,I$;>Z@&KJ6E.\-%
M_7Y=ODK7NIIW@KO5V7Y?KKZ7OK:QX9X7^(WCCXG6GP.M+?Q<_A[_ (2OPQ?Z
MEJ]_IMA:2SRR0BS\MX3(LL4;$RMGY9$*NX SL=/3/@M\2#K7@FP3Q+K5O)K?
M]LZEH$-Q=-%;RZG+:7-Q$&6-=JF5HH#(RQJ!PY"A1@=[;^%]&M+BPG@TFQAG
MT^*2"SECMD5K:.0J9$C(&45BB9 P#M&>@K)E^&?AZ37M%U1=/A@.CSW5Y:6D
M$,<<"W=QGS;HJ%YF(>4;\_\ +:0G);(:EI:2_J]_RT^XT=N116Z_X/\ P/N.
M3_:4\<:O\/?AQ:ZIHFKVNA7DNO:18/J%] LT$,-Q?P0RLZL5&W9(V?F4CL1U
MKS7Q9\0O'/P]C^)GAVR\97/B2]T.VT2]LM?UG3K5I;66\NFBDM94MHH8I%"1
MK(!M60"8_-]QA[9\6/AO'\4_#=CH\UVMG%;ZQIVJN7MQ,LJVMW%<&(J6'#B+
M9GG&[.#C!NZ'\+_!OAGP[)X?T?PEH6DZ#+,+A]+L=-AAM7D!4AS$JA2V44YQ
MG*CT%)6]FT][O[K1MZ:W_ID2OS)KLOONW\]++7I^'F-[#XNN/B3I_P .O^%F
MZYIBP:')K;ZXEEI?]HZE(;GRC$H>U:!8805W;8=Y,T.9.&W<;-\1/B7XD^$_
MA7Q5'JNHC0;-]4CU[6O!<&G)>W45M.\5O?QQZ@CP&VDBA>5UBRY,D?E[ER#]
M!^-/AOX1^)-K;6OB[PMHOBFVMG,D$.M:=#>)$Y&"RB16"G'&15;Q1\)/ WC?
M^RSXC\&>'M?.EKLL/[4TJ"Y^R+\O$6]#Y8^1?NX^Z/05*OR<O7O]_33NE:^M
MKW[6VN9NW]6L^^[UO;3:UCQ;P8QTSX]_%'Q6_P 0=7GT:U\.Z5JCVUS:6;0-
M;O%>,C.D=LLY6,*S*%=6)+!BW '/^&_'?C;Q9JVO^'-1UOQEIFGZUX,N-<M9
M_$%KH*75N5DC"O:):>;MB=964K=HSC:,,2'(^F;OP+X;U#Q1:^);KP]I5SXC
MM(&M;?6)K*)[N&$[LQI,5WJAW-E0<?,?6JGA'X7^#?A_O'A?PEH7AO>7+?V1
MIL-KDOLWD^6H^]Y<>?78N>@J9Q4^9=&FOO4E\]T_DUV:F%X6:WNG]SBW^377
M=>:?S/HOBKQAX+^"_P "/#N@:WXFU]O%6GQRF_TJ/1?[2ACCL$E2UM#=+#:[
M>"<R++(4C?&3\Z>\?"?Q1KUMX3TRV^(;-HWB&ZOY[+3XM:FLH[[4(UWO$72U
MD>$SF)&9EA./D9@J#Y5U5^#'P^7PG<>%U\"^&E\,W$_VJ;11I%O]BEFR#YC0
M[-A?*@[B,\#TIFF_!OP?HEYX<?2="L=&L?#[W$^FZ5IMI%;6=O/,-KSK$B "
M3:TBAACB63@DY'1.?/4E-[2?W;?\-Y[ORSC#V=.,%]E??O\ Y[=-KZ',?M='
M;^RY\5SD+_Q35_R>@_<-7,Z;XM\3^$O'46C-XWF\;V6L>$+SQ )9+*TCBTR2
M%HA$UN8(U_<2^>X59VE;]P,2-\^?>=2TRSUK3[BPU"T@O[&X0Q36US&LD4J$
M8*LK @@^AK&\._#?PEX1;5FT+PMHNBMJ\AEU$Z=I\,!O7.<M-L4>83N;EL_>
M/K6,KN#BNS_%-+[FT_E;KIJG[T6UM_FG^EOGY6?SA?\ Q!^).F_#WX2R#Q)X
M@\0:S\0%AFNYM#LM&@N+/;8&X,-BMV(X 9"N6-PTS;4DV $C9TU]X^\>Z/\
M#71M,\0KXJTGQ;JVO2Z9I<=A::--KNHVR123HQ)F;3H)0D;%W8E"L+[8T>1
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MK^>QAEGTYB -]NSH?+/RK]W^Z/2LX^[*,WJU_P#(.+_%WMZI[Z.<>>#AM?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
J%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140474163341856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Apr. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">RECURSION PHARMACEUTICALS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">46-4099738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">41 S Rio Grande Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Salt Lake City,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">UT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">84101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">269 - 0203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Class A Common Stock, par value $0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">RXRX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001601830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">230,273,797<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,389,871<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140474078338048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 296,326<span></span>
</td>
<td class="nump">$ 391,565<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">3,195<span></span>
</td>
<td class="nump">3,231<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="nump">2,599<span></span>
</td>
<td class="nump">3,094<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">41,495<span></span>
</td>
<td class="nump">40,247<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">343,615<span></span>
</td>
<td class="nump">438,137<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash, non-current</a></td>
<td class="nump">6,629<span></span>
</td>
<td class="nump">6,629<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">86,716<span></span>
</td>
<td class="nump">86,510<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">35,501<span></span>
</td>
<td class="nump">33,663<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">33,076<span></span>
</td>
<td class="nump">36,443<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">52,056<span></span>
</td>
<td class="nump">52,056<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets, non-current</a></td>
<td class="nump">254<span></span>
</td>
<td class="nump">261<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">557,847<span></span>
</td>
<td class="nump">653,699<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">5,115<span></span>
</td>
<td class="nump">3,953<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other liabilities</a></td>
<td class="nump">26,070<span></span>
</td>
<td class="nump">46,635<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Unearned revenue</a></td>
<td class="nump">36,618<span></span>
</td>
<td class="nump">36,426<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Notes payable</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">6,062<span></span>
</td>
<td class="nump">6,116<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">73,920<span></span>
</td>
<td class="nump">93,171<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Unearned revenue, non-current</a></td>
<td class="nump">37,391<span></span>
</td>
<td class="nump">51,238<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Notes payable, non-current</a></td>
<td class="nump">1,071<span></span>
</td>
<td class="nump">1,101<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, non-current</a></td>
<td class="nump">43,786<span></span>
</td>
<td class="nump">43,414<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liabilities</a></td>
<td class="nump">528<span></span>
</td>
<td class="nump">1,339<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">156,696<span></span>
</td>
<td class="nump">190,263<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note&#160;7)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.00001 par value; 2,000,000,000 shares (Class A 1,989,032,117 and Class B 10,967,883) authorized as of March&#160;31, 2024 and December&#160;31, 2023; 237,508,682 shares (Class A 230,043,061, Class B 7,464,871 and Exchangeable 750) and 234,270,384 shares (Class A 226,264,764, Class B 7,544,871 and Exchangeable 460,749) issued and outstanding as of March&#160;31, 2024 and December&#160;31, 2023, respectively</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">1,460,144<span></span>
</td>
<td class="nump">1,431,056<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,058,995)<span></span>
</td>
<td class="num">(967,622)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">401,151<span></span>
</td>
<td class="nump">463,436<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 557,847<span></span>
</td>
<td class="nump">$ 653,699<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480632/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140474163688704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">2,000,000,000<span></span>
</td>
<td class="nump">2,000,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">237,508,682<span></span>
</td>
<td class="nump">234,270,384<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common sock, shares outstanding (in shares)</a></td>
<td class="nump">237,508,682<span></span>
</td>
<td class="nump">234,270,384<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">1,989,032,117<span></span>
</td>
<td class="nump">1,989,032,117<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">230,043,061<span></span>
</td>
<td class="nump">226,264,764<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common sock, shares outstanding (in shares)</a></td>
<td class="nump">230,043,061<span></span>
</td>
<td class="nump">226,264,764<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">10,967,883<span></span>
</td>
<td class="nump">10,967,883<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">7,464,871<span></span>
</td>
<td class="nump">7,544,871<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common sock, shares outstanding (in shares)</a></td>
<td class="nump">7,464,871<span></span>
</td>
<td class="nump">7,544,871<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=rxrx_ExchangeableStockMember', window );">Exchangeable Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">750<span></span>
</td>
<td class="nump">460,749<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common sock, shares outstanding (in shares)</a></td>
<td class="nump">750<span></span>
</td>
<td class="nump">460,749<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=rxrx_ExchangeableStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=rxrx_ExchangeableStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140474172062704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 13,794<span></span>
</td>
<td class="nump">$ 12,134<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating costs and expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of revenue</a></td>
<td class="nump">11,166<span></span>
</td>
<td class="nump">12,448<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">67,560<span></span>
</td>
<td class="nump">46,677<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">31,408<span></span>
</td>
<td class="nump">22,874<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating costs and expenses</a></td>
<td class="nump">110,134<span></span>
</td>
<td class="nump">81,999<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(96,340)<span></span>
</td>
<td class="num">(69,865)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">4,188<span></span>
</td>
<td class="nump">4,538<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income tax benefit</a></td>
<td class="num">(92,152)<span></span>
</td>
<td class="num">(65,327)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="nump">779<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Net loss and comprehensive loss</a></td>
<td class="num">(91,373)<span></span>
</td>
<td class="num">(65,327)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="num">$ (91,373)<span></span>
</td>
<td class="num">$ (65,327)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Per share data</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share of Class A, B and Exchangeable common stock, basic (in dollars per share)</a></td>
<td class="num">$ (0.39)<span></span>
</td>
<td class="num">$ (0.34)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share of Class A, B and Exchangeable common stock, diluted (in dollars per share)</a></td>
<td class="num">$ (0.39)<span></span>
</td>
<td class="num">$ (0.34)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares (Class A, B and Exchangeable) outstanding, basic (in shares)</a></td>
<td class="nump">236,019,349<span></span>
</td>
<td class="nump">191,618,238<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares (Class A, B and Exchangeable) outstanding, diluted (in shares)</a></td>
<td class="nump">236,019,349<span></span>
</td>
<td class="nump">191,618,238<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember', window );">Operating revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 13,491<span></span>
</td>
<td class="nump">$ 12,134<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 303<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140474169998800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders&#8217; Equity (unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock (Class A, B and Exchangeable)</div></th>
<th class="th"><div>Additional Paid-in-Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">191,022,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="nump">$ 485,806<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 1,125,360<span></span>
</td>
<td class="num">$ (639,556)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">(65,327)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(65,327)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock option exercises and other (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,207,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock option exercises and other</a></td>
<td class="nump">882<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">882<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">8,814<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,814<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">192,230,854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2023</a></td>
<td class="nump">$ 430,175<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">1,135,056<span></span>
</td>
<td class="num">(704,883)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2023</a></td>
<td class="nump">234,270,384<span></span>
</td>
<td class="nump">234,270,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2023</a></td>
<td class="nump">$ 463,436<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">1,431,056<span></span>
</td>
<td class="num">(967,622)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (91,373)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(91,373)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock option exercises and other (in shares)</a></td>
<td class="nump">1,303,878<span></span>
</td>
<td class="nump">2,317,083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock option exercises and other</a></td>
<td class="nump">$ 2,088<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,088<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">16,127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock sales issuances, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">921,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock sales issuances, net of issuance costs</a></td>
<td class="nump">$ 10,873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2024</a></td>
<td class="nump">237,508,682<span></span>
</td>
<td class="nump">237,508,682<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2024</a></td>
<td class="nump">$ 401,151<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 1,460,144<span></span>
</td>
<td class="num">$ (1,058,995)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140474163435040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (91,373)<span></span>
</td>
<td class="num">$ (65,327)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">7,377<span></span>
</td>
<td class="nump">3,728<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">16,127<span></span>
</td>
<td class="nump">8,814<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TangibleAssetImpairmentCharges', window );">Asset impairment</a></td>
<td class="nump">108<span></span>
</td>
<td class="nump">1,169<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Lease expense</a></td>
<td class="nump">2,472<span></span>
</td>
<td class="nump">1,988<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other, net</a></td>
<td class="num">(560)<span></span>
</td>
<td class="nump">716<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other receivables and assets</a></td>
<td class="num">(1,040)<span></span>
</td>
<td class="num">(317)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Unearned revenue</a></td>
<td class="num">(13,655)<span></span>
</td>
<td class="num">(12,134)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">1,168<span></span>
</td>
<td class="num">(339)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxrx_IncreaseDecreaseInAccruedDevelopmentExpense', window );">Accrued development expense</a></td>
<td class="num">(273)<span></span>
</td>
<td class="nump">676<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="num">(18,857)<span></span>
</td>
<td class="num">(9,846)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(3,794)<span></span>
</td>
<td class="num">(2,444)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(102,300)<span></span>
</td>
<td class="num">(73,316)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(6,653)<span></span>
</td>
<td class="num">(5,175)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Purchase of an intangible asset</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(165)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(6,653)<span></span>
</td>
<td class="num">(5,340)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common shares, net of issuance costs</a></td>
<td class="nump">10,873<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from equity incentive plans</a></td>
<td class="nump">3,050<span></span>
</td>
<td class="nump">1,946<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of long-term debt</a></td>
<td class="num">(26)<span></span>
</td>
<td class="num">(24)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">13,897<span></span>
</td>
<td class="nump">1,922<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash, cash equivalents and restricted cash</a></td>
<td class="num">(219)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash, cash equivalents and restricted cash</a></td>
<td class="num">(95,275)<span></span>
</td>
<td class="num">(76,734)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, beginning of period</a></td>
<td class="nump">401,425<span></span>
</td>
<td class="nump">559,112<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of period</a></td>
<td class="nump">306,150<span></span>
</td>
<td class="nump">482,378<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental schedule of non-cash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Accrued property and equipment</a></td>
<td class="nump">80<span></span>
</td>
<td class="nump">244<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use asset additions and modifications</a></td>
<td class="nump">3,266<span></span>
</td>
<td class="nump">3,520<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxrx_FinancedEquipmentPurchase', window );">Financed equipment purchase</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,214<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental schedule of cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePaymentsUse', window );">Cash paid for operating leases</a></td>
<td class="nump">$ 3,955<span></span>
</td>
<td class="nump">$ 2,444<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxrx_FinancedEquipmentPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financed Equipment Purchase</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxrx_FinancedEquipmentPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxrx_IncreaseDecreaseInAccruedDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Accrued Development Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxrx_IncreaseDecreaseInAccruedDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482312/912-310-45-11<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePaymentsUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePaymentsUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TangibleAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TangibleAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140474072971312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of the Business<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Description of the Business</a></td>
<td class="text">Description of the Business <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recursion Pharmaceuticals, Inc. (Recursion, the Company, we or our) was originally formed as a limited liability</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">company on November 4, 2013 under the name Recursion Pharmaceuticals, LLC. In September 2016, the Company converted to a Delaware corporation and changed its name to Recursion Pharmaceuticals, Inc.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recursion is a clinical stage TechBio company decoding biology to industrialize drug discovery. The Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe, one of the world&#8217;s largest proprietary biological and chemical datasets. The Company integrates physical and digital components as iterative loops of atoms and bits scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in silico </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hypotheses into validated insights and novel chemistry.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2024, the Company had an accumulated deficit of $1.1 billion. The Company expects to incur substantial operating losses in future periods and will require additional capital to advance its drug candidates. The Company does not expect to generate significant revenue until the Company successfully completes significant drug development milestones with its subsidiaries or in collaboration&#160;with third parties, which the Company expects will take a number of years. In order to commercialize its drug candidates, the Company or its partners need to complete clinical development and comply with comprehensive regulatory requirements. The Company is subject to a number of risks and uncertainties similar to those of other companies of the same size within the biotechnology industry, such as the uncertainty of clinical trial outcomes, uncertainty of additional funding and a history of operating losses. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has funded its operations to date primarily through the issuance of convertible preferred stock and the issuance of Class A common stock (see Note 8, &#8220;Common Stock&#8221; for additional details). Additionally, the Company has received payments from its strategic partnerships (see Note 9, &#8220;Collaborative Development Contracts&#8221; for additional details). Recursion will likely be required to raise additional capital. As of March&#160;31, 2024, the Company did not have any unconditional outstanding commitments for additional funding. If the Company is unable to access additional funds when needed, it may not be able to continue the development of its products or the Company could be required to delay, scale back or abandon some or all of its development programs and other operations. The Company&#8217;s ability to access capital when needed is not assured and, if not achieved on a timely basis, could materially harm its business, financial condition and results of operations. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recursion believes that the Company&#8217;s existing cash and cash equivalents will be sufficient to fund the Company&#8217;s operating expenses and capital expenditures for at least the next 12 months.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140474078413136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation</a></td>
<td class="text">Basis of Presentation<div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited interim condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (SEC). Accordingly, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) have been condensed or omitted. These unaudited interim condensed consolidated financial statements should be read in conjunction with the Company&#8217;s audited consolidated financial statements and notes for the year ended December&#160;31, 2023. </span></div><div><span><br/></span></div><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is management&#8217;s opinion that these condensed consolidated financial statements include all normal and recurring adjustments necessary for a fair presentation of the Company&#8217;s financial statements. Revenue and net loss for any interim period are not necessarily indicative of future or annual results.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2024, the SEC issued rule 33-11275, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Enhancement and Standardization of Climate-Related Disclosures for Investors</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The new rule requires Recursion to provide certain disclosures in the footnotes to the </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">financial statements of climate-related information. These disclosures include the impact of severe weather and other natural conditions on the Company&#8217;s consolidated balance sheet and statement of operations, to the extent they are material. Recursion will also need to disclose a rollforward of the beginning and ending balances of its carbon offsets and renewable energy credits or certificates (RECs), if they are a material component of meeting the Company&#8217;s climate-related targets and goals. Additionally, the Company will need to disclose whether and, if so, how severe weather events and other natural conditions and disclosed climate-related targets or transition plans materially affected estimates and assumptions in the financial statements. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The standard&#8217;s effective dates, if adopted, will be phased in depending on the disclosure requirement starting the annual period ending December&#160;31, 2025. In April 2024, the SEC voluntarily stayed implementation of the new climate-related disclosure requirements pending judicial review. The Company is currently evaluating the impact this rule will have on its consolidated financial statements and related disclosures.   </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2023-9, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The new standard updates disclosure requirements for Accounting Standards Codification (ASC) 740 primarily by requiring additional information in the income tax rate reconciliation and additional disclosures about income taxes paid. This standard will be effective for Recursion starting the annual period ending December 31, 2025. Early adoption is permitted for annual financial statements that have not yet been issued. The amendments can be applied on a prospective or retrospective basis. The adoption of this standard will not impact Recursion&#8217;s consolidated balance sheet and statement of operations.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU No. 2023-7, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The standard requires new disclosures related to ASC 280 including: disclosing significant segment expenses by category; requiring all the ASC 280 disclosures for Companies with a single reportable segment and; requiring an increased frequency of the ASC 280 disclosures. Recursion must apply the amendments retrospectively to each prior reporting period presented. This standard will be effective for Recursion starting the annual period ending December 31, 2024. Early adoption is permitted. The adoption of this standard will not impact Recursion&#8217;s consolidated balance sheet and statement of operations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140474078440768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Financial Information<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxrx_SupplementalFinancialInformationAbstract', window );"><strong>Supplemental Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxrx_SupplementalBalanceSheetAndIncomeStatementInformationTextBlock', window );">Supplemental Financial Information</a></td>
<td class="text">Supplemental Financial Information <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Tempus agreement</span></div><div><span><br/></span></div><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">November 2023</span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Recursion entered into a </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">five</span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-year agreement with Tempus Labs, Inc. (Tempus) to purchase access to their records of patient-centric multimodal oncology data and use rights for therapeutic development purposes. This data will be used to improve the training of Recursion&#8217;s artificial intelligence and machine learning models and is expected to accelerate Recursion&#8217;s drug discovery process. Recursion is making annual payments, ranging between </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$22.0&#160;million</span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$42.0&#160;million</span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, up to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$160.0&#160;million</span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in aggregate, to Tempus in cash or equity at the Company&#8217;s option. The equity value is determined by using the <span style="-sec-ix-hidden:f-250">seven</span>-trading day period dollar volume-weighted average price (VWAP) for Recursion Class A common stock ending on the day immediately preceding the date that is five business days prior to the payment date. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recursion is expensing the record purchases as &#8220;Research and Development&#8221; expenses in the Condensed Consolidated Statements of Operations as the records are purchased. To the extent that the Recursion payments to Tempus are greater than or less than the records purchased amount, Recursion records the applicable amount to &#8220;Other Current Assets&#8221; or &#8220;Accrued Expenses and Other Liabilities&#8221; on the Condensed Consolidated Balance Sheet, respectively. As of March&#160;31, 2024, Recursion had recorded $16.0&#160;million within &#8220;Other Current Assets&#8221; on the Consolidated Balance Sheet related to the Tempus agreement.     </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.660%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.521%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,247&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,096&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,289&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,929&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,356&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,126&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,677&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,231&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,569&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,382&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48,853)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44,872)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,716&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,510&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense on property and equipment was $4.0&#160;million and $3.6&#160;million during the three months ended March 31, 2024 and 2023, respectively</span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company recorded an insignificant impairment and an impairment of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.2&#160;million </span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">during the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended March 31, 2024 and 2023, respectively,</span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> related to construction projects for leasehold improvements as the Company no longer intended to use them. The impairment was recorded in &#8220;General and Administrative&#8221; in the Condensed Consolidated Statements of Operations.   </span></div><div><span><br/></span></div><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended March 31, 2023, the </span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company initiated and completed a project to upgrade the BioHive supercomputer for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.7&#160;million</span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The supercomputer was classified as office equipment in the above table.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses and Other Liabilities</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.660%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.521%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,055&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,888&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,804&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,077&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued early discovery expenses</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,610&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,570&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued construction</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,439&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Materials received not invoiced</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,432&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued other expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,417&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expense and other liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,070&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,635&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Notes Payable</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, the Company entered into a financing agreement for borrowing $1.9 million as part of the supercomputer upgrade project. The debt will be repaid over a three-year period at a 7% interest rate. As of March&#160;31, 2024, the outstanding balance was $616 thousand. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, the Company borrowed $992 thousand, which was available as part of a lease agreement for use on tenant improvements. The note will be repaid over a 10-year period at an 8% interest rate. As of March&#160;31, 2024, the outstanding balance was $510 thousand.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Income, net</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,048&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,660&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,028&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,641&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2024 and 2023, interest income primarily related to earnings on cash and cash equivalents in money market funds. Interest income was included in &#8220;Other income, net&#8221; on the Condensed Consolidated Statements of Operations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxrx_SupplementalBalanceSheetAndIncomeStatementInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supplemental Balance Sheet And Income Statement Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxrx_SupplementalBalanceSheetAndIncomeStatementInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxrx_SupplementalFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supplemental Financial Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxrx_SupplementalFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140474075938272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Acquisitions</a></td>
<td class="text">Acquisitions<div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Valence Discovery Inc.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;16, 2023, Recursion acquired all of the outstanding equity interests in Valence Discovery Inc. (Valence), a privately-held machine learning (ML) / artificial intelligence (AI) digital chemistry company. The integration of Valence&#8217;s AI-based chemistry engine into Recursion&#8217;s operating system will allow Recursion to expand its technology-enabled drug discovery process. This will accelerate Recursion&#8217;s digital chemistry capabilities and its drug discovery process.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition of Valence was accounted for as a business combination using the acquisition method of accounting. The aggregate upfront consideration for the acquisition of Valence consisted of 2.2 million shares of Recursion Class A common stock, 4.4 million shares of a subsidiary of Recursion, exchangeable for shares of Recursion&#8217;s Class A common stock, 792 thousand shares issuable upon exercise of stock options held by Valence equity award holders and deferred liabilities for additional consideration. An insignificant number of the aforementioned shares of consideration had not yet been issued as of March&#160;31, 2024.The final number of shares to be issued has not yet been finalized and so are subject to change. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes total consideration:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"><tr><td style="width:1.0%"></td><td style="width:78.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.229%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of Recursion Class A common stock </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,096&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of Exchangeable stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,473&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of equity awards issued to Valance equity award holders</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,933&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred liabilities for additional consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total consideration</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,898&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value of assets acquired and liabilities assumed as of the acquisition date:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"><tr><td style="width:1.0%"></td><td style="width:78.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.229%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,235&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">536&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible asset - technology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(872)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,265)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,634&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,264&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired and liabilities assumed</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,898&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intangible asset related to Valence&#8217;s ML and AI digital chemistry platform. The estimated fair value of the intangible asset was determined using a cost approach. This valuation technique provides the fair value of an asset based on estimates of the total costs to develop the technology. Significant inputs used to determine the total cost includes the length of time required and service hours performed by Company employees. The technology intangible asset is being amortized on a straight-line basis over its four-year useful life.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill was calculated as the excess of the consideration transferred over the net assets recognized. The goodwill recognized represents the assembled workforce and expected synergies, including the ability to: (i) leverage Valence&#8217;s digital chemistry platform across Recursion&#8217;s business; (ii) leverage Valence&#8217;s ML and AI capabilities; (iii) integrate Recursion&#8217;s data and operating system into Valence&#8217;s platform; and (iv) accelerate Recursion&#8217;s pipeline. Goodwill was also impacted by the establishment of a deferred tax liability for the acquired identifiable intangible assets which have no tax basis. The goodwill is not deductible for tax purposes.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recursion&#8217;s condensed consolidated statement of operations during the three months ended March 31, 2024 included no net revenue and a $2.9&#160;million operating loss associated with Valence&#8217;s operations. As the acquisition occurred in May 2023, the Company is still finalizing the allocation of the purchase price to the individual assets acquired and liabilities assumed. The allocation of the purchase price included in the current period balance sheet is based on the best estimate of management and is preliminary and subject to change. The primary area subject to change relates to the valuation of other receivables. To assist management in the allocation, the Company engaged external specialists. The Company will finalize the amounts recognized as the information necessary to complete the analysis is obtained. The Company expects to finalize these amounts as soon as possible but no later than one year from the acquisition date.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cyclica Inc</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;25, 2023, Recursion acquired all of the outstanding equity interests in Cyclica Inc. (Cyclica), a privately-held Company that has built a digital chemistry software suite which enables mechanism of action deconvolution and generative chemistry suggestions based on desired targets. Cyclica&#8217;s platform is expected to enhance the optimization of Recursion&#8217;s compounds for efficacy while minimizing liabilities through generative machine learning approaches. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition of Cyclica was accounted for as a business combination using the acquisition method of accounting. The aggregate upfront consideration for the acquisition of Cyclica consisted of 5.8 million shares of Recursion Class A common stock, cash payments, 1.0 million shares issuable upon exercise of stock options held by Cyclica equity award holders and deferred liabilities for additional consideration. Approximately 182 thousand of the aforementioned shares of Class A common stock consideration had not yet been issued as of March&#160;31, 2024. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes total consideration:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"><tr><td style="width:1.0%"></td><td style="width:78.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.229%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of Recursion Class A common stock </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,915&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,505&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of equity awards issued to Cyclica equity award holders</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,852&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred liabilities for additional consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total consideration</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,617&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value of assets acquired and liabilities assumed as of the acquisition date:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"><tr><td style="width:1.0%"></td><td style="width:78.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.229%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,429&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,685&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">741&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets - technology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(579)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unearned revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,754)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,075)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities, current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(139)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,627&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,990&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired and liabilities assumed</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,617&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intangible assets are related to Cyclica&#8217;s digital chemistry platforms. The estimated fair value of the intangible assets were determined using a cost approach. This valuation technique provides the fair value of an asset based on estimates of the total costs to develop the technology. Significant inputs used to determine the total cost includes the length of time required and service hours performed by Company employees. The technology intangible assets are being amortized on a straight-line basis over their three-year useful lives.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill was calculated as the excess of the consideration transferred over the net assets recognized. The goodwill recognized represents the assembled workforce and expected synergies, including the ability to: (i) leverage Cyclica&#8217;s digital chemistry platform across Recursion&#8217;s business; (ii) leverage Cyclica&#8217;s ML and AI capabilities; (iii) integrate Recursion&#8217;s data and operating system into Cyclica&#8217;s platform; and (iv) accelerate Recursion&#8217;s pipeline. Goodwill was also impacted by the establishment of a deferred tax liability for the acquired identifiable intangible assets. The goodwill is not deductible for tax purposes.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recursion&#8217;s condensed consolidated statement of operations during the three months ended March 31, 2024 included immaterial net revenue and a $3.8 million operating loss associated with Cyclica&#8217;s operations. As the acquisition occurred in May 2023, the Company is still finalizing the allocation of the purchase price to the individual assets acquired and liabilities assumed. The allocation of the purchase price included in the current period balance sheet is based on the best estimate of management and is preliminary and subject to change. The primary area subject to change relates to the valuation of the other receivables. To assist management in the allocation, the Company engaged external specialists. The Company will finalize the amounts recognized as the information necessary to complete the analysis is obtained. The Company expects to finalize these amounts as soon as possible but no later than one year from the acquisition date.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pro forma financial information  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the unaudited pro forma combined results of operations of Recursion, Valence and Cyclica as if the acquisitions had occurred on January&#160;1, 2022:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.123%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended March 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenue</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,155&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73,514)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited pro forma financial information was prepared using the acquisition method of accounting and was based on the historical financial information of Recursion, Valence and Cyclica. In order to reflect the occurrence of the acquisitions on January&#160;1, 2022 as required, the unaudited pro forma financial information includes adjustments to reflect the incremental amortization expense to be incurred based on the fair values of the identifiable intangible assets acquired and the additional stock compensation expense associated with the issuance of equity compensation related to the acquisitions. The unaudited pro forma financial information is not necessarily indicative of what the consolidated results of operations would have been had the acquisitions been completed on January&#160;1, 2022. In addition, the unaudited pro forma financial information is not a projection of the future results of operations of the combined company nor does it reflect the expected realization of any cost savings or synergies associated with the acquisitions.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//805/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140474078440768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into various long-term real estate leases primarily related to office, research and development and operating activities. The Company&#8217;s leases have remaining terms from under 1 to 9 years and some of those leases include options that provide Recursion with the ability to extend the lease term for five years. The options are included in the lease term when it is reasonably certain that the option will be exercised. </span></div><div><span><br/></span></div><div style="margin-bottom:3pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:130%">For the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:130%">three months ended March 31, 2024 and 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:130%">, Recursion entered into lease modifications resulting in a decrease to the right-of-use asset and lease liability of $3.1 million and an increase to the right-of-use asset and lease liability $3.5 million</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:130%">, respectively</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:130%">. The modifications had no impact to the Condensed Consolidated Statements of Operations. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In </span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">January 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company entered into a lease agreement for office space in London, England with approximately </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,792 </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">square feet (the &#8220;London Lease&#8221;). The right of use began </span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">January 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> when the control of the asset was obtained. The London Lease term is </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5 years</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with a five-year renewal option. The London Lease includes provisions for escalating rent payments. Total fixed payments are expected to be approximately $7.9 million, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">additionally there will be variable expenses including building service charges related to the lease.</span></div><div><span><br/></span></div><div style="margin-bottom:3pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:130%">In </span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:130%">February 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:130%">, the Company entered into a lease agreement for the supercomputer for the exclusive use of physical space in a data center of approximately </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:130%">1,851 square feet (</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:130%">the &#8220;Data Center Lease&#8221;). The right of use is expected to begin in the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:130%">second quarter of 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:130%"> and the Data Center Lease term is </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:130%">5 years</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:130%"> with a five-year renewal option. The lease includes provisions for escalating rent payments. Total fixed lease payments are expected to be approximately $13.0 million with additional variable expenses, including utilities and tax expenses. The Company did not control the space or any of the assets being constructed as of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:130%">March&#160;31, 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:130%"> and therefore no right of use asset or lease liability was recorded on the Condensed Consolidated Balance Sheet as of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:130%">March&#160;31, 2024.</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:130%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the lease cost were:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.544%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,472&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,998&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">538&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">657&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease cost</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease cost</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,050&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,655&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The remaining lease term and discount rate were:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.222%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of operating lease liabilities as of March&#160;31, 2024 were:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.392%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating leases</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,300&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,748&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,882&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,281&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,850&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,948&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,009&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,161)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,848&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140474174373952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text">Goodwill and Intangible Assets <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes to the carrying amount of goodwill during the three months ended March 31, 2024 and 2023. No goodwill impairment was recorded during the three months ended March 31, 2024 and 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets, Net</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes intangible assets:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross carrying amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net carrying amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross carrying amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net carrying amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Definite-lived intangible assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,426&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,336)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,090&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,426&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,969)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,457&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite-lived intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">986&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">986&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">986&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">986&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,412&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,336)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,076&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,412&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,969)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,443&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>Amortization expense was $3.4 million and $152 thousand during the three months ended March 31, 2024 and 2023, respectively. The increase in amortization expense was due to the intangible assets purchased in the acquisitions, (see Note 4, &#8220;Acquisitions&#8221; for additional details). Amortization expense was included in Research and Development in the Condensed Consolidated Statements of Operations. No indefinite-lived intangible asset impairment charges were recorded during the three months ended March 31, 2024 and 2023.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//350/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140474077819808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contract Obligations</span></div><div><span><br/></span></div><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company enters into contracts with clinical research organizations, drug manufacturers and other vendors&#160;for preclinical and clinical research studies, research and development supplies and other services and products for operating purposes. These contracts generally provide for termination on notice and are cancellable contracts.</span></div><div><span><br/></span></div><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnification </span></div><div><span><br/></span></div><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has agreed to indemnify its officers and directors for certain events or occurrences, while the officer or director is or was serving at the Company&#8217;s request in such capacity. The Company purchases directors and officers liability insurance coverage that provides for reimbursement to the Company for covered obligations and this is intended to limit the Company&#8217;s exposure and enable it to recover a portion of any amounts it pays under its </span></div><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">indemnification obligations. The Company had no liabilities recorded for these agreements as of March&#160;31, 2024 and December&#160;31, 2023, as no amounts were probable. </span></div><div><span><br/></span></div><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Agreements </span></div><div><span><br/></span></div><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has signed employment agreements with certain key employees pursuant to which, if their employment is terminated following a change of control of the Company, the employees are entitled to receive certain benefits, including accelerated vesting of equity incentives. </span></div><div><span><br/></span></div><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Matters </span></div><div><span><br/></span></div><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may, from time to time, be involved in various legal proceedings arising in the normal course of business. An unfavorable resolution of any such matter could materially affect the Company&#8217;s future financial position, results of operations or cash flows. </span></div><div><span><br/></span></div><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, the Company entered into a lease agreement for laboratory and office space (the Industry Lease) with Industry Office SLC, LLC (the landlord). In March 2023, the Company sent a letter to the landlord detailing numerous construction delays and irregularities, deficiencies and deviations from applicable structural drawings and/or non-conforming conditions with applicable building codes. On June&#160;23, 2023, the landlord filed a lawsuit against the Company (</span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Industry Office SLC, LLC v. Recursion Pharmaceuticals, Inc.</span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 230904627) in the Third District Court for Salt Lake County, State of Utah (the Court), alleging anticipatory repudiation and breach of contract. The Plaintiff seeks monetary damages and attorney&#8217;s fees. In July 2023, the Company filed a motion to dismiss. In September 2023, Recursion was granted its motion to dismiss, and the Court provided the landlord until October&#160;23, 2023, to amend and re-file the dismissed complaint. On October&#160;23, 2023, the landlord filed an amended complaint again alleging anticipatory repudiation, breach of contract and breach of the implied covenant of good faith and fair dealing (the Amended Complaint) and seeks monetary damages and attorney&#8217;s fees. In November 2023, the Company filed a motion to dismiss the Amended Complaint. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Court set a hearing on the Company&#8217;s motion to dismiss in </span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">May 2024. As of</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2024, the Company had no liability recorded for these events as an unfavorable outcome was not probable.</span></div><div><span><br/></span></div><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Industry Lease, in September 2023, the Company filed claims in the Court against the landlord alleging, among other things, breach of contract and fraudulent misrepresentation (the Counterclaims). In October 2023, the landlord filed an answer and denied the Company&#8217;s allegations asserted in the Counterclaims. The Company and the landlord are currently engaged in discovery. On October&#160;27, 2023, the Company filed a motion for partial judgment on the pleadings, seeking judgment on one of its four counterclaims. The Court set a hearing on the Company&#8217;s motion for partial judgment on the pleadings in May 2024. The Company is unable to estimate the possible amount or range of amounts associated with the Counterclaims.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140474163678304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Common Stock</a></td>
<td class="text">Common Stock <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each share of Class A common stock entitles the holder to one vote per share and each share of Class B common stock entitles the holder to 10 votes per share on all matters submitted to a vote of the Company&#8217;s stockholders. Common stockholders are entitled to receive dividends, as may be declared by the Company&#8217;s Board of Directors. As of March&#160;31, 2024 and December&#160;31, 2023, no dividends had been declared. </span></div><div><span><br/></span></div><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">At-The-Market Offering</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In </span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">August 2023</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company entered into an Open Market Sales Agreement (the &#8220;Sales Agreement&#8221;) with Jefferies LLC (the &#8220;Sales Agent&#8221;), to provide for the offering, issuance and sale of up to an aggregate amount of </span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$300.0 million</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of its Class A common stock from time to time in &#8220;at-the-market&#8221; (ATM) offerings. As of&#160;March&#160;31, 2024, an amount of </span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$208.2 million</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> remained available for future sales under the Sales Agreement. For the three months ended March 31, 2024, the Company has sold </span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">921&#160;thousand</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shares and received net proceeds of </span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$10.9 million</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> under the agreement. Recursion is not required to sell additional shares under the Sales Agreement. The Company will pay the Sales Agent a commission of up to 3% of the aggregate gross proceeds received from all sales of Class A common stock. The Sales Agreement continues until the earlier of selling all shares available under the Sales Agreement or terminated by written notice from either of the parties. The ATM Offering is being made under a prospectus supplement dated August&#160;8, 2023, and related prospectus filed with the Securities and Exchange </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commission pursuant to our automatically effective shelf registration statement on Form S-3ASR (Registration No. 333-264845). </span></div><div><span><br/></span></div><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NVIDIA Private Placement</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In </span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">July 2023</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Recursion entered into a Stock Purchase Agreement for a private placement with NVIDIA Corporation (2023 Private Placement), pursuant to which the Company sold an aggregate of 7.7 million shares of the Company&#8217;s Class A common stock at a price of $6.49 per share for net proceeds of approximately </span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$49.9 million. </span></div><div><span><br/></span></div><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Valence Acquisition Exchangeable Shares</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In </span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">May 2023</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in connection with the acquisition of Valence, the Company entered into an agreement to issue up to 5.9 million shares of Class A common stock (the &#8220;Exchange Shares&#8221;), that may be issued upon exchange, retraction or redemption of exchangeable shares of a subsidiary of Recursion. Each exchangeable share of the subsidiary of Recursion entitles the holder to exchange those shares on a one-for-one basis for Recursion&#8217;s Class A common stock. The shares are entitled to receive dividends economically equivalent to dividends declared by Recursion, are non-voting and are subject to customary adjustments for stock splits or other reorganizations. In addition, the Company may require all outstanding exchangeable shares to be exchanged into an equal number of Class A common stock upon the occurrence of certain events and at any time following the seventh anniversary of the closing of the Valence acquisition. The exchangeable shares are substantially the economic equivalent of the Class A shares and classified as common stock within the Company&#8217;s stockholders&#8217; equity. The Company&#8217;s calculation of weighted-average shares outstanding includes the exchangeable shares. As of March&#160;31, 2024, 4.2&#160;million Exchangeable shares have been redeemed for Class A shares.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Registration Rights Agreements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Tempus agreement</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In </span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">November 2023</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in connection with the Tempus Agreement, the Company agreed to prepare and file a registration statement (or a prospectus supplement to an effective registration statement on Form S-3ASR that will become automatically effective upon filing with the SEC pursuant to Rule 462(e)) with the SEC, for resale of the shares of Class A common stock issued or issuable under the Tempus Agreement. A prospectus supplement to a registration statement (File No. 333-264845) was subsequently filed in </span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 2023</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to register shares issued to Tempus for the initial license fee under the Tempus Agreement for resale. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">After registration of any shares issued to Tempus under the Tempus Agreement, the Company has agreed to use commercially reasonable efforts to keep such registration statement effective until such date that all shares issued to Tempus covered by such registration statement have been sold or are able to be publicly sold by relying on Rule 144 of the Securities Act without registration.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">NVIDIA Private Placement</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In </span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">July 2023</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in connection with the 2023 Private Placement with NVIDIA, the Company entered into a Registration Rights Agreement providing for the registration for resale of the shares of Class A common stock issued in such transaction. A prospectus supplement to a registration statement (File No. 333-264845) was subsequently filed in </span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">August 2023</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to register the resale of the shares of Class A common stock issued to NVIDIA. The Company has agreed to use commercially reasonable efforts to keep the registration statement continuously effective until such date that all registrable securities under the agreement have been sold. In the event the holders cannot sell their shares due to certain circumstances causing the registration statement to be ineffective, the Company must pay each holder of shares outstanding on the date and each month thereafter 1% of the aggregate purchase price with the maximum payable amount of 5% of the aggregate purchase price. As of March&#160;31, 2024, there was no accrued liability related to this agreement, as it was not probable that a payment would be required.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Acquisitions</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In </span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">May 2023</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in connection with the acquisition of Valence, the Company entered into a Registration Agreement providing for the registration for resale of the shares of Class A common stock and Exchange Shares issued or issuable in such transaction. A registration statement on Form S-3ASR (File No. 333-272281) was filed to register </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the shares for resale by the holders. The registration statement must remain effective for a period of not less than three years. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In </span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">May 2023</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in connection with the acquisition of Cyclica, the Company entered into a Registration Agreement providing for the registration for resale of the shares of Class A common stock issued in such transaction. A prospectus supplement to a registration statement (File No. 333-264845) was subsequently filed in </span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 2023</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to register the shares for resale by the holders. The registration statement must be continuously effective until the earlier of the date that all shares have been sold thereunder or are able to be publicly sold by relying on Rule 144 of the Securities Act without registration. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">2022 Private Placement</span></div><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, i</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n connection with the 2022 Private Placement, the Company entered into a Registration Rights Agreement providing for the registration for resale of the shares of Class A common stock issued in such transaction. A prospectus supplement to a registration statement (File No. 333-264845) was subsequently filed in </span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">October 2022</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to register the resale of the shares of Class A common stock by the Purchasers. The agreement must remain effective until registrable securities covered by the agreement have been publicly sold by the holders or all shares cease to be registrable securities. In the event the holders cannot sell their shares due to certain circumstances causing the agreement to be ineffective, the Company must pay each holder of shares outstanding on the date and each month thereafter 1% of the aggregate purchase price paid by the holder without limit until the agreement is cured. As of March&#160;31, 2024, there was no accrued liability related to this agreement, as it was not probable that a payment would be required.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Class A and B Common Shares Authorization</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In </span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">April 2021</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company&#8217;s Board of Directors authorized two classes of common stock, Class A and Class B. The rights of the holders of Class A and B common stock are identical, except with respect to voting and conversion. Each share of Class A common stock is entitled to one vote per share. Each share of Class B common stock is entitled to 10 votes per share and is convertible at any time into one share of Class A common stock.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All Class B common stock is held by Christopher Gibson, Ph.D., the Company&#8217;s Chief Executive Officer (CEO), or his affiliates. As of March&#160;31, 2024, Dr. Gibson and his affiliates held outstanding shares of Class B common stock representing approximately 25% of the voting power of the Company&#8217;s outstanding shares. This voting power may increase over time as Dr. Gibson vests in and exercises equity awards outstanding. If all the exchangeable equity awards held by Dr. Gibson had been fully vested, exercised and exchanged for shares of Class B common stock as of March&#160;31, 2024, Dr. Gibson and his affiliates would hold approximately 26% of the voting power of the Company&#8217;s outstanding shares. As a result, Dr. Gibson will be able to significantly influence any action requiring the approval of Recursion stockholders, including the election of the Board of Directors; the adoption of amendments to the Company&#8217;s certificate of incorporation and bylaws; and the approval of any merger, consolidation, sale of all or substantially all of the Company&#8217;s assets, or other major corporate transaction.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140474077076848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Development Contracts<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborative Development Contracts</a></td>
<td class="text">Collaborative Development Contracts <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Roche and Genentech</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Description</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, Recursion entered into a collaboration and license agreement with Roche and Genentech (collectively referred to as Roche). Recursion is constructing, using the Company&#8217;s imaging technology and proprietary machine-learning algorithms, unique maps of the inferred relationships amongst perturbation phenotypes in a given cellular context with the goal to discover and develop therapeutic small molecule programs in a gastrointestinal cancer indication and in key areas of neuroscience. Roche and Recursion will collaborate to select certain novel inferences with respect to small molecules or targets generated from the Phenomaps for further validation and optimization as collaboration programs. Roche and Recursion may also combine sequencing datasets from Roche with Recursion&#8217;s Phenomaps and collaborate to generate new algorithms to produce multi-modal maps from which additional collaboration programs may be initiated. For every collaboration program that successfully identifies potential therapeutic small molecules or validates a target, Roche will have an option to obtain an exclusive license to develop and commercialize such potential therapeutic small molecules or to exploit such target in the applicable exclusive field.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Pricing</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, Recursion received a $150.0 million non-refundable upfront payment from the Company&#8217;s collaboration with Roche. Recursion is eligible for additional milestone payments based on performance progress of the collaboration. Each of the Phenomaps requested by Roche and created by Recursion may be subject to either an initiation fee, acceptance fee or both. Such fees could exceed $250.0 million for 16 accepted Phenomaps. In addition, for a period of time after Roche&#8217;s acceptance of certain Phenomaps, Roche will have the option to obtain, subject to payment of an exercise fee, rights to use outside the collaboration the raw images generated in the course of creating those Phenomaps. If Roche exercises its external use option for all 12 eligible Phenomaps, Roche&#8217;s associated exercise fee payments to Recursion could exceed $250.0 million. Under the collaboration, Roche may initiate up to 40 programs, each of which, if successfully developed and commercialized, could yield more than $300.0&#160;million in development, commercialization and net revenue milestones for Recursion, as well as tiered royalties on net revenue.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Accounting</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This agreement represents a transaction with a customer and therefore is accounted for in accordance with ASC 606. Recursion has determined that it has three performance obligations, one related to gastrointestinal cancer and two in neuroscience. These performance obligations are for performing research and development services for Roche to identify targets and medicines. The performance obligations also include potential licenses related to the intellectual property. The Company concluded that licenses within the contract are not distinct from the research and development services as they are interrelated due to the fact that the research and development services significantly impact the potential licenses. Any additional services are considered customer options and will be considered as separate contracts for accounting purposes.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has determined the transaction price to be $150.0 million, comprised of the upfront payment. Recursion will fully constrain the amounts of variable consideration to be received from potential milestones considering the stage of development and the risks associated with the remaining development required to achieve each milestone. Recursion will re-evaluate the transaction price each reporting period. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction price was allocated to the performance obligations based on the estimated relative stand-alone selling price of each performance obligation as determined using an expected cost plus margin approach. The Company recognizes revenue over time based on costs incurred relative to total expected costs to perform the research and development services. Recursion determined that this method provides a faithful depiction of the transfer of control to the customer. This method of recognizing revenue requires the Company to make estimates of total costs to provide the services required under the performance obligations. Significant inputs used to determine the total costs included the length of time required, service hours performed by Company employees and materials costs. A significant change in these estimates could have a material effect on the timing and amount of revenue recognized in future periods. Recursion has estimated the completion of the performance obligations by 2026.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Additional Revenue Disclosures</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of the revenue recognized during the three months ended March 31, 2024 and 2023, primarily all of it was included in the unearned revenue balance as of December&#160;31, 2023 and 2022, respectively. Revenue recognized was from upfront payments received at the inception of the related contracts, which decreased the initial unearned revenue recognized. As of March&#160;31, 2024, the Company had $6.5 million of costs incurred to fulfill a contract on its Condensed Consolidated Balance Sheet within &#8220;Other Current Assets.&#8221;</span></div>Unearned revenue was classified as short-term and long-term on the Condensed Consolidated Balance Sheets based on the Company&#8217;s estimate of revenue that will be recognized during the next twelve months.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140474077017520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, the Board of Directors and the stockholders of the Company adopted the 2021 Equity Incentive Plan (the 2021 Plan). The Company may grant stock options, restricted stock units (RSUs), stock appreciation rights, restricted stock awards and other forms of stock-based compensation. As of March&#160;31, 2024, 18.9 million shares of Class A common stock were available for grant.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the classification of stock-based compensation expense for employees and non-employees within the Condensed Consolidated Statements of Operations: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.490%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.106%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">766&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,011&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,666&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,683&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,077&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,578&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,509&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,272&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options are primarily granted to executive leaders at the Company, generally vest over four years and expire no later than 10 years from the date of grant. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity during the three months ended March 31, 2024 was as follows: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;(in thousands except share and per share amounts)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Exercise</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Price </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining&#160;Contractual Life (in years) </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value </span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,957,617&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.13&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,416&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,558,102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.09&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(178,609)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,303,878)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,575&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of March 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,033,232&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.99&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,131&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of March 31, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,909,647&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.49&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,959&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of options granted to employees is calculated on the grant date using the Black-Scholes option valuation model. The weighted-average grant-date fair values of stock options granted during the three months ended March 31, 2024 and 2023 were $6.41 and $5.32, respectively. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following weighted-average assumptions were used to calculate the grant-date fair value of stock options: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.052%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;text-indent:62.99pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;text-indent:62.99pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:67.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:67.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2024, $43.9 million of unrecognized compensation cost related to stock options is expected to be recognized as expense over approximately the next three years. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">RSUs</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity awards granted to employees primarily consist of RSUs and generally vest over four years. The weighted-average grant-date fair value of RSUs generally is determined based on the number of units granted and the quoted price of Recursion&#8217;s common stock on the date of grant.  </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes Recursion&#8217;s RSU activity during the three months ended March 31, 2024: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.133%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock units</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-average grant date fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,223,764&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.39&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,840,877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,023,464)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(409,634)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of March 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,631,543&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.63&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair market value of RSUs vested was $13.0 million during the three months ended March 31, 2024. As of March&#160;31, 2024, $124.8 million of unrecognized compensation cost related to RSUs is expected to be recognized as expense over approximately the next three years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140474077076848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not record any U.S. income tax expense during the three months ended March 31, 2024 and 2023. The Company has historically incurred operating losses and maintains a full valuation allowance against its U.S. net deferred tax assets. Foreign taxes were insignificant during the three months ended March 31, 2024 and 2023. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net operating losses (NOLs) and tax credit carry-forwards are subject to review and possible adjustment by the Internal Revenue Service (&#8220;IRS&#8221;) and may become subject to annual limitation due to ownership changes that occur under Section 382 of the Internal Revenue Code, as amended and similar state provisions. These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income. In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain shareholders or public groups in the stock of a corporation by more than 50% over a three-year period. As of March&#160;31, 2024, the Company was not limited on its NOLs and tax credit carry-forwards. The Company will continue to monitor future ownership changes for potential Section 382 limitations.  </span></div>The Company files income tax returns in the United States, Canada, United Kingdom, Utah, California and Massachusetts. The Company is not currently under examination in any of these jurisdictions. The Company is subject to income tax examinations on all federal returns since the 2017 tax return.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140474078163760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">Net Loss Per Share <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2024 and 2023, Recursion calculated net loss per share of Class A, Class B and Exchangeable common stock using the two-class method. Basic net loss per share is computed using the weighted-average number of shares outstanding during the period. Diluted net loss per share is computed using the weighted-average number of shares and the effect of potentially dilutive securities outstanding during the period. Potentially dilutive securities consist of stock options and other contingently issuable shares. For periods presented in which the Company reports a net loss, all potentially dilutive shares are anti-dilutive and as such are excluded from the calculation. </span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended March 31, 2024 and 2023</span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company reported a net loss and therefore basic and diluted loss per share were the same.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rights, including the liquidation and dividend rights, of the holders of the Company&#8217;s Class A, Class B and the Exchangeable common stock are identical, except with respect to voting. As a result, the undistributed earnings for each period are allocated based on the contractual participation rights of the Class A, Class B and the Exchangeable common stock as if the earnings for the period had been distributed. As the liquidation and dividend rights are identical, the undistributed earnings are allocated on a proportionate basis and the resulting amount per share for Class A, Class B and the Exchangeable common stock was the same during the three months ended March 31, 2024 and 2023.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth the computation of basic and diluted net loss per share of Class A, Class B and Exchangeable common stock:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:68.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.126%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.128%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91,373)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65,327)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236,019,349&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,618,238&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.39)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.34)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company excluded the following potential common shares from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.783%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.958%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.959%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Stock based compensation</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,159,250&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,534,876&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Tempus agreement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,143,690&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,302,940&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,534,876&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140474075994096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value hierarchy consists of the following three levels:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 &#8212; Valuations based on unadjusted quoted prices in active markets for identical assets that the company has the ability to access;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 &#8212; Valuations based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuations in which all significant inputs are observable in the market; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 &#8212; Valuations using significant inputs that are unobservable in the market and include the use of judgment by the company's management about the assumptions market participants would use in pricing the asset or liability.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to maintain a cash balance in a collateralized account to secure the Company&#8217;s credit cards. Additionally, the Company holds restricted cash related to an outstanding letter of credit issued by J.P. Morgan, which was obtained to secure certain Company obligations relating to tenant improvements. Recursion also holds restricted cash related to a Bill and Melinda Gates Foundation grant. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.098%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.297%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.452%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Basis of fair value measurement</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276,697&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276,697&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,824&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,824&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286,521&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286,521&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.098%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.297%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.452%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Basis of fair value measurement</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322,653&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322,653&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,860&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,860&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332,513&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332,513&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the financial instruments that are recognized at fair value on the Condensed Consolidated Balance Sheet, the Company has certain financial instruments that are recognized at amortized cost or some basis other than fair value. The carrying amount of these instruments are considered to be representative of their approximate fair values. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the Company&#8217;s financial instruments that are not measured at fair value: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.531%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.448%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Book values</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair values</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of notes payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes payable, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,126&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,126&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140474072932976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (91,373)<span></span>
</td>
<td class="num">$ (65,327)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140474162845552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2024 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=rxrx_TerryAnnBurrellMember', window );">Terry-Ann Burrell [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 1, 2024, Terry-Ann Burrell, a member of our Board of Directors, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 211,290 shares of the Company&#8217;s Class A common stock until May&#160;30, 2025.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Terry-Ann Burrell<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">member of our Board of Directors<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">March 1, 2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">455 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">211,290<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=rxrx_TinaMarriottMember', window );">Tina Marriott [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 1, 2024, Tina Marriott, President and Chief Operating Officer, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 672,000 shares of the Company&#8217;s Class A common stock until June&#160;27, 2025.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Tina Marriott<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">President and Chief Operating Officer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">March 1, 2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">483 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">672,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=rxrx_MichaelSecoraMember', window );">Michael Secora [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 1, 2024, Michael Secora, Chief Financial Officer, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 1,259,955 shares of the Company&#8217;s Class A common stock until June&#160;10, 2025.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Michael Secora<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Chief Financial Officer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">March 1, 2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">466 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">1,259,955<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MtrlTermsOfTrdArrTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MtrlTermsOfTrdArrTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrDuration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrDuration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrSecuritiesAggAvailAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrSecuritiesAggAvailAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=rxrx_TerryAnnBurrellMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=rxrx_TerryAnnBurrellMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=rxrx_TinaMarriottMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=rxrx_TinaMarriottMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=rxrx_MichaelSecoraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=rxrx_MichaelSecoraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140474077535680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited interim condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (SEC). Accordingly, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) have been condensed or omitted. These unaudited interim condensed consolidated financial statements should be read in conjunction with the Company&#8217;s audited consolidated financial statements and notes for the year ended December&#160;31, 2023. </span></div><div><span><br/></span></div><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is management&#8217;s opinion that these condensed consolidated financial statements include all normal and recurring adjustments necessary for a fair presentation of the Company&#8217;s financial statements. Revenue and net loss for any interim period are not necessarily indicative of future or annual results.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2024, the SEC issued rule 33-11275, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Enhancement and Standardization of Climate-Related Disclosures for Investors</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The new rule requires Recursion to provide certain disclosures in the footnotes to the </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">financial statements of climate-related information. These disclosures include the impact of severe weather and other natural conditions on the Company&#8217;s consolidated balance sheet and statement of operations, to the extent they are material. Recursion will also need to disclose a rollforward of the beginning and ending balances of its carbon offsets and renewable energy credits or certificates (RECs), if they are a material component of meeting the Company&#8217;s climate-related targets and goals. Additionally, the Company will need to disclose whether and, if so, how severe weather events and other natural conditions and disclosed climate-related targets or transition plans materially affected estimates and assumptions in the financial statements. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The standard&#8217;s effective dates, if adopted, will be phased in depending on the disclosure requirement starting the annual period ending December&#160;31, 2025. In April 2024, the SEC voluntarily stayed implementation of the new climate-related disclosure requirements pending judicial review. The Company is currently evaluating the impact this rule will have on its consolidated financial statements and related disclosures.   </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2023-9, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The new standard updates disclosure requirements for Accounting Standards Codification (ASC) 740 primarily by requiring additional information in the income tax rate reconciliation and additional disclosures about income taxes paid. This standard will be effective for Recursion starting the annual period ending December 31, 2025. Early adoption is permitted for annual financial statements that have not yet been issued. The amendments can be applied on a prospective or retrospective basis. The adoption of this standard will not impact Recursion&#8217;s consolidated balance sheet and statement of operations.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU No. 2023-7, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The standard requires new disclosures related to ASC 280 including: disclosing significant segment expenses by category; requiring all the ASC 280 disclosures for Companies with a single reportable segment and; requiring an increased frequency of the ASC 280 disclosures. Recursion must apply the amendments retrospectively to each prior reporting period presented. This standard will be effective for Recursion starting the annual period ending December 31, 2024. Early adoption is permitted. The adoption of this standard will not impact Recursion&#8217;s consolidated balance sheet and statement of operations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140474077860416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Financial Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxrx_SupplementalFinancialInformationAbstract', window );"><strong>Supplemental Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.660%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.521%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,247&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,096&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,289&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,929&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,356&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,126&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,677&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,231&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,569&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,382&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48,853)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44,872)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,716&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,510&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses and Other Liabilities</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses and Other Liabilities</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.660%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.521%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,055&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,888&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,804&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,077&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued early discovery expenses</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,610&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,570&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued construction</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,439&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Materials received not invoiced</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,432&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued other expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,417&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expense and other liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,070&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,635&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock', window );">Schedule of Interest Income and Expense Disclosure</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Income, net</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,048&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,660&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,028&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,641&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxrx_SupplementalFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supplemental Financial Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxrx_SupplementalFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140474078537056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock', window );">Schedule of Business Acquisitions, by Acquisition</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes total consideration:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"><tr><td style="width:1.0%"></td><td style="width:78.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.229%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of Recursion Class A common stock </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,096&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of Exchangeable stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,473&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of equity awards issued to Valance equity award holders</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,933&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred liabilities for additional consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total consideration</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,898&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes total consideration:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"><tr><td style="width:1.0%"></td><td style="width:78.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.229%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of Recursion Class A common stock </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,915&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,505&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of equity awards issued to Cyclica equity award holders</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,852&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred liabilities for additional consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total consideration</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,617&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Fair Value of Assets Acquired and Liabilities Assumed</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value of assets acquired and liabilities assumed as of the acquisition date:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"><tr><td style="width:1.0%"></td><td style="width:78.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.229%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,235&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">536&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible asset - technology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(872)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,265)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,634&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,264&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired and liabilities assumed</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,898&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value of assets acquired and liabilities assumed as of the acquisition date:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"><tr><td style="width:1.0%"></td><td style="width:78.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.229%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,429&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,685&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">741&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets - technology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(579)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unearned revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,754)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,075)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities, current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(139)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,627&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,990&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired and liabilities assumed</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,617&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock', window );">Schedule of Business Acquisitions, Pro Forma Information</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the unaudited pro forma combined results of operations of Recursion, Valence and Cyclica as if the acquisitions had occurred on January&#160;1, 2022:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.123%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended March 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenue</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,155&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73,514)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -SubTopic 10<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -SubTopic 10<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Paragraph 1<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140474079404608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Components of Lease Cost, Supplemental Cash Flow Information Related to Leases, Lease Term and Discount Rates</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the lease cost were:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.544%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,472&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,998&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">538&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">657&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease cost</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease cost</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,050&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,655&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The remaining lease term and discount rate were:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.222%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturities of Operating Lease Liabilities</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of operating lease liabilities as of March&#160;31, 2024 were:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.392%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating leases</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,300&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,748&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,882&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,281&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,850&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,948&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,009&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,161)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,848&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140474077751552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes intangible assets:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross carrying amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net carrying amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross carrying amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net carrying amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Definite-lived intangible assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,426&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,336)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,090&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,426&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,969)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,457&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite-lived intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">986&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">986&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">986&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">986&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,412&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,336)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,076&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,412&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,969)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,443&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Indefinite-Lived Intangible Assets</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes intangible assets:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross carrying amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net carrying amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross carrying amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net carrying amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Definite-lived intangible assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,426&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,336)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,090&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,426&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,969)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,457&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite-lived intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">986&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">986&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">986&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">986&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,412&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,336)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,076&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,412&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,969)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,443&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b),(d)<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140474078525472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-based Compensation Expenses</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the classification of stock-based compensation expense for employees and non-employees within the Condensed Consolidated Statements of Operations: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.490%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.106%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">766&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,011&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,666&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,683&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,077&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,578&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,509&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,272&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Share-based Payment Arrangement, Option, Activity</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity during the three months ended March 31, 2024 was as follows: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;(in thousands except share and per share amounts)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Exercise</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Price </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining&#160;Contractual Life (in years) </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value </span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,957,617&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.13&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,416&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,558,102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.09&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(178,609)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,303,878)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,575&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of March 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,033,232&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.99&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,131&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of March 31, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,909,647&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.49&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,959&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following weighted-average assumptions were used to calculate the grant-date fair value of stock options: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.052%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;text-indent:62.99pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;text-indent:62.99pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:67.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:67.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock', window );">Schedule of Nonvested RSU Activity</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes Recursion&#8217;s RSU activity during the three months ended March 31, 2024: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.133%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock units</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-average grant date fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,223,764&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.39&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,840,877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,023,464)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(409,634)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of March 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,631,543&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.63&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Subparagraph (c)<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140474078173696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Basic and Diluted Net Loss per Share</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth the computation of basic and diluted net loss per share of Class A, Class B and Exchangeable common stock:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:68.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.126%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.128%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91,373)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65,327)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236,019,349&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,618,238&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.39)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.34)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Net Loss per Share</a></td>
<td class="text"><div><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company excluded the following potential common shares from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.783%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.958%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.959%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Stock based compensation</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,159,250&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,534,876&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Tempus agreement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,143,690&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,302,940&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,534,876&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140474163550736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.098%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.297%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.452%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Basis of fair value measurement</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276,697&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276,697&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,824&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,824&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286,521&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286,521&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.098%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.297%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.452%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Basis of fair value measurement</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322,653&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322,653&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,860&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,860&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332,513&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332,513&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock', window );">Schedule of Fair Value Disclosure of Asset and Liability Not Measured at Fair Value</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the Company&#8217;s financial instruments that are not measured at fair value: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.531%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.448%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Book values</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair values</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of notes payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes payable, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,126&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,126&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information about fair value of asset and liability not measured at fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2E<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140474071703280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Description of the Business (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 1,058,995<span></span>
</td>
<td class="nump">$ 967,622<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140474067876432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Financial Information - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="nump">$ 3,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLeasehold', window );">Impairment of leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,653,000<span></span>
</td>
<td class="nump">5,175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate (as percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">616,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Notes payable | Station 41 lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 992,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate (as percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">510,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=rxrx_BioHiveSupercomputerMember', window );">BioHive Supercomputer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other Current Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxrx_LicenseAgreementPrepaidExpenses', window );">License agreement, prepaid expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rxrx_TempusLabsIncMember', window );">Tempus Labs, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxrx_LicenseAgreementTerm', window );">License agreement, term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxrx_LicenseAgreementTradingPeriodUsedForEquityValueDetermination', window );">License agreement, trading period</a></td>
<td class="text">7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rxrx_TempusLabsIncMember', window );">Tempus Labs, Inc | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxrx_LicenseAgreementAnnualPayments', window );">Annual payments</a></td>
<td class="nump">$ 22,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rxrx_TempusLabsIncMember', window );">Tempus Labs, Inc | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxrx_LicenseAgreementAnnualPayments', window );">Annual payments</a></td>
<td class="nump">42,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxrx_LicenseAgreementAggregatePayments', window );">Aggregate amount payable in cash or equity</a></td>
<td class="nump">$ 160,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxrx_LicenseAgreementAggregatePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Aggregate Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxrx_LicenseAgreementAggregatePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxrx_LicenseAgreementAnnualPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Annual Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxrx_LicenseAgreementAnnualPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxrx_LicenseAgreementPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Prepaid Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxrx_LicenseAgreementPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxrx_LicenseAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxrx_LicenseAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxrx_LicenseAgreementTradingPeriodUsedForEquityValueDetermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Trading Period Used For Equity Value Determination</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxrx_LicenseAgreementTradingPeriodUsedForEquityValueDetermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLeasehold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The adjustment to reduce the value of existing agreements that specify the lessee's rights to use the leased property. This expense is charged when the estimates of future profits generated by the leased property are reduced.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLeasehold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rxrx_Station41LeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rxrx_Station41LeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=rxrx_BioHiveSupercomputerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=rxrx_BioHiveSupercomputerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=rxrx_TempusLabsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=rxrx_TempusLabsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140474163523616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Supplemental Financial Information - Schedule of Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 135,569<span></span>
</td>
<td class="nump">$ 131,382<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation</a></td>
<td class="num">(48,853)<span></span>
</td>
<td class="num">(44,872)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">86,716<span></span>
</td>
<td class="nump">86,510<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=rxrx_LaboratoryEquipmentMember', window );">Lab equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">61,247<span></span>
</td>
<td class="nump">60,096<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">46,289<span></span>
</td>
<td class="nump">45,929<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">22,356<span></span>
</td>
<td class="nump">22,126<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AssetUnderConstructionMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 5,677<span></span>
</td>
<td class="nump">$ 3,231<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=rxrx_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=rxrx_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AssetUnderConstructionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AssetUnderConstructionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140474163657616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Supplemental Financial Information - Schedule of Accrued Expenses and Other Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxrx_SupplementalFinancialInformationAbstract', window );"><strong>Supplemental Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">$ 10,055<span></span>
</td>
<td class="nump">$ 22,888<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxrx_AccruedDevelopmentCostsCurrent', window );">Accrued development expenses</a></td>
<td class="nump">5,804<span></span>
</td>
<td class="nump">6,077<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxrx_AccruedEarlyDiscoveryExpensesCurrent', window );">Accrued early discovery expenses</a></td>
<td class="nump">2,610<span></span>
</td>
<td class="nump">2,570<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConstructionPayableCurrent', window );">Accrued construction</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,439<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxrx_MaterialsReceivedNotInvoiced', window );">Materials received not invoiced</a></td>
<td class="nump">1,184<span></span>
</td>
<td class="nump">2,432<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued other expenses</a></td>
<td class="nump">6,417<span></span>
</td>
<td class="nump">10,229<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expense and other liabilities</a></td>
<td class="nump">$ 26,070<span></span>
</td>
<td class="nump">$ 46,635<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxrx_AccruedDevelopmentCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Development Costs, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxrx_AccruedDevelopmentCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxrx_AccruedEarlyDiscoveryExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Early Discovery Expenses, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxrx_AccruedEarlyDiscoveryExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxrx_MaterialsReceivedNotInvoiced">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Materials Received Not Invoiced</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxrx_MaterialsReceivedNotInvoiced</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxrx_SupplementalFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supplemental Financial Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxrx_SupplementalFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for the acquisition of merchandise, materials, supplies and services pertaining to construction projects such as a housing development or factory expansion not classified as trade payables. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140474078640016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Financial Information - Schedule of Interest Income and Expense Disclosure (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxrx_SupplementalFinancialInformationAbstract', window );"><strong>Supplemental Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNonoperating', window );">Interest income</a></td>
<td class="nump">$ 4,048<span></span>
</td>
<td class="nump">$ 4,660<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(20)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestRevenueExpenseNet', window );">Interest income, net</a></td>
<td class="nump">$ 4,028<span></span>
</td>
<td class="nump">$ 4,641<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxrx_SupplementalFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supplemental Financial Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxrx_SupplementalFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestRevenueExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest revenue (income derived from investments in debt securities and on cash and cash equivalents) net of interest expense (cost of borrowed funds accounted for as interest).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestRevenueExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income from investments (for example, dividends) not considered a component of the entity's core operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140474077928624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions - Narrative (Details) - USD ($)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>May 25, 2023</div></th>
<th class="th"><div>May 16, 2023</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=rxrx_ValenceDiscoveryIncMember', window );">Valence Discovery Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual', window );">Net revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual', window );">Operating loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,900,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=rxrx_ValenceDiscoveryIncMember', window );">Valence Discovery Inc | Technology Intangible Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=rxrx_ValenceDiscoveryIncMember', window );">Valence Discovery Inc | Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Equity interest issued or issuable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=rxrx_ValenceDiscoveryIncMember', window );">Valence Discovery Inc | Class A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Equity interest issued or issuable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=rxrx_ValenceDiscoveryIncMember', window );">Valence Discovery Inc | Exchangeable Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Equity interest issued or issuable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=rxrx_CyclicaIncMember', window );">Cyclica Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual', window );">Operating loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,800,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=rxrx_CyclicaIncMember', window );">Cyclica Inc | Technology Intangible Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=rxrx_CyclicaIncMember', window );">Cyclica Inc | Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Equity interest issued or issuable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=rxrx_CyclicaIncMember', window );">Cyclica Inc | Class A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Equity interest issued or issuable (in shares)</a></td>
<td class="nump">182<span></span>
</td>
<td class="nump">5,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of earnings or loss of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=rxrx_ValenceDiscoveryIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=rxrx_ValenceDiscoveryIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=rxrx_ExchangeableStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=rxrx_ExchangeableStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=rxrx_CyclicaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=rxrx_CyclicaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140474077696144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Acquisitions - Schedule of Business Acquisitions, by Acquisition (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>May 25, 2023</div></th>
<th class="th"><div>May 16, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=rxrx_ValenceDiscoveryIncMember', window );">Valence Discovery Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Deferred liabilities for additional consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 396<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,898<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=rxrx_ValenceDiscoveryIncMember', window );">Valence Discovery Inc | Employee stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxrx_BusinessCombinationConsiderationTransferredEquityInterestsIssuable', window );">Fair value of equity interests issued, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,933<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=rxrx_ValenceDiscoveryIncMember', window );">Valence Discovery Inc | Class A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxrx_BusinessCombinationConsiderationTransferredEquityInterestsIssuable', window );">Fair value of equity interests issued, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,096<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=rxrx_ValenceDiscoveryIncMember', window );">Valence Discovery Inc | Exchangeable Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxrx_BusinessCombinationConsiderationTransferredEquityInterestsIssuable', window );">Fair value of equity interests issued, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,473<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=rxrx_CyclicaIncMember', window );">Cyclica Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash</a></td>
<td class="nump">$ 6,505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Deferred liabilities for additional consideration</a></td>
<td class="nump">344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total consideration</a></td>
<td class="nump">60,617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=rxrx_CyclicaIncMember', window );">Cyclica Inc | Employee stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxrx_BusinessCombinationConsiderationTransferredEquityInterestsIssuable', window );">Fair value of equity interests issued, value</a></td>
<td class="nump">3,852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=rxrx_CyclicaIncMember', window );">Cyclica Inc | Class A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxrx_BusinessCombinationConsiderationTransferredEquityInterestsIssuable', window );">Fair value of equity interests issued, value</a></td>
<td class="nump">$ 49,915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxrx_BusinessCombinationConsiderationTransferredEquityInterestsIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Consideration Transferred, Equity Interests Issuable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxrx_BusinessCombinationConsiderationTransferredEquityInterestsIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479668/805-30-25-5<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-8<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=rxrx_ValenceDiscoveryIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=rxrx_ValenceDiscoveryIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=rxrx_ExchangeableStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=rxrx_ExchangeableStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=rxrx_CyclicaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=rxrx_CyclicaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140474077606304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Acquisitions - Schedule of Fair Value of Assets Acquired and Liabilities Assumed (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>May 25, 2023</div></th>
<th class="th"><div>May 16, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 52,056<span></span>
</td>
<td class="nump">$ 52,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=rxrx_ValenceDiscoveryIncMember', window );">Valence Discovery Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,235<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherReceivables', window );">Other receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">536<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets - technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Accounts payable and accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(872)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,265)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total identifiable net assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,634<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,264<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Total assets acquired and liabilities assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,898<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=rxrx_CyclicaIncMember', window );">Cyclica Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,685<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherReceivables', window );">Other receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInvestments', window );">Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther', window );">Other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets - technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Accounts payable and accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(579)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue', window );">Unearned revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,754)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,075)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilitiesCurrent', window );">Other liabilities, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(66)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther', window );">Other liabilities, non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(139)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total identifiable net assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Total assets acquired and liabilities assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Investments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Liabilities, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Receivables</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Restricted Cash</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenue expected to be recognized as such within one year or the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=rxrx_ValenceDiscoveryIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=rxrx_ValenceDiscoveryIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=rxrx_CyclicaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=rxrx_CyclicaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140474169814272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions - Schedule of Business Acquisitions, Pro Forma Information (Details) - Recursion, Valence and Cyclica<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaRevenue', window );">Net revenue</a></td>
<td class="nump">$ 12,155<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (73,514)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=rxrx_RecursionValenceAndCyclicaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=rxrx_RecursionValenceAndCyclicaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140474074224560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Feb. 29, 2024 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Jan. 31, 2024 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease, renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxrx_IncreaseDecreaseInOperatingLeaseRightOfUseAssets', window );">Increase (decrease) in operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,100)<span></span>
</td>
<td class="nump">$ 3,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxrx_LesseeOperatingLeaseIncreaseDecreaseInOperatingLeaseLiabilityDueToLeaseModifications', window );">Increase (decrease) in lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,100)<span></span>
</td>
<td class="nump">$ 3,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Lessee, operating lease, liability, to be paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 66,009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxrx_LeaseDescriptionAxis=rxrx_LondonLeaseMember', window );">London Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease, renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxrx_LesseeOperatingLeaseSquareFootageOfLeasedSpace', window );">Square footage of leased space (in square feet) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Lessee, operating lease, liability, to be paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxrx_LeaseDescriptionAxis=rxrx_DataCenterLeaseMember', window );">Data Center Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease, renewal term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxrx_LesseeOperatingLeaseSquareFootageOfLeasedSpace', window );">Square footage of leased space (in square feet) | ft&#178;</a></td>
<td class="nump">1,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Lessee, operating lease, liability, to be paid</a></td>
<td class="nump">$ 13,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Remaining operating lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Remaining operating lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxrx_IncreaseDecreaseInOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Operating Lease Right-Of-Use Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxrx_IncreaseDecreaseInOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxrx_LesseeOperatingLeaseIncreaseDecreaseInOperatingLeaseLiabilityDueToLeaseModifications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Increase (Decrease) In Operating Lease Liability Due To Lease Modifications</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxrx_LesseeOperatingLeaseIncreaseDecreaseInOperatingLeaseLiabilityDueToLeaseModifications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxrx_LesseeOperatingLeaseSquareFootageOfLeasedSpace">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Square Footage Of Leased Space</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxrx_LesseeOperatingLeaseSquareFootageOfLeasedSpace</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxrx_LeaseDescriptionAxis=rxrx_LondonLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxrx_LeaseDescriptionAxis=rxrx_LondonLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxrx_LeaseDescriptionAxis=rxrx_DataCenterLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxrx_LeaseDescriptionAxis=rxrx_DataCenterLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140474194670224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Components of Lease Cost (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 2,472<span></span>
</td>
<td class="nump">$ 1,998<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">538<span></span>
</td>
<td class="nump">657<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease cost</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Lease cost</a></td>
<td class="nump">$ 3,050<span></span>
</td>
<td class="nump">$ 2,655<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140474078213808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Lease Term and Discount Rates (Details)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term (years)</a></td>
<td class="text">6 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">7.70%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140474078335472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Maturities of Operating Lease Liabilities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Remainder of 2024</a></td>
<td class="nump">$ 7,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">10,748<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">10,882<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">11,281<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2028</a></td>
<td class="nump">8,850<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxrx_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour', window );">Thereafter</a></td>
<td class="nump">16,948<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">66,009<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(16,161)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 49,848<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxrx_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, to be Paid, Due after Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxrx_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140474163375232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillPeriodIncreaseDecrease', window );">Change in carrying amount of goodwill</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible Assets, Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amount</a></td>
<td class="nump">44,426,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44,426,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(12,336,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,969,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net carrying amount</a></td>
<td class="nump">32,090,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,457,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite-lived intangible assets</a></td>
<td class="nump">986,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">986,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Intangible assets, gross</a></td>
<td class="nump">45,412,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,412,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">33,076,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,443,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">3,400,000<span></span>
</td>
<td class="nump">152,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of indefinite-lived intangible assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483147/928-340-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140474078060160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 27, 2023 </div>
<div>claim</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Loss contingency accrual | $</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of pending claims | claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyPendingClaimsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of pending claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyPendingClaimsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140474067546704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock (Details)<br> $ / shares in Units, shares in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 16, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>May 31, 2023</div></th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($) </div>
<div>vote </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Oct. 31, 2022</div></th>
<th class="th">
<div>Apr. 30, 2021 </div>
<div>class</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsStock', window );">Dividends, stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxrx_PercentOfAggregatePurchasePricePaidByTheHolderDueIfAgreementIsBroken', window );">Percent of aggregate purchase price paid by the holder due if agreement is broken</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxrx_RegistrationRightsAgreementAccruedLiability', window );">Registration rights agreement, accrued liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxrx_NumberOfClassesOfCommonStockAuthorized', window );">Number of classes of common stock authorized | class</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=rxrx_ChristopherGibsonAndAffiliatesMember', window );">Christopher Gibson and Affiliates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxrx_AffiliatedHoldersOwnershipPercentage', window );">Affiliated holders, ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxrx_AffiliatedHoldersPotentialOwnershipPercentageWhenOutstandingEquityAwardsVest', window );">Affiliated holders, potential ownership percentage when outstanding equity awards vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=rxrx_ValenceDiscoveryIncMember', window );">Valence Discovery Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxrx_RegistrationRightsAgreementTerm', window );">Registration rights agreement, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rxrx_NVDIAPrivatePlacementMember', window );">NVDIA Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxrx_PercentOfAggregatePurchasePricePaidByTheHolderDueIfAgreementIsBroken', window );">Percent of aggregate purchase price paid by the holder due if agreement is broken</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxrx_RegistrationRightsAgreementAccruedLiability', window );">Registration rights agreement, accrued liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rxrx_NVDIAPrivatePlacementMember', window );">NVDIA Private Placement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxrx_PercentOfAggregatePurchasePricePaidByTheHolderDueIfAgreementIsBroken', window );">Percent of aggregate purchase price paid by the holder due if agreement is broken</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxrx_CommonStockVotePerShare', window );">Vote per share of common stock (in votes) | vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from issuance of common shares, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxrx_CommonStockConversionRatio', window );">Common stock, conversion ratio</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A | At-the-Market offering program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxrx_SaleOfStockValueAuthorized', window );">Sale of stock, value authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxrx_SaleOfStockValueRemainingAuthorized', window );">Sale of stock value remaining authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 208,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">IPO, number of shares issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">921<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">IPO, net proceeds received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxrx_SaleOfStockPercentageOfCommission', window );">Sale of Stock, percentage of commission</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A | NVDIA Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock sales issuances, net of issuance costs (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxrx_CommonStockVotePerShare', window );">Vote per share of common stock (in votes) | vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=rxrx_ExchangeableStockMember', window );">Exchangeable Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Shares issued in the period, upon conversion (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=rxrx_ExchangeableStockMember', window );">Exchangeable Stock | Valence Discovery Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxrx_BusinessAcquisitionContingentConsiderationEquityInterestsIssuableNumberOfShares', window );">Contingent consideration, equity interests issuable (in shares) | shares</a></td>
<td class="nump">5,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxrx_AffiliatedHoldersOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Affiliated Holders, Ownership Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxrx_AffiliatedHoldersOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxrx_AffiliatedHoldersPotentialOwnershipPercentageWhenOutstandingEquityAwardsVest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Affiliated Holders, Potential Ownership Percentage When Outstanding Equity Awards Vest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxrx_AffiliatedHoldersPotentialOwnershipPercentageWhenOutstandingEquityAwardsVest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxrx_BusinessAcquisitionContingentConsiderationEquityInterestsIssuableNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition , Contingent Consideration, Equity Interests Issuable, Number Of Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxrx_BusinessAcquisitionContingentConsiderationEquityInterestsIssuableNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxrx_CommonStockConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Conversion Ratio</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxrx_CommonStockConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxrx_CommonStockVotePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Vote Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxrx_CommonStockVotePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxrx_NumberOfClassesOfCommonStockAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Classes Of Common Stock Authorized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxrx_NumberOfClassesOfCommonStockAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxrx_PercentOfAggregatePurchasePricePaidByTheHolderDueIfAgreementIsBroken">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percent of Aggregate Purchase Price Paid By The Holder Due If Agreement is Broken</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxrx_PercentOfAggregatePurchasePricePaidByTheHolderDueIfAgreementIsBroken</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxrx_RegistrationRightsAgreementAccruedLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Registration Rights Agreement, Accrued Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxrx_RegistrationRightsAgreementAccruedLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxrx_RegistrationRightsAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Registration Rights Agreement, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxrx_RegistrationRightsAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxrx_SaleOfStockPercentageOfCommission">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Percentage of Commission</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxrx_SaleOfStockPercentageOfCommission</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxrx_SaleOfStockValueAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Value, Authorized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxrx_SaleOfStockValueAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxrx_SaleOfStockValueRemainingAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock Value Remaining Authorized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxrx_SaleOfStockValueRemainingAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid stock dividends declared for classes of stock, for example, but not limited to, common and preferred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -SubTopic 405<br> -Topic 942<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481071/942-405-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=rxrx_ChristopherGibsonAndAffiliatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=rxrx_ChristopherGibsonAndAffiliatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=rxrx_ValenceDiscoveryIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=rxrx_ValenceDiscoveryIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=rxrx_NVDIAPrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=rxrx_NVDIAPrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=rxrx_AtTheMarketOfferingProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=rxrx_AtTheMarketOfferingProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=rxrx_ExchangeableStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=rxrx_ExchangeableStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140474078278160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Development Contracts (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 31, 2022 </div>
<div>USD ($) </div>
<div>program </div>
<div>performance_obligation </div>
<div>phenomap</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Unearned revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,618<span></span>
</td>
<td class="nump">$ 36,426<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Unearned revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rxrx_RocheAndGenentechMember', window );">Roche and Genentech | Collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Remaining unearned revenue</a></td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxrx_RevenuePerformanceObligationNumberOfObligations', window );">Number of performance obligations under the agreement (in performance obligations) | performance_obligation</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation revenue</a></td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rxrx_RocheAndGenentechMember', window );">Roche and Genentech | Collaborative arrangement | Phenomaps creation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxrx_RevenueRemainingPerformanceObligationVariableConsiderationAmount', window );">Research project, fees and milestones payments receivable for an option on a lead series</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxrx_ContractWithCustomerMaximumAcceptedProduct', window );">Number of eligible phenomaps (in phenomaps) | phenomap</a></td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rxrx_RocheAndGenentechMember', window );">Roche and Genentech | Collaborative arrangement | Phenomaps raw images</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxrx_RevenueRemainingPerformanceObligationVariableConsiderationAmount', window );">Research project, fees and milestones payments receivable for an option on a lead series</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxrx_ContractWithCustomerMaximumAcceptedProduct', window );">Number of eligible phenomaps (in phenomaps) | phenomap</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rxrx_RocheAndGenentechMember', window );">Roche and Genentech | Collaborative arrangement | Developed and commercialized programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxrx_RevenueRemainingPerformanceObligationVariableConsiderationAmount', window );">Research project, fees and milestones payments receivable for an option on a lead series</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxrx_RevenueRemainingPerformanceObligationNumberOfProjectsThatMayBeInitiated', window );">Number of projects that may be initiated (in projects) | program</a></td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rxrx_RocheAndGenentechMember', window );">Roche and Genentech | Collaborative arrangement | Gastrointestinal cancer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxrx_RevenuePerformanceObligationNumberOfObligations', window );">Number of performance obligations under the agreement (in performance obligations) | performance_obligation</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rxrx_RocheAndGenentechMember', window );">Roche and Genentech | Collaborative arrangement | Neuroscience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxrx_RevenuePerformanceObligationNumberOfObligations', window );">Number of performance obligations under the agreement (in performance obligations) | performance_obligation</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxrx_ContractWithCustomerMaximumAcceptedProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Maximum Accepted Product</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxrx_ContractWithCustomerMaximumAcceptedProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxrx_RevenuePerformanceObligationNumberOfObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Performance Obligation, Number Of Obligations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxrx_RevenuePerformanceObligationNumberOfObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxrx_RevenueRemainingPerformanceObligationNumberOfProjectsThatMayBeInitiated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Remaining Performance Obligation, Number Of Projects That May Be Initiated</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxrx_RevenueRemainingPerformanceObligationNumberOfProjectsThatMayBeInitiated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxrx_RevenueRemainingPerformanceObligationVariableConsiderationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Remaining Performance Obligation, Variable Consideration Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxrx_RevenueRemainingPerformanceObligationVariableConsiderationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=rxrx_RocheAndGenentechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=rxrx_RocheAndGenentechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxrx_RevenueRemainingPerformanceObligationAxis=rxrx_PhenomapsCreationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxrx_RevenueRemainingPerformanceObligationAxis=rxrx_PhenomapsCreationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxrx_RevenueRemainingPerformanceObligationAxis=rxrx_PhenomapsRawImagesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxrx_RevenueRemainingPerformanceObligationAxis=rxrx_PhenomapsRawImagesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxrx_RevenueRemainingPerformanceObligationAxis=rxrx_DevelopedAndCommercializedProgramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxrx_RevenueRemainingPerformanceObligationAxis=rxrx_DevelopedAndCommercializedProgramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxrx_RevenueRemainingPerformanceObligationAxis=rxrx_GastrointestinalCancerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxrx_RevenueRemainingPerformanceObligationAxis=rxrx_GastrointestinalCancerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxrx_RevenueRemainingPerformanceObligationAxis=rxrx_NeuroscienceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxrx_RevenueRemainingPerformanceObligationAxis=rxrx_NeuroscienceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140474074323952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Options granted in period, weighted average grant date fair value (in dollars per share)</a></td>
<td class="nump">$ 6.41<span></span>
</td>
<td class="nump">$ 5.32<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unvested stock options, unamortized stock-based compensation cost</a></td>
<td class="nump">$ 43.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unvested stock options, unamortized stock-based compensation cost, weighted average period recognition</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock options, vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock options, expiration period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock options, vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unvested stock options, unamortized stock-based compensation cost, weighted average period recognition</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Fair market value of vested shares</a></td>
<td class="nump">$ 13.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation cost</a></td>
<td class="nump">$ 124.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=rxrx_A2021EquityIncentivePlanMember', window );">2021 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant (in shares)</a></td>
<td class="nump">18,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=rxrx_A2021EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=rxrx_A2021EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140474071872896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock-based Compensation Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based payment arrangement, expense</a></td>
<td class="nump">$ 15,509<span></span>
</td>
<td class="nump">$ 8,272<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based payment arrangement, expense</a></td>
<td class="nump">766<span></span>
</td>
<td class="nump">1,011<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based payment arrangement, expense</a></td>
<td class="nump">7,666<span></span>
</td>
<td class="nump">2,683<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based payment arrangement, expense</a></td>
<td class="nump">$ 7,077<span></span>
</td>
<td class="nump">$ 4,578<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140474077498000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Share-based Payment Arrangement, Option, Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares&#160;</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options, outstanding, number at beginning of period (in shares)</a></td>
<td class="nump">14,957,617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">2,558,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Cancelled (in shares)</a></td>
<td class="num">(178,609)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(1,303,878)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options, outstanding, number at end of period (in shares)</a></td>
<td class="nump">16,033,232<span></span>
</td>
<td class="nump">14,957,617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable, (in shares)</a></td>
<td class="nump">8,909,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options, outstanding, at beginning of period (in dollars per share)</a></td>
<td class="nump">$ 6.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">10.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Cancelled (in dollars per share)</a></td>
<td class="nump">12.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">2.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options, outstanding, at end of period (in dollars per share)</a></td>
<td class="nump">6.99<span></span>
</td>
<td class="nump">$ 6.13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable (in dollars per share)</a></td>
<td class="nump">$ 5.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options, outstanding, weighted average remaining contractual life</a></td>
<td class="text">7 years 3 months 18 days<span></span>
</td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options, exercisable, weighted average remaining contractual life</a></td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options, outstanding, intrinsic value</a></td>
<td class="nump">$ 64,131<span></span>
</td>
<td class="nump">$ 72,416<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Exercise, intrinsic value</a></td>
<td class="nump">11,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable, intrinsic value</a></td>
<td class="nump">$ 51,959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140474163572768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Share-based Payment Award, Stock Options, Valuation Assumption (Details) - Stock based compensation<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 3 months 18 days<span></span>
</td>
<td class="text">6 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">65.00%<span></span>
</td>
<td class="nump">64.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.20%<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140474163384064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of RSU Activity (Details) - Restricted stock<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward', window );"><strong>Stock units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance, outstanding (in shares) | shares</a></td>
<td class="nump">15,223,764<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">1,840,877<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(1,023,464)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(409,634)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance, outstanding (in shares) | shares</a></td>
<td class="nump">15,631,543<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-average grant date fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance, outstanding (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 8.39<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">10.46<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">8.60<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">7.99<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance, outstanding (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 8.63<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140474078715472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="num">$ (779,000)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations', window );">Federal Income Tax Expense (Benefit), Continuing Operations</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current and deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current and deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140474078618352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Schedule of Basic and Diluted Net Loss per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (91,373)<span></span>
</td>
<td class="num">$ (65,327)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding, basic (in shares)</a></td>
<td class="nump">236,019,349<span></span>
</td>
<td class="nump">191,618,238<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding, diluted (in shares)</a></td>
<td class="nump">236,019,349<span></span>
</td>
<td class="nump">191,618,238<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic (in dollars per shares)</a></td>
<td class="num">$ (0.39)<span></span>
</td>
<td class="num">$ (0.34)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted (in dollars per shares)</a></td>
<td class="num">$ (0.39)<span></span>
</td>
<td class="num">$ (0.34)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140474071569584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Net Loss Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of loss per share, amount (in shares)</a></td>
<td class="nump">16,302,940<span></span>
</td>
<td class="nump">8,534,876<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of loss per share, amount (in shares)</a></td>
<td class="nump">11,159,250<span></span>
</td>
<td class="nump">8,534,876<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=rxrx_TempusAgreementMember', window );">Tempus agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of loss per share, amount (in shares)</a></td>
<td class="nump">5,143,690<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=rxrx_TempusAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=rxrx_TempusAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140474067465216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Assets and Liabilities Measured on Recurring Basis (Details) - Fair Value, Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxrx_RestrictedCashAndCashEquivalentsFairValueDisclosure', window );">Restricted cash</a></td>
<td class="nump">$ 9,824<span></span>
</td>
<td class="nump">$ 9,860<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">286,521<span></span>
</td>
<td class="nump">332,513<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">276,697<span></span>
</td>
<td class="nump">322,653<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxrx_RestrictedCashAndCashEquivalentsFairValueDisclosure', window );">Restricted cash</a></td>
<td class="nump">9,824<span></span>
</td>
<td class="nump">9,860<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">286,521<span></span>
</td>
<td class="nump">332,513<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">276,697<span></span>
</td>
<td class="nump">322,653<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxrx_RestrictedCashAndCashEquivalentsFairValueDisclosure', window );">Restricted cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxrx_RestrictedCashAndCashEquivalentsFairValueDisclosure', window );">Restricted cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxrx_RestrictedCashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restricted Cash and Cash Equivalents, Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxrx_RestrictedCashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140474163643984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Asset and Liability Not Measured at Fair Value (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember', window );">Book values</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems', window );"><strong>Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Total liabilities</a></td>
<td class="nump">$ 1,126<span></span>
</td>
<td class="nump">$ 1,142<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember', window );">Book values | Notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems', window );"><strong>Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of notes payable</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Notes payable, net of current portion</a></td>
<td class="nump">1,071<span></span>
</td>
<td class="nump">1,101<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair values</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems', window );"><strong>Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Total liabilities</a></td>
<td class="nump">1,126<span></span>
</td>
<td class="nump">1,142<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair values | Notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems', window );"><strong>Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of notes payable</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Notes payable, net of current portion</a></td>
<td class="nump">$ 1,071<span></span>
</td>
<td class="nump">$ 1,101<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2E<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>71
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MW*" &^P#-^6+(%'0@ K=L,C81^TYTPOW?CH;W]Z@R9?1]'KD7MS?C=W1U>P
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M3NR E&QPR?0WL?^#-()F%B\13%7?8%_;1G,')*72(F^<#8.<\OH7/S<;T7%
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MG[7L9Y/8=\F;_TZE,4\IW[ZF8#99P9#EJ(*P51".*V!8*?!IB-VHHRTWMZK
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M.!5=$$MFL4TE:E.):E3G!.H-?4B+(BT>Y).3D2*FX$)F@:])2?DE($*&BC\
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MK$FC!?( ?%][&,;PP N,?P.Y_C]02P,$%     @ =H&I6&Y1ST)E!P  QA,
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MVS82_164,DG958Q$4A0E>2Y5,[YLLF6OISS>[,/6/D D)&)-$@P CJR_W],
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MBP$][Y*+]8R;@@%P\7LK[8%QZV![K:J&UX<A"-50J1'HHI>\Y64KR/=<H*)
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MNEQ,_&MG?V-5X[[);)2UJG*7A4!W:Q+ \ZU"17<W9&#X2'?Q/U!+ P04
M" !V@:E8CP#Z,9X+  #R*0  &0   'AL+W=O<FMS:&5E=',O<VAE970Q,"YX
M;6SM6FUSVS82_BL8-=.Q9VA9HEYLY<4SCMO>Y::Y9I*T]^'F/D D1*(E 08@
MI2B__IX%2(J2*#ONY>;2FWY)) K[OOOL+LSG&VU^LZD0)?N89\J^&*1E63R]
MO+11*G)NA[H0"K^LM,EYB:\FN;2%$3QV1'EV&8Y&\\N<2S6X>>Z>O3$WSW55
M9E*)-X;9*L^YV;X4F=Z\&(P'S8.W,DE+>G!Y\[S@B7@GRI^+-P;?+ELNL<R%
MLE(K9L3JQ>!V_/3EE,Z[ [](L;&=SXPL66K]&WUY%;\8C$@AD8FH) X<_ZW%
MG<@R8@0U/M0\!ZU((NQ^;KC_X&R'+4MNQ9W._B'C,GTQN!ZP6*QXE95O]>:O
MHK9G1OPBG5GW+]OXL[/I@$65+75>$T.#7"K_/_]8^Z%#<#TZ01#6!*'3VPMR
M6G['2W[SW.@-,W0:W.B#,]510SFI*"CO2H-?)>C*F]OH0R6M) _9YY<E.-+S
MRZBF?NFIPQ/4$_9:JS*U['L5BWB?_A*:M.J$C3HOPWL9ON9FR";C@(6C<'H/
MOTEKWL3QFYS@][*R>&(MN]/Y4BKN,T'%[-9:9'S'>O;/VZ4M#;+D7WU^\&*F
M_6*H<I[:@D?BQ0"E8859B\'-M]^,YZ-G]Q@Q;8V8WL?]P1A]/C7[A6="18)]
M)VVDU\)LV2L5#=E/BKWF6S:>.\=/ O961)6QOFQ ;D3,>)8QO6)E*AB*VY;P
MHE0)$_BYW#*I2@'+2XM/IZ2<U<_/ \998>2:ER+;7J0BBY'240K%62:X4<3W
M[/6/Y^R2<5/*E8PDSYR(+).)8WUV^^J<Q3*1)7XAI)((WI9%.B^XV@[9>ZA)
M!(GQ,8?FM?1OO[D.QU?/++M]=4'U''?(A4I("1#JG0M: B A<8-R=FM+D:-4
MX1/X!>'<.0RDXF-!.2;AC5)$J=*93K870O%E!G&QJ1*HWKBF,#I"AI+*TM8L
MHPBP!5FB1XL>HWG!ES)#B(5EC>#34H2/:9WV.\>P#;<D6E?P6\P ^(P>L&53
M0U&GANA9XI*ARRP79:ICXEGSP:%:9)(8D9!%5;$R  UP [+'HHX/23ODUE'-
M';:D%AZ&PQ!0B%3 &9MRI!T]W47@+N/0]I;TS>E(J:/? C8=3GNH.-K1$GI(
M=*0]+@&B&*5<)8*BYO3KD=5&I5_FU2*$5;JR%)6:7%I;.995@8/BHS"1M(*X
M.B)DF2]55Q;+;>N"NM#XAIN8I3J#ZWRTT8.$H0K-Y"X-7/3BV#F2DJ7K["&[
M5<AQ*Q-%M<41#%7E2V&:^N:@%NB\=%C$';OW8Y;RF"E=LBV0="F$<J814KBS
M@/(H;;%\2$FPDJ3+3E;-&!6S% UQ"NH]IHY(?B*^Y$0-2! 4M%_1UXG4!\EG
MV4I3,;K,="[VHP:(24AYZ(>G[ Q@U<3'GK,?N#1LS;-*/)Q0[ D;CX/18GY
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M$FB@D#E"@7_615A@ Q*\RZ3-T*/DT@PT30!YKBJK"\3$@A\& )<2_JV\4KD
MQ+H]N14:+K@"(AULN09*L8,,MR.ZM@ "E'N**<L:[Y%Y@FE3:KA B6QUT(E.
M@] LL(%EA@@PR#C,^J/OGL^/G_T8@/;?C0H1;@%?@)Y)%(:.V\E>", P0Q@
M>N<C9Z%SWVBYU 9R4(3Z))  SQKPKLA)&&\A3K%YI:LET9(3"U2&A.3@21:
MN0&MR6 L$9EFMBIJ821K- KD8'#J4YVZ!8DJRTG3; ]!D 4A1>U\2G4AR+BL
M7$-PXU@MMT$TL.(Y5?I.B@>N3>[D.P=K>DB(L63.D[M,,*8A,Z(M:^*!>,ND
M[WHIN_Q*9:I:PGY[]V1,9Z&[\W(#D C9)84V$:^KVKBM4N)RI_PN$X->63BB
M^"C#/_ D57U+O%NU;8\IA  *A$:F;(%[63D6NJ!8M!\J0VZZ N)P#=8*II\
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MDC3B+&IQKA8'"?X@S52<S2=B,5LL#] [:]0[8WIG(_1N?JFTVXE_7:ZL,XB
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M+W=O<FMS:&5E=',O<VAE970Q-2YX;6RE66UO&S<2_BN$&A1W@"+)LN,6B6W
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MEP-X7SK$L'D0![LOJME_4$L#!!0    ( ':!J5C=;]4')04  *D-   9
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MSB:!;R7=@U6UNXPOE<75W@US?$L)30OP?J60U_:!-NB_SA;_ 5!+ P04
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MWJ(@3("^WW*N#H9)T._E]#=02P,$%     @ =H&I6)GMEQ@9!0  ;!D  !D
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M5>WL1@,[+:GTN2-U<<LKOF6V@R"$:UERS277>@35=O13]1&VI%(#:UD@)1Z
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MI(85&UKS36X^PS:?W.)5LM7NEVR\;HX>JT$;V6V-<=]QX5?VM*W#GD$9OV)
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MI4$8AN2R7-62P"W8VAOBL+$\U_63Z!\-^O'Q0V)P2=F(9/R]NTN".$N/-PE
MP9>6S[@7)TGOQGS2F"4]^$6I8L6%H)9/7-NL>:V+7EUOWS$(U)SB(=4K/2<\
MMR0B=^=1D WVA:;?BR@T2Z*FH<>YQ<>AH:.*UW2XQ9J0@*=1-(_#& ^^,HQI
M?W@,GR0R+>E*XQ(E^><H"OII[\7XQD'8I_@V('?$!2WBHRS;>R^5?-/21,GP
M2TD2#X,L[C\D21(&PV'XU4GRY::3M4TG^[^/\:56X&='"E8S/[_P)A_6M"^C
M?=-Q<77Y6$M64_LE Q>DT6MR;P+-.3Z2AB94G[LTRC?=USQZ1P+7+]&]C,YO
MVU> TIT_2W<#)2M Y3YRM)#P&Y,U3?/0C&KQLU*X*34B5,UTB&XZ!)KM\G([
MW"7P!P5YFV[T\L=!E*;^4"CRZ%$_"=*H=[PO8MV=N;="/??3O0&?\<T(W)ZV
M'Q#GS=S\0-Y\?1"F.2?S!,Z(-3SI4_O7S43?;*Q:^"EZJBS-Y'Y9TD<0:D=
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M$V6I]_IA28\=U,Z!UJ=*V97A$K3/I]%W4$L#!!0    ( ':!J5AGD)#+0@4
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M=;OCV@>K:K]7MLK2EO+'DOX6H'8&]'ZGJ*_=@PO0_]%8_@M02P,$%     @
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M^8108&X] W/+%F<HA"=R:?SL.$D?T@,/]WOVNZ#=:5DQ@S,EOO'"EE-R3:#
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M*H@B/]QAMK=ZG?G.P*;PP I%."Q0YYR,,&C9].YFHD59M[^YT-A,Z^$2/W=
M&@-\OA!";R:FHW8?4,D?4$L#!!0    ( ':!J5B8I+?TJ (  "T'   9
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M:0\PW\^%T,\[MH/ZWP>F_P-02P,$%     @ =H&I6,"BC-)#!   "1H  !D
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MT=+#=X=#0_)-_NI^P:7D<7ZX)ECM3+J#NK[D7#XU]-> \NO/]#]02P,$%
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M(#?@91\_A''PI<?@H#,XZ%//[L 43 [2O&N3O,M@*Q%;"5-<FRP9!,'4WSC
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M;9.L-4-7R2)A/A(6(&'AZ&S'BDP7(V$4!#/T>K77ZY55K[]M5D^J3U5=<%D
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M3^_) T^WVKQ[R%0FK=Y6W4*M."C-A]("*"V$TB(H+8;2*(IF:KFV[IP1M+Z
M^G10F@^E!5!:"*5%4%H,I5$4S=1S;>TY=F_O+SF_PMZ&SEL!U/JK:/;3!0)H
MSA!*BZ"T&$JC*)JI[MH$=.PN(.),"WN*SN*%VH)06@"EA17-=KH%-&$,I5$4
MS51N;?DY5B_F5,U,_B1?DA_I:M-^U >U_J T'TH+H+002HN@M!A*HRB:.9&B
M=@#= ;)Z=J&F'Y3F0VD!E!9":1&4%D-I%$4S]5Q[@Z[=&_Q+JF=[&SIO!5!;
ML*(=5,\'[G( S1E":1&4%D-I%$4SU5V[@J[=%=SUUO>MFH3Z@%":#Z4%4%H(
MI4506@RE413-U&[M [I0']"%^H!0F@^E!5!:"*5%4%H,I5$4S=1S[0.Z=A_K
MNYY+NU:U0SF?]N@$_ ]I7DZW%3^K(T3]I%7D4%,02O.AM !*"RM:\^ST@_'!
M")HPAM(HBF8JMW;_7+O[]UA=54"(#9M=O!7%>R5KY<Z*+$NXJ)=J%=>3VENU
M##4*H32_HETW]#+Z.!P?%L50 Q!*BZ"T&$JC*)HIY]H =.V3]QYX,65L)LB<
M%ZM2U8D^<Z[1(9>:O2 Y*X\+]Y^8%D*V2QGJ$4)IOGL\9VXX'@_TWZ&<H?X?
ME!9!:3&41E$T4\ZU_^?:_;])HXJX4!K-MXSO+G2D39-6N1[/U3K8&T[L.3MK
M$#H[#TH+SZ^,")HPAM(HBF:*K[;GW#.3]'8##&IG?R]_D4OVRY>$/Y?=YIQQ
M?=[\FA<+GK1Z'79TYUX3:LM!:0&4%D)I$9060VD413/%73MX+G36G@OU[J T
M'TH+H+002HN@M!A*HRB:><FJVKOS[+/W'I.L+'.K4F&;9!O6F/C?IFD[L:NF
M*UJS%O4&U9^YS_6AB0,H+832(B@MAM(HBF8*MC;G/+LY9PBVTBMG^@*ANK0X
MHURHYP:E^5!: *6%%:VYC;J#:[=E&XV@B6,HC:)HIG)KX\VS&V_TX?<+DN^O
MNB*:(VCE@-ENB1XE.SU"9L_16<)0BPY*"Z"TL*(U#^G&[N%!'31E#*51%,T4
M;^/:EE8GI!*O.HI;OXV4<39EZ?9$1XN]N"7VZI;8RUMBKV_I'76TSJ!M8"Z"
MYHVA-(JBF5*M337/;JJ]50B/NY*V,8._&LY576Y:M)Z48R=WUBW42X/2 B@M
MK&@')PQYAYJ%VFE0&D713,W6=IIGM]/J,;,.T^KLS,YJA;IE4%H I8506@2E
MQ5 :1=%,5=>NF@>=5N=!+3,HS8?2 B@MA-(B*"V&TBB*9NJYMM6\]]MJ1*@R
M0^R-X%/6\/L/[*"SZ: TWSOVPZZNCKQB:,X02HN@M!A*HRB:*>K:KO/>8]=]
M;M4DU(V#TGPH+8#20B@M@M)B*(VB:*9V:S?.@[IQ'M2-@])\*"V TD(H+8+2
M8BB-HFCFK3=J-VYH=^,0YP/;4W05.93F0VD!E!96-..DGZ-;=$!].2B-HFBF
M=&M?;FCWY8(?TV62+UCRE+%==]PJ3J@#!Z7Y4%H I8506@2EQ5 :1=%,&=<F
MW=!%5A1#J!T'I?E06@"EA5!:!*7%4!I%T4P]U[[=T.[;&?,T]$T@]81E56&D
MQ>R";-:JM&B<'?S>L0I[SLZJA]I[4%H I845K5EB#-TC:P^:,X;2*(IFJKEQ
M;SJ[M7=<9"B=OOLRQW9X9]E"W3TH+8#20B@M@M)B*(VB:*:\:Q=P> DM/J#^
M'Y3F0VD!E!9":1&4%D-I%$4S]5S[?T/[K+I)D<M4==>YU%6&2&=L=]&VB[=;
M)Z2Y9"JQK'P4W:N_NP89'>U++\>'^]*)O8&=10TU :&T$$J+H+082J,HVD[4
M_<9=V%>,+]B$99E0>MWD<G<W\?U2PME<7^/MT[VK[^)^L'SB? J<\N[N->;N
M9ITLV)>$+])<D(S-%7+P\4J)MKQLX=L+6:S+>[T_%5(6J_+IDB5J:]$?4._/
MBT*^O= )7@K^7#;[[O]02P,$%     @ =H&I6,.[TE+3!0  \RH  !D   !X
M;"]W;W)K<VAE971S+W-H965T-#8N>&ULQ5IA;]LV$/TKA%<,+5!4$NTX2><8
M:**MZ[!V0;IN'X9AH.6SS54259*VVV$_?A2E2*8CLQ9ZJ[_8HL1[/#X>3WPB
M)ULAWZL5@"8?LS175X.5UL7S(%#)"C*FGHD"<O-D(63&M"G*9: *"6QNC;(T
MH&$X#C+&\\%T8N_=RNE$K'7*<[B51*VSC,E/UY"*[=4@&MS?N./+E2YO!--)
MP9;P%O2[XE::4M"@S'D&N>(B)Q(65X,7T?-X&)8&ML9O'+9JYYJ479D)\;XL
MO)I?#<+2(T@AT24$,W\;N($T+9&,'Q]JT$'39FFX>WV/_H/MO.G,C"FX$>GO
M?*Y75X.+ 9G#@JU3?2>V/T+=H;,2+Q&ILK]D6]<-!R19*RVRVMAXD/&\^F<?
M:R)V#,;T@ &M#>B> 3UD,*P-AL<:C&J#D66FZHKE(6::32=2;(DL:QNT\L*2
M::U-]WE>COM;+<U3;NSTU/"5LIF0K*2?Q+ QD5"8<=7D1N1:FF%1Y'$,FO%4
M/2&/",_)KRNQ5BR?JTF@C0<E3I#4K5U7K=$#K47DM4%=*?)]/H>Y:Q\8SQOW
MZ;W[U]0+^!/+GY%A])30D%+R[FU,'C]Z0@HIEI)EI !I9T:>P%]BEO(EL[%6
MK" 7&2LZ_+_Q-_>:R::YT7US'3"Q'R:&I($9=L,X; R;P1Q:W.%1@_E"2I8O
MP0ZF&2ZG_(M>@21ZQ7+B&OWQL\$DKS1DZL^N\:T<&'4[4":IYZI@"5P-3!92
M(#<PF'[[330.O^LB&Q,L1@)SB!\UQ(]\Z--W.3"9P]QDP@WD:^ABSHO0E[D*
M;&S!RM2^F0['X^AB$FQV*>FJ-:+CII;3U[.FKV?>OKKQPMJ@ZNJT%ZIOIS'!
M8B0PA\)Q0^'XU/-TC$D\)EB,!.80?]X0?_[%\]2+T)>Y\P<S<'P6AGO3%*E%
MAY&+AI$++R-WPJPD;=B]A-Q$'"0K\B_I-<>]#?0E#!,L1@)SB+ULB+T\]1R_
MQ"0>$RQ& G.(C\)V21OZ8QI*P</S)5D?,=]KL-TY&IDYNC]+;_R-]F4("\VE
M:&?5'WDI>K/.9B;HQ&)WC4S:-;(RU,UM5)KIOY101>ICL_H_4/^)R1K=R^U.
MSBOOSG97)OMT>SO0FVXD-)=NVM)-CXS(;OJ\\4F/C$^O"[T)0T)S"6N%3.1=
MKO=]+9EGM[6H4R21<#CP4/4+*EJ,A>92WDJ8:'3J%U:$JH%0T6(L-)?]5E1%
M?E5U9S"9-%%>2/$W)/HI60 H2WW&4U!:Y*98L$_E""B3+Q+@&S9+@9AT8JH1
M4=A$4GY*(RFP.3$^<NC^1G/V(*/0SHR"*KBPT%R"6\D5>87%SAL/3-;E)7-%
MDS+LB^V^9%]EAS\17=<-[;Z\HO$^=:B2"0O-I:X539%?-7U),I9L2WC&E@<B
M$55LH:+%6&@NZ:TNBRY.GHY1E1LJ6HR%YK+?BK?(*U&^;CJ^/#(=HTHT+#3W
MLWVKT:A?H^&EX[HA)QW3/>K\SO2E#@O-I:[5;M2OW?JGXWI;Q^C@TBH1608R
MX2SE_YA;]69)9VCZ/>F;(5#18BPT=Q1:24?IJ?,SQ51T-ZAH,1::RWZK#^EG
M].%7S,^U*\XV2MB1G_TN]R;X_U"#M%6#U+^CM?.!J&)8E1&L2<8^D1D0GG/-
MF3;IP^;JNHI-U54ZZ21R]"!3CQZ0B"KJL-!<$EM11S\CZGIGZI=,:2FXJ:HT
MSUE*DO)+D>QD$W5O#14MQD)S>6^U'CWY_AI%W6!#18NQT%SV6[E(_7+QQ-^6
M:^^<]>!^DD$5BEAH+MVM4*2H.WCFV1M82Z$2#H;,3@91=2$J6HR%YI+=ZD)Z
M\ET]BKJMAXH68Z&YIYM:T3@\5C2>)+,,'RK-?:'I[T#O(TVH0C/8.25H!.#2
MGK941@ZN<UT=&&SN-B<Z7]ASC$%;O3H.^IK))3=TI[ PIN&S<\.)K$Y85@4M
M"GOF<":T%IF]7)E5-LBR@GF^$$+?%\H&FG.NT_\ 4$L#!!0    ( ':!J5CZ
M>8\EE 0  &87   9    >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;,U846_B
M.!#^*U9N==I*+8D=H+0'2"W=U56Z[E6M>O=PN@>3&+":Q*QMH.RO/]LQ26"#
M6U"J'@^0.)[Q?%]FS.?IKQA_%C-")'A)DTP,O)F4\TO?%]&,I%BTV)QDZLF$
M\11+=<NGOIAS@F-CE"8^"H*NGV*:><.^&;OGPSY;R(1FY)X#L4A3S-?7)&&K
M@0>]S< #G<ZD'O"'_3F>DD<BG^;W7-WYA9>8IB03E&6 D\G NX*7(V0,S(R_
M*%F)RC704,:,/>N;VWC@!3HBDI!(:A=8_2S)B"2)]J3B^&Z=>L6:VK!ZO?'^
MU8!78,98D!%+_J:QG V\G@=B,L&+1#ZPU>_$ NIH?Q%+A/D&*SLW\$"T$)*E
MUEA%D-(L_\4OEHB*@?)3;X"L =HU:.\Q"*U!:(#FD1E8-UCB89^S%>!ZMO*F
M+PPWQEJAH9E^C8^2JZ=4V<GAHV31\]FU(B(&(Y:J[!#8\'L&OF'.L289?+XA
M$M-$G*C1I\<;\/G3"?@$?"!FF!,!: :>,BK%J1I4UW<T290'T?>E"E OXT<V
MF.L\&+0GF!#<L4S.!/B2Q23>MO<5L (=VJ"[1DZ'=YBW0 A/ 0I0NR:>T=O-
M0T<X84%V:/R%^\C6?)V-?R;[2C&=38DJ#PG&:U"==X_79OAJA7D,_OE#N02W
MDJ3BWSI^\_7;]>OK+>%2S'%$!IZJ>4'XDGC#7W^!W>"W.G(:<K9%5;N@JNWR
M/OQSKHD18*J(D8H&E5=SPBF+3\'*E*8:PTO"U5:3SP$QE@1,,.5@B9.%2EIE
M$K,DP5QHTSQ93^I(RR/IF4CTMK<<=EMMV/>753)^GM1IA:B8M 6R4X#L.$$^
M94LB-!*AJQ"P'/,I6&0X95S2'YM'-A>B:LY$3,@Z-/F2$%4B;8>MBQTXSL".
M?+?= G;W?6'7Y$">'.J/)6)3M1>IF77<N.,*P9JH;*DK!:?AD72=%W2=.\,R
M6S2P!5&'RFE^:-$WY&P+::] VOO@_;'7)%4-.=NBZJ*@ZN(-25&4CBXHFDUM
M&=0A=[MK[T]]I^&1*&%0RI/@$)SD94YYGA/[H;[B$@;[P;I-CT5;$6/0&=K#
MXU.];'*:'9JW37G;!HE*D.B#J]P&T!1=#7G;IJO4C-"ILPZO]%?\.4K=;7DL
MTE+R0;?F>U#0.(T*95 +SNGBX%?;D+=MP*7\@YV/KH2&=)ZEZSU4(RQE(_R_
MZL97 G,(1[?EL925TA&ZM>-7?1Y*,7\FTAZ+V 1L6#2G]UJXN=-NY0@!PYT#
MA'OA8X&52A$ZU97*!?O*?KSU7&0=;AV,(&JW>KO WD/6P5+70;<20P&"X,OW
M!95K<)M%JM1U!^8^P?6)V9 ZL]#?0^NA4NNAX(.W0]20O+/-H_<0BZ@4B\@M
M%K\MTC'ANJ!M'PXO,4WP."%@PKCMBN@N2/ZXMO5AE^A4:Z)W$>C/3EFX@SD4
MK%_I6*:$3TTC5ZC:760R;^\5HT6S^,JT2'?&K^'E*&_YEF[R#O0=YE.:"9"0
MB7(9M,X52)XW=?,;R>:F+SIF4K+47,X(C@G7$]3S"6-R<Z,7*%KKP_\ 4$L#
M!!0    ( ':!J5@ MOQ@:P,  *0.   9    >&PO=V]R:W-H965T<R]S:&5E
M=#0X+GAM;,57;6_:,!#^*U9639W4-F^00 =(0+NMTBJALFX?IGTPR4&B)G%F
M&VCWZV<[(2201JN6JE_ =NX>/_?<);H;; E]8 $ 1X]QE+"A%G">7NHZ\P*(
M,;L@*23BR9+0&'.QI2N=I12PKYSB2+<,P]%C'";::*#.9G0T(&L>A0G,*&+K
M.,;T:0(1V0XU4]L=W(6K@,L#?31(\0KFP._3&14[O4#QPQ@2%I($45@.M;%Y
M.35MZ: LOH>P9:4UDJ$L"'F0FQM_J!F2$43@<0F!Q=\&IA!%$DGP^)V#:L6=
MTK&\WJ%_4L&+8!:8P91$/T*?!T.MIR$?EG@=\3NR_0)Y0%V)YY&(J5^TS6T-
M#7EKQDF<.PL&<9AD__@Q%Z+D('#J':S<P3ITZ#SC8.<.2CD]8Z;"NL(<CP:4
M;!&5U@)-+I0VREM$$R8RC7-.Q=-0^/'1G!/OX7PBA/#1E,2B.AA6^IZC>999
M1)8HLUH<6UT_RC4P='H%'(<1^R <[^=7Z/3D SI!88*^!63-<.*S@<X%7WFK
M[N7<)ADWZQEN-KHE"0\8NDY\\*O^NHBS"-;:!3NQ&@%O,;U MGF&+,/JU/"9
M_KN[W4#'+K2W%9[]G/8!II"K.L-/XN7@:$PI3E8@UV<[=7TD]$-3G(8<1^$?
M\,_0."9K8?WSJX!$-QQB]JM.W^S^3OW]\@MQR5+LP5 3GP &= /:Z/T[TS$^
MUHG3$EA%JDXA5:<)O2)5FDN%RU)!)E6="!FRHY#E5VTS,KM=HS_0-^7HCJUZ
MEFL51A76W8)UMY'UE# N7Q\*&TC6M>0: 5Z:H9; *K$Z1:S.&Q>STZ94+8%5
MI'(+J=Q7*^8,N5LJ4]=Q#DKYV,8T3+.^E'L%YUXCYSNA J9>H++GBWJ.2"K)
MUG%L1'IIHEH"JP3=+X+NOW%-]]N4JB6PBE2FL6\DC%>KZASZH*P/Z[K&RG)Z
M=GUAFZ4.R&PD_AD2H#A2.<2^Z+%"QBF6W64MU4:PEZ:L+;1JZ-8^=.N-"SPG
MT)9<+:%5Y=KW:V9CC_-_)6X?-1BNX;J')7YLU>FZO8,2UTO]?@QTI<8@ACR9
MD:P;+DZ+46NL!HR#\XD<P=0<L8?)YC?1ZZ["A*$(E@+2N'#%6T>SD2C;<)*J
MJ6)!N)A1U#(08R10:2">+PGANXV\H!A,1W\!4$L#!!0    ( ':!J5A%[@V3
MKP0  $(5   9    >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;+5877.J.!C^
M*QGVS$X[8X4$0>VJ,ZT]9W<O.MLY;O=<1XB:*1 WB5K__29 00%3RNG>: AY
M/Y[W(WG(Y,#XB]@0(L%K'"5B:FVDW-[:M@@V),:BS[8D46]6C,=8JD>^ML66
M$QRF0G%D(\?Q[1C3Q)I-TKDG/INPG8QH0IXX$+LXQOQX3R)VF%K0>IOX3M<;
MJ2?LV62+UV1!Y//VB:LGN] 2TI@D@K($<+*:6G?P=HY2@73%/Y0<Q,D8:"A+
MQE[TPY_AU'*T1R0B@=0JL/K;DSF)(JU)^?%OKM0J;&K!T_&;]F\I> 5FB069
ML^@'#>5F:HTL$)(5WD7R.SO\07) GM87L$BDO^"0KW4L$.R$9'$NK#R(:9+]
MX]<\$"<"R+L@@'(!5!& _@4!-Q=P4Z"99RFL!RSQ;,+9 7"]6FG3@S0VJ;1"
M0Q.=QH7DZBU5<G*VD"QXN;E7@0C!G,6J.@1.XWL#%JIDPEU$ %N!Q09S<K-,
MESWAH\JC!'><XV1-]+@'_MIJJ1ZXTVFA\@BN'HC$-!+72M/SX@%<?;D&7X -
MA-8D $W <T*EZ*E)-?Y[PW8")Z&8V%*ATK[908[@/D. +B!PP2-+Y$: KTE(
MP@;YN5D>(H,"6X6SB"EZB^D],FI\Q+P/7-@#R$&#)H?,X@\D*,1=@SMND6(W
MU><VZ],;P:W8XH!,+=7I@O ]L69I0L6OOT#?^:TIYIG*P4=47E0V_R1E9^@'
M!?J!2?LL*TQ59VH/$U*5&$W6/9#LXB7A $NP)&N:)&I2E_F6<,I"<*4J,JO3
MZZ;89 :]U*#>)O<S.!A[0Q\.)_;^%+?1LXZXO0*W9\3]NVI.2=[%XM6P(,\;
M00=5H!B-=83B%U!\(Y0Y3@*US[\/QJ^!N8'#D>^,*V",YCJ"&19@AD8P7U\)
M#ZAX'\RP 8SKN*/AJ(+&:*\CFE&!9O13W462L'U?C>I]Y3NNB]QJ,38LK#;@
M&9IQ@6;<)C=X&9'>>\Z.:SZ,QL[8'U3W */%CMF!3GFZ.Z:]?_8CI3$DO+G;
M$ZYH&7@K/_#$:4 :3UOG,[?^S])VCO^$W< .]6G8]D,619@+/95EOS'YN=71
M2?;]/G0KJ3?[UA4[*K&CUB= 2UB90@A/.\OIU_9/L^&NP$H^ XV$H7(>M(3F
M-D!#_6JWFBUW159R%6@F*^>'0TMD@SHRU*\>$F;#78&59 2:V<C%/JP?$"U1
M>W74?G]<JU3/W*CG<$I" LV,Y.2@^(C/?LT9KS^HN?Q_L!-8TA-HYB?-F3KD
MYPC ^3G"B;XCT/MGH#Z>N/H:W^$(1'35?*:8;0[!D>CPN2#.OL3@"(3XV/0Q
M.&^GRA2*DMO EN2&G/*"GPV%V::?AP(5H4"70V%4U;522K($S6RIN5*H"@%-
M! W 'D>[YA!D>OW3IAQ %U8;H;YLB ;0;VY>5'(B9.0<Q2;;RM=<UQG7A-[0
MJ_AJ-MDQ%:BD.<A,<\Z(:QM4L!9:#XZ]ZE9DMOI15/;)+55,^#J]O!.J:7:)
MS"ZLBMGB@O NO1:SR^79[>(CYHJ^"1"1E1)U^D.5'YY=V&4/DFW3.Z\EDY+%
MZ7!#<$BX7J#>KQB3;P_:0'%M.OL/4$L#!!0    ( ':!J5CLSHV1]@(  %L(
M   9    >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;*U676_:,!3]*U>9-+52
M(2'AH^L@$M!.J[1JJ&C=P[0'DUR(5<?.; /EW\]V( ,6$ ]](;%SS_$Y]UKW
MTE\+^:HR1 UO.>-JX&5:%W>^KY(,<Z*:HD!NOLR%S(DV2[GP52&1I Z4,S\,
M@JZ?$\J]N._V)C+NBZ5FE.-$@EKF.9&;$3*Q'G@M;[?Q3!>9MAM^W"_( J>H
M?Q03:59^Q9+2'+FB@H/$^< ;MN[&/1OO EXHKM7>.U@G,R%>[>(Q'7B!%80,
M$VT9B'FL<(R,62(CX\^6TZN.M,#]]QW[%^?=>)D1A6/!?M)49P/OUH,4YV3)
M]+-8?\6MGX[E2P13[A?6V]C @V2IM,BW8*,@I[Q\DK=M'O8 8><$(-P"PDL!
MT180.:.E,F?KGF@2]Z58@[31ALV^N-PXM'%#N:WB5$OSE1J<CJ=:)*^-D4E$
M"F.1F\NAB,MO Z;FQJ1+AB#F,,V(Q,;,A4W(QI11PW!-9'H#C@&^%Q:E;N"%
ML&7),%3F:KAMN+I'32A3UY;6Q9=4R=Z)?5\;/U:5GVRUCTKMX0GM$3P)KC,%
M#SS%]!#OFSQ4R0AWR1B%9PF?B&Q"U+J!, C;-7K&E\.C,W*BJC:1XXM.U68O
MZ0>U&4I)^ )=%6:;T\6!7]\,)3QJS-7ONOR6Y[?KS[<-Y$X5),&!9SJ$0KE"
M+_[XH=4-/M<EYYW(#E+5KE+5/L<>/[P5IB\8_QIE#E>4PP:)5-=UIL\S=4LD
M1)"7EZMU"RG9J#K'[\%T8+=3V>U<9G<EF+D2C.I-G=.2Y),CL>U\%0?-;J?O
MK_9-U :UJZ #?=U*7_<R?2E=T11Y"AN*+*W3V/W_^".!YR(.U/4J=;VSZIZI
M>FW,)2)0;NX+*@V2:*Q35Q*U@H/L!.WP2&)]6-0YTNGO]>D<Y<*-+V6ZX)+K
MLDM5N]6$'+K!<+0_,I.S''3_:,JQ:WK0@G(%#.>&,FCV3'EE.<K*A1:%FP8S
MH<UL<:^9F?XH;8#Y/A="[Q;V@.K_1/P74$L#!!0    ( ':!J5@&I4Y"20,
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MH10RO*)JQC??H79H8/0EG,KR'VWJO8Z%DI54O*B%-4%!6/7$3W4@]@1\[XB
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MY3#7C2H(LT&_SSA7VXDQT+2^\6]02P,$%     @ =H&I6#V.L--[ @  608
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M+E"5JH.L[AA9NBQ82(/)XIHY9C\H6X#S2RG-KF,7:/\FR6]02P,$%     @
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M:0)@?RF$WDW, ^HOH/%?4$L#!!0    ( ':!J5@&_P;T)0,  ( ,   9
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MN,)/!! Z -\O.%?;@5Z@^N@(_@)02P,$%     @ =H&I6.*\(XUL!   "QL
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M!7BY\U*>2+8J-B^>F)0L+0Z7!,\(UP;J]SEC<GNB]T/J_:_Q_U!+ P04
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M.((Y  \8$L?V/;CS/HI6[ZEH_3^^T6]02P,$%     @ =H&I6)>*NQS
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MGWKG<MJE?.WY7N/U_Y/J<CXW72]_67[O'-WC%YP#_&_Q^ 502P,$%     @
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MK779'/)9][G$Y!-02P$"% ,4    " !V@:E8!T%-8H$   "Q    $
M        @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( ':!J5CT
M<\)T[@   "L"   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM
M;%!+ 0(4 Q0    ( ':!J5B97)PC$ 8  )PG   3              "  <P!
M  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ =H&I6"&9Y1A'!@
MJ",  !@              ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM
M;%!+ 0(4 Q0    ( ':!J5A,ZD\DFP8  '0;   8              " @8H.
M  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    " !V@:E8BPHW
MK(4#   Z#P  &               @(%;%0  >&PO=V]R:W-H965T<R]S:&5E
M=#,N>&UL4$L! A0#%     @ =H&I6!%E9HD=!0  ]!8  !@
M ("!%AD  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( ':!
MJ5AN4!?:E@4  #P?   8              " @6D>  !X;"]W;W)K<VAE971S
M+W-H965T-2YX;6Q02P$"% ,4    " !V@:E8!"&!TA4'   M'P  &
M        @($U)   >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%
M  @ =H&I6!N6/)I8!P  #Q$  !@              ("!@"L  'AL+W=O<FMS
M:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( ':!J5AN4<]"90<  ,83   8
M              " @0XS  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"
M% ,4    " !V@:E87%S EK@'  "P$P  &               @(&I.@  >&PO
M=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ =H&I6(\ ^C&>"P
M\BD  !D              ("!ET(  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX
M;6Q02P$"% ,4    " !V@:E8-OZ>QT(&  "E#P  &0              @(%L
M3@  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( ':!J5C!
M#IWS#@,  +('   9              " @>54  !X;"]W;W)K<VAE971S+W-H
M965T,3(N>&UL4$L! A0#%     @ =H&I6.1I=*L!"   %10  !D
M     ("!*E@  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ':!J5C=;]4')04  *D-   9              "
M@5""  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ =H&I
M6-^!-5^E!0  S0X  !D              ("!K(<  'AL+W=O<FMS:&5E=',O
M<VAE970Q.2YX;6Q02P$"% ,4    " !V@:E8#_:!YTD"  "C!0  &0
M        @(&(C0  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0
M   ( ':!J5B9[9<8&04  &P9   9              " @0B0  !X;"]W;W)K
M<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ =H&I6#B:%QF !P  3Q0
M !D              ("!6)4  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q0
M2P$"% ,4    " !V@:E8V4DPVNT#  #2"0  &0              @($/G0
M>&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( ':!J5A6(T21
MP 0  &(-   9              " @3.A  !X;"]W;W)K<VAE971S+W-H965T
M,C0N>&UL4$L! A0#%     @ =H&I6" !INN& P  5 @  !D
M ("!*J8  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    " !V
M@:E8+\T%QO("  !*"0  &0              @('GJ0  >&PO=V]R:W-H965T
M<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( ':!J5AGD)#+0@4  .X,   9
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M970S,2YX;6Q02P$"% ,4    " !V@:E8T:,0.+ #  !/$0  &0
M    @($YQ   >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    (
M ':!J5BG3A&Z&0,  $P)   9              " @2#(  !X;"]W;W)K<VAE
M971S+W-H965T,S,N>&UL4$L! A0#%     @ =H&I6)BDM_2H @  +0<  !D
M             ("!<,L  'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"
M% ,4    " !V@:E8O:%1%(D%  !*,   &0              @(%/S@  >&PO
M=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( ':!J5C HHS20P0
M  D:   9              " @0_4  !X;"]W;W)K<VAE971S+W-H965T,S8N
M>&UL4$L! A0#%     @ =H&I6!%?. SJ!0  R2P  !D              ("!
MB=@  'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4    " !V@:E8
M]LV !&P"  !I!0  &0              @(&JW@  >&PO=V]R:W-H965T<R]S
M:&5E=#,X+GAM;%!+ 0(4 Q0    ( ':!J5AA:QEK2P4  'HH   9
M      " @4WA  !X;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%
M  @ =H&I6'5Y#@>M @  =@<  !D              ("!S^8  'AL+W=O<FMS
M:&5E=',O<VAE970T,"YX;6Q02P$"% ,4    " !V@:E8<(S] BH"  #0!
M&0              @(&SZ0  >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+
M 0(4 Q0    ( ':!J5BXGWX*R@(  -\'   9              " @13L  !X
M;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @ =H&I6->;!*/:
M P  VQ   !D              ("!%>\  'AL+W=O<FMS:&5E=',O<VAE970T
M,RYX;6Q02P$"% ,4    " !V@:E8IC8H8VT"  !&!P  &0
M@($F\P  >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( ':!
MJ5C?F(:/"PL  &"!   9              " @<KU  !X;"]W;W)K<VAE971S
M+W-H965T-#4N>&UL4$L! A0#%     @ =H&I6,.[TE+3!0  \RH  !D
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M=#4P+GAM;%!+ 0(4 Q0    ( ':!J5@&I4Y"20,   8+   9
M  " @987 0!X;"]W;W)K<VAE971S+W-H965T-3$N>&UL4$L! A0#%     @
M=H&I6#V.L--[ @  608  !D              ("!%AL! 'AL+W=O<FMS:&5E
M=',O<VAE970U,BYX;6Q02P$"% ,4    " !V@:E8-\E'#0P#   -"0  &0
M            @('('0$ >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4
M Q0    ( ':!J5@&_P;T)0,  ( ,   9              " @0LA 0!X;"]W
M;W)K<VAE971S+W-H965T-30N>&UL4$L! A0#%     @ =H&I6.*\(XUL!
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M96QS+RYR96QS4$L! A0#%     @ =H&I6.]]"K"5!   /"4   \
M     ( ![3 ! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( ':!J5@,/Y#\
MY0$  '\A   :              "  :\U 0!X;"]?<F5L<R]W;W)K8F]O:RYX
M;6PN<F5L<U!+ 0(4 Q0    ( ':!J5B/X;=ITP$  #8A   3
M  "  <PW 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !  $  =Q$  - Y
$ 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>150</ContextCount>
  <ElementCount>295</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>55</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>11</UnitCount>
  <MyReports>
    <Report instance="rxrx-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="rxrx-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - Condensed Consolidated Balance Sheets (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited</Role>
      <ShortName>Condensed Consolidated Balance Sheets (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="rxrx-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Condensed Consolidated Balance Sheets (unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="rxrx-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="rxrx-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Condensed Consolidated Statements of Stockholders??? Equity (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders??? Equity (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="rxrx-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="rxrx-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Disclosure - Description of the Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/DescriptionoftheBusiness</Role>
      <ShortName>Description of the Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="rxrx-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/BasisofPresentation</Role>
      <ShortName>Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="rxrx-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Supplemental Financial Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/SupplementalFinancialInformation</Role>
      <ShortName>Supplemental Financial Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="rxrx-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Acquisitions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/Acquisitions</Role>
      <ShortName>Acquisitions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="rxrx-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="rxrx-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Goodwill and Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/GoodwillandIntangibleAssets</Role>
      <ShortName>Goodwill and Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="rxrx-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="rxrx-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/CommonStock</Role>
      <ShortName>Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="rxrx-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Collaborative Development Contracts</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/CollaborativeDevelopmentContracts</Role>
      <ShortName>Collaborative Development Contracts</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="rxrx-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="rxrx-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="rxrx-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="rxrx-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="rxrx-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="rxrx-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="rxrx-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>9954471 - Disclosure - Basis of Presentation (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/BasisofPresentationPolicies</Role>
      <ShortName>Basis of Presentation (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="rxrx-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9954472 - Disclosure - Supplemental Financial Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/SupplementalFinancialInformationTables</Role>
      <ShortName>Supplemental Financial Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.recursion.com/role/SupplementalFinancialInformation</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="rxrx-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9954473 - Disclosure - Acquisitions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/AcquisitionsTables</Role>
      <ShortName>Acquisitions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.recursion.com/role/Acquisitions</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="rxrx-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9954474 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.recursion.com/role/Leases</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="rxrx-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9954475 - Disclosure - Goodwill and Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/GoodwillandIntangibleAssetsTables</Role>
      <ShortName>Goodwill and Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.recursion.com/role/GoodwillandIntangibleAssets</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="rxrx-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9954476 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.recursion.com/role/StockBasedCompensation</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="rxrx-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9954477 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.recursion.com/role/NetLossPerShare</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="rxrx-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9954478 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.recursion.com/role/FairValueMeasurements</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="rxrx-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9954479 - Disclosure - Description of the Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/DescriptionoftheBusinessDetails</Role>
      <ShortName>Description of the Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.recursion.com/role/DescriptionoftheBusiness</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="rxrx-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9954480 - Disclosure - Supplemental Financial Information - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/SupplementalFinancialInformationNarrativeDetails</Role>
      <ShortName>Supplemental Financial Information - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="rxrx-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9954481 - Disclosure - Supplemental Financial Information - Schedule of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/SupplementalFinancialInformationScheduleofPropertyandEquipmentDetails</Role>
      <ShortName>Supplemental Financial Information - Schedule of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="rxrx-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9954482 - Disclosure - Supplemental Financial Information - Schedule of Accrued Expenses and Other Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/SupplementalFinancialInformationScheduleofAccruedExpensesandOtherLiabilitiesDetails</Role>
      <ShortName>Supplemental Financial Information - Schedule of Accrued Expenses and Other Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="rxrx-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9954483 - Disclosure - Supplemental Financial Information - Schedule of Interest Income and Expense Disclosure (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/SupplementalFinancialInformationScheduleofInterestIncomeandExpenseDisclosureDetails</Role>
      <ShortName>Supplemental Financial Information - Schedule of Interest Income and Expense Disclosure (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="rxrx-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9954484 - Disclosure - Acquisitions - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/AcquisitionsNarrativeDetails</Role>
      <ShortName>Acquisitions - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="rxrx-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9954485 - Disclosure - Acquisitions - Schedule of Business Acquisitions, by Acquisition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails</Role>
      <ShortName>Acquisitions - Schedule of Business Acquisitions, by Acquisition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="rxrx-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9954486 - Disclosure - Acquisitions - Schedule of Fair Value of Assets Acquired and Liabilities Assumed (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/AcquisitionsScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails</Role>
      <ShortName>Acquisitions - Schedule of Fair Value of Assets Acquired and Liabilities Assumed (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="rxrx-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9954487 - Disclosure - Acquisitions - Schedule of Business Acquisitions, Pro Forma Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/AcquisitionsScheduleofBusinessAcquisitionsProFormaInformationDetails</Role>
      <ShortName>Acquisitions - Schedule of Business Acquisitions, Pro Forma Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="rxrx-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9954488 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="rxrx-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9954489 - Disclosure - Leases - Components of Lease Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/LeasesComponentsofLeaseCostDetails</Role>
      <ShortName>Leases - Components of Lease Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="rxrx-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9954490 - Disclosure - Leases - Lease Term and Discount Rates (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/LeasesLeaseTermandDiscountRatesDetails</Role>
      <ShortName>Leases - Lease Term and Discount Rates (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="rxrx-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9954491 - Disclosure - Leases - Maturities of Operating Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails</Role>
      <ShortName>Leases - Maturities of Operating Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="rxrx-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9954492 - Disclosure - Goodwill and Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/GoodwillandIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.recursion.com/role/GoodwillandIntangibleAssetsTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="rxrx-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9954493 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.recursion.com/role/CommitmentsandContingencies</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="rxrx-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9954494 - Disclosure - Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/CommonStockDetails</Role>
      <ShortName>Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.recursion.com/role/CommonStock</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="rxrx-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9954495 - Disclosure - Collaborative Development Contracts (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/CollaborativeDevelopmentContractsDetails</Role>
      <ShortName>Collaborative Development Contracts (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.recursion.com/role/CollaborativeDevelopmentContracts</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="rxrx-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9954496 - Disclosure - Stock-Based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/StockBasedCompensationNarrativeDetails</Role>
      <ShortName>Stock-Based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="rxrx-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9954497 - Disclosure - Stock-Based Compensation - Summary of Stock-based Compensation Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/StockBasedCompensationSummaryofStockbasedCompensationExpensesDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock-based Compensation Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="rxrx-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9954498 - Disclosure - Stock-Based Compensation - Schedule of Share-based Payment Arrangement, Option, Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/StockBasedCompensationScheduleofSharebasedPaymentArrangementOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of Share-based Payment Arrangement, Option, Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="rxrx-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9954499 - Disclosure - Stock-Based Compensation - Schedule of Share-based Payment Award, Stock Options, Valuation Assumption (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of Share-based Payment Award, Stock Options, Valuation Assumption (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="rxrx-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9954500 - Disclosure - Stock-Based Compensation - Schedule of RSU Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/StockBasedCompensationScheduleofRSUActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of RSU Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="rxrx-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9954501 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.recursion.com/role/IncomeTaxes</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="rxrx-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9954502 - Disclosure - Net Loss Per Share - Schedule of Basic and Diluted Net Loss per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/NetLossPerShareScheduleofBasicandDilutedNetLossperShareDetails</Role>
      <ShortName>Net Loss Per Share - Schedule of Basic and Diluted Net Loss per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="rxrx-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9954503 - Disclosure - Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="rxrx-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9954504 - Disclosure - Fair Value Measurements - Assets and Liabilities Measured on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Assets and Liabilities Measured on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="rxrx-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9954505 - Disclosure - Fair Value Measurements - Asset and Liability Not Measured at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/FairValueMeasurementsAssetandLiabilityNotMeasuredatFairValueDetails</Role>
      <ShortName>Fair Value Measurements - Asset and Liability Not Measured at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 5 fact(s) appearing in ix:hidden were eligible for transformation: ecd:TrdArrDuration, rxrx:LicenseAgreementTradingPeriodUsedForEquityValueDetermination, us-gaap:ImpairmentOfLeasehold -  rxrx-20240331.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="rxrx-20240331.htm">rxrx-20240331.htm</File>
    <File>rxrx-20240331.xsd</File>
    <File>rxrx-20240331_cal.xml</File>
    <File>rxrx-20240331_def.xml</File>
    <File>rxrx-20240331_lab.xml</File>
    <File>rxrx-20240331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>rxrx-20240331_g1.jpg</File>
    <File>rxrx-20240331_g2.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="482">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/ecd/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>78
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "rxrx-20240331.htm": {
   "nsprefix": "rxrx",
   "nsuri": "http://www.recursion.com/20240331",
   "dts": {
    "inline": {
     "local": [
      "rxrx-20240331.htm"
     ]
    },
    "schema": {
     "local": [
      "rxrx-20240331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "rxrx-20240331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "rxrx-20240331_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "rxrx-20240331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "rxrx-20240331_pre.xml"
     ]
    }
   },
   "keyStandard": 258,
   "keyCustom": 37,
   "axisStandard": 23,
   "axisCustom": 2,
   "memberStandard": 30,
   "memberCustom": 24,
   "hidden": {
    "total": 10,
    "http://xbrl.sec.gov/dei/2023": 5,
    "http://xbrl.sec.gov/ecd/2023": 3,
    "http://fasb.org/us-gaap/2023": 1,
    "http://www.recursion.com/20240331": 1
   },
   "contextCount": 150,
   "entityCount": 1,
   "segmentCount": 55,
   "elementCount": 538,
   "unitCount": 11,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 482,
    "http://xbrl.sec.gov/dei/2023": 30,
    "http://xbrl.sec.gov/ecd/2023": 24
   },
   "report": {
    "R1": {
     "role": "http://www.recursion.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited",
     "longName": "0000002 - Statement - Condensed Consolidated Balance Sheets (unaudited)",
     "shortName": "Condensed Consolidated Balance Sheets (unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical",
     "longName": "0000003 - Statement - Condensed Consolidated Balance Sheets (unaudited) (Parenthetical)",
     "shortName": "Condensed Consolidated Balance Sheets (unaudited) (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.recursion.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited",
     "longName": "0000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)",
     "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.recursion.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited",
     "longName": "0000005 - Statement - Condensed Consolidated Statements of Stockholders\u2019 Equity (unaudited)",
     "shortName": "Condensed Consolidated Statements of Stockholders\u2019 Equity (unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-26",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-26",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited",
     "longName": "0000006 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited)",
     "shortName": "Condensed Consolidated Statements of Cash Flows (unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.recursion.com/role/DescriptionoftheBusiness",
     "longName": "0000007 - Disclosure - Description of the Business",
     "shortName": "Description of the Business",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.recursion.com/role/BasisofPresentation",
     "longName": "0000008 - Disclosure - Basis of Presentation",
     "shortName": "Basis of Presentation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.recursion.com/role/SupplementalFinancialInformation",
     "longName": "0000009 - Disclosure - Supplemental Financial Information",
     "shortName": "Supplemental Financial Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "rxrx:SupplementalBalanceSheetAndIncomeStatementInformationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "rxrx:SupplementalBalanceSheetAndIncomeStatementInformationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.recursion.com/role/Acquisitions",
     "longName": "0000010 - Disclosure - Acquisitions",
     "shortName": "Acquisitions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.recursion.com/role/Leases",
     "longName": "0000011 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.recursion.com/role/GoodwillandIntangibleAssets",
     "longName": "0000012 - Disclosure - Goodwill and Intangible Assets",
     "shortName": "Goodwill and Intangible Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.recursion.com/role/CommitmentsandContingencies",
     "longName": "0000013 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.recursion.com/role/CommonStock",
     "longName": "0000014 - Disclosure - Common Stock",
     "shortName": "Common Stock",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.recursion.com/role/CollaborativeDevelopmentContracts",
     "longName": "0000015 - Disclosure - Collaborative Development Contracts",
     "shortName": "Collaborative Development Contracts",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.recursion.com/role/StockBasedCompensation",
     "longName": "0000016 - Disclosure - Stock-Based Compensation",
     "shortName": "Stock-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.recursion.com/role/IncomeTaxes",
     "longName": "0000017 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.recursion.com/role/NetLossPerShare",
     "longName": "0000018 - Disclosure - Net Loss Per Share",
     "shortName": "Net Loss Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.recursion.com/role/FairValueMeasurements",
     "longName": "0000019 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R21": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ecd:NonRule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ecd:NonRule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.recursion.com/role/BasisofPresentationPolicies",
     "longName": "9954471 - Disclosure - Basis of Presentation (Policies)",
     "shortName": "Basis of Presentation (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.recursion.com/role/SupplementalFinancialInformationTables",
     "longName": "9954472 - Disclosure - Supplemental Financial Information (Tables)",
     "shortName": "Supplemental Financial Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.recursion.com/role/AcquisitionsTables",
     "longName": "9954473 - Disclosure - Acquisitions (Tables)",
     "shortName": "Acquisitions (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.recursion.com/role/LeasesTables",
     "longName": "9954474 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.recursion.com/role/GoodwillandIntangibleAssetsTables",
     "longName": "9954475 - Disclosure - Goodwill and Intangible Assets (Tables)",
     "shortName": "Goodwill and Intangible Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.recursion.com/role/StockBasedCompensationTables",
     "longName": "9954476 - Disclosure - Stock-Based Compensation (Tables)",
     "shortName": "Stock-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.recursion.com/role/NetLossPerShareTables",
     "longName": "9954477 - Disclosure - Net Loss Per Share (Tables)",
     "shortName": "Net Loss Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.recursion.com/role/FairValueMeasurementsTables",
     "longName": "9954478 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.recursion.com/role/DescriptionoftheBusinessDetails",
     "longName": "9954479 - Disclosure - Description of the Business (Details)",
     "shortName": "Description of the Business (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R31": {
     "role": "http://www.recursion.com/role/SupplementalFinancialInformationNarrativeDetails",
     "longName": "9954480 - Disclosure - Supplemental Financial Information - Narrative (Details)",
     "shortName": "Supplemental Financial Information - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Depreciation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Depreciation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.recursion.com/role/SupplementalFinancialInformationScheduleofPropertyandEquipmentDetails",
     "longName": "9954481 - Disclosure - Supplemental Financial Information - Schedule of Property and Equipment (Details)",
     "shortName": "Supplemental Financial Information - Schedule of Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.recursion.com/role/SupplementalFinancialInformationScheduleofAccruedExpensesandOtherLiabilitiesDetails",
     "longName": "9954482 - Disclosure - Supplemental Financial Information - Schedule of Accrued Expenses and Other Liabilities (Details)",
     "shortName": "Supplemental Financial Information - Schedule of Accrued Expenses and Other Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.recursion.com/role/SupplementalFinancialInformationScheduleofInterestIncomeandExpenseDisclosureDetails",
     "longName": "9954483 - Disclosure - Supplemental Financial Information - Schedule of Interest Income and Expense Disclosure (Details)",
     "shortName": "Supplemental Financial Information - Schedule of Interest Income and Expense Disclosure (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InvestmentIncomeNonoperating",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InvestmentIncomeNonoperating",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.recursion.com/role/AcquisitionsNarrativeDetails",
     "longName": "9954484 - Disclosure - Acquisitions - Narrative (Details)",
     "shortName": "Acquisitions - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-63",
      "name": "us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-63",
      "name": "us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.recursion.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails",
     "longName": "9954485 - Disclosure - Acquisitions - Schedule of Business Acquisitions, by Acquisition (Details)",
     "shortName": "Acquisitions - Schedule of Business Acquisitions, by Acquisition (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-60",
      "name": "us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-60",
      "name": "us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.recursion.com/role/AcquisitionsScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails",
     "longName": "9954486 - Disclosure - Acquisitions - Schedule of Fair Value of Assets Acquired and Liabilities Assumed (Details)",
     "shortName": "Acquisitions - Schedule of Fair Value of Assets Acquired and Liabilities Assumed (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:Goodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-61",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.recursion.com/role/AcquisitionsScheduleofBusinessAcquisitionsProFormaInformationDetails",
     "longName": "9954487 - Disclosure - Acquisitions - Schedule of Business Acquisitions, Pro Forma Information (Details)",
     "shortName": "Acquisitions - Schedule of Business Acquisitions, Pro Forma Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-72",
      "name": "us-gaap:BusinessAcquisitionsProFormaRevenue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:BusinessAcquisitionProFormaInformationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-72",
      "name": "us-gaap:BusinessAcquisitionsProFormaRevenue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:BusinessAcquisitionProFormaInformationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.recursion.com/role/LeasesNarrativeDetails",
     "longName": "9954488 - Disclosure - Leases - Narrative (Details)",
     "shortName": "Leases - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:LesseeOperatingLeaseRenewalTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:LesseeOperatingLeaseRenewalTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.recursion.com/role/LeasesComponentsofLeaseCostDetails",
     "longName": "9954489 - Disclosure - Leases - Components of Lease Cost (Details)",
     "shortName": "Leases - Components of Lease Cost (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.recursion.com/role/LeasesLeaseTermandDiscountRatesDetails",
     "longName": "9954490 - Disclosure - Leases - Lease Term and Discount Rates (Details)",
     "shortName": "Leases - Lease Term and Discount Rates (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.recursion.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails",
     "longName": "9954491 - Disclosure - Leases - Maturities of Operating Lease Liabilities (Details)",
     "shortName": "Leases - Maturities of Operating Lease Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.recursion.com/role/GoodwillandIntangibleAssetsDetails",
     "longName": "9954492 - Disclosure - Goodwill and Intangible Assets (Details)",
     "shortName": "Goodwill and Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillPeriodIncreaseDecrease",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:GoodwillPeriodIncreaseDecrease",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillPeriodIncreaseDecrease",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:GoodwillPeriodIncreaseDecrease",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.recursion.com/role/CommitmentsandContingenciesDetails",
     "longName": "9954493 - Disclosure - Commitments and Contingencies (Details)",
     "shortName": "Commitments and Contingencies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:LossContingencyAccrualAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:LossContingencyAccrualAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.recursion.com/role/CommonStockDetails",
     "longName": "9954494 - Disclosure - Common Stock (Details)",
     "shortName": "Common Stock (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DividendsStock",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DividendsStock",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.recursion.com/role/CollaborativeDevelopmentContractsDetails",
     "longName": "9954495 - Disclosure - Collaborative Development Contracts (Details)",
     "shortName": "Collaborative Development Contracts (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:ContractWithCustomerLiabilityCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-103",
      "name": "us-gaap:ContractWithCustomerLiabilityCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.recursion.com/role/StockBasedCompensationNarrativeDetails",
     "longName": "9954496 - Disclosure - Stock-Based Compensation - Narrative (Details)",
     "shortName": "Stock-Based Compensation - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.recursion.com/role/StockBasedCompensationSummaryofStockbasedCompensationExpensesDetails",
     "longName": "9954497 - Disclosure - Stock-Based Compensation - Summary of Stock-based Compensation Expenses (Details)",
     "shortName": "Stock-Based Compensation - Summary of Stock-based Compensation Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.recursion.com/role/StockBasedCompensationScheduleofSharebasedPaymentArrangementOptionActivityDetails",
     "longName": "9954498 - Disclosure - Stock-Based Compensation - Schedule of Share-based Payment Arrangement, Option, Activity (Details)",
     "shortName": "Stock-Based Compensation - Schedule of Share-based Payment Arrangement, Option, Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.recursion.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionDetails",
     "longName": "9954499 - Disclosure - Stock-Based Compensation - Schedule of Share-based Payment Award, Stock Options, Valuation Assumption (Details)",
     "shortName": "Stock-Based Compensation - Schedule of Share-based Payment Award, Stock Options, Valuation Assumption (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-111",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-111",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.recursion.com/role/StockBasedCompensationScheduleofRSUActivityDetails",
     "longName": "9954500 - Disclosure - Stock-Based Compensation - Schedule of RSU Activity (Details)",
     "shortName": "Stock-Based Compensation - Schedule of RSU Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-114",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-114",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.recursion.com/role/IncomeTaxesDetails",
     "longName": "9954501 - Disclosure - Income Taxes (Details)",
     "shortName": "Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.recursion.com/role/NetLossPerShareScheduleofBasicandDilutedNetLossperShareDetails",
     "longName": "9954502 - Disclosure - Net Loss Per Share - Schedule of Basic and Diluted Net Loss per Share (Details)",
     "shortName": "Net Loss Per Share - Schedule of Basic and Diluted Net Loss per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R54": {
     "role": "http://www.recursion.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossPerShareDetails",
     "longName": "9954503 - Disclosure - Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Net Loss Per Share (Details)",
     "shortName": "Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Net Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.recursion.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails",
     "longName": "9954504 - Disclosure - Fair Value Measurements - Assets and Liabilities Measured on Recurring Basis (Details)",
     "shortName": "Fair Value Measurements - Assets and Liabilities Measured on Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-125",
      "name": "rxrx:RestrictedCashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-125",
      "name": "rxrx:RestrictedCashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.recursion.com/role/FairValueMeasurementsAssetandLiabilityNotMeasuredatFairValueDetails",
     "longName": "9954505 - Disclosure - Fair Value Measurements - Asset and Liability Not Measured at Fair Value (Details)",
     "shortName": "Fair Value Measurements - Asset and Liability Not Measured at Fair Value (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-141",
      "name": "us-gaap:LongTermDebtFairValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-141",
      "name": "us-gaap:LongTermDebtFairValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxrx-20240331.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "rxrx_A2021EquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.recursion.com/20240331",
     "localname": "A2021EquityIncentivePlanMember",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2021 Equity Incentive Plan",
        "label": "2021 Equity Incentive Plan [Member]",
        "documentation": "2021 Equity Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r568"
     ]
    },
    "rxrx_AccruedDevelopmentCostsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.recursion.com/20240331",
     "localname": "AccruedDevelopmentCostsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.recursion.com/role/SupplementalFinancialInformationScheduleofAccruedExpensesandOtherLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/SupplementalFinancialInformationScheduleofAccruedExpensesandOtherLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued development expenses",
        "label": "Accrued Development Costs, Current",
        "documentation": "Accrued Development Costs, Current"
       }
      }
     },
     "auth_ref": []
    },
    "rxrx_AccruedEarlyDiscoveryExpensesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.recursion.com/20240331",
     "localname": "AccruedEarlyDiscoveryExpensesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.recursion.com/role/SupplementalFinancialInformationScheduleofAccruedExpensesandOtherLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/SupplementalFinancialInformationScheduleofAccruedExpensesandOtherLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued early discovery expenses",
        "label": "Accrued Early Discovery Expenses, Current",
        "documentation": "Accrued Early Discovery Expenses, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.recursion.com/role/SupplementalFinancialInformationScheduleofAccruedExpensesandOtherLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited",
      "http://www.recursion.com/role/SupplementalFinancialInformationScheduleofAccruedExpensesandOtherLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other liabilities",
        "totalLabel": "Accrued expense and other liabilities",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.recursion.com/role/SupplementalFinancialInformationScheduleofPropertyandEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/SupplementalFinancialInformationScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less: Accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r136",
      "r434"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r619"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r568",
      "r741"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-in-Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r325",
      "r326",
      "r327",
      "r460",
      "r672",
      "r673",
      "r674",
      "r721",
      "r743"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r625"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r625"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r625"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r625"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r59",
      "r291"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "rxrx_AffiliatedHoldersOwnershipPercentage": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.recursion.com/20240331",
     "localname": "AffiliatedHoldersOwnershipPercentage",
     "presentation": [
      "http://www.recursion.com/role/CommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Affiliated holders, ownership percentage",
        "label": "Affiliated Holders, Ownership Percentage",
        "documentation": "Affiliated Holders, Ownership Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "rxrx_AffiliatedHoldersPotentialOwnershipPercentageWhenOutstandingEquityAwardsVest": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.recursion.com/20240331",
     "localname": "AffiliatedHoldersPotentialOwnershipPercentageWhenOutstandingEquityAwardsVest",
     "presentation": [
      "http://www.recursion.com/role/CommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Affiliated holders, potential ownership percentage when outstanding equity awards vest",
        "label": "Affiliated Holders, Potential Ownership Percentage When Outstanding Equity Awards Vest",
        "documentation": "Affiliated Holders, Potential Ownership Percentage When Outstanding Equity Awards Vest"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r590",
      "r601",
      "r611",
      "r636"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r593",
      "r604",
      "r614",
      "r639"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r625"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r632"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r597",
      "r605",
      "r615",
      "r632",
      "r640",
      "r644",
      "r652"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r650"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationSummaryofStockbasedCompensationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payment arrangement, expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r320",
      "r328"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.recursion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.recursion.com/role/GoodwillandIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization expense",
        "label": "Amortization of Intangible Assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r39",
      "r43"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.recursion.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive securities excluded from computation of loss per share, amount (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r189"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.recursion.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities [Axis]",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.recursion.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.recursion.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name [Domain]",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.recursion.com/role/CollaborativeDevelopmentContractsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r350"
     ]
    },
    "us-gaap_AssetUnderConstructionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetUnderConstructionMember",
     "presentation": [
      "http://www.recursion.com/role/SupplementalFinancialInformationScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Construction in progress",
        "label": "Asset under Construction [Member]",
        "documentation": "Asset in process of being built."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r140",
      "r161",
      "r196",
      "r204",
      "r208",
      "r213",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r351",
      "r353",
      "r374",
      "r428",
      "r494",
      "r568",
      "r581",
      "r688",
      "r689",
      "r729"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r147",
      "r161",
      "r213",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r351",
      "r353",
      "r374",
      "r568",
      "r688",
      "r689",
      "r729"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.recursion.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.recursion.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets, Fair Value Disclosure",
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "rxrx_AtTheMarketOfferingProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.recursion.com/20240331",
     "localname": "AtTheMarketOfferingProgramMember",
     "presentation": [
      "http://www.recursion.com/role/CommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "At-the-Market offering program",
        "label": "At-The-Market Offering Program [Member]",
        "documentation": "At-The-Market Offering Program"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r647"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r648"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r643"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r643"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r643"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r643"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r643"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r643"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.recursion.com/role/AcquisitionsNarrativeDetails",
      "http://www.recursion.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails",
      "http://www.recursion.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.recursion.com/role/StockBasedCompensationScheduleofRSUActivityDetails",
      "http://www.recursion.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Axis]",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r646"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r645"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r644"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r644"
     ]
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetLocationAxis",
     "presentation": [
      "http://www.recursion.com/role/SupplementalFinancialInformationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Location [Axis]",
        "label": "Balance Sheet Location [Axis]",
        "documentation": "Information by location on balance sheet (statement of financial position)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetLocationDomain",
     "presentation": [
      "http://www.recursion.com/role/SupplementalFinancialInformationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Location [Domain]",
        "label": "Balance Sheet Location [Domain]",
        "documentation": "Location in the balance sheet (statement of financial position)."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r67"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.recursion.com/role/BasisofPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.recursion.com/role/BasisofPresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "rxrx_BioHiveSupercomputerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.recursion.com/20240331",
     "localname": "BioHiveSupercomputerMember",
     "presentation": [
      "http://www.recursion.com/role/SupplementalFinancialInformationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BioHive Supercomputer",
        "label": "BioHive Supercomputer [Member]",
        "documentation": "BioHive Supercomputer"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://www.recursion.com/role/AcquisitionsNarrativeDetails",
      "http://www.recursion.com/role/AcquisitionsScheduleofBusinessAcquisitionsProFormaInformationDetails",
      "http://www.recursion.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails",
      "http://www.recursion.com/role/AcquisitionsScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.recursion.com/role/CommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition, Acquiree [Domain]",
        "label": "Business Acquisition, Acquiree [Domain]",
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "auth_ref": [
      "r346",
      "r562",
      "r563"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://www.recursion.com/role/AcquisitionsNarrativeDetails",
      "http://www.recursion.com/role/AcquisitionsScheduleofBusinessAcquisitionsProFormaInformationDetails",
      "http://www.recursion.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails",
      "http://www.recursion.com/role/AcquisitionsScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.recursion.com/role/CommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition [Axis]",
        "label": "Business Acquisition [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r62",
      "r346",
      "r562",
      "r563"
     ]
    },
    "rxrx_BusinessAcquisitionContingentConsiderationEquityInterestsIssuableNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.recursion.com/20240331",
     "localname": "BusinessAcquisitionContingentConsiderationEquityInterestsIssuableNumberOfShares",
     "presentation": [
      "http://www.recursion.com/role/CommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent consideration, equity interests issuable (in shares)",
        "label": "Business Acquisition , Contingent Consideration, Equity Interests Issuable, Number Of Shares",
        "documentation": "Business Acquisition , Contingent Consideration, Equity Interests Issuable, Number Of Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued",
     "presentation": [
      "http://www.recursion.com/role/AcquisitionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity interest issued or issuable (in shares)",
        "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares",
        "documentation": "Number of shares of equity interests issued or issuable to acquire entity."
       }
      }
     },
     "auth_ref": [
      "r112"
     ]
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionLineItems",
     "presentation": [
      "http://www.recursion.com/role/AcquisitionsNarrativeDetails",
      "http://www.recursion.com/role/AcquisitionsScheduleofBusinessAcquisitionsProFormaInformationDetails",
      "http://www.recursion.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails",
      "http://www.recursion.com/role/AcquisitionsScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition [Line Items]",
        "label": "Business Acquisition [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r346"
     ]
    },
    "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionProFormaInformationTextBlock",
     "presentation": [
      "http://www.recursion.com/role/AcquisitionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Business Acquisitions, Pro Forma Information",
        "label": "Business Acquisition, Pro Forma Information [Table Text Block]",
        "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate."
       }
      }
     },
     "auth_ref": [
      "r660",
      "r661"
     ]
    },
    "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionsProFormaNetIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.recursion.com/role/AcquisitionsScheduleofBusinessAcquisitionsProFormaInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss",
        "label": "Business Acquisition, Pro Forma Net Income (Loss)",
        "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period."
       }
      }
     },
     "auth_ref": [
      "r344",
      "r345"
     ]
    },
    "us-gaap_BusinessAcquisitionsProFormaRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionsProFormaRevenue",
     "crdr": "credit",
     "presentation": [
      "http://www.recursion.com/role/AcquisitionsScheduleofBusinessAcquisitionsProFormaInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net revenue",
        "label": "Business Acquisition, Pro Forma Revenue",
        "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period."
       }
      }
     },
     "auth_ref": [
      "r344",
      "r345"
     ]
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationConsiderationTransferred1",
     "crdr": "credit",
     "calculation": {
      "http://www.recursion.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.recursion.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total consideration",
        "label": "Business Combination, Consideration Transferred",
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r2",
      "r9"
     ]
    },
    "rxrx_BusinessCombinationConsiderationTransferredEquityInterestsIssuable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.recursion.com/20240331",
     "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuable",
     "crdr": "credit",
     "calculation": {
      "http://www.recursion.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails": {
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of equity interests issued, value",
        "label": "Business Combination, Consideration Transferred, Equity Interests Issuable",
        "documentation": "Business Combination, Consideration Transferred, Equity Interests Issuable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred",
     "crdr": "credit",
     "calculation": {
      "http://www.recursion.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails": {
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred liabilities for additional consideration",
        "label": "Business Combination, Consideration Transferred, Liabilities Incurred",
        "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r2",
      "r65",
      "r349"
     ]
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationDisclosureTextBlock",
     "presentation": [
      "http://www.recursion.com/role/Acquisitions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisitions",
        "label": "Business Combination Disclosure [Text Block]",
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r347"
     ]
    },
    "us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual",
     "crdr": "credit",
     "presentation": [
      "http://www.recursion.com/role/AcquisitionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Operating loss",
        "label": "Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual",
        "documentation": "This element represents the amount of earnings or loss of the acquiree since the acquisition date included in the consolidated income statement for the reporting period."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual",
     "crdr": "credit",
     "presentation": [
      "http://www.recursion.com/role/AcquisitionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net revenues",
        "label": "Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual",
        "documentation": "This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.recursion.com/role/AcquisitionsScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/AcquisitionsScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.recursion.com/role/AcquisitionsScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/AcquisitionsScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other",
        "documentation": "Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.recursion.com/role/AcquisitionsScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/AcquisitionsScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Accounts payable and accrued liabilities",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable",
        "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue",
     "crdr": "credit",
     "calculation": {
      "http://www.recursion.com/role/AcquisitionsScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/AcquisitionsScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Unearned revenue",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue",
        "documentation": "Amount of deferred revenue expected to be recognized as such within one year or the normal operating cycle, if longer, assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.recursion.com/role/AcquisitionsScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/AcquisitionsScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Deferred income taxes",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
     "crdr": "debit",
     "calculation": {
      "http://www.recursion.com/role/AcquisitionsScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/AcquisitionsScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets - technology",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles",
        "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r64"
     ]
    },
    "rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.recursion.com/20240331",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.recursion.com/role/AcquisitionsScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/AcquisitionsScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Investments",
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Investments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "crdr": "debit",
     "calculation": {
      "http://www.recursion.com/role/AcquisitionsScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/AcquisitionsScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total identifiable net assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net",
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r64"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther",
     "crdr": "credit",
     "calculation": {
      "http://www.recursion.com/role/AcquisitionsScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/AcquisitionsScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other liabilities, non-current",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other",
        "documentation": "Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.recursion.com/20240331",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.recursion.com/role/AcquisitionsScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/AcquisitionsScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other liabilities, current",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Liabilities, Current",
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Liabilities, Current"
       }
      }
     },
     "auth_ref": []
    },
    "rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.recursion.com/20240331",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherReceivables",
     "crdr": "debit",
     "calculation": {
      "http://www.recursion.com/role/AcquisitionsScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/AcquisitionsScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other receivables",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Receivables",
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Receivables"
       }
      }
     },
     "auth_ref": []
    },
    "rxrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.recursion.com/20240331",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash",
     "crdr": "debit",
     "calculation": {
      "http://www.recursion.com/role/AcquisitionsScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/AcquisitionsScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Restricted Cash",
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Restricted Cash"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
     "crdr": "debit",
     "calculation": {
      "http://www.recursion.com/role/AcquisitionsScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.recursion.com/role/AcquisitionsScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets acquired and liabilities assumed",
        "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net",
        "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued property and equipment",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r35",
      "r36"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r134",
      "r543"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAxis",
     "presentation": [
      "http://www.recursion.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents [Axis]",
        "label": "Cash and Cash Equivalents [Axis]",
        "documentation": "Information by type of cash and cash equivalent balance."
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.recursion.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash equivalents",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period",
        "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r93",
      "r159"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net change in cash, cash equivalents and restricted cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r93"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r623"
     ]
    },
    "rxrx_ChristopherGibsonAndAffiliatesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.recursion.com/20240331",
     "localname": "ChristopherGibsonAndAffiliatesMember",
     "presentation": [
      "http://www.recursion.com/role/CommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Christopher Gibson and Affiliates",
        "label": "Christopher Gibson And Affiliates [Member]",
        "documentation": "Christopher Gibson And Affiliates"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.recursion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.recursion.com/role/AcquisitionsNarrativeDetails",
      "http://www.recursion.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails",
      "http://www.recursion.com/role/CommonStockDetails",
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical",
      "http://www.recursion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Domain]",
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r143",
      "r144",
      "r145",
      "r161",
      "r183",
      "r184",
      "r186",
      "r188",
      "r194",
      "r195",
      "r213",
      "r233",
      "r235",
      "r236",
      "r237",
      "r240",
      "r241",
      "r259",
      "r260",
      "r263",
      "r266",
      "r273",
      "r374",
      "r454",
      "r455",
      "r456",
      "r457",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r482",
      "r503",
      "r522",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r658",
      "r669",
      "r675"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.recursion.com/role/CommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Line Items]",
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r144",
      "r145",
      "r194",
      "r259",
      "r260",
      "r261",
      "r263",
      "r266",
      "r271",
      "r273",
      "r454",
      "r455",
      "r456",
      "r457",
      "r557",
      "r658",
      "r669"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r624"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r624"
     ]
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://www.recursion.com/role/CollaborativeDevelopmentContracts"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Development Contracts",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r124",
      "r128"
     ]
    },
    "us-gaap_CollaborativeArrangementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementMember",
     "presentation": [
      "http://www.recursion.com/role/CollaborativeDevelopmentContractsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative arrangement",
        "label": "Collaborative Arrangement [Member]",
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity."
       }
      }
     },
     "auth_ref": [
      "r350"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://www.recursion.com/role/CollaborativeDevelopmentContractsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r350"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies (Note\u00a07)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r73",
      "r430",
      "r481"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.recursion.com/role/CommitmentsandContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r226",
      "r227",
      "r539",
      "r683"
     ]
    },
    "us-gaap_CommonClassAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonClassAMember",
     "presentation": [
      "http://www.recursion.com/role/AcquisitionsNarrativeDetails",
      "http://www.recursion.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails",
      "http://www.recursion.com/role/CommonStockDetails",
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical",
      "http://www.recursion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Class A",
        "terseLabel": "Class A",
        "label": "Common Class A [Member]",
        "documentation": "Classification of common stock representing ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r743"
     ]
    },
    "us-gaap_CommonClassBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonClassBMember",
     "presentation": [
      "http://www.recursion.com/role/CommonStockDetails",
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical",
      "http://www.recursion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Class B",
        "terseLabel": "Class B",
        "label": "Common Class B [Member]",
        "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r743"
     ]
    },
    "rxrx_CommonStockConversionRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.recursion.com/20240331",
     "localname": "CommonStockConversionRatio",
     "presentation": [
      "http://www.recursion.com/role/CommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, conversion ratio",
        "label": "Common Stock, Conversion Ratio",
        "documentation": "Common Stock, Conversion Ratio"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock (Class A, B and Exchangeable)",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r571",
      "r572",
      "r573",
      "r575",
      "r576",
      "r577",
      "r578",
      "r672",
      "r673",
      "r721",
      "r740",
      "r743"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r482"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical",
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common sock, shares outstanding (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r79",
      "r482",
      "r500",
      "r743",
      "r744"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, $0.00001 par value; 2,000,000,000 shares (Class A 1,989,032,117 and Class B 10,967,883) authorized as of March\u00a031, 2024 and December\u00a031, 2023; 237,508,682 shares (Class A 230,043,061, Class B 7,464,871 and Exchangeable 750) and 234,270,384 shares (Class A 226,264,764, Class B 7,544,871 and Exchangeable 460,749) issued and outstanding as of March\u00a031, 2024 and December\u00a031, 2023, respectively",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r431",
      "r568"
     ]
    },
    "rxrx_CommonStockVotePerShare": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.recursion.com/20240331",
     "localname": "CommonStockVotePerShare",
     "presentation": [
      "http://www.recursion.com/role/CommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vote per share of common stock (in votes)",
        "label": "Common Stock, Vote Per Share",
        "documentation": "Common Stock, Vote Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r629"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r628"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r630"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r627"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited",
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss and comprehensive loss",
        "terseLabel": "Comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r149",
      "r151",
      "r156",
      "r424",
      "r438"
     ]
    },
    "us-gaap_ConstructionPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConstructionPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.recursion.com/role/SupplementalFinancialInformationScheduleofAccruedExpensesandOtherLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/SupplementalFinancialInformationScheduleofAccruedExpensesandOtherLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued construction",
        "label": "Construction Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for the acquisition of merchandise, materials, supplies and services pertaining to construction projects such as a housing development or factory expansion not classified as trade payables. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_ContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.recursion.com/role/CollaborativeDevelopmentContractsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining unearned revenue",
        "label": "Contract with Customer, Liability",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r275",
      "r276",
      "r279"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/CollaborativeDevelopmentContractsDetails",
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unearned revenue",
        "label": "Contract with Customer, Liability, Current",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r275",
      "r276",
      "r279"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unearned revenue, non-current",
        "label": "Contract with Customer, Liability, Noncurrent",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r275",
      "r276",
      "r279"
     ]
    },
    "rxrx_ContractWithCustomerMaximumAcceptedProduct": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.recursion.com/20240331",
     "localname": "ContractWithCustomerMaximumAcceptedProduct",
     "presentation": [
      "http://www.recursion.com/role/CollaborativeDevelopmentContractsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of eligible phenomaps (in phenomaps)",
        "label": "Contract With Customer, Maximum Accepted Product",
        "documentation": "Contract With Customer, Maximum Accepted Product"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfGoodsAndServicesSold",
     "crdr": "debit",
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of revenue",
        "label": "Cost of Goods and Services Sold",
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r408"
     ]
    },
    "us-gaap_CostOfSalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfSalesMember",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationSummaryofStockbasedCompensationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of revenue",
        "label": "Cost of Sales [Member]",
        "documentation": "Primary financial statement caption encompassing cost of sales."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostsAndExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating costs and expenses",
        "label": "Costs and Expenses",
        "documentation": "Total costs of sales and operating expenses for the period."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.recursion.com/role/CollaborativeDevelopmentContractsDetails",
      "http://www.recursion.com/role/SupplementalFinancialInformationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Axis]",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r164",
      "r165",
      "r245",
      "r261",
      "r401",
      "r544",
      "r546"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.recursion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "rxrx_CyclicaIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.recursion.com/20240331",
     "localname": "CyclicaIncMember",
     "presentation": [
      "http://www.recursion.com/role/AcquisitionsNarrativeDetails",
      "http://www.recursion.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails",
      "http://www.recursion.com/role/AcquisitionsScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cyclica Inc",
        "label": "Cyclica Inc [Member]",
        "documentation": "Cyclica Inc"
       }
      }
     },
     "auth_ref": []
    },
    "rxrx_DataCenterLeaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.recursion.com/20240331",
     "localname": "DataCenterLeaseMember",
     "presentation": [
      "http://www.recursion.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Data Center Lease",
        "label": "Data Center Lease [Member]",
        "documentation": "Data Center Lease"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.recursion.com/role/SupplementalFinancialInformationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Axis]",
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r76",
      "r77",
      "r114",
      "r115",
      "r166",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r383",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r670"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.recursion.com/role/SupplementalFinancialInformationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, interest rate (as percent)",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r243"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.recursion.com/role/SupplementalFinancialInformationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Name [Domain]",
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r166",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r383",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r670"
     ]
    },
    "us-gaap_DebtInstrumentTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentTerm",
     "presentation": [
      "http://www.recursion.com/role/SupplementalFinancialInformationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, term",
        "label": "Debt Instrument, Term",
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "crdr": "credit",
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liabilities",
        "label": "Deferred Income Tax Liabilities, Net",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r331",
      "r332",
      "r429"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://www.recursion.com/role/SupplementalFinancialInformationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r45"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "label": "Depreciation, Depletion and Amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r200"
     ]
    },
    "rxrx_DevelopedAndCommercializedProgramsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.recursion.com/20240331",
     "localname": "DevelopedAndCommercializedProgramsMember",
     "presentation": [
      "http://www.recursion.com/role/CollaborativeDevelopmentContractsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Developed and commercialized programs",
        "label": "Developed And Commercialized Programs [Member]",
        "documentation": "Developed And Commercialized Programs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r293",
      "r321",
      "r322",
      "r324",
      "r565"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DividendsStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DividendsStock",
     "crdr": "debit",
     "presentation": [
      "http://www.recursion.com/role/CommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends, stock",
        "label": "Dividends, Stock",
        "documentation": "Amount of paid and unpaid stock dividends declared for classes of stock, for example, but not limited to, common and preferred."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r107"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.recursion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.recursion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://www.recursion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Information [Line Items]",
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://www.recursion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Information [Table]",
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.recursion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://www.recursion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Quarterly Report",
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r585"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.recursion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r618"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.recursion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Per share data",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited",
      "http://www.recursion.com/role/NetLossPerShareScheduleofBasicandDilutedNetLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net loss per share of Class A, B and Exchangeable common stock, basic (in dollars per share)",
        "terseLabel": "Net loss per share, basic (in dollars per shares)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r181",
      "r183",
      "r186",
      "r187",
      "r188",
      "r192",
      "r363",
      "r364",
      "r425",
      "r439",
      "r547"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited",
      "http://www.recursion.com/role/NetLossPerShareScheduleofBasicandDilutedNetLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net loss per share of Class A, B and Exchangeable common stock, diluted (in dollars per share)",
        "terseLabel": "Net loss per share, diluted (in dollars per shares)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r183",
      "r186",
      "r187",
      "r188",
      "r192",
      "r363",
      "r364",
      "r425",
      "r439",
      "r547"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.recursion.com/role/NetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss Per Share",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r180",
      "r189",
      "r190",
      "r191"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of exchange rate changes on cash, cash equivalents and restricted cash",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r375"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.recursion.com/role/SupplementalFinancialInformationScheduleofAccruedExpensesandOtherLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/SupplementalFinancialInformationScheduleofAccruedExpensesandOtherLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued compensation",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationSummaryofStockbasedCompensationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unvested stock options, unamortized stock-based compensation cost, weighted average period recognition",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r323"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation cost",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r720"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unvested stock options, unamortized stock-based compensation cost",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r720"
     ]
    },
    "us-gaap_EmployeeStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockMember",
     "presentation": [
      "http://www.recursion.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee stock",
        "label": "Employee Stock [Member]",
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.recursion.com/role/AcquisitionsNarrativeDetails",
      "http://www.recursion.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossPerShareDetails",
      "http://www.recursion.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.recursion.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock based compensation",
        "verboseLabel": "Stock Options",
        "label": "Employee Stock Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.recursion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.recursion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.recursion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.recursion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.recursion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r583"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.recursion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.recursion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.recursion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r583"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.recursion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.recursion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r583"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.recursion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.recursion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r657"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.recursion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r583"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.recursion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r583"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.recursion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r583"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.recursion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r583"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r130",
      "r152",
      "r153",
      "r154",
      "r167",
      "r168",
      "r169",
      "r171",
      "r177",
      "r179",
      "r193",
      "r214",
      "r215",
      "r274",
      "r325",
      "r326",
      "r327",
      "r337",
      "r338",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r362",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r398",
      "r448",
      "r449",
      "r450",
      "r460",
      "r522"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r626"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r590",
      "r601",
      "r611",
      "r636"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r587",
      "r598",
      "r608",
      "r633"
     ]
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "presentation": [
      "http://www.recursion.com/role/FairValueMeasurementsAssetandLiabilityNotMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair values",
        "label": "Estimate of Fair Value Measurement [Member]",
        "documentation": "Measured as an estimate of fair value."
       }
      }
     },
     "auth_ref": [
      "r250",
      "r373",
      "r553",
      "r554"
     ]
    },
    "rxrx_ExchangeableStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.recursion.com/20240331",
     "localname": "ExchangeableStockMember",
     "presentation": [
      "http://www.recursion.com/role/AcquisitionsNarrativeDetails",
      "http://www.recursion.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails",
      "http://www.recursion.com/role/CommonStockDetails",
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exchangeable Stock",
        "label": "Exchangeable Stock [Member]",
        "documentation": "Exchangeable Stock"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r632"
     ]
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "presentation": [
      "http://www.recursion.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByBalanceSheetGroupingTable",
     "presentation": [
      "http://www.recursion.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r70",
      "r71"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.recursion.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r250",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r367",
      "r402",
      "r403",
      "r404",
      "r553",
      "r554",
      "r559",
      "r560",
      "r561"
     ]
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByMeasurementBasisAxis",
     "presentation": [
      "http://www.recursion.com/role/FairValueMeasurementsAssetandLiabilityNotMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Basis [Axis]",
        "label": "Measurement Basis [Axis]",
        "documentation": "Information by measurement basis."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r69",
      "r250",
      "r553",
      "r554"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.recursion.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency [Axis]",
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r366",
      "r367",
      "r368",
      "r369",
      "r371"
     ]
    },
    "us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems",
     "presentation": [
      "http://www.recursion.com/role/FairValueMeasurementsAssetandLiabilityNotMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]",
        "label": "Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r370"
     ]
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosureItemAmountsDomain",
     "presentation": [
      "http://www.recursion.com/role/FairValueMeasurementsAssetandLiabilityNotMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurement [Domain]",
        "label": "Fair Value Measurement [Domain]",
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value."
       }
      }
     },
     "auth_ref": [
      "r250",
      "r553",
      "r554"
     ]
    },
    "us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable",
     "presentation": [
      "http://www.recursion.com/role/FairValueMeasurementsAssetandLiabilityNotMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Disclosure of Asset and Liability Not Measured at Fair Value [Table]",
        "label": "Fair Value Disclosure of Asset and Liability Not Measured at Fair Value [Table]",
        "documentation": "Disclosure of information about fair value of asset and liability not measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r370"
     ]
    },
    "us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock",
     "presentation": [
      "http://www.recursion.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value Disclosure of Asset and Liability Not Measured at Fair Value",
        "label": "Fair Value Disclosure of Asset and Liability Not Measured at Fair Value [Table Text Block]",
        "documentation": "Tabular disclosure of information about fair value of asset and liability not measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r370"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.recursion.com/role/FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r365"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.recursion.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r250",
      "r281",
      "r286",
      "r367",
      "r402",
      "r559",
      "r560",
      "r561"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.recursion.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r250",
      "r281",
      "r286",
      "r367",
      "r403",
      "r553",
      "r554",
      "r559",
      "r560",
      "r561"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.recursion.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 3",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r250",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r367",
      "r404",
      "r553",
      "r554",
      "r559",
      "r560",
      "r561"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.recursion.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency [Domain]",
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.recursion.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r250",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r402",
      "r403",
      "r404",
      "r553",
      "r554",
      "r559",
      "r560",
      "r561"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.recursion.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Recurring",
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r365",
      "r371"
     ]
    },
    "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FederalIncomeTaxExpenseBenefitContinuingOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.recursion.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal Income Tax Expense (Benefit), Continuing Operations",
        "label": "Federal Income Tax Expense (Benefit), Continuing Operations",
        "documentation": "Amount of current and deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current and deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r333"
     ]
    },
    "rxrx_FinancedEquipmentPurchase": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.recursion.com/20240331",
     "localname": "FinancedEquipmentPurchase",
     "crdr": "debit",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financed equipment purchase",
        "label": "Financed Equipment Purchase",
        "documentation": "Financed Equipment Purchase"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://www.recursion.com/role/AcquisitionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Useful life",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "calculation": {
      "http://www.recursion.com/role/GoodwillandIntangibleAssetsDetails": {
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/GoodwillandIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Accumulated Amortization",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r222"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.recursion.com/role/AcquisitionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r220",
      "r221",
      "r222",
      "r223",
      "r409",
      "r410"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.recursion.com/role/GoodwillandIntangibleAssetsDetails": {
       "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/GoodwillandIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross carrying amount",
        "label": "Finite-Lived Intangible Assets, Gross",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r410"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.recursion.com/role/AcquisitionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r42"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.recursion.com/role/GoodwillandIntangibleAssetsDetails_1": {
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.recursion.com/role/GoodwillandIntangibleAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.recursion.com/role/GoodwillandIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net carrying amount",
        "label": "Finite-Lived Intangible Assets, Net",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r409"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r594",
      "r605",
      "r615",
      "r640"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r594",
      "r605",
      "r615",
      "r640"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r594",
      "r605",
      "r615",
      "r640"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r594",
      "r605",
      "r615",
      "r640"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r594",
      "r605",
      "r615",
      "r640"
     ]
    },
    "rxrx_GastrointestinalCancerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.recursion.com/20240331",
     "localname": "GastrointestinalCancerMember",
     "presentation": [
      "http://www.recursion.com/role/CollaborativeDevelopmentContractsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gastrointestinal cancer",
        "label": "Gastrointestinal Cancer [Member]",
        "documentation": "Gastrointestinal Cancer"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r505"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationSummaryofStockbasedCompensationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Goodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.recursion.com/role/AcquisitionsScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/AcquisitionsScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Goodwill",
        "terseLabel": "Goodwill",
        "label": "Goodwill",
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r216",
      "r423",
      "r551",
      "r568",
      "r679",
      "r680"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.recursion.com/role/GoodwillandIntangibleAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill and Intangible Assets",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "documentation": "The entire disclosure for goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillImpairmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.recursion.com/role/GoodwillandIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill impairment",
        "label": "Goodwill, Impairment Loss",
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r217",
      "r218",
      "r219",
      "r551"
     ]
    },
    "us-gaap_GoodwillPeriodIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillPeriodIncreaseDecrease",
     "presentation": [
      "http://www.recursion.com/role/GoodwillandIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in carrying amount of goodwill",
        "label": "Goodwill, Period Increase (Decrease)",
        "documentation": "Amount of increase (decrease) of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r678"
     ]
    },
    "us-gaap_GrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GrantMember",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grant revenue",
        "label": "Grant [Member]",
        "documentation": "Award of money not required to be repaid."
       }
      }
     },
     "auth_ref": [
      "r692"
     ]
    },
    "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.recursion.com/role/GoodwillandIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of indefinite-lived intangible assets",
        "label": "Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)",
        "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value."
       }
      }
     },
     "auth_ref": [
      "r667",
      "r681"
     ]
    },
    "us-gaap_ImpairmentOfLeasehold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOfLeasehold",
     "crdr": "debit",
     "presentation": [
      "http://www.recursion.com/role/SupplementalFinancialInformationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of leasehold improvements",
        "label": "Impairment of Leasehold",
        "documentation": "The adjustment to reduce the value of existing agreements that specify the lessee's rights to use the leased property. This expense is charged when the estimates of future profits generated by the leased property are reduced."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r44"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss before income tax benefit",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r85",
      "r117",
      "r196",
      "r203",
      "r207",
      "r209",
      "r426",
      "r436",
      "r549"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationSummaryofStockbasedCompensationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Axis]",
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r224",
      "r225",
      "r506"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationSummaryofStockbasedCompensationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Domain]",
        "label": "Income Statement Location [Domain]",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r225",
      "r506"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.recursion.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r330",
      "r334",
      "r335",
      "r336",
      "r339",
      "r341",
      "r342",
      "r343",
      "r459"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited",
      "http://www.recursion.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Income tax benefit",
        "terseLabel": "Income tax expense (benefit)",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r126",
      "r178",
      "r179",
      "r201",
      "r333",
      "r340",
      "r440"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "rxrx_IncreaseDecreaseInAccruedDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.recursion.com/20240331",
     "localname": "IncreaseDecreaseInAccruedDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued development expense",
        "label": "Increase (Decrease) In Accrued Development Expense",
        "documentation": "Increase (Decrease) In Accrued Development Expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unearned revenue",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r407",
      "r666"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r662",
      "r666"
     ]
    },
    "rxrx_IncreaseDecreaseInOperatingLeaseRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.recursion.com/20240331",
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.recursion.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (decrease) in operating lease right-of-use assets",
        "label": "Increase (Decrease) in Operating Lease Right-Of-Use Assets",
        "documentation": "Increase (Decrease) in Operating Lease Right-Of-Use Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other current liabilities",
        "label": "Increase (Decrease) in Other Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in other expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other receivables and assets",
        "label": "Increase (Decrease) in Other Operating Assets",
        "documentation": "Amount of increase (decrease) in operating assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.recursion.com/role/GoodwillandIntangibleAssetsDetails": {
       "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.recursion.com/role/GoodwillandIntangibleAssetsDetails_1": {
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/GoodwillandIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite-lived intangible assets",
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)",
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit."
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r597",
      "r605",
      "r615",
      "r632",
      "r640",
      "r644",
      "r652"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r650"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r586",
      "r656"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r586",
      "r656"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r586",
      "r656"
     ]
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.recursion.com/role/GoodwillandIntangibleAssetsDetails": {
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/GoodwillandIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Intangible assets, gross",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      },
      "http://www.recursion.com/role/GoodwillandIntangibleAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.recursion.com/role/GoodwillandIntangibleAssetsDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited",
      "http://www.recursion.com/role/GoodwillandIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets, net",
        "totalLabel": "Intangible assets, net",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r41"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsNetExcludingGoodwillAbstract",
     "presentation": [
      "http://www.recursion.com/role/GoodwillandIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible Assets, Net",
        "label": "Intangible Assets, Net (Excluding Goodwill) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.recursion.com/role/SupplementalFinancialInformationScheduleofInterestIncomeandExpenseDisclosureDetails": {
       "parentTag": "us-gaap_InterestRevenueExpenseNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/SupplementalFinancialInformationScheduleofInterestIncomeandExpenseDisclosureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Interest expense",
        "label": "Interest Expense",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r119",
      "r155",
      "r199",
      "r382",
      "r507",
      "r579",
      "r742"
     ]
    },
    "us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
     "presentation": [
      "http://www.recursion.com/role/SupplementalFinancialInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Interest Income and Expense Disclosure",
        "label": "Interest Income and Interest Expense Disclosure [Table Text Block]",
        "documentation": "Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestRevenueExpenseNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestRevenueExpenseNet",
     "crdr": "credit",
     "calculation": {
      "http://www.recursion.com/role/SupplementalFinancialInformationScheduleofInterestIncomeandExpenseDisclosureDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.recursion.com/role/SupplementalFinancialInformationScheduleofInterestIncomeandExpenseDisclosureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Interest income, net",
        "label": "Interest Revenue (Expense), Net",
        "documentation": "Amount of interest revenue (income derived from investments in debt securities and on cash and cash equivalents) net of interest expense (cost of borrowed funds accounted for as interest)."
       }
      }
     },
     "auth_ref": [
      "r196"
     ]
    },
    "us-gaap_InvestmentIncomeNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentIncomeNonoperating",
     "crdr": "credit",
     "calculation": {
      "http://www.recursion.com/role/SupplementalFinancialInformationScheduleofInterestIncomeandExpenseDisclosureDetails": {
       "parentTag": "us-gaap_InterestRevenueExpenseNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/SupplementalFinancialInformationScheduleofInterestIncomeandExpenseDisclosureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income",
        "label": "Investment Income, Nonoperating",
        "documentation": "The aggregate amount of income from investments (for example, dividends) not considered a component of the entity's core operations."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "rxrx_LaboratoryEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.recursion.com/20240331",
     "localname": "LaboratoryEquipmentMember",
     "presentation": [
      "http://www.recursion.com/role/SupplementalFinancialInformationScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lab equipment",
        "label": "Laboratory Equipment [Member]",
        "documentation": "Laboratory Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.recursion.com/role/LeasesComponentsofLeaseCostDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.recursion.com/role/LeasesComponentsofLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Lease cost",
        "label": "Lease, Cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r389",
      "r567"
     ]
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://www.recursion.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Components of Lease Cost, Supplemental Cash Flow Information Related to Leases, Lease Term and Discount Rates",
        "label": "Lease, Cost [Table Text Block]",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r726"
     ]
    },
    "rxrx_LeaseDescriptionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.recursion.com/20240331",
     "localname": "LeaseDescriptionAxis",
     "presentation": [
      "http://www.recursion.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease Description [Axis]",
        "label": "Lease Description [Axis]",
        "documentation": "Lease Description"
       }
      }
     },
     "auth_ref": []
    },
    "rxrx_LeaseDescriptionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.recursion.com/20240331",
     "localname": "LeaseDescriptionDomain",
     "presentation": [
      "http://www.recursion.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease Description [Domain]",
        "label": "Lease Description [Domain]",
        "documentation": "Lease Description [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.recursion.com/role/SupplementalFinancialInformationScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold improvements",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://www.recursion.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Lease, Description [Line Items]",
        "label": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r388"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://www.recursion.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Lease, Description [Table]",
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r388"
     ]
    },
    "rxrx_LesseeOperatingLeaseIncreaseDecreaseInOperatingLeaseLiabilityDueToLeaseModifications": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.recursion.com/20240331",
     "localname": "LesseeOperatingLeaseIncreaseDecreaseInOperatingLeaseLiabilityDueToLeaseModifications",
     "crdr": "debit",
     "presentation": [
      "http://www.recursion.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (decrease) in lease liability",
        "label": "Lessee, Operating Lease, Increase (Decrease) In Operating Lease Liability Due To Lease Modifications",
        "documentation": "Lessee, Operating Lease, Increase (Decrease) In Operating Lease Liability Due To Lease Modifications"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.recursion.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Maturities of Operating Lease Liabilities",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r727"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.recursion.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.recursion.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.recursion.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails",
      "http://www.recursion.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, operating lease, liability, to be paid",
        "totalLabel": "Total lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r397"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.recursion.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r397"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.recursion.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r397"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.recursion.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r397"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.recursion.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r397"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "crdr": "credit",
     "calculation": {
      "http://www.recursion.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remainder of 2024",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r727"
     ]
    },
    "rxrx_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.recursion.com/20240331",
     "localname": "LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.recursion.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Due after Year Four",
        "documentation": "Lessee, Operating Lease, Liability, to be Paid, Due after Year Four"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.recursion.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less: imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r397"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "presentation": [
      "http://www.recursion.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining operating lease term",
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r724"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://www.recursion.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease, renewal term",
        "label": "Lessee, Operating Lease, Renewal Term",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "rxrx_LesseeOperatingLeaseSquareFootageOfLeasedSpace": {
     "xbrltype": "areaItemType",
     "nsuri": "http://www.recursion.com/20240331",
     "localname": "LesseeOperatingLeaseSquareFootageOfLeasedSpace",
     "presentation": [
      "http://www.recursion.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Square footage of leased space (in square feet)",
        "label": "Lessee, Operating Lease, Square Footage Of Leased Space",
        "documentation": "Lessee, Operating Lease, Square Footage Of Leased Space"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://www.recursion.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease term",
        "label": "Lessee, Operating Lease, Term of Contract",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.recursion.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r161",
      "r213",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r352",
      "r353",
      "r354",
      "r374",
      "r480",
      "r548",
      "r581",
      "r688",
      "r729",
      "r730"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r116",
      "r433",
      "r568",
      "r671",
      "r677",
      "r722"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities and stockholders\u2019 equity",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r133",
      "r161",
      "r213",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r352",
      "r353",
      "r354",
      "r374",
      "r568",
      "r688",
      "r729",
      "r730"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "rxrx_LicenseAgreementAggregatePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.recursion.com/20240331",
     "localname": "LicenseAgreementAggregatePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.recursion.com/role/SupplementalFinancialInformationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate amount payable in cash or equity",
        "label": "License Agreement, Aggregate Payments",
        "documentation": "License Agreement, Aggregate Payments"
       }
      }
     },
     "auth_ref": []
    },
    "rxrx_LicenseAgreementAnnualPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.recursion.com/20240331",
     "localname": "LicenseAgreementAnnualPayments",
     "crdr": "credit",
     "presentation": [
      "http://www.recursion.com/role/SupplementalFinancialInformationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual payments",
        "label": "License Agreement, Annual Payments",
        "documentation": "License Agreement, Annual Payments"
       }
      }
     },
     "auth_ref": []
    },
    "rxrx_LicenseAgreementPrepaidExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.recursion.com/20240331",
     "localname": "LicenseAgreementPrepaidExpenses",
     "crdr": "credit",
     "presentation": [
      "http://www.recursion.com/role/SupplementalFinancialInformationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License agreement, prepaid expenses",
        "label": "License Agreement, Prepaid Expenses",
        "documentation": "License Agreement, Prepaid Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "rxrx_LicenseAgreementTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.recursion.com/20240331",
     "localname": "LicenseAgreementTerm",
     "presentation": [
      "http://www.recursion.com/role/SupplementalFinancialInformationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License agreement, term",
        "label": "License Agreement, Term",
        "documentation": "License Agreement, Term"
       }
      }
     },
     "auth_ref": []
    },
    "rxrx_LicenseAgreementTradingPeriodUsedForEquityValueDetermination": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.recursion.com/20240331",
     "localname": "LicenseAgreementTradingPeriodUsedForEquityValueDetermination",
     "presentation": [
      "http://www.recursion.com/role/SupplementalFinancialInformationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License agreement, trading period",
        "label": "License Agreement, Trading Period Used For Equity Value Determination",
        "documentation": "License Agreement, Trading Period Used For Equity Value Determination"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LicenseAndServiceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LicenseAndServiceMember",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating revenue",
        "label": "License and Service [Member]",
        "documentation": "Right to use intangible asset and performance of related service. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark."
       }
      }
     },
     "auth_ref": [
      "r692"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.recursion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "rxrx_LondonLeaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.recursion.com/20240331",
     "localname": "LondonLeaseMember",
     "presentation": [
      "http://www.recursion.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "London Lease",
        "label": "London Lease [Member]",
        "documentation": "London Lease"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.recursion.com/role/FairValueMeasurementsAssetandLiabilityNotMeasuredatFairValueDetails": {
       "parentTag": "us-gaap_LongTermDebtFairValue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/FairValueMeasurementsAssetandLiabilityNotMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current portion of notes payable",
        "label": "Long-Term Debt, Current Maturities",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r141"
     ]
    },
    "us-gaap_LongTermDebtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtFairValue",
     "crdr": "credit",
     "calculation": {
      "http://www.recursion.com/role/FairValueMeasurementsAssetandLiabilityNotMeasuredatFairValueDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.recursion.com/role/FairValueMeasurementsAssetandLiabilityNotMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Long-Term Debt, Fair Value",
        "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.recursion.com/role/FairValueMeasurementsAssetandLiabilityNotMeasuredatFairValueDetails": {
       "parentTag": "us-gaap_LongTermDebtFairValue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/FairValueMeasurementsAssetandLiabilityNotMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Notes payable, net of current portion",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r142"
     ]
    },
    "us-gaap_LongTermNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermNotesPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Notes payable, non-current",
        "label": "Notes Payable, Noncurrent",
        "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://www.recursion.com/role/FairValueMeasurementsAssetandLiabilityNotMeasuredatFairValueDetails",
      "http://www.recursion.com/role/SupplementalFinancialInformationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Axis]",
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://www.recursion.com/role/FairValueMeasurementsAssetandLiabilityNotMeasuredatFairValueDetails",
      "http://www.recursion.com/role/SupplementalFinancialInformationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Domain]",
        "label": "Long-Term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r47"
     ]
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingencyAccrualAtCarryingValue",
     "crdr": "credit",
     "presentation": [
      "http://www.recursion.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss contingency accrual",
        "label": "Loss Contingency Accrual",
        "documentation": "Amount of loss contingency liability."
       }
      }
     },
     "auth_ref": [
      "r228",
      "r659"
     ]
    },
    "us-gaap_LossContingencyPendingClaimsNumber": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingencyPendingClaimsNumber",
     "presentation": [
      "http://www.recursion.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of pending claims",
        "label": "Loss Contingency, Pending Claims, Number",
        "documentation": "Number of pending claims pertaining to a loss contingency."
       }
      }
     },
     "auth_ref": [
      "r684",
      "r685"
     ]
    },
    "rxrx_MaterialsReceivedNotInvoiced": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.recursion.com/20240331",
     "localname": "MaterialsReceivedNotInvoiced",
     "crdr": "credit",
     "calculation": {
      "http://www.recursion.com/role/SupplementalFinancialInformationScheduleofAccruedExpensesandOtherLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/SupplementalFinancialInformationScheduleofAccruedExpensesandOtherLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Materials received not invoiced",
        "label": "Materials Received Not Invoiced",
        "documentation": "Materials Received Not Invoiced"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.recursion.com/role/CommonStockDetails",
      "http://www.recursion.com/role/LeasesNarrativeDetails",
      "http://www.recursion.com/role/SupplementalFinancialInformationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r229",
      "r230",
      "r231",
      "r232",
      "r288",
      "r406",
      "r447",
      "r472",
      "r473",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r540",
      "r541",
      "r550",
      "r557",
      "r564",
      "r570",
      "r690",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r624"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r624"
     ]
    },
    "rxrx_MichaelSecoraMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.recursion.com/20240331",
     "localname": "MichaelSecoraMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Michael Secora [Member]",
        "documentation": "Michael Secora"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.recursion.com/role/LeasesNarrativeDetails",
      "http://www.recursion.com/role/SupplementalFinancialInformationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r229",
      "r230",
      "r231",
      "r232",
      "r288",
      "r406",
      "r447",
      "r472",
      "r473",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r540",
      "r541",
      "r550",
      "r557",
      "r564",
      "r570",
      "r690",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r643"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.recursion.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money market funds",
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r693"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r651"
     ]
    },
    "rxrx_NVDIAPrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.recursion.com/20240331",
     "localname": "NVDIAPrivatePlacementMember",
     "presentation": [
      "http://www.recursion.com/role/CommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NVDIA Private Placement",
        "label": "NVDIA Private Placement [Member]",
        "documentation": "NVDIA Private Placement"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r625"
     ]
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://www.recursion.com/role/DescriptionoftheBusiness"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Description of the Business",
        "label": "Nature of Operations [Text Block]",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r127"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r158"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r158"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r94",
      "r95"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited",
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited",
      "http://www.recursion.com/role/NetLossPerShareScheduleofBasicandDilutedNetLossperShareDetails",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss and comprehensive loss",
        "verboseLabel": "Net loss",
        "terseLabel": "Net Income (Loss)",
        "label": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r95",
      "r118",
      "r131",
      "r148",
      "r150",
      "r154",
      "r161",
      "r170",
      "r172",
      "r173",
      "r174",
      "r175",
      "r178",
      "r179",
      "r185",
      "r196",
      "r203",
      "r207",
      "r209",
      "r213",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r364",
      "r374",
      "r437",
      "r502",
      "r520",
      "r521",
      "r549",
      "r579",
      "r688"
     ]
    },
    "rxrx_NeuroscienceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.recursion.com/20240331",
     "localname": "NeuroscienceMember",
     "presentation": [
      "http://www.recursion.com/role/CollaborativeDevelopmentContractsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Neuroscience",
        "label": "Neuroscience [Member]",
        "documentation": "Neuroscience"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.recursion.com/role/BasisofPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recent Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r624"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r594",
      "r605",
      "r615",
      "r632",
      "r640"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r622"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r621"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r632"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r651"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r651"
     ]
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental schedule of non-cash investing and financing activities",
        "label": "Noncash Investing and Financing Items [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income, net",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Nonvested RSU Activity",
        "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_NotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NotesPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.recursion.com/role/SupplementalFinancialInformationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Notes payable",
        "label": "Notes Payable",
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r115",
      "r738"
     ]
    },
    "us-gaap_NotesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NotesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Notes payable",
        "label": "Notes Payable, Current",
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_NotesPayableOtherPayablesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NotesPayableOtherPayablesMember",
     "presentation": [
      "http://www.recursion.com/role/FairValueMeasurementsAssetandLiabilityNotMeasuredatFairValueDetails",
      "http://www.recursion.com/role/SupplementalFinancialInformationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Notes payable",
        "label": "Notes Payable, Other Payables [Member]",
        "documentation": "A written promise to pay a note to a third party."
       }
      }
     },
     "auth_ref": []
    },
    "rxrx_NumberOfClassesOfCommonStockAuthorized": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.recursion.com/20240331",
     "localname": "NumberOfClassesOfCommonStockAuthorized",
     "presentation": [
      "http://www.recursion.com/role/CommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of classes of common stock authorized",
        "label": "Number Of Classes Of Common Stock Authorized",
        "documentation": "Number Of Classes Of Common Stock Authorized"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OfficeEquipmentMember",
     "presentation": [
      "http://www.recursion.com/role/SupplementalFinancialInformationScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office equipment",
        "label": "Office Equipment [Member]",
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating costs and expenses",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r196",
      "r203",
      "r207",
      "r209",
      "r549"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.recursion.com/role/LeasesComponentsofLeaseCostDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/LeasesComponentsofLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease cost",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r390",
      "r567"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Lease expense",
        "label": "Operating Lease, Expense",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r723"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.recursion.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Present value of lease liabilities",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r386"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r386"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities, non-current",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r386"
     ]
    },
    "us-gaap_OperatingLeasePaymentsUse": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasePaymentsUse",
     "crdr": "credit",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for operating leases",
        "label": "Operating Lease, Payments, Use",
        "documentation": "Amount of cash outflow from operating lease to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r387",
      "r393"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r385"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.recursion.com/role/LeasesLeaseTermandDiscountRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average discount rate",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r396",
      "r567"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.recursion.com/role/LeasesLeaseTermandDiscountRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average remaining lease term (years)",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r395",
      "r567"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.recursion.com/role/SupplementalFinancialInformationScheduleofAccruedExpensesandOtherLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/SupplementalFinancialInformationScheduleofAccruedExpensesandOtherLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued other expenses",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current assets",
        "label": "Other Assets, Current",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r568"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets, non-current",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "us-gaap_OtherCurrentAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCurrentAssetsMember",
     "presentation": [
      "http://www.recursion.com/role/SupplementalFinancialInformationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Current Assets",
        "label": "Other Current Assets [Member]",
        "documentation": "Primary financial statement caption encompassing other current assets."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r68"
     ]
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNoncashIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other, net",
        "label": "Other Noncash Income (Expense)",
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r624"
     ]
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherReceivablesNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other receivables",
        "label": "Other Receivables, Net, Current",
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r592",
      "r603",
      "r613",
      "r638"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r595",
      "r606",
      "r616",
      "r641"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r595",
      "r606",
      "r616",
      "r641"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r620"
     ]
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireBusinessesGross",
     "crdr": "credit",
     "calculation": {
      "http://www.recursion.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails": {
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash",
        "label": "Payments to Acquire Businesses, Gross",
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r348"
     ]
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchase of an intangible asset",
        "label": "Payments to Acquire Intangible Assets",
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited",
      "http://www.recursion.com/role/SupplementalFinancialInformationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchases of property and equipment",
        "terseLabel": "Purchases of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r623"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r623"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r622"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r632"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r625"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r621"
     ]
    },
    "rxrx_PercentOfAggregatePurchasePricePaidByTheHolderDueIfAgreementIsBroken": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.recursion.com/20240331",
     "localname": "PercentOfAggregatePurchasePricePaidByTheHolderDueIfAgreementIsBroken",
     "presentation": [
      "http://www.recursion.com/role/CommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percent of aggregate purchase price paid by the holder due if agreement is broken",
        "label": "Percent of Aggregate Purchase Price Paid By The Holder Due If Agreement is Broken",
        "documentation": "Percent of Aggregate Purchase Price Paid By The Holder Due If Agreement is Broken"
       }
      }
     },
     "auth_ref": []
    },
    "rxrx_PhenomapsCreationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.recursion.com/20240331",
     "localname": "PhenomapsCreationMember",
     "presentation": [
      "http://www.recursion.com/role/CollaborativeDevelopmentContractsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Phenomaps creation",
        "label": "Phenomaps Creation [Member]",
        "documentation": "Phenomaps Creation"
       }
      }
     },
     "auth_ref": []
    },
    "rxrx_PhenomapsRawImagesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.recursion.com/20240331",
     "localname": "PhenomapsRawImagesMember",
     "presentation": [
      "http://www.recursion.com/role/CollaborativeDevelopmentContractsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Phenomaps raw images",
        "label": "Phenomaps Raw Images [Member]",
        "documentation": "Phenomaps Raw Images"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Axis]",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Domain]",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719"
     ]
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "presentation": [
      "http://www.recursion.com/role/FairValueMeasurementsAssetandLiabilityNotMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Portion at Fair Value Measurement",
        "label": "Portion at Fair Value Measurement [Member]",
        "documentation": "Measured at fair value for financial reporting purposes."
       }
      }
     },
     "auth_ref": [
      "r372"
     ]
    },
    "us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PortionAtOtherThanFairValueFairValueDisclosureMember",
     "presentation": [
      "http://www.recursion.com/role/FairValueMeasurementsAssetandLiabilityNotMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Book values",
        "label": "Portion at Other than Fair Value Measurement [Member]",
        "documentation": "Not measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r372"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of common shares, net of issuance costs",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.recursion.com/role/SupplementalFinancialInformationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of long-term debt",
        "label": "Proceeds from Issuance of Long-Term Debt",
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r454"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "crdr": "debit",
     "presentation": [
      "http://www.recursion.com/role/CommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of common shares, net of issuance costs",
        "label": "Proceeds from Issuance of Private Placement",
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "crdr": "debit",
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from equity incentive plans",
        "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised",
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r13"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Axis]",
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r210",
      "r408",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r542",
      "r558",
      "r569",
      "r663",
      "r686",
      "r687",
      "r691",
      "r739"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Domain]",
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r210",
      "r408",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r542",
      "r558",
      "r569",
      "r663",
      "r686",
      "r687",
      "r691",
      "r739"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.recursion.com/role/SupplementalFinancialInformationNarrativeDetails",
      "http://www.recursion.com/role/SupplementalFinancialInformationScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Axis]",
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.recursion.com/role/SupplementalFinancialInformationScheduleofPropertyandEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/SupplementalFinancialInformationScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, gross",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r135",
      "r435"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.recursion.com/role/SupplementalFinancialInformationNarrativeDetails",
      "http://www.recursion.com/role/SupplementalFinancialInformationScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Line Items]",
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.recursion.com/role/SupplementalFinancialInformationScheduleofPropertyandEquipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited",
      "http://www.recursion.com/role/SupplementalFinancialInformationScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r427",
      "r435",
      "r568"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.recursion.com/role/SupplementalFinancialInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Property and Equipment",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.recursion.com/role/SupplementalFinancialInformationNarrativeDetails",
      "http://www.recursion.com/role/SupplementalFinancialInformationScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Domain]",
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r620"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r620"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.recursion.com/role/CommonStockDetails",
      "http://www.recursion.com/role/LeasesNarrativeDetails",
      "http://www.recursion.com/role/SupplementalFinancialInformationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r229",
      "r230",
      "r231",
      "r232",
      "r280",
      "r288",
      "r316",
      "r317",
      "r318",
      "r405",
      "r406",
      "r447",
      "r472",
      "r473",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r540",
      "r541",
      "r550",
      "r557",
      "r564",
      "r570",
      "r573",
      "r682",
      "r690",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://www.recursion.com/role/CommonStockDetails",
      "http://www.recursion.com/role/LeasesNarrativeDetails",
      "http://www.recursion.com/role/SupplementalFinancialInformationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r229",
      "r230",
      "r231",
      "r232",
      "r280",
      "r288",
      "r316",
      "r317",
      "r318",
      "r405",
      "r406",
      "r447",
      "r472",
      "r473",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r540",
      "r541",
      "r550",
      "r557",
      "r564",
      "r570",
      "r573",
      "r682",
      "r690",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r587",
      "r598",
      "r608",
      "r633"
     ]
    },
    "rxrx_RecursionValenceAndCyclicaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.recursion.com/20240331",
     "localname": "RecursionValenceAndCyclicaMember",
     "presentation": [
      "http://www.recursion.com/role/AcquisitionsScheduleofBusinessAcquisitionsProFormaInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recursion, Valence and Cyclica",
        "label": "Recursion, Valence And Cyclica [Member]",
        "documentation": "Recursion, Valence And Cyclica"
       }
      }
     },
     "auth_ref": []
    },
    "rxrx_RegistrationRightsAgreementAccruedLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.recursion.com/20240331",
     "localname": "RegistrationRightsAgreementAccruedLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.recursion.com/role/CommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Registration rights agreement, accrued liability",
        "label": "Registration Rights Agreement, Accrued Liability",
        "documentation": "Registration Rights Agreement, Accrued Liability"
       }
      }
     },
     "auth_ref": []
    },
    "rxrx_RegistrationRightsAgreementTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.recursion.com/20240331",
     "localname": "RegistrationRightsAgreementTerm",
     "presentation": [
      "http://www.recursion.com/role/CommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Registration rights agreement, term",
        "label": "Registration Rights Agreement, Term",
        "documentation": "Registration Rights Agreement, Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.recursion.com/role/CommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party [Domain]",
        "label": "Related Party, Type [Domain]",
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r287",
      "r399",
      "r400",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r499",
      "r501",
      "r527"
     ]
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.recursion.com/role/CommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party [Axis]",
        "label": "Related Party, Type [Axis]",
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r287",
      "r399",
      "r400",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r499",
      "r501",
      "r527",
      "r728"
     ]
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfLongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Repayment of long-term debt",
        "label": "Repayments of Long-Term Debt",
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r457"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.recursion.com/role/CollaborativeDevelopmentContractsDetails",
      "http://www.recursion.com/role/SupplementalFinancialInformationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Domain]",
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r164",
      "r165",
      "r245",
      "r261",
      "r401",
      "r545",
      "r546"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r329",
      "r737"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationSummaryofStockbasedCompensationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r588",
      "r599",
      "r609",
      "r634"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r589",
      "r600",
      "r610",
      "r635"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r596",
      "r607",
      "r617",
      "r642"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://www.recursion.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents [Domain]",
        "label": "Cash and Cash Equivalents [Domain]",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "rxrx_RestrictedCashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.recursion.com/20240331",
     "localname": "RestrictedCashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.recursion.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash",
        "label": "Restricted Cash and Cash Equivalents, Fair Value Disclosure",
        "documentation": "Restricted Cash and Cash Equivalents, Fair Value Disclosure"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedCashCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash",
        "label": "Restricted Cash, Current",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r664",
      "r668"
     ]
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash, non-current",
        "label": "Restricted Cash, Noncurrent",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r665",
      "r668"
     ]
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.recursion.com/role/StockBasedCompensationScheduleofRSUActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted stock",
        "label": "Restricted Stock [Member]",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationNarrativeDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RSUs",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited",
      "http://www.recursion.com/role/DescriptionoftheBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "negatedLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r107",
      "r432",
      "r451",
      "r452",
      "r458",
      "r483",
      "r568"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r167",
      "r168",
      "r169",
      "r171",
      "r177",
      "r179",
      "r214",
      "r215",
      "r325",
      "r326",
      "r327",
      "r337",
      "r338",
      "r355",
      "r357",
      "r358",
      "r360",
      "r362",
      "r448",
      "r450",
      "r460",
      "r743"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total revenue",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r197",
      "r198",
      "r202",
      "r205",
      "r206",
      "r210",
      "r211",
      "r212",
      "r277",
      "r278",
      "r408"
     ]
    },
    "rxrx_RevenuePerformanceObligationNumberOfObligations": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.recursion.com/20240331",
     "localname": "RevenuePerformanceObligationNumberOfObligations",
     "presentation": [
      "http://www.recursion.com/role/CollaborativeDevelopmentContractsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of performance obligations under the agreement (in performance obligations)",
        "label": "Revenue, Performance Obligation, Number Of Obligations",
        "documentation": "Revenue, Performance Obligation, Number Of Obligations"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueRemainingPerformanceObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.recursion.com/role/CollaborativeDevelopmentContractsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining performance obligation revenue",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue."
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "rxrx_RevenueRemainingPerformanceObligationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.recursion.com/20240331",
     "localname": "RevenueRemainingPerformanceObligationAxis",
     "presentation": [
      "http://www.recursion.com/role/CollaborativeDevelopmentContractsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue, Remaining Performance Obligation [Axis]",
        "label": "Revenue, Remaining Performance Obligation [Axis]",
        "documentation": "Revenue, Remaining Performance Obligation"
       }
      }
     },
     "auth_ref": []
    },
    "rxrx_RevenueRemainingPerformanceObligationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.recursion.com/20240331",
     "localname": "RevenueRemainingPerformanceObligationDomain",
     "presentation": [
      "http://www.recursion.com/role/CollaborativeDevelopmentContractsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue, Remaining Performance Obligation [Domain]",
        "label": "Revenue, Remaining Performance Obligation [Domain]",
        "documentation": "Revenue, Remaining Performance Obligation [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "rxrx_RevenueRemainingPerformanceObligationNumberOfProjectsThatMayBeInitiated": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.recursion.com/20240331",
     "localname": "RevenueRemainingPerformanceObligationNumberOfProjectsThatMayBeInitiated",
     "presentation": [
      "http://www.recursion.com/role/CollaborativeDevelopmentContractsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of projects that may be initiated (in projects)",
        "label": "Revenue, Remaining Performance Obligation, Number Of Projects That May Be Initiated",
        "documentation": "Revenue, Remaining Performance Obligation, Number Of Projects That May Be Initiated"
       }
      }
     },
     "auth_ref": []
    },
    "rxrx_RevenueRemainingPerformanceObligationVariableConsiderationAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.recursion.com/20240331",
     "localname": "RevenueRemainingPerformanceObligationVariableConsiderationAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.recursion.com/role/CollaborativeDevelopmentContractsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research project, fees and milestones payments receivable for an option on a lead series",
        "label": "Revenue, Remaining Performance Obligation, Variable Consideration Amount",
        "documentation": "Revenue, Remaining Performance Obligation, Variable Consideration Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenuesAbstract",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "label": "Revenues [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use asset additions and modifications",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r394",
      "r567"
     ]
    },
    "rxrx_RocheAndGenentechMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.recursion.com/20240331",
     "localname": "RocheAndGenentechMember",
     "presentation": [
      "http://www.recursion.com/role/CollaborativeDevelopmentContractsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Roche and Genentech",
        "label": "Roche and Genentech [Member]",
        "documentation": "Roche and Genentech"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r651"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r651"
     ]
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.recursion.com/role/CommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "IPO, net proceeds received",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.recursion.com/role/CommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Domain]",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://www.recursion.com/role/CommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "IPO, number of shares issued (in shares)",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "rxrx_SaleOfStockPercentageOfCommission": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.recursion.com/20240331",
     "localname": "SaleOfStockPercentageOfCommission",
     "presentation": [
      "http://www.recursion.com/role/CommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock, percentage of commission",
        "label": "Sale of Stock, Percentage of Commission",
        "documentation": "Sale of Stock, Percentage of Commission"
       }
      }
     },
     "auth_ref": []
    },
    "rxrx_SaleOfStockValueAuthorized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.recursion.com/20240331",
     "localname": "SaleOfStockValueAuthorized",
     "crdr": "credit",
     "presentation": [
      "http://www.recursion.com/role/CommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, value authorized",
        "label": "Sale of Stock, Value, Authorized",
        "documentation": "Sale of Stock, Value, Authorized"
       }
      }
     },
     "auth_ref": []
    },
    "rxrx_SaleOfStockValueRemainingAuthorized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.recursion.com/20240331",
     "localname": "SaleOfStockValueRemainingAuthorized",
     "crdr": "credit",
     "presentation": [
      "http://www.recursion.com/role/CommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock value remaining authorized",
        "label": "Sale of Stock Value Remaining Authorized",
        "documentation": "Sale of Stock Value Remaining Authorized"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.recursion.com/role/SupplementalFinancialInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accrued Expenses and Other Liabilities",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.recursion.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.recursion.com/role/NetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Net Loss per Share",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "presentation": [
      "http://www.recursion.com/role/AcquisitionsNarrativeDetails",
      "http://www.recursion.com/role/AcquisitionsScheduleofBusinessAcquisitionsProFormaInformationDetails",
      "http://www.recursion.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails",
      "http://www.recursion.com/role/AcquisitionsScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r62",
      "r346"
     ]
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
     "presentation": [
      "http://www.recursion.com/role/AcquisitionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]",
        "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r62"
     ]
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://www.recursion.com/role/CollaborativeDevelopmentContractsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r350"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.recursion.com/role/NetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Basic and Diluted Net Loss per Share",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r676"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationSummaryofStockbasedCompensationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock-based Compensation Expenses",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://www.recursion.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r366",
      "r367"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://www.recursion.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Finite-Lived Intangible Assets",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r42"
     ]
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://www.recursion.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Indefinite-Lived Intangible Assets",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]",
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r100"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.recursion.com/role/SupplementalFinancialInformationNarrativeDetails",
      "http://www.recursion.com/role/SupplementalFinancialInformationScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Table]",
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "presentation": [
      "http://www.recursion.com/role/AcquisitionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value of Assets Acquired and Liabilities Assumed",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.recursion.com/role/StockBasedCompensationScheduleofRSUActivityDetails",
      "http://www.recursion.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r290",
      "r292",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-based Payment Arrangement, Option, Activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r12",
      "r56"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.recursion.com/role/CommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock by Class [Table]",
        "label": "Schedule of Stock by Class [Table]",
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r49",
      "r50",
      "r51",
      "r52",
      "r53",
      "r54",
      "r105",
      "r106",
      "r107",
      "r143",
      "r144",
      "r145",
      "r194",
      "r259",
      "r260",
      "r261",
      "r263",
      "r266",
      "r271",
      "r273",
      "r454",
      "r455",
      "r456",
      "r457",
      "r557",
      "r658",
      "r669"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.recursion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r582"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.recursion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r584"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options, vesting period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r565"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationScheduleofRSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r310"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationScheduleofRSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r310"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationScheduleofRSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r308"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationScheduleofRSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r308"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationScheduleofRSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance, outstanding (in shares)",
        "periodEndLabel": "Ending balance, outstanding (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r305",
      "r306"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationScheduleofRSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance, outstanding (in dollars per share)",
        "periodEndLabel": "Ending balance, outstanding (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r305",
      "r306"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationScheduleofRSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average grant date fair value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationScheduleofRSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Vested (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r309"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair market value of vested shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash."
       }
      }
     },
     "auth_ref": [
      "r312"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationScheduleofRSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r309"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r317"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r316"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r318"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.recursion.com/role/StockBasedCompensationScheduleofRSUActivityDetails",
      "http://www.recursion.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r290",
      "r292",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationScheduleofRSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock units",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares available for grant (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationScheduleofSharebasedPaymentArrangementOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable, (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r299"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationScheduleofSharebasedPaymentArrangementOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r299"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationScheduleofSharebasedPaymentArrangementOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise, intrinsic value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r312"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationScheduleofSharebasedPaymentArrangementOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Cancelled (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r303"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationScheduleofSharebasedPaymentArrangementOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r301"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options granted in period, weighted average grant date fair value (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r311"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationScheduleofSharebasedPaymentArrangementOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options, outstanding, intrinsic value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationScheduleofSharebasedPaymentArrangementOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Options, outstanding, number at beginning of period (in shares)",
        "periodEndLabel": "Options, outstanding, number at end of period (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r297",
      "r298"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationScheduleofSharebasedPaymentArrangementOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationScheduleofSharebasedPaymentArrangementOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Options, outstanding, at beginning of period (in dollars per share)",
        "periodEndLabel": "Options, outstanding, at end of period (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r297",
      "r298"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationScheduleofSharebasedPaymentArrangementOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-Average Exercise Price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.recursion.com/role/AcquisitionsNarrativeDetails",
      "http://www.recursion.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails",
      "http://www.recursion.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.recursion.com/role/StockBasedCompensationScheduleofRSUActivityDetails",
      "http://www.recursion.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Domain]",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationScheduleofSharebasedPaymentArrangementOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r302"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationScheduleofSharebasedPaymentArrangementOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cancelled (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r303"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationScheduleofSharebasedPaymentArrangementOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r301"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options, expiration period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r566"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r315"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationScheduleofSharebasedPaymentArrangementOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable, intrinsic value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationScheduleofSharebasedPaymentArrangementOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options, exercisable, weighted average remaining contractual life",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationScheduleofSharebasedPaymentArrangementOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options, outstanding, weighted average remaining contractual life",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r108"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://www.recursion.com/role/CommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued, price per share (in dollars per share)",
        "label": "Shares Issued, Price Per Share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.recursion.com/role/LeasesComponentsofLeaseCostDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/LeasesComponentsofLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term lease cost",
        "label": "Short-Term Lease, Cost",
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less."
       }
      }
     },
     "auth_ref": [
      "r391",
      "r567"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.recursion.com/role/AcquisitionsNarrativeDetails",
      "http://www.recursion.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails",
      "http://www.recursion.com/role/CommonStockDetails",
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical",
      "http://www.recursion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Axis]",
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r143",
      "r144",
      "r145",
      "r161",
      "r183",
      "r184",
      "r186",
      "r188",
      "r194",
      "r195",
      "r213",
      "r233",
      "r235",
      "r236",
      "r237",
      "r240",
      "r241",
      "r259",
      "r260",
      "r263",
      "r266",
      "r273",
      "r374",
      "r454",
      "r455",
      "r456",
      "r457",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r482",
      "r503",
      "r522",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r658",
      "r669",
      "r675"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r28",
      "r130",
      "r152",
      "r153",
      "r154",
      "r167",
      "r168",
      "r169",
      "r171",
      "r177",
      "r179",
      "r193",
      "r214",
      "r215",
      "r274",
      "r325",
      "r326",
      "r327",
      "r337",
      "r338",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r362",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r398",
      "r448",
      "r449",
      "r450",
      "r460",
      "r522"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical",
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited",
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r168",
      "r169",
      "r193",
      "r408",
      "r453",
      "r471",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r482",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r501",
      "r504",
      "r505",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r522",
      "r574"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical",
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited",
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r168",
      "r169",
      "r193",
      "r408",
      "r453",
      "r471",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r482",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r501",
      "r504",
      "r505",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r522",
      "r574"
     ]
    },
    "rxrx_Station41LeaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.recursion.com/20240331",
     "localname": "Station41LeaseMember",
     "presentation": [
      "http://www.recursion.com/role/SupplementalFinancialInformationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Station 41 lease",
        "label": "Station 41 Lease [Member]",
        "documentation": "Station 41 Lease"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r591",
      "r602",
      "r612",
      "r637"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://www.recursion.com/role/CommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued in the period, upon conversion (in shares)",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r27",
      "r51",
      "r107",
      "r252"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.recursion.com/role/CommonStockDetails",
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock sales issuances, net of issuance costs (in shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r78",
      "r79",
      "r107",
      "r454",
      "r522",
      "r534"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited",
      "http://www.recursion.com/role/StockBasedCompensationScheduleofSharebasedPaymentArrangementOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock option exercises and other (in shares)",
        "negatedTerseLabel": "Exercised (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r78",
      "r79",
      "r107",
      "r302"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock sales issuances, net of issuance costs",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r78",
      "r79",
      "r107",
      "r460",
      "r522",
      "r534",
      "r580"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock option exercises and other",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r28",
      "r107"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited",
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r82",
      "r83",
      "r97",
      "r484",
      "r500",
      "r523",
      "r524",
      "r568",
      "r581",
      "r671",
      "r677",
      "r722",
      "r743"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders\u2019 equity",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.recursion.com/role/CommonStock"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r160",
      "r258",
      "r260",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r272",
      "r274",
      "r361",
      "r525",
      "r526",
      "r538"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.recursion.com/role/CommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Axis]",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "rxrx_SupplementalBalanceSheetAndIncomeStatementInformationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.recursion.com/20240331",
     "localname": "SupplementalBalanceSheetAndIncomeStatementInformationTextBlock",
     "presentation": [
      "http://www.recursion.com/role/SupplementalFinancialInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental Financial Information",
        "label": "Supplemental Balance Sheet And Income Statement Information [Text Block]",
        "documentation": "Supplemental Balance Sheet And Income Statement Information"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental schedule of cash flow information",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "rxrx_SupplementalFinancialInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.recursion.com/20240331",
     "localname": "SupplementalFinancialInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Financial Information [Abstract]",
        "documentation": "Supplemental Financial Information"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r631"
     ]
    },
    "us-gaap_TangibleAssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TangibleAssetImpairmentCharges",
     "crdr": "debit",
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset impairment",
        "label": "Tangible Asset Impairment Charges",
        "documentation": "The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r102"
     ]
    },
    "us-gaap_TechnologyBasedIntangibleAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TechnologyBasedIntangibleAssetsMember",
     "presentation": [
      "http://www.recursion.com/role/AcquisitionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Technology Intangible Assets",
        "label": "Technology-Based Intangible Assets [Member]",
        "documentation": "Technology-based intangible assets, including, but not limited to, patented technology, unpatented technology, and developed technology rights."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "rxrx_TempusAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.recursion.com/20240331",
     "localname": "TempusAgreementMember",
     "presentation": [
      "http://www.recursion.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tempus agreement",
        "label": "Tempus Agreement [Member]",
        "documentation": "Tempus Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "rxrx_TempusLabsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.recursion.com/20240331",
     "localname": "TempusLabsIncMember",
     "presentation": [
      "http://www.recursion.com/role/SupplementalFinancialInformationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tempus Labs, Inc",
        "label": "Tempus Labs, Inc [Member]",
        "documentation": "Tempus Labs, Inc"
       }
      }
     },
     "auth_ref": []
    },
    "rxrx_TerryAnnBurrellMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.recursion.com/20240331",
     "localname": "TerryAnnBurrellMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Terry-Ann Burrell [Member]",
        "documentation": "Terry-Ann Burrell"
       }
      }
     },
     "auth_ref": []
    },
    "rxrx_TinaMarriottMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.recursion.com/20240331",
     "localname": "TinaMarriottMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tina Marriott [Member]",
        "documentation": "Tina Marriott"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r623"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r630"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r650"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r652"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.recursion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r653"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r654"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r652"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r652"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r655"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r653"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.recursion.com/role/CollaborativeDevelopmentContractsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r350"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r649"
     ]
    },
    "rxrx_ValenceDiscoveryIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.recursion.com/20240331",
     "localname": "ValenceDiscoveryIncMember",
     "presentation": [
      "http://www.recursion.com/role/AcquisitionsNarrativeDetails",
      "http://www.recursion.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails",
      "http://www.recursion.com/role/AcquisitionsScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.recursion.com/role/CommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valence Discovery Inc",
        "label": "Valence Discovery Inc [Member]",
        "documentation": "Valence Discovery Inc"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.recursion.com/role/LeasesComponentsofLeaseCostDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.recursion.com/role/LeasesComponentsofLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable lease cost",
        "label": "Variable Lease, Cost",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r392",
      "r567"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited",
      "http://www.recursion.com/role/NetLossPerShareScheduleofBasicandDilutedNetLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted-average shares (Class A, B and Exchangeable) outstanding, diluted (in shares)",
        "terseLabel": "Weighted average common shares outstanding, diluted (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r182",
      "r188"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited",
      "http://www.recursion.com/role/NetLossPerShareScheduleofBasicandDilutedNetLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted-average shares (Class A, B and Exchangeable) outstanding, basic (in shares)",
        "terseLabel": "Weighted average common shares outstanding, basic (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r181",
      "r188"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "940",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "7",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-7"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "8",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-8"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "SubTopic": "405",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481071/942-405-45-2"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b),(d)",
   "SubTopic": "30",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Subparagraph": "(c)",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13",
   "SubTopic": "20",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-13"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "((a)(1),(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-4"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(CFRR 211.02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "37",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479303/805-10-55-37"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "30",
   "Section": "25",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479668/805-30-25-5"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480401/815-10-55-182"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-11"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-12"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//350/tableOfContent"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-2"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//805/tableOfContent"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "210",
   "Topic": "954",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-5"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//808/tableOfContent"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(210.5-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//260/tableOfContent"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-2"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2E"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482736/825-10-45-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//842-20/tableOfContent"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482312/912-310-45-11"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii",
   "Section": "6"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10"
  },
  "r660": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "SubTopic": "10",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r661": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(3)",
   "SubTopic": "10",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r662": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r663": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4H",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H"
  },
  "r664": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r667": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r668": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r669": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r673": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r674": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r675": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55"
  },
  "r676": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r678": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3"
  },
  "r682": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r683": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r684": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r685": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r686": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r687": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r689": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r690": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r691": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r692": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r693": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r695": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r696": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r697": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r698": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r699": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r700": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r701": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r702": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r703": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r704": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r705": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r706": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r707": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r708": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r709": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r710": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r711": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r712": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r713": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r714": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r715": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r716": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r717": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r718": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r719": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r720": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r721": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r723": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4"
  },
  "r724": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r725": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r726": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r727": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r728": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r729": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r730": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r731": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r732": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r733": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r734": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r735": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r736": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r737": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r738": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r739": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r740": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r741": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r743": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r744": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>79
<FILENAME>0001601830-24-000052-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001601830-24-000052-xbrl.zip
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M%>J\8$@7],_@8JIB@O'_W>0J-1LR>YQC]T2VD\HGTQPX>C9';O[. !],/[6
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MWWZBR\/:XU18A )"<8\%*E=J0[VR/ [8-9M*WJ@;TQN;[8-\]H_NP)K;HPS
M*S[-$L*5_XS6.=VV]&<+.R7='E -_:3@ZZ2CE5!.\-VU.&M$1+D1!K?!I!IM
M*?"_8<)9WI+C6VL]WDU3B,^W'B_;"D;=V-FA[G5XPYQ#&.S($#0UNH5-D DX
MZ]?::]U,W9SSID,<1O8\R:4?>E_?6;EW-RYMGI]SJ-4MIZGQS9BJ=@4.MZ@;
MF+J?-:/VGZ;9UH;?GVYL^'V4@B@)9<ONP?2YXSC\?6_LD-W$BRQ8:'U5U-R:
MG>1\!]KG7+F+9YCZ=#7<+290,WM%G._$((3?SI/]71^!N1%'HBXM==1KY;;A
MUY:A].2*HK/=-5)R\&N>!"=M8XZRD0. 5BBKL!1P;A!N!;GEQZ 9>%@0FG%%
MU_"0?M#!19%6UB,3LTL=WH%@UD1'Z_SG^1# A!S>=52J]4!+:1J) ),(3(*@
M#'"=4YW,:U"?Z!I[=I&^0KP10??#1J!=%)*&"?=T_\5QL*,$UX#:>L/;V:A+
MLX#'IJ4RG@\OM&.@)_WCOK,2A]+6R>K:H'7X^#_\)ZJM X$M_U7EL*V#PVW)
M=BVG]Y\W;$^R2L &4'FP!/V_934TOS.I'YNR>X=A*?@VQ0N%2OZ!; $^/S@$
M^26. K*"L?TEG,UMV98'" #M=IIO9*5U-V2/0;,'OG2K'=I:&=/"O%G6ZN9Z
M_O%FE7]T<7=GB+*%)X:7M82<8&G)K_5JIC.!G:E+1A:CD9 8$L>P6T*$,#]-
MJ>1S2YZTM#6=ME;^28YH=@/+#-D9]"5WWBX 3Y230,T4 >YZ[KO5US&!//KL
MLX["Z,]-Z]/0+H='_2<']PCM\LFRQL?6^?M!>4H3N*@5V)K-DR7;8M9Q06I.
MNPGJ"E\J;LV8B$5X0(CBBXVPJ6#.8'HN0]A"]7DA140(E=B[/\->T$J9]+"Y
M60>;SY-EG2])BJZXW?VH59/EP#L1)+S))VQ#:55W7[O52'4&>F,\YB*.A1!H
MDZ>*6U]3:SB&\_)X>V+^74FC9D(]MY"A[/R3MGBVPW=N!:9[N=EMG0N*GN![
M5D40 2-:3M1KQG^PM4R6$X.N8[]>A&0UI,4^CAM72WUB)^+96",=&I,*9ICD
M: 4&4V2L$01T):C3=E#;P%"'N&A\Y74[<!S:%WS(H*V@8RIS+N?UKM?L7+KV
MA!1;<S22]KJ?2YC6?;3^62(!Y4VNN)D(AT_RG-IT2$RL<0NW5H\ZY@P )@9E
M -FHO"-T[ R[=C_V7'N-[#FV_5'/YN(S:P,,.YY)%YB#<>*-C3ML1I'X(ZS)
MQ:J6<U1^*I3?D994DF=^*HG?QG%2"28=?3:I)"Y MY67LE-F$PK'W"G0],W%
MO^TE/UQXJ^O-8Q5>84@TC?9D$C']Y]7=&J%%%@A>8MUWHON \HEK\ /)EUR-
MN1!_$-F.T6-0&\T,PSS1.I_%O6]&SQ5@J=G8P)EE8.-<_LRJ0M)&_;[B8UTW
MVVA?0O1U666E'PR59P!Z='2A_,XK3G9(?<,]A40%!4<0==,[Y2&Z-V@ZZ"-5
M]PYVQKL[![MV9R_1SU^!6G5>WUGR035=0XWHM\3I8 0*9E7CPD1&Y99:<4Q)
M9[K8Y?9O^%N$\:56OSU2SS!WD?\F)C5.+(@YM1D1^8 >JDC/4N#0^"L,SP6(
MPD?Q7 =+*9.! X4B@X]4#64)!"O*ABF'0*PPA2HIV[K9UHH0:G!Q_VG?HB@/
M[M]/ANI>B,J)=;UZ%9**3KZK#P()A>4BG]7D[]N KAR>_'9^,3H[#3[\<GS^
MZ_')\+?+T<GQ^XM>,#H]^0Y=^1VZ\CMTY88=]HV$J=BVL[R11/SFCNIWZ,KV
M_GR1HW;3?-^WH/^EF8'"?:H7P7DV4^F:G1CL?]%QVCO86^^!_]LXBY;P?]-R
MEOS\_U!+ P04    " !V@:E8D)PA!9Q%  !A\P$ '@   &5X:&EB:70Q,#(M
M=FER86YI=')A;G-I=&EO+FAT;>U]:U?;2+;H]_LK=+OGSH&[!,,K 9*>7LL!
MT_$< AP;DNGSY:RR5+:K(TL>/2#,KS_[454JR;*!=#H6M'NM3F);CZI=^_W\
M:9)/HY]_FD@1_OQ_?OJ_6UO>:1(44QGG7I!*D<O0*S(5C[U/H<P^>UM;^JJ3
M9':?JO$D]_9V]@Z\3TGZ6=T*_CU7>21_-L_YZ6_\^:>_T4M^&B;A_<\_A>K6
M4^'??U"OCX='>[NO@N'!KCAX-1P='1WN[!\?OI;#X<[K5Z/C_]G] 6Z%R_F>
M++^/Y-]_F*IX:R+Q_6\.]V;YVSL5YI,WNSL[_^^'RG6Y_))OB4B-XS>T6OAU
ME,#>],]!$B7IFQ]WZ+^W^,O62$Q5=/_F/Z[55&;>A;SS^LE4Q/_A9R+.MC*9
MJA%?F*E_2W@CO)P^WNG5P',B%4NS.EY2]Y_O>^]ZU][NSO;>3W_#Z\V>YG<F
MTC%L;ICD>3)]LXN;<S81 $!E^LUWL?O0+O9P%]?]SL6@=]V[O/ ZO_2[W0_=
MBVNO<W'J];OGW<Z@ZU6W]NA-_59DN1K=\U<J#F&/;_9?S[[]8=6W>="\S8G*
MO.L4GJ!RE<1>9YQ*210AXM#KRTB*3'H;?_WQ:&]OYZW9\Q^T4GKB&Y4#I()'
M')%=ZQ^\K*4 ),CLOMWT (Y3$4IO>$^@&\K\3LK8&TS$2/VKD-Y'!5!6+05E
M=SJ+DGLI6P%)QKR@2#/$R*N)2*<BD$6N A%EOM>+@VUO(Y](KY6@/$FF,Q'?
MMP*2&_#&2 :YNI71O9?*D4Q3$')YXHG,:RT$KT2:*YFU ()>DGK H]6M"@L1
MS8-0M!> K4# [:\4DBN5_/WN2>^Z<SY8N/;V2O-/[[M]4$Y\S_!S[PZP5/*'
M$$43$KWF4'_]\=7QVV^P2=!RTY]?!+ R6"6 27A!$H\42)T\2>\U^$@GBF0.
M>.G=J7SB0M(+R7;X(-)@XNWM^F@F[+981'7+'9W3CMK *];HN! =9R@0 S43
MI*(+JZ*W%\.N*BMNE:+N>S/0+ L!*P A?C=10+,5=NG &ZY1<95G@OU^^#;S
MNE] 046]RCN9B'@L\;H36$.:1*2_#N2M!'T_D-Y5).(6GU1UH6TXH#4C6,0(
M@)+RK4\JBKR2@_N(=B.%BU8B N-HE*#@ K)#2^D6OT8*S/ 9?#VB9R<=JCRM
M4>>\7&LOVKJ;5OE]NUC,&H,U!KNX- 8N@UJ2Q6K\,9DA"F;(B8$K!Q-T-F5@
M\,-:DE$CXPV2Z120-LN3X+.W(44P08QN)Y)>TN[:@)%(]'_]\>#P+1BTXDZD
M(<$7P)RG*L!387@6L<JSMD.U/[CQ.KB'5@ V4AG"#\3_ZI;#=!_*(&&6_J8
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M.4SB(L.HS*T(=-T8/GTFE+8NDM'(9UB'"$'M6ZUE^+T02CYX3I1\)>Y-EL9
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M),GH=?!(>";&?HN,NGJ8N6FZ 1 MJ&FH8GUN(=74JUOW62PY!/>)<^WN85+
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MXC90J>_(B.X_@2</!N>:;$X!.>!@B#8'W1/&L05" [\V)P*(RI3^OO.QRS<
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M\HJ_.^YCAO%01"^JCS.R"2A^LZK#,HFDTI'+U1@,TL-0YG=2FAX_#>XT0.%
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M[S^HU\=#T Q>!<.#77'P:C@Z.CK<V3\^?"V'PYW7KT;'_W/P0\L<%GL'K3:
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MB %!./,&NE(.NP YR%L!_4-BYF7@ZMY#QB7CZF#K8'?W,9CY9X+*!Y$&$^_
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MA[\K^$&,Z7?R+<R$"DF(,BL 4H9]!LX^04N+@ZA 0/K6\H_4% 0A_XPW"$-
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M!:1:D@RRN8RR21O X@CC5(83FML$1K)($<[0G8C&.K >S45!5M^JI,B U8@
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ME#-FWL,+=KTT0\R2I9 4JV*\8#2!R0\J<IOJ5>+2A!R;N&6,\I-"ALDO>9Z
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MI\7PYQP9\[=A$M[#7Y-\&OW\OU!+ P04    " !V@:E8W=^ZI<T&  !?'
M%    &5X:&EB:70S,3$M<3 Q,C0N:'1MW5G;<MLV$'WO5Z#V-'%F*,?R)1?9
M\4SJI!T_=)JDG<EC!R26(L8@P0"@9.7K>Q:@+K;DQ+DT=9('Q206P%[.GEV
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M)N?^ZO9?_RKH>P;]&9(ZEB3Q2LY3J$ZS^ [M!X[8@_1.[T%\E_@O4$L#!!0
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M-X*_'C0@XYJ[_2?766NGCU#:>I(FR0\#[S>?54I:W$QC<'@-:QRM9/G:QE3
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M]TPT%]2)^>ABW$<ME;6JF23[$(JE(CI['/(7=^GM,USK+_S/B=\!4$L#!!0
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MB1T0YV3@+[^+^C;\'VA ;)=:UX2YMCOT3P7PNORNZK$!+X&AHLOOW1Y1)<B
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MQQF73QC%T<%+7WLHM8"#DA\\EGZY[88T]0N2E@OL'(T(Q<_8%HLC*IE3[-O
MF80I %B<,(I%!A<)ZV>@.N(MT5Z)#PD0[1T5P'4T:I)RID&&<N#A@9@R %_X
MO)F*D"Z7RV7Y&QD7RZ.,N4".IA17\9N#6@$<W,TBA[IOIA'GX5"_X.U 4' !
M$BEAR(4@:RR@.<>;(.:P5=F0D;&_NF]]"=LW8(O,Q)O/<W)6%6!<WN.'@Q48
MAW?[P8(=(>5-S^?R&U%BBAD*_/M!B)X4'Z(![^72F5\>?_"#T+)1_,ZFMJ:8
M+V&?J!V^#V8(O$6\$K\2JQ+SQN.U1NL!P42C8>1J_!K^$S?-L84=,#(! \M#
MK>>QGUSMO&!S-?@OG_PA&N=%LT#$A$#1(2FI5,*/\;-1TBM],-I IY!G E(&
MNV2L;L=1DM\:\B-]V\&SN9BL8IH)\)4^=AZTZ!CD=X"MDP4JR(#"#8AEBB.B
MB9G<;;%PB/K=LBVX.J):H1*$!_:<(+;$V>XX0^@B0\!%;C3(F^,0.\KT/<YU
M'(.Q&E\MQ_ELEGAV+CK5* T\@=/493/4\B?8[C,:&T,N$8!FQFA@P"Y*Y&Z)
MW$B0$Q#^D7#F+43!(F(6#N?D" (3"1#J1A9_= 'E'>,HPYI/^T\2R>3(ZUB!
M)8Y#[&\I.)1,L/$HE]F>%9K!9Z7$XM8L&FMRW_0FE,^B<>R?8*^//%!V@!@F
M1F6A6A2C[B)L<!R X$WKZGD=?+. 3@R&?$6Y"_<ZV.>43[+A9H&-O\>/Y/X4
M/.G'Q2/:XI[%K^%W]BQX..]'*,P06.VWKSUUT=18D.X+Y!/1[K(*F.E[?%@L
MNT"ZC,'D1[.?/T0X>?'V); G%[LMR4QXC0M]4\(#AYNB@9>' '/@K1096XL,
M?$9L[B9..6]53,'JGZ _C(U.><PDV]J:QU@<!TAL:#<<]X%1X=,$&%VHEQ'.
MR1L,D'^9-Q8>@ U&@H^V-N7A'1&NP*<B@<Q61EPW1.<"D[Q*O&_O7*<X*PF+
M/=L\JHQ]PQ>E+F\Q'EOI<S9<Y*YQ0YT$D2_U@OW*)]%HU>3YG&O3I#-KALV\
M<(@&(E 3D$6,:V1P'.<>AWA>@$A*I&^/=(&3.(H5#;,DOD\#7WSFCJ[%T&/B
M86)T_<5H=B2 4$1>1?Q+7$_%+0F*H_ARI)9Q1H@0"X!PPE_#Z<7S2J%=$/-&
MO"C4J/5,7).N-9_B^!E@*_"$NPRL:8(S-PAQ/&L480%%OAC,*9%6"-(8!5>'
MQB8V5?C\!HRRH=]D,E2$_,=Y(RK"46P@KW2KXP-J?!-_!2.B&0^*;B0'T+6F
MQT?P8I3,LH?C$J_%:-(Q=V;5>:V((4SQ T>/C;X.]Y 'C(#[ TXOR$HU$9&J
MTK=A(\.IJ@34'+G\;R$S!:H74 C(QJQ4-3GPFR,T=,RITJ<N'=@XS1SM+:Z'
M4TLZ$;;6]".A'UZ\D4[UDP!TQ'D3RGC", IEQ$Z"AHB%O]C>WY!1_1"N1*D;
M!CA@=MZBQA-!/*2"%^'@%Q%BP:=GW@VR?B((H!37Q8EKP44$_@)>=?&(?A;C
MXDS-@RL^?&E&.M8D_@BMH<1EFG'L+%**-%/BJ!C1ZP9T*)P0,YK&WH]&U-$H
MH"FXU?:Y5YG80-P@BF1H=(BTC.WDF<)8EB!0=*KB,H4R!VP61H8TY1S$8(X=
M0L<VJ9L@<"XBG1:3_-<G"A*0?\W)09A1EC(&!Q)6!V\CC.>\I 6DJKC DXXR
M!,$<V":BUS/M5#1S3#&)Q?;'_,%P<619@3-*)C2$>WQUEH$@Y#OO@.B% 1X7
MEJ12"*E8E/NDD2N*-@Q>\(#)1EPCWCUBH%E0"S]H#ON<H$ L(W%Q5/ZDD155
MHF0KE*3/ ,7QGC!>XP@N.(YCC]'HC(ZS'SP#OO6]"69P\6EH.*PN="T1@AA[
M%HV,6H=/L09+9QBB1(A_,9D'#D]B#YLC.K9Y+ALWL'$0GC-+#)@-R_.3)R#M
M<-)QZ0L8UC1 $VG._\T.:_6!H6/U[;VXRL2>4 13=/H9:9.L= B03BYE/L;"
M^)0F":CM! \5%OB?0Y*[PZ"64UY1:L)BDF,"E\:F<UI J#&-P.L$H29D$)TY
M)SBF&'.<@KXH;;-";+.EX!(-, ,)4#F"!R7?B4P-<?100GY[R(._&6*>+$]N
M4C..Z+EAP\&\: ^)6"#/NAF6_N-.6$"W?3ZO)8V()"Z^=)HV2%(B%D_CAQ3E
M%>A2$\/PQ!<'JV:4ZLU/Q&+<34O,%7)*LIBGF*0U(,1#T4DB XTB6V;<MUTR
M2Y<1+@)>6?+5#@?6PL?G(6],6$(,1*?5!+3,)$B";8E=!U[:7+)A]LG( NO-
M<@@7<?M">8)X9"V6J-R>T=)J/ZZ52T+GJ=..Z#IWF)P(T^B\$H\C/<;QD2,]
M][V4]95U?3*L9>]U?:6<6:?0-\A)FDMGH"[S,*O!S<Q.7ZY0@$\VB^["\$&I
M%+;7[ZD8JCDB.,(:GN^+0*LH E!G%0 1*N)8+/Y S=GYVH+J+M&RJSN#64"#
MD F[*!4N6U6),7-@\+E1#@( -<D8CHRI2<C\L$SM*B;<0BSZ[Q#@[TPQQ!70
M*$1+L7E5E!V$IV6. []@+B5<-*$LJNS #\RF 591SP)MBZXHS_/E\E.\@#LY
M(G&3*S!8!0A=^-/V1U&X(<K>'7BKWLYPEUB5^4Q9[!Z_E<6TB76.I6PFM2=!
M).NCZL%HR2K?"] 1Y>?J7&S,#@C%U:+&] 5>E;(MQ8W@!]I6Y%B\N:41=2R1
M"#]W?L4S!&;PBW@(LW4 P-1D-*[ 2^/7]41.I3M (,%*QK;/K6+ &D\V2:5*
M*L^VYPAW*7IY%5\^?7.U)1-NK[OL\82(8G>$>#:4<>!VF-#PXC'7@.)ARA!+
M_@,P/(@]]@5Y"72CL%U >5P[(=A!8#PFYA+/>Q>V/RF= $N;HE*<YTXG8G/Q
M5*F$>3$PYP&=/^F<2 /:QJ8/F( #_QD$+X3%82 OM*I]G@NPF'*'6BO.5\?K
M+3JA'. EHK87@L+\F)7G@B@+&8_*33P'#'LZ\Z 2,T(X4%SUDV%I!^X _5FE
M3$H9@8 " (UM$URGB1W]Q>MY A[Y$1J+UUZ@+1+Z<3F.FK1!N;K[Q\W7JM;A
M]_$F:BC;0!'Y/&5QZ'A]U#$>GB.9W,A'^R\*O#(%V'% 6"HS5GAJ45KS*+62
M'9X>Y^7%B5])/:(82IK4@)?D58043DQZ;K6BSN.H\9()KPOBEKLFSYX-G@AC
M'@/;UJ(.F8K\*7/:I\P7S8.F"I("!GDER)TX543%U?>\*88MRD+<A9IND<5C
M\1R>F7N^&.YZJ\O"(.K-,SMR7GDDAI>F>X6D^W8LO+*4_X4PJ->/ZF4M[)WD
M!=P_'  +,N&CB^Y)O.7*0E*R.DNE2_D6A#$2^2!1O%2<N\#3\:0&(P8>XZU<
M6!P$B&M4U)E#GB(5P?FI4W$:)[S/LG&70G@E;6QO&S!LP3",LISM<3\$D9N.
MW^T>;DF=H99<7,2)Q2S_ -,27-[/+DHU9 !TD/ J9O#8 3=P>/JT8%#!]E3(
MZ)1XC^PA=U@JUZW1,[,I4Q4^);WO()E$/R[T_U(5Y!$3S!=N\,*:I,(&*?Z9
M.%'7&MZEB[<60#_3Y9'201C%V2*NB>S3%$-%3Q,\Q+\$9A$,-N.G$KN%V"2,
M8%P:T_,#$A7YIT03H H%4PGJ B+0&;GI#GF)^^3Q-BSHI&66C?("<-$P5B&.
MD[X^.2@GD?TVR[W!8$'_#]'TH<3A]CCD6ANP +X:3;,'""X?6W Y62@C08!G
MY1%ZN>'/ RO)325&BCK7B3G+2W0*AJ6&D><DU!=R!6$HZZ(>D_@8#PTYPBM
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MEF'Q\=:M+8&6ACUXU5:[[#DB#PUL%W/=G@9T3@-U399*YC.W!K_2 04\64I
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M K)@2%Q (([3 & ^VRP(O=!7S*F)L$; \->' 0<7+";P/(?K8$8FM@4R)&!
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MQ.(3#GB/LA2D.'_WQ"2P/ID3L<M@M':K>7$U@6UGST4+Z&%@,TY$B2%>E(E
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M+U&%'!&:E#])MY/%'[V+J_;AUE6E1W*B87N'PV&_1-52,CCL=A\<_4&E7DY
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MKFNW\"F491C_@;NR*$*&L2_VG?'S:30^;YU'C=ZX2M#5UOK\V8L-DW[Z^*]
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M?U+^YZL[7V.&;CJWT-)4 XW?[UKC$5F7O=;%5;^>QK!0QF3M##P7)30L:KV
M@U;Q#XP94EY$IC549 DO;128%OU#-6 9,]V="F\UC4'J/6?=;\G#)Z<V[3AF
M(T9NR51->R_;#C_N!<!:F(<)L'A<_5;\!.+R,."'*ATTUF*V]"BW&1J".O<H
M<3D!)67.9P2V\QN!_7,9@3V:^S'HIF,86L+R*A%AQ8S ]WCG-WSGVRQ!L%N2
M>@(DB H(GYX\0*>",M3PB"7!EHQ]P[QVZHS/8P:VMYN!@Z.8@9V2FX'MW<W
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MV&J\O8Y]@G[5?(LGI"%CXB]U"P[;UTW+>UW7UM(?+!TD$K_WF_ $;1KW^E[
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M_];@UN :'AR+0S?:@^Z:3@#6)FT1Y($!1C7<&EZ_Z>'UF5N<R+IVC0)WHC^
M'D5-""X;FE@Q"Y#,X#D='S[ &N,/ O<+WI8^F8#YFVEL3@+T);4)$+-MF+@^
M:<:17QA8'#%TPH@A&NB&[LVT"1#]N6ELFV?^48Q L;A+E,[-#$^<0VL@L.5H
MGU!*D$X GQ/-%@>^'WD-&FP _OL5/@L<N\#SX<\TF>4U2Y;PEW?\^?M/-S7M
MTZ<;_HH%3X)-CU_7X8,R#L>J([XX&CN$BZ+KE(Z&^JH,&2/=V!@20M(":0/O
M#%@SC\%D7[+C88+C-0TLH#.?7'V,*QHFQY64NV_*BR5"UM'C-R3B-SX0O")+
M&[OZ(Q.L/?X53@9TZB6\$O4S+@/^R?%L*5QC#QD%IC7FSXQ1)-W9VK\#6[#>
MQ&U'FP_W-S%1&L+V]4</9!K<"HA"+T&^VBM%6J>16>LH;,U5/]2U;P*\7@^O
MX^M,![8V1$!9-KB$6]NH'V7Y&Q=;TVZ0Q+\X=:W5;@P;G5ZK_UI)GN\S$P[^
MO0F[,4%0W( $8AZXURU?^Z3_P),'FP;D':424";\[NLS)FKZ^&NP?BP0<:2B
M0 ,9YH)YQQ4+4%QL 2/)H5.%T:U)&,YA8_BK!=?LFY,)D+_XX6'$&@@='C#6
MY_I4TBL(.,>U14Q^"22K6R0K:YG!2HJ8Y@XM 'AI;'IST^,OW8N%SR#1_,WH
MUC (,75UFR;H^5[Z^S7IV<OMJTC!.$G+<&:FI=T9OA-:BS&J1U-1X*[@/ZZX
MG*C8B'R%P!)#L!7P7(AUUCTG@WML?G3\$<Q(VV^IEG%%*S='&;(Y!@?'%/2P
M]6B&B3;120C8]"\71(Q.PHI(Y5HNZD8MZC5]<*\;_P(OCMW=3K>N92XB4F.G
M"T-\#RD'$SJZ-A,ZI6P<.U-/IW=BVIM6?20I\EDG)NN 18*&P>F/[2Q[3CF!
M26HKO?L^R'2/8^'/#%]8!G Q"IRT/9W !Y'"J6G;\2,'M]2F(-R +?AJR$9)
MVV_H8Z440EJH&" QYEZ4;T<.CELHH2!6<K:&\0!D;$J@^#,TI-:*V(FK!SB/
M!L0I,#D(99Y!R=I3*5LT77D9;$9*M;!9&]C>(T:.R>:S33'.E#*T9A6X!@7D
M^E&Y0^+%R?B5TH31WC%Q0U%_WT);>PKBG!Y$0U,?A+O,T&?]VG9)3JDMW?71
M4_DK&$_)6)<B<P%&_)A/%_4)"M/X1T"YX'%34'P=L]+F5MFU/\S'KU]!N\ _
M;^B@O@1(30EF!2HVL#CF$4X*+C>+88<75Q.@K(PQ8EF7D%>)['2(>%N1M(_?
MMHGY!1(%H(TP (&>)G\9#H*K%.14,U=S54!$!<6 K!QP-)&P0D9,DM8.*8M"
M:A &9ZU!&.2M0;CW'>/'S+'&PO4^4+ 'G[.I_*#52&?Y6XWL\@.X?GI!\=,9
MY2LS%G*<Z8P;-<$'%+K>#.439A,LH$;M&DUD/ "/#D#&X]A4Y/-&0E\K,Q[@
M%E9%QKI"*?>G^_,-'S>=]A_PW:_"O<<%Y901K>;%%8BTM(C ]6@+S-73-BF)
MF+'K=\7O>K#7KM,[PZK -!HN;<R+[<PA7T8&O3S-"T9ST_<YD*KS,22CKZ$<
M]&*L5-=N8N<@?[DV, OD"DZ>/?8HUC\'^3@2N&E+QV#2:)GYNG>.[F+\"!QL
MF8:6YG/N_$*156_OU5;H3G*8DZV<Y7>#QM%6TMDQ[Q->&]GJ(R'L\-*>5IC\
MVK\$57P)=/,#%/[=9")0WY=WLNSM.9S4ZV *=GUBYM?I=KPIS&QCZ2V%??'V
M[G64MV&"C<U[63F\\C=9/"Q#S/\6=._P@3"NO/*UV%<HS)0HM^+B&R(<\'D\
MS'C)>BM/YRQ[L-!XN?H45C!%\RZ:4WOZ^\Q5P3Y84X%/2@C/YV["2@B=Z.O
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M)@3-PZIV$&@$GS@1FVXL1A"%Q J*/X%F"\O9,"V3I!_5]+WF.-9O.5V*$<F
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M;'EZ=X\V_/?,7$08*YEV)X)B;<B;2RFX<!ZCZ,WJX:</ V4SG%KBR]AO$TX
MIQ&*Q'=@<<7.&X<I$>PQ&?,_L0(&]8$<K*0_@MI+O \<E@FY.*G^CN17%%G%
M7A6B4$X"K+'!-XMQ+7SI6"Y!M?M0R]'FFUX[KVP;2;%9.:,>\I,1R%<'DRS
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MMD%'ED>KO=G0V@R,>O+5=BZN;,=/"<RT!$6IYV+WP5+[O7Y?UTRF15__&8K
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MMVN2R1%_QAGASOAA<L$*S5,MPAF!X2K)D?%B\'X=S1<VT>,<D4_9?JK'D.7
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MRL:MHJI7E#QX'<?FI?9^ZJ&6Z ]AFM%,I%RF.KP4,V,"31187?30;PYH:PS
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M?D=OM@ID8I2PW_L6=/IZK]-66U#B%C0Z>JO;45M0HLE3-/IXWB;/^0;:OPN
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MYEX'I1(Q\ (G=LVIQF-Y*8ZV.+4@-[#0>8MCSN-&6^PIV9QD+&?5G23%5E0
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M(6,B)2,R,J TJ3VLFYLKY$2\KXW2=^09CG@%GRZ[MI+:<RQ,#Z8^)5PU-!:
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M;JV.1E\-?'L&_S>.)N[/_P-02P,$%     @ =H&I6-&5/V*;$   MJX  !$
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MZV$+"^8-]<L'JIK7V@0:#2F5.LP[!]:.,O#+N[\B%2PPF5B)\)T+6V-)8I>
M;G;+5=1P1,4DZ[.3\K*,)I)*6!I,9,%"9A9(G]L(44GJO[AY?-Q9O!0H^+YP
M<1!>&Q1>P::-!Z\L^7[KC_M4W W.70+M*>'#?$V@ZZL1%^R_^&9KTI<Z/7S:
M&A 7+S_!&Y!@BBQ)[N'B71]O05'"QZM3\-Z[$W O&'<>]=TFP85?>"^4#Z*8
M\E'M+X+[D]-64)HI.FY9P4THX2^>HD,JKN !,IG?F)2JYC6S,??5'0JJGSP*
M@O<9WFL%OD+S7G(1O.X\LE<JQLS3;9=;^9<Q-3>)XXNP;(4VB8A*- IH13U;
MG^7 &UUF$ +<4,0S6>- N:#"!01KKTU\7^&)P\>$E:E/CSY1SZ<]BN4#(/2&
M4%#YKN^RH1;_C0B&BN)+T9D37H+0'>.6J5R@7\ZX2O,$S_K!+1[P@/99M6X!
M'1#&.H#'W&2WU!=<V@QA+<8^J^3F0.^41SUYC"AYS4H7]PI@3!N_\3[YLB Z
M56>N?GUF#N8O9;O)ME&1F#(C'X6!F2YN7GKXZ8-[?<EA<AC2NV OJ?. U]GE
MCW45V6RR^B"4E*CY#;-'A+H0?W!!BHT[LV@=AK0SQG_#Z,X'L;:.EZ@HKDH1
M11UJ] !SR%VP1*9GQ1).1A')"P96&YS$S8VLRTK'D\<*%<ZDK>!2_:D5[ZK'
M$;TAX@=5=X,!Q0CM7O"A(.-BPS73U<%\>W3(4'ODV\,KK.7<_0/OKL"%,-"]
MOCL8',&E\]<,W/L"AD69/RD44-35X?E"H"8< P=@[A'W'&4:AM1BFEHX09^G
MT.[>D*(B>MPHKE%N\3IT,>U')-X^<Z$)\ZJ25[H6L)S/;)?9Q!A8I<O5 8CH
MP!W$]/TP;.V!AS3T< *Z<J L&^B09_'H:#?KZ&@/^HY@MJ(.7CF5.Z)L4N3J
M$^9&1Z2'($-ST-&67&PGV65K8>K=P0":'Z\8^RVX1>[NV8/_1VP"T;*-8=0P
M?R(I1[R9)-+$%W1=R84H'0:.RW^HK>3CB*@;,CNC5YC3(ZK YUL;_PTY$A5R
M;=QSN%?"FC,*UF'8RPIU8606P403_+WRLH\#S2Y\^LB#*G$'QJK@WG=9*:Y^
MN;"Z>E\71)%SBJ]Q*6$>.87K8"(];H\H3#I?*!Z;I?:HN":YQ6LQ<J?-+7QM
M4V)[>+AW-->,*_&HJW4NY_.[GN<3-]RG5M"%#61U#=1[T1I?F-8' PW]4(,U
M&^GJT$4S/,F%S/RC()X<4"&"\%7-HK=+R2MP'U'[*DYJ9=:US5N5\D.Z4R;S
MS:,T@S78B:-.'#;&>ZN#',=BO3$ \(9ENGYP*(:+69S+,/@N^02U&-1+H5 <
M65=B48M*WWZ[N.K>"_8$GO"]2VQJQK&0I [C6/0^1R+<6;SP&AWE./=AD"E8
MN"Q'7-<)*CJ2]CM3HW-?*CZFXH9,V=@?0\7H!,(="(0<W\YO@"HL7CUP*L@1
MAT#&GO\J>>8TC[H"G_*HAO!IB#VTLB^6IJQKI4TOY>R&-<[-#96FWY"AEYYL
MUYGDRWTKAVEH_'.5J*O1/8*7.H. Y0P5==WBN3*G<(UFR87#TN!OEYP?<\GJ
M"ELJ7WK/%5HL<3,2I[^/J'?G*]03MZ<%(8D^=26_05!2/BG[(B&OFKQ-+*C/
M50XV*S(IB_;XE:#<H/U/ I$K)BWCF?Z1G\$$R)P+GW8'$(K^FQ)QR7U1*2M9
M@EM=NTMB4RHXA. #(W ]A*3 <<PGJ<,Z1.'RP/R7?$^I,I]7=X\3D'R#D6A^
MYZD9PL7RK[T9N;NWN]>),D/8O]D3QIZ>87^,@:H6$?@ZO:HKZ'92%?O[&Y-7
MT\7B&YB.!<S $FI)P0"<6ZY ;PYA3_[28C%170?MU.[ZHNU5V85??T_56J,,
MO#<C@#"\O.O/"&U20FO:,S+>3!V_&TPMI.=S<O+1I*<G"7/CKDW.IJ)QS;Y4
M"#B>^/,LD2D$S"Q<AQ P=,_O!O.<3[@;\5[ Z( >Z]GL<42#8 :<UZM!7(\K
M>2;X#YH?!JR'^;H=CU4"!=/F ITTO!M\E>'H4&')U\2HKNN^]Q"[@I5-9(\\
M7XTAOI/%G2"_?"U\L*"/7H/NQGV'F47KT)F7Y_-[02?0QZ*EB])^0(JNMNNN
ML5&=0V]"UB5M<+EX+4PP3*AIGP+#,!B=P/]$]R/<TF_H8>7I:U'=Y3W(1<OC
MV67KLQ)^/A),*CX!M^\+ZTM0T'/B3* !MG*TM8#L$1SC&R) IC*Y/!DEZS!$
M+FYOQHX"?]#G?,)M.4K.#]_'Y^D+DD$K\'KM0$ ?<9?VB([)IS?_ U!+ P04
M    " !V@:E8]<Y!TN(=  "<, $ %0   ')X<G@M,C R-# S,S%?8V%L+GAM
M;.U=67,;1Y)^GU^AU;YN6G4?CO%,Z+ G%"%;#DF>F7U"U)$E(08$M "H8W[]
M9C4)"B1!$D<UV.)NA$V*((C.K/PJCZH\_OS7+R>31Y]POAC/IC\]YC^PQX]P
MFF9Y/'W_T^,_WOT"[O%?__*G/_WY/P#^^>S-JT<O9NGT!*?+1\_G&):8'WT>
M+S\\6G[ 1_^8S?\U_A0>_3X)RS*;GP#\I?NSY[./7^?C]Q^6CP03:O6VU6_G
M/TK4VCDF@:-"4#XP\!$+Y!R<TBG9S/U_O?\Q9QM#D1P8=PY4"AZ\]P:8LQAS
MP6"%ZCYT,I[^Z\?Z)88%/B+VIHONQY\>?U@N/_[XY,GGSY]_^!+GDQ]F\_=/
M!&/RR>K=C\_?_N7:^S_+[MV<'OFD^^W%6Q?C36^DC^5/_OGKJ[?I YX$&$\7
MRS!-]0&+\8^+[L57LQ26W:K?2=>C&]]1?X+5VZ"^!%R Y#]\6>3'?_G3HT=G
MRS&?3? -ED?U^Q]O7EYZY!S3:2?^']+LY$E]QY/GLVG&Z0(S_6,QFXQSE?2S
M,*DLO/V N%R<3L-I'M.KQ%'WA.77C_C3X\7XY.,$5Z]]F&/YZ?'\R_P+5-$S
M>4;7?^[R\4^^,9'"))U.NC5[13^?/Z02W!L_^&6)]*=G2[FB8S)+E]XTJ8*<
MS5=_.0D1)]VKH],%O _AX^C5.,3Q9+P<X^+I-+]=SM*_/LPFF7;=S_]S.EY^
M'6'Q2@GTH+++H*S*M =<A&A,X%;JH".[O*J5X05QW,&AA$7L,''^0,*&D$]P
MLERL7JD"D-WB;TO3V<HWX7ED64XB9@&:.0U*R 0^.P&<Z<QCMBXXV1][ESE9
M0]'3>7HTFQ/+I/@>/_J,54F=Z\ S6L(\78/7Y?UW_HXGB].3D^XS@4!TLOK[
M,I^=](B$Y:S-DI^)E%@Y5.;/9R<GXV4U#Y4[VFQ+,B-D3BI!&:,JFFL0(5GB
M+D1PT43P&'U,G&/BI3$&;B%G&TR(AX")5B)IAI$-_,6H4R!F("J;0"$25E4H
M(%")PIC@1KC&T+A+WVU&A'P(B#A0 ,V L*ZM6%(A)E^ !0*ATJ) </2C,"D8
M)WUDV!H!-QJ(@SAY?CJ?TUX;.:=19_)6!18#RDA!LE$.6 K.9HF)_-S^&#JG
M8J"&;R=IWV+C]EGKAJ9NNIR'M/P'A3_/3Q?+V0G.5[1]_6TV3>?$8=&:>>Z@
M1*8HNN&TM:R44&QV'I-5%%$T-WM;D390$W@0.OJ02CN%-YN^?X?SD]]F2US\
M'KZ&.,%1=(F5H#B4HD3E5D,(!<%SXPO7*K/0VBW:1,= K=]AJN+0]6XF^=<?
M<1ZJX_4**4S?!$C.O$P2,\10R%VWI,@\<@O&Z&"%5CRHUC"XDZAM,*&^,TRT
ME40S@+S @O3X_'*:2&6]"U_6^/T-EZ-L,9B@&40>R<1Q0RRG1*B5*B$R G71
MC>%Q!TG;@$-_9^!H*84^W.25P\.EILA-(^C@28=%2Q#U)8/#0C&;Y24K=63G
M<G>^GJ8T.Z6H]%PQKWC3T6+6AH',D='VXQ*<LPQ0L9*=1:ZE:,S;9DH&ZCSO
M@X&K.&^P],W@3;3,3S%OX% 49[)4 7S2Y*,E@:22/06ZQCF&-F2,L3T2-A,S
M4%^Y$1@:". X<=6*,F0F%^TT\*A)R2OFP"ODX)E&'U!EC:T5X#9T#=2);H&2
MYF)I!IAU[WY%B'%&")X=.&4\(3=;<!P-:&V2$CHEU]Q ;B!CH/YS"S@<NNA]
M1U87)DU)KR37X$5*%.?'!)%B?]!&J:A=L47SXX15.V#B'MSF%IAH*(IVWL5B
M@<O%"'GV.;,((C!6'7</SA 51(FU.699 K9V);HGMZ'_XJ"3^>B*0A Q58/L
M)<08$DCK39(ND^1:'Q)<(F!(+O$>DKWF^>R]N,WP^087R_DX+3$_#XL/:Z<0
M0<D0!-E.:XH%A8JLJ+:J'DI@HLW"N$V-17T3+4/R?1M(O<F2-P/ [_,9J<WE
MU]\G8;I\.LWU0NYCO:VMYPW<RR"$)S8=$D5D0R&FPL DE.2(1R=<:^MU&SU#
M<F\; *'9TO?DS+RIR_BZ_+' CMF1=<2M3 P23QQ440R\,Q9\+EB"T2ZQUDDT
MMQ(T)/>V 1S:+7XS/+R<+L/T_9A\[#/^")@_?TF3TYJ<^;?9+'\>3R8CS[":
M+@W2QU+S(A,$APXB8\HY'SDSK8])MJ%K2(YN W0T%T4SD%P\G24CK4!%SQ22
M(%KO-+EPP#6+MA2O2VE]<KJ+L,WW(^R]EK2=%5A^P/DYRKYY)R8&53!+BL<H
MAE(UE2_JC( ")<LZ9F];'VEL)&0;4=OO1]2'+W;C6/7B+,VC,D51?(SDA:P"
M9W))$[J"3 4NFM^#W!SK[7&.2\YU33BD;]6Q^A0F70KB\GF8S[^2TOQ[F)SB
M*%L9E>"*HJQ$"\UTAD"L ;/19RU"2*EY=LPVA TOTMT'%]<.<9O+I*= >,5L
M,%S;ZH [6VL^I*AY&LJ E![I?YY,<]]F(R'#"X%;P.'P-6]K\]Y@0@(E^5C5
MO5K1(T6)(E/HY9@@[=[=)VA#]'CF$U=":FQ^A'LC-<,+@5L H='J]^$!7;!'
M 9:2A8RZXY[HJ G/2%]2PI1=KGYW:T-QG8KA1;S-I+__:O=9&*!2,=JJ!-:I
MJHNL Q<P@2LN9644UV@:2[U](52MP)A-N\\],[ EHY%,:TBH+:@N0LS,00E6
M1<Q&*YY;.SU7:!B2?W.@W#<5O.R]W.V<^9S'E?<P^3V,\\OI\_!QO R345+&
M)2DYQ* %192>0T@8P$OB+ ;T3K1&] VD#,FG:0R!%HO?T+-=AO$4\\]A/B4?
M>_$TI=.3NM287V 9IS&IVVR$BBD#\4L>MW,%0G$6=.9)\ZQLC*VK7^ZF:DBN
M3F-\-!;)%:C\^<G5%7M%/[>MQ7Z[I*]=4=^LG!]<TV]#+? [^3C'#_0'XT_X
M:K;HH5![GV?W5\5]\$HT*O%^/EMT%98_?_E8:5R,9 Z<>Z'!*:R%!I)\:.\B
M>)8M:OI1R-8WN%=I.-QS62Q?EWH:VI4AXOS3..'B+>W#D16%2<$R2"MJEGQ.
MI$J# @Q9^:)5L,T3TF^F9DC>S$$XN.[+-!% RU,:I(^IAT@O\!-.9MU]Z3FK
M(^<5Q0>)U?B#D\YD""'R"*%F_E@9/5/MS=@M! W)PVD*BW9B:'<+A5/2O1.B
MZ&D^&4_'BV75Q)]P1915PJ$/Y'4;JRBB] *"#IX\<2M\EE(9VSIUZ0Z2AN3?
M-$5'2U$TO,JN)375#/]"W)^U(3@EW^N;R7Z&93;'B](;7/S\A0@G08RG8?[U
M):U?=T-3\Y!G$WK,^Y?3)<YQL:0 3WE$(:"42("WY-9'EFIM/"LR6LE8\WBZ
M1W::)9%\HW&4G$V,]CT8GP.0;9#@!>D%:7+D-GC+<NMS] UD#,E,#P6/-V:A
M["F]AFGUT]EE6E;ZPP?)K2?5(5,JQ)3UX&(P1!C30F8;N&T-IAN)&9*)'RJD
MVDBR';!PN8[ME()%Z>M!3 05A0*OR%F113*33$:?6E]S7R)@R';-)X8BB@@F
MUN.JG!2Y ]$"$R9A\(9A:I_9=22[=K_:?W\,7L\+&X;\&SMJ1.BYDGA&WF09
M+T<R.*8*!13><*S%@ 4\.:(0C?;(8XS2M.Y0=P,I.^I\^*Z0=-C"M\]$7F..
M)^L]SP7(X%A0A<Q/#)K"B.309ND2]ZVO+NYT(O<YPOB$TU-<[=:K-8T729WU
M0I3^RR20D43,S&H&22'9254+HKC28*4566H='6L=8.Q!YI 4[*'XN7[BT:_4
M&I8O7XGD2Q(B9^200KU(*#9#*,6#"?6DW1HLJ8^#TIN/@>]98;9&QD$+WK+Q
MY;?+AC/.R#*\+AT.?=16JP3(6*JWCAH<"Z3%,4>7E75)M';C;B%GR ZOX80$
MVJV LG:"SC7Q&@,'VK4L6\VSP=;!P/\1A[<5/H_I_NZ"AM[=7RNSXLXETB6*
MD6>GR9@D8<!ESIBS*KG2^OSZ>W!_^\7586*XYVOYFE/[RV3VN><;^ V/.<YE
M^UW\-;I7K[FH]*3?Y[-/8_JT9U__6-0&7;^0^IBFZO&EY?C36>LO+YR)KC@(
M6DE07=U.Y!JD<$5@"9ZGUE7^VU/7H% XD4/;Z=F7B\5I;5W_NKS]$$A7_D'K
M/*<M0X*A;5AOBNO+ST(GO9.Z@3H$U$+7!;WMS%7N<FI>?^R4]"@X&V/!#&B8
M!_*2;,VF*5"R"JB99-*WCG!Z96A(MK<G!&\H9QX(0!JF&WP,7SMU\[JLFGF^
MP+@<21WKX8>$U#4:"K6Y?= &=&#9JX)2R_:9!IMI&90Y/A+4FLBE90N%#<!?
M2P,>:<:0(DL#-H9:QBDE$).U/9$L3CN;@FGMO-U)U)#2#^Y50^TKJ)874INX
MOSBH6.,^ZZR]% J4JV<+W 6(CD*27'BQ*?*D7.LCT.VI:WLQ)TH6SG$%EIG:
M":H(B)@B"%O(_]:^N-*\A=K-%W.#M."'(N3:1>W> FC8AYC"N33N%H7^/<%N
MQ:?YZ<ELOAS_NWM]E*QG.9('D'-VH!211ZX  Z%E%DD)QU3KBKQMZ!I2+L"1
M$--<7.V*N38ZF"-EF*7GD8(/NLYZ,PIBL@*<K#TBE;:Y>:7#9DJ^ _/;&BP-
M1-(,'N_6FZF\//D8QO/J3SXG$M\3FSH:I@UY&9JKFN02:J.=3+RR(CBGCQ.R
MM<-V.T5#JOP\$EP:BJBG!EFK-"8AN4R.U;[5H5#4421$JP5D:60J3D@F6E^Q
M;21D2"V/C@22PP72MFB\7B40VY?3W$J2F?DDN[EFM2VQKQD4"9BLA5S,&"=[
MZ2"PB9@=.R7=RW%!<Y TD4S+*YYY1>L+//M.#%<"OW%]UE5(L9Q9;?F'BE,L
MRBV""]8"MP&5]\REW,-EY!:4[=B!Z4% J >9]8BG6YNEC^I@SI!] 6XP ,&<
MM&/R"7*2*AI:"]T\?WI'$K=!F'M8AJQ/(?:(M"N3/$:Y5D5[8<#(4C< <>_J
M*+P<E=6T+)(W3Z>^DZAMT.0?.IH.$=3!^*G7RIMIJI,_-I00:O+;BD$-DM=K
M]CI)R4G2HR'%:(S5AJLK'O7UF^M='[K5@1][&#CI52!].TK7!\:,6$@68U9@
M-2?RC,C@2BX0M2S*^I*1M^[.M#5Q6^'J@9TD]R.Y/H&U>7;$2!M69\I$,$Z9
MVHC*@$/!P1=GI%6&F6+[!]9FXK8"U@,[<.Y'<GU?Y;V<?L+%E54(1GACZG"K
M+CL\.%*FWM=[S6!,R=*C:=U-?7OJ#KX2/[^>?S=[FO[G=#S'&WO=CU(1)M<>
M-[%@URV T8KX#$4:I9&G%%+K-B7;4[?C)>"]A+J'@NO:+7D_LFN7;G&5OJNM
MT4<AAJQM'?(CO27N=8$@R7?AVBL3K"N^^27/G41]#VDZO2/I($FUJY6HS68O
MMR"^W(F6,'[YA;5W_H[S\2Q?-T/G.6L_?TD?B$5\$Y;X<RF8EB-9G(C*2/"F
MKB!Q!B&Z"%)3H*Z4L\PTGQ5X5 Z/F/^2K# Q\ A"UX)Q=!*"4#7[!YG+NK"U
MX;KWG/]RS_46P\7XAJR3/L1_'SY=3M:XHB-DH6)U;RE*)C4&6L105/8EF2.E
M9]WIT]US-ZKO'IZ'BK]O>&[*G>2)_#+Z DDILK:6K'JT=<Q<CJ@5LAA3ZWO(
M?>L3[KD=UG</ST/%WPR>9RR^+NMLOYX>M,"C+(Q-5CHP)=9!>5& 8_1CMM+'
MI% ET?JTKP<VAI32\QT!_KX!U6]5W]O3CQ\G785;F)SOX3!Y.2VS^9D<WZ8/
MF$\G."NKJ#RL!>0O:E_AR>(RJ=O5^;5Y<)/*OQ[6H%$MX*T3&T4.7 LN0(1:
M+EQJ7V^6/00K;"@Q*I%[*&';<EAF0U[_-J_9X8XG1-HVD'Q6-6NS@,^1022'
M/(<<HL36.OAVBH84?37#R=8C0W<72KM) ^O-R^].![_Y--%I'2-] 9:Z=E/%
MDA:FA9$Z&%+!F4O6.B^E%>V#.MWK#7WW(NFAV-OSN\M5FQ<R.=V5YMI=YE&L
M[_9D'-D6[[D^C2SS]9OEU2BA9%)FI9X912;K])5 6#,(Q03.C?<4M/>@5383
M<WB7GRFYL*>IVUUGB3PK-HV1Q3AMZ]@E4OTU$]XQ%$#LRZ"CL2*TCNUOIF9(
MMK@-,JYW?6HBB3:95;^21I[3OER<C5##_-ML^7+Z:39.F$=!E! "9D@ZU-MV
M86MO*P,!C2\6 U=)W:6>[GS*D,X6VPJ\[0*WD?=*U8;YY.N+\2+-/N'\ZTKQ
MKICEO&#-S0)O:_Y#SK;VK"%KGWV]7+/1VK"5W+=YVI .[WJ0?_,%;W>\1M[%
M["N2R].Y91N8=A*YC;S.SR2O3RG-B2)EH4[E$Y9'0]]:'Y;=1=20CK[ZL0]M
MY=)4;:QE=W:]"R\(RM9GR42=,\5KBF<"EW2$DJQ4J<1$BFP7A7'#<X94I-:?
MJFBQR(W'F=[(JS.<6V014@A$4VUQYU+!.KY%,1%-G<G16$/<3M&.-6K?$41Z
MD,A0XN-5V\2S KMPT1"UVLO);'$ZQZ/$Q]N3<>3X>,_U:10?KYY^WL?X_-GU
M0,AH'R3Z1 O.ZG /H\$74E#"*QFBTLR8]AG.-Q!S>%[WV0>OJA:8LD'+*"$;
MZ4"Q&""X4$ D64H6P@O?OFGF)1(&E4#:!@374[+W7_2&&?TU':/NP_,FH&LS
M1T:^Q&QX0A#"U%HG(LL;YB!8G05F-)JUKL^_C9XA!<M]0:*1-/HU;EU6ZJ*;
MU+OXIJB?G2[&4UPLUG\;OZ[]=( =._")34Q62ZX;6:?5PY_/3B(9T?JX>L V
MSN=-G-_-PW11D)RCS,F%5D7I:,&F:.H\"@4.;<UJ$=KZ9(64K?-I=Z'O4$VV
MP[/6/$?:9]5WS",6+!I$ 3;'&E9F!3%S!C6@3+1@0O/6YOPPBH=T5MP;#J\J
MR",*N;^ZBQ43N#B[?>9!LYBM!5.O]A3%+N %^0'%,FTQQ.QDZ_;'=]$T)%-[
M-' U%52;HZ<=>#\;K[[R2Q9=G\Y:L!XEDS;9ZC;45BTA6' F,O"UD%T4$;4P
M=YG?1K0,Z;2[=U3=A_SNP^W[)8SG?P^3TWJ5W14GG6^>3*'ZF@ZFWYV>U/.]
MQC[@?H_OT2%LL![]>8=O,,W>3\?_QOPRUY[B91PNBLI6=#[=1&>-;)A.1<HL
M@*582\YK@E3) 9 KX4R.2F'KBM/&+/3@8^Y-S@L\V_?OPI?UNGXEA.+<,(K]
MI:AU_0D\!@1>(G)R4 J*(2_R9JX&=9ISG]MB"W_V/@'5S.=MNL:S,_=]NES[
M77<1,+),>L:((Z6X V5M@& 9 VNSJB,;&0NM[VB/P]F@\B(?ZH9I!*Q!;IKG
MUQA;J8?S$\N1*"5+IAUXR5,=4IN! F *9J*2FI4N'![PWKF3P1V#C?_?0O</
MLT'NI&^]%Q:C(KSTNFC(HG;@L=F XQHA^BCH%U&8YLFB/;$RI$RBA[HY]D5.
M;T='!W"RNI=:C'A4Q6.Q()4,M*&E!\^QUB#(ZE)B*LG>%<KW2>"0\J2&@.S!
M@&%XL-[< FTMGXC55'1)G$E6V5.TU'6O@M%>RVP*HBY'Q_I=5 ^J4_F#W %-
M<3-(I^><D;-WGH=$7JDB5'?Z;$ YR\%)9R )F40*TF%NG>W8+T<[MF-_\-MD
M@#@:H,FH/)Q5LX3.L?.<;""S%A3WU0(R"4$%!R:C$4XJ(W"[<I$^J1Q27_@A
M0'U8L!@>RB]W_!A)CB);6ECK C%3T\]<*052+G5<#!IR\XZ.\<LT#JE7_8-$
M^ &0&+*'L_Z+*YW^:Z/.: R%[$'3/H["U=+$ A*CS59*DQD;OL-S,X.[]NU_
M^('"\'$VS*UTUB9JO3&4M@%SP-JJO$[)\$&#2\%"5DQKZ[CP/ QY[USC:%##
M"![L7CD,2/>].?XVF^7/X\GDQG5.R@3GK:_3/UPUFH5"'^7!9=KZ*1A'>WT8
MN^(N5H:D?NK*>A'1<5G;X=C:P DCA&!=[2H@9!2:7.XA'TY<6]'!I7,?'?^]
M7OSOB)AFBF6U0J,<.-E\4<N90ZZC/.A?TAM +[@RDGODK7W+U;,'GMI][T#;
M2T;])MYVQ\QUD3[.IM4JSDKW2BV0/R"?=HM/;9(FNROUC;)?+QXR\NB8\EP"
M>=KD0Y0ZK-3& K3[N2(A9F];=Q>_>'C;P<D=.X1=;9DM=7:S!D6J"X+-G((&
M[W3,.2;;NH[K.A5#,E?[2?KVB<@[KW0S&_'W,.]4WC<R7.:11^V@3HTA4Q4M
MQ*@LB)Q<##E:T=Q87"-B2%:CC;P/6^=FXG[[839?OL/YR3<Z<DE!T4/!.F%
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M"TR)H2_("UC'+*A<@V01"P'SQF2;R/&]<_IW/RY\:( GRV,SK37LH_"];<T
M4:S[=CS;E_+?P^ 2W^%X=D'48Y@PV^#!BEJ:()TFF:,![20KGOMH0NNNA6O
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M[S$MTIC7 =51JZ^E@ [<[6MWXNX&1\VTOC>32%*2FY1K[Y00@<Q=@T,50/O
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M,"BT*2PZYUL_#G54V;V:@AMN1 2IF0=5-,WCND)39!-]MDC3NW5V\]/,[MW
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MWGH*4+"KAF3=2?73WKLR@?M&[H[FA.3MYUE.Y?#3:PP3O/7WBWG>RYB-L=%
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MJL6&0<<UB(4?O Z,3<XJUB&U?;SQ^$G$#LJ_2]\.FNN02!&=XMPC8$$!BJL
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M:][0<RF0=@5LL\]]]FTVROP"ID2O-.<6N#:RII5R"")IL$4XU,(SSG)C&1^
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M/IZ'Z>_AVS-\5;FL>?.][%F.%'X#SXDF "=GP+N(@)&KG(OV^FYZP2Y+V..
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M#U&K1CE'7ELDBTC01LK?UY"5%$(23!J5"Q(<QH]Y8\:VAC<X##7  D6 08.
MY,R(.&"0![Y5PNJ1##M(KF2DIX7%%M7NA><LE@:Y3R<P$74[,0$#$!LA@8MI
M Z7!R&C?31QJ@0P[2J[CPW?Q2.G17,O'C\5RI*4:E:TSBB3[FMI5>P%()3(.
M[:R#0JI]+%0M7U3C<0E*3W4:K6U'\J:^(SML+JK>+$\/A'G]3JI>(/J4LYU4
MIF,?&K5_M2+M,SI.BM567=I#FZ%]K60YWLQY,G^?SGJA\O18_YK4L]S\FU[B
MF=Y;T#I .MMHI'YS=NF5EU0ERT1]<YM[3]W'MKLE[W:X'7.X&V0^MO9@B-8X
M/_W^C0:[R7UGV6J<IL_%7L':[4\W#&&& P@(4J1HE(< P[38-DB)*92(RJ/S
MGD:Y[QKSMYN%;1P<*7=W=87'(_HUHB3E$YYER>)K*R2N0P0%UPQ0HR* (1&
M4<* H0IB$3(BHM;JZ ;;]TI+-R=X_+6YA#-)Y"?7=JKE(N,;/!B;*(Z@ @*Y
M;1.6S "ND)NZ(2;4A,+=H+-(J3%^IZQT=4/CHK$A'6T>%Q?A,N73PP]02P,$
M%     @ =H&I6,R]8C?(9P$ V'P! !0   !R>')X+3(P,C0P,S,Q7V<Q+FIP
M9^2Z=U!3X1LN& 1$00@=I46E*DV0(@B)B#21)M*;2 =IT@($HB @7;I2I4N-
M]&( (501D!H)-8ETD(02 @18?G?NWBVS=V=W9V=W9_8]Y_GK.^TY[_>6YWSG
M_,_Y$H#YJ8:V!H"*B@J0<;$!SF<!:@#J2Y?^LU\8S<5.>X66EH:&EIZ.[O*5
M:_37KC'0,S P,K$R,S*Q,#$P,',RL["Q<W!P7 -R7>=DO\[*SL'^GXM045^<
M0T-[E9;V*CLC R/[_VD[_P%@N7*)EL:1FNHVX!(+%34+U7D/  0 4-%2_1<#
M_%>CNG3QC)?IKERE9[@XH)$9<(F*FOH2#?5_GOIB-/1B'$##0LMZ2UKU,INA
M'=UM'W:9=\D%5P0>UW9Q/!\C"-Y_]2;\*CTGU_4;W$+"(J)W[LK*R2L\4%12
M>Z*NH:FE_=3HA;&)J9FYA;V#HY.SBZN;KY]_0" T*#CB?614](>8V)34M/2,
MS$^?LPJ+BDM*R[Z65]35-S0V-;>TMG6C>GK[^@<&?XY/3$Y-H__,8+ X_-_E
ME=6U]0WB[M[^ >F0?'3\'UY4 &JJ_]'^-WFQ7/"Z1$-#34/W'UY4EP+_<P +
M#>TMZ<NLJH9T=CYLMV7>76%_G%Q0VW55X/YS L>K-V/TG(*R6"'B?ZC]%V;_
MQXB%_U]B]M^(_4^\,(!KU%07SJ-F 4  IT:%L:* _^=! ";:-M%%@=EE,3:?
MFWML! Q4&YM]EA_!UXM(QTSN%GZK)E;?3)W+,I=;D--MJ*7UUD'2^LK"8%#]
MPFI+[#17ABOK]33'/ WZ+\$I[OVPH!,KBBR!;9 &@]MH+O_HT="[EPU^GTBW
M:GL)ID<^PL/C3)G\AU^9;?GNNDX_>_5.LX Z@^(^,L4I'6E0],>T64?<<@KN
M<Q)@C$U_4*(\7N]U9-=\1G-X)+016H23(HLV[]SP ]+=%W&58XAW7G0[!R1X
MHQ>;#WL>9@K//ANK0JLH-_L>9QV5QNX+A*/ZM_*_&"S]BF:JYKT;5MTYG*^I
M=A("TTFH(QW+%IV4SD?ORDVX=!(,02R6=0F6W0$*VO/5(@Y>:+E=:_8%IHB3
MRXU0S5M5U>*"IB7HOV/'/$N+L[/8PP^"6OY0+Z3B?68%J_X5]?S#3(K8(NP^
M7@+89R(65+#1E%7R_=I.4QH87/25XDZ<;D JXJQMNX[#%UTL<J>3 \INZVC3
M.V\H@?I:*AS3EBD*]K@]*<9['*D9EXK*)$<7DHX0[?EULJ8]D,L0+YTXD^;Q
ML]N606/>11;U>IK(Y'. X9'I# ;X07:'W=7D."\UA*G SOL[OJ79^R=J0ZRG
M.KI<%>-"47N I:!NEP_&1Z9B=,PZ-8\?0@0>QXK6V*]>BA7]\O];?)8=F^W>
M_;G)JU7R^<^2*)\V..V8'$@:.2TI[4!^)X=@XQ"2XY#Y#?2W9AD%"N'Y0R .
M$NEG4"3^Y.AV*)-ZRJO[6P[>:;*6@_NQ.V<ZE7?/)CJ;Y/HZY="1,&HH">.6
MRK%2SP6$O$KF'SI#!Q\)M IF."F*]POF/W?E>/P5\)+>XOA8UNZQ\C?-@VG#
M5*S,,QF4G8#CU$'JO\7]S$>%L=95QI_$.&S,WGT$-]9N7U4/]HP^ 6\>'T9Y
MR#UHE)!<-.QH#-EDO.Q:&Q3H^5GXB4TNU0\5'YM79=ZC3S^,R+3%_?E;$%<0
MDU:DX::G!)':&+5N"(TLC+T[\NT_T8[0)-\AXGOR:>1Z6B:$W=OY32_O::=W
M!MX]%#N=/N1897_QD^5KCD--HI4)9Y12_#?RISN/+<M.PU2 :$AD)X<L,&Z!
M,]J*<(K.I8;5/Z;HT.2.]=M3-K\A!CO#\V\T)H6#[R6939B7UGYZ/RE^]4A2
M8'0-58N81%PFHW2(.U%^IR$:+9;58)*TH*=2DC'X/?\5$B*M%VO#;VK+ $DC
M-T=N>)-NZ:4O/X8S;)T#TH](H::_,(6Q8J-@@&AA ;(ML6\DY'/BGP*-Y)'[
MD=0B^^R,PO/)<AS8+-!V)F'6:E+"HV,VU)YC<N&)0F:&%]]WL$_SKSXE])>U
M<P#K=F/2A^#.]Q,ZDW;9>N]$/!Z;^;B+OKS'<I+G[FI8#HR55X%IZ'^R\SJ(
ME4E(/S 9D\U&U[ML?2T>6%^(3[+H(?86(O=LR,-V7RC&=039+/])=+/%:TS*
MG'KX=WN:M/[G_;PFHRA;4!=1K/O;9L:QQUDZ;XKRJ]GG<3_3/%X[\T<WNJS_
M%/M<#7Q<8QM3I/[J[N/?KK*4W.W#W<Z6C:_%(\&^&IK53D&X,:O1'JD/;5S=
M.XS#-="HG:T,Z6^JC3K*B<&WO_Y-M1I]!W>1HB=OZD\C;I\$I&0I/P[IG9+@
MOY3,K!6F*9 X55BFP._0H,(=%"#32!=;]E0O*Z"]H2,K3&Q'L]30?(&?R)2+
MJ^8<-1VO23G40\;KT/; _2</.0I:_$<Y>%Q&;FB\^(N5<VI^/&;6(4G,2%BR
MYM2UM.F,TYU(3N?&V>]&V;^%L%G\'N7KN2/[FEO!X">J@,:!6WS;I\W7P)C7
M5FP,G&FYN>RGK2[$$UTM(.U27/+_?L3_WXH[HM2]G6Z+"6I+AZB@A+0*9=4*
MI^FN^S]9P:[@6(@%I=^5WYQ?V\'5,4!R5W'H/EN*]H%P>R"I@IRSR Z6=O-5
MNQ,J]E2X^Y?S<G=^;O]4O8V:K75XP9:KV+_1S1K& 7RJH_>J;7NYJ\YJW9%4
M'U:=W33HT,YFE!#]PX0[^JV7OXJ[V535?CO<4)?60]92U7M;Y!K_ZZ1TJGX]
M76C_IK77N[!;T._8K7KAR'*W8-V26=$V2Y?Z5M\AT9>/7MX/5ZRJZ'N>4'B@
M7#6> -.X@6(4NF&M LL];*@B!=;/K@0O9-; U,?]$XQ^Y/$3VJ-CD>I8EY7Q
M:I@.NV)+?9,BCUH*N[?W_8'A($V*0-OE3+PNE_KT%[3L,L_+:;L,.<L/_Z[C
M#Q\=V+SX>X(N@ :^&%,V7F*$=S7EB4XJWU!N0Y.JE&HJV=]NL'!T:2_<T_)7
M%*BM@L3SWZDC.O?H,YP#G(;\*U2+9V?6Z]U-F67D*!_P,CGQ^)Q+03]J+ *?
MNTV?-6_OKL%6Z#!&/2.Q98-^1UG/X]H;4CV)#=D>&A"&CN/<D6J")M8F,Q3_
M77X2:>)(2&C&2!;/@#(E?=Y&\[W1W+0)+*8P*X#YQ@]RG?N4Z"+MINS=XWBL
M]33VBM]+7WK,[GV58R?LP<D%/7C#2\CK$WY33V/P<*?;*MV.UZFTC34N@<L0
MG;TTQ^T<U8D5;[%ES/"0_ICFO\?K.+!&9W5B\F)##S-TW#@J(O%+^DW9CFEP
M8\"<=;6Z[NQGT<K!S=!,HYQS0*18(5,GI_*M<T#HX!G'$.4)V3^$L'*B%XL[
M&S*IFZR.G$\L*FMU\108I(G?O7(S=O]J&!WYJ&'&H[_;C*;:8;IPZ:E"563S
MU?[APQ]'H=(OP&#7>G*@&MGYRV)%5^5ZFX!FD OO_4?#8LS5B=&\Z"=W%633
M$(=AT9WO?PDI&RL9]E14Z)9V!FRE6:X<RED4-_X+XF,WM(Y&1X8JGC!3/."T
M9-09<_MSF$O6T,KO5AQ#ONH:+_ 7_5%B/F//=&JOCY> FB]#5:U6&:VUGBKH
M0Y7[<^,O6,FRY&S'--]XCF<<H<7-6\>0U'.  "D\=F_T+80U%=?9W<YF*QA:
MC=OUG(1?&T0!-\GH G3O4TE6GY B,H(CJCP"H2SGZ*K:<&KRSMSF[CD@V=;L
M'(!0[-RGMFCDF&H(S*BW_/4=^_F:9T>%QA5*N03?+]=!#3?](C 568> [H=S
MG]&[A+'7?QNO4N;A1PA-MDV._VM]Z"!84>:VH^Q1XY8%[X$G!L.X<W&SK@ML
MS2>RKYPNR=,7O3D&^6S:&I%Y?@2+H.# _D)H\.!KV3_SQ6;&,52?EA/UVWTZ
MV<#TZV<W?U-\0@K,471QRNJEH9'_EM]P_*!V48E^NG_6>&,RT,0:[.%VAC\
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MS*T*SAH->_V'E73FK<Q/)SB-1BV^#SZ,4[Y/E#GKV[,9V]^,LQ5!33>WE6=
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MBCB<^/-GPX;IM]=*JG7C]YPB;0;1'P:*GIK/8IVW[YP(2L6$,4/O=X$89"5
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M)V<)6\.HI=>9T['-G0.@P>_/G.JJC0TC<MKX;;RR# <)QM*-I-BQP%"NX7/
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MQ.A0\&^V?>X/]:/SN*:0(=BASDMD.EMK_:?-B>/&;2UQ0?8KG;H_KP* -KJ
M4(43O;!))?C6L#/6' %3J(!F>;&X068RFMKT)A2R#-+_!^K>.ZCI[UL;#:*
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MX2/HJB]+F!]4#?JD2+&8:?D>K-RQ#UV\[*6HL_?AY"U(,>Q.J2MF[M)8P5B
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M'&@ 9\S*R@@5,;="'GI'O>R,DOL-=S&*G#9_NSHZVAT2]%8-<3#?,VT38_9
MS/\7!WMHT-8 WMZ69.>V$._475^'R9$@*'WQVCV3$_:MH<U4?7,*I%^5\CB!
MLC7OMC:6:UVC]\)4_:[["Z!KK6&%G.GU$A<K@]!6K[]GW/U+1IXFZ^MK[)I1
M%U?@\?]<5PY[0 .\C>[X;8#3IT_'#61LZ,#:)QO+!SX?>/-NM7>:@GA@@S %
M?"NFPT._3?DX@/IUOIEG--_@655^'^D/&:86+K7A*FD?5\R5QU764M]4A[ZL
M S([JWU=K,DJM-1M3\VD#<T2=N\+];?(;4+M ;&T<#,SH+9%BO'BE1\QC,E
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M)9D$]IUHLJ.1":?%-3;M0=>VV >G&N3?:@""/O;DC5J,H4M&?#:(LMI6UV]
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M,WB!;T7<H:4E.7R,JE/!]A\+SFOJ M2M1K. >80GY28I5^U=15^?>W!Q>J:
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MWA%EG@#F>B:_Y=33X2>O_RWRXWR'$+U6@SG#>$I@L%]A]M;)FRW,5U1=SX5
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MSK],XTH![/'NM- -? A3I[P"GRM"Z8\9:OD]\$#,TKZNDW9"B5R' +8F+?9
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M/]9&(GS=5GISRC)ANYL'PX;IKPK*E!%XL78$$(M?^',73;ESU@!F!TEU?G(
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M[[EB116>'?U;<B$KV/O<SR L]+?29I:&"NQRBBH6NM?)H^WB]D)\#?+:VST
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M7.CZ<911IQM&7)SSC/W>>,[\T62/RN^K][W#+NKL').?!8_KD-WCL1 EY$5
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M#.65[-NEQ4O\OP7/3ACA*1%[#YO/M-X+7+Y9@O-=V($X12?PI^CJ:L28[NU
M8G)BY./H__/^:O_=LXTG_W0:_HU7]T"/U_/ZM5 4(5?FI%]LJO2^6R R/N,3
M<W"Y]@%R7_27$^(@9S^+YQ2;C>92Z7OM"Z;XVG(\+ND7??2GE<//?&<-R>.&
M!K!":!5Q-387Z8M+MANX9:\9]] \:55)IIXSYQ;WXJ0ARA=!^88Z#7B3CP;
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MP_0/ X0BA\8SCG^SLHR,C(O**&1NIJ O>V_K>S]@U5;_.-0YF>1'BJZAR7V
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M3E!UP+]UE\>]7T)U'(Y)WC76D]\YC70<-&^/!N!T4\S:W?ZH&M^ONL]/O.O
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MYJHN,AM,CM552-,@+-B*(R9T!DQ]>[^@//=!&"NCF LEB0'_[+3[8G.33WO
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M%V$D/\WW=T;$:.M@@U8VHNOM_*V\"SR]SBFD;/'FQB&V%+N'+3+TN1S^ES.
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MZ'9X#ZH!QM2D9A>3M9#Z8:0LN0VG:&GG?/5W\"?OEZ)EGG2,X#V!_ -R#U0
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M/W+]O>A,@<5OXN+YUQ )P+Q=\XVS]Y3X0&!F WK':GK4^$I!7T72I?EJDI1
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M]'D'ORK>NGV6JT#EH.50B#'82YDZGOP)'WTS>(T..\>!MU+9]83@I?'%:2%
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MWRA+NU:*M^4?@GC6#<!,R6Z%)%30$8A7XVF _#N-]4>X@]Q>^H];X;2J.TB
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M;'F^Y9RE7H7E=%N%]L6O8>876+=4G+ OCCDR@O80)8K@B-*K_]Q; 'AZ/5]
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M[!$H*TAC\RY9OIZ0\<X<*S#\,-B5R.ZJOD;9-Y=2+K_R6S?A:T2W3&P#ON\
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M7'M3-N?' 4Z-_J</^W$,46#[VY*J/PH]#_@43%EI1SFC!0V$IR]>GG<7]7A
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M:HNNGO=&W"2'[NF=<E4_B%E]QZ$145@X07 JK>"7U92NFE*V^FHAJ^(5Y>4
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MR^)926U8&%RC7C\\.1W7 \AMLW>4^37K(LP3&7MR3TXF,[\O*A]),%4[\U@
M./FH6,TNC8(8)F+S.-<M5"[IT5,<KF=M!YV#AE<-UI4QHPVN\1\U!EC- $=!
M>_KFRZEOWMQONL2HZF\"HG-SD?2Y*G/6:P9!F=XG[V%X&E"E?,]Y_YV/K#=/
MPL%H&;/-PK=*D6BEJ\>Z@FH1A62M4-IT3W#1,^5V\R31+P=P%=LL)(KX7W9:
MY0R:DUUR)!L"%<C#)H;S34%,)GFKO&S_!WQF_B\,X,7\_P)02P,$%     @
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MVU85([% '%@/2T[X'P=,U6>W_A4968I7_.<=63X@J[G47\5&7J!74EXXA8.
MDY3L, [+*_Y2!B\XDS.P*&K'5PI[23:)9IY;1/#O"'A[TKW+"%>IR$*IX)A<
M44'[-^'\+@>4=9YQS>O9"BQTJ!\=9_:G0P1= -<R\QGW[5IL*NXY;E7X%N?C
MB21UK]E7NN^T'->3>Q7*RO#4/6<6*'5OZ<?\^A1#%2 0PT86*E9$[QJ!1.\^
MT(Y@:@$JN"D]BFN$QHD7$""[!24=TIXT]B6>4+7P<&I1>"MBE\\O/[ +S0*I
MMCX-K)CH-Q(%W?TWX\CYBOAE;<8"P2T9XA[&535">[SNB(U.%BBOU^W/278>
M'+O[WWO_C\:131+:.ZS-\(]F@8Q5W6VA;\%SQX@[>%G&L9K"_V RWKUV!(+
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MCZB\_<O ;![=1;L?10C2:2Z83%O5*%^=3#BKLN5!8J.S.S$:7,/5"F$G-GD
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MX+ 0S!/Q9\I>BD]^<WZ8,7EZ^[7V><Z(OL/%BZFA5QM; P:6ZE9$[3A+82%
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MN]=ASB @,Y%5YE.17V'*C/H-/?47Y^B:?NB,XP]4.,)MA]<VCI^H>,=;;%#
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MIZROFP8"CC7RX3** ETX21-TQ;<&%&HM'=5\(.K^>%"B &R4*G:V]M7+ETS
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M%[G$GK,+M.\XE%2_Z%:\ ?+76X<7CF'E[;SGJ58,O8TEY 87UW2&!CV[&':
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M4=@C-WN:#>KZ5A1K+RJF/R(9#%UPM*L!O^]RZ?\:W-(/"[K-V\8FWYGW7D-
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MYU,32_JYJY>R30JP6 *KYP,_&P^_M_4:GU3&J%=MS-:@4I=\JFHI%DT:G-2
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M7?'7S GJSMWB5RPGLT83O5^T@D7$7_"<_'CK>^:X[9Y)[N4BO?<!ZU*CXB3
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MCBU1=W[]8DO5-6'A3NE@.@VGN#"S)PRNMW1N/12DNO1:LLX4J]:D*#&,&4;
MI2@5'LKI6D,\+*T/--.<7[@5:_(6#I3E9L45W'B2G<(\Y7Z1N'7+;Q56,W:(
MJG(;]>]604Q-E!QZR]=B=-H0#-#)5C05V%/X _=;O2'Y^S591A5=[Z:G3&:4
MP-=6:]TSOOUD%O"WUG9_90%L[=5O ='*,[GNH^C76%T'B6(FJ])?FV;ZP6]
M$X6F/Z_[EZF\%5300<^@1 /8$/Y,6%B8I"7EPP Q2[$^)38/U ;;>I20.:^
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MCL83>]!, OR@@??"'?;?J&13=KRL+B^_=+:1YS/QV.Z"L1"\3,!Z@[(B)XC
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M.7>NTMP3O9"9S^RU-;WL\D)ZGMTGSTT3MJY* O"@.P+$3UR2E@8F=$W3F,:
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MPU-,!$(2AJA&.6_AYN61B2<!/AX9GBY@'V?%CVA42(! ])^BHO1@F4XH,D@
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M^MOGHE*' I=O-,&Z<Y 3(6YR**\7O898L'S(<\_]TZ</+AO=NME^!P&CNE3
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MT17"N<6HLO)Z%!IN:;V:$^BKXY"#3(ZB<,]7+0_YCFNP/4W^%])1S+Z>^(W
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M=[L(_Y'YI&^@[6"G.UQEX)?,3Q=J'^.J90R.$Z#T*J%5,?@)_GZ6"E60Y]E
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M9, '^HNML/P76Z&O@\+!&(/^[31,!1"N%_X3PEQASLH=T,'N7UR&N$ 8!Q4
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MR"OC#Z4A\N .<P9C#1KKGWP6<INH-LDYD/F@Q'X??&UUN-5S],B&+P^1";E
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ML?L,=N!8!$F7'_]) 7QX7$:\#4@6BMPNO$:VV;U. =QS <V"B6=4A#(Q0Q1
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MM7?G?\K.^V:AX_J/;BS_>Q\7_Y[&^6?357GXN-+'K,'G,I?8:.CV047@* J
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M=ECS'T.(_E7JR^W_NNOQ@T8XF[[6[[X%_%<26&")OT*S6=1E:KZ)_QA<G@B
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M-N;@UGT=_\6C6JO81@'^NNL4:X7\2_W@V). LPS'[N$#_5VQIY8GRHQ#I$?
MPDWC5+4[8CZ0'35;UV\5HQ6-BU_RN#1_Y,'%I^-ZG2_$NIMMF!")#O:^2C_>
M?W<[_,%S2U=T+XU,:T_V\@WL33W9CRKV:*CVH3*ZG(FHOEWP)CE%>#788\>:
MX2:?'0#YAN;S=JO=*/*UZ40C[22HH5.GR730+XO<H6L @\L1SH@38^P^C3/C
M!*'1BN5W&^1.BER.HPKHIV@9$F1*]\A$LPHK 3460<6%(?/JW5.A.'1H=CR0
M!=*,_MB>;:[R!(+^H?#\@XU5FK%KSU[3\8 L4.@);S/,A%C%TFCQ::@(V?@@
M!INF4[9<1VLT@&($-W'LI_H=QE@]=?^PB$Y[IHTM?R0A(#W"9GU-JXMO8&9E
M[%O(*#*RULW)#>I&P-P<+%VPGTYA6%Y]A.VT$%EQY[<7S.L0V-B<8Z$ KI&^
M#F5N\!]#-*A.7_%E#&>#L9*9E4UD-G$"G#ORV,.A\BFFT>0T\56>"A+N%'0R
MY\F\G5[>DXFQ8\#6)P<3:EDQ$_IK@],BOCPC*)1*?28&A,>^V@+1P$)W' 9<
M>65Y@::$HP8FR]SO7^TFQ8IFM:NT)XY(_G#T35.C-R_&U/_36621R/MBH(TP
MSRZ)Z\N=O/+7-@X]")B^.GOPA]\[\OF;1#,_ #SJ*@J<SLTCF"H6WR2&WNU^
M_.UI!81UY=6)V4WV.'='IIH",0U%#Z1J9HC"I6[?$@H@^?'2A#'9B/3F']V@
M_>^2KE#5K.EEVCG@B'A]-3JT]O0U:>\KXNNY*>YJ?)+/U?AJ3],@@YE6U@G,
M;OCFP<-=?@J '5Q8W1SFH9 :SZL&WT L',]6.5<.W/B"N+H/1P=)R%MPW@I[
MW.M!%88LB\BXSAL>C,G&]Y?O:.<XB.[GC9)2J(@?1@RF &XU=_V9GB9)JK4)
MM,\AAEBOI "([P\?476,8R_94WQ6DR3@GK9));V-';SF03J('*4 .C: ?45T
M)%+:./8S*?6_1 WX5V+_)EH%/5B;M""G):./_ P6S[3UWP:HO3@A3"S<YJF7
M!=ED?XJX?BN"J:=\&G]8].Q$N";.E+GA0PG;0^.NN<1F^%#]0(@Y>OC080S3
MVOU47H8A1?=N#'Q@?$Q\2&PF5E\=IHGY^;#4FNA'5J6:-!;4EG6'FMY/_H4K
M[7]X\GB4\[<]J-Y+^.U\PP6QG.K+F6]^WS?%+SQ9&,7]$I>D6^A2 =[+WT4Q
M?PL][#7^QL^%=)-MMSI;P#\Z,O[GDOEZ:*U/%HQ_)6UXPU)SIYAL/.1Z$%JT
M.O)N3P(S4:NR(_55RL_XQ)WLJH<EI!<+^4@E"L!_;W)BC]A/ >#3^H#$9GX\
M5HF' @!R8\FL^]0Q/EN25C"%F._#S"E*?5OX9PID+<'2]K;%J_P3%UR-4Q$-
M)#R41+*C3B[0$C_I<201G,I( :2%@RF DX=J%$"8_K82B+2?,-K0L:4@T@7$
M^<+DR+XR")+P-A-90I,DWG6< NAJ05+G)3F#"K0N[Z<*DWUTUAY9>_&RSZ?]
MJG8RY[P?8G[:F )H0-REPD0V'Q K!:"2LWN]3/ETR&;7K^NG .@WZ[&;A$*J
MU0?,1Q!"5/*H(I)F</#6)#50W7/^UTWX]2 8-E'_*/#IN-:EEEF[^:LV_&H4
M?AI3#IN,;DO/7S7@[P>ACP#<7 *[T/_!@3\X\ <'_N# 'QSX@P/_G3C@;OJ+
M" +M4%]%HO(VKWS3?D6?AS!9D/O%TFM$UVEJU;]+Y/&_SI65_U%C_"_/<D5^
M9L1G">QR$7!?POY.+=J,N#JY5[X1K%)<TQ&TF6Y'FQWB74\M^-O]9_\7^]/Z
MAQC^[Z?(.!C1&M=ZZ *=L5,6)JL:@;>;@5LLYHSSK4@ZF>PE,1EX[$/@5%J?
M,G#97TJ7N#FYL#5R&[+MTWZ&-ISV+K !N.@/_*FI(E*]E_^9RG/^X,^_(,)N
MOWPT7+G^J^[?9^2?QOKA7CWO71J2D[K>\C*?CSY:0?6O8K-T[P^Q^;_.EK]Y
M@5TB]_?M8K\U2&7)X'VLBTHQJ@E& 00?STBE69TQ_*MJN?//#1GXYP%P_Q^F
M*_X'SBDJ!Y#495?Q&"=WA7:KPO%TNOD9XPPCF<O]65 (!W+L@:HZF]'Y__,]
MF?]\LK'[Q8.UHC$U\JTD\,$&8J',5#&P^ A'B&[C0'CCP,M0=2'<L@9N^2;]
MO_+!-?Z+EP_6L)>!.U8N%(#HGS?LS *+ :)LR8'%//_E#[7?>Q>Q%_B]1)X"
MB/]3]+H/Y+:/\^0'?XZ"9##[4^$+_[!3_Y]XK?T;/S3_:A+IQ!UFD.BH JF1
M@5ON=%86OO>QTMN3]:XAP[.VYUIO2&_WW_@4?ELMR:A%1WA[&L $>:*UODM^
MV#[JQN[\.C,F^J.-S+G[#&JQMIW:S4-#>=;5*DWE^NJJ/3_M%QXO/E"%B^&I
M2Z80?J> (-S [8AE>,7E6ECG/B"2_>;%+6G=\P^;6.JYYB(J3B<H[HO$$M#-
M:;0DF9 V,">QO9','G'@,00VZS]?QLGSW*Q=4F&M9?:K5%BD:1D.$33.2FAY
M*5N#ZV)=&#_??<%&VTU4_&[(W!#7S6O<MQ^GOU"55Z+51)Q?G7.]9RPUN1X\
M?IH8Y-CJKV2207P[+-O^,FOI[MB>Z+M'I I%T !Z'5E<7B,2VMX>5"PJ.@VQ
MKDQIT.2^W"XE,0F@$4Q]F[%04F^?*9Q9U<5$TL)'ABI)R05M =D6JKL",\0$
M^\L/;W&MLMI,C%V54$5C0+P+>)NFM!,DC8K*2GQ:B"N8S6RDXDM.M]L)QQZA
M^0"),@!,B?^.PG?CGGE-=>=47B)J$L%IO^O%X3\-9%HV'4OU[<U=',[FY+P^
M74+L;A>?$KDUW\IWKHQP/R_ 44DUIWY*YW.2MP.?SO>!#5C?TY0+HG6QI[,9
M3BEZ1MI/9*#_,O'8H_)@C:H#,JN&:A\&MI;'H'=84M1TT341.LD2Y\>XDJY[
M:%8RA']ZXIJNU.EUM:2@8,2VVF(NRULXQ@9"/ZHKU#,BH'ZM%7#F.<TD0Y\*
M[^"*TOUT2/5 ''"XO%-C6+'&9$?2,THK(ZKB X-D]CEFIF*>\3&@V<AZV<%;
M!RBPE\SK,_?7_6HC_M!:ATSBF9:V3?.Z \:ZV<.*1-H]D-!!<K#19<,3V>%?
MER1A7%_.N]SJST9[P<?KYQSUU9_ $"W<3*$\^MQ"Z#Q[8=UJ;QY<WE@K<,B1
ME0>7\$A1T#RL\&'85CJCE\CIWE9+'BP^F9@YTJ1POS7 @$N,QS1@1ZCL08SB
M: ?/P_O#0_*?AEUZ<M$$]T!/-R>'XZB\3A<HA)?TK=6-1\FHQW%C[N'IVPZE
M.U63*\_X&'DL#X_;ZS_@!C4QT2^/LT#9%U,%>V3XZ8L,]-QJ=!9R/K*T/- B
M>Y7JYM]'GYMTD%\T7$Z5_*8DA:M24BNR3W*,2=<(%EA"#SHUVKV?.6HEPIPN
M\10P']W("QD:;S ='M,-N<+N=_G\#)\J>R,1.BT>H*2.XX4V&UB6A.+JA._6
M]L[WHX(?5U1 RW[XUG[]#>:HY6.%@,=5P[ 6*3G4>N_=A30?(+)RS;:H<)W=
M-@D<,$-@7RM]!,$15\G?]XMVM>(+:2S&(;$I&==5Q]Y9)7W&RS5WT<)!WDUX
M:+B2\M1 V2E'8[7^AW77CW_M(1M6C*X^LREARKF?,KPB4@C.&- W=Z\B)..H
M6H]TWP$7;M.JPMT#UW'N+N*6V4%"&6=RU8(:&K[RAO)QTL;TH."/IM,82<H]
M"!3<<(I1O-$4_/;#(?I!740/[VI* 4:#OG)RTD:8+;X:"7J[_WTT,RMI2L3;
M(]7$X :+3GG$IZOY7(*I+ZSJK&'&S?M,$>4W9)",]EX>0:[>KQIXU>[41,R-
MWRJZ_^H+U]7GG_S\ZH_>Y;.N^\O$,I:9C@Q.92(^A3BX33.Q+_BRH:I=V%CM
MD\)D(2(OH]_W? RX,7\D!N)(IZ-NV+V= FPRU4TMR &;V7D]G=%11JV^:[\F
MU=)X=6%)Z^GY5R=NR#@7Y*;\Z*1.Z[<OH#3BL1%PN6GH*BUN@AGB1>PM,6W;
M/1#;44PKT\-Z79&5^#Y=77%B*T][&GJZ<>ISK:A07:YP<&Z%7-1"L>?9.AC-
M^;8+8[6YJCPO6C1- <.9M1O\PU(XY:Z@F$8\"81_5KTYYN/O6DXXEE%M'WZ@
M%,4<XQ3CT8[FZCK;Z<Y,S-*H) ]LH.RY$!_/->>O5*GM"+,4^5O/[]JTN\%E
M58SH,MA\4AU?#HSI*EQ-C2Q:)%_L>;:M>W5_Q+!7_*+)*O+9G,FC5%DN8TT#
MM2M'F57K"V.'(4,O]-797OSZ?+.,LVE?$19.4JE&!0_V]%E6Q(H9KMX:K:B7
M"%6L<#SF8<5UMI-F#M)MC@PFB\"$ZQ7F4C*)H2T*Q_V*[-35(]+>VSTW,[?@
M< BY&/Y=:A:C7WXN5<3#=*"< F!<E$LJ*4;8YRRZ.TGORJ'+KEVOYPXKJRD]
M]1[P17#2H!JU3V?&:5OT .Z &PF7T^B[.%C^Y9E,GM96379M6+/O5__NAP[?
M8S^*7#^E=ROZ!GO,U'JHREF\;E^\QV""<?4[[7,?%TWY4EP*P<UL_@UW=BJB
MVB6;?G \ZG_DJ=,[@NYB%N..XBF1%#Q_9#DTV))7%ZH:O::KG)?T_; &5%F:
M^#1 (^2>K:. -EMAUA6&K#B9;L,RL[\,TI4K?[I=M4E5;'SR*#P\R6>L]WJP
MX$/WL-2[+UNGS15]NY.,UK@-@,N)[\'E6?P?1B+&;8C&7?>7'SU_@P0EZ:[!
MC_LTG7V'9,O7#S.%*$/'=NQ+MR))TM8)AXN(]:$L,K>4#GD+N[LRV+6/"%S?
MUI73[Q--W[RVM:U1E>"5'R;1@-?3 ^7:]L"5\^WC]U_O&)%=99EY0A/&WPN$
M.:5J=7U[,FC6OE X#@*I?3(W2<28&436540/]EJ TH&X+&GLN@X%X-OYH]-W
M\&X.!8"UQB#Z:I7S(=R^*=X>T)D1NQ,]9O)N0NIT1R?/1?C<['R Q_IM1W)9
M=#IDF<BL?&MY^H;NWJFJ%NW'=+XI$)];K_3,O[9_<YKJ^&IX;UI#3&_ *&YL
MV\AX":59BVC4@"#&$\B'27]3,7PS>U&N>BV#,2+-X=+8:*N=VIF9-#(::S="
MX&R$GH'I-5DN>4%>#2)BK2-L9^]#-;ZW0O:G E]D<,3$(SM/G[N?=,^OX)2$
MDQF*R\2K)G60.I^XJ-WP A_L_.AM+(P*1^O$#P]D-MW8$4/E-65,V^W\I#<'
M:7MI6A3 ;S9H3)V?^N,'"L"\E +XPD1%9HF_S9#./OW#9)V:_QI%V8*#6Q!T
MO+6@),<$CW-@V2N$JA'5]OAEH;Y_>S/^_T-1PYS<K?"D8B,=XOSYYN'0VI4*
M8+E*(M0*RLKE(6B7MVN3#S#^6JY_F/+?L6,%*Q2 ;?%%[2BNN;T@VEUKC$W!
M%M50)5=0 "6AI&:=]H)+WF5WX(\BWO69"Q12?^XXZ-7N.Y[A^/%TF,BM*N@1
M"0>A<Q2 J[$A6,GW+S<:_IV>Z=ALQWF36GB-C4I[+V'?F@UK>CI'R31EOQ (
MD^#Y/@//$D[J1<H2J_!T#10 -TJ<$0SS1\9;')\9-2M^-R43RW&K^TN<O($5
MN 95=Z+XRE7GI/L660/#95H;$^,VV8.1L+1INK!I8M14Y"F89KVI"@:NG#.T
MY,&ZY'LQ!A0-+>?:43\C^JY-ZT#1>2UKCE=>9D5F\VL&/L^"D+#*3N";)I_A
M9X.IJ=;BR9&VCM(/'+)"]1LM@ZU8.Z$"(N>=.DY'8&SEO_9(ED%&$,L(XA$C
M;?3L'O+;%I")Y(,7*Z/:*;<(_O-!?]).7IAWU=DZ2$LUB.#S^-N/<6F :]$M
M_B]%JOJ.>#"L@>$&>.N$*0M@(SI5[%NQDFK^16V;[*Z"6PD>5V=>VTZ)5C4R
M/[\I7]_LZ=;5$*YX^S!#A54H 9>2RH7'^KN9F7'%#V7[@=Y\>1QU^<TK#K6S
ML0PI';3;<[75Z[B*]%U^%CC_5)W+U-,:8J1E;5U$>R,?7WE5:5]ZTLV!M6J_
MQ8T3@O<>3'?L2KP-$WF5SSQ0$99=7%9SD-.64&BZ/3)7YA'& [T/;9'#9GJY
M3N2!GPZJ7(4E''A,N?\O]MX[JJFW6Q>-(BH"H@B"(D0%43I*DY8("@B("-(#
M1$!J#)$>(!!%03H" @I2I(J4T$,/THM(;XD0" +2$VH@(5R^<_?^SN\WQO[V
M../><<\Y]][]Q_IGS7>MK+>L=S[/S%S/3,BU1-KIH-D:XW?$UL^KE.!7JX_E
M;DY"BB>_R[_>Y#XE-X6,)R6]4>&_%@.E>+_YTGE3US8Y,8^]YH+2^D/R"L@!
M^E'*4)%[<[T-S4P-VI>*@3EG+B7E&0@ +TKP9]74;U3YAJ@6;"9\G\3>70]?
M<E5ANK'0RH$_95A-GM47+LK$FTU,=MF:36GMB)QXWSZ'1M;M!+V*_?S<H7K!
M8.A- N8YL2B1"%XNR5=0O*4JR5B%SAU /,9?-%ZE0HTHQKO!*_6Z69/4Y'8I
MI67-$,;->NPCJ3ZA:]AO],4N &IY28RI&<HIL1((7+3 1*L8S+ &J$-\%VH:
M!KT M;#"1ZB.X+D7'S0(]?$;GQ>X?S<*4 -\,\P#>_+SJ"X!RC3^&S&&$-C)
MB!4QR5B%Y'*XP=R[SUK5\C+"O^9*S8%L@5>6] X!;%MR,6Q6W ,.8ZZ2&CMI
MXZ4)$1_Y=Z76QN/.7 CR:/,:B2E/NNZSB-;<9C1NWAUQ-XB'%!P<','T?7E@
M&.A\-=D#62O%]:>,:F#\>3G_J_H+]0(NNX60B5=-^0M?.RQDB6$"G*/UR@C,
M(N/6 &)++&QTE-^0\"1$U]S!^03L<G>A4<W[MV?.ZIY3&OOI5XF+J!=FJ%27
M#\C!K.072!:6H!R[+_)9_C8VPJFNF  ;UX&'0@CP+2O;#X!-_L+[=N^KJ1Y%
MU/2F0P#GBW5/!!<R27^4<97JO0UL]1-5\_@Z<7*H?B\;&W[Z@R8WT-O6\-O;
MATPG\X,6/IAT;=!K:L"2C@3'!?C<&K$GA3P/I;G0QA(8=61L:PP+<JX;B6A3
MD@J]HK&0,+A]VE4_J2&+N'%[SR>KV,_>S.MD944#3'_L:B)<?O^H.R+957&Z
MYHG&VG:V<9HZ\2$FS#K;)\[!OJ-=4B&&5'4&'S5GIE=N6^Q SI[\>_\%L]&O
M-O]*B5<G7NE8W\ 4<VJ_/ L;1'&0YV>/Z,EW",<IY[$?^-3<#Z-$O$2+MG>G
M[L\ O(DC:+[\0W*>2(Z_Y]KNT!QLKQL_D8 (T&C8WH+ -AOJ8]_,8F+PDI^*
MG92D@O\A\ M+;DV[43$@%P#B&ZZN+HTV\0J@= C_^<75-"5]^NH;JPHPEPJ?
MVZR(BB!/A*>BBBE0ZHMP#DNCY56/CPH(H C[T)<^G;UW6D/IAF1P$YH-0I>G
M,$?CIGL]]/1,(%%G'LX,G3FI&\:Y."R^*!C4#O%^?^Z^HF7DT+ XW884Y=_L
M9CU.;208#M(#N.?&0E90$NQ5;_(($K_#)4EU\G7S4Y%"/M%S7<Z_'1[H??>,
M-)7)\Z?MX!(RBNLK$>LC5X92HA9@%BR$/J)WH-^-7:>^+X$"C $T!^,F-:75
M[V0P24]^UJ1_[7=5\C 44A'_38NOH54T3D;V:O>Y&J:ST1PZB_67*#+-P/.S
MM?'-UF(#*@;\^<;5 3P&(2OJ$.7['R>JXM]$;G_'G$K6/X=\#,;S:)>1$^;+
M2>Q/#5(@@Q((3^TUSU[-7XL[;JN;WJ'\NUK7]TYJ>(M%/IM/)2/T1^4X\$+(
M<-V^*[!]HS1._YNC]="9/Q6?'V/=<!,#G(,35+8?*JU7U^"1XZCS%9\%IT1P
M-[L)=%,I77#U:':-8O*Z_>*/I-_K\XV;B[6W,K,S_H/BXTQSF$CT>16967TN
ME\"+@X$7NV:AYRUT^O4]^WVMGS)%[L4&;KH&F)]J\,!QH!V($6G\T<O&@U[+
M4&;+TLUK@W9UOG8.?9/O48N1GD(UV]O%(4!>NLF05TPH/B8$5X9!*6<N*]SI
M/9NMGTQ]TGL%*0BX=>KK7,S-'.4V:S#U#875?%@.?7(Y+,/9XNP[YT+5#^&\
M/X<>V-^:,.2;.^'1P30FMSKX87'0('=03YC@4SGH_P*SN D6:WW:3*(8MI(2
MM(T,XX+>&LL/QEMHRXFXX]<VH3/#^^#F+&,HV^)]R]M5%1)V/+E77LC ^3H[
M>"?3$@K,&EDHQRB.;RI47[1?@VMV\V7Q_LGIO\WT1P]N&FL@)Y]<7K/O(&"0
MRJMS=C''8=>%4)(9+B:3(4;9G&4?6DSGPL%2%AFGG=(Y97.&,[$U%-<"667Z
M[?E[!HX/Z7G5]LS8>!9#E?IX:(G7[RG@P2<4,&.)R(V)@"[I4D3O[<_E;,76
M7_75._\P*$,TQZJ18I>VW7=70>$&O<RZJ+K.Q^+FM^'!.U@I:OR>$,/*).;^
M#$?T%&M2LQZ-B^JCV^]YA$DD8+G$G,8$?Q5I\V47N(T]WQIWK-T9'TDR,DK+
M8A7L7' I:0;8A&&"@<]6K+\.%*!@8C+**>!@3[$4'^R&S_NOFWA1S0<98IP
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M+:3!=N[E"8-G;T,7TA1<K_IPSUDDM8MLPQ\N\5CSD%>PO==UQMAADAO=:I=
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M.J2G8P@)UNM?;VQCCTK&?C1ULH\-*OLLK<BF_?,T4_@ZB)M^D^+SNEY#CM%
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MOK7HEE6B(];!7X)[-A%WN5Y;896]$,G*.&?U..#LD%YYG9[A)?'7^DK. \5
MKW&[D]>/&=O=F8.*!=6,4R<H3*;D[$#N?A5Y.(FB$"'W?/!%,4;PSGVG((5D
MWXEC?!/7PO4*WK-^Z+N4;[UE=V-,OYTHX4]O'\DF[8O1B]"=6[5B;_OKE3%(
MYG4O"4A'\GJDY\=5J[F*X8H"<TF#L1.R0!ML<(I8/>\/=QG.%)WI=T4SB,A8
M6)H"B'.D7@Q#!5O&?=]6?NCUQ6G1WS5.W+W"$&+Y*"-+Q==4=#SVX0E'[H,
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MRH+%D7-\^\>0U;F1RSDPC+2AN)B_A-B^&UP^$5.*/O!MVE-*B-D_!M7U-P6
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M8=4#'*[L)Y\ $'SPHU4:Q\YLD 6IM(U+0S+AQ_C4N++(^\R?LO17D:NV.G,
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M'2E1Y4/;+TV)_(:5YT0%TO;2EZ0 R,UNPD::' B2 W)N-K;(XB'1%<:JJ1:
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M2C0$G-_/RYP)5#H";JO<\><(V%E";>+8$\>5AEF,&UOP^055^@9&%:?&A^Q
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MJ2%!>DNH@80P_,Z9N?>N[[DSGOEGULS<\\=>:__S/NO9SW[VI[SK7>\&'P$
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M,8=X<\3!47.Y?YTCL<-F\W8O+#L2<PF_(LST)':"H!E32'GKH5"#1"XS@J*
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MKHB'V*C!,P51 8:E!/G>0(;?=!G$+T@SEB+5<)Q=FD8GV9[^AG[LUIO-\4<
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MQ5'-BKKU39-LY^L"RGP=JJVE(>YHD"X!]P:D[4B]2(FX6_O+5SK8RQD):E(
MZW'-;8G?9F.K35#U[/6FJU&N(%?PYT*871,H=ENVQBP3 =:=X;$4N6GN:X^E
MYFRN_]9AZ-T"\IS%Q/[E.!2YR;G7AW ? 6X49/E:)P=8%IJF>15)I?>LM;>7
MY*4-+(X6+</B7H6<I0')]-J: 1HK624"U?8^*UBKS=+?(LC&WE44X?P<OM4/
ML)]&TZ5HC,,T#J+'20J>$!N;6D4QY7 X8+2Y.#3.OG]>-%KOB5B2E][^:]X.
MUL*_:#>58+X@!(3$$O#\=Y&EN9"8/I=;@G>1XI"A&K[>;W!:]S7<%P<RH6I9
MP2RU!S3X8*UZ#14C(HUUZ=;?N$:7O^A_J+SQM'[GYHP97EB#.9$\KLGKEL4P
MHG&9HDQOEEV7V;;\,&7=%\GY6-2]M/6"VNS\B\VSP?A_Y"#\3]1UA5;9;E >
M3\=ZRD@7"BA^.7=7(2:I,,BPX'#%5BW?#3JZ\(&"(*S'L+9 (MEAFH3G=3.M
M7YT3P&#Q(IE*.SPZ%?A#-DV/][K^;$:%>X:%>],,@JV7RF -"U%G, T.L(]0
MM1Z_[QX.U!*>LO>[NS64'Q3Q-W@5ZZ6$L!P!BM)ZBZ7BOR[?J1V.,72\I=9N
M)3Y^[-0L*G_MXXBIS6ICC7=(*^WUG6]V@'PP5U96ZZ7ZFJC"3UR[T_>B"<EL
MR?W 7_X6#+R<D_#KQRM(MY7H2(L(HW.L3%]P05FM$NMQ8DFVMC>*Q$71 0Z7
M'1^NK[^4'L;\I>'?RSE>V\/.'@%85.N: G\[$_*ME6-2$K\F)V(J[%:"Y4:G
M@$5$#5:2YKLR[%-;R]OI=X9S< Z1"\]3Q?*BO,;J9 #O8L9$XCOU"\G<WS6N
M:9X..>?*%2(X7,V(9.QU\OSJ8K&[ZL%V]\OE>SJK;SZ*\/+RSBIM0/[&E.;
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MOY(=,/_W6=R_/?:9T>>_ OQ7@/__!+CY;P&,_EN ?YO1A_Y;@'^;::)F_H\
M_S:+^[?'_L<,_A;@OV?P'P+<_)\N8>@?2_CO&?SO2_A;@/]/[<+_ @'^V4C_
MR4[\9P;_MP/\SUM9?O'_!1?4_J\\I%7:IJ]6D.(B?-4]3%.[AK977.0*$P?8
M# 2"9BR2 XS73N11$CM4$>$T$4*U@=.([_URH"^XA]>]=$UV[7YMVX\$W5H#
M44_MJI]WF_$)ER*-J, 5.H_K1*7;1NPHA)3K"WFWJZI.,-1@#$_5&?X$77^6
MQFLM^20)^?'K\N+WV9>ST3@# D(0T:(W"^1VUGQ*U:2);%IW[L:I^&<OW!;K
MF\IUGYPMZK=3M>P7DB-YM FRMAP!!$# $MTCP'D3LOC'M-UT7\(:^_PX;DWF
M3%-O\;TA&T[$9+,R_H;<\_@WI)%5/ LJ?44X2OB2A]R+<MDUH)SB$-13YD%%
M'U>O>:0\SXOKS9U:[;>"4^J/ (;PS(&L8B-@X3:64>B3-MR;K*M/ZJLB:\VJ
M%U3/&+IUJ*Y^LY*(R*L<+ ?.HIN4I2ZVBSY-:'G2<6,W=5/G)'W[75^OQR68
MIB&$TRXN^E\OZJ[:=!'6-/#W&JI(AQU5EU08.<J(=\GWB'W^Z6Z?LKLGF701
MZ[&3N2K7ZL!T%FK 4O$6.,U@RL6?IHSOL73ZLZOQ+0>CU#C@,Z72*<0Q%")/
M@9B1Y]K1K1/7JOEA/G6T.VQ-5I-<:>.<'[KW6;B\^<^H87SE5'PP@A5DX=;'
M= 9*1'N]<I,W2VKN\K@C+3 XIJ\BX F.V4.LU%NLWD $&HOO<0$\$6"JZ%L>
MZL\?'^KJ"@'5!Q[8H+$_J!"2\0[ZQQZ2$[9!9\OF@=VX2V4=1Q!$&FJKJ;KI
M5:MT<U3B^@1JHS\5S<O3%] A72+A++J-3,9P4Q!M'L!6Z-V5EO&.)#)EJ%WU
M;7O^886>[+,,_,<'^092X5L7STZ:HYGS_CBE4'1G^/LYX(\'=P0A!'IF_KBK
M!5]^]OM2RV;+&E%4=[3L#B.UZ),2/-D#7ZK-FYS^<NMD5>:L3P.$= 10!V&<
MC0:2DG?]=D9*Z(7#%I!+J#(W75(X\LNX:QH]GAB0H@9>T^CZZ4=&&5_.FM$8
MC01.K4WJ^*LR>=N^A1N2$#.8T"\4R(SY:#*I$8;HF!8F,_G9B0PC")QNTOD3
MA=,RY7MG.;>^*/ < >"E Q726QR10P-P5J94/NU&.X916<RM.\2P^F&XO?A[
MSXM!CA@@**:$AU8$S>J7SZ]-?F<1JRESZ8H-5-)K?V)N?66I;-W6H:A)+:02
M$A)%%T94?$4FP<&D#Y-+FEPT,Y"()V+60)-+_ NA9TGF3\JZF%F%VFJ?RE5Y
M7=:Y)QJCS!E\HT> ,/=^_<.2V(I"BB_-$E&$9ZV!K-@QU>MMBX&OAAO(NM][
MS(Q=GX54B<\#/:49YI(>0&Y$!J&RIQ-I0*1VPV9/.G$3&MR+[!B7G5HM#Y:W
MB2F,HX^0W<Q(QK^5#Z.TJT<UIA:<$)GJ;79VO8U0JH:_^RU\-)/##'U@7*>P
M''YE5%9Q0JU)CP]L.:Q(94J/ZE5W%W'[(6+2@THA.OR^!9W0%6\\N?!=Q3(U
MF\N)HCG39-^<YI<[4V(@>P5163@@DK8D5S[N4X-.:AE=->_D":M2)H5X7&]-
M-(1O;T>Y#4 \E.Q].;O$]P;QE$N/=OP\C,:SP;"JMI0L%A*F @E)J%&US< -
MQ4?O>W[Q6^G45OH)$R&>K2NS61P5NDS*&-?Y4N0RN(QP&5P(.E285H(E7TE8
MR@E[/VE0JR,BPM85KA:P[VU(,7$LI4E2ZAP+G&OBH $$QG?VI*Q44J$9J;UT
M[VOL[M:[#:%[64N/SYR]@EUWR"R*N_^+?F%)Z 3EM9LG0?/$&,QK?(-PN-:T
M6J\<FU*D-);P.\_KXZ^S2:\H%ONU+_R+L2*)@260=7/AV>Z&[74=4A08[=&1
M1KN5M=L4E[^(_!C"2[N&.-%+ IO^:@2*QR,A,#^P,+OK\\$[+U=EKCJW;X>Y
M/[?*,8>HB;TT]TR0#CM,IPNNC ,C0=<.TCL_P^;[Q@E*^V5T?M<4?]7JKC?:
MR1Z^G5D&X.8%SH\&;P3C]:%3-:BTN0P"%CB+F=K%50_$W K2=RW U=!=/ [\
M<?;+6'[*$8!^$7\1)O& RC"A21 =F3#8@J]E.QT70.BY<N818%EY[0=UK)]'
MW1?^B(3_[J>,N4(1>A$B (O2)V,2BZI@$[;9NK5HO7)L5?F@7GGY)Q-@3]]/
M4P)HQ'9A(:[WPA% -V2 '8)LL;55/#P-BY]/&9<LM9X.RKNH2'[OF#!^4JP^
MYF)54Z7 S^*!38'(HO8['L'^2T/@W2T_BY%%'\6ZG)HA.VI/89!8X7XZA!.$
M. )<Z&]>*S\,I1I #V-2QV@;TG0-=T+-5(-;,%[-3[YOTL%)I!SY3O:X5O$T
M!DIV_F.8$1E%Q7,XI]8_3R;$,4]2H.Z7.1XK;K@XRJR)%?WT<G]&OOBCSX\U
MK9XQ[JRAMSU9&1*6Q3A"NT*0W#;@$1TJVRZ).0LU)<O9KM-[H5(M1'L7*A(%
M:!C[Y>X!G&M7YT>0QB60R=O8D% 3TX+\!8_DP:$-;/[.KP-ZY+Z6(46%X/&N
M?N/=-A9 43T"?!<Z/0*2]BYP_8+BCV-MU<@;NC?Z2-M%T>1&[\G2GT[G&#9$
M;/NCQ8^W684L3$2V0KA@]7LZF$':_2L#V]R#<B^>?VA*KFY[Y,8LB%G,RY(<
M*S26Y35LLQAX*Q$X,N&!,W#%[:L<CF85&%AZ]/RA4U4\E)SL5].DOVLZ(IAT
M/]M0RMW.?ZX<= _I%OFUC8^HCPN3D<TWD=O/?4.>^!EP(EI-]S4U[T=7KSU]
M9%P0%]6HE;>82-$T'-WN\AGK;5I'SJS@.=H\>$>X>&;?..=6)+KTCQ<X\CPY
M=4U'B5.XJKH:NP\YV!CR477+VJ-CRYOJEXJVFSBW(*WXMV5$I ",ZPC0*<1?
M.Y)N2.)*,5A)V5 T<761EG_.?C)\3N'^<Z%G[B_8:A?Z,=PT]='5$!F7(4I8
M0?SL8Y"VMW= R01-9<01@WW5(_G8$3?H5YTP->-PPNJNSFF7"J'+W 9!RT)>
M$)\ZCRW\4%VJ9EVO^_M#\CQZ%@K?U:@D;\26:@@NOERN3U*Y,=&#<"I\6VWN
MM"7G+H*._O#S[*_-(M "8(:C7:YNMDRM=5KJUS8_*GO-NM'RD9:"U,=<L*]%
M8D"?+HO\JT"AY)Z0 0W^D6/B:''>!I]7LKW;:3KD:_[M=;QCG0%X44XT5N&/
MW&;\]8?W3\\X."GU=2*[R 9$=#CH3@X, ;'E;@WTR_,0'46Y98K-9_F^?88.
ME_Y!=#E__HH<0TKM0[!LAZE'_.:&_YX5F(R=:XI9;9K84=T(QW+G4K*NU%>0
MT.\4IR[LXM;&[>J^:KO+*ET[;UNI(_+I3YQ7967I$@<GB"G\%!:9H7'1"O&,
M9EF%H@1!9PVEO[-;3=94$S8XEOQ3ZOT^>29=#WY=/FMQ&IU6P.\4]#+W\I4Q
M#'[-L*"?R QN"33O#T,=^M]+42M,. (\)F5N1$(OU_Z4OJ1K7!-_\CXA3]KW
MR@1/S##;?%J=DF,/CL[:M0\.EBE?U:_&WZC&(BDAX]NZOY(LN[)9Z1<G*56F
M%-D"&+7%7[4\L9!R@8Y[5#&Z)N1VKX&;#Y',V:(&>C$C&OU>1 /4U*UWNWD0
M9G4$($!H\FCR0FBUQT68B.ZPKQOXD)$J-&NZ.>*0IJZL5VHNI$>XCW,E"$C"
MLGELE^><.VX8(^AZG=O8G[TJ/XDXXP'-43PP?AOX"AYPK!';LB2,OQU&43FL
MLW7[,^<#IJT[IIVF^+VQZUO1ODI]8+A'[4BC9SG%7X<23,STDF4UC=/'CD(=
MAT2JPI^'\[YOPQ7=D.H$.22_R_I\]FH%UA'+VD7 ,U.ZY3^[9O%_JR-KSXUF
MVY>(Y.6,# I+OGK^[.+KS?*0V\I/]9/M.%J4K24B-)U9W^U-7QVB7P6[HC%2
M;V8-@J6&VF1S)UM\J-=&]<X4ITL(/;M?.KC KV'_EL<G-\1<??\J;;^I9PEO
M69#]6LJPQ92^G=J]6=.$LCX"?-J8YB3O9L\R6[:G!6>HR!L2FAZX6$)5OUHF
M3=SQK ?)=Z_6WDD,_3!I?YH,I.JX[-GQDKB0.3#CMA#1U(X/C0?NZ4]WKY6S
ML0.5H@N(\]=PC(L+:<T#M#LJS?AWPAPY(S1UHOH=N&%I9ZGSUF*:V.@7YNYT
M1K ]1]=)57!MPN0;)_ER0;#?*;;7K*]HFC.(T.,:-ZJ3.;3)8>/E$?FK<0])
M^JZ#3<D_WK,_3C.\MM_ZT@\0/Y<9T_>2Q6M4LGT[ N\1$+R$K//5U4YMK)^:
M&*+SX0>=!JR%<CU+7+A24ZUMIZ,\%9_BC3'.UC#6/9M6T?@$S3$_H1WCEBSQ
M8_53W+&\0I4P&Z#W!WDZ_ED>G;Z7$&"*"G%ERFBC^HL@V+_=Y"V'S(BAW\O0
MN9:N4[YLY&%U,\ UI=0-3.>"YIC&\-3")JCLSQS:R7,JC32!".>F7VTDN7\J
MH[C25[03B8CWY3O2X"BK>ZSV,M:?8A9X6L'==E>V: D,YFJA3U9Z LL9W50H
MR(%*Q-Q0FK_+X8$>/6I# U4*QG,$1[6GV;T]3"PVWJ6Z166O78.BK<#[.O)S
MO>(ANH@;UVK5WF@^L/QYL/'*:1!TR_O+%$QC?9;@'D<^D=] :H^-EVU[M"3K
MS"?/G.'\8'<I2.J^?0S/4_X+=^-M>4G8<=!3$GV6L!&N),SD[$<7)"MR27KF
M]SSEC!YLRH[_Z/ 0FCPFF*!B=O-1&$^[O:17:Z;T4I L7<@M<'L_<+RH,\N5
MU7!G&QJ2NFGHKUL)*^E$D*(IK<UIW+]#AHZW4'"J'3D.FLIVVBS+R_:;*@R!
M-]7^Z/#ND[>UA0>1&IJME9"Q=.9)F#<!_:Y1I<0E? ED663G_+]Q=IY?33S_
MW\Y'!52:]"8@TKM(%1!4I!M1E"(M-KHA(BU ($J7*B"@($0ZB"%20JB)= &I
MH4@@0$)1>D(-$,*/[[G_@_O1/MIS9G=F7N_K.K,[L\_O,0$N[4V<>*1CTY)1
M/)M0O&V7*>:Q?0NV&0GG#,C5)F?&&L8%>HII8L8V2D;1BO!8X?*6T=1L$-$*
MA6PG])\ME)1[AK[3D2\)';/S-#;Q$F@YI*\'$ -V#BY3<CZZ:M4M;V%;$$;K
MNHJ+XBQT*0-1RN;;YH=@DD@<S%<@J9)[]5':@!%<+%?SF-"HE]H";BXW.B?;
M*V1[-A^)B,H3&O''B7C-.U#NEQFH&-14W&.HI-]%]*6-+7PB8/80F5>A!@/C
M5.2/U'B^!R]^N\:8SUP/0Y46).#[0*W_/'*)+88"TBC&65KEWY%:NTY$C7@[
M\<4=:FFDZWBO1_CUJAA7JL@43&M,:0,=G,A1H[Q1O]WC#67KN">]H'?UXU03
MWR:N%IM>Y@5G7_N+WSEJ>;B#N^1!:-ZKNZ2QSPX!ETT-JB5+,Q4]N^QS1T[I
MS\]S'Q3=^82,;W@0@#L6>Y!^Y6[D0I85#HQPW\]#.F5U#HK#VRIH(#).\#CV
MR.J(%8AX>"20NW# L!:8Q'F#!]1R2\5BL%!J2R62>@-[;448$J/_R+-T)7-&
M)-(J\R^PX4=#DWUED6=1]/DGA7*"?]\45A+_7+1)P*K"Y+/:0T#=82P_&1QI
M[4;C6/%N*2T'F2]]3$ME+@=2<JF5$_4OK\7\5/EIVF2H?$_S6[X*;A&>B4B.
M?E2+S[H[L92)@$^'@=CR7IG1NA99Q!W"8)[4U9^ZE5541U##Q/HSL,I?8$U*
M^V'1"8!3TXIOL/1Z5YM;3687R=$JU[5]0^[[WSZ)J3Y"[OT&4DZH.$&DO;'#
M00FK-[' &$ W9KE0E*=$F,R25YM$GPW=]N!5RR!)]^F\M$[N^ABV+$V<VF;D
MKGNO%@3VKAM]7AG!S>$&2WW6)5<4%)?@$5B1&LI@]R 7W!4:L!NG>;:,2*1A
M["FNXQG?)INF)1/L1GVX[!Y$3TZ;7'VXV T1E.X:K\S:>S?\'=7L.U>!$X1Z
M;7>)LY,PV/@C\[IAM_$7SK>;T[WUQU]W2YK%OW^3WUQW?DM>YY>FHGWG_@D@
MDF'K/)M9DCEN[L_ .N_^"UEJ(?<KMFL[*->5!NQYHA.&2^U1F9M_G02+/LH\
M%L5)65^N8^E+7'CKIZ\YCZ"9-7O.<W(>)ZR= "@I?=X"IU-R!IX+R-(+3*H?
MT/VR.U\,JR&K1ND")R)@[!7>.'8?3<CY99<;>1M]QBU#XH]:\/X7D'_O)JP]
MOR%C=J]+GNG'G1=6<M=E,]"ZD/<@YC7Z8YP8ND%?5*OP6W?Q;>UHM[0NDTR1
M3[7X1?.G16XWQA]48*](]7Y+WWHKT9>I/[+<N)*E  ]I<BFOS HQT=].O+I_
MA/H]O_]$]A]^M73LL5V7N$@SS_\V-# >.P'$?W^68]D\]*IP& 4Q$//*4TB_
M_T7QN&Q*1&BX]J"]%K+$RT9+K$ H>H6$IU *9CO@XNN[5GR>W-""*2#%+;DN
MNQ+UE$S</;]1.5G*9791NC?B^W7]7U%%9_(' BQG%L,(1PVX/JI:@G5"5AH\
M-![# /ZMVF%ZOF(@PQBDVB85P%^N9!D2'CI9'A="P-B!B=[)K4&9<!.X^H*@
M7MUI\O9KA?--P"0TZH8]A/O'2MM:[G@3A0KP,W>QM8WUW,&V;U4W\T1DLZ?/
MMSX-=S'O]#?@I*A4%:P:L@:(&MT;5=Y40:+704Z9YXLROF^@[OH)3KZ5NIZI
M]E4?(0?@4-16#<J%VTUM3O0[VI2'R&^= $ JQS<A"V'BQC"]KS##\=K3XH4U
MH R^U=>P*!+V%N<#SE6TG+49?^I8X -&7?W4KI5O.#GV>2FI@/OSY"V3Y]X3
M<%<X:^M7+ZPB A@:IG>O/GD4_FP9SA&@RF)O?/VSD9.4=G+;$^= Q5KHS_B;
MQ"1OOGZXZNI"DP$V.VW'CH'K&_.?7,W?4>8CX_@9PI/TN[1Y"OFF7_M?$*4%
MFXYD_>>#)'@SIV9W]UI&2_:]MJA1,#M/%'RJ?46R;YZ2.&[ 0W&.3:2+?O,V
M9*^%7X)&C/QMK_J7)1Q1=&;)=60AE-<T>+TP$6QL3[2#<0#."UI@E$\ R'4&
M*+@PNJ (L5MQ;*@\6*YO3$:JM@7N^:U@0*[Q6UOL!LQ;Q/U!]3BRU<?+KG%"
M^AP+MFB8*]DP*B0PGY)'WM@D]7<5SC49BC]9R1:(]=F1:6K"[[AECOE$V3)K
M90KFCB^!:A1\N+!LWOO\F"XK + "=F=T0V6G_E6SFE_AGVZ28SE6R&M&(L<L
MZ;E$YZ>:;.V1)5/"K(;9P@'4;:NNZZ9D4,L)@,.^#Z17A[6J49_((RKC$.H.
ML.\,[T*#=JH)^@1P?C8&#7;L.3+]HRS3N!4$GJUB!0]PJ">Z,^=30'$XD@HE
M/+KR&+&&(&1><CE&A)\ %'\G@7S6V.8#U=]]\4=]-I"#JG3M=QA<!PG05#O$
M]"8V_5F]X1>\^4,TMFOO*>>ZFKG?Q@ _#3PA%J6)MIEU[4U&[YT*V6)W-%V<
MTM2>%<)1NQ]$T+\&].7[?,USD+U 71G/S68<)_<U,E.0_#$@0!6?.7MP\P0@
M'8!?<I4W@*HL8TX :8[;@9M;JO3[M'*!]B?-VEY8T7']A^6TB./:55%#8ZT*
M1;.ZK6DUMX8\P;&[KV\L;G\!W"A1[8RJS6FMRYZ-"4!Q>(7+C;KAP:]4DXJJ
M;TL%;D_S9WRM3[OV/7,S*;%;Z>N[ ?VCO;+A_%$T)%K (3KE_4:MLF&'GU59
M/TDN0+:Y+G$Y*[4P!M]-X+J7(IQ6+Z[%>0ZO;\/&_>\4,.B.I!;U3@=$;+,T
M"N@7#"G_LV*]>F9RK7+= 21##9]0LZNW[1H/O&7!_)/O>S!_-9QBV/=WQ5-Q
MK4E[>\*J_;!AF8#I5%8TI1K@\H$0Z$2(2JQXG(J8AI&(8]/ NP>9Y[#@V0C
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MOS;I:VK>A#5W)\>G*@:5O81X FCZ\/'%M4>3T,U6W<85<2&8'7-. '\QZ03
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MT6J7'3NRPVJ'>]BFF(?5"YDN7/5)Q(J/U,*CKM%JNA 7-3;YEO==="F=B(@
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M;#"HU[]MT/>&$OR9H-;DMMX\K].SZAP _;N&)$V=WG!C#*RR [:\Q0U-MV_
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M.S %9BHZ&+OCF*37E4H#!["[7!#K'1]#GP=GDP.VYZ4*S :L/B5L[?&M&%Z
MF6LGP"3$RE438>KS94N?.QRZHY")_/>^!7X\NVYWP_7ISU39.N8;#_;GOBGG
MXG@1BU+W6B;?M.S214#9[N[&P0,M5(?95H8.];$N UGTA_;"B+*.;3"0:-#.
M7!F95DK[=>?3;\=G(C;7YRHV!!5SK2[072BH)%2 (E"%,0<L[5!Q/0I'^+VL
M=DQK]9'PG#?.XWY,]DB0F%]:<)4-@(-:T8=J?<0LQ5FK3MG#PNJ"YB#[XP(-
M9[]6AYB*N?[[<G\QWO(OFJDR2>6.]M-30+_+8"6V9X_>% M&IXG^$R(KW?DA
MD[+.=V3L@6"G<\Y/ ?4<ZFNH/NF%0/V@AYY^TP[V1 VEO>6;W1_'A\W^NOU9
M>@T* 92&+!X(W.<H^FA'UT;-A$;S_778[X:<A\HX.HH&/6H46'5G7UQ]XAED
MEVK?,;>>O6%VU1^=F/%&['E"E-\7Q4N; K!PBO:[7;UU0YNQ2H/)9Q"^Q05;
M75?BYB2XB,.:_.C<?<E8+JSKJZOS2\]2[UMF3!X*=CGU&/S-'W8R30Q7AUK^
M;(Q.2BX-#=8D+C:YF/)G%!-7I)5; 8.JDP7I/0E*AL$R8SKZ%%]F''6JU46(
MRO,/0RCN)A1LA8_Y>I<0G28G@^O5$BK*"CR4$\Y\U_]KE9'1>$V:;QA+H#?E
M[O(FMCZN&@ ,GI7=0N4R^!E#C3X-LDGZ3T[SLI/_T*:N1BO%]:L+]#E4PCJ]
M5DWYVW&BT_0T[F-G@5UJNB^S1M>9QJ7%+1PYBSP3Z5FVO=."TSY4_Y>M."BP
M]Y9RB>)63J[(]5_.UDH/$,TL.BS.Z/RXQV-&+5#N;![^_F.A3^3,OT+OV %\
M8^,F*RU[L).@I%L<94<A_+976'$(Z(PZ 2CRW8@A<1L+7>8NE#SW\I+7]W5?
M?]QN?H7QZQ'8*TJ4@0:&4ILUD;H2) !\<6ZSV!D9-2$A]/M"R/,C/8LS!B^X
M^9F$?#_<VL)QT!VHSOMQS3S>!A58=E.R=IR_2/&1OM'OZKK8AQY7?]U+*ID1
M__0L><"\IX=I7;JW27O?D3YLG9#H-&NUE7X"F'JR ^;[17>B!FR^90C2<D!X
MB8CYQU55F99R/D:"10U=$B87;U_Y]?C2>5E]+B>Q%"K*<;19C[(G4U-M(#O6
M?)<A.CYG)G5IRA(LVNZB[P5Z4WZD)F>/X9;0*U=VSCP,5YG8<7ZB:GPZQ$&;
M(9,!-3>_Q5-/  !:(9FSP^K2J@,R#T-*X&1>/CR>R>"+RF;Z/8&Y-&6^T#OK
M=>1UM<8L[2TL G VIHA:FJ(?,#<;C[V(GP%QKNAROM\-UE@8!K]2,:Q51H[,
M/'%8(P9/"3WNBDY?6Q'H9VW^(!1WU*MZ@*019A%]R'='E>;'.0P!W.+V<N#P
MFH:M:0+,L8@FT(YIW&B"U@D[9\=DNMGZI;7:V/#R![DI?(MG5;_VX,(5NV0/
MP]J8E%"J+)FI?ZGA9FP$3)O4K_>@(?(17J:Z'K^4YMVJV,]6)=WFID-Z6ED_
MA?[XK-H828]?A%6&"1P4'^;M&@>#N[L2'%%<T$!OUOHY2O]87:DR8<7!))^)
M?@)P,\M]66L;QY+@?4/I-L?%8->&RO=85:CN3>U;H^(@M"5[8!O0MFUY7\GZ
M2??Y;,N8YVJ7+1*CFM8!C1%O?O(%N!W!6S&S[L]MZRQ1RPU_'KK 3^$A18R-
MJIQ9$0 .+7,P+?E35ZJ[TJBY@9!T )CGR6U(F&2KI> $GZ4QOS%Y15.?MXID
M7/$VG P1*]7LQQ/"L,02_ :8U%+7&WGS>W57U707:W=6=*[)3H](C,/8%O($
M\+_]'H\'?YR.5CQ]8B9Y)K[MU%(T5&,-1.HGZ);E[87_ZC9Y_6:=W/OB>A0Z
MHN-8O#8#F%( E], ,LT,"*&)E/O-R]!C;-?2<P>?<W2#KE=N&N#*/W0"\,AC
MQG ;0R)/ .(<!2I3V[?61I9"Q9J,7\]<IXV1Q/^;=7RR$C213@1Z[VW*FHU4
M[FK%3.GP_%9^GMX3]\%7*N?Q^BL>=)5=QPF@EN4=3+JL!!%4X>0"ZBDUKB@N
M22IQ7GG3\C%Q!:.0.6QV[TEBY!41._GZI.5Z!@[5<-SJMF,YN#A+!07_\[?+
MG84]1M=0PZITNSXPN-/;>6B1O^-O+#9"Y]/T!Q+C7UP[>.,_L&4QQY6-)ADF
MB[%2L:72R:D5YE(%?4<6\C[??93!&^O,Q E^O*5PMR_W)G"05;?R?R_0BF88
MZ7T" ,/]UH";F"QR^K'=3-!CN_1E>&U69+.KYL!G4@+Q#MAYIP%M*8_FY%AY
M;0\\(S_U6D68^"+M3"!I^-=KDS9S/GU#<?V;!5#3-DSV[DYC#*K"\])*"F?T
MCK.1]>]7\0Z^;-=Z-![POU*TJ/@7_M18L4)[F39[ DB%OW8&9:'HVB< *>SV
M:=V^.1YN2.,T1@^[@WW17,@_V-+B[L(G3E[6LXX2B?H?NL&7DZZ -"\0+ERT
M%,^PCX-)'AG#;E*7D(5_/'0/1AWMDXKPE6E=BZ\V)A\T=8KB320\4XWXHPP_
MY8B_24+&UTP=,FKAK_U43@#C)X#R95X[UF?4FC;AK*2KE%KM?>]O@U)#4^8&
M64%\N=-59T:ZF:8ZKGP>54Q+_?5;'S._\,J1 NJ$<,+NX)K10SF/&RV=)UMR
MC%LPU9\4/\JPEC^S=Q=B^93[[G+RC6)L^[;NH1Q*LX::B4'"S*B[R9\UJWY0
M!G+ $/9B_/G\K(>9VKG9GG=J"I3<_KS6X;ZA,*O"UY6Q YK8/?;.7WYL%T?G
MH=4@Z294P[B=&*II-,RO8/+/;0T#90JPHMV3_7?2U99"2'U#TJ+-X_3%]"NZ
M&[<;+ /AY_2=P^8-8PC@):1.XSA2NGYD5VB,[QS&MJ8'HO'.+IJ-J@[0^2\:
MI#A[R,#IE52^Q^UNX18/9Q\'^=L-B.G2)JDL[4&&?.@CD10V7(P^4Q@;R]WZ
MD0V#V7*)VKIZ?\LJ?^X;]@,/62:G^2_>Z ]I-A2&21LFJ>K+9$VHDEG9"Q^@
M$ZP:4C6.ARZ,3O^N^O35-@EKESIF7Z&0UOM344]V$9Z1CIMGN-;7$NJZ?8V#
MDU+6Y2E[)X#[8ZKS8YO/J_ [R^B8AH9AU-?DE=XK;%E:B91W0=P112VX3]?^
M^<4Z[1!*.S;9/##\'YQ7RB]GA?@WUNI)!K%["R5J1'W[P.R:*"?%KQQ]+C)J
MQPY^VL$+C+]_$*M;)P#-_<*R@N9'9('N"E'+N=D.4??6K/UQX1- [/?]9MW*
M%-]G 5YK^86!=<W1@A5LI'@^G:<7KLPC)QBZ4/4V[-4P3NO1RLQ#3BD7(*3$
MV<G!OK9^JW-L]*&&5N<[VXX!A**B_U-+S)W@3*QIF''PWWB<!^<9J*K]:&V+
MG7V>7K]2YW%1W2%XK-=S^2J+>:6+W.>G4956N1+V7>-][,B$/ 7:,$F5F18O
MRFJ-;0*;DRP_2_[ JZ"L1P2>EVO^_G!W&2S"!]/_'7_GQ@!?G.4,NO'C,7%@
M)GX.S9F<QSI"=YBY7#]ZVD6BHX'JT\8E1/-G8+\K()4+*%M)"!L2JV\J%=_1
M(]CE[#<S/')\%AD1?[#Z$R2NI GA@9E0Q9K(5ES+6/&A )ZBJ7\8[.5,PN"[
MBY(FZQZR>1OFEM]^IE5=O7M&*4-V" D_?2HK4@O$&?$DQ_S'L)C4F( #OK)V
M-4'U6EG2$J;^O?1=<#O'+]ZWW3K6=X Z"KG"5@NGR3R$VM39!:*RAW9T%27;
ML I5U,P$_HI24[AHT??>2&M\I9*,CI1[;WV2%& ^PN[<TXC;_7Z$K"[$!4^#
M:W64,>+Z@D-T9^^DJ>]Q1N"XN.=3BY\3!:HUWTN_)A6QIS%?OZ7Z+<7V9CHD
M?_JA"P]U?R]YN%F(!.*S]W"8WIN1QPN+P-$E61IU@?LJ5"Z??2!7'0]OJB^K
MP7;+Z^;XG193<E:,1HZAH+.S5_AC,2[GPZGCO$=[M_<"ZO\)J!Z5VAYH!W2[
MR+N01'I]+GCA'E44-+-TS]8J=[>SNY/#*T*9EAKR_^G>3P\N7:X+?*,7G'Y<
MU. >+^!ONX57F?LV7Q>\AV.G14QU.DA75KCSK?%/*#R1''WE7OWE:>JVD:[4
M>SSMX\NG.U>_#8*N\GZLT_A7*6Y-PY.49;OX9X2;6IH3'M0W.,IM&%97$MK7
ME2[8"^\8[P5\W.&J?5=]J\N,^?/QUV:6$\ %@3VY<9E0]&ARBM+P,@;H#0YM
MOH+)6S!>:)=4ES-.'<7N3#6%+#T_R'XX?A0NOH3=<1S97SX!L- 1TX-W"YI5
M]R*."_U!9Z"&79FZ!IB;I?$[%0\J K-?XI\0G'5LXX5\[@%?I5_SGV*M#]SF
MN1BD$H:UC,*@/1?!55W1Q*HO@.M6O#.I2Z$7][.N3F?&;R/.,89FSM#>?_.L
MTV6NN3GOE;FT>K\Q_5Y3Q, !G\TGQ^D>[G;U,DBV1F  @?21]Y4#9;:;DYE6
MT_$^?SDD:73"3\B6L.2LLB&B.!['H((K9Z0C2%EL9O&F.J8W^>("/;?091_3
M[:R,F@N:9;L1M8%)6F@26+PM>YJ\M=J9F7UW&YMUG>!R)2-M223T\_,M=U>Y
MUN8L-V 2WK,;^)7NAJZF5!9^HV7NS>S9HX^-S#"Q[<+.QPLCP0+<5[N4QV6R
MS1]*&CQ+NGBF\N>:4%GBQW3O0<HB_>;B=OU4;4.H(W4)/T%T+WOHHEX9/B;&
MA]]5_<^TU,%;>"^7W%!YU9*H9SPJJS5C;=G@HK/^N7E8REB,GT E?7Y[T;L8
M>SK/IY)>=!A<'D8S-U*U4B_WO8D%-F6.=[EB>*XT9NOTWA5R-NL[<P*X!OQ]
M_AQ"R0EAR1 Y;K=]\Q!;V;?Y9T=8L4^980CU,Z8,1I52F0LF0K UA>W?&FE!
MIKB6N+L/6:=YDP726,,&VP=X$A<6'<4*+R<H>?UK'8ZQ^;AP*31^Y*$OV" [
MK,/$PEQSS"F ;^E0>YUGCO.2=V:V"P()]%4>F\[VMS,"-CFJH@MUT>5-:N?Y
M85WMO>X<T+;<OL]HSI09YI'F>P31\0J_R\O0;/^L=LLFL)9BR17EYJPVR5=I
MF:[.27+@WQ5)O__+0"(G#H\?VCD<P$&%-R_&;X,A>XDT.&D=_F 8%5#Q+K2$
MV.U:KHG-"M(7?I5<52W24/B^L,Z$.Y_;HC=VJ1V6E)Q@3<LBM<C,=OH15UP>
MN_!ACFQ_S-Q-VK.G(_2"+@8QUGS:?&XV4LW1?+_W%.1[G5+']G1#%'O\$?'<
MJ"Y5,8<5X6^H*'\4NP<!65VKH%]7GTFW.&!M25"Z]K94OPSP\@N>FK)N10)Q
MT+6I=O'^JS>]']=3:+?]"IT\0I(RR#65_WY_Z $O=?, ?-5-%^E%/K\TWZ1(
M+H:> #YK.QLB50_$^HV#96,-;GHRY&A),CD0_>S[T>!\8/ET-UF5<R7;>.YE
M!F\O*NC<0XV+WX,N63(K3FEB2(8IIVQ64D8(S(6'L9-JO6DOQC02^@W7 U>3
M\(XB<2\$N"H7^HR; ?_,VU6>'SH?,-A1PQ%!@2Z@),1*\O%'W8RG0F:MYUX*
MQW1U3=VKB1@8F%&TM(2.RX'G;J5VQ5_[]DT'  "<+7X]PT+;G4N).\S(0,2B
M'1/&<;5' 4F_L\&C_)@?;XN36CI2E1[Q<31E:KD9??C)=R6$Z=%]735Y><72
MUP7URHZ=(4G=74B6MLQ'GY0D1E0"<LV^*0K!H1\<.\Q9O-+P-Q0C/SUV9WJW
M4(M+.L2V'-VVI]E9G<K7Q>RI1U%>UTV6R$M[/<C,%SP^K L53AJF"N9I0C<
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MUXKZ(.K_*#OOIR:^]^W'@DJ3WIM4D2I=J:+2112E!H@*""&$B+10\Q;I5;J
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M9LRJWP(ASL7VW8Y^T,!"!R"HV_-VQO*CP_O"P-!=_ZI_SWGD6WT_9FUJRB]
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MF'OOE0LJNK&]GUD ^7&W7IGR@E33-LO2."J[XV-4DF%>=QK$6&QM-Y=ONVR
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MSC!A^X=UD6:A$WM/,(V?'939.G:D"X E4Q\,&Z*?3*/5_FMTQT3K7 L1=@M
M=%8RP2TH=W'R'33)A#I9AP7XMO=Q;I>T56Q/#&M-P0WF:(;O+_IUQ#Y<QOPY
M,+&<5-ZZQOUV[(#>7IVG)&'BCMR*=;I1X:NDKJ(H; WSCX)DPRM9S2@UN4J#
M5=^\A9&  .C74HRSBV ZI&^.R)2KB3B]OWD2&5\7[V):&]MAJ;X<CVQ=R9-/
M5,EC*)=G<'CA^299O,\P&S$A4KTE*L=]=7N>K/?==B./6;P>P@>1#6Q/5U<)
M;\@RN*O)//UMME.IYJ@W8ND3[2V_C0.F6$'.D2"#[VLH7,K4]'H]UB?83ZNP
M][5K?'R9+,&LIEN8H5!_Y+KP!WPHH\^,/T?J(N^G5,&1UG. T)Y3]TRJ[:PJ
MBD U)+;*$Q(3J4*;699UA$+B86.P)R%8I_VD-F"BR-/]DXFKD\+T@U[8G33K
M(=6UOX^?CFET/;V/X OISQHL6L3PS!F4Z"ZT7NF<9+&?L[6#G]H2-QZ&#'#4
M_LP&*J?SA3E_ 'IMP;X4.$FJ[(=4(M=GA6JX HK.*K+=G!)8M):PK/[)]PQ'
MO9C5E*J_"QB]NBY1,4$=>1HR<K));L;O'%/"N7?U]+Q-B)9F$SA$&S0^_K'K
MCVN7XRXYT(5<(Y<8#;O#O'MK8S$L:]1[8Q2KURY^7C*6?L]F>KV+>9RM,PL\
M&?$"O]7HUNZ)9AU6LL)CS?ZW(Y&IGV7#J41:L2TVT,^S*@\;H2RW5:?K&&[^
M[M)M?CI3I0[<TQI_V9ST(HA7(&.+FCG.0"HS/^99UVWX7J/%H?;(+Q>(X[?R
MR<Y^%*C,[!P I0S(+9HE5?J< U) J4U^#@:QD#R:(-"BZ?5./UQ'EF#V HQY
MHTEV^&=58SI$P\1>>YOG8?"W;P99!B]3MQ5N844<Z>Q;=V,D1TL.1O?%P8(@
MJZ.\>^> WQ&DV2*2\:C]^ %\!RFC:716Q;&/OCTV\[86&[6EG\SA/N\Z//[X
M:X]=EW4XF%ZN*Y)X&S2J,D3K8.)77&MKEE WQ#;(:D.O@ERRZF65[^W_;Z:[
M@?]21#L_PZEI JK$S2_C,-WO$.5G&Q3+N,3\I.)P1%'ZA^'79>X":<"[=[_V
M57QC$,WDP) @#"6&FFGN8==[@6);F./;9-][B;$A-,WDV*_KZH]9VQGS(0$A
MWX*<WQ=]K6\T"8VY7&^B;-APCUMLB5DZ'D46+;<.&=XCS\[NME-9)*IRM[44
MLG0]SVH4'\'$YKR_1^%_??R8,[AZ765+V7P*.$DR"HFN5/&$83+F=X[V,8[=
MVG34(5NNWT/TZP&I:%9B.8;-?,)(A3%DL)<5F-UHHCFW_E;^7H$&2[(22DC>
M[1O1JTV(M1;#:P^/79"+)FB<^9[<CD P@T-N-38$&BK2V=K@C!RY(RY;F##=
MJ[D[W=GS#-WHN("4-F^<>(5J,0CF?4USJEA=R,J=;E_40V=HH'_O-E^$I]U!
M1C<3P&V6!T/B3%ED% (-*Q\[ANZ>/FHV?:CAYVOQ7/@_]/#>9:-?%EA6=E;>
MNNUFZ)3V+(I:)[ZU=XJC8LI$,TEYOUR7B%HK>02HP7.HO8\TXUL\E37>]QQ@
M@0+_VW9L2!#Q<,[\%M\?:**OV/P1^N:KE>B"3BB&&7U+K6/FD1V,8=UJ]@YQ
M)C?6\77)K)V=GBO1]/T25N-7Q(-9^"LLJZ.X;T[SW!H0CP]6'0QL;ERHJT7%
M%V7Y?Q'1CU'L[X<# $:WB^],3"HX #L]85)F5[^+)5C_56Q*^O0KX89HZTNG
M\1%J!?)8#&WK(V5;G ?J&CP'Y&*4XDE"H;"ZQ.A<6A*#(AZ9$$U#L5+HZ1?S
M4M<O_4G3!O@V:+@5-YED$]+'-3DK1-J)5 EVF) 5W'G42NP.+ZEGE,%YY/G(
MI!BM"+_D,9\@T5C>Z@8+]=/S7QCAU@%2>^]%R^A73'W>LVIKW,;(_;2B_^Z)
MTW^]_ZP-R,,_OUCT-OGI9C!"B,SE$!\:5"J^1-W""(08#(5PD:\L<(Q2#%6"
M;PX.V303EU=BG<M,2&Q $N":SP/L$N@AY]6W":HR<?]4+PW9[FOH1 34H>+1
MO)!K*Z/_<OG^R'N7_9TPF).IH;\;H8"BT:T/VKZUVW#]B^\?<HUQ7F>& X\)
M$K>,3+6-JT<#*?6[1F*NIU6UR_F?7O''M_QW8[#5XF"%6KMRYBS;%%$%]L50
MGV2LI56\P_"VT"-(?+]@^> :H*ZOCZSJ7O"H8C$V<$V.W]DBP?CQ+\^QN$_W
MN7-OD5^4N>'F.B$]'C+I\ASDD#GCZIO;O/<=8]9YBGX3&W/N6GD2&M;S+/)K
M4MD)DEI%)V7LQ0L+DP9>*WG<(0-441BG-?RCL>%!J01Q.2(R^!5:;9QR-TFK
M-+6\3#94!\=!.>)SUJUY)17B>Z6%*-^VF7>=W+.A6G^H_C8*S3 :I 8M;O-7
MP0*-H.)8CCVQ!R/ZG$[/MO;J1XP3J'5VJW':PJYH&JB"BE4K^. .=0@"+5Y'
MJ>WU_').3(/Q->CQUWSB>*^HKP>YKYZQLG$.T*@\:_S[&>/")UN>T:<*N8!-
M4.FBK="_G06H1AM5:*0$,[+4-$KEGR8_M+(IDO)88J;QD= \?M3GGGS%^SA8
M!7V+HC%>VZK1?D*ZXP<FP&@@O-"#G%1Y+R\OL9^V_Y@?[48WUB/2<FC%K[\W
M:'S^W%)[W$BG#M$Y<*%(NW)?SG(LK'Z< R0K^R3))8>O)S)LQF3^UQ9+*YBS
MN#E)_-+DD/<#G"N'FM2IDDT3Z>""0$MLRP7!4Y%)Q4E9K%\_%4Z6PV$$@PZF
M\ Q;SA)"((B1'$$AFY@25\H@Y6XH3@4]V?0]_HE=\?+.\;B]:_J/=:3X#Z[,
M7$.^P16 0W>G-TQN-*J&N!W_%NE\G*V4T_R!KRHN5%K['- U*SA2VPHT;YVL
MQ6II&'H)%OA[^O,^<OHES9&)?:-XI;2=I9WIN6U?T8[T3MGQ?<3N4VK ]FMN
MR778Y@SBU V57-_].4B'S/$#SM>E?6TLS[P&4S>L>?_'>D:U#)1^P,_?'_+>
M0?(_X3?7>/3ID[]^/6Y4X8JDWMAL,HL(N;D^:K^^I?.Q#BR_,R7VJ;RJ#CG]
M0"]U&64G?!P:=VWUJW8=(8_#%:TZ+'N0=W.3D_<PR:NY9TP96]B(RH!P0*N%
MI?Z^TFV;#Y4VC\!Y M^? [(S5OKB\W.:RD+X,4E[L CJ)?)!B#0<TC$K/"Z,
ML6<#MF"23\S8-_Q .&93F!_#:^])O=IJ)[:'"H*4_\X!]U81-D08(2]&DVO1
MU(&Z^G2$(D[(SO:E)<SP=5AEM99-UW92R(L-J'"9_VC:$FAP*^; 5+M3%6<P
M6G)4)1YB/0*5"]IZ9 A//A22S>@#,QM^%'M=72B4^L5O)5\^'5N-.CBS/=DI
M-3\ZVJ4(G - S:8QLRSG@+"\OG$$09+:NZ=3ZZ%3@ZG6G Z.]-O6W%&B J&G
MIR%V^Y5JQ.V\[W"7A:-./*/TORH([T%K1I1R_=B5;'\[(+V!)?YCG2!.!&]T
MZTE) \>_\4<=O >1X;4:9XX6C4 MU=_7&QL;WADF*--D_KQT^\,?AMRQ6MM#
M2RH:K,K;C"\[\SWC@K4=^X4',2UD)\:.4HQ(.7F104KBQ:$G4C9KMJF3YP!P
M?(D-#I(=#=TB)V)_WXK;VA,7I[K3(VIDP_Y0I&(M/H<&Z95N: LGWK!BGK7'
M>M[470MJ9-.ZOP4,D2"3B)-MO,GKL^+D#P0$XX8IJ]FA@(LUJJ;A1KM4UQU[
MZRO;TC STE%D73#PR6BYBK5\A8KI_3H(5[V$H0?RBDCFFS3=^"[GQ *VR!=_
M/EK65Z][HX_NA$A1+8-5TT]0K7G3C5;S6ZLAJU<(H*F]!S7DJD4S 0B5C[B"
M1+K9MG"=:)?)QGF!;/0$<EHT'E<*KO4DW^&^^N;NKU6Q#[Y#!/%I7$;7I>_V
M[8)YBV!'SBUW$Y.KB*D_N/OO^@#0X2H JT*";H] 1ASZ%AQ$&,P6+%@88@4+
M<H\NI3[("!C8MTS2#&-EUHS[6L_^Q>7>]9$*(=9U>L$TX7'WL(":JZ/X+=K8
M+H5,0-CJ45A^#:7Q^&5N:$VJA>&N2E$C@H;<S/LC.>YX8F?_'"#:KLT81#,1
M)%0!GB.FN-:CJL!-WNDLD.O=)[/ESM.Q?(KKJ*C7*%9)L?"TOG=??ZY\(W;_
M.UT$W20+=:G>)8=.X#L82SH)<XQNG*B4:Y&&*!=75ILG@=]R.A(2Q=R650M*
M+QQ[V-O">+<Y$$/6D4/ZU@3PZ$FN82HW>H^:;/.4K*D#5*F,MCFV?ZM9@UWG
M@,XF4V0\$CD972?K;=M+;Y9SE!&]4LTB]9,NACV=#S[[CX3ZUUVVX:!)*MI7
M=]>^0SR*]1!I;JEI)%'K",N19[S2X-<0X+VEB&6;5Y:S!.X=R2DZQF#&'^0R
MDV&5>"Z3UJ9=V$&T4VB7O"Q^T#NZR//3#3L1A>.H]806RSJ0DODJ:&)N*9R]
M(!#AX)) +IG?KD&"=7BWH![N;Q"\ZZ%8TSVQ=\*>KZ!["C=\XU?OVW<+U'2*
M5_Y'"9['\(/<T#R)[4W(W%;G$OR&?#G(3E<V;*+GC6)'Z96S(AYNH3M9_(I"
M>4=AE57#-IV2S2<A7.< Q=RJ9VN5L!Q,KY#R''6@J5];>_(VK[>V!'&B"GD.
M<-?!:2*0X,MS@04M+D\_B-4UX#;L%!1V>BRO@'U/;&,D8Y9C8J; N[;RFSO7
MR[\T8<A>[74ZH0ZBU([)Y='M_?J)<P!!55!N)+\I61<J59E^E>WGPQX;2]U6
MBT/6\BM;> M-7:)+%XA9-NAU.>3CPV&* ;*M"'QXXI$3J#)>U%J7@[?C"DQ'
MQ2\E]5>3EB6?,7MAK=#/C16>A89. 8G&.JGF$CC4'()"VS='9G.77A5BH="0
M)J/1$MK(X!\&?L6/%C2TWD[L@M@WW&(A#'\::J@]CX$J4M_)GVOC^J\PE^-3
MUC9ZT*2W:27P/&/B0>=D1KG;)SL['-#?(^COO$(T\!V?_IRZ-NW5[<5[][Z?
MUL1-;,):=4:WFZ:JLU9C(PTPT^> RF[O3,*L*EF)Q&9./ <D! GD&Q$\"1@6
MM_=NPVZ31UST_I>2#9>3IY CK,@,*WJ=+-4R2075N4QMJ2!N<B02\1L_0I&8
MY5&WZI!6877C'5CN\%K?BQ6O<V(VH)?YOLX.1ZC0<3E6/_@&G#X <8 #)*KR
MU_U0#J;4*IE/UIW+S?Z#2<H5BI?HP_1U% 04)F,F2N->FIODHWI=,_JPVY-^
M 6%?I-23 EH1?-2 <X#Q+,\BXH/M.2"Z=B[FG2T(_--T(?&F];IMX),1CH2%
MF=N]GVD6%$=*I%/BN_D!P1_;E2!L:[Z)E5/6Z[A&T'XL5)6T/?\H)3ZYY;D2
MPZL]WEW#51YU;\N$IZ;USMSZ=\3_''=W("X%^2S HA/+0&Y),^N?R E#-G4M
M&9WJ6?FX=F4YF7- -0OG@/$/;0E9425 A[3JTIH/+#3@;*<=P^;ZS %,FG,+
M44CLN&OL_$D$6%%$,VPIK"@VQ<8 T%^XWRV*=_T>LVPDEW=6>0X0%NK<GBHZ
MHX:@S+974-34<X!XON'Q8O?<-;2(6X!0!X(6'F!&?Q'==!8V&WW8QWVD8\.:
MZ_S-%<2;@=VT-I=<!Z<H?YX9*K$=PQ%^DURPR - H&V/#JG=EB.-@& 'YRK_
MD3E \JYN93DO9(0B9%/@5T-]?S+<O_[]>^K+TD".XO1C6^PV:'S[-V>X&7@5
MT;6S@QA/S$*XP"Z1N[OSZ$,N3V^VZXU29 DYK*/F-0VC'LO)>\^2]D=AK";T
MOUEI'C=\JK)QDNLIO'KU0RG1[]!MG,JWF<M1,U;;X(,4;7^RT&V7W7TR-M@0
M85B0YNWO"#&<<PJG*V]^J<3130\R&9>]#1RMV_1W&97?\N%^DV4"%JO-='Z9
MKGI'S*GTGO.KEY7/=*]G;91:X2S2]"9V3O8QR;LB"I[%WX)9412F(9(FEQE9
MA<0Z]X3H%RZ6\GN=@*"#A\Z]^/C")#:B=4SV3<Z,J*MFFJ'82\\,5F,Q27@B
MHB\+]>L<(&@+M_L+5@]'=KPGUUA-["@WPUCF7!_N3FR ES^8'I3+:L)XDNCU
MR^H2=-\ AH;9K11C8JJI:"&J+E=@_5P&80!V)GL.:!=2A_O-Z\0'72?D1487
MF>1OJF,B@@S*W+SP&[8Y. -/2,#DY\[1;LWBEUP**2O2'E)3B(6*BY>)83@P
MO0F+E??4RF;BW!A"."XWY\DIE=CB%NR^M\,^#&$;H%)>7SZLI_7.!-D0/;()
MX""3[^0,TV&*EL!8NND/MTEZ9]BJ@?3C/K%L5QWUNU?Y514+$R!&V$Q3DRV)
MO +(@:';AC$D<&ZU\K@&VZ)$S.@^!]#O* L8M"O 8;:M"-IU--_XZ_$ZOECK
MK>6:N>5I8#6PQ]G<)=O;7>2VFT#[;<$C00)OI'">D,+S_\Q^]G9Z=2^H162;
M_/$Q5,F&;,G;-R:,/AV3,6JL;TA^T*5IPNU$AS=D,#3OM+KO?!UD/>%]#KBY
MKA907!8,+0:G>RH?J66DR#QKXXVK::ZZ]/)2LM&O'U^F\:G-S51?2LA*DW6?
MPH4F_D,OYR/"T?;;0<W$DE^S2N3$>::;:T>BCVJ)%AEQ<G6-*I(>Q=3AE']-
M+4<L>'I'VKBWKHLS:CE':I>XQ5C&[8*X2).'3%':@OC$FQ>#3%L.L5)/V=P#
M/<5]43WBTM]VU<N;HM2G]/N+&IG^HBOB_R;]\_1:!DGZ-^]JV"KI:?8"DNT9
ML;.I9P]BV12G.*5?2OU9V]<)L/-*Z0Y8&_\H>6M)4)<];:$Q )&#>8PIWK8Q
MUJP$K9\#=LUV=BV/M75ND"<7).I.'\%U'IO>%+I)_MB!F<)%E 3Z*/NETTHD
ME116,DC3%[5SXY<92#3.O7(WKP-)\O-SB3N3"V]3"&R$1F4$OVOTJR/<S'*'
M'V\0UO6PXX;CAW0GGUTJ3%$QK I'I@L)*\_C@)>9$,TB=U1:W3;_V=IG1>0B
M9)?^TM,(285V)ZO3Q42_# VK-Y('ZCV>4/)>W6*;JF^IV*&"/)?4A]H0W'P[
M@J"UK)GBM& DW,IPV-U#N"'YCF/N\#;.O4=40MRGP<+FA5>Q3>BRE>9XWC_\
M0B.%@V3>!\G6TGA!\HB'.3K#_!9,34 F-H13?4UL<R>;LKO3H]T?X5A 6/S0
M_@!'8<D=8_/ &A7NPK1:4+[)KD$4'#O?'14B8^JI%H4W_7.M:'[ I-VJ"FQ5
M/<OG7^$<59ZDT<[T^8.CV))P;]>-XQ_!\K\0S$'V"TQ,&]HJ=<3!F%R!JL:8
M":W+U,#18"]-0:.D_OH_9[DJ]MU8T-TJG^/NC+U3/0[6VJ_KK744(.+4BZ(A
M7/0V[^7H::H5%8<I'N(FFK7E^+5K\Y(Y2LS\WXS".3NA/H\8JCF^Q-]'(KQ2
M^2(_ZQZ'4@JTX)4F(QB"^ 7=%]A11ZA]%P=>[D)3.LY[(9,Y)4.G^CLI?/7_
MIO#WD7W2QFGBEAZ%*"BFY7.;KHV@0058U.2LL';+6#_0-<B( -YW:C%HE^VL
MI09Y5L!G'7,)W=>CK \K0+\OK(/:.)\7A;EY(*NS8!559\9(!IFU5JL&5(.[
MWMJ8-EJWZ[V)VZ":\ C,]8L)6V+OZSQ\;F,P8R27\7]/=\RK.OTE#[3[G)*L
MF3UOW^QF>]1Q#N"0*55);UX <PY\8OF,E"54W];:DZUM$/W>;8N(:N%;A#%0
MGHZU.,Y'><NZ,7K\GAUZ,>R#/ZZ=3\;71DA_KA!!?4DVM]2/+UAU8UZD :))
M!K&U>31_@0Z;:@C'^H;6^M&%%*S?C%9'+\.=\*OQ(X:Q*;\&C:Y(Y"TD7E@,
MX_#;\;K8O*IU8HOKGK\[V<4G_AH[&U8Q(>?LSA8W.J:/&BUO@K?:#%:^7N:W
M6;E8,H/JFQD2&->^3L[?:SNI_W8X( @3V@@1KR*])"F9"'X1JW.]ZOO0'BG1
MQD OE+.\5*7H;\R4?@=T,<%78V71HC.;R7#?;G/2XR8-' Y\9,7VR+4^^5J2
MH$OTD[#_##UY5^])-?2>L,:82ES,U5\FNT9!+3,+SU>2LV?^UTNE=G0LS;&;
M232+U[XM?\',-.NQW]H(,&9X+D3 X&534Y;&)K?#X(#+[BL6]:<#/*^*"J-$
MF0W?*8 LGUMP8;41TB$*B*_+OFFU-9CYR0U_^[PV?'9L7ASG2?R2YWJN&GQD
MUL0 IGT#4_.Z]OTT0,C;O1VLZ?@)SE_K "!1OW&%RVDZ@PFG$/G+>#,O]R 5
MY<E)]=:AO\YU+Y:,KHK,^)J(^IN(%64F!?UBSSC"2:MQ8<6YFE#362"?N<T_
MDSFG:%!Z]-FZ*"%ORL V--CQMSH=.;2]VTPHHGBDMGB48@$M'2+@'=F?8OW
MT-> >JN[[3S@MPU.WH;C47+=N HT WGQ*?DZL;LMZVFIAP\3(\X:MZGJV[2\
MDLA9_ G'G:6,J8^N$'XNGW%+ZK^&1,=7"I7.PQ2;(@BNJ['(>L;_Z$2,A'=C
M/O9 /TFD>Q*;#'#O%E%]F32H'BKMT"3^O%=E=F@;6GEVAQJ8*=G0&G0.8,]8
M"SJ;SYLZZM#F%6(*&44XJU%$J;+CFKI^:.KV]B.:<>32\ZX:LR:C0LO&!T.B
MC&TV#?=L1\=#;FRB9J]-[+MN[Y-\@A?A029\M<GNG+W?V[R?Y63NJ3YN![ T
M)&;S)[Z.M!NM4(G-D9!].&%JB>/>OEUEE#K$_M1:_U_F](]._LOZM/K=CZS<
MV#Q3Q=!]1@&WN8X[F2@[YX BQ.X3Z?;]Q _46Z,A?.N"0FI-<'0-J04M?D&[
M*5C5RG*3P)\"F7N:I9>3XINKU1RSCN@DS3WKFI2IX!DZ(V,Y)A=$I\JQTJH0
M^=FLQACZCBVD"5TI<% 4&:U3+X+.Z#C)+I_(]!3X/O(0^8615_U[*@_]9RPS
M4MAY0Y.1B.V8%2*WED*&P4U6810E[\GW]M;KVB(MF,276?H@.=_J]%E)F:5C
MFQF"S.#@(\[EQ)KGSSEZDD$3T2&QV(;EG?HYT##J&+7^9V\G/H1^,LB9<,;3
MHJI\[!,O!*R>$*X?EQ-#H1IVG;#Z(X7OE?W-W_U67;IYOZ<_A9#;&%Q!T1_W
M$#)#(=CA(4.F$3=*DG5I.CSMRK,_=S6:CE9P,WRBE6J5'I?\GG:O[\NZ5E$@
M9<2,:+)-4[CXW -)5IU<F)M;"VJOI YH2T;:#1\TLPFV^LYRC=8R&@\$>9:1
MP:Q ,S4VF0F%Q@:KO6EHVB7[KQ_W?@KIDH7:?\(-VK(X(R&.G)G0XK]M+ARI
M7.9VW1Y57>SZ-897>M@9KK_BJ4J^I%*E/(Q_)#9J6*7'F^'/_]^/KT[)9@]H
M=(O<ZFVW,\&E8%3Z242./^L0U \BA64?_LE0D5 887[CUL=01F_C]QE*P?9S
MBU2/#GTI.@5[#O12QE+&9NENWF^=J^2A!8/_1/_D>)OH7.U<G'EAF?W2I!%3
M6P6IG!Z4[:P*Z_(S85V!W7O-G2@OZOFO0IN>O'EZO4.("=H=B2!<G5 IRS$Z
M.*XL@3[E"XPM\%,6&?I'!1JM:"85%L_3F"<\2_L;//=T4GGK#83LKD(/G"J_
M?2H[[;LG$P]3'4?(/6#J.;7G [>UWUG3L__62\G%!/\/)7;,[?J,_N&/8>>
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M[,;F? M::DJ5I;M2;-'<(_.UPE^[J^^9)*5W>AY.+12:'VU[I=.<6^<: L\
M']JL[0/'=]H_T10FE.:>=N%ND4ZWXT4F]]F;T)QM-Y%CV/WY#T)!O+8&4?4^
MTL\_9E[5ELM^R[%;0V+KM6KO9OY(XR S%0%5K88.<@7TDV+C9#ZD,SU[\4O5
MZ_*&(SJGC+LZKP?/3)4G7\2-X7L$^,: >E>*.XDX6;M>Z9+HEW?Y+\<_:;CQ
MSW?(PWI51>5]T(_P 1P?*X]!E8]43[38#^S5NWH/]OO+ZQ;![?L[M+Q4^6V)
M44$I6]@K\N$'#6[*!,R4F&/R@I)6C'6?0M%7S[B_6SD8U0_ZUSKQ%?DL /DN
MC1%E>/MZA#KS\'MY+I@1.;!CNDW<6HLH&2JBD3S_%6CNB<W):5;.Z:RO^)Q7
MVW?33>RZI6E[4&SQZ<*E]#U;\$$0"4KBA!.2KZ^H"7Y\/;[<T-B8IC4F_/&-
MFXO>!;]$(:=(Z53H',7<?OX,$-/&20EV]74GV#.ZT7B0S9DCN8P"G=+/,IX
MY-9Y/PQ]N H"&M>]:]D\5MY!8MHVJX?[RR"MH>YM.9X3\,(0JY:C20S1M0=Q
MD2+1*R#>>EX6E6X'=NS-$_/CL#=*LN4AO)7/?E2G2;I^'"T.8"KY$!?0)!L_
M1XEM[HN$,1>&H/K:23_DY&!ZA+B;ZU8N6=O>:1YO>\>>_?@9S]*A8?V?7&+5
MH+"0US[^.O46B;GK],G:22?M&@D?O5U=='?69I77H+4J35@H/2#I@L-G)F8>
M]M-K!.:/0.DR_;*5MANDK60'V5GS':N_[B\?L\UV=Q1^J1"Z^LS9S'R-+OQZ
MCU^O3^(YYV/VZQ&0%OW5Z:_(K49\,$U2^NB]'18_M6C/ PVTQ[P^+3S7VF X
MZ$IR[*;^RF%60)J_4P#<]?63%ZG3BARF;R/ DC.\J?K>+@>MFC9DKH0V:>A4
MV"<)TJ<T@NSSWDY^1EE/+.[X@5"\DW+7()M!G)5+%+!<%-!%U5%>FQ)@^8,0
MGA#.T\*4QKQ*<6G_I*\[#>$W-;5ZJ;-]_=4C^C<?XM7I2BJI*J3D6*!1&33S
M%:DAH1R:;$C78-6SE,. "LAG_:FE*.G7X2+J?BMMW0)^*U@L<T@<D3OS4%G*
M;J]$[@Q "MTVK8X1/M'W,';7I,.N<<.=T_WA'!=Q5CWO(D++/2(W4BP# 7V,
MB>5=DI<O C$]FC?/Y?F<?!.Z293>I4$#$E/SYVFW &Q(0?3.!6<G'S%S!:"!
M\.4A(1.V[L'&U&&5J&,=T]$-Y1E%]W*+&0^5W#?OCKB,9,I;;ZFI3%YVMC7]
MN/&*Y5=%'53G22-R EXRJK3JM1\$G-/FJD\L6=]X-7=7E)4_-B%CY'I1/OLJ
M5L[0"@^Q[MLS@/5IOL^*'\63ZNQ)H*]A;O(L8-H=$F3SBECN PB]NP#'F!B&
M\"=K<@*.2/6Z_]RE,<AIMTYT>%1G49\W.O+M\KNOZ*=D/C,29PE9[D2?U[^D
M-V^^G4&/LT Y47,%#CS\T?I[!X"0>9G/ZAF(+1#T5E4)C9QJXZ*H]JCM-S3!
MH?I/)O8KW7@G&9^? 0RB@[\4O.XHLN31E[JY11<1T=IJX(Z(VG/.VG$HMHA#
MR!;5-GVVOKVZB0G]9;.PI+4KUIE[]>#GO_&^N<0IOW;Z]3#UO9F"=YD*\9O'
MC7MG %1HX#@9?\OC>*HKC+&K(#DV5((,B57.,:0',_]PQZJ#7]<;ZXX^L[LO
M4V3\64\H.'9D(/6[S.]L6/BA"=F\AU&"\*H9D01[6NC!&]:=/<=N<UW)-VC'
MVBX6%R8GN9G4>>6>H/2A:["SJI?TWG[[N3S$J.2R-9'J!0 DM 9W\S=;4&%?
MD;7L?W6,C2F$&S7?O.R_)%*+_IA%%Y#:.YI14?BN0!SK'P1,;>,35JLWFR$C
ML3\ILM/<01KIT\>G4Z*)'%K*FR6> ;3; F?3I772 \#;QO85 3O@ZCQ@6*<I
M$10=< ;@DB&0^>S7;A WF74$[DPHS7!OR2ZTAG>J-F5O3)+ZI'LEU'F?"7DE
MJACIPC4%*.N]>+KSH8GG52[[Y$(V74HF?/$?E#4Q^U&O^MZ_.[6?.]ZY(9K;
M3I5E^Y$3\T[_[MU>?'XQR35FL6["2_ )QF[*[+% T27+7F/R,T>A.KE[0CL3
M)HQYZ8]6[EEBF3L15Z#678&Y J,PP?Q5WBOK]9E6IM%?+W/6U5S0!SXOL/A<
M<4.T,/FY:&'=^6"-2@=9GDQ9X0W"BY;,/F6''+:$!F)G9"?+A.>'0-UV_)3^
M$,)#UQZN7,GZMC]3UA\1GIOY*L:R'?&Z17>UO\;&)+NE!2?%**B Q_R\@E^0
M.:HRU0R+W,MG^H 9(\K?UA7$:IKT1,7U+J3_5RG_\O&U%..P-Q9A'DF@#;,S
M %;_VG34\G]M;R-_. E07;WGF6871)4%DO)7<_F1J3-Z&+C28)!$ZB*A[J.#
M3H:.O%CD'4"=(J?+FI[8CKLVM5P_)&RO=&JV_HAG>JX=U&]/GEJ"Q56!PJI"
MAUA/\[&5ZV%LWC+[SN.CRZB=O&[61ZQOC.E[HCY:*0SP7+ =X!,=*R5K(XE)
MS N@KC, _ZQ;<Y657#1<KJ[@[Y"3IV,S\DL]ZY/=W_U*C@^7/='%H[?DPPS^
MT+A6LVSS$NI;?L'](4R4:!IX6BFA10EJ,J)U\LR;R>Q9*DCA"<_[@9__3.59
M8#Q_MC38UV@72*V?OLZWLKV*VRR->(Y)O6/&H\MUP3&Q, 8Z^-V[)^+FWXXX
MG:S$<OBMS+FM'LL@;:QU< Y+ENF$@6<QGO9B[M0JX"3QH;Y9RU3[FQFXX1F
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M*@:M7C3HY72EV6;(*R30WX?/49GOW]>B';HG?0P!KV'43:K@)-"9#XJQ:9H
M^B[,7>0(?\@&(E]-<"JRG]5E4]R(UP>+'L9>6+P3\UD1Y>N7*W>:2Y4OAZF/
M4^4)MM(ZI"<X'0;KO5:I^_/0HF]#!T&$V+ZEF1:E0EW4'><LHQ1T5@E)<YX]
M[+I_DN\K5FC I*TQM^S,"U)@3'14247W&P?)AMU2^0<*M5_I=RH2ZKWZ$SSV
M5VDARJKE[E9&.YA1\:/2875B3AMR(3DN[S+DWS@51,(N+9B,"_,^B]#+<)OV
M]+8.$I;[7%>8\E&4,3'4U"=%?*I;GG=ZB(SIH4?8V%M"F=:6^"6Z[DY;Q\HU
MK*I,"=GH+7[-8WW^/!:GH-"1$'[Q)#D!R$; "U@\=2)Z7=(G<_RG"/]MAD5^
M"S3JDPKGU+)D__"3+?I68E:K0^'J\:LIC*6%M>50B"K6^Q\JRJA:_&_YDNZC
MHQE'D:T'][7X 64EQ2VEF6E>X,/;:$2!I/C]_O4*2.D4!I2RF_DA5!3V](_2
MJ7YWFY2&A/T5^>CEB6K_$8['!8.,)9U20"]7SO1[&1:VO&:2<DO=/L07&2.:
M9114+^TVDI)&D'6U)6=DLE&4P)P[E$^,ETZ>7W5)MQ[@%-&-5)#:G $&]_*!
M7=./!;O"KM $H>JO6L?WF"]"P4_'$8Y0.832G @.Y[[PCF=T[B:GF1#K#:'/
MBN9H<=)(I\"%!G 8 ]3D&6FQY>I560G#Z(GKCO0715\^D&K:_[E75:DSH]4'
M+FW9*CG$KMNJ(./+)$#I6QA#VB>-AF8#ZV%:NZ;[^ZT60ECD.5@J%E,0O=BE
MIDJWP?)>H*9SP2G:J@<">"V.UH6SXA2EY'BL7.2^>$JGQ910BNPHY43YZ6':
M<J]HE]56$V'.QWFB:A/.NT3X;YJ3<XWFU9@>:3W,^0HKAE53.V7%7Z3Q:42
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MO)-Z:DY]0 "1V?KN]N)X&LAOT8VUY#T!'@&)3-#'I9;ZU-\@D681&0V8YZ8
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M_W;%Z%Y;BM2Y$;&#,2Z*#_@^.K5\FL!3KAV$DE 1_@GP@%W=T?UVM@;$][6
MYKWC5_K!;IGFK$/_=.[-SLM_6__\\U;:QU3IX@D:&T6T6T HS6X"R$\XU;=)
M%:S3* LJZ9 =?*:Y^#7]<XW]@6_\L-ICB7;9O+1Z[U,(9XN<JS=Z-,YNS/?
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M/3B-OK2N"IU/$YRWR%E; 7L%SOIOVCD#$90_%HVJ-[M>L2VI0F)5TS E7I3
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MH]"C$D06!Q2FE*4PC'V2A7X>14%L=CEA YAH=271$S*+US:29U' HXBGD-%
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M!?E\!B?S0D&?K[(]B&@'0]JTJU+PF\)-*Q 4[0Y5P[<F=D 'FC3]U:0KU8Z
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M1F$0BST]\R#&6/R:)VF &4O2V A%]S3)B=?]47A(\(=DH^W)9MJF^[0N];R
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MVIM4"5M\@*_=3\Z,)^NJR8QKXN34WGQ0X46/SLJ2EY*<>/_Z"Y"41$E\H"&
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M=& +M0U$>UHT-Q.U7*"\&0T"]_NM@XD],,_=BG\A3UIHI\,C.%X5% G]%6%
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M,$_B)&593E&1IAG"J0P=2!A0E":A=$HLB-)<JYK:/:N.0X\6X9DTQX9TW9C
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MD5RI*"*%C'\CSHJ0$IP36*E>+R7')JJ00C^O-]7]@/H\#Y9+Z->07D[!BMQ
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MK=,IV$4WG.ZG#!-<#T^/OZR>%\J(P4W]>@=P;2Q5ENAA\:1*YW_Y<G_76KR
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M#5SA@WAZWFVD)]G<K=C^+J!(LE0PAFBABNX"/T.$Y42U.F<QQ;Z@3*OHKH^
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MNC<&48]7X#A,&[4(7O7:GO1P1#LDKU"[+[=Z'GB[+QI397&\H/<2;9%]A9T
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M!JS..;*8B\7'7H!WQ,FMU;<#R_.Y;VW&Z9X0\V&^7(63_V_Z]=SM<B52!*?
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M/"_[4]R\>:\#2*-+DD%V6H+B04-D10(+VG Z]M:[UJ[E_92,JR^[@V #<74
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M.>.H@#F(R[UAYM,BY#IU?=TO]>]+S+_.%Y5[JQ_G%=98;R<N!C-->#9!RI"
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M@-RE8NR;JF8(.9#!'4#DFO Z4\YG080SKD!E;2&XP, (R6/@1=KF77YW \2
MET+- +$?.[MMRW+.F:OP+LSR>C+IV6SU,:QJ#^ #O=$G/[FE1[K;-H;Q2GV1
MG%EKH6B-H((0X 1W@!)%U(67_[^];VMNZU;6?)__@AG<+R]3)=MQCJL26V5K
M>]=Y8N$J\80BO4G*B>;73X.B;A1)+9)8!*CD(8ZO6'WYNM$--+JY[E1(WTA4
M^N^8#]]C./L)OWNYYA:1#$@TQ @P'VJR-;GH8<N$W"\H%Y)A^=UIZ5F?N]+8
M5$2["T*V1[2%E=/ 9K65OZ<F?1ZG/G>5A>TV$A8H[+ZY4XS6')FH/?S@'8DX
MYL[DQP3?&AJ;BI9[ ]^ARFG\K.9W.[^9+AJS3=+&5L<'[Y8[?:7DSKD_>SV=
M[1 +<;7RB B6Q]XXAZRB&#&G+"%44BI+[RE]O,E\Y3SSSF&#_7])'\%\[.B_
MHYT./"6244>0R=/?..2CR-CLLAD5T0FB]&IQYG'.G]=2V]3.N@MJ]CJ /EQA
M#>RQ78_:/X-I7_P91S_C[Y/Q_&HVH$8Y1C5!-N5>,IA"+)$3* ?./( G"RG4
MNAA9I;6I/;=W6!ZJK!,"93:XBS\G QJLD#X:A(-S=[6+)I?E!DJY(!0;3HYQ
M';R%Q+:.P(X P7U4<VK( RC%@3=$<,TE8D:#:1D%1L8)02Q"*(UCQ#J5SCEV
M)K*M\[9CH6]G]9P8_CY.;J:#D)^I,9H?';F$."5YOE!.K3S&@CDMK#I&G?,V
M&FL7855!W\[*:;&@[X&YB\F[>&Z' 9@[2_#!!PZYIE1I 8%N$A1QBX$YJBBB
MVFM"@].$K\!OA[J^5S]?N^+J8&0=2?(GY-@&,5IMG5,HR @.VQ*69T1!Z !Q
M1-#*Y1$X?]."JZ,[LIV4T< $EJU\_6L<EJ>2,?SRE\\]WZ[SKP;$FT@$2-**
MF%_PYE-00S!2WB0+AJ33Z@BZ?A&WB="Z<TN/!;\B:FIG^M4&+@>>2A"<"DC&
M #Z<Z)1GWQD($IPW&AN(%4J?ZVT@I>YLSX*P*B'J9B\>[N?"V/&3B?!W+Z .
MN&CHL&J9BX5=R2]TD?!DFLZ+SX*7&4UF-]/X #X<O#)&"41HWNWR<VZ7+$8Q
M$<X#!%=VM0/YP3:Y$X&E!I2=Q^EP$E:?*PTX9"FPK7/DJ;*(1T:1Q58B2:VA
MV"?8]$N7FVZGJ.YU0G_8V33<K(!>&HCT[[GY=/W##J<YE%RTSXTQ"ADA W;$
M:/#"1B*CI4)*.IDT)H''TG']>DKJW@8<'U4'Z*$!-*T*Z7.<0U0XN@FPSS_(
M\J&)*S FK$E("0\A8L@/W1B(BP:OF5<!<U[:@^U"7]U+@.,AKS>=-8#'C\/Q
M< [!Y<_X0HJ_3K-]6:EIHLPBY2)'W.<&D KD&# +W.6F0+QTR=]K--7=1_M#
MPZ1'U;0-M3/O;ZYO1CE5A>QX.A_^OX4Z!]%)E836*%$307S>@)M/!(EH$O%"
M"D5+'V7L3F7=#;@%.)907SM''%L8S0-+?7(<(E6#8,^@B#NFD#8Z(.PDPY88
M:TCI37D[176WX1;PMZM:&CC:_30.,6WFZ(4(!YX(+B(G$-B:[.RM1482BIB@
M//)DJ;6E+T9WI;'NM?S1@-BKZAK8I]<&&VNXXAISQA.*>70,5X8B!_D6PCQP
MH15EA)2N8NU&6=W[^2/"L+B:FO"+KXMO@ 6+(@J&HK6Y,STD_D;E1K5@3LR[
M"+E>Z<?Q7>BJ>WU?#7@'JZ@!V#T-6[^D50X'6+IL.0')!,X;,BV++!4$?BE5
M\)'FEOB% ;>=HKI;[?&.7@KJI86=]>'H\B4OCU'%*$<5+RV*4R$X8P*B"*(1
MQU$@*P@X\JA=8IA"H%OZZ?LA]-;=A8]X.'@LG39[E?M^<GT]G"]J;.PXY Y:
MP&(<^\/>C'58M<Q5[J[D%[K*??+9L]7/OD2HRTW<);8H) S;:<K9+3<2I10=
MIA2K$$N/\=N)P(,KG2!V??S$[9GWTQL[.IN_M]/I+?SF=SNZB0/L<<*>02B!
M8VYM(#'2N;@B,>%Y8#[*XC.2.Q%6]T"Z/R2]*'0JKJ4&-N45IL[!N.&G[T=V
M>#W[?+,8B0#1*Z/ %')60P(OC4?&BHB\T)H3'TT*Q9MQO4I5W6/G:J [5#]-
M;Z.3\;?YQ/]QX+:YLDJY;7(;>86VQ5_^<S.<WSY&9@(@HBA!R:L$ 3X/R.D\
MI-AX&[#E4JC2MX_/*3BXA]7#)/N%Z-[= G!GL[MQ&\D9#M&>0D1(EN=^$\A>
M/ 2#B>HHJ,$$EW8K6\BINXD=H/<77:T*B;R!O>D;*"!F)[M@8<G08M97A)2$
M$AE1"C) RN(\LBSW/XF6: L2<J%T;=]&8NHBIYBZ5V%41/8-@.@I_<N1481'
M;1<BR3.AN20):24-$EI&;KV3W)=&STLJ*L.FC'HG167= EH6^_R"C[/E1+ @
MJ!.2,^0=R<_^J$>."XZ4H\QKK46TI4L=7U)1.<<Z4*^K,#E,R&W!Y-W]Y$"L
M?+(@ :T#R4^3)<KC E$P6"8#@3[O-F)[/YB\JSF>KW^8["/DVD]P?_G+7^7A
MQ'DK7HADR0.AQ"CO'?(0RH%<A 2H ]YE,(PRR@6.W48,;?A W8*80A@H)L$&
MG,6W&S<;AJ&=WGZS#X':8J^53CINF$%1X_R626JD8;/-&R[UVFLJ;*<9[;N$
ML9N(J>LZ>@MCB\B^!1 ]DO_97L-/+Z9V/(-D\7$2:E#,!.P9<IYBQ*VV>?10
M0-9'K2-GA,K2U[2O4U4YS"VC_E50E=5%[8WJ;'YQ%7^WTS_B_$N"SP_'E^?3
MR>747M_[6V:TR-1SGCL4\*1SXXN H@-GGEF)RG7:L5[[4F6P%%;KI"\9UP;,
MY^\?/IV=3X<_<S_0$?">$\DE'UY)I4$Z*)$\A($JC%P2&#&M*-?)TK#:\&$#
M5K9\I/)6U2-,2DFV@0WKW<UL.,[O_?U_;H:SX4([V?&"7XT^^82,]P:"-\>1
M$5P@27UN6LR,<Z5CG@VDU V4^XIX2LB]4?CDGTYC7!H9D\$J0AC"V$40$B/(
M&.;!;7),DR5>K [*[ 5(SXBJNX$547T'..VOA]H[UW?PW6-_U]#Z9YS>?AK[
MI7>E-DC.0"@.PZ[+9?)(,Q80<8K#SFPB,ZK3OK7Q$^UAXP ]3HH+M2(T9M/Y
MX&L^:%A8BT^)8JX5BC(_V^+:(R>S6#@+D4C+J.M49@.K/O$I\*M'?_+L@W6+
M64MO0_O+L@4 +'%KJ-/2.HRTU YQ^ 5$<ERC0!07.)&43*<C_RX0J.D<#E#6
MJKKWD%QEA?]N_QI>W]SG7U')1#R$[$SD:R\5@'#I)<KMB_(P(!Y4ISO!5U3^
M[*.5E;Z/RB8EY-= >/DU+M[KGMOI_/9)_C9[=_OT3Q9FP32326I(M##W(!\5
MD6/"(,R(HI8K[TGI(ISNU-6M,^\KA^E).XWA;AEW46.3,$8AS_/46\\@7'+.
M(,J5PDKFT;>E$^*75-0-3OO2]Q98[2'\VLG+^ZOI<#:?_+B*TU^';@:J&8>S
ME(:C89Z#MO3#7&,AF,((4CL+?E@P9##$W4$'9KVQ$D+Q3GE,EZ^U@YI]U#GI
M4[8-^)JG5[&_/4SRCC9J&L ;>YWR<VP?("?S!BD?A%4N:<U*=[A?2TC=YZ)]
M[5R'R[RZEWFL=/X^6<S[^G8%(AT0H5+DV"'A+8;L .<YNLDB32#T$U2R%^.K
M-SF6]1]HI\)I3[U-"@NQ 0_R8?AS&.(XS!:<#+23*B8!WC51B/&9SL^FN4(@
M$AJ=3I;YTKU?GE/03GG381@I(-_:;N+)+=CBW=/9S?QJ,AW^OQ@&P@7+:1*(
MASR7TH(G-<)Z)*6'_P?%J+.=/,7F;[13XU3 610296N(>!A9^H2?P+0P5D/,
M;IQ&/&J-;,#YECM:"-PM>,#]H+'F8W7/57O&R*'";6!S>7J/OGC(!K_(F^3L
MTVQVDQL+/<D$!SI$D9@+D.=A$)S"N2 =]E%&@&M',*:D^(./'>BK>PQ3?F/J
M33=MX>[]9#R##7BZT-37Z&/N4_#E&7/.:@*[,4%.>9DGP2>D36((@_/5V'$2
M<?$2S5T(K)M&]8J\PMII:']<#E&VE_ ;BZ?$L_S:=!"(3,Y&AJ21)O?#T$@G
M\.=2<QEE<$G0G7?']9^J._NFO[VQ@&!;\%"9E3M/^^%F42JX:"5_YX$_QS\7
M?P0"\XI%"DF"DU0A3O*46I% 8-P034TRJ7@E53?*ZHZVZ<$GE=='"RA[LJ&?
M3X?^\92"0ZX9<P6JHKD651&,+(T*)<^D,,9)SDOW-MQ(3-UY-CU@J8C4&X#/
M^73B8PRSCR"TS(X=>W"ZJ[6K@QAIDB)(I("]/.<I(F.B14PXQJP!?DGI5_[=
M*.MVWHA/!UD]**1VR+2F:.VA%\K\67AXUT#ATQ@^'&?SA7WEL_SGR<N "&Z)
M30IXST4*)!JDI:!(>*UT8,&PU3%=&P*LPH1UP^*I''[7U%IMQ#XY^ =.?\9%
M&YFOF=E!9")Z:A/"^<$B%Q CV#RYP%#-:##<J=5[_M<O4%:^T0U')W! 7E*6
M#>R56P/(1]YRSI)_/L\]%+_E)D1@/&  3AML Z2U+N3"/"P)LKF7MK8I&*,9
M\Z+T=,'#*.Z&PQ,XGZ^@P-H>;)E"?TEGEY?3Q7")\YNIO[*S>!>NVF%X=WMQ
M%?]K,@(U?KB)G^!O3N,BN/@T>S>=_!'' Y%P"$%&)+#RB)LDD:9Y+)5("MRV
M"])W>S%8@IIN:#R5FX"CZZ<V(+_&RV'NB[4X!1Q>7LUG#_PL6C "-0_#0:U6
MB@L%YB7RB':,);(^1*12,C(&)[SLML?N\-%N\#J!P_]>I=TPBB[B]'J0L%,T
M3TQA0E+$8\Q%/R:@X"PDX,PX++MYK%<^U TM)W!@7URJM1%RGW4L1!1G=P?(
MR_CSR2UKQ%1P3SEBT1!@22ED;$ZG.>9<2>,,"YV TNU[W?!R*D?U/<BX-FP>
MJD3#W8X[^_+G&'Z\&OYXO(P8:,$IH2%W@ 6I<>8HLD%9)+V5V"HA&>WV*K[+
MU[I!Y@3.W_N1;W. .9_,@8VA':WA[-]7<?SE9CZ;VT7?WV6?T#_M-,R^Q]E\
MD 05TFF'K,Z#1FB>A@X$(THD3H93;#JV6RA)53< GL"A?5U]-=RK>02@GN1M
M_V?\$'_&T>3']=W9WJ)_[6&##SJN7:JO\SZL%.KV_&5Z:<?+\2[Y7'0R&H8[
M,QF'\R<\?4D?AV,[]@"YA[Z=LX=FP0DSX8WC2%B&$1=$(I,2!%I*0W*GM:2B
M]&U=$<++]99^IL2SZ30_;KSOS?YY,O8;_OCI2Z.[RG\I7*08G *308%UVH1L
MA 09@[M@EF.M3>F6$N6YJ%M(?WQ,;VZ 7047E5\UOY_<Y.N4'_E15&Y/M'@T
MEX@B47..K".PZS@<D2$8(R<P$88E94FG-S^O/&Y>]^U6NF/7P<*DH&)J]T>(
M/Y;GC \I_BI+RT=X,N5[:"$0HWGF(B84&8$=2B3EHKR$4RS20*,K0?6>V1^N
M\TG?"JB=#7V=@(F"#?X:Q\!0]%?+MY:6)2>H,LCID+O1* B9(?5'D-#1Q)35
MBM-.B<V&#U3LO="/'B>%A=K M>D%_+TOZ8DWONO<Z:55!#)\+EV 1,XI9#&)
M"'X57336&UYZ#-9:0EIIF%MU9RNGJ@;P]E)X=KV\[CNGD$0QDR FD=M;Q>"1
M@Y_"+T.T3@8<BX^EVY'$NM%7 5"L#D3M44,- '"3*=_W'TA)A^ ]8OG2C2L-
M,02#'Z0$\^2: %>T,-ZV4U077KV"X<4L@F*:J1YQQ9]Q_.0%X7F<ILGT>E$N
MZD;#2_O0-S)B\/@@&61<[@@H<@=;9F2.&1RC3C+>L9=(YT^VTI*UZI[:HY9.
M GOW8R/ *#D68*DTY+&&FB'M<R])G8Q)*;*@23GTU4P5^U3XSIC:0_JU475^
M%<= ]8_9^VE<\/#HE;V/P2+X#[QRXN#P(Z4H4*_S%$X=5CNW;:I"6_^!UM&R
MCRHGA>7:##:^VC\_7=O+AV9.22F+F4^Y090'J7 "]@2;M[8$N]QPPZ9N_6PV
M?:%.?E@!'8=(MC8\EE=^,2S&^%Y?QVF^D<A%*,OQ#/=,:6Y%DCZ_+\XW$EPJ
MY#C/821PFM^\PV]U@DO7+]8)A8X'GUXD7QM.O]K9?#H9CN=Q-A^.[>A]EMGT
MWBYT"I8[AE2NM^7<2Z1%5,A[*<!]>G"<W5X?;?M*G:XGQX--,0G7ALKG>#.=
MS/PPMTY?DB]!%CC0!.3#;LJ)H,AYSQ'&DEK(*;%;;7*RJ;3PQ=IU&I0<#Q8'
M2K/ALY\=4L[?'HJ=@D@,&T<0U3P?]%L*WM,[1%@4ACEJB2@_L[0<_:VTQ&_B
M:+T:,)HPBKLRK'\/YU?O;V;S"80)C^\/4C I:O 6C')P]\889'$*B"CME?<X
M,ED>Y5L(JMS"LAI.7@"VE-)J[]&=MJ[O=CK,1O[L9?/9=;[2'029WSD$C0BE
M%G$//W,^3ZX5"MOHC(?(MMP9UA9**G?.K W-XVNS-G37&>%R8L.9]_''?)%G
MA1L_'R@J/-.2(\>T1ISEUQ8\@D4RQBB)R;".>4GW;U;NW]D$''O24&W@=;*R
M^W= P.#_1#^?75S9^>_V]EW\-![.%[7V@V!P<,E[1(('8R.0!1CM(HJ.\!"2
M,&*US.,0U_DZ097;B38!V1JZ;03/6UE]_)W9P"B;2&[ "M(T$-]8EJ^"$^P4
M2F N3."IZT/2G3Y<N05I2_CL15<-9$.=S&^@N?#>@_2T4 [QB URBBBDO<">
M.*FD886SHDZ$5>Y46AN@_2FQ 61N3?G>WTRSA@;$$B(<4XA8E_L$)X:,Y P2
M0<TE%L('6KY\Z76Z*O=";067Q578[//%NXDO=A;SO=./"')<[ ^Y>.SN%>#>
MCQ<[KESFZ>(^;!1ZN)A'O8XFLYOI79O=AX\O)S*]G\SFLT5O))?).[>WSU]W
M"2V,XBXA(9W+C5(#TI ](^RL-S1!:&A*][,ZC.)R3Q47WWBAM*=V_^[V\>\L
MZ5B\'[X[2%:!07PL-4HTBCR"*D$F:"1BDOI<OL^U*[VY%R.^[O'H$3&[^47B
M,=7?0%AP/K+CAW=/Q J"<9(HF$ 1=[DL)'&#&+>*!$F=$;(P=)]^OY6'B$>%
MP&J+V'WUT1"6EC?%PFH?F!+():T0Q\J@W <4<2M"@APNBE!Z%M5S"NKB:7]-
M;H#$'F*M?3)S!AHB]RUD<_\-B'HR._=U0RGA$)F&"#4LROW!8_. D<TCE7 T
M&&+D3@<QV[_3!@[V4=^D'UDVX"ONW"7\Y85YJ!2IY"$B$9W,_8/!8P)#R%$L
M+=>8X]6GI(<_TWI*0"L/!6ON//MKI $X[2^X1[;'8<54.?4A6980Y@("RA <
MLC)JD*87C&LML"S>:Z0'/BH_ =L?5NOF,M34<0,X_^7ZQVAR&^/B9.'+CR<5
M_\%J00.%=$=(V%=8X,@:;1'UC$E@A&)3>OS:1F(J!_+5<3+I0VE[H^]GG+I)
ML?L-2+:''K+Q!3/_&@_GLZ_?_K5D1P6%J< !.>%RWPS.D*&6H\ 9]9(KQT/I
MU]9;":J\K;>&PW+*:\ 3KC"S9,+I8$V$P)HLJGX24\CJ_(K8.0B K(==1O>+
MP)I/0TX%>7LHJP'$O2K534)]O/W11A P+(HBYQAQ*3DR!H+T&&12GGHN5>D\
MYW"J6WGQ73,Y.K+N3QGMST<#G?VTPU$6_\?)]%?XM_.!B$99CG-+^@1^Q$L*
M5D_S004X$>NM,Z1T<Z"^>&D\SBV,R5(F41(@IVPHBQ^^+Q[)+8?5D $C%AL"
M^;%E4>7.<QAI3P@BCB;"0K#,E[Z!*4E_XP%WHP9Q*!!:,0+W.N]NE?=?_OHQ
MO*O@O^-\X'!B)!>L")'GAGEJD8MYJ!S&W'FF!?>]; \EB&\\ZC\"_(\.@5:P
MOX_<[XZ"9HM=;_9IR?V_8Q[2$L/9SSBUEW'QAQ_L/'ZTP^EW.[J) ZM=Q +D
M02-/B,-VB4RB"JGH)6R6WH.P6MDC]F.Q\N/2!NRH43@U8&T/AZEQ^G/HXWII
M?<XS_F:9[<5<AXO)W(Z>_GDN)?H\F?]WG'^-?G(YSCTMGIS.SL %V:0X];E1
M'$,\:<@5%::(&>,9SM/#5X=VE#M-[Y.QND\0*EM6>]!YR_9TYW\@JUO^5OY[
M9*"DH]P3CQ@X'= ?\\B2W/R!&I)LDE;:TB=@Q^6P[AN*MVIAAX.I 5/;6SGW
M53^S^?1F<=#Y97X5IQ=7=KQT.M\7\KS?\Q<2?;+!.V8A8?0HI"1R-U^+#-:0
M62I,% @J1E_Z9K@.IW6?B9QJV'@\<#5@@OV%  \KW?VC52$.B(B4VP!A <N-
MKU1^.,:9@K# &XJ%MIJ7OANOQFPG0^QMNN%;W0.+0NS$GGY]N[F^MM/;R=W(
MP!>G3+_\E7\:#YEJ5^2[?3X;.T0$C3PJ UGK&!@B*N3,*&KD<! (:ZZ2YX)0
M$0J[P%8>E75R"F>CQ9+#/'IM-?1=4'IWCQV)(T('@CR8->+">.0$LTAAY940
M@6M<6HR],'+:C\UVP/+FQV:U8-% )/9I#/XN/@P6_&W)XJ)*V$<AM#,.@+@8
MP:HL;&2.H<"D<E@'Q3TOC/ MY+3R+*T:6";]:*Y=$-X_U?%@S1X[I(V!*- E
MBYQC'C&<"(\XIA?]Q_N"80N%_,74W@U.>^B@ 4!E$_N2OMG10ZMUYA(WBFM$
M0L@3XA)&D!8[I*P2P6+"Y6K'X (M-5:(:!(X^RCX14.,0Z3= %R^@B: @*NS
M<7@RV7H9RB]9HDQY$JS*#T;!58.I(4<@(2718FRBMV!DY4N:7R.K;J5/?Y J
MK9$&0)9'3$[M"#@Z"]?#\3!'L/GQZ'.F@J4._#1!RN=2"\H3<LSDP:=@.4(I
MP8N7)G<BK&Y-37] *Z^5!J!6)D1]/(>+20B3Q1J(-(@SSY%.5B.<VQAA'Y7V
MI2.PPBRT\K*XE>2A)D(:,) E9T\/<]<<X@T$SJ?/EB,7X0?.(:#1C'/DA<8B
M&!\\*;WG=Z.L;B19%3RKS^7+:_+4SN27SF627M9U/EZVW%U.G'G8VX;SV_('
M] <0T>MI?2GAM'%T'R75$B)=I'@"&*?<WMJF@**,G'B;7V6\L:/[ ZLPO]S,
M9W,[#L/QY=?):/1Q,LU_.."0&_ D"0C.AGQ/)Y )BB)!8\2&$QE)\>9PO7!R
MTH?WNZ"Y='EN 6 T$,<4E,+=<[ !I])3KS4BDCK$%615SAF-HG+1,0(_E:7K
M(XHS<:+O 0LBLS]CV0,F>]O)CT6P"%G_=-Z$M3POZ?]U.IG-!IH$:[EV2 6G
MP(?E]M,Z2$1H",QII2%Z;<Q>UK!QH@\&V[680Z'21)>90X4 BDAQ.(?PX$$2
M RR=]CPHI+1EX#A(0":"]_#1!DHY#S@6KYHHS\:)OC!LUUX.A<KN]F+N[&4<
M+W.H>E$N),MYZ*?9[":&#S?3AZ?$=Z_LG[Y0^>6O/,@7Q#$0,@E)"4=4J!P'
M:X*<B!9AF8^N.>?"%H^Y=J;R1!\#]@CY?A7=$**+1X]2,)Q<(HC&N_%P"FEF
M,'(Q!HJ=C5RT%C3MEV2T]X2OW2W@,)@<F&3\,@Y-V,K25^3[G:40,+$F6661
ME_EQE4L,695G-7O- H]>IN8"IA=,U$TO3OB4ZC XO*T#JI4G]/>[ZOETZ&/V
M86GIPZ+DV!O!$#8>PD9'*&RR(2(29-3$^,!8,\W=]N:R;@)RPA;5,Z#^/B8W
M<$(2985&P8$[XC(WN=<,').#4#2Q8$3QZ7E'8NW-G!_W@O Z!KD3W$[GQ'EC
MK\PN762>"TAB%T5P. _FS&\/G8/(P$KXP1$K/<,A'OU]>3GVWLP)=1,V60EV
MI[ [OB::-2>56^6#J9,@$(UHLN"WF.0@&I:0ILPZ9ZT-M/0(OV/S^&9.PT_"
M-OL$X%LPT'ONNTF',LV%X0$1EB\9>)Y6J$&5VA,N$DB,\J.W02[*X9LYMS\)
MX^P/?*=@FH5"?8*M"C2!!D6*B.O<S(9ZAYR5S@NM0N#J#6>6IW!IT(0Q5H#;
MV[MFV.Z@""&6.0;!@DF(4X^S5$B>9AB"U)C&>/3@M0QK=;?%$SY [0,ZK>QM
M+[KY=&B;_:JS^1KS(T7X_?>3\4)]-W9T$:?7=!"L-9PGCX1D%''K*-(L.40X
MQ 1.2DQ)Z6=U%=BLN^?5MK2&(?4&K&ZS,]HD(C+ VDN1B$98JSR?W@BD3619
MKSZJQ 0I7VUU?#;K]K\]8:OK&U*M6%V9P/H32&(XG@W]71O2F 3E6DHDF3*(
M&T:02RDWH'&441XH-0T7=CUGIFX;V]H65!T>;\!.7AP&+?J+KLB$1^,%#R $
MG/O4!RV0<5XBH9AA#%NF<&MC1+KP5;?W[ E;3W'0M&)(9?;DYX(@ ^J5CS:K
M*O&(.&,66>X#$MAB;BR+4O1R0M$+-YV,QKQ5HZD/D#?4^2$+Y^DCA"R-.Z'.
M9C?7B]\[:A.('>BIU0]B7Y&UT1I"\4@)R\]*#"'Y%%LCIS"8'XU>6D"ZP*73
MVE:Z.N]_:W?72(F$Q#$V"OE$$G@N:V W91)Q;@UG-%KLBE<,ER+^I!M [(+9
MS=V;CZG^!H*IQ]GPN>5K'AFG L%($ZXA$@3IN2@=PI(2H7UDFI:^*WU&0"M=
MF8\*@M4>5'MKI $X[2^X1[;'X7QDQY_M=5QV9*0RB43!II65^4I5&N1RIN(8
M3M(D;P+KY6:C,!]UP7T K(J5M132<0,X?VA:]QCA+9M[ZOR>G"2&<D-%Q+&-
M2&,'V4M(U#H;B%.E7>A&8AI_>M [3C:UJ3Q(:0V@;^]3H=\>NB1*FH@#62%"
M! :."<@Q@"L0(<:8_W.B]"S4PZENI>]JS?#@R+IO!>W['.<\#+1[3+EGN86G
MOVMH<$T&5A+B@%\4O8=M4&N';/ >@7*$\)1*7SS-[8^;QKU]85R6.O,K"Y)6
MS&4?16R3Q/<)I.##T7!^^Q52\=PL'X)'HI#3DN94FR-K64(1\V"4%=05;^%]
M!+9.]%5800-J"#9OU9(^#'\.0QR'A4! 5U:D7,9L\] )(AC*G7N0P2$7[$.L
M6_R\I7>F3O3]5L-6M#=DWIH-?1W._O@XC?E6+@*NY@N!6.^X$2F@Y ELSQ%'
M$(VW2%'A6=)6PU[=L@VM8^I$GUDU:$,'0^9D;W&_?OO7$1KTK_G*<6Y<7V.O
MD7M4+)@TQN2I*A'L(%"D \4H$1.$%TS14+J$\:W<H\;(F24$\BR219<T!(M@
MI4A8QH-2VA!)2OOU?^Y1=\1L?_>HNZB_@3AGY7HE24M%E,@"Q! W!L(U!RD/
M8TH2A[F(OK39O\E[U)U L/T>=0>-- "G7NY.K(HFYJ9'P"S(@!J.'*,>40VR
MI#9*RXZ>;9[Z/>HNL#K&/>HN.FX YU\A))\.<Y*[B/>6UW$DUR-+$9!,^0TU
M(0PY!?+5$C())2RAUA4&ZEI"&C]1[QT?+\>H'JBL!A!7(+GU,?%H=(*]2+@\
M_LTA$XA%-"85O)!<AF9.'-[<W>DA(<&1=7_*:/\\&=]52/SRGQM(L3^-P?1O
M%NK9T.P[3ZV-##P ['L*=D*ND#$BHN =)5*#HE3Q=.U8S#6^#Q1&;2FCZ15"
MIVQ;+^4QOXK3BRN[E-<,)/<3]MH8EFVZ;<0^,0@K<58:=U+ESDX:14J"](IZ
M;9JY)MJ5N1.UK7[!7<H$>T7:Z?3%W5L\SSN7#B1)0>:P0] \I\[GJEEG$F+8
M0"(8#'6DF3UN1]Y.M/;AC9CA 3A[TQOA]X5O>I +I5Y2[@A* ?+6/)\BS_ 2
M\,N8/#:,<-E,XK4C;R=:-?%&[.\ G+V!R5JOBF?9)/B)A'00(=) 4!#"(XZ-
M14;XG%IHR"ZH#"$V,ZYA=_9.M/SBC1CC86C[.]CC:M3NL28L]_MU6C"(%ZA%
MVBN#M#,B*.R)\:7/R]O*#]MK<OM&;/$0I)UZ=]ONPEEI[;:(YC^ ,WDH2'NJ
M:,*4TIA39!B&X((*C(P6D&<;12AQ 0?;3!?<?D1PHKEFY>/4!N#XIG/-[N(;
M2)>LT DC[Q:^6F$0ES-($$N=-D(:>?0Q#T?@^T2/:ELPG :=P$XH_MN=];XN
M/D.=C"%H1'.8QA63R$E!4#*!V^BM).E4#X/+>(+V=O"_E2?H$\]O.A!X?ACX
MNN"<IEX)H9%/7B N<S6@T/G5BTD0&Q*FQ>E$ SLR?Z+'UG\K1] GGM^T(W@R
M&^]UJ25+B0Z6HLBIA9PP!*2)9(@QA[FBDBA^](&I1^'\1 _+_U8NH#<DOVG[
MWR&7BH&:(+!&5@OPF9@&Y(B1"$OCN$Y)&M]+(YE3.!%H[W#^;V7[/:&XZ.E^
MZ;?1G\;PTWAA_XJS ]X^KUFES-OFU\@K]';YX3./#T(?'GD&(Y2ATB*L6#["
M)AZY1!V2WIGD%-5,E.[@LX6<0_> AZ5SRXSQ++Z+XYB&\X'040F:>\U *HNX
MB+FO'X44EVKJ?)#6I-*]F#>04O?LM!025KU6";DW$$)\C"#^/!9C+3=Y0--P
M?#,<7WX!W[70V6R@N08WH13R(5\!4:J0]9ZA1 -64DL1?>FD?W<JZQ[3]06Z
MGK75;,./SW'^VV0V@S1^$0D\ML* F&#H[3A\&(YN\E7]W=_[L?Q[!VR !WZQ
MS&99DNU"&^LO=IHGMSW0] #K9(SU. KDE:;Y2D4B+75 4=- @]74%G_WOXF6
M0WTBB//.PK)0!Y1A$22)R$& "%Z=8V0Q@1^,EM%31Z4HS=@S NINGT7TO>K&
M]A?PWAX* G\W*;1GKF03=_5!R^>=3VN<%E8Z2"DZGX)')+H\OS>/,PS4(ZE\
M[@>E=>"EM\N="*R[4_:"K_X4U$#$MH&YY5;P@L>!8S:(W&K2:"L1EY0@'65^
M5A$P542R0/AQ\+>)Q+HW*<=$8!$E-8#!59G=&1*-DG#"%%*+J@K@"+GH&!(F
M$K Q@@4I/8%Q+2%UC^5[P=/A F\0-4MK&&!EM"8V /@A6^92:\"]5B@Q(P)-
M$EL=>L;-DI2ZA[I'0<X^0C^]O/ ,,N&0.1W^C-_ROQO.AW'VRU]^= ,Y4!9]
M/FN^N2-ADE;6Z2-O+$-1SWEE#V+K.^_$@7&FHD5@). #E00<^_QX0"5!DV&I
M_-RNOO+.QTXQV_7P\;D>OJ15@N[:Q5#&.$\,HT!4'G3D/'(4.Z1DU)8X[)4J
M?BU?E(-&,]]=$+>Y2>315=Q  ' @S^]NUR^P:$?G'>/&>XLDA4V-<\F15K!1
M&F&D2%(E4K[O9'_LM-+%\O@H76UEV0ADFK6>)PWN#%7<YIMK2S1!7'"-M!4!
M)2T91(_"$E7Z9?)K-%5N6-D*>#J!>D]--H#,S=/EO%,YGPA(Y.:(/%*)')&0
MO@0NG)2*]7 DT.9(P+(Z[SS>;Q<%5$123J0&%Q&,<79V.8V+LI\E!S0)HDCT
M"&N6.3"P>YCH$),Q2!U98M2\EI5M7K[NZ7<OH"@DRP;\RH'^^[>'5ZLA.AF=
M)\A8I;(8#7)@&"BZ().)ANA4NN2G%.VM-"\]]4AP/S"<OA&<74]NQO.!I$$K
MX Y!IFH09XXBG03DL)A*'*5+297>B(L0WN*FW3?FR@)_#P T>][[4*_[>[2Y
MJ&I1]7LVF\7YS([#;T/K\L0]D,[RST.>_ &K3)>7O8>4Q!;[=IDSW'Y$4>BT
M]H&XQ_JWQR$K7&(;>$@H1 VVP' > >PX"A@G(AS!RI9V1=OH.;B"\G[M=[?O
M[,B.??QV%>/\U^GDY@?(^F[C,UIZDA38/Y$8LD4AD,ZCMATWSIJ4*#>EK[BZ
MT%77NQ9#R8LRR=(J:2 ,>,+3$XO_.(W_N8EC?[LXDXC,Y ZV$%[QE)MG"HHL
M\QQ%ZB1AS LF2I=Z=""K$9 5P\)FL!513$M86\?0,C/U1H -BHA(SD>YL1#*
M.Q<0-H11KYQ@U/:%M<UD-8.U,E#8!+5">FD4:K.'0&5Y;&'SZ80R&$6(HW-3
M4H^LY2$WG4J."V:$+-WDKPM=C8"M%!@Z@.T@S;2$MG>W#S_]KV&< E%7M[_%
MGW&TL%$M!.=>,^2CLXBKR&%C4!:YH$VD F(15_HBI1ME=0^#CKF5EE)/2Z![
M:D@O^5N:;,*1&$L]PM0MQA PV!]4 N:B(T$+8XHWVM^)P$:<7D&$=/%[1=35
M$A8_C7_<S&<+B9&E+W=&:Q:(0P[GEB<Q, 1RC"B/7%<B.6U2Z1;S6\AI!&?E
M0; );@=JI%%PT24K06/E#:$H>0A"P#AM[BN?V^YAXS5)7)C>TH67Y#2RCU8!
MUSX::11<;,F*X5(JB1D2$J3#>7Y!I@B#G,HR'*A)RI>N=-Q"3MWG+'7!M8]&
M&@#7>SN[.AN'_+_<5.2G'2U.TW,H(9.4F#"+DC+Y/3_D.DX(@GCBRG/!L9.E
MKXXW4],(M/J*_PNIH0% /<Z+7<_3^M]=&H_BG*K #6(A/TB$U9&C+"&9.^PH
M2DBPI5. 0^BM&ZF5PLS&@;\]*[ !L/X^&<?;W^WTCSC_>#,.]UQX8PU$ A(I
MJB3BN36J]BHBFR?/>F$<_%@8ANLIJ0NPXR%A4EPM#8#K<=-8LV5\'([A]X9V
M] WTN0A5WMN[UEV/I1.8ZAB986#%$4*)O+58#PD]$91&K[4BMG0CHT-IKOL
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M:6)I=#,Q,BUQ,#$R-"YH=&U02P$"% ,4    " !V@:E86\;$)G\#  !5#
M%               @ %=?@  97AH:6)I=#,R,2UQ,#$R-"YH=&U02P$"% ,4
M    " !V@:E8GLQGNC0- 0#R8 P $0              @ $.@@  <GAR>"TR
M,#(T,#,S,2YH=&U02P$"% ,4    " !V@:E8T94_8IL0  "VK@  $0
M        @ %QCP$ <GAR>"TR,#(T,#,S,2YX<V102P$"% ,4    " !V@:E8
M]<Y!TN(=  "<, $ %0              @ $[H $ <GAR>"TR,#(T,#,S,5]C
M86PN>&UL4$L! A0#%     @ =H&I6,"M!&_^4   TY$# !4
M ( !4+X! ')X<G@M,C R-# S,S%?9&5F+GAM;%!+ 0(4 Q0    ( ':!J5C,
MO6(WR&<! -A\ 0 4              "  8$/ @!R>')X+3(P,C0P,S,Q7V<Q
M+FIP9U!+ 0(4 Q0    ( ':!J5BZQ-5V=- " '=S P 4              "
M 7MW P!R>')X+3(P,C0P,S,Q7V<R+FIP9U!+ 0(4 Q0    ( ':!J5A)9'?T
MS.0  %4]"0 5              "  2%(!@!R>')X+3(P,C0P,S,Q7VQA8BYX
M;6Q02P$"% ,4    " !V@:E8C7\:?IJ&   Q6 8 %0              @ $@
M+0< <GAR>"TR,#(T,#,S,5]P<F4N>&UL4$L%!@     -  T ; ,  .VS!P
!  $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>rxrx-20240331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:rxrx="http://www.recursion.com/20240331"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="rxrx-20240331.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-30</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-30</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rxrx:ExchangeableStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rxrx:ExchangeableStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rxrx:TempusLabsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rxrx:TempusLabsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rxrx:TempusLabsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">rxrx:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">rxrx:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AssetUnderConstructionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AssetUnderConstructionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">rxrx:BioHiveSupercomputerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rxrx:Station41LeaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rxrx:Station41LeaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rxrx:Station41LeaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rxrx:ValenceDiscoveryIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-16</startDate>
            <endDate>2023-05-16</endDate>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rxrx:ValenceDiscoveryIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rxrx:ExchangeableStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-16</startDate>
            <endDate>2023-05-16</endDate>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rxrx:ValenceDiscoveryIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-16</startDate>
            <endDate>2023-05-16</endDate>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rxrx:ValenceDiscoveryIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-16</startDate>
            <endDate>2023-05-16</endDate>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rxrx:ValenceDiscoveryIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-16</startDate>
            <endDate>2023-05-16</endDate>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rxrx:ValenceDiscoveryIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-16</instant>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rxrx:ValenceDiscoveryIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-16</instant>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rxrx:ValenceDiscoveryIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rxrx:CyclicaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-25</startDate>
            <endDate>2023-05-25</endDate>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rxrx:CyclicaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-25</startDate>
            <endDate>2023-05-25</endDate>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rxrx:CyclicaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-31</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rxrx:CyclicaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-25</startDate>
            <endDate>2023-05-25</endDate>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rxrx:CyclicaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-25</startDate>
            <endDate>2023-05-25</endDate>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rxrx:CyclicaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-25</instant>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rxrx:CyclicaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-25</instant>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rxrx:CyclicaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rxrx:RecursionValenceAndCyclicaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rxrx:LeaseDescriptionAxis">rxrx:LondonLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rxrx:LeaseDescriptionAxis">rxrx:LondonLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rxrx:LeaseDescriptionAxis">rxrx:DataCenterLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-01</startDate>
            <endDate>2024-02-29</endDate>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rxrx:LeaseDescriptionAxis">rxrx:DataCenterLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-29</instant>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
        </entity>
        <period>
            <instant>2023-10-27</instant>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rxrx:AtTheMarketOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-31</endDate>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rxrx:AtTheMarketOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rxrx:AtTheMarketOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rxrx:NVDIAPrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-07-31</endDate>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-31</instant>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-07-31</endDate>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-16</instant>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rxrx:ExchangeableStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rxrx:NVDIAPrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-31</instant>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rxrx:NVDIAPrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-31</instant>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rxrx:NVDIAPrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rxrx:ValenceDiscoveryIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">rxrx:ChristopherGibsonAndAffiliatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rxrx:RocheAndGenentechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rxrx:RocheAndGenentechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rxrx:RevenueRemainingPerformanceObligationAxis">rxrx:PhenomapsCreationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rxrx:RocheAndGenentechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rxrx:RevenueRemainingPerformanceObligationAxis">rxrx:PhenomapsRawImagesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rxrx:RocheAndGenentechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rxrx:RevenueRemainingPerformanceObligationAxis">rxrx:DevelopedAndCommercializedProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rxrx:RocheAndGenentechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rxrx:RocheAndGenentechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rxrx:RevenueRemainingPerformanceObligationAxis">rxrx:GastrointestinalCancerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rxrx:RocheAndGenentechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rxrx:RevenueRemainingPerformanceObligationAxis">rxrx:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rxrx:A2021EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">rxrx:TempusAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">rxrx:TempusAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">rxrx:TerryAnnBurrellMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">rxrx:TerryAnnBurrellMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">rxrx:TinaMarriottMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">rxrx:TinaMarriottMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">rxrx:MichaelSecoraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">rxrx:MichaelSecoraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="claim">
        <measure>rxrx:claim</measure>
    </unit>
    <unit id="vote">
        <measure>rxrx:vote</measure>
    </unit>
    <unit id="class">
        <measure>rxrx:class</measure>
    </unit>
    <unit id="phenomap">
        <measure>rxrx:phenomap</measure>
    </unit>
    <unit id="program">
        <measure>rxrx:program</measure>
    </unit>
    <unit id="performance_obligation">
        <measure>rxrx:performance_obligation</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-26">0001601830</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-27">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-28">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-29">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-30">--12-31</dei:CurrentFiscalYearEndDate>
    <rxrx:LicenseAgreementTradingPeriodUsedForEquityValueDetermination contextRef="c-37" id="f-250">P7D</rxrx:LicenseAgreementTradingPeriodUsedForEquityValueDetermination>
    <us-gaap:ImpairmentOfLeasehold contextRef="c-1" decimals="INF" id="f-301" unitRef="usd">0</us-gaap:ImpairmentOfLeasehold>
    <ecd:TrdArrDuration contextRef="c-145" id="f-604">P455D</ecd:TrdArrDuration>
    <ecd:TrdArrDuration contextRef="c-147" id="f-605">P483D</ecd:TrdArrDuration>
    <ecd:TrdArrDuration contextRef="c-149" id="f-606">P466D</ecd:TrdArrDuration>
    <dei:DocumentType contextRef="c-1" id="f-1">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="c-1" id="f-2">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2024-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-4">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-40323</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-6">RECURSION PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-7">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-8">46-4099738</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-9">41 S Rio Grande Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-10">Salt Lake City,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-11">UT</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-12">84101</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-13">385</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-14">269 - 0203</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-15">Class A Common Stock, par value $0.00001</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-16">RXRX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-17">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-18">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-19">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-20">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-21">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-22">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="c-1" id="f-23">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-2" decimals="INF" id="f-24" unitRef="shares">230273797</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-25" unitRef="shares">7389871</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-3" id="f-31" unitRef="usd">296326000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-5" decimals="-3" id="f-32" unitRef="usd">391565000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent contextRef="c-4" decimals="-3" id="f-33" unitRef="usd">3195000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent contextRef="c-5" decimals="-3" id="f-34" unitRef="usd">3231000</us-gaap:RestrictedCashCurrent>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c-4" decimals="-3" id="f-35" unitRef="usd">2599000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c-5" decimals="-3" id="f-36" unitRef="usd">3094000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c-4" decimals="-3" id="f-37" unitRef="usd">41495000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c-5" decimals="-3" id="f-38" unitRef="usd">40247000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-4" decimals="-3" id="f-39" unitRef="usd">343615000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-5" decimals="-3" id="f-40" unitRef="usd">438137000</us-gaap:AssetsCurrent>
    <us-gaap:RestrictedCashNoncurrent contextRef="c-4" decimals="-3" id="f-41" unitRef="usd">6629000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent contextRef="c-5" decimals="-3" id="f-42" unitRef="usd">6629000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-43" unitRef="usd">86716000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-5" decimals="-3" id="f-44" unitRef="usd">86510000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-4" decimals="-3" id="f-45" unitRef="usd">35501000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-5" decimals="-3" id="f-46" unitRef="usd">33663000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-4" decimals="-3" id="f-47" unitRef="usd">33076000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-5" decimals="-3" id="f-48" unitRef="usd">36443000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill contextRef="c-4" decimals="-3" id="f-49" unitRef="usd">52056000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-5" decimals="-3" id="f-50" unitRef="usd">52056000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-4" decimals="-3" id="f-51" unitRef="usd">254000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-5" decimals="-3" id="f-52" unitRef="usd">261000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-4" decimals="-3" id="f-53" unitRef="usd">557847000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-5" decimals="-3" id="f-54" unitRef="usd">653699000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-4" decimals="-3" id="f-55" unitRef="usd">5115000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-5" decimals="-3" id="f-56" unitRef="usd">3953000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-57" unitRef="usd">26070000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-58" unitRef="usd">46635000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-4" decimals="-3" id="f-59" unitRef="usd">36618000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-5" decimals="-3" id="f-60" unitRef="usd">36426000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:NotesPayableCurrent contextRef="c-4" decimals="-3" id="f-61" unitRef="usd">55000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="c-5" decimals="-3" id="f-62" unitRef="usd">41000</us-gaap:NotesPayableCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-4" decimals="-3" id="f-63" unitRef="usd">6062000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-5" decimals="-3" id="f-64" unitRef="usd">6116000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-65" unitRef="usd">73920000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-66" unitRef="usd">93171000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-67" unitRef="usd">37391000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-5" decimals="-3" id="f-68" unitRef="usd">51238000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:LongTermNotesPayable contextRef="c-4" decimals="-3" id="f-69" unitRef="usd">1071000</us-gaap:LongTermNotesPayable>
    <us-gaap:LongTermNotesPayable contextRef="c-5" decimals="-3" id="f-70" unitRef="usd">1101000</us-gaap:LongTermNotesPayable>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-71" unitRef="usd">43786000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-5" decimals="-3" id="f-72" unitRef="usd">43414000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="c-4" decimals="-3" id="f-73" unitRef="usd">528000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="c-5" decimals="-3" id="f-74" unitRef="usd">1339000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:Liabilities contextRef="c-4" decimals="-3" id="f-75" unitRef="usd">156696000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-5" decimals="-3" id="f-76" unitRef="usd">190263000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-4" id="f-77" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-5" id="f-78" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-79"
      unitRef="usdPerShare">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-5"
      decimals="INF"
      id="f-80"
      unitRef="usdPerShare">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-4" decimals="INF" id="f-81" unitRef="shares">2000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-5" decimals="INF" id="f-82" unitRef="shares">2000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-6" decimals="INF" id="f-83" unitRef="shares">1989032117</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-7" decimals="INF" id="f-84" unitRef="shares">1989032117</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-8" decimals="INF" id="f-85" unitRef="shares">10967883</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-9" decimals="INF" id="f-86" unitRef="shares">10967883</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c-4" decimals="INF" id="f-87" unitRef="shares">237508682</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-4" decimals="INF" id="f-88" unitRef="shares">237508682</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-6" decimals="INF" id="f-89" unitRef="shares">230043061</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-6" decimals="INF" id="f-90" unitRef="shares">230043061</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="c-8" decimals="INF" id="f-91" unitRef="shares">7464871</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-8" decimals="INF" id="f-92" unitRef="shares">7464871</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-10" decimals="INF" id="f-93" unitRef="shares">750</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-10" decimals="INF" id="f-94" unitRef="shares">750</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-5" decimals="INF" id="f-95" unitRef="shares">234270384</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-5" decimals="INF" id="f-96" unitRef="shares">234270384</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-7" decimals="INF" id="f-97" unitRef="shares">226264764</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-7" decimals="INF" id="f-98" unitRef="shares">226264764</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-9" decimals="INF" id="f-99" unitRef="shares">7544871</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-9" decimals="INF" id="f-100" unitRef="shares">7544871</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="c-11"
      decimals="INF"
      id="f-101"
      unitRef="shares">460749</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-11"
      decimals="INF"
      id="f-102"
      unitRef="shares">460749</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c-4" decimals="-3" id="f-103" unitRef="usd">2000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-5" decimals="-3" id="f-104" unitRef="usd">2000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c-4" decimals="-3" id="f-105" unitRef="usd">1460144000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c-5" decimals="-3" id="f-106" unitRef="usd">1431056000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-4" decimals="-3" id="f-107" unitRef="usd">-1058995000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-5" decimals="-3" id="f-108" unitRef="usd">-967622000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-109" unitRef="usd">401151000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-5" decimals="-3" id="f-110" unitRef="usd">463436000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-4" decimals="-3" id="f-111" unitRef="usd">557847000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-5" decimals="-3" id="f-112" unitRef="usd">653699000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-12" decimals="-3" id="f-113" unitRef="usd">13491000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-13" decimals="-3" id="f-114" unitRef="usd">12134000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-14" decimals="-3" id="f-115" unitRef="usd">303000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-15" decimals="-3" id="f-116" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-3" id="f-117" unitRef="usd">13794000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-16" decimals="-3" id="f-118" unitRef="usd">12134000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-1" decimals="-3" id="f-119" unitRef="usd">11166000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-16" decimals="-3" id="f-120" unitRef="usd">12448000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-3" id="f-121" unitRef="usd">67560000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-16" decimals="-3" id="f-122" unitRef="usd">46677000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-123" unitRef="usd">31408000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-16" decimals="-3" id="f-124" unitRef="usd">22874000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses contextRef="c-1" decimals="-3" id="f-125" unitRef="usd">110134000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c-16" decimals="-3" id="f-126" unitRef="usd">81999000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-127" unitRef="usd">-96340000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-16" decimals="-3" id="f-128" unitRef="usd">-69865000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-129" unitRef="usd">4188000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-16" decimals="-3" id="f-130" unitRef="usd">4538000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-131" unitRef="usd">-92152000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-16" decimals="-3" id="f-132" unitRef="usd">-65327000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-133" unitRef="usd">-779000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-16" decimals="-3" id="f-134" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-135" unitRef="usd">-91373000</us-gaap:NetIncomeLoss>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="-3" id="f-136" unitRef="usd">-91373000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-16" decimals="-3" id="f-137" unitRef="usd">-65327000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c-16" decimals="-3" id="f-138" unitRef="usd">-65327000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-139"
      unitRef="usdPerShare">-0.39</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-140"
      unitRef="usdPerShare">-0.39</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-16"
      decimals="2"
      id="f-141"
      unitRef="usdPerShare">-0.34</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-16"
      decimals="2"
      id="f-142"
      unitRef="usdPerShare">-0.34</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="0" id="f-143" unitRef="shares">236019349</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="0" id="f-144" unitRef="shares">236019349</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-16" decimals="0" id="f-145" unitRef="shares">191618238</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-16" decimals="0" id="f-146" unitRef="shares">191618238</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-17"
      decimals="INF"
      id="f-147"
      unitRef="shares">234270384</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-17" decimals="-3" id="f-148" unitRef="usd">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-18" decimals="-3" id="f-149" unitRef="usd">1431056000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-19" decimals="-3" id="f-150" unitRef="usd">-967622000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-5" decimals="-3" id="f-151" unitRef="usd">463436000</us-gaap:StockholdersEquity>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-20" decimals="-3" id="f-152" unitRef="usd">-91373000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="-3" id="f-153" unitRef="usd">-91373000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-21"
      decimals="INF"
      id="f-154"
      unitRef="shares">2317083</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-22" decimals="-3" id="f-155" unitRef="usd">2088000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-1" decimals="-3" id="f-156" unitRef="usd">2088000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-22" decimals="-3" id="f-157" unitRef="usd">16127000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-1" decimals="-3" id="f-158" unitRef="usd">16127000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-21"
      decimals="INF"
      id="f-159"
      unitRef="shares">921215</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-22" decimals="-3" id="f-160" unitRef="usd">10873000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-1" decimals="-3" id="f-161" unitRef="usd">10873000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-23"
      decimals="INF"
      id="f-162"
      unitRef="shares">237508682</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-23" decimals="-3" id="f-163" unitRef="usd">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-24" decimals="-3" id="f-164" unitRef="usd">1460144000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-25" decimals="-3" id="f-165" unitRef="usd">-1058995000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-166" unitRef="usd">401151000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-26"
      decimals="INF"
      id="f-167"
      unitRef="shares">191022864</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-26" decimals="-3" id="f-168" unitRef="usd">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-27" decimals="-3" id="f-169" unitRef="usd">1125360000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-28" decimals="-3" id="f-170" unitRef="usd">-639556000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-29" decimals="-3" id="f-171" unitRef="usd">485806000</us-gaap:StockholdersEquity>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-30" decimals="-3" id="f-172" unitRef="usd">-65327000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-16" decimals="-3" id="f-173" unitRef="usd">-65327000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-31"
      decimals="INF"
      id="f-174"
      unitRef="shares">1207990</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-32" decimals="-3" id="f-175" unitRef="usd">882000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-16" decimals="-3" id="f-176" unitRef="usd">882000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-32" decimals="-3" id="f-177" unitRef="usd">8814000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-16" decimals="-3" id="f-178" unitRef="usd">8814000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-33"
      decimals="INF"
      id="f-179"
      unitRef="shares">192230854</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-33" decimals="-3" id="f-180" unitRef="usd">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-34" decimals="-3" id="f-181" unitRef="usd">1135056000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-35" decimals="-3" id="f-182" unitRef="usd">-704883000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-36" decimals="-3" id="f-183" unitRef="usd">430175000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-184" unitRef="usd">-91373000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-16" decimals="-3" id="f-185" unitRef="usd">-65327000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-1" decimals="-3" id="f-186" unitRef="usd">7377000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-16" decimals="-3" id="f-187" unitRef="usd">3728000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-188" unitRef="usd">16127000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-16" decimals="-3" id="f-189" unitRef="usd">8814000</us-gaap:ShareBasedCompensation>
    <us-gaap:TangibleAssetImpairmentCharges contextRef="c-1" decimals="-3" id="f-190" unitRef="usd">108000</us-gaap:TangibleAssetImpairmentCharges>
    <us-gaap:TangibleAssetImpairmentCharges contextRef="c-16" decimals="-3" id="f-191" unitRef="usd">1169000</us-gaap:TangibleAssetImpairmentCharges>
    <us-gaap:OperatingLeaseExpense contextRef="c-1" decimals="-3" id="f-192" unitRef="usd">2472000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense contextRef="c-16" decimals="-3" id="f-193" unitRef="usd">1988000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c-1" decimals="-3" id="f-194" unitRef="usd">560000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c-16" decimals="-3" id="f-195" unitRef="usd">-716000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c-1" decimals="-3" id="f-196" unitRef="usd">1040000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c-16" decimals="-3" id="f-197" unitRef="usd">317000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-1" decimals="-3" id="f-198" unitRef="usd">-13655000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-16" decimals="-3" id="f-199" unitRef="usd">-12134000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-1" decimals="-3" id="f-200" unitRef="usd">1168000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-16" decimals="-3" id="f-201" unitRef="usd">-339000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <rxrx:IncreaseDecreaseInAccruedDevelopmentExpense contextRef="c-1" decimals="-3" id="f-202" unitRef="usd">-273000</rxrx:IncreaseDecreaseInAccruedDevelopmentExpense>
    <rxrx:IncreaseDecreaseInAccruedDevelopmentExpense contextRef="c-16" decimals="-3" id="f-203" unitRef="usd">676000</rxrx:IncreaseDecreaseInAccruedDevelopmentExpense>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities contextRef="c-1" decimals="-3" id="f-204" unitRef="usd">-18857000</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities contextRef="c-16" decimals="-3" id="f-205" unitRef="usd">-9846000</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-1" decimals="-3" id="f-206" unitRef="usd">-3794000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-16" decimals="-3" id="f-207" unitRef="usd">-2444000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-208" unitRef="usd">-102300000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-16" decimals="-3" id="f-209" unitRef="usd">-73316000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-210" unitRef="usd">6653000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-16" decimals="-3" id="f-211" unitRef="usd">5175000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="c-1" decimals="-3" id="f-212" unitRef="usd">0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="c-16" decimals="-3" id="f-213" unitRef="usd">165000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-214" unitRef="usd">-6653000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-16" decimals="-3" id="f-215" unitRef="usd">-5340000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-1" decimals="-3" id="f-216" unitRef="usd">10873000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-16" decimals="-3" id="f-217" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="c-1" decimals="-3" id="f-218" unitRef="usd">3050000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="c-16" decimals="-3" id="f-219" unitRef="usd">1946000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-1" decimals="-3" id="f-220" unitRef="usd">26000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-16" decimals="-3" id="f-221" unitRef="usd">24000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-222" unitRef="usd">13897000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-16" decimals="-3" id="f-223" unitRef="usd">1922000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-1" decimals="-3" id="f-224" unitRef="usd">-219000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-16" decimals="-3" id="f-225" unitRef="usd">-2000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-226" unitRef="usd">-95275000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-16" decimals="-3" id="f-227" unitRef="usd">-76734000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-5" decimals="-3" id="f-228" unitRef="usd">401425000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-29" decimals="-3" id="f-229" unitRef="usd">559112000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-4" decimals="-3" id="f-230" unitRef="usd">306150000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-36" decimals="-3" id="f-231" unitRef="usd">482378000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-1" decimals="-3" id="f-232" unitRef="usd">80000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-16" decimals="-3" id="f-233" unitRef="usd">244000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-1" decimals="-3" id="f-234" unitRef="usd">3266000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-16" decimals="-3" id="f-235" unitRef="usd">3520000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <rxrx:FinancedEquipmentPurchase contextRef="c-1" decimals="-3" id="f-236" unitRef="usd">0</rxrx:FinancedEquipmentPurchase>
    <rxrx:FinancedEquipmentPurchase contextRef="c-16" decimals="-3" id="f-237" unitRef="usd">1214000</rxrx:FinancedEquipmentPurchase>
    <us-gaap:OperatingLeasePaymentsUse contextRef="c-1" decimals="-3" id="f-238" unitRef="usd">3955000</us-gaap:OperatingLeasePaymentsUse>
    <us-gaap:OperatingLeasePaymentsUse contextRef="c-16" decimals="-3" id="f-239" unitRef="usd">2444000</us-gaap:OperatingLeasePaymentsUse>
    <us-gaap:NatureOfOperations contextRef="c-1" id="f-240">Description of the Business &lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Recursion Pharmaceuticals, Inc. (Recursion, the Company, we or our) was originally formed as a limited liability&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;company on November 4, 2013 under the name Recursion Pharmaceuticals, LLC. In September 2016, the Company converted to a Delaware corporation and changed its name to Recursion Pharmaceuticals, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Recursion is a clinical stage TechBio company decoding biology to industrialize drug discovery. The Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe, one of the world&#x2019;s largest proprietary biological and chemical datasets. The Company integrates physical and digital components as iterative loops of atoms and bits scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;in silico &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;hypotheses into validated insights and novel chemistry.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2024, the Company had an accumulated deficit of $1.1 billion. The Company expects to incur substantial operating losses in future periods and will require additional capital to advance its drug candidates. The Company does not expect to generate significant revenue until the Company successfully completes significant drug development milestones with its subsidiaries or in collaboration&#160;with third parties, which the Company expects will take a number of years. In order to commercialize its drug candidates, the Company or its partners need to complete clinical development and comply with comprehensive regulatory requirements. The Company is subject to a number of risks and uncertainties similar to those of other companies of the same size within the biotechnology industry, such as the uncertainty of clinical trial outcomes, uncertainty of additional funding and a history of operating losses. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has funded its operations to date primarily through the issuance of convertible preferred stock and the issuance of Class A common stock (see Note 8, &#x201c;Common Stock&#x201d; for additional details). Additionally, the Company has received payments from its strategic partnerships (see Note 9, &#x201c;Collaborative Development Contracts&#x201d; for additional details). Recursion will likely be required to raise additional capital. As of March&#160;31, 2024, the Company did not have any unconditional outstanding commitments for additional funding. If the Company is unable to access additional funds when needed, it may not be able to continue the development of its products or the Company could be required to delay, scale back or abandon some or all of its development programs and other operations. The Company&#x2019;s ability to access capital when needed is not assured and, if not achieved on a timely basis, could materially harm its business, financial condition and results of operations. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Recursion believes that the Company&#x2019;s existing cash and cash equivalents will be sufficient to fund the Company&#x2019;s operating expenses and capital expenditures for at least the next 12 months.&lt;/span&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-4" decimals="-8" id="f-241" unitRef="usd">-1100000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-242">Basis of Presentation&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unaudited interim condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (SEC). Accordingly, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) have been condensed or omitted. These unaudited interim condensed consolidated financial statements should be read in conjunction with the Company&#x2019;s audited consolidated financial statements and notes for the year ended December&#160;31, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;It is management&#x2019;s opinion that these condensed consolidated financial statements include all normal and recurring adjustments necessary for a fair presentation of the Company&#x2019;s financial statements. Revenue and net loss for any interim period are not necessarily indicative of future or annual results.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2024, the SEC issued rule 33-11275, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;The Enhancement and Standardization of Climate-Related Disclosures for Investors&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The new rule requires Recursion to provide certain disclosures in the footnotes to the &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;financial statements of climate-related information. These disclosures include the impact of severe weather and other natural conditions on the Company&#x2019;s consolidated balance sheet and statement of operations, to the extent they are material. Recursion will also need to disclose a rollforward of the beginning and ending balances of its carbon offsets and renewable energy credits or certificates (RECs), if they are a material component of meeting the Company&#x2019;s climate-related targets and goals. Additionally, the Company will need to disclose whether and, if so, how severe weather events and other natural conditions and disclosed climate-related targets or transition plans materially affected estimates and assumptions in the financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The standard&#x2019;s effective dates, if adopted, will be phased in depending on the disclosure requirement starting the annual period ending December&#160;31, 2025. In April 2024, the SEC voluntarily stayed implementation of the new climate-related disclosure requirements pending judicial review. The Company is currently evaluating the impact this rule will have on its consolidated financial statements and related disclosures.   &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2023-9, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The new standard updates disclosure requirements for Accounting Standards Codification (ASC) 740 primarily by requiring additional information in the income tax rate reconciliation and additional disclosures about income taxes paid. This standard will be effective for Recursion starting the annual period ending December 31, 2025. Early adoption is permitted for annual financial statements that have not yet been issued. The amendments can be applied on a prospective or retrospective basis. The adoption of this standard will not impact Recursion&#x2019;s consolidated balance sheet and statement of operations.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023, the FASB issued ASU No. 2023-7, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting (Topic 280)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The standard requires new disclosures related to ASC 280 including: disclosing significant segment expenses by category; requiring all the ASC 280 disclosures for Companies with a single reportable segment and; requiring an increased frequency of the ASC 280 disclosures. Recursion must apply the amendments retrospectively to each prior reporting period presented. This standard will be effective for Recursion starting the annual period ending December 31, 2024. Early adoption is permitted. The adoption of this standard will not impact Recursion&#x2019;s consolidated balance sheet and statement of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c-1" id="f-243">&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unaudited interim condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (SEC). Accordingly, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) have been condensed or omitted. These unaudited interim condensed consolidated financial statements should be read in conjunction with the Company&#x2019;s audited consolidated financial statements and notes for the year ended December&#160;31, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;It is management&#x2019;s opinion that these condensed consolidated financial statements include all normal and recurring adjustments necessary for a fair presentation of the Company&#x2019;s financial statements. Revenue and net loss for any interim period are not necessarily indicative of future or annual results.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-244">&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2024, the SEC issued rule 33-11275, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;The Enhancement and Standardization of Climate-Related Disclosures for Investors&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The new rule requires Recursion to provide certain disclosures in the footnotes to the &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;financial statements of climate-related information. These disclosures include the impact of severe weather and other natural conditions on the Company&#x2019;s consolidated balance sheet and statement of operations, to the extent they are material. Recursion will also need to disclose a rollforward of the beginning and ending balances of its carbon offsets and renewable energy credits or certificates (RECs), if they are a material component of meeting the Company&#x2019;s climate-related targets and goals. Additionally, the Company will need to disclose whether and, if so, how severe weather events and other natural conditions and disclosed climate-related targets or transition plans materially affected estimates and assumptions in the financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The standard&#x2019;s effective dates, if adopted, will be phased in depending on the disclosure requirement starting the annual period ending December&#160;31, 2025. In April 2024, the SEC voluntarily stayed implementation of the new climate-related disclosure requirements pending judicial review. The Company is currently evaluating the impact this rule will have on its consolidated financial statements and related disclosures.   &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2023-9, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The new standard updates disclosure requirements for Accounting Standards Codification (ASC) 740 primarily by requiring additional information in the income tax rate reconciliation and additional disclosures about income taxes paid. This standard will be effective for Recursion starting the annual period ending December 31, 2025. Early adoption is permitted for annual financial statements that have not yet been issued. The amendments can be applied on a prospective or retrospective basis. The adoption of this standard will not impact Recursion&#x2019;s consolidated balance sheet and statement of operations.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023, the FASB issued ASU No. 2023-7, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting (Topic 280)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The standard requires new disclosures related to ASC 280 including: disclosing significant segment expenses by category; requiring all the ASC 280 disclosures for Companies with a single reportable segment and; requiring an increased frequency of the ASC 280 disclosures. Recursion must apply the amendments retrospectively to each prior reporting period presented. This standard will be effective for Recursion starting the annual period ending December 31, 2024. Early adoption is permitted. The adoption of this standard will not impact Recursion&#x2019;s consolidated balance sheet and statement of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <rxrx:SupplementalBalanceSheetAndIncomeStatementInformationTextBlock contextRef="c-1" id="f-245">Supplemental Financial Information &lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Tempus agreement&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;November 2023&lt;/span&gt;&lt;span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Recursion entered into a &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;five&lt;/span&gt;&lt;span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-year agreement with Tempus Labs, Inc. (Tempus) to purchase access to their records of patient-centric multimodal oncology data and use rights for therapeutic development purposes. This data will be used to improve the training of Recursion&#x2019;s artificial intelligence and machine learning models and is expected to accelerate Recursion&#x2019;s drug discovery process. Recursion is making annual payments, ranging between &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$22.0&#160;million&lt;/span&gt;&lt;span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$42.0&#160;million&lt;/span&gt;&lt;span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, up to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$160.0&#160;million&lt;/span&gt;&lt;span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in aggregate, to Tempus in cash or equity at the Company&#x2019;s option. The equity value is determined by using the &lt;span style="-sec-ix-hidden:f-250"&gt;seven&lt;/span&gt;-trading day period dollar volume-weighted average price (VWAP) for Recursion Class A common stock ending on the day immediately preceding the date that is five business days prior to the payment date. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Recursion is expensing the record purchases as &#x201c;Research and Development&#x201d; expenses in the Condensed Consolidated Statements of Operations as the records are purchased. To the extent that the Recursion payments to Tempus are greater than or less than the records purchased amount, Recursion records the applicable amount to &#x201c;Other Current Assets&#x201d; or &#x201c;Accrued Expenses and Other Liabilities&#x201d; on the Condensed Consolidated Balance Sheet, respectively. As of March&#160;31, 2024, Recursion had recorded $16.0&#160;million within &#x201c;Other Current Assets&#x201d; on the Consolidated Balance Sheet related to the Tempus agreement.     &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.660%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.521%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48,853)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(44,872)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense on property and equipment was $4.0&#160;million and $3.6&#160;million during the three months ended March 31, 2024 and 2023, respectively&lt;/span&gt;&lt;span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company recorded an insignificant impairment and an impairment of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$1.2&#160;million &lt;/span&gt;&lt;span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;during the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;three months ended March 31, 2024 and 2023, respectively,&lt;/span&gt;&lt;span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; related to construction projects for leasehold improvements as the Company no longer intended to use them. The impairment was recorded in &#x201c;General and Administrative&#x201d; in the Condensed Consolidated Statements of Operations.   &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;three months ended March 31, 2023, the &lt;/span&gt;&lt;span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Company initiated and completed a project to upgrade the BioHive supercomputer for &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$1.7&#160;million&lt;/span&gt;&lt;span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The supercomputer was classified as office equipment in the above table.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued Expenses and Other Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.660%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.521%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,077&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued early discovery expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued construction&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Materials received not invoiced&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued other expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expense and other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Notes Payable&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2023, the Company entered into a financing agreement for borrowing $1.9 million as part of the supercomputer upgrade project. The debt will be repaid over a three-year period at a 7% interest rate. As of March&#160;31, 2024, the outstanding balance was $616 thousand. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2018, the Company borrowed $992 thousand, which was available as part of a lease agreement for use on tenant improvements. The note will be repaid over a 10-year period at an 8% interest rate. As of March&#160;31, 2024, the outstanding balance was $510 thousand.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Interest Income, net&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.537%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three months ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March 31, 2024 and 2023, interest income primarily related to earnings on cash and cash equivalents in money market funds. Interest income was included in &#x201c;Other income, net&#x201d; on the Condensed Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;</rxrx:SupplementalBalanceSheetAndIncomeStatementInformationTextBlock>
    <rxrx:LicenseAgreementTerm contextRef="c-37" id="f-246">P5Y</rxrx:LicenseAgreementTerm>
    <rxrx:LicenseAgreementAnnualPayments contextRef="c-38" decimals="-5" id="f-247" unitRef="usd">22000000</rxrx:LicenseAgreementAnnualPayments>
    <rxrx:LicenseAgreementAnnualPayments contextRef="c-39" decimals="-5" id="f-248" unitRef="usd">42000000</rxrx:LicenseAgreementAnnualPayments>
    <rxrx:LicenseAgreementAggregatePayments contextRef="c-39" decimals="-5" id="f-249" unitRef="usd">160000000</rxrx:LicenseAgreementAggregatePayments>
    <rxrx:LicenseAgreementPrepaidExpenses contextRef="c-40" decimals="-5" id="f-251" unitRef="usd">16000000</rxrx:LicenseAgreementPrepaidExpenses>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c-1" id="f-252">&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.660%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.521%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48,853)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(44,872)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-41" decimals="-3" id="f-253" unitRef="usd">61247000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-42" decimals="-3" id="f-254" unitRef="usd">60096000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-43" decimals="-3" id="f-255" unitRef="usd">46289000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-44" decimals="-3" id="f-256" unitRef="usd">45929000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-45" decimals="-3" id="f-257" unitRef="usd">22356000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-46" decimals="-3" id="f-258" unitRef="usd">22126000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-47" decimals="-3" id="f-259" unitRef="usd">5677000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-48" decimals="-3" id="f-260" unitRef="usd">3231000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-4" decimals="-3" id="f-261" unitRef="usd">135569000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-5" decimals="-3" id="f-262" unitRef="usd">131382000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-4" decimals="-3" id="f-263" unitRef="usd">48853000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-5" decimals="-3" id="f-264" unitRef="usd">44872000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-265" unitRef="usd">86716000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-5" decimals="-3" id="f-266" unitRef="usd">86510000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation contextRef="c-1" decimals="-5" id="f-267" unitRef="usd">4000000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-16" decimals="-5" id="f-268" unitRef="usd">3600000</us-gaap:Depreciation>
    <us-gaap:ImpairmentOfLeasehold contextRef="c-16" decimals="-5" id="f-269" unitRef="usd">1200000</us-gaap:ImpairmentOfLeasehold>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-49" decimals="-5" id="f-270" unitRef="usd">1700000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="c-1" id="f-271">&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued Expenses and Other Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.660%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.521%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,077&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued early discovery expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued construction&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Materials received not invoiced&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued other expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expense and other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-272" unitRef="usd">10055000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-273" unitRef="usd">22888000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <rxrx:AccruedDevelopmentCostsCurrent contextRef="c-4" decimals="-3" id="f-274" unitRef="usd">5804000</rxrx:AccruedDevelopmentCostsCurrent>
    <rxrx:AccruedDevelopmentCostsCurrent contextRef="c-5" decimals="-3" id="f-275" unitRef="usd">6077000</rxrx:AccruedDevelopmentCostsCurrent>
    <rxrx:AccruedEarlyDiscoveryExpensesCurrent contextRef="c-4" decimals="-3" id="f-276" unitRef="usd">2610000</rxrx:AccruedEarlyDiscoveryExpensesCurrent>
    <rxrx:AccruedEarlyDiscoveryExpensesCurrent contextRef="c-5" decimals="-3" id="f-277" unitRef="usd">2570000</rxrx:AccruedEarlyDiscoveryExpensesCurrent>
    <us-gaap:ConstructionPayableCurrent contextRef="c-4" decimals="-3" id="f-278" unitRef="usd">0</us-gaap:ConstructionPayableCurrent>
    <us-gaap:ConstructionPayableCurrent contextRef="c-5" decimals="-3" id="f-279" unitRef="usd">2439000</us-gaap:ConstructionPayableCurrent>
    <rxrx:MaterialsReceivedNotInvoiced contextRef="c-4" decimals="-3" id="f-280" unitRef="usd">1184000</rxrx:MaterialsReceivedNotInvoiced>
    <rxrx:MaterialsReceivedNotInvoiced contextRef="c-5" decimals="-3" id="f-281" unitRef="usd">2432000</rxrx:MaterialsReceivedNotInvoiced>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-282" unitRef="usd">6417000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-283" unitRef="usd">10229000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-284" unitRef="usd">26070000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-285" unitRef="usd">46635000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="c-50" decimals="-5" id="f-286" unitRef="usd">1900000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:DebtInstrumentTerm contextRef="c-50" id="f-287">P3Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-51" decimals="2" id="f-288" unitRef="number">0.07</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:NotesPayable contextRef="c-52" decimals="-3" id="f-289" unitRef="usd">616000</us-gaap:NotesPayable>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="c-53" decimals="-3" id="f-290" unitRef="usd">992000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:DebtInstrumentTerm contextRef="c-53" id="f-291">P10Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-54" decimals="2" id="f-292" unitRef="number">0.08</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:NotesPayable contextRef="c-55" decimals="-3" id="f-293" unitRef="usd">510000</us-gaap:NotesPayable>
    <us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock contextRef="c-1" id="f-294">&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Interest Income, net&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.537%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three months ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock>
    <us-gaap:InvestmentIncomeNonoperating contextRef="c-1" decimals="-3" id="f-295" unitRef="usd">4048000</us-gaap:InvestmentIncomeNonoperating>
    <us-gaap:InvestmentIncomeNonoperating contextRef="c-16" decimals="-3" id="f-296" unitRef="usd">4660000</us-gaap:InvestmentIncomeNonoperating>
    <us-gaap:InterestExpense contextRef="c-1" decimals="-3" id="f-297" unitRef="usd">20000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-16" decimals="-3" id="f-298" unitRef="usd">19000</us-gaap:InterestExpense>
    <us-gaap:InterestRevenueExpenseNet contextRef="c-1" decimals="-3" id="f-299" unitRef="usd">4028000</us-gaap:InterestRevenueExpenseNet>
    <us-gaap:InterestRevenueExpenseNet contextRef="c-16" decimals="-3" id="f-300" unitRef="usd">4641000</us-gaap:InterestRevenueExpenseNet>
    <us-gaap:BusinessCombinationDisclosureTextBlock contextRef="c-1" id="f-302">Acquisitions&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Valence Discovery Inc.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May&#160;16, 2023, Recursion acquired all of the outstanding equity interests in Valence Discovery Inc. (Valence), a privately-held machine learning (ML) / artificial intelligence (AI) digital chemistry company. The integration of Valence&#x2019;s AI-based chemistry engine into Recursion&#x2019;s operating system will allow Recursion to expand its technology-enabled drug discovery process. This will accelerate Recursion&#x2019;s digital chemistry capabilities and its drug discovery process.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The acquisition of Valence was accounted for as a business combination using the acquisition method of accounting. The aggregate upfront consideration for the acquisition of Valence consisted of 2.2 million shares of Recursion Class A common stock, 4.4 million shares of a subsidiary of Recursion, exchangeable for shares of Recursion&#x2019;s Class A common stock, 792 thousand shares issuable upon exercise of stock options held by Valence equity award holders and deferred liabilities for additional consideration. An insignificant number of the aforementioned shares of consideration had not yet been issued as of March&#160;31, 2024.The final number of shares to be issued has not yet been finalized and so are subject to change. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes total consideration:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:78.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of Recursion Class A common stock &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of Exchangeable stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of equity awards issued to Valance equity award holders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred liabilities for additional consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the fair value of assets acquired and liabilities assumed as of the acquisition date:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:78.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible asset - technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(872)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,265)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total identifiable net assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets acquired and liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The intangible asset related to Valence&#x2019;s ML and AI digital chemistry platform. The estimated fair value of the intangible asset was determined using a cost approach. This valuation technique provides the fair value of an asset based on estimates of the total costs to develop the technology. Significant inputs used to determine the total cost includes the length of time required and service hours performed by Company employees. The technology intangible asset is being amortized on a straight-line basis over its four-year useful life.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill was calculated as the excess of the consideration transferred over the net assets recognized. The goodwill recognized represents the assembled workforce and expected synergies, including the ability to: (i) leverage Valence&#x2019;s digital chemistry platform across Recursion&#x2019;s business; (ii) leverage Valence&#x2019;s ML and AI capabilities; (iii) integrate Recursion&#x2019;s data and operating system into Valence&#x2019;s platform; and (iv) accelerate Recursion&#x2019;s pipeline. Goodwill was also impacted by the establishment of a deferred tax liability for the acquired identifiable intangible assets which have no tax basis. The goodwill is not deductible for tax purposes.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Recursion&#x2019;s condensed consolidated statement of operations during the three months ended March 31, 2024 included no net revenue and a $2.9&#160;million operating loss associated with Valence&#x2019;s operations. As the acquisition occurred in May 2023, the Company is still finalizing the allocation of the purchase price to the individual assets acquired and liabilities assumed. The allocation of the purchase price included in the current period balance sheet is based on the best estimate of management and is preliminary and subject to change. The primary area subject to change relates to the valuation of other receivables. To assist management in the allocation, the Company engaged external specialists. The Company will finalize the amounts recognized as the information necessary to complete the analysis is obtained. The Company expects to finalize these amounts as soon as possible but no later than one year from the acquisition date.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cyclica Inc&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May&#160;25, 2023, Recursion acquired all of the outstanding equity interests in Cyclica Inc. (Cyclica), a privately-held Company that has built a digital chemistry software suite which enables mechanism of action deconvolution and generative chemistry suggestions based on desired targets. Cyclica&#x2019;s platform is expected to enhance the optimization of Recursion&#x2019;s compounds for efficacy while minimizing liabilities through generative machine learning approaches. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The acquisition of Cyclica was accounted for as a business combination using the acquisition method of accounting. The aggregate upfront consideration for the acquisition of Cyclica consisted of 5.8 million shares of Recursion Class A common stock, cash payments, 1.0 million shares issuable upon exercise of stock options held by Cyclica equity award holders and deferred liabilities for additional consideration. Approximately 182 thousand of the aforementioned shares of Class A common stock consideration had not yet been issued as of March&#160;31, 2024. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes total consideration:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:78.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of Recursion Class A common stock &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of equity awards issued to Cyclica equity award holders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred liabilities for additional consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the fair value of assets acquired and liabilities assumed as of the acquisition date:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:78.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets - technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(579)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unearned revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,754)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,075)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other liabilities, current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other liabilities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(139)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total identifiable net assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets acquired and liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The intangible assets are related to Cyclica&#x2019;s digital chemistry platforms. The estimated fair value of the intangible assets were determined using a cost approach. This valuation technique provides the fair value of an asset based on estimates of the total costs to develop the technology. Significant inputs used to determine the total cost includes the length of time required and service hours performed by Company employees. The technology intangible assets are being amortized on a straight-line basis over their three-year useful lives.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill was calculated as the excess of the consideration transferred over the net assets recognized. The goodwill recognized represents the assembled workforce and expected synergies, including the ability to: (i) leverage Cyclica&#x2019;s digital chemistry platform across Recursion&#x2019;s business; (ii) leverage Cyclica&#x2019;s ML and AI capabilities; (iii) integrate Recursion&#x2019;s data and operating system into Cyclica&#x2019;s platform; and (iv) accelerate Recursion&#x2019;s pipeline. Goodwill was also impacted by the establishment of a deferred tax liability for the acquired identifiable intangible assets. The goodwill is not deductible for tax purposes.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Recursion&#x2019;s condensed consolidated statement of operations during the three months ended March 31, 2024 included immaterial net revenue and a $3.8 million operating loss associated with Cyclica&#x2019;s operations. As the acquisition occurred in May 2023, the Company is still finalizing the allocation of the purchase price to the individual assets acquired and liabilities assumed. The allocation of the purchase price included in the current period balance sheet is based on the best estimate of management and is preliminary and subject to change. The primary area subject to change relates to the valuation of the other receivables. To assist management in the allocation, the Company engaged external specialists. The Company will finalize the amounts recognized as the information necessary to complete the analysis is obtained. The Company expects to finalize these amounts as soon as possible but no later than one year from the acquisition date.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Pro forma financial information  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the unaudited pro forma combined results of operations of Recursion, Valence and Cyclica as if the acquisitions had occurred on January&#160;1, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:76.677%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.123%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three months ended March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(73,514)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unaudited pro forma financial information was prepared using the acquisition method of accounting and was based on the historical financial information of Recursion, Valence and Cyclica. In order to reflect the occurrence of the acquisitions on January&#160;1, 2022 as required, the unaudited pro forma financial information includes adjustments to reflect the incremental amortization expense to be incurred based on the fair values of the identifiable intangible assets acquired and the additional stock compensation expense associated with the issuance of equity compensation related to the acquisitions. The unaudited pro forma financial information is not necessarily indicative of what the consolidated results of operations would have been had the acquisitions been completed on January&#160;1, 2022. In addition, the unaudited pro forma financial information is not a projection of the future results of operations of the combined company nor does it reflect the expected realization of any cost savings or synergies associated with the acquisitions.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued contextRef="c-56" decimals="-5" id="f-303" unitRef="shares">2200000</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued contextRef="c-57" decimals="-5" id="f-304" unitRef="shares">4400000</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued contextRef="c-58" decimals="-3" id="f-305" unitRef="shares">792000</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock contextRef="c-1" id="f-306">&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes total consideration:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:78.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of Recursion Class A common stock &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of Exchangeable stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of equity awards issued to Valance equity award holders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred liabilities for additional consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes total consideration:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:78.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of Recursion Class A common stock &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of equity awards issued to Cyclica equity award holders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred liabilities for additional consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock>
    <rxrx:BusinessCombinationConsiderationTransferredEquityInterestsIssuable contextRef="c-56" decimals="-3" id="f-307" unitRef="usd">11096000</rxrx:BusinessCombinationConsiderationTransferredEquityInterestsIssuable>
    <rxrx:BusinessCombinationConsiderationTransferredEquityInterestsIssuable contextRef="c-57" decimals="-3" id="f-308" unitRef="usd">22473000</rxrx:BusinessCombinationConsiderationTransferredEquityInterestsIssuable>
    <rxrx:BusinessCombinationConsiderationTransferredEquityInterestsIssuable contextRef="c-59" decimals="-3" id="f-309" unitRef="usd">1933000</rxrx:BusinessCombinationConsiderationTransferredEquityInterestsIssuable>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred contextRef="c-60" decimals="-3" id="f-310" unitRef="usd">396000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:BusinessCombinationConsiderationTransferred1 contextRef="c-60" decimals="-3" id="f-311" unitRef="usd">35898000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock contextRef="c-1" id="f-312">&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the fair value of assets acquired and liabilities assumed as of the acquisition date:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:78.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible asset - technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(872)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,265)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total identifiable net assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets acquired and liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the fair value of assets acquired and liabilities assumed as of the acquisition date:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:78.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets - technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(579)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unearned revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,754)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,075)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other liabilities, current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other liabilities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(139)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total identifiable net assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets acquired and liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents contextRef="c-61" decimals="-3" id="f-313" unitRef="usd">4235000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <rxrx:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherReceivables contextRef="c-61" decimals="-3" id="f-314" unitRef="usd">536000</rxrx:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherReceivables>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="c-61" decimals="-3" id="f-315" unitRef="usd">15000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable contextRef="c-61" decimals="-3" id="f-316" unitRef="usd">872000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities contextRef="c-61" decimals="-3" id="f-317" unitRef="usd">3265000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet contextRef="c-61" decimals="-3" id="f-318" unitRef="usd">15634000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:Goodwill contextRef="c-61" decimals="-3" id="f-319" unitRef="usd">20264000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet contextRef="c-61" decimals="-3" id="f-320" unitRef="usd">35898000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-62" id="f-321">P4Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual contextRef="c-63" decimals="INF" id="f-322" unitRef="usd">0</us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual>
    <us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual contextRef="c-63" decimals="-5" id="f-323" unitRef="usd">-2900000</us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued contextRef="c-64" decimals="-5" id="f-324" unitRef="shares">5800000</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued contextRef="c-65" decimals="-5" id="f-325" unitRef="shares">1000000</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued contextRef="c-66" decimals="-3" id="f-326" unitRef="shares">182000</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <rxrx:BusinessCombinationConsiderationTransferredEquityInterestsIssuable contextRef="c-64" decimals="-3" id="f-327" unitRef="usd">49915000</rxrx:BusinessCombinationConsiderationTransferredEquityInterestsIssuable>
    <us-gaap:PaymentsToAcquireBusinessesGross contextRef="c-67" decimals="-3" id="f-328" unitRef="usd">6505000</us-gaap:PaymentsToAcquireBusinessesGross>
    <rxrx:BusinessCombinationConsiderationTransferredEquityInterestsIssuable contextRef="c-68" decimals="-3" id="f-329" unitRef="usd">3852000</rxrx:BusinessCombinationConsiderationTransferredEquityInterestsIssuable>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred contextRef="c-67" decimals="-3" id="f-330" unitRef="usd">344000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:BusinessCombinationConsiderationTransferred1 contextRef="c-67" decimals="-3" id="f-331" unitRef="usd">60617000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents contextRef="c-69" decimals="-3" id="f-332" unitRef="usd">2429000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <rxrx:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash contextRef="c-69" decimals="-3" id="f-333" unitRef="usd">1685000</rxrx:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash>
    <rxrx:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherReceivables contextRef="c-69" decimals="-3" id="f-334" unitRef="usd">741000</rxrx:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherReceivables>
    <rxrx:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInvestments contextRef="c-69" decimals="-3" id="f-335" unitRef="usd">1000000</rxrx:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInvestments>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther contextRef="c-69" decimals="-3" id="f-336" unitRef="usd">385000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="c-69" decimals="-3" id="f-337" unitRef="usd">28000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable contextRef="c-69" decimals="-3" id="f-338" unitRef="usd">579000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue contextRef="c-69" decimals="-3" id="f-339" unitRef="usd">1754000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities contextRef="c-69" decimals="-3" id="f-340" unitRef="usd">2075000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <rxrx:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilitiesCurrent contextRef="c-69" decimals="-3" id="f-341" unitRef="usd">66000</rxrx:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilitiesCurrent>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther contextRef="c-69" decimals="-3" id="f-342" unitRef="usd">139000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet contextRef="c-69" decimals="-3" id="f-343" unitRef="usd">29627000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:Goodwill contextRef="c-69" decimals="-3" id="f-344" unitRef="usd">30990000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet contextRef="c-69" decimals="-3" id="f-345" unitRef="usd">60617000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-70" id="f-346">P3Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual contextRef="c-71" decimals="-5" id="f-347" unitRef="usd">-3800000</us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual>
    <us-gaap:BusinessAcquisitionProFormaInformationTextBlock contextRef="c-1" id="f-348">&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the unaudited pro forma combined results of operations of Recursion, Valence and Cyclica as if the acquisitions had occurred on January&#160;1, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:76.677%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.123%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three months ended March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(73,514)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:BusinessAcquisitionProFormaInformationTextBlock>
    <us-gaap:BusinessAcquisitionsProFormaRevenue contextRef="c-72" decimals="-3" id="f-349" unitRef="usd">12155000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss contextRef="c-72" decimals="-3" id="f-350" unitRef="usd">-73514000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c-1" id="f-351">Leases &lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has entered into various long-term real estate leases primarily related to office, research and development and operating activities. The Company&#x2019;s leases have remaining terms from under 1 to 9 years and some of those leases include options that provide Recursion with the ability to extend the lease term for five years. The options are included in the lease term when it is reasonably certain that the option will be exercised. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;For the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;three months ended March 31, 2024 and 2023&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;, Recursion entered into lease modifications resulting in a decrease to the right-of-use asset and lease liability of $3.1 million and an increase to the right-of-use asset and lease liability $3.5 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;, respectively&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;. The modifications had no impact to the Condensed Consolidated Statements of Operations. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In &lt;/span&gt;&lt;span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;January 2024&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company entered into a lease agreement for office space in London, England with approximately &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,792 &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;square feet (the &#x201c;London Lease&#x201d;). The right of use began &lt;/span&gt;&lt;span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;January 2024&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; when the control of the asset was obtained. The London Lease term is &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5 years&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; with a five-year renewal option. The London Lease includes provisions for escalating rent payments. Total fixed payments are expected to be approximately $7.9 million, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;additionally there will be variable expenses including building service charges related to the lease.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;In &lt;/span&gt;&lt;span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;February 2024&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;, the Company entered into a lease agreement for the supercomputer for the exclusive use of physical space in a data center of approximately &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;1,851 square feet (&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;the &#x201c;Data Center Lease&#x201d;). The right of use is expected to begin in the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;second quarter of 2024&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt; and the Data Center Lease term is &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;5 years&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt; with a five-year renewal option. The lease includes provisions for escalating rent payments. Total fixed lease payments are expected to be approximately $13.0 million with additional variable expenses, including utilities and tax expenses. The Company did not control the space or any of the assets being constructed as of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;March&#160;31, 2024&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt; and therefore no right of use asset or lease liability was recorded on the Condensed Consolidated Balance Sheet as of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;March&#160;31, 2024.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of the lease cost were:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.613%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three months ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The remaining lease term and discount rate were:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:78.578%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.222%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of operating lease liabilities as of March&#160;31, 2024 were:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.392%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Operating leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remainder of 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,161)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm contextRef="c-73" id="f-352">P1Y</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm contextRef="c-74" id="f-353">P9Y</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="c-4" id="f-354">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <rxrx:LesseeOperatingLeaseIncreaseDecreaseInOperatingLeaseLiabilityDueToLeaseModifications contextRef="c-1" decimals="-5" id="f-355" unitRef="usd">-3100000</rxrx:LesseeOperatingLeaseIncreaseDecreaseInOperatingLeaseLiabilityDueToLeaseModifications>
    <rxrx:IncreaseDecreaseInOperatingLeaseRightOfUseAssets contextRef="c-1" decimals="-5" id="f-356" unitRef="usd">-3100000</rxrx:IncreaseDecreaseInOperatingLeaseRightOfUseAssets>
    <rxrx:IncreaseDecreaseInOperatingLeaseRightOfUseAssets contextRef="c-16" decimals="-5" id="f-357" unitRef="usd">3500000</rxrx:IncreaseDecreaseInOperatingLeaseRightOfUseAssets>
    <rxrx:LesseeOperatingLeaseIncreaseDecreaseInOperatingLeaseLiabilityDueToLeaseModifications contextRef="c-16" decimals="-5" id="f-358" unitRef="usd">3500000</rxrx:LesseeOperatingLeaseIncreaseDecreaseInOperatingLeaseLiabilityDueToLeaseModifications>
    <rxrx:LesseeOperatingLeaseSquareFootageOfLeasedSpace contextRef="c-75" decimals="0" id="f-359" unitRef="sqft">6792</rxrx:LesseeOperatingLeaseSquareFootageOfLeasedSpace>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-76" id="f-360">P5Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="c-76" id="f-361">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c-76" decimals="-5" id="f-362" unitRef="usd">7900000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <rxrx:LesseeOperatingLeaseSquareFootageOfLeasedSpace contextRef="c-77" decimals="0" id="f-363" unitRef="sqft">1851</rxrx:LesseeOperatingLeaseSquareFootageOfLeasedSpace>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-78" id="f-364">P5Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="c-78" id="f-365">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c-78" decimals="-5" id="f-366" unitRef="usd">13000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LeaseCostTableTextBlock contextRef="c-1" id="f-367">&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of the lease cost were:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.613%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three months ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The remaining lease term and discount rate were:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:78.578%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.222%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost contextRef="c-1" decimals="-3" id="f-368" unitRef="usd">2472000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-16" decimals="-3" id="f-369" unitRef="usd">1998000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-1" decimals="-3" id="f-370" unitRef="usd">538000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-16" decimals="-3" id="f-371" unitRef="usd">657000</us-gaap:VariableLeaseCost>
    <us-gaap:ShortTermLeaseCost contextRef="c-1" decimals="-3" id="f-372" unitRef="usd">40000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost contextRef="c-16" decimals="-3" id="f-373" unitRef="usd">0</us-gaap:ShortTermLeaseCost>
    <us-gaap:LeaseCost contextRef="c-1" decimals="-3" id="f-374" unitRef="usd">3050000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c-16" decimals="-3" id="f-375" unitRef="usd">2655000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-4" id="f-376">P6Y4M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-4" decimals="3" id="f-377" unitRef="number">0.077</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c-1" id="f-378">&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of operating lease liabilities as of March&#160;31, 2024 were:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.392%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Operating leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remainder of 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,161)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear contextRef="c-4" decimals="-3" id="f-379" unitRef="usd">7300000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-4" decimals="-3" id="f-380" unitRef="usd">10748000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c-4" decimals="-3" id="f-381" unitRef="usd">10882000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c-4" decimals="-3" id="f-382" unitRef="usd">11281000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c-4" decimals="-3" id="f-383" unitRef="usd">8850000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <rxrx:LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour contextRef="c-4" decimals="-3" id="f-384" unitRef="usd">16948000</rxrx:LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c-4" decimals="-3" id="f-385" unitRef="usd">66009000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c-4" decimals="-3" id="f-386" unitRef="usd">16161000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c-4" decimals="-3" id="f-387" unitRef="usd">49848000</us-gaap:OperatingLeaseLiability>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="c-1" id="f-388">Goodwill and Intangible Assets &lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no changes to the carrying amount of goodwill during the three months ended March 31, 2024 and 2023. No goodwill impairment was recorded during the three months ended March 31, 2024 and 2023.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Assets, Net&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes intangible assets:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.268%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.888%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.326%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net carrying amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Definite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,336)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,969)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,336)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,969)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;Amortization expense was $3.4 million and $152 thousand during the three months ended March 31, 2024 and 2023, respectively. The increase in amortization expense was due to the intangible assets purchased in the acquisitions, (see Note 4, &#x201c;Acquisitions&#x201d; for additional details). Amortization expense was included in Research and Development in the Condensed Consolidated Statements of Operations. No indefinite-lived intangible asset impairment charges were recorded during the three months ended March 31, 2024 and 2023.</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:GoodwillPeriodIncreaseDecrease contextRef="c-16" decimals="INF" id="f-389" unitRef="usd">0</us-gaap:GoodwillPeriodIncreaseDecrease>
    <us-gaap:GoodwillPeriodIncreaseDecrease contextRef="c-1" decimals="INF" id="f-390" unitRef="usd">0</us-gaap:GoodwillPeriodIncreaseDecrease>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-16" decimals="INF" id="f-391" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-1" decimals="INF" id="f-392" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="c-1" id="f-394">&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes intangible assets:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.268%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.888%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.326%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net carrying amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Definite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,336)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,969)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,336)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,969)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock contextRef="c-1" id="f-393">&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes intangible assets:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.268%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.888%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.326%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net carrying amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Definite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,336)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,969)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,336)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,969)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-4" decimals="-3" id="f-395" unitRef="usd">44426000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-4" decimals="-3" id="f-396" unitRef="usd">12336000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-4" decimals="-3" id="f-397" unitRef="usd">32090000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-5" decimals="-3" id="f-398" unitRef="usd">44426000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-5" decimals="-3" id="f-399" unitRef="usd">8969000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-5" decimals="-3" id="f-400" unitRef="usd">35457000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-4" decimals="-3" id="f-401" unitRef="usd">986000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-4" decimals="-3" id="f-402" unitRef="usd">986000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-5" decimals="-3" id="f-403" unitRef="usd">986000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-5" decimals="-3" id="f-404" unitRef="usd">986000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="c-4" decimals="-3" id="f-405" unitRef="usd">45412000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-4" decimals="-3" id="f-406" unitRef="usd">12336000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-4" decimals="-3" id="f-407" unitRef="usd">33076000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="c-5" decimals="-3" id="f-408" unitRef="usd">45412000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-5" decimals="-3" id="f-409" unitRef="usd">8969000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-5" decimals="-3" id="f-410" unitRef="usd">36443000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-1" decimals="-5" id="f-411" unitRef="usd">3400000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-16" decimals="-3" id="f-412" unitRef="usd">152000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill contextRef="c-16" decimals="INF" id="f-413" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill contextRef="c-1" decimals="INF" id="f-414" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-415">Commitments and Contingencies&lt;div&gt;&lt;span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contract Obligations&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the normal course of business, the Company enters into contracts with clinical research organizations, drug manufacturers and other vendors&#160;for preclinical and clinical research studies, research and development supplies and other services and products for operating purposes. These contracts generally provide for termination on notice and are cancellable contracts.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Indemnification &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has agreed to indemnify its officers and directors for certain events or occurrences, while the officer or director is or was serving at the Company&#x2019;s request in such capacity. The Company purchases directors and officers liability insurance coverage that provides for reimbursement to the Company for covered obligations and this is intended to limit the Company&#x2019;s exposure and enable it to recover a portion of any amounts it pays under its &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;indemnification obligations. The Company had no liabilities recorded for these agreements as of March&#160;31, 2024 and December&#160;31, 2023, as no amounts were probable. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Employee Agreements &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has signed employment agreements with certain key employees pursuant to which, if their employment is terminated following a change of control of the Company, the employees are entitled to receive certain benefits, including accelerated vesting of equity incentives. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Matters &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may, from time to time, be involved in various legal proceedings arising in the normal course of business. An unfavorable resolution of any such matter could materially affect the Company&#x2019;s future financial position, results of operations or cash flows. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2021, the Company entered into a lease agreement for laboratory and office space (the Industry Lease) with Industry Office SLC, LLC (the landlord). In March 2023, the Company sent a letter to the landlord detailing numerous construction delays and irregularities, deficiencies and deviations from applicable structural drawings and/or non-conforming conditions with applicable building codes. On June&#160;23, 2023, the landlord filed a lawsuit against the Company (&lt;/span&gt;&lt;span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Industry Office SLC, LLC v. Recursion Pharmaceuticals, Inc.&lt;/span&gt;&lt;span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Case No. 230904627) in the Third District Court for Salt Lake County, State of Utah (the Court), alleging anticipatory repudiation and breach of contract. The Plaintiff seeks monetary damages and attorney&#x2019;s fees. In July 2023, the Company filed a motion to dismiss. In September 2023, Recursion was granted its motion to dismiss, and the Court provided the landlord until October&#160;23, 2023, to amend and re-file the dismissed complaint. On October&#160;23, 2023, the landlord filed an amended complaint again alleging anticipatory repudiation, breach of contract and breach of the implied covenant of good faith and fair dealing (the Amended Complaint) and seeks monetary damages and attorney&#x2019;s fees. In November 2023, the Company filed a motion to dismiss the Amended Complaint. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Court set a hearing on the Company&#x2019;s motion to dismiss in &lt;/span&gt;&lt;span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;May 2024. As of&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;March&#160;31, 2024, the Company had no liability recorded for these events as an unfavorable outcome was not probable.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Industry Lease, in September 2023, the Company filed claims in the Court against the landlord alleging, among other things, breach of contract and fraudulent misrepresentation (the Counterclaims). In October 2023, the landlord filed an answer and denied the Company&#x2019;s allegations asserted in the Counterclaims. The Company and the landlord are currently engaged in discovery. On October&#160;27, 2023, the Company filed a motion for partial judgment on the pleadings, seeking judgment on one of its four counterclaims. The Court set a hearing on the Company&#x2019;s motion for partial judgment on the pleadings in May 2024. The Company is unable to estimate the possible amount or range of amounts associated with the Counterclaims.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyAccrualAtCarryingValue contextRef="c-4" decimals="INF" id="f-416" unitRef="usd">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualAtCarryingValue contextRef="c-5" decimals="INF" id="f-417" unitRef="usd">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualAtCarryingValue contextRef="c-4" decimals="INF" id="f-418" unitRef="usd">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyPendingClaimsNumber contextRef="c-79" decimals="INF" id="f-419" unitRef="claim">4</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-420">Common Stock &lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each share of Class A common stock entitles the holder to one vote per share and each share of Class B common stock entitles the holder to 10 votes per share on all matters submitted to a vote of the Company&#x2019;s stockholders. Common stockholders are entitled to receive dividends, as may be declared by the Company&#x2019;s Board of Directors. As of March&#160;31, 2024 and December&#160;31, 2023, no dividends had been declared. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;At-The-Market Offering&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In &lt;/span&gt;&lt;span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;August 2023&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company entered into an Open Market Sales Agreement (the &#x201c;Sales Agreement&#x201d;) with Jefferies LLC (the &#x201c;Sales Agent&#x201d;), to provide for the offering, issuance and sale of up to an aggregate amount of &lt;/span&gt;&lt;span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$300.0 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of its Class A common stock from time to time in &#x201c;at-the-market&#x201d; (ATM) offerings. As of&#160;March&#160;31, 2024, an amount of &lt;/span&gt;&lt;span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$208.2 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; remained available for future sales under the Sales Agreement. For the three months ended March 31, 2024, the Company has sold &lt;/span&gt;&lt;span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;921&#160;thousand&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; shares and received net proceeds of &lt;/span&gt;&lt;span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$10.9 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; under the agreement. Recursion is not required to sell additional shares under the Sales Agreement. The Company will pay the Sales Agent a commission of up to 3% of the aggregate gross proceeds received from all sales of Class A common stock. The Sales Agreement continues until the earlier of selling all shares available under the Sales Agreement or terminated by written notice from either of the parties. The ATM Offering is being made under a prospectus supplement dated August&#160;8, 2023, and related prospectus filed with the Securities and Exchange &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commission pursuant to our automatically effective shelf registration statement on Form S-3ASR (Registration No. 333-264845). &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;NVIDIA Private Placement&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In &lt;/span&gt;&lt;span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;July 2023&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Recursion entered into a Stock Purchase Agreement for a private placement with NVIDIA Corporation (2023 Private Placement), pursuant to which the Company sold an aggregate of 7.7 million shares of the Company&#x2019;s Class A common stock at a price of $6.49 per share for net proceeds of approximately &lt;/span&gt;&lt;span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$49.9 million. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Valence Acquisition Exchangeable Shares&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In &lt;/span&gt;&lt;span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;May 2023&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, in connection with the acquisition of Valence, the Company entered into an agreement to issue up to 5.9 million shares of Class A common stock (the &#x201c;Exchange Shares&#x201d;), that may be issued upon exchange, retraction or redemption of exchangeable shares of a subsidiary of Recursion. Each exchangeable share of the subsidiary of Recursion entitles the holder to exchange those shares on a one-for-one basis for Recursion&#x2019;s Class A common stock. The shares are entitled to receive dividends economically equivalent to dividends declared by Recursion, are non-voting and are subject to customary adjustments for stock splits or other reorganizations. In addition, the Company may require all outstanding exchangeable shares to be exchanged into an equal number of Class A common stock upon the occurrence of certain events and at any time following the seventh anniversary of the closing of the Valence acquisition. The exchangeable shares are substantially the economic equivalent of the Class A shares and classified as common stock within the Company&#x2019;s stockholders&#x2019; equity. The Company&#x2019;s calculation of weighted-average shares outstanding includes the exchangeable shares. As of March&#160;31, 2024, 4.2&#160;million Exchangeable shares have been redeemed for Class A shares.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Registration Rights Agreements&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Tempus agreement&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In &lt;/span&gt;&lt;span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;November 2023&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, in connection with the Tempus Agreement, the Company agreed to prepare and file a registration statement (or a prospectus supplement to an effective registration statement on Form S-3ASR that will become automatically effective upon filing with the SEC pursuant to Rule 462(e)) with the SEC, for resale of the shares of Class A common stock issued or issuable under the Tempus Agreement. A prospectus supplement to a registration statement (File No. 333-264845) was subsequently filed in &lt;/span&gt;&lt;span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 2023&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to register shares issued to Tempus for the initial license fee under the Tempus Agreement for resale. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;After registration of any shares issued to Tempus under the Tempus Agreement, the Company has agreed to use commercially reasonable efforts to keep such registration statement effective until such date that all shares issued to Tempus covered by such registration statement have been sold or are able to be publicly sold by relying on Rule 144 of the Securities Act without registration.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;NVIDIA Private Placement&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In &lt;/span&gt;&lt;span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;July 2023&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, in connection with the 2023 Private Placement with NVIDIA, the Company entered into a Registration Rights Agreement providing for the registration for resale of the shares of Class A common stock issued in such transaction. A prospectus supplement to a registration statement (File No. 333-264845) was subsequently filed in &lt;/span&gt;&lt;span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;August 2023&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to register the resale of the shares of Class A common stock issued to NVIDIA. The Company has agreed to use commercially reasonable efforts to keep the registration statement continuously effective until such date that all registrable securities under the agreement have been sold. In the event the holders cannot sell their shares due to certain circumstances causing the registration statement to be ineffective, the Company must pay each holder of shares outstanding on the date and each month thereafter 1% of the aggregate purchase price with the maximum payable amount of 5% of the aggregate purchase price. As of March&#160;31, 2024, there was no accrued liability related to this agreement, as it was not probable that a payment would be required.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In &lt;/span&gt;&lt;span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;May 2023&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, in connection with the acquisition of Valence, the Company entered into a Registration Agreement providing for the registration for resale of the shares of Class A common stock and Exchange Shares issued or issuable in such transaction. A registration statement on Form S-3ASR (File No. 333-272281) was filed to register &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the shares for resale by the holders. The registration statement must remain effective for a period of not less than three years. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In &lt;/span&gt;&lt;span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;May 2023&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, in connection with the acquisition of Cyclica, the Company entered into a Registration Agreement providing for the registration for resale of the shares of Class A common stock issued in such transaction. A prospectus supplement to a registration statement (File No. 333-264845) was subsequently filed in &lt;/span&gt;&lt;span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;June 2023&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to register the shares for resale by the holders. The registration statement must be continuously effective until the earlier of the date that all shares have been sold thereunder or are able to be publicly sold by relying on Rule 144 of the Securities Act without registration. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;2022 Private Placement&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2022, i&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;n connection with the 2022 Private Placement, the Company entered into a Registration Rights Agreement providing for the registration for resale of the shares of Class A common stock issued in such transaction. A prospectus supplement to a registration statement (File No. 333-264845) was subsequently filed in &lt;/span&gt;&lt;span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;October 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to register the resale of the shares of Class A common stock by the Purchasers. The agreement must remain effective until registrable securities covered by the agreement have been publicly sold by the holders or all shares cease to be registrable securities. In the event the holders cannot sell their shares due to certain circumstances causing the agreement to be ineffective, the Company must pay each holder of shares outstanding on the date and each month thereafter 1% of the aggregate purchase price paid by the holder without limit until the agreement is cured. As of March&#160;31, 2024, there was no accrued liability related to this agreement, as it was not probable that a payment would be required.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Class A and B Common Shares Authorization&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In &lt;/span&gt;&lt;span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;April 2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company&#x2019;s Board of Directors authorized two classes of common stock, Class A and Class B. The rights of the holders of Class A and B common stock are identical, except with respect to voting and conversion. Each share of Class A common stock is entitled to one vote per share. Each share of Class B common stock is entitled to 10 votes per share and is convertible at any time into one share of Class A common stock.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All Class B common stock is held by Christopher Gibson, Ph.D., the Company&#x2019;s Chief Executive Officer (CEO), or his affiliates. As of March&#160;31, 2024, Dr. Gibson and his affiliates held outstanding shares of Class B common stock representing approximately 25% of the voting power of the Company&#x2019;s outstanding shares. This voting power may increase over time as Dr. Gibson vests in and exercises equity awards outstanding. If all the exchangeable equity awards held by Dr. Gibson had been fully vested, exercised and exchanged for shares of Class B common stock as of March&#160;31, 2024, Dr. Gibson and his affiliates would hold approximately 26% of the voting power of the Company&#x2019;s outstanding shares. As a result, Dr. Gibson will be able to significantly influence any action requiring the approval of Recursion stockholders, including the election of the Board of Directors; the adoption of amendments to the Company&#x2019;s certificate of incorporation and bylaws; and the approval of any merger, consolidation, sale of all or substantially all of the Company&#x2019;s assets, or other major corporate transaction.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <rxrx:CommonStockVotePerShare contextRef="c-6" decimals="INF" id="f-421" unitRef="vote">1</rxrx:CommonStockVotePerShare>
    <rxrx:CommonStockVotePerShare contextRef="c-8" decimals="INF" id="f-422" unitRef="vote">10</rxrx:CommonStockVotePerShare>
    <us-gaap:DividendsStock contextRef="c-1" decimals="INF" id="f-423" unitRef="usd">0</us-gaap:DividendsStock>
    <us-gaap:DividendsStock contextRef="c-80" decimals="INF" id="f-424" unitRef="usd">0</us-gaap:DividendsStock>
    <rxrx:SaleOfStockValueAuthorized contextRef="c-81" decimals="-5" id="f-425" unitRef="usd">300000000</rxrx:SaleOfStockValueAuthorized>
    <rxrx:SaleOfStockValueRemainingAuthorized contextRef="c-82" decimals="-5" id="f-426" unitRef="usd">208200000</rxrx:SaleOfStockValueRemainingAuthorized>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="c-83" decimals="-3" id="f-427" unitRef="shares">921000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-83" decimals="-5" id="f-428" unitRef="usd">10900000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <rxrx:SaleOfStockPercentageOfCommission contextRef="c-83" decimals="2" id="f-429" unitRef="number">0.03</rxrx:SaleOfStockPercentageOfCommission>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c-84" decimals="-5" id="f-430" unitRef="shares">7700000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c-85"
      decimals="2"
      id="f-431"
      unitRef="usdPerShare">6.49</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="c-86" decimals="-5" id="f-432" unitRef="usd">49900000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <rxrx:BusinessAcquisitionContingentConsiderationEquityInterestsIssuableNumberOfShares contextRef="c-57" decimals="-5" id="f-433" unitRef="shares">5900000</rxrx:BusinessAcquisitionContingentConsiderationEquityInterestsIssuableNumberOfShares>
    <rxrx:CommonStockConversionRatio
      contextRef="c-87"
      decimals="INF"
      id="f-434"
      unitRef="number">1</rxrx:CommonStockConversionRatio>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="c-88" decimals="-5" id="f-435" unitRef="shares">4200000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <rxrx:PercentOfAggregatePurchasePricePaidByTheHolderDueIfAgreementIsBroken contextRef="c-89" decimals="2" id="f-436" unitRef="number">0.01</rxrx:PercentOfAggregatePurchasePricePaidByTheHolderDueIfAgreementIsBroken>
    <rxrx:PercentOfAggregatePurchasePricePaidByTheHolderDueIfAgreementIsBroken contextRef="c-90" decimals="2" id="f-437" unitRef="number">0.05</rxrx:PercentOfAggregatePurchasePricePaidByTheHolderDueIfAgreementIsBroken>
    <rxrx:RegistrationRightsAgreementAccruedLiability contextRef="c-91" decimals="INF" id="f-438" unitRef="usd">0</rxrx:RegistrationRightsAgreementAccruedLiability>
    <rxrx:RegistrationRightsAgreementTerm contextRef="c-92" id="f-439">P3Y</rxrx:RegistrationRightsAgreementTerm>
    <rxrx:PercentOfAggregatePurchasePricePaidByTheHolderDueIfAgreementIsBroken contextRef="c-93" decimals="2" id="f-440" unitRef="number">0.01</rxrx:PercentOfAggregatePurchasePricePaidByTheHolderDueIfAgreementIsBroken>
    <rxrx:RegistrationRightsAgreementAccruedLiability contextRef="c-4" decimals="INF" id="f-441" unitRef="usd">0</rxrx:RegistrationRightsAgreementAccruedLiability>
    <rxrx:NumberOfClassesOfCommonStockAuthorized contextRef="c-94" decimals="INF" id="f-442" unitRef="class">2</rxrx:NumberOfClassesOfCommonStockAuthorized>
    <rxrx:CommonStockVotePerShare contextRef="c-6" decimals="INF" id="f-443" unitRef="vote">1</rxrx:CommonStockVotePerShare>
    <rxrx:CommonStockVotePerShare contextRef="c-8" decimals="INF" id="f-444" unitRef="vote">10</rxrx:CommonStockVotePerShare>
    <rxrx:CommonStockConversionRatio contextRef="c-6" decimals="INF" id="f-445" unitRef="number">1</rxrx:CommonStockConversionRatio>
    <rxrx:AffiliatedHoldersOwnershipPercentage contextRef="c-95" decimals="2" id="f-446" unitRef="number">0.25</rxrx:AffiliatedHoldersOwnershipPercentage>
    <rxrx:AffiliatedHoldersPotentialOwnershipPercentageWhenOutstandingEquityAwardsVest contextRef="c-95" decimals="2" id="f-447" unitRef="number">0.26</rxrx:AffiliatedHoldersPotentialOwnershipPercentageWhenOutstandingEquityAwardsVest>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="c-1" id="f-448">Collaborative Development Contracts &lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Roche and Genentech&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Description&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2021, Recursion entered into a collaboration and license agreement with Roche and Genentech (collectively referred to as Roche). Recursion is constructing, using the Company&#x2019;s imaging technology and proprietary machine-learning algorithms, unique maps of the inferred relationships amongst perturbation phenotypes in a given cellular context with the goal to discover and develop therapeutic small molecule programs in a gastrointestinal cancer indication and in key areas of neuroscience. Roche and Recursion will collaborate to select certain novel inferences with respect to small molecules or targets generated from the Phenomaps for further validation and optimization as collaboration programs. Roche and Recursion may also combine sequencing datasets from Roche with Recursion&#x2019;s Phenomaps and collaborate to generate new algorithms to produce multi-modal maps from which additional collaboration programs may be initiated. For every collaboration program that successfully identifies potential therapeutic small molecules or validates a target, Roche will have an option to obtain an exclusive license to develop and commercialize such potential therapeutic small molecules or to exploit such target in the applicable exclusive field.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Pricing&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2022, Recursion received a $150.0 million non-refundable upfront payment from the Company&#x2019;s collaboration with Roche. Recursion is eligible for additional milestone payments based on performance progress of the collaboration. Each of the Phenomaps requested by Roche and created by Recursion may be subject to either an initiation fee, acceptance fee or both. Such fees could exceed $250.0 million for 16 accepted Phenomaps. In addition, for a period of time after Roche&#x2019;s acceptance of certain Phenomaps, Roche will have the option to obtain, subject to payment of an exercise fee, rights to use outside the collaboration the raw images generated in the course of creating those Phenomaps. If Roche exercises its external use option for all 12 eligible Phenomaps, Roche&#x2019;s associated exercise fee payments to Recursion could exceed $250.0 million. Under the collaboration, Roche may initiate up to 40 programs, each of which, if successfully developed and commercialized, could yield more than $300.0&#160;million in development, commercialization and net revenue milestones for Recursion, as well as tiered royalties on net revenue.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Accounting&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;This agreement represents a transaction with a customer and therefore is accounted for in accordance with ASC 606. Recursion has determined that it has three performance obligations, one related to gastrointestinal cancer and two in neuroscience. These performance obligations are for performing research and development services for Roche to identify targets and medicines. The performance obligations also include potential licenses related to the intellectual property. The Company concluded that licenses within the contract are not distinct from the research and development services as they are interrelated due to the fact that the research and development services significantly impact the potential licenses. Any additional services are considered customer options and will be considered as separate contracts for accounting purposes.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has determined the transaction price to be $150.0 million, comprised of the upfront payment. Recursion will fully constrain the amounts of variable consideration to be received from potential milestones considering the stage of development and the risks associated with the remaining development required to achieve each milestone. Recursion will re-evaluate the transaction price each reporting period. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The transaction price was allocated to the performance obligations based on the estimated relative stand-alone selling price of each performance obligation as determined using an expected cost plus margin approach. The Company recognizes revenue over time based on costs incurred relative to total expected costs to perform the research and development services. Recursion determined that this method provides a faithful depiction of the transfer of control to the customer. This method of recognizing revenue requires the Company to make estimates of total costs to provide the services required under the performance obligations. Significant inputs used to determine the total costs included the length of time required, service hours performed by Company employees and materials costs. A significant change in these estimates could have a material effect on the timing and amount of revenue recognized in future periods. Recursion has estimated the completion of the performance obligations by 2026.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Additional Revenue Disclosures&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Of the revenue recognized during the three months ended March 31, 2024 and 2023, primarily all of it was included in the unearned revenue balance as of December&#160;31, 2023 and 2022, respectively. Revenue recognized was from upfront payments received at the inception of the related contracts, which decreased the initial unearned revenue recognized. As of March&#160;31, 2024, the Company had $6.5 million of costs incurred to fulfill a contract on its Condensed Consolidated Balance Sheet within &#x201c;Other Current Assets.&#x201d;&lt;/span&gt;&lt;/div&gt;Unearned revenue was classified as short-term and long-term on the Condensed Consolidated Balance Sheets based on the Company&#x2019;s estimate of revenue that will be recognized during the next twelve months.</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:ContractWithCustomerLiability contextRef="c-96" decimals="-5" id="f-449" unitRef="usd">150000000</us-gaap:ContractWithCustomerLiability>
    <rxrx:RevenueRemainingPerformanceObligationVariableConsiderationAmount contextRef="c-97" decimals="-5" id="f-450" unitRef="usd">250000000</rxrx:RevenueRemainingPerformanceObligationVariableConsiderationAmount>
    <rxrx:ContractWithCustomerMaximumAcceptedProduct
      contextRef="c-97"
      decimals="INF"
      id="f-451"
      unitRef="phenomap">16</rxrx:ContractWithCustomerMaximumAcceptedProduct>
    <rxrx:ContractWithCustomerMaximumAcceptedProduct
      contextRef="c-98"
      decimals="INF"
      id="f-452"
      unitRef="phenomap">12</rxrx:ContractWithCustomerMaximumAcceptedProduct>
    <rxrx:RevenueRemainingPerformanceObligationVariableConsiderationAmount contextRef="c-98" decimals="-5" id="f-453" unitRef="usd">250000000</rxrx:RevenueRemainingPerformanceObligationVariableConsiderationAmount>
    <rxrx:RevenueRemainingPerformanceObligationNumberOfProjectsThatMayBeInitiated
      contextRef="c-99"
      decimals="INF"
      id="f-454"
      unitRef="program">40</rxrx:RevenueRemainingPerformanceObligationNumberOfProjectsThatMayBeInitiated>
    <rxrx:RevenueRemainingPerformanceObligationVariableConsiderationAmount contextRef="c-99" decimals="-5" id="f-455" unitRef="usd">300000000</rxrx:RevenueRemainingPerformanceObligationVariableConsiderationAmount>
    <rxrx:RevenuePerformanceObligationNumberOfObligations
      contextRef="c-100"
      decimals="INF"
      id="f-456"
      unitRef="performance_obligation">3</rxrx:RevenuePerformanceObligationNumberOfObligations>
    <rxrx:RevenuePerformanceObligationNumberOfObligations
      contextRef="c-101"
      decimals="INF"
      id="f-457"
      unitRef="performance_obligation">1</rxrx:RevenuePerformanceObligationNumberOfObligations>
    <rxrx:RevenuePerformanceObligationNumberOfObligations
      contextRef="c-102"
      decimals="INF"
      id="f-458"
      unitRef="performance_obligation">2</rxrx:RevenuePerformanceObligationNumberOfObligations>
    <us-gaap:RevenueRemainingPerformanceObligation contextRef="c-96" decimals="-5" id="f-459" unitRef="usd">150000000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-103" decimals="-5" id="f-460" unitRef="usd">6500000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-461">Stock-Based Compensation &lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2021, the Board of Directors and the stockholders of the Company adopted the 2021 Equity Incentive Plan (the 2021 Plan). The Company may grant stock options, restricted stock units (RSUs), stock appreciation rights, restricted stock awards and other forms of stock-based compensation. As of March&#160;31, 2024, 18.9 million shares of Class A common stock were available for grant.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the classification of stock-based compensation expense for employees and non-employees within the Condensed Consolidated Statements of Operations: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:68.490%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.104%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.106%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three months ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,077&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock options are primarily granted to executive leaders at the Company, generally vest over four years and expire no later than 10 years from the date of grant. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock option activity during the three months ended March 31, 2024 was as follows: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:39.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.467%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;(in thousands except share and per share amounts)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Exercise&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Price &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Remaining&#160;Contractual Life (in years) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,957,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.0&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,558,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(178,609)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,303,878)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,033,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.3&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable as of March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,909,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.2&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of options granted to employees is calculated on the grant date using the Black-Scholes option valuation model. The weighted-average grant-date fair values of stock options granted during the three months ended March 31, 2024 and 2023 were $6.41 and $5.32, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following weighted-average assumptions were used to calculate the grant-date fair value of stock options: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:60.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.052%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.053%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;text-indent:62.99pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;text-indent:62.99pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:67.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:67.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2024, $43.9 million of unrecognized compensation cost related to stock options is expected to be recognized as expense over approximately the next three years. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;RSUs&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity awards granted to employees primarily consist of RSUs and generally vest over four years. The weighted-average grant-date fair value of RSUs generally is determined based on the number of units granted and the quoted price of Recursion&#x2019;s common stock on the date of grant.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes Recursion&#x2019;s RSU activity during the three months ended March 31, 2024: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.133%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.783%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.784%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,223,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,840,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,023,464)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(409,634)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,631,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair market value of RSUs vested was $13.0 million during the three months ended March 31, 2024. As of March&#160;31, 2024, $124.8 million of unrecognized compensation cost related to RSUs is expected to be recognized as expense over approximately the next three years.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-104"
      decimals="INF"
      id="f-462"
      unitRef="shares">18900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c-1" id="f-463">&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the classification of stock-based compensation expense for employees and non-employees within the Condensed Consolidated Statements of Operations: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:68.490%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.104%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.106%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three months ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,077&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-105" decimals="-3" id="f-464" unitRef="usd">766000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-106" decimals="-3" id="f-465" unitRef="usd">1011000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-107" decimals="-3" id="f-466" unitRef="usd">7666000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-108" decimals="-3" id="f-467" unitRef="usd">2683000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-109" decimals="-3" id="f-468" unitRef="usd">7077000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-110" decimals="-3" id="f-469" unitRef="usd">4578000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-3" id="f-470" unitRef="usd">15509000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-16" decimals="-3" id="f-471" unitRef="usd">8272000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-111" id="f-472">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-111" id="f-473">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c-1" id="f-474">&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock option activity during the three months ended March 31, 2024 was as follows: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:39.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.467%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;(in thousands except share and per share amounts)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Exercise&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Price &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Remaining&#160;Contractual Life (in years) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,957,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.0&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,558,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(178,609)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,303,878)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,033,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.3&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable as of March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,909,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.2&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-5" decimals="INF" id="f-475" unitRef="shares">14957617</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-5"
      decimals="2"
      id="f-476"
      unitRef="usdPerShare">6.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-80" id="f-477">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-5" decimals="-3" id="f-478" unitRef="usd">72416000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-1" decimals="INF" id="f-479" unitRef="shares">2558102</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-480"
      unitRef="usdPerShare">10.09</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="c-1" decimals="INF" id="f-481" unitRef="shares">178609</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-482"
      unitRef="usdPerShare">12.70</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-1" decimals="INF" id="f-483" unitRef="shares">1303878</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-484"
      unitRef="usdPerShare">2.80</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-1" decimals="-3" id="f-485" unitRef="usd">11575000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-4" decimals="INF" id="f-486" unitRef="shares">16033232</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-4"
      decimals="2"
      id="f-487"
      unitRef="usdPerShare">6.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-1" id="f-488">P7Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-4" decimals="-3" id="f-489" unitRef="usd">64131000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c-4" decimals="INF" id="f-490" unitRef="shares">8909647</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-4"
      decimals="2"
      id="f-491"
      unitRef="usdPerShare">5.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-492">P6Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c-4" decimals="-3" id="f-493" unitRef="usd">51959000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-1"
      decimals="2"
      id="f-494"
      unitRef="usdPerShare">6.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-16"
      decimals="2"
      id="f-495"
      unitRef="usdPerShare">5.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c-1" id="f-496">&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following weighted-average assumptions were used to calculate the grant-date fair value of stock options: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:60.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.052%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.053%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;text-indent:62.99pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;text-indent:62.99pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:67.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:67.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-111" id="f-497">P6Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-112" id="f-498">P6Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-111" decimals="2" id="f-499" unitRef="number">0.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-112" decimals="2" id="f-500" unitRef="number">0.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-111" decimals="3" id="f-501" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-112" decimals="3" id="f-502" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-111" decimals="3" id="f-503" unitRef="number">0.042</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-112" decimals="3" id="f-504" unitRef="number">0.035</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="c-4" decimals="-5" id="f-505" unitRef="usd">43900000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-1" id="f-506">P3Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-113" id="f-507">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock contextRef="c-1" id="f-508">&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes Recursion&#x2019;s RSU activity during the three months ended March 31, 2024: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.133%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.783%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.784%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,223,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,840,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,023,464)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(409,634)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,631,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-114"
      decimals="INF"
      id="f-509"
      unitRef="shares">15223764</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-114"
      decimals="2"
      id="f-510"
      unitRef="usdPerShare">8.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-115"
      decimals="INF"
      id="f-511"
      unitRef="shares">1840877</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-115"
      decimals="2"
      id="f-512"
      unitRef="usdPerShare">10.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-115"
      decimals="INF"
      id="f-513"
      unitRef="shares">1023464</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-115"
      decimals="2"
      id="f-514"
      unitRef="usdPerShare">8.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-115"
      decimals="INF"
      id="f-515"
      unitRef="shares">409634</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-115"
      decimals="2"
      id="f-516"
      unitRef="usdPerShare">7.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-116"
      decimals="INF"
      id="f-517"
      unitRef="shares">15631543</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-116"
      decimals="2"
      id="f-518"
      unitRef="usdPerShare">8.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="c-115" decimals="-5" id="f-519" unitRef="usd">13000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions contextRef="c-116" decimals="-5" id="f-520" unitRef="usd">124800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-115" id="f-521">P3Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c-1" id="f-522">Income Taxes &lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company did not record any U.S. income tax expense during the three months ended March 31, 2024 and 2023. The Company has historically incurred operating losses and maintains a full valuation allowance against its U.S. net deferred tax assets. Foreign taxes were insignificant during the three months ended March 31, 2024 and 2023. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net operating losses (NOLs) and tax credit carry-forwards are subject to review and possible adjustment by the Internal Revenue Service (&#x201c;IRS&#x201d;) and may become subject to annual limitation due to ownership changes that occur under Section 382 of the Internal Revenue Code, as amended and similar state provisions. These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income. In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain shareholders or public groups in the stock of a corporation by more than 50% over a three-year period. As of March&#160;31, 2024, the Company was not limited on its NOLs and tax credit carry-forwards. The Company will continue to monitor future ownership changes for potential Section 382 limitations.  &lt;/span&gt;&lt;/div&gt;The Company files income tax returns in the United States, Canada, United Kingdom, Utah, California and Massachusetts. The Company is not currently under examination in any of these jurisdictions. The Company is subject to income tax examinations on all federal returns since the 2017 tax return.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations contextRef="c-1" decimals="INF" id="f-523" unitRef="usd">0</us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations contextRef="c-16" decimals="INF" id="f-524" unitRef="usd">0</us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:EarningsPerShareTextBlock contextRef="c-1" id="f-525">Net Loss Per Share &lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March 31, 2024 and 2023, Recursion calculated net loss per share of Class A, Class B and Exchangeable common stock using the two-class method. Basic net loss per share is computed using the weighted-average number of shares outstanding during the period. Diluted net loss per share is computed using the weighted-average number of shares and the effect of potentially dilutive securities outstanding during the period. Potentially dilutive securities consist of stock options and other contingently issuable shares. For periods presented in which the Company reports a net loss, all potentially dilutive shares are anti-dilutive and as such are excluded from the calculation. &lt;/span&gt;&lt;span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;three months ended March 31, 2024 and 2023&lt;/span&gt;&lt;span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company reported a net loss and therefore basic and diluted loss per share were the same.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The rights, including the liquidation and dividend rights, of the holders of the Company&#x2019;s Class A, Class B and the Exchangeable common stock are identical, except with respect to voting. As a result, the undistributed earnings for each period are allocated based on the contractual participation rights of the Class A, Class B and the Exchangeable common stock as if the earnings for the period had been distributed. As the liquidation and dividend rights are identical, the undistributed earnings are allocated on a proportionate basis and the resulting amount per share for Class A, Class B and the Exchangeable common stock was the same during the three months ended March 31, 2024 and 2023.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables set forth the computation of basic and diluted net loss per share of Class A, Class B and Exchangeable common stock:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:68.446%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.126%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.128%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands, except share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(91,373)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(65,327)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236,019,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,618,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company excluded the following potential common shares from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:68.783%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.958%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.959%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Stock based compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,159,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,534,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Tempus agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,143,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,302,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,534,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c-1" id="f-526">&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables set forth the computation of basic and diluted net loss per share of Class A, Class B and Exchangeable common stock:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:68.446%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.126%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.128%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands, except share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(91,373)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(65,327)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236,019,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,618,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-527" unitRef="usd">-91373000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-16" decimals="-3" id="f-528" unitRef="usd">-65327000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="0" id="f-529" unitRef="shares">236019349</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="0" id="f-530" unitRef="shares">236019349</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-16" decimals="0" id="f-531" unitRef="shares">191618238</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-16" decimals="0" id="f-532" unitRef="shares">191618238</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-533"
      unitRef="usdPerShare">-0.39</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-534"
      unitRef="usdPerShare">-0.39</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-16"
      decimals="2"
      id="f-535"
      unitRef="usdPerShare">-0.34</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-16"
      decimals="2"
      id="f-536"
      unitRef="usdPerShare">-0.34</us-gaap:EarningsPerShareBasic>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c-1" id="f-537">&lt;div&gt;&lt;span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company excluded the following potential common shares from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:68.783%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.958%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.959%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Stock based compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,159,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,534,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Tempus agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,143,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,302,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,534,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-117" decimals="0" id="f-538" unitRef="shares">11159250</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-118" decimals="0" id="f-539" unitRef="shares">8534876</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-119" decimals="0" id="f-540" unitRef="shares">5143690</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-120" decimals="0" id="f-541" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-1" decimals="0" id="f-542" unitRef="shares">16302940</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-16" decimals="0" id="f-543" unitRef="shares">8534876</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c-1" id="f-544">Fair Value Measurements&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value hierarchy consists of the following three levels:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 &#x2014; Valuations based on unadjusted quoted prices in active markets for identical assets that the company has the ability to access;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 &#x2014; Valuations based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuations in which all significant inputs are observable in the market; and&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 &#x2014; Valuations using significant inputs that are unobservable in the market and include the use of judgment by the company's management about the assumptions market participants would use in pricing the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is required to maintain a cash balance in a collateralized account to secure the Company&#x2019;s credit cards. Additionally, the Company holds restricted cash related to an outstanding letter of credit issued by J.P. Morgan, which was obtained to secure certain Company obligations relating to tenant improvements. Recursion also holds restricted cash related to a Bill and Melinda Gates Foundation grant. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the Company&#x2019;s assets and liabilities that are measured at fair value on a recurring basis:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.098%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.297%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.204%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.449%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.452%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Basis of fair value measurement&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;276,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;276,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.098%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.297%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.204%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.449%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.452%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Basis of fair value measurement&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;332,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;332,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the financial instruments that are recognized at fair value on the Condensed Consolidated Balance Sheet, the Company has certain financial instruments that are recognized at amortized cost or some basis other than fair value. The carrying amount of these instruments are considered to be representative of their approximate fair values. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the Company&#x2019;s financial instruments that are not measured at fair value: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.531%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.443%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.443%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.992%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.443%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.448%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Book values&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair values&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of notes payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Notes payable, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="c-1" id="f-545">&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the Company&#x2019;s assets and liabilities that are measured at fair value on a recurring basis:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.098%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.297%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.204%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.449%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.452%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Basis of fair value measurement&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;276,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;276,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.098%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.297%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.204%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.449%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.452%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Basis of fair value measurement&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;332,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;332,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-121" decimals="-3" id="f-546" unitRef="usd">276697000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-122" decimals="-3" id="f-547" unitRef="usd">276697000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-123" decimals="-3" id="f-548" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-124" decimals="-3" id="f-549" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <rxrx:RestrictedCashAndCashEquivalentsFairValueDisclosure contextRef="c-125" decimals="-3" id="f-550" unitRef="usd">9824000</rxrx:RestrictedCashAndCashEquivalentsFairValueDisclosure>
    <rxrx:RestrictedCashAndCashEquivalentsFairValueDisclosure contextRef="c-126" decimals="-3" id="f-551" unitRef="usd">9824000</rxrx:RestrictedCashAndCashEquivalentsFairValueDisclosure>
    <rxrx:RestrictedCashAndCashEquivalentsFairValueDisclosure contextRef="c-127" decimals="-3" id="f-552" unitRef="usd">0</rxrx:RestrictedCashAndCashEquivalentsFairValueDisclosure>
    <rxrx:RestrictedCashAndCashEquivalentsFairValueDisclosure contextRef="c-128" decimals="-3" id="f-553" unitRef="usd">0</rxrx:RestrictedCashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-125" decimals="-3" id="f-554" unitRef="usd">286521000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-126" decimals="-3" id="f-555" unitRef="usd">286521000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-127" decimals="-3" id="f-556" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-128" decimals="-3" id="f-557" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-129" decimals="-3" id="f-558" unitRef="usd">322653000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-130" decimals="-3" id="f-559" unitRef="usd">322653000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-131" decimals="-3" id="f-560" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-132" decimals="-3" id="f-561" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <rxrx:RestrictedCashAndCashEquivalentsFairValueDisclosure contextRef="c-133" decimals="-3" id="f-562" unitRef="usd">9860000</rxrx:RestrictedCashAndCashEquivalentsFairValueDisclosure>
    <rxrx:RestrictedCashAndCashEquivalentsFairValueDisclosure contextRef="c-134" decimals="-3" id="f-563" unitRef="usd">9860000</rxrx:RestrictedCashAndCashEquivalentsFairValueDisclosure>
    <rxrx:RestrictedCashAndCashEquivalentsFairValueDisclosure contextRef="c-135" decimals="-3" id="f-564" unitRef="usd">0</rxrx:RestrictedCashAndCashEquivalentsFairValueDisclosure>
    <rxrx:RestrictedCashAndCashEquivalentsFairValueDisclosure contextRef="c-136" decimals="-3" id="f-565" unitRef="usd">0</rxrx:RestrictedCashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-133" decimals="-3" id="f-566" unitRef="usd">332513000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-134" decimals="-3" id="f-567" unitRef="usd">332513000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-135" decimals="-3" id="f-568" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-136" decimals="-3" id="f-569" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock contextRef="c-1" id="f-570">&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the Company&#x2019;s financial instruments that are not measured at fair value: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.531%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.443%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.443%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.992%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.443%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.448%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Book values&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair values&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of notes payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Notes payable, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock>
    <us-gaap:LongTermDebtCurrent contextRef="c-137" decimals="-3" id="f-571" unitRef="usd">55000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-138" decimals="-3" id="f-572" unitRef="usd">41000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-139" decimals="-3" id="f-573" unitRef="usd">55000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-140" decimals="-3" id="f-574" unitRef="usd">41000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-137" decimals="-3" id="f-575" unitRef="usd">1071000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-138" decimals="-3" id="f-576" unitRef="usd">1101000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-139" decimals="-3" id="f-577" unitRef="usd">1071000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-140" decimals="-3" id="f-578" unitRef="usd">1101000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtFairValue contextRef="c-141" decimals="-3" id="f-579" unitRef="usd">1126000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue contextRef="c-142" decimals="-3" id="f-580" unitRef="usd">1142000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue contextRef="c-143" decimals="-3" id="f-581" unitRef="usd">1126000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue contextRef="c-144" decimals="-3" id="f-582" unitRef="usd">1142000</us-gaap:LongTermDebtFairValue>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-1" id="f-583">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-1" id="f-584">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-1" id="f-585">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:MtrlTermsOfTrdArrTextBlock contextRef="c-145" id="f-586">&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 1, 2024, Terry-Ann Burrell, a member of our Board of Directors, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 211,290 shares of the Company&#x2019;s Class A common stock until May&#160;30, 2025.&lt;/span&gt;&lt;/div&gt;</ecd:MtrlTermsOfTrdArrTextBlock>
    <ecd:TrdArrAdoptionDate contextRef="c-145" id="f-587">March 1, 2024</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrIndName contextRef="c-145" id="f-588">Terry-Ann Burrell</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle contextRef="c-145" id="f-589">member of our Board of Directors</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-145" id="f-590">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="c-146"
      decimals="INF"
      id="f-591"
      unitRef="shares">211290</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:MtrlTermsOfTrdArrTextBlock contextRef="c-147" id="f-592">&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 1, 2024, Tina Marriott, President and Chief Operating Officer, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 672,000 shares of the Company&#x2019;s Class A common stock until June&#160;27, 2025.&lt;/span&gt;&lt;/div&gt;</ecd:MtrlTermsOfTrdArrTextBlock>
    <ecd:TrdArrAdoptionDate contextRef="c-147" id="f-593">March 1, 2024</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrIndName contextRef="c-147" id="f-594">Tina Marriott</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle contextRef="c-147" id="f-595">President and Chief Operating Officer</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-147" id="f-596">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="c-148"
      decimals="INF"
      id="f-597"
      unitRef="shares">672000</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:MtrlTermsOfTrdArrTextBlock contextRef="c-149" id="f-598">&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 1, 2024, Michael Secora, Chief Financial Officer, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 1,259,955 shares of the Company&#x2019;s Class A common stock until June&#160;10, 2025.&lt;/span&gt;&lt;/div&gt;</ecd:MtrlTermsOfTrdArrTextBlock>
    <ecd:TrdArrAdoptionDate contextRef="c-149" id="f-599">March 1, 2024</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrIndName contextRef="c-149" id="f-600">Michael Secora</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle contextRef="c-149" id="f-601">Chief Financial Officer</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-149" id="f-602">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="c-150"
      decimals="INF"
      id="f-603"
      unitRef="shares">1259955</ecd:TrdArrSecuritiesAggAvailAmt>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
